-DOCSTART- -X- N

children NNS Age
with IN None
Autism NNP Condition
Spectrum NNP Condition
Disorders NNP Condition
( ( None
ASD NNP Condition
) ) None
. . None
47 CD Size
preschool NN Age
and CC Age
K-1 JJ Age
students NNS Age
in IN None
ASD NNP Condition
classrooms NNS None
participated VBD None
from IN None
Los NNP None
Angeles NNP None
Unified NNP None
School NNP None
District NNP None
. . None
children NNS None
with IN None
ASD NNP Condition
and CC None
other JJ None
special JJ Condition
needs NNS Condition
. . None
-DOCSTART- -X- N

primary JJ None
breast NN None
cancer NN None
patients NNS None
: : None
primary JJ None
breast NN None
cancer NN None
patients NNS None
treated VBN None
in IN None
community NN None
settings NNS None
highly RB None
distressed JJ None
patients NNS None
Three CD None
hundred VBD None
and CC None
fifty-three JJ None
women NNS None
within IN None
one CD None
year NN None
of IN None
diagnosis NN None
with IN None
primary JJ None
breast NN None
cancer NN None
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
supportive-expressive JJ None
group NN None
therapy NN None
or CC None
to TO None
an DT None
education NN None
control NN None
condition NN None
. . None
Participants NNS None
were VBD None
recruited VBN None
from IN None
two CD None
academic JJ None
centers NNS None
and CC None
nine CD None
oncology NN None
practices NNS None
, , None
which WDT None
were VBD None
members NNS None
of IN None
NCI NNP None
's POS None
Community NNP None
Clinical NNP None
Oncology NNP None
Program NNP None
( ( None
CCOP NNP None
) ) None
and CC None
were VBD None
followed VBN None
over IN None
2 CD None
years NNS None
. . None
Highly NNP None
distressed JJ None
women NNS None
women NNS None
with IN None
primary JJ None
breast NN None
cancer NN None
. . None
women NNS None
with IN None
higher JJR None
initial JJ None
levels NNS None
of IN None
distress NN None
. . None
-DOCSTART- -X- N

randomized VBN None
trial NN None
with IN None
32 CD Size
male JJ Sex
volunteers NNS None
. . None
-DOCSTART- -X- N

vasopressin NN None
secretion NN None
in IN None
man NN Sex
. . None
healthy JJ Condition
subjects NNS Condition
. . None
24 CD None
healthy JJ None
volunteers NNS None
. . None
-DOCSTART- -X- N

multiple JJ None
cytochrome NN None
P450s NNP None
. . None
12 CD Size
healthy JJ Condition
male JJ Sex
subjects NNS None
. . None
-DOCSTART- -X- N

Sixty-two JJ None
patients NNS None
( ( None
19 CD None
men NNS None
and CC None
43 CD None
women NNS None
; : None
mean JJ None
age NN None
, , None
54 CD None
years NNS None
; : None
range NN None
, , None
32-77 CD None
years NNS None
) ) None
with IN None
heartburn NN None
and CC None
regurgitation NN None
and CC None
normal JJ None
upper JJ None
endoscopy NN None
findings NNS None
patients NNS None
with IN None
reflux NN None
symptoms NNS None
. . None
-DOCSTART- -X- N

scheduled JJ Condition
vaccination NN Condition
children NNS None
. . None
in IN None
239 CD None
children NNS None
aged VBN None
4-12 CD None
years NNS None
old JJ None
. . None
in IN None
4- JJ None
to TO None
12-year-old JJ None
children NNS None
. . None
239 CD None
children NNS None
were VBD None
enrolled VBN None
by IN None
25 CD None
family NN None
practitioners NNS None
4- JJ None
to TO None
12-year-old JJ None
children NNS None
. . None
children NNS None
-DOCSTART- -X- N

elective JJ Condition
appendectomy NN Condition
in IN None
renal JJ Condition
transplant NN Condition
recipients NNS None
75 CD Size
children NNS Age
after IN None
renal JJ None
transplantation NN None
-DOCSTART- -X- N

COPD NNP None
. . None
patients NNS None
with IN None
stable JJ None
and CC None
partially RB None
reversible JJ None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
( ( None
COPD NNP None
) ) None
. . None
Sixteen JJ None
outpatients NNS None
with IN None
partially RB Condition
reversible JJ Condition
, , None
stable JJ Condition
COPD NNP Condition
patients NNS None
suffering VBG None
from IN None
partially RB None
reversible JJ None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
. . None
-DOCSTART- -X- N

patient JJ None
satisfaction NN None
with IN None
reflux JJ None
treatment NN None
gastroesophageal NN Condition
reflux NN Condition
disease NN Condition
( ( None
GERD NNP Condition
) ) None
180 CD Size
patients NNS None
with IN None
chronic JJ Condition
and CC Condition
prolonged JJ Condition
episodes NNS Condition
of IN Condition
reflux NN Condition
were VBD None
investigated VBN None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
visual-motor JJ None
integration NN None
difficulties NNS None
pre-existing JJ None
psychological JJ None
adjustment NN None
and CC None
self-esteem JJ None
levels NNS None
in IN None
kindergarten NN None
and CC None
first JJ None
grade NN None
children NNS None
with IN None
poor JJ None
visual-motor JJ None
integration NN None
skills NNS None
, , None
from IN None
low JJ None
socioeconomic JJ None
backgrounds NNS None
. . None
One CD None
hundred CD None
and CC None
sixteen JJ None
mainstream NN None
kindergarten NN None
and CC None
first-grade JJ None
children NNS None
, , None
from IN None
low JJ None
socioeconomic JJ None
backgrounds NNS None
, , None
scoring VBG None
below IN None
the DT None
25th CD None
percentile NN None
on IN None
a DT None
measure NN None
of IN None
visual-motor NN None
integration NN None
( ( None
VMI NNP None
) ) None
were VBD None
recruited VBN None
-DOCSTART- -X- N

non-ST JJ Condition
elevation NN Condition
acute NN Condition
coronary JJ Condition
syndromes NNS Condition
. . Condition
non-ST-segment JJ None
elevation NN None
acute NN None
coronary JJ None
syndromes NNS None
. . None
240 CD None
patients NNS None
with IN None
either DT None
unstable JJ None
angina NN None
or CC None
non-ST-elevation JJ None
myocardial JJ None
infarction NN None
in IN None
the DT None
previous JJ None
2 CD None
weeks NNS None
-DOCSTART- -X- N

Twelve NNP None
healthy JJ None
male NN None
volunteers NNS None
Both DT None
antibiotics NNS None
were VBD None
well RB None
tolerated VBN None
in IN None
this DT None
single-dose JJ None
administration NN None
study NN None
. . None
Both DT None
drugs NNS None
had VBD None
rather RB None
short JJ None
biological JJ None
elimination NN None
half-lives NNS None
and CC None
a DT None
predominantly RB None
renal JJ None
route NN None
of IN None
elimination NN None
. . None
-DOCSTART- -X- N

attention-deficit/hyperactivity NN None
disorder NN None
symptoms NNS None
in IN None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
. . None
attention-deficit/hyperactivity NN None
disorder NN None
( ( None
ADHD NNP None
) ) None
in IN None
patients NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
97 CD None
patients NNS None
aged VBD None
6 CD None
to TO None
17 CD None
years NNS None
with IN None
ADHD NNP None
and CC None
ASD NNP None
were VBD None
randomly RB None
assigned VBN None
ADHD NNP None
patients NNS None
without IN None
ASD NNP None
. . None
Children NNP None
with IN None
ASD NNP None
; : None
-DOCSTART- -X- N

oncologic JJ None
patients NNS None
cancer NN None
patients NNS None
. . None
cancer NN None
patients NNS None
with IN None
pain NN None
. . None
240 CD None
patients NNS None
with IN None
diagnosed JJ None
malignancy NN None
and CC None
pain NN None
> VBP None
3 CD None
days NNS None
and CC None
average JJ None
pain NN None
> JJ None
or= NN None
3/10 CD None
will MD None
participate VB None
in IN None
a DT None
cluster NN None
randomized VBN None
trial NN None
on IN None
18 CD None
wards NNS None
in IN None
2 CD None
German JJ None
university NN None
hospitals NNS None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
and CC Condition
ADHD NNP Condition
symptoms NNS Condition
. . None
24 CD Size
children NNS Age
( ( None
19 CD Size
boys NNS Sex
; : None
5 CD Size
girls NNS Sex
) ) None
who WP None
met VBD None
American NNP None
Psychiatric NNP None
Association NNP None
, , None
Diagnostic NNP None
and CC None
Statistical NNP None
Manual NNP None
of IN None
Mental NNP None
Disorders NNP None
, , None
4th CD None
ed NN None
. . None
elementary JJ Age
school-age NN Age
, , Age
community-based JJ Age
children NNS Age
( ( None
mean JJ None
chronological JJ None
age=8.8 NN Age
years NNS Age
, , None
SD=1.7 NNP None
; : None
mean JJ None
intelligence NN None
quotient NN None
[ NNP None
IQ NNP None
] NNP None
=85 NNP None
; : None
SD=16.8 NNP None
) ) None
. . None
children NNS Age
with IN None
ASD NNP Condition
and CC None
significant JJ Condition
ADHD NNP Condition
symptoms NNS Condition
. . None
-DOCSTART- -X- N

patients NNS None
One CD None
group NN None
received VBD None
computer-generated JJ None
, , None
customized JJ None
letters NNS None
explaining VBG None
recommended VBD None
preventive JJ None
procedures NNS None
for IN None
each DT None
family NN None
member NN None
. . None
A DT None
second JJ None
group NN None
received VBD None
a DT None
form JJ None
letter NN None
listing NN None
recommendations NNS None
for IN None
all DT None
preventive JJ None
procedures NNS None
for IN None
all DT None
age NN None
and CC None
sex NN None
groups NNS None
. . None
A DT None
third JJ None
group NN None
( ( None
control VB None
group NN None
) ) None
received VBD None
no DT None
letters NNS None
. . None
A DT None
private JJ None
medical JJ None
centre NN None
, , None
without IN None
university NN None
affiliation NN None
, , None
in IN None
rural JJ None
Quebec NNP None
. . None
From IN None
8770 CD Size
patients NNS None
who WP None
met VBD None
study NN None
criteria NNS None
, , None
719 CD Size
families NNS None
were VBD None
randomly RB None
selected VBN None
. . None
Data NNS None
were VBD None
available JJ None
for IN None
1971 CD None
of IN None
1998 CD None
patients NNS None
in IN None
these DT None
families NNS None
. . None
-DOCSTART- -X- N

Shouldice NNP Condition
, , Condition
Lichtenstein NNP Condition
and CC Condition
transabdominal JJ Condition
preperitoneal NN Condition
hernia NN Condition
repairs NNS None
. . None
Some DT None
280 CD Size
men NNS Sex
with IN None
a DT None
primary JJ Condition
hernia NN Condition
were VBD None
randomized VBN None
-DOCSTART- -X- N

85 CD None
patients NNS None
with IN None
advanced JJ None
ovarian JJ None
carcinomas NN None
cases NNS None
of IN None
advanced JJ None
tumors NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
gastric JJ Condition
cancer NN Condition
: : None
patients NNS None
with IN None
non-resectable JJ None
gastric JJ None
and CC None
gastro-oesophageal JJ Condition
adenocarcinoma NN Condition
. . None
Three CD Size
hundred VBD Size
and CC Size
sixty-nine JJ Size
patients NNS None
with IN None
histological JJ None
proof NN None
of IN None
adenocarcinoma NN Condition
, , None
who WP None
had VBD None
received VBN None
no RB None
more RBR None
than IN None
a DT None
single JJ None
regimen NN None
of IN None
5-fluorouracil-based JJ None
chemotherapy NN None
pre-defined JJ None
sub-group NN None
of IN None
123 CD Size
patients NNS None
who WP None
had VBD None
received VBN None
prior RB None
chemotherapy NN None
patients NNS None
who WP None
had VBD None
previously RB None
received VBN None
chemotherapy NN None
. . None
-DOCSTART- -X- N

elderly JJ Condition
patients NNS Condition
undergoing VBG Condition
hip JJ Condition
fracture NN Condition
repair NN Condition
. . Condition
patients NNS None
undergoing VBG None
hip JJ None
fracture NN None
repair NN None
under IN None
spinal JJ None
anesthesia NN None
to TO None
light NN None
( ( None
BIS NNP None
> NNP None
80 CD None
) ) None
or CC None
deep JJ None
( ( None
BIS NNP None
approximately RB None
50 CD None
) ) None
sedation NN None
. . None
-DOCSTART- -X- N

persons NNS None
with IN None
a DT None
psychiatric JJ None
disability NN None
and CC None
their PRP$ None
staff NN None
. . None
persons NNS None
with IN None
psychiatric JJ None
disabilities NNS None
, , None
and CC None
their PRP$ None
caregivers NNS None
. . None
persons NNS None
with IN None
psychiatric JJ None
disabilities NNS None
persons NNS None
with IN None
a DT None
psychiatric JJ None
disability NN None
. . None
clients NNS None
with IN None
psychiatric JJ None
disabilities NNS None
living VBG None
in IN None
supported JJ None
housing NN None
and CC None
their PRP$ None
staff NN None
. . None
Forty-one CD None
persons NNS None
with IN None
a DT None
DSM- NNP None
? . None
V NNP None
diagnosis NN None
of IN None
severe JJ None
mental JJ None
illness NN None
from IN None
psychiatric JJ None
disability NN None
from IN None
10 CD None
supported VBD None
housing NN None
facilities NNS None
and CC None
41 CD None
of IN None
their PRP$ None
caregivers NNS None
participated VBN None
in IN None
this DT None
12-month JJ None
study NN None
during IN None
2005-2006 JJ None
in IN None
Sweden NNP None
. . None
carers NNS None
persons NNS None
with IN None
psychiatric JJ None
disabilities NNS None
. . None
-DOCSTART- -X- N

Fifty NNP Size
sedentary JJ Condition
males NNS Sex
-DOCSTART- -X- N

women NNS Sex
with IN None
oligo- JJ None
or CC None
anovulatory JJ Condition
infertility NN Condition
: : None
follicular NN None
development NN None
and CC None
ovulation NN None
in IN None
infertile JJ None
women NNS None
with IN None
ovulatory JJ Condition
dysfunction NN Condition
. . None
Infertile NNP None
women NNS None
with IN None
ovulatory JJ None
dysfunction NN None
, , None
aged VBN None
18-35 CD Age
years NNS Age
, , None
and CC None
body NN None
mass NN None
index NN None
< VBD None
35 CD None
kg/m NN None
( ( None
2 CD None
) ) None
. . None
-DOCSTART- -X- N

during IN None
transesophageal JJ None
echocardiography NN None
. . None
317 CD None
consecutive JJ None
patients NNS None
-DOCSTART- -X- N

Between NNP None
March NNP None
2008 CD None
and CC None
February NNP None
2011,157 CD Size
patients NNS None
who WP None
had VBD None
tubal JJ Condition
EP NNP Condition
diagnosed VBN None
by IN None
a DT None
non-laparoscopic JJ None
approach NN None
and CC None
were VBD None
hemodynamically RB None
stable JJ None
were VBD None
enrolled VBN None
in IN None
a DT None
prospective JJ None
study NN None
in IN None
Qassim NNP None
, , None
Saudi NNP None
Arabia NNP None
. . None
-DOCSTART- -X- N

male JJ None
patients NNS None
. . None
in IN None
male JJ None
patients NNS None
with IN None
urethral JJ None
strictures NNS None
Fifty NNP None
patients NNS None
aged VBD None
22 CD None
to TO None
83 CD None
( ( None
mean JJ None
age NN None
61.8 CD None
) ) None
with IN None
primary JJ None
( ( None
n JJ None
= NN None
26 CD None
, , None
52 CD None
% NN None
) ) None
and CC None
recurrent NN None
( ( None
n JJ None
= NN None
24 CD None
, , None
48 CD None
% NN None
) ) None
urethral JJ None
strictures VBZ None
0.3 CD None
to TO None
2.4 CD None
cm NNS None
long RB None
qualified VBD None
for IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

acquired VBN Condition
nystagmus NN Condition
in IN None
multiple JJ Condition
sclerosis NN Condition
: : None
patients NNS None
with IN None
multiple JJ None
sclerosis NN None
eight CD Size
patients NNS None
with IN None
definite JJ None
multiple JJ None
sclerosis NN None
. . None
Three CD None
out IN None
of IN None
eight CD None
patients NNS None
dropped VBD None
out RP None
due JJ None
to TO None
adverse JJ None
effects NNS None
. . None
Three CD None
patients NNS None
decided VBD None
to TO None
continue VB None
gabapentin JJ None
therapy NN None
. . None
-DOCSTART- -X- N

neurosurgical JJ Condition
patients NNS None
. . None
neurosurgical JJ Condition
patients NNS None
Thirty NNP Size
neurosurgical JJ Condition
patients NNS None
neurosurgical JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

cytomegalovirus NN Condition
retinitis NN Condition
in IN Condition
patients NNS Condition
with IN Condition
AIDS NNP Condition
. . Condition
patients NNS None
with IN None
acquired JJ None
immunodeficiency NN None
syndrome NN None
( ( None
AIDS NNP None
) ) None
. . None
two CD None
doses NNS None
( ( None
165-microg/injection JJ None
[ NN None
35 CD None
eyes NNS None
, , None
30 CD Size
patients NNS None
] JJ None
and CC None
330-microg/injection JJ None
[ NN None
153 CD None
eyes NNS None
, , None
120 CD Size
patients NNS None
] JJ None
) ) None
-DOCSTART- -X- N

treatment NN None
of IN None
primary JJ None
open JJ None
angle NN None
glaucoma NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
asthma NN None
patients NNS None
with IN None
asthma NNS None
Patients NNS None
with IN None
asthma JJ None
stabilized VBN None
on IN None
CFC NNP None
albuterol NN None
Patients NNS None
with IN None
asthma JJ None
-DOCSTART- -X- N

depression NN Condition
after IN Condition
admission NN Condition
for IN Condition
a DT Condition
cardiac JJ Condition
condition NN Condition
: : None
cardiac JJ None
patients NNS None
depression NN None
in IN None
patients NNS None
hospitalized VBN None
in IN None
South NNP None
Australia NNP None
for IN None
a DT None
range NN None
of IN None
cardiac JJ None
conditions NNS None
The DT None
subgroup NN None
identified VBD None
as IN None
depressed VBN None
was VBD None
entered VBN None
into IN None
the DT None
nested JJ None
IDACC NNP None
trial NN None
1455 CD None
participants NNS None
screened VBN None
were VBD None
classified VBN None
as IN None
depression NN None
cases NNS None
Australian JJ None
setting NN None
hospitalized JJ None
cardiac JJ None
patients NNS None
. . None
depression NN None
in IN None
cardiac JJ None
patients NNS None
-DOCSTART- -X- N

chronic JJ Condition
hepatitis NN Condition
B NNP Condition
of IN None
20 CD Size
patients NNS None
] JJ None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
. . None
42 CD Size
patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
. . None
24 CD Size
healthy JJ None
volunteers NNS None
under IN Condition
fasting VBG Condition
conditions NNS None
. . None
-DOCSTART- -X- N

treatment-resistant JJ Condition
aggressive JJ Condition
children NNS Condition
. . Condition
61 CD None
treatment-resistant JJ None
, , None
hospitalized VBN None
school-aged JJ None
children NNS None
. . None
undersocialized JJ None
, , None
aggressive JJ None
, , None
with IN None
a DT None
profile NN None
of IN None
highly RB None
explosive JJ None
and CC None
aggressive JJ None
behavior NN None
. . None
Children NNP None
were VBD None
assessed VBN None
at IN None
the DT None
end NN None
of IN None
a DT None
two-week JJ None
placebo-baseline JJ None
period NN None
and CC None
again RB None
after IN None
four CD None
weeks NNS None
of IN None
treatment NN None
. . None
-DOCSTART- -X- N

dependent JJ Condition
amphetamine NN Condition
users NNS None
. . None
dependent JJ Condition
amphetamine NN Condition
users NNS None
Amphetamine JJ None
users NNS None
( ( None
n JJ None
= NNP None
19 CD Size
) ) None
were VBD None
divided VBN None
into IN None
two CD None
groups NNS None
, , None
high JJ None
dependence NN None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
and CC None
low JJ None
dependence NN None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
, , None
based VBN None
on IN None
amphetamine JJ None
Severity NNP None
of IN None
Dependence NNP None
Scale NNP None
scores NNS None
, , None
and CC None
compared VBN None
to TO None
an DT None
age-matched JJ None
control NN None
group NN None
( ( None
n JJ None
= NNP None
9 CD Condition
) ) None
. . None
dependent JJ None
users NNS None
-DOCSTART- -X- N

outpatient JJ None
paediatric JJ None
anaesthesia NN None
. . None
31 CD Age
oral JJ Age
midazolam-atropine NN Age
premedicated VBD Age
children NNS Age
aged VBN Age
6.9 CD Age
( ( Age
s.e NN Age
. . Age
0.4 CD None
) ) None
years NNS None
who WP None
had VBD None
been VBN None
anaesthetised VBN Condition
with IN Condition
either DT Condition
propofol/alfentanil/N2O NN Condition
or CC Condition
thiopentone/halothane/N2O NN Condition
. . None
-DOCSTART- -X- N

middle-aged JJ None
and CC None
older JJR None
adults NNS None
. . None
decreased JJ Condition
central JJ Condition
arterial JJ Condition
compliance NN Condition
in IN None
young JJ None
men NNS None
. . None
older JJR None
adults NNS None
with IN None
reduced JJ Condition
baseline NN Condition
arterial JJ Condition
compliance NN Condition
. . None
middle-aged JJ None
and CC None
older JJR None
adults NNS None
. . None
37 CD Size
healthy JJ Condition
, , None
sedentary JJ Condition
men NNS Sex
and CC None
women NNS Sex
( ( None
52+/-2 JJ Age
years NNS Age
) ) None
performed VBD None
13 CD None
weeks NNS None
of IN None
ST NNP None
( ( None
n=13 NN None
) ) None
, , None
ST+aerobic NNP None
exercise NN None
( ( None
n=12 JJ None
) ) None
or CC None
stretching VBG None
exercises NNS None
Participants NNS None
were VBD None
rigorously RB None
screened VBN None
for IN None
cardiovascular JJ Condition
disease NN Condition
and CC None
underwent JJ None
pre-post JJ None
testing NN None
for IN None
carotid JJ Condition
arterial JJ Condition
compliance NN Condition
( ( None
via IN None
simultaneous JJ None
ultrasound NN None
and CC None
applanation NN None
tonometry NN None
) ) None
, , None
carotid-femoral JJ None
pulse NN None
wave NN None
velocity NN None
, , None
plasma JJ None
endothelin-1 NN None
and CC None
angiotensin NN None
II NNP None
concentrations NNS None
and CC None
carotid JJ None
artery NN None
vasoreactivity NN None
( ( None
cold JJ None
pressor NN None
test NN None
) ) None
middle-aged JJ None
and CC None
older JJR None
adults NNS None
. . None
-DOCSTART- -X- N

type NN None
1 CD None
diabetes NNS None
for IN None
patients NNS None
with IN None
long-standing JJ None
poor JJ None
glycemic JJ None
control NN None
. . None
type JJ Condition
1 CD Condition
diabetic JJ Condition
patients NNS None
with IN None
long-standing JJ None
poor JJ Condition
glycemic JJ Condition
control NN Condition
. . None
A NNP None
total NN None
of IN None
79 CD Size
patients NNS None
in IN None
11 CD None
Dutch NN None
centers NNS None
patients NNS None
with IN None
a DT None
history NN None
of IN None
long-term JJ None
poor JJ Condition
glycemic JJ Condition
control NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
experience JJ None
trauma NN Condition
to TO Condition
the DT Condition
trigeminal JJ Condition
nerve NN Condition
during IN Condition
orthognathic JJ Condition
surgery NN Condition
, , None
impairing VBG None
sensation NN None
and CC None
sensory JJ None
function NN None
on IN None
the DT None
face NN None
. . None
people NNS None
who WP None
performed VBD None
sensory JJ None
re-training JJ None
exercises NNS None
reported VBD None
the DT None
retrained JJ None
persons NNS None
exhibited VBD None
less RBR None
impairment JJ None
-DOCSTART- -X- N

thrombotic JJ Condition
disorders NNS Condition
. . Condition
venous JJ Condition
thromboembolism NN Condition
( ( Condition
VTE NNP Condition
) ) Condition
in IN None
the DT None
orthopedic JJ None
surgical JJ None
setting NN None
. . None
acute JJ Condition
coronary JJ Condition
syndromes NNS Condition
-DOCSTART- -X- N

Premenstrual NNP None
women NNS Sex
with IN None
laparoscopically RB None
diagnosed VBN None
endometriosis NN None
who WP None
required VBD None
GnRH NNP None
agonist JJ None
therapy NN None
for IN None
treatment NN None
and CC None
did VBD None
not RB None
have VB None
significant JJ None
depressive JJ None
or CC None
premenstrual JJ None
mood NN None
symptoms NNS None
at IN None
baseline NN None
. . None
Participants NNPS None
were VBD None
randomly RB None
assigned VBN None
to TO None
either CC None
the DT None
sertraline JJ None
treatment NN None
group NN None
or CC None
to TO None
the DT None
placebo NN None
group NN None
for IN None
the DT None
3-month JJ None
duration NN None
of IN None
the DT None
GnRH NNP None
agonist NN None
therapy NN None
. . None
-DOCSTART- -X- N

adult JJ Age
asthmatic JJ None
patients NNS None
. . None
adult NN None
asthmatic JJ None
patients NNS None
Twenty NNP Size
adult NN None
patients NNS None
with IN None
asthma NNS None
were VBD None
studied VBN None
. . None
no DT None
cardiovascular JJ None
disease NN None
or CC None
medication NN None
. . None
-DOCSTART- -X- N

cirrhosis NN None
: : None
28 CD None
nonazotemic JJ None
cirrhotic JJ None
patients NNS None
with IN None
controlled JJ None
ascites NNS None
. . None
ascites NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
at IN None
the DT None
stable JJ None
phase NN None
] NNP None
. . None
patients NNS None
with IN None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
( ( None
COPD NNP Condition
) ) None
at IN None
the DT None
stable JJ Condition
phase NN Condition
. . None
Thirty-six JJ Size
patients NNS None
with IN None
COPD NNP Condition
patients NNS None
with IN None
COPD NNP None
in IN None
the DT None
stable JJ None
phase NN None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
intellectual JJ None
disabilities NNS None
. . None
parents NNS None
and CC None
Prelinguistic NNP None
Milieu NNP None
Teaching NNP None
for IN None
the DT None
children NNS None
( ( None
RPMT NNP None
) ) None
. . None
Thirty-nine JJ None
prelinguistic JJ None
toddlers NNS None
with IN None
intellectual JJ None
disabilities NNS None
and CC None
their PRP$ None
primary JJ None
caregivers NNS None
participated VBD None
in IN None
this DT None
study NN None
. . None
-DOCSTART- -X- N

male JJ Sex
adolescents NNS Age
adolescents NNS None
18 CD Size
male NN Sex
adolescents NNS Age
-DOCSTART- -X- N

venepuncture NN Condition
. . None
venous JJ Condition
cannulation NN Condition
. . None
120 CD Size
children NNS Age
. . None
-DOCSTART- -X- N

Norfloxacin NNP None
modulates VBZ None
the DT None
inflammatory JJ None
response NN None
and CC None
directly RB None
affects VBZ None
neutrophils NNS None
in IN None
patients NNS None
with IN None
decompensated JJ Condition
cirrhosis NN Condition
. . None
Patients NNPS None
with IN None
cirrhosis NN Condition
undergoing VBG None
selective JJ None
intestinal JJ None
decontamination NN None
with IN None
norfloxacin JJ None
Thirty-one CD Size
patients NNS None
with IN None
cirrhosis NN None
receiving VBG None
norfloxacin NN None
( ( None
400 CD None
mg/day NN None
) ) None
were VBD None
included VBN None
. . None
Fifty-nine JJ None
ascitic JJ None
fluid NN None
samples NNS None
patients NNS None
with IN None
cirrhosis NN Condition
. . None
-DOCSTART- -X- N

diabetic JJ Condition
foot NN Condition
wounds NNS Condition
. . None
patients NNS None
treated VBN None
with IN None
negative-pressure JJ None
wound NN None
therapy NN None
( ( None
NPWT NNP None
) ) None
162 CD Size
diabetic JJ Condition
patients NNS None
with IN None
post-amputation JJ Condition
wounds NNS Condition
( ( None
up IN None
to TO None
the DT None
trans-metatarsal JJ None
level NN None
) ) None
Patients NNS None
randomized VBD None
to TO None
V.A.C NNP None
. . None
( ( None
n JJ None
= NNP None
77 CD Size
) ) None
received VBD None
therapy NN None
with IN None
dressing NN None
changes NNS None
Control NN None
patients NNS None
( ( None
n JJ None
= NNP None
85 CD Size
) ) None
received VBN None
standard JJ None
MWT NNP None
. . None
groups NNS None
in-patient JJ None
hospital NN None
stay NN None
patient NN None
diabetic JJ Condition
patients NNS None
with IN None
post NN Condition
amputation NN Condition
wounds VBZ Condition
-DOCSTART- -X- N

patients NNS None
with IN None
osteoarthritis NN Condition
. . None
osteoarthritis NN Condition
( ( Condition
OA NNP Condition
) ) Condition
of IN Condition
the DT Condition
hip NN Condition
and CC Condition
knee NN Condition
. . None
548 CD Condition
patients NNS Condition
( ( None
median JJ None
age NN None
63 CD Age
years NNS Age
) ) None
with IN None
OA NNP Condition
of IN Condition
the DT Condition
hip NN Condition
or CC Condition
knee NN Condition
were VBD None
randomized VBN None
OA NNP Condition
of IN Condition
the DT Condition
hip NN Condition
and CC Condition
knee NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
prostate JJ Condition
cancer NN Condition
. . Condition
men NNS None
with IN None
prostate NN Condition
cancer NN Condition
-DOCSTART- -X- N

recurrent NN None
chronic JJ None
hyperplastic JJ None
sinusitis NN None
with IN None
nasal JJ None
polyposis NN None
. . None
One CD None
hundred JJ None
seventy NN None
patients NNS None
with IN None
bilateral JJ None
obstructive CD None
or CC None
minimally RB None
obstructive JJ None
chronic JJ None
hyperplastic JJ None
sinusitis NN None
with IN None
nasal JJ None
polyposis NN None
. . None
All DT None
patients NNS None
were VBD None
surgically RB None
treated VBN None
in IN None
the DT None
ENT NNP None
Department NNP None
, , None
University NNP None
of IN None
Siena NNP None
Medical NNP None
School NNP None
. . None
One CD None
month NN None
after IN None
surgery NN None
1 CD None
patients NNS None
patients NNS None
treated VBN None
with IN None
furosemide NN None
or CC None
mometasone NN None
patients NNS None
who WP None
did VBD None
not RB None
receive VB None
any DT None
treatment NN None
chronic JJ None
hyperplastic JJ None
sinusitis NN None
with IN None
nasal JJ None
polyposis NN None
. . None
-DOCSTART- -X- N

diabetic JJ Condition
patients NNS None
after IN None
amputation NN Condition
for IN None
gangrene NN Condition
: : None
II NNP None
. . None
231 CD Size
non-insulin-dependent JJ Condition
diabetic JJ Condition
men NNS None
with IN None
either DT None
a DT None
recent JJ None
amputation NN None
for IN None
gangrene NN Condition
or CC None
active JJ None
gangrene NN Condition
. . None
-DOCSTART- -X- N

90 CD Size
ASA NNP Condition
class NN Condition
I-II NNP Condition
urologic JJ Condition
patients NNS None
during IN None
extracorporeal JJ None
shock NN None
wave NN None
lithotripsy NN None
. . None
six CD None
groups NNS None
-DOCSTART- -X- N

Hodgkin NNP Condition
's POS Condition
disease NN Condition
in IN None
childhood NN Age
and CC None
adolescence NN Age
: : None
72 CD Size
children NNS Age
and CC None
adolescents NNS Age
( ( None
aged VBN None
5 CD None
to TO None
19 CD None
years NNS None
old JJ None
, , None
median JJ None
16 CD None
) ) None
with IN None
Hodgkin NNP Condition
's POS Condition
disease NN Condition
, , None
clinical JJ None
stages NNS None
IA-IIB NNP None
( ( None
IA NNP None
, , None
18 CD None
; : None
II2A NNP None
, , None
two CD None
areas NNS None
involved VBN None
on IN None
the DT None
same JJ None
side NN None
of IN None
the DT None
diaphragm NN None
, , None
23 CD None
; : None
II3+A NNP None
, , None
three CD None
areas NNS None
or CC None
more JJR None
, , None
16 CD None
; : None
IIB NNP None
, , None
15 CD None
) ) None
Patients NNS None
without IN None
evidence NN None
of IN None
mediastinal JJ Condition
involvement NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
intermediate JJ Condition
and CC Condition
high-grade JJ Condition
non-Hodgkin NN Condition
's POS Condition
lymphoma NN Condition
. . None
Twenty-seven JJ Size
patients NNS None
were VBD None
fully RB None
evaluable JJ None
. . None
-DOCSTART- -X- N

frail JJ Condition
older NN Age
adults NNS Age
: : None
frail JJ Condition
older JJR Age
people NNS Age
living VBG None
in IN None
the DT None
community NN None
. . None
Seattle NNP None
total NN None
of IN None
201 CD Size
chronically RB None
ill JJ None
older JJR None
adults NNS None
seniors NNS None
aged VBD None
70 CD Age
and CC Age
older JJR Age
recruited VBN None
through IN None
medical JJ None
practices NNS None
. . None
101 CD Size
intervention NN None
participants NNS None
chronically RB Condition
ill JJ Condition
older JJR None
adults NNS None
. . None
-DOCSTART- -X- N

female JJ Sex
undergraduate JJ Sex
students NNS Sex
( ( Sex
n=342 NN Sex
) ) Sex
. . Sex
women NNS Sex
's POS Sex
-DOCSTART- -X- N

the DT None
elderly JJ Age
visually RB Condition
impaired VBN Condition
. . None
the DT None
elderly JJ None
with IN None
age-related JJ Condition
macular JJ Condition
degeneration NN Condition
A DT None
total NN None
of IN None
229 CD Size
persons NNS None
were VBD None
randomized VBN None
to TO None
the DT None
study NN None
elderly JJ None
with IN None
decreased JJ None
vision NN None
-DOCSTART- -X- N

actinic JJ Condition
keratosis NN Condition
Actinic NNP Condition
keratosis NN Condition
28 CD Size
patients NNS Size
with IN None
a DT None
clinical JJ Condition
diagnosis NN Condition
of IN Condition
actinic JJ Condition
keratosis NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
prostate NN Condition
cancer NN Condition
treated VBN None
by IN None
castration NN None
plus CC None
anandron NN None
or CC None
placebo NN None
: : None
399 CD Size
out IN None
of IN None
457 CD Size
patients NNS None
recruited VBN None
in IN None
this DT None
study NN None
were VBD None
divided VBN None
in IN None
a DT None
good JJ None
or CC None
poor JJ None
prognostic JJ None
group NN None
depending VBG None
on IN None
the DT None
presence NN None
of IN None
two CD None
or CC None
more JJR None
poor JJ None
prognostic JJ None
factors NNS None
, , None
these DT None
were VBD None
pain NN None
requiring VBG None
treatment NN None
, , None
> VBZ None
5 CD None
bone NN None
metastases NNS None
, , None
hydronephrosis NN None
, , None
and CC None
alkaline JJ None
phosphatase NN None
> VBD None
2 CD None
ULN NNP None
. . None
patients NNS None
with IN None
metastatic JJ Condition
prostate NN Condition
cancer NN Condition
-DOCSTART- -X- N

Asperger NNP Condition
Syndrome NNP Condition
. . None
group NN None
of IN None
adults NNS Age
with IN None
Asperger NNP None
Syndrome NNP None
( ( None
AS IN None
) ) None
individuals NNS None
with IN None
AS NNP None
over-detected JJ None
faux NN None
pas NN None
stories NNS None
individuals NNS None
with IN None
AS NNP None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
3 CD None
children NNS None
with IN None
autism NN None
children NNS None
children NNS None
with IN None
autism NN None
-DOCSTART- -X- N

chronic JJ Condition
anti-HBe-positive JJ Condition
hepatitis NN Condition
B NNP Condition
Seventy-two JJ Size
consecutive JJ None
anti-HBe-positive JJ None
chronic NN None
hepatitis NN None
B NNP None
patients NNS None
( ( None
59 CD Size
male NN Sex
and CC None
13 CD Size
female NN Sex
, , None
median JJ None
age NN None
41 CD Age
yr NN Age
) ) None
stratified VBN None
by IN None
sex NN None
and CC None
histology NN None
-DOCSTART- -X- N

human JJ None
pregnancy NN Condition
. . None
32 CD Size
gravid JJ Condition
women NNS Sex
undergoing VBG None
elective JJ Condition
cesarean JJ Condition
section NN Condition
at IN None
term NN None
. . None
-DOCSTART- -X- N

Fifteen JJ Size
subjects NNS None
participated VBN None
in IN None
the DT None
experiment NN None
. . None
-DOCSTART- -X- N

septic JJ Condition
shock NN Condition
: : Condition
adrenal JJ Condition
insufficiency NN Condition
in IN None
septic JJ Condition
shock NN Condition
40 CD Size
patients NNS None
with IN None
septic JJ Condition
shock NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
acquired JJ Condition
immunodeficiency NN Condition
syndrome NN Condition
( ( Condition
AIDS NNP Condition
) ) Condition
/AIDS-related VBD Condition
complex JJ Condition
. . None
patients NNS None
with IN None
acquired JJ Condition
immunodeficiency NN Condition
syndrome NN Condition
( ( Condition
AIDS NNP Condition
) ) None
or CC None
AIDS-related JJ Condition
complex NN Condition
( ( Condition
ARC NNP Condition
) ) Condition
who WP None
were VBD None
intolerant JJ None
to TO None
zidovudine VB None
because IN None
of IN None
neutropenia NN Condition
A DT None
total NN None
of IN None
17 CD Size
patients NNS None
were VBD None
entered VBN None
Five CD Size
of IN None
eight CD Size
patients NNS None
in IN None
group NN None
A NNP None
and CC None
seven CD Size
of IN None
nine CD Size
in IN None
group NN None
B NNP None
had VBD None
a DT None
history NN None
of IN None
Pneumocystis NNP Condition
carinii NN Condition
pneumonia NN Condition
( ( Condition
PCP NNP Condition
) ) Condition
. . None
All DT None
were VBD None
homosexual JJ None
males NNS Sex
, , None
except IN None
one CD Size
female NN Sex
in IN None
group NN None
A NNP None
who WP None
was VBD None
the DT None
sex NN None
partner NN None
of IN None
a DT None
bisexual JJ None
male NN None
with IN None
AIDS NNP Condition
. . None
All DT None
patients NNS None
had VBD None
neutropenia VBN Condition
-DOCSTART- -X- N

rabbits NNS None
under IN None
high JJ None
ambient JJ None
temperature NN None
. . None
rabbits NNS None
Rabbits NNS None
oxidation NN None
. . None
Rabbits NNS None
in IN None
rabbits NNS None
under IN None
-DOCSTART- -X- N

patients NNS None
who WP None
had VBD None
received VBN None
a DT None
hip NN Condition
replacement NN Condition
. . None
258 CD None
patients NNS None
were VBD None
evaluated VBN None
. . None
-DOCSTART- -X- N

Lead-exposed JJ None
Children NNP None
( ( None
TLC NNP None
) ) None
toddlers NNS None
. . None
young JJ None
children NNS None
Lead-Exposed JJ None
Children NNP None
lead-exposed JJ None
children NNS None
Baltimore NNP None
, , None
Cincinnati NNP None
and CC None
Columbus NNP None
, , None
Newark NNP None
and CC None
Philadelphia NNP None
. . None
Children NNP None
were VBD None
eligible JJ None
for IN None
TLC NNP None
if IN None
they PRP None
were VBD None
between IN None
12 CD None
and CC None
33 CD None
months NNS None
of IN None
age NN None
, , None
had VBD None
a DT None
confirmed VBN None
blood NN None
lead NN None
concentration NN None
between IN None
20 CD None
and CC None
44 CD None
micrograms/dL NN None
and CC None
lived VBD None
in IN None
a DT None
residence NN None
suitable JJ None
for IN None
lead JJ None
dust NN None
reduction NN None
. . None
children NNS None
A DT None
total NN None
of IN None
1854 CD None
children NNS None
were VBD None
evaluated VBN None
and CC None
780 CD None
children NNS None
were VBD None
randomised VBN None
between IN None
August NNP None
1994 CD None
and CC None
January NNP None
1997 CD None
. . None
The DT None
mean JJ None
age NN None
of IN None
randomised JJ None
children NNS None
was VBD None
24 CD None
months NNS None
and CC None
mean VB None
blood NN None
lead JJ None
level NN None
26 CD None
micrograms/dL NN None
. . None
Three-quarters NNS None
were VBD None
African-American JJ None
. . None
Most JJS None
children NNS None
had VBD None
poor JJ None
, , None
single JJ None
mothers NNS None
who WP None
had VBD None
completed VBN None
12 CD None
or CC None
fewer JJR None
years NNS None
of IN None
school NN None
and CC None
who WP None
lived VBD None
in IN None
older JJR None
, , None
poorly RB None
maintained VBD None
residences NNS None
. . None
-DOCSTART- -X- N

idiopathic JJ Condition
club JJ Condition
foot NN Condition
in IN None
infants NNS None
: : None
after IN None
surgery NN None
for IN None
club JJ None
foot NN None
. . None
24 CD None
of IN None
27 CD Size
consecutive JJ None
children NNS None
with IN None
a DT None
mean JJ None
age NN None
of IN None
24 CD None
months NNS None
( ( None
5 CD None
to TO None
75 CD None
) ) None
following VBG None
posteromedial JJ None
release NN None
for IN None
idiopathic JJ None
club JJ None
foot NN None
. . None
-DOCSTART- -X- N

obese JJ None
breast NN None
cancer NN None
survivors NNS None
. . None
women NNS None
who WP None
have VBP None
had VBN None
breast VBN None
cancer NN None
obese JJ None
women NNS None
who WP None
have VBP None
had VBD None
a DT None
diagnosis NN None
of IN None
breast NN None
cancer NN None
. . None
Forty-eight JJ None
women NNS None
( ( None
body NN None
mass NN None
index NN None
of IN None
30 CD None
to TO None
44 CD None
kg/m NNS None
( ( None
2 CD None
) ) None
) ) None
were VBD None
enrolled VBN None
. . None
-DOCSTART- -X- N

unexplained JJ None
syncope NN None
: : None
vasovagal JJ None
syncope NN None
. . None
patients NNS None
with IN None
unexplained JJ None
syncope NN None
and CC None
healthy JJ None
controls NNS None
. . None
Forty-eight NNP None
patients NNS None
with IN None
unexplained JJ None
syncope NN None
and CC None
negative JJ None
passive JJ None
head-up NN None
tilt NN None
at IN None
70 CD None
degrees NNS None
for IN None
40 CD None
min NN None
, , None
and CC None
14 CD None
healthy JJ None
controls NNS None
negative JJ None
passive JJ None
head-up NN None
tilt NN None
-DOCSTART- -X- N

high JJ Condition
risk NN Condition
trauma NN Condition
patients NNS None
: : None
A DT None
group NN None
of IN None
48 CD Size
critically RB Condition
injured JJ Condition
patients NNS None
-DOCSTART- -X- N

subjects NNS None
with IN None
chronic JJ None
psoriasis NN None
. . None
36 CD None
subjects NNS None
with IN None
chronic JJ None
plaque NN None
psoriasis NN None
. . None
-DOCSTART- -X- N

non-small JJ None
cell NN None
lung NN None
cancer NN None
: : None
patients NNS None
with IN None
or CC None
without IN None
nodal JJ None
micrometastases NNS None
patients NNS None
with IN None
non-small JJ None
cell NN None
lung NN None
cancer NN None
. . None
Lymph NNP None
nodes NNS None
from IN None
patients NNS None
( ( None
n=94 NN None
) ) None
patients NNS None
without IN None
an DT None
early JJ None
locoregional JJ None
spread NN None
of IN None
cancer NN None
cells NNS None
. . None
-DOCSTART- -X- N

patients NNS None
participating VBG None
in IN None
a DT None
psychosocial JJ Condition
intervention NN Condition
program NN Condition
. . None
post-myocardial JJ Condition
infarction NN Condition
patients NNS None
who WP None
participated VBD None
in IN None
a DT None
randomized JJ None
trial NN None
of IN None
home-based JJ None
psychosocial JJ None
nursing NN None
interventions NNS None
( ( None
the DT None
Montreal NNP Condition
Heart NNP Condition
Attack NNP Condition
Readjustment NNP None
Trial NNP None
[ NNP None
M-HART NNP None
] NNP None
) ) None
. . None
433 CD Size
patients NNS None
( ( None
36.0 CD None
% NN None
women NNS Sex
) ) None
from IN None
the DT None
M-HART NNP None
treatment NN None
group NN None
who WP None
received VBD None
two CD None
home NN None
visits NNS None
after IN None
achieving VBG None
a DT None
high JJ None
psychological JJ None
distress NN None
score NN None
( ( None
ie JJ None
, , None
> JJ None
or CC None
=5 NN None
) ) None
on IN None
the DT None
General NNP None
Health NNP None
Questionnaire NNP None
( ( None
GHQ NNP None
) ) None
. . None
men NNS Sex
and CC None
women NNS Sex
men NNS Sex
and CC None
women NNS Sex
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
essential JJ Condition
hypertension NN Condition
. . None
group NN None
of IN None
16 CD Size
essential JJ None
hypertensive JJ None
patients NNS None
. . None
-DOCSTART- -X- N

periodontal JJ None
furcation NN None
pockets NNS None
46 CD None
upper JJ None
and CC None
lower JJR None
molars NNS None
with IN None
furcation NN None
grade NN None
II NNP None
involvement NN None
16 CD None
patients NNS None
with IN None
periodontal JJ None
disease NN None
-DOCSTART- -X- N

children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
. . None
children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
. . None
children NNS None
with IN None
autistic JJ None
disorder NN None
accompanied VBN None
by IN None
severe JJ None
tantrums NNS None
, , None
aggressive JJ None
and/or NN None
self-injurious JJ None
behaviors NNS None
. . None
children NNS None
and CC None
adolescents NNS None
with IN None
autistic JJ None
disorder NN None
. . None
-DOCSTART- -X- N

Patients NNP None
scheduled VBD None
to TO None
undergo VB None
ESD NNP None
for IN None
early JJ Condition
gastric JJ Condition
cancer NN Condition
or CC Condition
adenoma NN Condition
were VBD None
randomly RB None
assigned VBN None
to TO None
sedation NN None
with IN None
midazolam NN None
or CC None
propofol NN None
, , None
and CC None
consciousness JJ None
level NN None
was VBD None
evaluated VBN None
by IN None
bispectral JJ None
index NN None
( ( None
BIS NNP None
) ) None
monitoring NN None
. . None
we PRP None
178 CD Size
patients NNS None
patients NNS None
after IN None
ESD NNP None
-DOCSTART- -X- N

recurrent NN Condition
or CC Condition
persistent JJ Condition
nasopharyngeal NN Condition
carcinomas NN Condition
after IN Condition
radiotherapy NN Condition
residual JJ None
nasopharyngeal NN None
carcinomas NN None
( ( None
NPC NNP Condition
) ) None
Thirty NNP Size
six CD Size
NPC NNP None
patients NNS None
underwent JJ None
head NN None
and CC None
neck NN None
CT NNP None
, , None
Tc-MIBI NNP None
SPECT NNP None
, , None
and CC None
FDG-PET NNP None
four CD None
months NNS None
after IN None
radiotherapy NN None
36 CD None
patients NNS None
. . None
No DT None
patients NNS None
had VBD None
multiple JJ None
foci NN None
of IN None
NPC NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
migraine NN None
. . None
Forty-one CD None
migraine JJ None
subjects NNS None
( ( None
26 CD None
males NNS None
, , None
15 CD None
females NNS None
) ) None
, , None
mean JJ None
age NN None
36 CD None
+/- JJ None
2 CD None
years NNS None
( ( None
range VB None
36-39 CD None
years NNS None
) ) None
, , None
and CC None
20 CD None
healthy JJ None
control NN None
subjects NNS None
( ( None
14 CD None
males NNS None
, , None
six CD None
females NNS None
) ) None
, , None
mean JJ None
age NN None
36 CD None
+/- JJ None
2 CD None
years NNS None
( ( None
range VB None
36-39 CD None
years NNS None
) ) None
patients NNS None
without IN None
hypertension NN None
and CC None
other JJ None
cardiovascular JJ None
disease NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
Asperger NNP Condition
syndrome NN Condition
children NNS Age
with IN None
Asperger NNP Condition
syndrome NN Condition
( ( Condition
AS IN Condition
) ) Condition
Forty-nine JJ Size
children NNS Age
with IN None
AS NNP Condition
children NNS Age
with IN None
AS NNP Condition
-DOCSTART- -X- N

hepatocellular JJ Condition
carcinoma NN Condition
. . None
hepatocellular JJ None
carcinoma NN None
Twenty NNP Size
patients NNS None
with IN None
hepatocellular JJ None
carcinoma NN None
measuring VBG None
< $ None
25 CD None
mm NN None
-DOCSTART- -X- N

15 CD Size
adult NN Age
subjects NNS None
diagnosed VBN None
with IN None
autism NN Condition
or CC Condition
Asperger NNP Condition
's POS Condition
disorder NN Condition
, , None
and CC None
comprehension NN None
of IN None
affective JJ None
speech NN None
( ( None
happy JJ None
, , None
indifferent JJ None
, , None
angry JJ None
, , None
and CC None
sad NN None
) ) None
-DOCSTART- -X- N

children NNS Age
, , Age
adolescents NNS Age
, , Age
and CC Age
adults NNS Age
with IN Age
mental JJ Age
retardation NN Age
and CC Age
pervasive JJ Age
developmental NN Age
disorders NNS Age
. . Age
children NNS Age
, , Age
adolescents NNS Age
, , Age
and CC Age
adults NNS Age
with IN Age
mental JJ Age
retardation NN Age
( ( Age
MR NNP Age
) ) Age
and CC Age
pervasive JJ Age
developmental NN Age
disorders NNS Age
( ( Age
PDD NNP Age
) ) Age
. . Age
children NNS Condition
, , Condition
adolescents NNS Condition
, , Condition
and CC Condition
adults NNS Condition
with IN Condition
MR NNP Condition
and CC Condition
PDDs NNP Condition
21-subject JJ None
subset NN None
during IN None
the DT None
course NN None
of IN None
a DT None
double-blind JJ None
, , None
placebo-controlled JJ None
trial NN None
. . None
children NNS Age
and CC Age
adolescents NNS Age
( ( Age
n=10 NN Age
) ) Age
, , Age
mean JJ Age
age NN Age
of IN Age
12.5 CD Age
years NNS Age
adults NNS Age
, , Age
mean JJ Age
age NN Age
of IN Age
35.3 CD Age
years NNS Age
-DOCSTART- -X- N

Two CD Size
hundred CD Size
and CC Size
twenty-nine JJ Size
adult NN Age
patients NNS None
with IN None
differentiated JJ None
thyroid NN Condition
cancer NN Condition
requiring VBG None
radioiodine NN None
WBS NNP None
were VBD None
studied VBN None
. . None
patients NNS None
with IN None
disease NN None
or CC None
tissue NN None
limited VBN None
to TO None
the DT None
thyroid NN None
bed NN None
100 CD None
% NN None
of IN None
patients NNS None
, , None
respectively RB None
, , None
with IN None
metastatic JJ Condition
disease NN Condition
. . None
patients NNS None
with IN None
disease NN None
or CC None
tissue NN None
limited VBN None
to TO None
the DT None
thyroid NN None
bed NN None
patients NNS None
with IN None
metastatic JJ Condition
disease NN Condition
. . None
patients NNS None
undergoing JJ None
evaluation NN None
for IN None
thyroid JJ Condition
cancer NN Condition
persistence NN None
and CC None
recurrence NN None
. . None
-DOCSTART- -X- N

10 CD Size
consecutive JJ None
patients NNS None
with IN None
a DT None
minute NN None
ventilation-sensing NN None
, , None
rate-modulating JJ None
ventricular JJ None
pacemaker NN None
implanted VBN None
for IN None
complete JJ None
heart NN None
block NN None
. . None
All DT None
patients NNS None
had VBD None
paroxysmal JJ Condition
( ( None
seven CD Size
patients NNS None
) ) None
or CC None
chronic JJ None
( ( None
three CD Size
patients NNS None
) ) None
atrial JJ Condition
fibrillation NN Condition
and CC None
were VBD None
referred VBN None
for IN None
catheter JJR None
ablation NN None
of IN None
the DT None
atrioventricular JJ None
junction NN None
. . None
-DOCSTART- -X- N

primary JJ Condition
open-angle JJ Condition
glaucoma NN Condition
-- : None
results NNS None
black JJ None
Jamaican JJ None
population NN None
. . None
48 CD None
eyes NNS None
of IN None
30 CD Size
black JJ None
Jamaican JJ None
patients NNS None
with IN None
primary JJ Condition
open-angle JJ Condition
glaucoma NN Condition
. . None
All DT None
eyes NNS None
had VBD None
uncontrolled VBN Condition
intra-ocular JJ Condition
pressures NNS Condition
( ( Condition
greater JJR Condition
than IN Condition
or CC Condition
equal JJ Condition
to TO Condition
22 CD Condition
mm NNS Condition
Hg NNP Condition
) ) Condition
despite IN None
medical JJ None
therapy NN None
. . None
Jamaican NNP None
glaucoma NN Condition
patients NNS None
. . None
-DOCSTART- -X- N

pregnant JJ None
women NNS Sex
southern JJ Condition
India NNP Condition
. . None
pregnant JJ None
women NNS None
225 CD None
anaemic JJ None
pregnant JJ None
women NNS None
control NN None
group NN None
A NNP None
control NN None
group NN None
B NNP None
pregnant JJ None
women NNS None
-DOCSTART- -X- N

young JJ Age
healthy JJ Condition
women NNS Sex
. . None
96 CD Size
healthy JJ Condition
undergraduate JJ None
women NNS Sex
-DOCSTART- -X- N

children NNS None
with IN None
ASD NNP None
: : None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
. . None
( ( None
N NNP None
= NNP None
70 CD None
) ) None
Parents NNS None
of IN None
children NNS None
with IN None
more RBR None
advanced JJ None
language NN None
skills NNS None
-DOCSTART- -X- N

antiretroviral-naive JJ Condition
HIV-infected JJ Condition
adults NNS Age
: : None
antiretroviral-naive JJ Condition
patients NNS None
over IN None
48 CD None
weeks NNS None
. . None
-DOCSTART- -X- N

growing VBG None
turkeys NNS None
of IN None
different JJ None
ages NNS None
. . None
growing VBG None
turkeys NNS None
at IN None
4 CD Age
, , Age
8 CD Age
and CC Age
12 CD Age
weeks NNS Age
of IN None
age NN None
. . None
-DOCSTART- -X- N

women NNS Sex
who WP None
have VBP None
a DT None
negative JJ Condition
colposcopic NN Condition
examination NN Condition
or CC Condition
who WP Condition
have VBP Condition
no DT Condition
cervical JJ Condition
intraepithelial JJ Condition
neoplasia NN Condition
( ( Condition
CIN NNP Condition
) ) Condition
on IN Condition
colposcopic NN Condition
biopsy NN Condition
551 CD Size
women NNS Sex
who WP None
had VBD None
colposcopy NN None
in IN None
Wales NNP None
for IN None
a DT None
low-grade JJ Condition
cytological JJ Condition
abnormality NN Condition
and CC None
who WP None
were VBD None
followed VBN None
through IN None
Cervical NNP None
Screening NNP None
Wales NNP None
for IN None
subsequent JJ None
CIN NNP None
. . None
women NNS Sex
with IN None
a DT None
negative JJ Condition
colposcopy NN Condition
or CC Condition
a DT Condition
biopsy NN Condition
without IN Condition
CIN NNP Condition
. . None
-DOCSTART- -X- N

women NNS Sex
women NNS None
receiving VBG Condition
depot NN Condition
medroxyprogesterone NN Condition
injections NNS Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
non-ulcer JJ Condition
dyspepsia NN Condition
. . None
non-ulcer JJ Condition
dyspepsia NN Condition
patients NNS None
. . None
129 CD Size
H. NNP None
pylori NN Condition
infected VBD Condition
patients NNS None
with IN None
severe JJ Condition
epigastric JJ Condition
pain NN Condition
, , None
without IN Condition
gastro-oesophageal JJ Condition
reflux NN Condition
symptoms NNS None
124 CD Size
such JJ None
patients NNS None
to TO None
receive VB None
identical-appearing JJ None
placebos NNS None
. . None
non-infected JJ Condition
patients NNS None
patients NNS None
with IN None
non-ulcer JJ Condition
dyspepsia NN Condition
H. NNP None
pylori-infected JJ Condition
patients NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
conditions NNS None
and CC None
severe JJ None
sleep NN Condition
problems NNS Condition
not RB None
amenable JJ None
to TO None
behaviour VB None
management NN None
strategies NNS None
: : None
Twenty-two JJ Size
children NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
who WP None
had VBD None
not RB None
responded VBN None
to TO None
supported VB None
behaviour JJ None
management NN None
strategies NNS None
for IN None
severe JJ None
dysomnias NN Condition
17 CD Size
children NNS Age
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

STEMI NNP None
Austrian JJ None
multi-centre JJ None
randomized VBN None
ReoPro-BRIDGING NN None
Study NNP None
. . None
ReoPro-BRIDGING JJ None
Austrian JJ None
multi-centre NN None
study NN None
Fifty-five JJ Sex
patients NNS Sex
with IN Sex
STEMI NNP Sex
were VBD Sex
randomized VBN Sex
either RB Sex
to TO Sex
start VB Sex
abciximab NN Sex
( ( Sex
0.25 CD Sex
mg/kg NN Sex
bolus NN Sex
followed VBN Sex
by IN Sex
10 CD Sex
microg/min NNS Sex
infusion NN Sex
) ) Sex
during IN Sex
the DT Sex
organization NN Sex
phase NN Sex
for IN Sex
pPCI NN Sex
( ( Sex
Group NNP Sex
1 CD Sex
, , Sex
n=28 NN Sex
) ) Sex
or CC Sex
immediately RB Sex
before IN Sex
pPCI NN Sex
( ( Sex
Group NNP Sex
2 CD Sex
, , Sex
n=27 NN Sex
) ) Sex
. . Sex
-DOCSTART- -X- N

third JJ Condition
stage NN Condition
of IN Condition
labor NN Condition
. . None
Three CD Size
hundred VBD Size
and CC Size
fifty-five JJ Size
women NNS Size
third JJ Condition
stage NN Condition
of IN Condition
labor NN Condition
-DOCSTART- -X- N

atrial JJ Condition
fibrillation NN Condition
: : None
patients NNS None
with IN None
AF NNP None
. . None
Patients NNS None
with IN None
persistent JJ Condition
AF NNP Condition
or CC None
AF NNP Condition
induced VBD Condition
during IN None
a DT None
routine JJ None
electrophysiology NN Condition
study NN Condition
( ( None
EPS NNP None
) ) None
patients NNS None
with IN None
induced JJ None
AF NNP None
AF NNP None
in IN None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
left JJ Condition
ventricular JJ Condition
dysfunction NN Condition
. . None
Urban NNP None
teaching VBG None
hospital JJ None
clinical JJ None
research NN None
center NN None
. . None
Individuals NNS None
with IN None
New NNP None
York NNP None
Heart NNP None
Association NNP None
functional JJ None
class NN None
II-III NNP None
heart NN Condition
failure NN Condition
( ( None
mild JJ None
to TO None
moderate VB None
) ) None
. . None
patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
heart NN Condition
failure NN Condition
. . None
-DOCSTART- -X- N

low JJ Condition
dose VBP Condition
intravenous JJ Condition
urography NN Condition
. . None
392 CD None
patients NNS None
-DOCSTART- -X- N

adults NNS Age
with IN None
type JJ Condition
1 CD Condition
diabetes NNS Condition
. . None
intensively RB Age
treated VBN Age
adults NNS Age
with IN None
type JJ Condition
1 CD Condition
diabetes NNS Condition
. . None
83 CD Age
of IN Age
86 CD Age
individuals NNS Age
> JJ Age
or=25 CD Age
years NNS Age
of IN Age
age NN Age
with IN None
type JJ None
1 CD None
diabetes NNS None
who WP None
used VBD None
CGM NNP None
as IN None
part NN None
of IN None
a DT None
6-month JJ None
randomized JJ None
clinical JJ None
trial NN None
in IN None
a DT None
subsequent JJ None
6-month JJ None
extension NN None
study NN None
. . None
intensively RB None
treated VBN None
adults NNS Age
with IN None
type JJ Condition
1 CD Condition
diabetes NNS Condition
-DOCSTART- -X- N

secondary JJ Condition
hyperparathyroidism NN Condition
in IN None
stages NNS Condition
3 CD Condition
and CC Condition
4 CD Condition
CKD NNP Condition
. . None
secondary JJ None
hyperparathyroidism NN None
( ( None
SHPT NNP Condition
) ) None
in IN None
patients NNS None
with IN None
chronic JJ Condition
kidney NN Condition
disease NN Condition
( ( None
CKD NNP Condition
) ) None
stage NN Condition
5 CD Condition
. . None
Three NNP None
randomized VBD None
, , None
placebo-controlled JJ None
, , None
phase-3 JJ None
trials NNS None
were VBD None
conducted VBN None
in IN None
patients NNS None
with IN None
stages NNS None
3 CD None
and CC None
4 CD None
CKD NNP None
with IN None
SHPT NNP None
. . None
Enrollment NNP None
criteria NNS None
included VBD None
an DT None
estimated VBN None
glomerular JJ None
filtration NN None
rate NN None
between IN None
15 CD None
and CC None
60 CD None
mL/min/1.73 NN None
m2 NN None
( ( None
0.25 CD None
and CC None
1.00 CD None
mL/s/1.73 NNS None
m2 NN None
) ) None
, , None
an DT None
average NN None
of IN None
2 CD None
consecutive JJ None
intact JJ None
parathyroid NN None
hormone NN None
( ( None
iPTH NN None
) ) None
levels NNS None
greater JJR None
than IN None
150 CD None
pg/mL NN None
( ( None
ng/L JJ None
) ) None
, , None
2 CD None
consecutive JJ None
serum NN None
calcium NN None
levels NNS None
between IN None
8.0 CD None
and CC None
10.0 CD None
mg/dL NN None
( ( None
2.00 CD None
and CC None
2.50 CD None
mmol/L NN None
) ) None
, , None
and CC None
2 CD None
consecutive JJ None
serum NN None
phosphorus NN None
levels NNS None
of IN None
5.2 CD None
mg/dL NN None
or CC None
less JJR None
( ( None
< NN None
or CC None
= $ None
1.68 CD None
mmol/L NN None
) ) None
. . None
Two CD Size
hundred VBD Size
twenty NN Size
patients NNS None
participated VBD None
( ( None
n JJ None
= NN None
107 CD Size
, , None
paricalcitol NN None
; : None
n CC None
= $ None
113 CD Size
, , None
placebo NN None
) ) None
. . None
-DOCSTART- -X- N

posterior JJ Condition
uveitis NN Condition
noninfectious JJ Condition
posterior JJ Condition
uveitis NN Condition
. . None
0.59-mg JJ None
FA NNP None
intravitreous JJ None
implant NN None
in IN None
110 CD Size
patients NNS None
and CC None
the DT None
2.1-mg JJ None
FA NNP None
intravitreous JJ None
implant NN None
in IN None
168 CD Size
patients NNS None
. . None
subjects NNS None
with IN None
noninfectious JJ Condition
posterior JJ Condition
uveitis NN Condition
. . None
-DOCSTART- -X- N

children NNS Condition
diagnosed VBN Condition
with IN Condition
Asperger NNP Condition
syndrome NN Condition
. . Condition
children NNS Condition
diagnosed VBN Condition
with IN Condition
Asperger NNP Condition
syndrome NN Condition
. . Condition
Forty-five JJ None
children NNS None
and CC None
their PRP$ None
parents NNS None
-DOCSTART- -X- N

transurethral JJ None
resections NNS None
] VBP None
short JJ None
procedures NNS None
for IN None
transurethral JJ None
resection NN None
Fifty-seven NNP Size
patients NNS Condition
scheduled VBN Condition
for IN Condition
transurethral JJ Condition
resection NN Condition
of IN Condition
the DT Condition
prostate NN Condition
or CC Condition
a DT Condition
vesical JJ Condition
tumor NN Condition
. . Condition
Patients NNS None
were VBD None
ASA NNP Condition
I-III NNP Condition
, , None
over IN Age
55 CD Age
years NNS Age
of IN Age
age NN Age
-DOCSTART- -X- N

21 CD Condition
patients NNS Condition
with IN Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
who WP Condition
were VBD Condition
receiving VBG Condition
placebo NN Condition
, , Condition
acebutolol NN Condition
, , Condition
and CC Condition
propranolol NN Condition
in IN Condition
a DT Condition
double-blind NN Condition
26 CD None
patients NNS None
with IN None
chronic JJ None
angina NNS None
pectoris VBP None
13 CD None
patients NNS None
with IN None
stable JJ None
angina NNS None
pectoris VBP None
patients NNS None
with IN None
coronary JJ None
disease NN None
and CC None
a DT None
wide JJ None
range NN None
of IN None
ejection NN None
fractions NNS None
reduced VBN None
resting NN None
left VBD None
ventricular JJ None
function NN None
. . None
-DOCSTART- -X- N

abdominal JJ Condition
aortic JJ Condition
aneurysmectomy NN Condition
. . None
university-affiliated JJ None
hospital NN None
and CC None
regional JJ None
referral JJ None
center NN None
. . None
Patients NNP None
undergoing VBG None
elective JJ None
abdominal JJ Condition
aortic JJ Condition
aneurysmectomy NN Condition
( ( None
n=18 JJ Size
per IN None
group NN None
) ) None
. . None
-DOCSTART- -X- N

acute JJ Condition
neck NN Condition
pain NN Condition
: : None
patients NNS None
with IN None
acute JJ Condition
NP NNP Condition
( ( None
n JJ None
= NNP None
72 CD Size
) ) None
were VBD None
treatment NN None
of IN None
acute JJ None
neck NN None
pain NN None
. . None
The DT None
neck NN None
pain NN None
and CC None
improved VBN None
-DOCSTART- -X- N

acute JJ None
allergic JJ None
conjunctivitis NN None
. . None
allergic JJ None
conjunctivitis NN None
. . None
allergic JJ None
conjunctivitis NN None
. . None
acute JJ None
allergic JJ None
conjunctivitis NN None
-DOCSTART- -X- N

gynaecological JJ Condition
day-case NN Condition
surgery NN Condition
. . None
day-case JJ Condition
gynaecological JJ Condition
procedures NNS Condition
was VBD None
evaluated VBN None
in IN None
55 CD Size
healthy JJ Condition
volunteers NNS Condition
in IN None
a DT None
single JJ None
blinded JJ None
fashion NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
autism NN Condition
spectrum NN Condition
disorders NNS Condition
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
Children NNP Age
aged VBD None
between IN None
4 CD Age
; : Age
0 CD Age
and CC Age
6 CD Age
; : Age
11 CD Age
years NNS Age
who WP None
are VBP None
diagnosed VBN None
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
Parents NNS None
of IN None
all DT None
participants NNS None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
-DOCSTART- -X- N

asthma NN Condition
in IN None
adults NNS Age
31 CD Size
adult NN Age
asthmatic JJ Condition
patients NNS None
-DOCSTART- -X- N

crossover NN None
multicentre NN None
study NN None
. . None
66 CD None
uncomplicated JJ None
essential JJ None
hypertensives NNS None
, , None
with IN None
diastolic JJ None
blood NN None
pressure NN None
of IN None
greater JJR None
than IN None
100 CD None
and CC None
less JJR None
than IN None
115 CD None
mmHg NN None
. . None
uncomplicated JJ None
essential JJ None
hypertensives NNS None
. . None
-DOCSTART- -X- N

hyperinsulinemic JJ Condition
subjects NNS None
. . None
subjects NNS None
with IN None
hyperinsulinemia NN Condition
. . None
A DT None
total NN None
of IN None
36 CD Size
obese JJ Condition
nondiabetic JJ None
volunteers NNS None
with IN None
hyperinsulinemia NN Condition
( ( None
10 CD Size
males/26 NN Sex
females NNS Sex
, , None
aged VBD None
34-65 JJ Age
y NN None
, , None
BMI NNP None
28-43 CD None
kg/m NN None
( ( None
2 CD None
) ) None
, , None
fasting VBG None
insulin JJ None
12-45 JJ None
mU/l NN None
) ) None
. . None
subjects NNS None
with IN None
hyperinsulinemia PDT Condition
-DOCSTART- -X- N

patients NNS None
with IN None
left JJ Condition
ventricular JJ Condition
dysfunction NN Condition
. . None
patients NNS None
with IN None
left JJ None
ventricular JJ None
dysfunction NN None
. . None
patients NNS None
with IN None
left JJ None
ventricular JJ None
dysfunction NN None
. . None
6,781 CD Size
patients NNS None
randomized VBN None
into IN None
the DT None
Studies NNPS None
of IN None
Left NNP None
Ventricular NNP None
Dysfunction NNP None
trials NNS None
. . None
-DOCSTART- -X- N

over IN None
1,200 CD None
respondents NNS None
, , None
people NNS None
assigned VBD None
memory NN None
aids NNS None
reported VBD None
over IN None
50 CD None
per IN None
cent NN None
more JJR None
symptom JJ None
episodes NNS None
than IN None
those DT None
not RB None
assigned JJ None
memory NN None
aids NNS None
. . None
-DOCSTART- -X- N

Ninety NNP Size
two CD Size
normal JJ Condition
birthweight JJ Condition
infants NNS Age
aged VBD None
6 CD Age
months NNS Age
-DOCSTART- -X- N

nonmelanoma JJ Condition
skin NN Condition
cancer NN Condition
Nutritional JJ None
Prevention NN None
of IN None
Cancer NNP None
Trial NNP None
was VBD None
a DT None
double-blind JJ None
, , None
randomized VBN None
, , None
placebo-controlled JJ None
clinical JJ None
trial NN None
prevent VB None
nonmelanoma JJ Condition
skin JJ Condition
cancer NN Condition
among IN None
1312 CD Size
patients NNS None
from IN None
the DT None
Eastern NNP Condition
United NNP Condition
States NNPS Condition
who WP None
had VBD None
previously RB Condition
had VBN Condition
this DT Condition
disease NN Condition
. . None
-DOCSTART- -X- N

postmenopausal JJ None
women NNS None
undergoing VBG None
continuous JJ None
combined VBN None
hormonal JJ None
replacement NN None
therapy NN None
( ( None
HRT NNP None
) ) None
. . None
41 CD None
postmenopausal JJ None
women NNS None
obtained VBN None
before IN None
and CC None
1 CD None
year NN None
after IN None
the DT None
initiation NN None
of IN None
HRT NNP None
subjects NNS None
undergoing VBG None
continuous JJ None
combined VBN None
HRT NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
aortic JJ None
valve NN None
disease NN None
. . None
40 CD None
patients NNS None
with IN None
aortic JJ None
valve NNS None
stenosis NN None
( ( None
AS IN None
) ) None
and CC None
20 CD None
patients NNS None
with IN None
aortic JJ None
insufficiency NN None
( ( None
AI NNP None
) ) None
-DOCSTART- -X- N

Three CD None
groups NNS None
of IN None
unimpaired JJ Condition
participants NNS None
trained VBN None
with IN None
the DT None
target NN None
arm JJ None
movement NN None
broken VBD None
down RB None
in IN None
three CD None
ways NNS None
: : None
1 CD None
) ) None
elbow NN None
flexion/extension NN None
and CC None
the DT None
unified JJ None
shoulder NN None
motion NN None
independently RB None
( ( None
anatomical JJ None
decomposition NN None
) ) None
, , None
2 CD None
) ) None
three CD None
component JJ None
shoulder NN None
motions NNS None
in IN None
Euler NNP None
coordinates NNS None
and CC None
elbow JJ None
flexion/extension NN None
( ( None
Euler NNP None
decomposition NN None
) ) None
, , None
or CC None
3 CD None
) ) None
the DT None
motion NN None
of IN None
the DT None
tip NN None
of IN None
the DT None
elbow NN None
and CC None
motion NN None
of IN None
the DT None
hand NN None
with IN None
respect NN None
to TO None
the DT None
elbow NN None
, , None
independently RB None
( ( None
visual JJ None
decomposition NN None
) ) None
. . None
less JJR None
experience NN None
with IN None
the DT None
target NN None
motion NN None
-DOCSTART- -X- N

rheumatoid JJ None
arthritis NN None
with IN None
special JJ None
regard NN None
to TO None
morning NN None
stiffness NN None
and CC None
pain NN None
on IN None
awakening VBG None
. . None
8 CD None
centres NNS None
out-patients NNS None
with IN None
definite NN None
or CC None
classical JJ None
rheumatoid NN None
arthritis NN None
. . None
83 CD None
evaluable JJ None
patients NNS None
-DOCSTART- -X- N

milk NN None
production NN None
of IN None
dairy NN None
cattle NNS None
in IN None
Canada NNP None
Gastrointestinal NNP Condition
nematodes NNS Condition
, , None
such JJ None
as IN None
Ostertagia NNP Condition
ostertagi NN Condition
and CC None
several JJ Condition
species NNS Condition
of IN Condition
Cooperia NNP Condition
, , None
are VBP None
ubiquitous JJ None
in IN None
temperate NN None
climates NNS None
and CC None
have VBP None
been VBN None
shown VBN None
to TO None
have VB None
detrimental JJ None
effects NNS None
on IN None
production NN None
in IN None
adult NN None
dairy NN None
cattle NNS None
. . None
lose VBP None
approximately RB None
0.35 CD None
kg NNS None
of IN None
milk NN None
per IN None
parasitized VBN None
cow NN None
per IN None
day NN None
. . None
ELISA JJ None
results NNS None
from IN None
individual JJ None
cow NN None
milk NN None
samples NNS None
were VBD None
used VBN None
to TO None
predict VB None
milk NN None
production NN None
response NN None
-DOCSTART- -X- N

severe JJ None
low-output JJ None
heart NN None
failure NN None
: : None
patients NNS None
with IN None
low-output JJ None
heart NN None
failure NN None
. . None
203 CD None
patients NNS None
with IN None
severe JJ None
heart NN None
failure NN None
-DOCSTART- -X- N

4,724 CD Size
patients NNS None
took VBD None
part NN None
in IN None
IES NNP None
, , None
and CC None
206 CD Size
patients NNS None
were VBD None
included VBN None
in IN None
a DT None
bone NN None
sub-study NN None
. . None
-DOCSTART- -X- N

Pharmacokinetics NNS None
of IN None
azithromycin NN None
in IN None
lung NN None
tissue NN None
, , None
bronchial JJ None
washing NN None
, , None
and CC None
plasma NN None
in IN None
patients NNS None
given VBN None
multiple JJ None
oral JJ None
doses NNS None
of IN None
500 CD None
and CC None
1000 CD None
mg JJ None
daily RB None
. . None
pharmacokinetics NNS None
of IN None
azithromycin NN None
-DOCSTART- -X- N

Seven NNP None
healthy JJ None
subjects NNS None
patients NNS None
with IN None
ischaemic JJ None
heart NN None
disease NN None
. . None
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
. . None
75 CD None
healthy JJ None
volunteers NNS None
( ( None
8 CD None
subjects NNS None
in IN None
each DT None
of IN None
the DT None
10 CD None
cohorts NNS None
; : None
5 CD None
subjects NNS None
participated VBN None
in IN None
two CD None
cohorts NNS None
) ) None
were VBD None
randomized VBN None
( ( None
6:2 CD None
) ) None
-DOCSTART- -X- N

80 CD None
adults NNS Age
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

seasonal JJ Condition
allergic JJ Condition
conjunctivitis NN Condition
: : None
ocular JJ Condition
itching NN Condition
associated VBN None
with IN None
AC NNP Condition
in IN None
subjects NNS None
enrolled VBN None
in IN None
a DT None
natural JJ None
exposure NN None
trial NN None
. . None
Eligible JJ None
subjects NNS None
-DOCSTART- -X- N

analgesia NN None
in IN None
labour NN None
. . None
during IN None
labour NN None
. . None
We PRP None
studied VBD None
41 CD Size
pregnant JJ None
women NNS Sex
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
spotty JJ None
calcification NN None
total NN None
of IN None
1,347 CD Size
stable JJ None
patients NNS None
with IN None
angiographic JJ None
coronary JJ None
artery NN None
disease NN None
Patients NNS None
with IN None
spotty JJ None
calcification NN None
were VBD None
identified VBN None
based VBN None
on IN None
the DT None
presence NN None
of IN None
lesions NNS None
( ( None
1 CD None
to TO None
4 CD None
mm NNS None
in IN None
length NN None
) ) None
containing VBG None
an DT None
arc NN None
of IN None
calcification NN None
of IN None
< $ None
90? CD None
Patients NNS None
with IN None
spotty JJ None
calcification NN None
were VBD None
older JJR None
( ( None
age NN None
56 CD None
years NNS None
vs. IN None
years NNS None
; : None
p VBZ None
= $ None
0.001 CD None
) ) None
, , None
more RBR None
likely JJ None
to TO None
be VB None
male JJ None
( ( None
68 CD None
% NN None
vs. FW None
% NN None
; : None
patients NNS None
with IN None
spotty JJ None
calcification NN None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN Condition
children NNS Age
( ( Age
5-12 CD Age
years NNS Age
) ) Age
with IN None
autism NN Condition
55 CD Condition
children NNS None
-DOCSTART- -X- N

women NNS Condition
versus IN Condition
men NNS Condition
. . Condition
Nuclear JJ None
medicine NN None
laboratory NN None
in IN None
a DT None
university-affiliated JJ None
hospital NN None
. . None
Consecutive JJ None
patients NNS None
who WP None
were VBD None
referred VBN None
for IN None
evaluation NN None
of IN None
known VBN None
or CC None
suspected VBN None
coronary JJ None
artery NN None
disease NN None
. . None
Patients NNS None
were VBD None
judged VBN None
not RB None
to TO None
be VB None
able JJ None
to TO None
exercise VB None
adequately RB None
. . None
men NNS None
and CC None
women NNS None
. . None
women NNS None
and CC None
men NNS None
. . None
-DOCSTART- -X- N

dynamic JJ Condition
hip NN Condition
screw NN Condition
and CC None
the DT None
gamma NN Condition
locking VBG Condition
nail NN Condition
. . None
200 CD Size
petrochanteric JJ Condition
femoral JJ Condition
fractures NNS Condition
in IN None
elderly JJ Age
patients NNS None
. . None
-DOCSTART- -X- N

African JJ None
American JJ None
hypertensives NNS Condition
: : None
hypertensive JJ Condition
African JJ None
Americans NNPS None
( ( None
n JJ None
= NNP None
88 CD Size
) ) None
on IN None
a DT None
low JJ None
salt NN None
( ( None
100 CD None
mEq NNS None
Na+/day NNP None
) ) None
hypertensive JJ Condition
African JJ None
Americans NNPS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
human JJ Condition
immunodeficiency NN Condition
virus NN Condition
infection NN Condition
. . None
human JJ Condition
immunodeficiency NN Condition
virus NN Condition
type NN Condition
1 CD Condition
( ( Condition
HIV-1 NNP Condition
) ) Condition
12 CD Condition
HIV-infected JJ None
patients NNS None
( ( None
mean JJ None
[ NNP None
+/- JJ None
standard NN None
deviation NN None
] NNP None
CD4+ NNP None
cell NN None
count NN None
, , None
304 CD None
+/- JJ None
213/mm3 CD None
) ) None
were VBD None
enrolled VBN None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
. . None
children NNS None
with IN None
autism NN None
to TO None
act VB None
as IN None
dolphin JJ None
trainers NNS None
at IN None
the DT None
poolside NN None
and CC None
to TO None
learn VB None
( ( None
nonverbal JJ None
) ) None
communication NN None
through IN None
hand NN None
gestures NNS None
with IN None
the DT None
virtual JJ None
dolphins NNS None
. . None
children NNS None
with IN None
autism NN None
helping VBG None
children NNS None
with IN None
autism NN None
-DOCSTART- -X- N

In IN None
SUSTAIN NNP None
, , None
172 CD None
patients NNS None
with IN None
low JJ Condition
levels NNS Condition
of IN Condition
HDL-C NNP Condition
will MD None
be VB None
randomized VBN None
In IN None
ASSURE NNP None
, , None
310 CD None
patients NNS None
with IN None
angiographic JJ Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
and CC None
low JJ None
HDL-C NNP None
levels NNS None
will MD None
be VB None
randomized VBN None
-DOCSTART- -X- N

Seventy-three JJ Size
patients NNS None
undergoing VBG None
elective JJ Condition
perianal JJ Condition
surgery NN Condition
-DOCSTART- -X- N

eczema NN Condition
: : None
Seventy-two JJ Size
patients NNS None
with IN None
eczema NNS Condition
-DOCSTART- -X- N

health NN None
economics NNS None
of IN None
realtime NN None
teledermatology NN None
compared VBN None
with IN None
conventional JJ None
care NN None
: : None
urban JJ None
versus NN None
rural JJ None
perspective NN None
. . None
patients NNS None
from IN None
urban JJ None
and CC None
rural JJ None
areas NNS None
. . None
Over IN None
two CD None
years NNS None
, , None
274 CD Size
patients NNS None
required VBD None
a DT None
hospital JJ None
outpatient NN None
dermatology NN None
referral JJ None
-- : None
126 CD Size
patients NNS None
( ( None
46 CD None
% NN None
) ) None
urban JJ None
patients NNS None
rural JJ None
patients NNS None
. . None
in IN None
urban JJ None
areas NNS None
in IN None
rural JJ None
areas NNS None
-DOCSTART- -X- N

normotensive JJ Condition
patients NNS None
with IN None
advanced JJ Condition
malignancies NNS Condition
. . None
advanced JJ Condition
cancer NN Condition
patients NNS Condition
. . None
41 CD Condition
normotensive JJ Condition
advanced VBD Condition
solid JJ Condition
tumor NN Condition
patients NNS Condition
findings NNS None
in IN None
normotensive JJ None
patients NNS None
suggest VBP None
-DOCSTART- -X- N

patients NNS None
with IN None
C. NNP None
difficile-associated JJ None
diarrhea NN None
( ( None
CDAD NNP None
) ) None
77 CD None
patients NNS None
with IN None
CDAD NNP None
patients NNS None
with IN None
CDAD NNP None
individuals NNS None
with IN None
CDAD NNP None
-DOCSTART- -X- N

gastric JJ None
cancer NN None
of IN None
the DT None
cardia NN None
or CC None
subcardia NN None
: : None
gastric JJ None
cancer NN None
of IN None
the DT None
cardia NN None
or CC None
subcardia NN None
. . None
Between NNP None
July NNP None
, , None
1995 CD None
, , None
and CC None
December NNP None
, , None
2003 CD None
, , None
167 CD None
patients NNS None
were VBD None
enrolled VBN None
from IN None
27 CD None
Japanese JJ None
hospitals NNS None
The DT None
projected JJ None
sample NN None
size NN None
was VBD None
302 CD None
. . None
After IN None
the DT None
first JJ None
interim JJ None
analysis NN None
, , None
the DT None
predicted JJ None
probability NN None
of IN None
LTA NNP None
having VBG None
a DT None
significantly RB None
better RBR None
overall JJ None
survival NN None
than IN None
TH NNP None
at IN None
the DT None
final JJ None
analysis NN None
was VBD None
only RB None
3.65 CD None
% NN None
, , None
and CC None
the DT None
trial NN None
was VBD None
closed VBN None
immediately RB None
. . None
patients NNS None
with IN None
cancer NN None
of IN None
the DT None
cardia NN None
or CC None
subcardia NN None
-DOCSTART- -X- N

patients NNS None
with IN None
amyotrophic JJ Condition
lateral JJ Condition
sclerosis NN Condition
. . None
Fifty-seven CD Size
patients NNS None
with IN None
amyotrophic JJ Condition
lateral JJ Condition
sclerosis NN Condition
( ( Condition
ALS NNP Condition
) ) Condition
patients NNS None
with IN None
ALS NNP Condition
-DOCSTART- -X- N

mild NN None
and CC None
moderate JJ None
hypertension NN Condition
. . None
22 CD Size
patients NNS None
with IN None
mild JJ Condition
or CC Condition
moderate JJ Condition
essential JJ Condition
hypertension NN Condition
-DOCSTART- -X- N

pain NN None
relief NN None
during IN None
labor NN Condition
. . None
Fifty-nine NNP Size
full JJ None
term NN None
parturients NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
one CD None
of IN None
two CD None
groups NNS None
in IN None
active JJ Condition
labor NN Condition
. . None
-DOCSTART- -X- N

Outcomes NNS None
in IN None
patients NNS None
with IN None
diabetes NNS Condition
mellitus VBP Condition
undergoing VBG Condition
percutaneous JJ Condition
coronary JJ Condition
intervention NN Condition
in IN None
the DT None
current JJ None
era NN None
: : None
patients NNS None
undergoing VBG Condition
percutaneous JJ Condition
coronary JJ Condition
intervention NN Condition
( ( None
PCI NNP Condition
) ) None
. . None
patients NNS None
undergoing VBG Condition
PCI NNP Condition
in IN None
the DT None
current JJ None
era NN None
. . None
The DT None
11 CD Size
482 CD Size
patients NNS None
enrolled VBN None
in IN None
the DT None
Prevention NNP None
of IN None
REStenosis NNP None
with IN None
Tranilast NNP None
and CC None
its PRP$ None
Outcomes NNP None
( ( None
PRESTO NNP None
) ) None
Trial NNP None
-DOCSTART- -X- N

growth NN None
hormone-deficient JJ None
women NNS None
. . None
GH-deficient NNP None
( ( None
GHD NNP None
) ) None
women NNS None
In IN None
two CD None
separate JJ None
studies NNS None
, , None
eight CD None
GHD NNP None
women NNS None
GHD NNP None
women NNS None
GHD NNP None
women NNS None
-DOCSTART- -X- N

employed NNS None
depressed JJ Condition
patients NNS None
: : None
employed JJ None
patients NNS None
with IN None
major JJ Condition
depressive JJ Condition
disorder NN Condition
( ( Condition
MDD NNP Condition
) ) Condition
. . None
Gainfully NNP None
employed VBD None
( ( None
?20 NNP None
h/wk NN None
) ) None
male NN None
and CC None
female JJ None
outpatients NNS None
with IN None
MDD NNP None
were VBD None
randomly RB None
assigned VBN None
( ( None
2:1 CD None
ratio NN None
) ) None
to TO None
12 CD None
weeks NNS None
of IN None
double-blind JJ None
treatment NN None
with IN None
desvenlafaxine JJ None
50 CD None
mg/d NN None
or CC None
placebo NN None
. . None
population NN None
. . None
A DT None
predefined JJ None
, , None
modified VBD None
ITT NNP None
population NN None
( ( None
ie JJ None
, , None
those DT None
in IN None
the DT None
ITT NNP None
population NN None
with IN None
baseline JJ None
HAM-D?? NNP None
?20 NN None
) ) None
was VBD None
MDD NNP None
in IN None
gainfully RB None
employed VBN None
adults NNS None
. . None
-DOCSTART- -X- N

resuscitation NN Condition
-- : Condition
head JJ Condition
blunt NN None
head NN None
injury NN None
patients NNS None
. . None
air NN None
and CC None
land NN None
emergency NN None
medical JJ None
services NNS None
and CC None
2 CD None
trauma NN None
centers NNS None
serving VBG None
a DT None
population NN None
of IN None
4 CD Size
million CD Size
people NNS Size
. . Size
study NN None
population NN None
consisted VBD None
of IN None
head NN None
injured VBN None
, , None
blunt VB None
trauma JJ None
adult NN Condition
patients NNS None
with IN None
a DT None
Glasgow NNP Condition
Coma NNP Condition
Scale NNP None
of IN None
lower JJR None
than IN None
9 CD None
. . None
132 CD Size
eligible JJ Size
patients NNS Size
, , None
113 CD Size
were VBD None
randomized VBN None
. . None
Nineteen NNP None
eligible JJ None
patients NNS None
blunt NN Condition
trauma NN Condition
patients NNS Condition
with IN Condition
head JJ Condition
injuries NNS Condition
; : Condition
-DOCSTART- -X- N

autism NN Condition
and CC None
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
. . None
thousands NNS None
of IN None
children NNS None
with IN None
autistic JJ Condition
disorders NNS Condition
60 CD Size
children NNS Age
( ( None
age NN None
, , None
3 CD Age
to TO Age
14 CD Age
years NNS Age
) ) None
with IN None
autism NN None
or CC None
pervasive JJ None
developmental JJ None
disorder NN None
. . None
60 CD None
children NNS None
, , None
4 CD None
could MD None
not RB None
be VB None
evaluated VBN None
56 CD None
children NNS None
( ( None
28 CD Size
in IN None
each DT None
group NN None
) ) None
completed VBD None
the DT None
study NN None
. . None
children NNS None
-DOCSTART- -X- N

sweating NN None
threshold NN None
gain NN None
of IN None
sweating VBG None
. . None
Six NNP None
healthy JJ None
male NN None
volunteers NNS None
were VBD None
evaluated VBN None
-DOCSTART- -X- N

12 CD Size
healthy JJ None
young JJ None
volunteers NNS None
. . None
-DOCSTART- -X- N

tracheal JJ None
intubating NN None
conditions NNS None
60 CD Size
patients NNS None
-DOCSTART- -X- N

type NN None
2 CD None
diabetic JJ None
patients NNS None
: : None
45 CD None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
mellitus FW None
( ( None
DM NNP None
) ) None
Forty-five JJ None
patients NNS None
with IN None
type JJ None
2 CD None
DM NNP None
initially RB None
were VBD None
compared VBN None
with IN None
15 CD None
healthy JJ None
controls NNS None
matched VBN None
for IN None
age NN None
and CC None
sex NN None
. . None
type JJ None
2 CD None
DM NNP None
healthy JJ None
individuals NNS None
-DOCSTART- -X- N

carvedilol NN None
in IN None
humans NNS None
. . None
healthy JJ None
volunteers NNS None
after IN None
a DT None
single JJ None
i.v NN None
. . None
and CC None
oral JJ None
administration NN None
-DOCSTART- -X- N

Psoriasis NN Condition
of IN Condition
the DT Condition
scalp NN Condition
40 CD Size
patients NNS None
Gy NNP None
of IN None
Grenz NNP None
rays NNS None
37 CD Size
patients NNS None
who WP None
completed VBD None
the DT None
trial NN None
patients NNS None
who WP None
healed VBD None
-DOCSTART- -X- N

bacteriuria NN Condition
in IN Condition
elderly JJ Condition
women NNS Condition
. . Condition
bacteriuria NN None
in IN None
a DT None
group NN None
of IN None
non-catheterized JJ None
elderly JJ None
women NNS None
Thirty-one JJ None
women NNS None
received VBD None
single-dose JJ None
treatment NN None
and CC None
22 CD None
conventional-dose JJ None
treatment NN None
. . None
selected VBN None
elderly JJ None
women NNS None
with IN None
bacteriuria NN None
-DOCSTART- -X- N

patients NNS None
with IN None
high JJ Condition
normal JJ Condition
blood NN Condition
pressure NN Condition
and/or RB None
high JJ Condition
normal JJ Condition
blood NN Condition
glucose NN Condition
( ( Condition
SNAC NNP Condition
) ) Condition
: : None
individuals NNS None
with IN None
high JJ Condition
risk NN Condition
for IN Condition
disease NN Condition
patients NNS None
at IN None
risk NN None
( ( None
ie JJ None
high-normal JJ Condition
blood NN Condition
pressure NN Condition
or CC Condition
impaired JJ Condition
glucose JJ Condition
tolerance NN Condition
) ) None
. . None
Staged NNP None
Nutrition NNP None
and CC None
Activity NNP None
Counseling NNP None
( ( None
SNAC NNP None
) ) None
study NN None
cardiovascular JJ None
disease NN None
risk NN None
factors NNS None
and CC None
vascular JJ None
function NN None
in IN None
patients NNS None
at IN None
risk NN None
in IN None
primary JJ None
care NN None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASDs NNP None
) ) None
. . None
72 CD None
Danish JJ None
children NNS None
( ( None
aged VBN Age
4 CD Age
years NNS Age
to TO Age
10 CD Age
years NNS Age
11 CD Age
months NNS Age
) ) None
assigned VBD None
to TO None
diet VB None
( ( None
A DT None
) ) None
or CC None
non-diet JJ None
( ( None
B NNP None
) ) None
groups NNS None
by IN None
stratified JJ None
randomisation NN None
. . None
26 CD None
diet JJ None
children NNS None
and CC None
29 CD None
controls NNS None
children NNS None
diagnosed VBN None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

humans NNS None
. . None
Scopolamine-induced JJ None
cognitive JJ None
impairment NN None
was VBD None
used VBN None
in IN None
healthy JJ None
men NNS None
Eighteen JJ None
subjects NNS None
-DOCSTART- -X- N

healthy JJ Condition
human JJ Condition
volunteers NNS None
: : None
healthy JJ Condition
human JJ Condition
volunteers NNS None
. . None
Forty NNP Size
healthy JJ None
subjects NNS None
healthy JJ Condition
volunteers NNS None
-DOCSTART- -X- N

acute JJ None
bronchitis NN None
. . None
patients NNS None
with IN None
acute JJ None
bronchitis NN None
three CD None
primary JJ None
care NN None
centers NNS None
in IN None
North NNP None
Carolina NNP None
. . None
140 CD None
patients NNS None
presenting VBG None
with IN None
acute JJ None
bronchitis NN None
were VBD None
tested VBN None
for IN None
M NNP None
pneumoniae NN None
, , None
91 CD None
of IN None
whom WP None
were VBD None
treated VBN None
patients NNS None
with IN None
acute JJ None
bronchitis NN None
-DOCSTART- -X- N

individuals NNS None
with IN None
chronic JJ Condition
ankle NN Condition
instability NN Condition
. . None
chronic JJ Condition
ankle NN Condition
instability NN Condition
( ( Condition
CAI NNP Condition
) ) Condition
. . None
individuals NNS None
with IN None
CAI NNP Condition
. . None
Forty-three JJ Size
subjects NNS None
-DOCSTART- -X- N

acute JJ Condition
myocardial JJ Condition
infarction NN Condition
: : Condition
A DT None
total NN None
of IN None
269 CD Size
patients NNS None
, , None
who WP None
presented VBD None
with IN None
symptoms NNS None
and CC None
electrocardiographic JJ None
signs NNS None
suggesting VBG None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
were VBD None
randomized VBN None
to TO None
acute VB None
intravenous JJ None
and CC None
subsequent JJ None
oral JJ None
therapy NN None
with IN None
propranolol NN None
( ( None
n JJ None
= NNP None
134 CD None
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= NNP None
135 CD None
) ) None
. . None
patients NNS None
with IN None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
-DOCSTART- -X- N

Comparison NNP None
of IN None
synemol JJ None
cream NN None
and CC None
other JJ None
topical JJ None
corticosteroid NN None
creams NNS None
using VBG None
the DT None
vasoconstrictor NN None
bioassay NN None
. . None
human JJ None
vasoconstrictor NN None
bioassay NN None
open JJ None
applications NNS None
of IN None
Synemol NNP None
cream NN None
( ( None
0.025 CD None
% NN None
) ) None
, , None
Diprosone NNP None
cream NN None
( ( None
0.05 CD None
% NN None
) ) None
, , None
Aristocort-A NNP None
cream NN None
( ( None
0.5 CD None
% NN None
) ) None
, , None
and CC None
Valisone NNP None
cream NN None
( ( None
0.1 CD None
% NN None
) ) None
. . None
vasoconstriction NN None
-DOCSTART- -X- N

patients NNS None
with IN None
schizophrenia NN Condition
. . None
Forty-seven JJ Size
patients NNS None
with IN None
schizophrenia JJ Condition
meeting NN None
criteria NNS None
for IN None
deficit NN Condition
syndrome NN Condition
Thirty-nine JJ Size
patients NNS None
-DOCSTART- -X- N

endometriosis-related JJ None
infertility NN None
patients NNS None
endometriosis NN None
( ( None
EMs NNP None
) ) None
-related VBD None
infertility NN None
patients NNS None
130 CD None
EMs-related JJ None
infertility NN None
patients NNS None
of IN None
blood NN None
stasis NN None
and CC None
toxin NN None
accumulation NN None
syndrome NN None
diagnosed VBD None
and CC None
treated VBN None
by IN None
laparoscopic NN None
surgery NN None
-DOCSTART- -X- N

patients NNS None
with IN None
primary JJ Condition
Raynaud NNP Condition
's POS Condition
phenomenon NN Condition
in IN None
South NNP None
Korea NNP None
Ninety-three JJ Size
subjects NNS None
Korean JJ Condition
patients NNS None
RP NNP None
patients NNS None
-DOCSTART- -X- N

UK NNP None
registered JJ None
population NN None
aged VBD None
over IN Age
65 CD Age
years NNS Age
in IN None
east JJ None
London NNP None
practices NNS None
. . None
East NNP None
London NNP None
and CC None
Essex NNP None
network NN None
of IN None
researchers NNS None
( ( None
ELENoR NNP None
) ) None
. . None
Participants NNS None
were VBD None
1,820 CD Size
low-risk JJ None
patients NNS None
aged VBD None
65 CD Age
to TO Age
74 CD Age
years NNS None
who WP None
had VBD None
not RB None
previously RB None
been VBN None
in IN None
a DT None
recall NN None
system NN None
for IN None
influenza JJ None
immunisation NN None
at IN None
their PRP$ None
general JJ None
practice NN None
. . None
patients NNS None
making VBG None
a DT None
telephone NN None
appointment NN None
low-risk JJ None
older JJR None
population NN None
in IN None
inner-city JJ None
areas NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
Sj?gren NNP None
's POS None
syndrome JJ None
] NN None
. . None
in IN None
patients NNS None
with IN None
Sj?gren NNP None
's POS None
Syndrome NNP None
( ( None
SS NNP None
) ) None
in IN None
METHODS NNP None
Fifty-seven JJ None
middle-aged JJ None
and CC None
old JJ None
women NNS None
with IN None
SS NNP None
were VBD None
Sj?gren NNP None
's POS None
Syndrome NNP None
patients NNS None
and CC None
-DOCSTART- -X- N

inpatient JJ None
treatment NN None
of IN None
cocaine NN None
dependence NN None
. . None
cocaine NN None
addiction NN None
. . None
66 CD None
recently RB None
abstinent JJ None
cocaine-dependent JJ None
patients NNS None
on IN None
an DT None
inpatient JJ None
substance NN None
abuse NN None
treatment NN None
unit NN None
utilizing VBG None
an DT None
intensive JJ None
12-step JJ None
milieu-oriented JJ None
psychosocial JJ None
therapy NN None
. . None
-DOCSTART- -X- N

implantable JJ Condition
cardioverter NN Condition
defibrillators NNS Condition
( ( None
ICDs NNP Condition
) ) None
. . None
Patients NNPS Condition
with IN Condition
standard JJ Condition
ICD NNP Condition
indications NNS Condition
undergo VBP None
defibrillation NN None
threshold NN None
testing NN None
( ( None
DFT NNP None
) ) None
at IN None
the DT None
time NN None
of IN None
ICD NNP Condition
implant NN Condition
, , None
with IN None
reconfirmation NN None
of IN None
lowest JJS None
successful JJ None
energy NN None
twice RB None
( ( None
DFT++ NNP None
) ) None
. . None
Enrollment NNP None
is VBZ None
complete JJ None
( ( None
702 CD Size
patients NNS None
) ) None
-DOCSTART- -X- N

myometrium NN None
and CC None
uterine JJ None
myomas NN None
of IN None
gnRH JJ None
analogue-treated JJ None
women NNS None
. . None
women NNS Sex
with IN None
uterine JJ Condition
myomas NN Condition
, , None
untreated VBD Condition
or CC Condition
treated VBN Condition
with IN Condition
GnRH NNP Condition
analogue NN Condition
. . None
females NNS None
with IN None
myomas NN None
-DOCSTART- -X- N

patients NNS None
with IN None
osteoarthritis NN Condition
of IN None
the DT None
knee NN None
. . None
1578 CD None
patients NNS None
with IN None
osteoarthritis JJ None
-DOCSTART- -X- N

Japanese JJ None
familial JJ Condition
hypercholesterolemia NN Condition
. . None
familial JJ Condition
hypercholesterolemia NN Condition
( ( Condition
FH NNP Condition
) ) Condition
24 CD Size
initial JJ None
patients NNS None
, , None
17 CD Size
heterozygous JJ Condition
FH NNP Condition
patients NNS None
( ( None
age NN None
: : None
54.1 CD Age
years NNS None
; : None
5 CD Size
males NNS Sex
) ) None
Fifteen JJ Size
patients NNS None
completed VBD None
the DT None
trial NN None
-DOCSTART- -X- N

full-thickness JJ Condition
rotator NN Condition
cuff NN Condition
tears NNS Condition
: : None
arthroscopic NN None
rotator NN None
cuff NN None
repair NN None
with IN None
and CC None
without IN None
acromioplasty JJ None
. . None
Eighty-six JJ Size
patients NNS None
sixty-eight NN Size
of IN None
them PRP None
completed VBD None
the DT None
study NN None
. . None
Four CD None
participants NNS None
( ( None
9 CD None
% NN None
) ) None
in IN None
the DT None
group NN None
that WDT None
had VBD None
arthroscopic VBN None
cuff JJ None
repair NN None
alone RB None
, , None
one CD None
with IN None
a DT None
Type-2 JJ None
and CC None
three CD None
with IN None
a DT None
Type-3 JJ None
acromion NN None
, , None
required VBN None
additional JJ None
surgery NN None
patients NNS None
who WP None
had VBD None
rotator NN None
cuff NN None
repair NN None
with IN None
or CC None
without IN None
acromioplasty JJ None
. . None
group NN None
-DOCSTART- -X- N

unstable JJ Condition
angina NN None
unstable JJ None
angina NNS None
. . None
patients NNS None
The DT None
study NN None
population NN None
included VBD None
403 CD Size
of IN None
the DT None
original JJ None
479 CD None
patients NNS None
in IN None
the DT None
trial NN None
who WP None
had VBD None
completed VBN None
six CD None
days NNS None
of IN None
blinded JJ None
therapy NN None
without IN None
refractory JJ None
angina NN None
or CC None
myocardial JJ None
infarction NN None
. . None
-DOCSTART- -X- N

postmenopausal JJ None
breast NN None
cancer NN None
survivors NNS None
with IN None
bone JJ None
loss NN None
223 CD None
postmenopausal NN None
breast NN None
cancer NN None
survivors NNS None
postmenopausal NN None
breast NN None
cancer NN None
survivors NNS None
( ( None
BCS NNP None
) ) None
with IN None
bone NN None
loss NN None
Postmenopausal NNP None
BCS NNP None
( ( None
223 CD None
) ) None
-DOCSTART- -X- N

attitude JJ None
certainty NN None
: : None
Attitude NNP None
certainty NN None
attitude NN None
certainty NN None
factor NN None
analysis NN None
and CC None
correlational JJ None
data NNS None
existing VBG None
attitude NN None
strength NN None
-DOCSTART- -X- N

oral JJ Condition
surgery NN Condition
patients NNS Condition
Forty-seven JJ None
subjects NNS None
were VBD None
entered VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

healthy JJ None
postmenopausal NN Condition
women NNS Condition
. . None
Seventy-six NNP Size
healthy JJ None
postmenopausal NN Condition
women NNS Condition
RESULTS NNP None
Seventy-one JJ None
women NNS None
with IN None
a DT None
mean NN None
? . None
SD NNP None
age NN None
of IN None
58.8 CD None
? . None
4.9 CD None
y NN None
-DOCSTART- -X- N

patients NNS None
with IN None
diabetic JJ Condition
macular JJ Condition
edema NN Condition
. . None
Fifty NNP None
eyes NNS None
among IN None
50 CD None
patients NNS None
with IN None
DME NNP None
, , None
retinal JJ None
thickness NN None
? . None
300 CD None
microns NNS None
and CC None
best-corrected JJ None
visual JJ None
acuity NN None
( ( None
BCVA NNP None
) ) None
20/40 CD None
to TO None
20/200 CD None
. . None
-DOCSTART- -X- N

following VBG None
sudden JJ None
cardiac JJ Condition
arrest NN Condition
: : None
sudden JJ None
cardiac JJ None
arrest NN None
survivors NNS None
. . None
Survivors NNPS None
of IN None
out-of-hospital JJ None
ventricular JJ None
fibrillation NN None
or CC None
asystole NN None
( ( None
N NNP None
= NNP None
129 CD Size
) ) None
, , None
documented VBN None
by IN None
electrocardiograms NNS None
from IN None
registries NNS None
of IN None
a DT None
citywide NN None
Medic NNP None
One NNP None
unit NN None
and CC None
two CD None
countywide NN None
emergency NN None
units NNS None
sudden JJ None
cardiac JJ None
arrest NN None
survivors NNS None
. . None
-DOCSTART- -X- N

pelvic JJ Condition
inflammatory JJ Condition
disease NN Condition
( ( None
PID NNP Condition
) ) None
. . None
43 CD Size
participants NNS None
, , None
40 CD Size
were VBD None
randomized VBN None
to TO None
tissue VB None
sampling VBG None
. . None
PID NNP None
. . None
-DOCSTART- -X- N

Fourteen JJ None
patients NNS None
with IN None
paired JJ None
intrabony NN None
periodontal JJ None
defects NNS None
of IN None
? . None
4 CD None
mm NN None
participated VBN None
in IN None
-DOCSTART- -X- N

percutaneous JJ None
coronary JJ None
intervention NN None
in IN None
chronic JJ None
total JJ None
occlusion NN None
-- : None
CAtholic NNP None
Total NNP None
Occlusion NNP None
Study NNP None
( ( None
CATOS NNP None
) ) None
trial NN None
. . None
chronic JJ None
total JJ None
occlusion NN None
( ( None
CTO NNP None
) ) None
. . None
patients NNS None
with IN None
CTO NNP None
lesion NN None
with IN None
a DT None
reference NN None
vessel NN None
diameter NN None
? . None
2.5mm CD None
. . None
The DT None
option NN None
in IN None
patients NNS None
undergoing VBG None
PCI NNP None
for IN None
CTO NNP None
with IN None
DESs NNP None
. . None
-DOCSTART- -X- N

hazardous JJ Condition
drinking VBG Condition
college NN Age
students NNS Age
: : None
hazardous JJ Condition
drinking NN Condition
among IN None
university JJ Age
students NNS Age
. . None
One-hundred JJ Size
and CC Size
nineteen JJ Size
introductory NN None
psychology NN None
students NNS None
who WP None
either DT None
had VBD None
two CD None
episodes NNS None
of IN None
heavy JJ None
episodic JJ None
drinking NN None
in IN None
the DT None
past JJ None
month NN None
or CC None
scored VBN None
?8 NNS None
on IN None
the DT None
AUDIT NNP None
participated VBD None
in IN None
this DT None
randomized VBN None
controlled VBD None
trial NN None
for IN None
course NN None
credit NN None
. . None
hazardous JJ None
drinking NN None
students NNS None
who WP None
are VBP None
experiencing VBG None
higher JJR None
levels NNS None
of IN None
alcohol-related JJ None
consequences NNS None
. . None
-DOCSTART- -X- N

childhood NN Age
lymphoblastic JJ Condition
leukaemia NN Condition
: : None
childhood NN Age
lymphoblastic JJ Condition
leukaemia NN Condition
childhood NN None
lymphoblastic JJ None
leukaemia NN None
. . None
Consecutive JJ None
children NNS Age
with IN None
lymphoblastic JJ Condition
leukaemia NN None
diagnosed VBN None
in IN None
the DT None
UK NNP None
and CC None
Ireland NNP None
between IN None
April NNP None
, , None
1997 CD None
, , None
and CC None
June NNP None
, , None
2002 CD None
-DOCSTART- -X- N

2 CD Condition
separate JJ Condition
multicenter NN Condition
388 CD None
patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
uncomplicated JJ None
essential JJ None
hypertension NN None
. . None
-DOCSTART- -X- N

early JJ None
discharge NN None
after IN None
uncomplicated JJ None
myocardial JJ Condition
infarction NN Condition
. . None
383 CD Size
myocardial JJ Condition
infarction NN Condition
( ( Condition
MI NNP Condition
) ) Condition
patients NNS None
aged VBN None
below IN None
70 CD Age
years NNS None
, , None
252 CD Size
( ( None
66 CD None
% NN None
) ) None
were VBD None
judged VBN None
after IN None
the DT None
third JJ None
day NN None
in IN None
hospital NN None
to TO None
have VB None
had VBN None
uncomplicated VBN Condition
infarctions NNS Condition
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
solid JJ Condition
tumors NNS Condition
. . Condition
fasted JJ None
patients NNS None
Twenty-five JJ None
patients NNS None
-DOCSTART- -X- N

Eighty-three JJ None
technically RB None
successful JJ None
PTA NNP Condition
procedures NNS Condition
were VBD None
studied VBN None
. . None
Fifty-six CD None
were VBD None
for IN None
intermittent JJ None
claudication NN None
, , None
14 CD None
for IN None
ischaemic JJ Condition
rest NN Condition
pain NN Condition
, , None
and CC None
13 CD None
for IN None
non-healing JJ Condition
ulcers NNS Condition
. . None
-DOCSTART- -X- N

early JJ None
thermal JJ None
burns NNS Condition
early JJ None
thermal NN None
burns NNS None
injury NN None
in IN None
adult NN Age
patients NNS None
with IN None
< JJ Condition
40 CD Condition
% NN Condition
total JJ Condition
body NN Condition
surface NN Condition
area NN Condition
( ( Condition
TBSA NNP Condition
) ) None
Seventeen JJ Size
subjects NNS None
were VBD None
randomized VBN None
into IN None
control NN None
( ( None
n JJ None
= NNP None
9 CD Size
) ) None
and CC None
HBOT NNP None
treatment NN None
( ( None
n JJ None
= NNP None
8 CD Size
) ) None
arms NNS None
. . None
Two CD None
HBOT NNP None
patients NNS None
and CC None
four CD None
control NN None
patients NNS None
developed VBD None
-DOCSTART- -X- N

bulimia NN Condition
nervosa NN Condition
Ninety-one CD None
female JJ None
bulimic JJ None
outpatients NNS None
depressed JJ Condition
and CC None
nondepressed JJ None
Sixty-eight JJ Size
patients NNS None
who WP None
completed VBD None
the DT None
study NN None
-DOCSTART- -X- N

metabolic JJ None
syndrome NN None
. . None
patients NNS None
with IN None
metabolic JJ Condition
syndrome VBP Condition
subjects NNS None
with IN None
metabolic JJ Condition
syndrome NN Condition
were VBD None
treated VBN None
with IN None
allopurinol NN None
( ( None
n JJ None
= NNP None
28 CD Size
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= NNP None
22 CD Size
) ) None
for IN None
one CD None
month NN None
. . None
patients NNS None
with IN None
metabolic JJ None
syndrome NN None
-DOCSTART- -X- N

outpatients NNS None
with IN None
a DT None
major JJ None
depressive JJ Condition
disorder NN Condition
outpatients NNS None
with IN None
primary JJ Condition
depression NN Condition
-DOCSTART- -X- N

psychogenic JJ Condition
nonepileptic JJ Condition
seizures NNS Condition
: : None
psychogenic JJ Condition
nonepileptic JJ Condition
seizures NNS Condition
( ( Condition
PNES NNP Condition
) ) None
. . None
Sixty-six JJ Size
PNES NNP None
patients NNS None
were VBD None
randomized VBN None
video-EEG JJ None
telemetry NN None
for IN None
most JJS None
patients NNS None
. . None
Exclusion NNP None
criteria NNS None
included VBD None
comorbid JJ None
history NN None
of IN None
epilepsy NN None
, , None
< VBP None
2 CD None
PNES/month NNP None
, , None
and CC None
IQ NNP None
< NNP None
70 CD None
. . None
PNES NNP None
patients NNS None
. . None
patients NNS None
with IN None
PNES NNP Condition
-DOCSTART- -X- N

acute NN Condition
otitis NN Condition
media NNS Condition
in IN Condition
children NNS Condition
under IN Condition
2 CD Condition
years NNS Condition
of IN Condition
age NN Condition
. . Condition
children NNS None
younger JJR None
than IN None
2 CD None
years NNS None
of IN None
age NN None
with IN None
acute JJ None
otitis NN None
media NNS None
. . None
291 CD None
children NNS None
6 CD None
to TO None
23 CD None
months NNS None
of IN None
age NN None
, , None
with IN None
acute JJ None
otitis NN None
media NNS None
diagnosed VBN None
with IN None
the DT None
use NN None
of IN None
stringent NN None
criteria NNS None
children NNS None
6 CD None
to TO None
23 CD None
months NNS None
of IN None
age NN None
with IN None
acute JJ None
otitis NN None
media NNS None
-DOCSTART- -X- N

feline JJ None
chlamydophilosis NN None
. . None
feline JJ None
chlamydophilosis NN None
cats NNS None
within IN None
an DT None
affected JJ None
group NN None
chlamydia NN None
( ( None
Chlamydophila NNP None
felis RB None
) ) None
infection NN None
in IN None
cats NNS None
. . None
five CD None
cats NNS None
treated VBN None
. . None
-DOCSTART- -X- N

volunteers NNS None
. . None
steady-state JJ None
conditions NNS None
in IN None
volunteers NNS None
. . None
12 CD Size
healthy JJ Condition
volunteers NNS None
over IN None
6 CD None
days NNS None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
an DT None
initial JJ None
course NN None
of IN None
chemotherapy NN None
who WP None
report VBP None
pain NN None
and CC None
fatigue NN None
at IN None
baseline NN None
and CC None
who WP None
are VBP None
receiving VBG None
conventional JJ None
care NN None
alone RB None
with IN None
those DT None
receiving VBG None
conventional JJ None
care NN None
plus CC None
a DT None
nursing NN None
intervention NN None
Chemotherapy NNP None
clinics NNS None
of IN None
two CD None
comprehensive JJ None
and CC None
two CD None
community NN None
cancer NN Condition
centers NNS None
. . None
53 CD Size
patients NNS None
in IN None
the DT None
experimental JJ None
arm NN None
and CC None
60 CD Size
in IN None
the DT None
control NN None
arm NN None
who WP None
reported VBD None
pain NN None
and CC None
fatigue NN None
at IN None
baseline NN None
. . None
-DOCSTART- -X- N

in IN None
normal JJ None
male JJ None
college NN None
students NNS None
. . None
-DOCSTART- -X- N

cognitive JJ None
behaviour NN None
therapy NN None
program NN None
for IN None
managing VBG None
chronic JJ None
pain NN None
and CC None
emotional JJ None
well-being NN None
. . None
Sixty-three JJ None
adults NNS None
with IN None
chronic JJ None
pain NN None
were VBD None
randomised VBN None
31 CD None
Treatment NNP None
Group NNP None
participants NNS None
people NNS None
with IN None
chronic JJ None
pain NN None
. . None
-DOCSTART- -X- N

honey-bee JJ None
stings NNS None
patients NNS None
on IN None
the DT None
immediate JJ None
treatment NN None
of IN None
bee JJ None
stings NNS None
-DOCSTART- -X- N

photo NN None
and CC None
age-damaged JJ None
skin NN None
: : None
photoaging NN None
of IN None
facial JJ None
skin NN None
. . None
Fifteen NNP None
female JJ None
volunteers NNS None
were VBD None
enrolled VBN None
; : None
skin NN None
photoaging NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ None
idiopathic JJ None
urticaria NN None
( ( None
CIU NNP None
) ) None
AH-resistant NNP None
and CC None
AH NNP None
responder VBP None
CIU NNP None
patients NNS None
. . None
CIU NNP None
patients NNS None
with IN None
treatment NN None
failure NN None
under IN None
fexofenadine NN None
at IN None
180 CD None
mg NN None
q.d NN None
. . None
Those DT None
with IN None
significant JJ None
improvement NN None
of IN None
urticaria JJ None
activity NN None
score NN None
under IN None
fexofenadine NN None
at IN None
180 CD None
mg NNS None
The DT None
control NN None
group NN None
consisted VBD None
of IN None
sex- JJ None
and CC None
age-matched JJ None
patents NNS None
with IN None
allergic JJ None
rhinitis NN None
. . None
Forty-six JJ None
subjects NNS None
were VBD None
included VBN None
in IN None
the DT None
CIU NNP None
group NN None
, , None
21 CD None
were VBD None
in IN None
the DT None
R-CIU NNP None
group NN None
, , None
and CC None
44 CD None
were VBD None
in IN None
the DT None
control NN None
group NN None
. . None
-DOCSTART- -X- N

gastrointestinal JJ Condition
dysfunction NN Condition
in IN None
children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
. . None
125 CD Size
children NNS None
( ( None
ages VBZ None
2-17 CD Age
years NNS Age
) ) None
with IN None
autism NN Condition
and CC None
persistent JJ None
GI NNP Condition
symptoms NNS Condition
. . None
children NNS Age
with IN None
autism NN Condition
-DOCSTART- -X- N

Western JJ None
Myanmar NNP None
. . None
Western JJ None
Myanmar NNP None
human JJ None
population NN None
4,824 CD Size
female JJ Sex
anopheline NN None
mosquitoes NNS None
916 CD None
person NN None
nights NNS None
yielded VBD None
3,009 CD None
female JJ None
anopheline NN None
mosquitoes NNS None
between IN None
6 CD None
pm NNS None
and CC None
6 CD None
am VBP None
. . None
A DT None
large JJ None
proportion NN None
of IN None
children NNS Age
Western JJ None
Myanmar NNP None
-DOCSTART- -X- N

[ NN None
Evaluating VBG None
an DT None
interactive JJ None
, , None
multi-media JJ None
learning NN None
system NN None
for IN None
the DT None
study NN Condition
of IN Condition
primary JJ Condition
open JJ Condition
angle NN Condition
glaucoma NN Condition
] NNP None
open-angle JJ None
glaucoma NN None
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS None
who WP None
received VBD None
D53 NNP None
immunostimulant NN None
. . None
Twelve VB Size
nonsmoking VBG Condition
healthy JJ Condition
subjects NNS None
respiratory JJ Condition
tract JJ Condition
infection NN Condition
. . None
-DOCSTART- -X- N

whooping JJ Condition
cough NN Condition
. . None
three CD None
Swedish JJ None
hospitals NNS None
. . None
73 CD Size
children NNS Age
aged VBD Age
less JJR Age
than IN Age
36 CD Age
months NNS Age
who WP None
were VBD None
admitted VBN None
with IN None
a DT None
clinical JJ None
diagnosis NN None
of IN None
whooping JJ Condition
cough NN Condition
. . None
47 CD Size
children NNS None
with IN None
less JJR None
than IN None
or CC None
equal JJ None
to TO None
14 CD None
days NNS None
of IN None
disease NN None
before IN None
therapy NN None
. . None
-DOCSTART- -X- N

412 CD Size
patients NNS None
with IN None
hepatitis NN Condition
C NNP Condition
infection NN Condition
-DOCSTART- -X- N

Japanese JJ None
smokers NNS None
: : None
Japanese JJ None
smokers NNS None
. . None
eight CD Sex
male JJ Sex
habitual JJ Sex
smokers NNS Sex
Japanese JJ None
habitual JJ None
smokers NNS None
. . None
-DOCSTART- -X- N

maternal JJ None
mental JJ Condition
health NN Condition
after IN None
a DT None
child NN Condition
's POS Condition
diagnosis NN Condition
of IN Condition
autism NN Condition
spectrum JJ Condition
disorder NN Condition
: : None
mothers NNS Condition
of IN None
children NNS Condition
with IN Condition
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( Condition
ASD NNP Condition
) ) Condition
autism NN None
clinic NN None
and CC None
6 CD None
community-based JJ None
early JJ None
intervention NN None
programs NNS None
that WDT None
primarily RB None
serve VBP None
low-income JJ None
families NNS None
. . None
Participants NNS None
were VBD None
mothers NNS Sex
of IN None
122 CD Size
young JJ None
children NNS None
( ( None
mean JJ None
age NN None
, , None
34 CD None
months NNS None
) ) None
who WP None
recently RB None
received VBD None
a DT None
diagnosis NN Condition
of IN Condition
ASD NNP Condition
. . None
Fifty-nine JJ Size
mothers NNS None
-DOCSTART- -X- N

hypertensive JJ Condition
patients NNS Condition
with IN Condition
stable JJ Condition
angina NN Condition
hypertensive JJ None
patients NNS None
with IN None
stable JJ None
angina NNS None
30 CD Size
hypertensive JJ None
patients NNS None
( ( None
20 CD Size
with IN Size
and CC Size
10 CD Size
without IN Size
stable JJ Size
angina NN Size
) ) None
. . None
-DOCSTART- -X- N

mild JJ None
depressions NNS None
with IN None
somatic JJ None
symptoms NNS None
. . None
39 CD None
patients NNS None
with IN None
depression NN None
with IN None
somatic JJ None
symptoms NNS None
-DOCSTART- -X- N

severe JJ Condition
depression NN Condition
: : None
multicentre NN None
study NN None
was VBD None
conducted VBN None
in IN None
86 CD Size
severely RB None
depressed JJ None
inpatients NNS None
( ( None
> JJ None
or= RB None
25 CD None
on IN None
the DT None
17-item JJ None
Hamilton NNP None
depression NN Condition
rating NN None
scale NN None
[ NNP None
HAMD NNP None
] NNP None
total JJ None
score NN None
) ) None
86 CD Size
patients NNS None
-DOCSTART- -X- N

surgical JJ None
patients NNS None
with IN None
aneurysmal JJ None
subarachnoid JJ None
hemorrhage NN None
. . None
among IN None
patients NNS None
enrolled VBN None
in IN None
the DT None
Intraoperative NNP None
Hypothermia NNP None
for IN None
Aneurysm NNP None
Surgery NNP None
Trial NNP None
. . None
One CD None
thousand NN None
patients NNS None
with IN None
initial JJ None
World NNP None
Federation NNP None
of IN None
Neurological NNP None
Surgeons NNP None
grades NNS None
of IN None
I PRP None
to TO None
III NNP None
undergoing VBG None
clipping NN None
of IN None
intracranial JJ None
aneurysms NNS None
after IN None
subarachnoid JJ None
hemorrhage NN None
were VBD None
randomized VBN None
to TO None
intraoperative VB None
normothermia NN None
( ( None
36 CD None
degrees NNS None
C-37 JJ None
degrees NNS None
C NNP None
) ) None
or CC None
hypothermia NN None
( ( None
32.5 CD None
degrees NNS None
C-33.5 JJ None
degrees NNS None
C NNP None
) ) None
. . None
surgical JJ None
subarachnoid JJ None
hemorrhage NN None
patients NNS None
-DOCSTART- -X- N

root JJ Condition
canal JJ Condition
filling NN Condition
materials NNS None
for IN None
primary JJ Condition
molars NNS Condition
: : None
primary JJ Condition
molars NNS Condition
-DOCSTART- -X- N

161 CD Size
recurrence-free JJ Condition
breast NN Condition
cancer NN Condition
patients NNS None
. . None
breast NN None
cancer NN None
patients NNS None
, , None
treated VBD None
according VBG None
to TO None
the DT None
Danish JJ None
Breast NNP None
Cancer NNP None
Cooperative NNP None
Group NNP None
protocols VBZ None
. . None
One NNP Size
hundred CD Size
and CC Size
sixty-one JJ Size
recurrence-free JJ None
breast NN None
cancer NN None
patients NNS None
were VBD None
examined VBN None
for IN None
radiation-induced JJ None
brachial JJ None
plexopathy NN None
after IN None
a DT None
median JJ None
follow-up JJ None
period NN None
of IN None
50 CD None
months NNS None
( ( None
13-99 JJ None
months NNS None
) ) None
. . None
high-risk JJ None
patients NNS None
younger JJR Age
patients NNS None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
myocardial JJ Condition
infarction NN Condition
patients NNS None
with IN None
suspected JJ None
acute JJ None
myocardial JJ None
infarction NN None
In IN None
the DT None
first JJ None
study NN None
388 CD None
patients NNS None
with IN None
suspected JJ None
acute JJ None
myocardial JJ None
infarction NN None
473 CD None
patients NNS None
with IN None
suspected JJ None
acute JJ None
myocardial JJ None
infarction NN None
Patients NNS Condition
-DOCSTART- -X- N

patients NNS None
with IN None
primary JJ None
open-angle JJ None
glaucoma NN None
: : None
primary JJ None
glaucoma NN None
triple JJ None
procedure NN None
in IN None
patients NNS None
with IN None
primary JJ None
open-angle JJ None
glaucoma NN None
with IN None
and CC None
without IN None
one CD None
or CC None
more JJR None
of IN None
the DT None
prognostic JJ None
factors NNS None
for IN None
filtration NN None
failure NN None
of IN None
primary JJ None
glaucoma NN None
triple JJ None
procedure NN None
. . None
African-American JJ None
race NN None
197 CD None
consecutive JJ None
patients NNS None
with IN None
primary JJ None
open-angle JJ None
glaucoma NN None
patients NNS None
with IN None
primary JJ None
open-angle JJ None
glaucoma NN None
undergoing VBG None
primary JJ None
glaucoma NN None
triple JJ None
procedure NN None
. . None
-DOCSTART- -X- N

elective JJ Condition
spinal JJ Condition
surgery NN Condition
. . Condition
Fifty-seven JJ None
patients NNS None
undergoing VBG Condition
elective JJ Condition
spinal JJ Condition
surgery NN Condition
anterior/posterior NN Condition
( ( Condition
A/P NNP Condition
) ) Condition
spinal JJ Condition
fusion NN Condition
patients NNS Condition
, , Condition
posterior JJ Condition
thoracolumbar NN Condition
scoliosis NN Condition
fusion NN Condition
patients NNS Condition
( ( Condition
PSF NNP Condition
) ) Condition
, , Condition
and CC Condition
degenerative JJ Condition
posterior JJ Condition
lumbar NN Condition
fusion NN Condition
patients NNS Condition
( ( Condition
LF NNP Condition
) ) Condition
-DOCSTART- -X- N

hypogonadal JJ Condition
men NNS Sex
with IN None
metabolic JJ Condition
syndrome NN Condition
. . None
52 CD Size
hypogonadal JJ Condition
men NNS Sex
[ VBP None
mean JJ None
age NN None
57 CD Size
yr NN Size
and CC None
mean VB None
testosterone NN None
( ( None
T NNP None
) ) None
< VBD None
320 CD None
ng/dl JJ None
] NN None
with IN None
metabolic JJ Condition
syndrome NN Condition
( ( Condition
MS NNP Condition
) ) Condition
. . None
hypogonadal JJ Condition
men NNS Sex
with IN None
MS NNP Condition
-DOCSTART- -X- N

metastatic JJ Condition
, , Condition
hormone-sensitive JJ Condition
breast NN Condition
cancer NN Condition
: : None
An DT None
Eastern JJ None
Cooperative NNP None
Oncology NNP None
Group NNP None
study NN None
. . None
Between NNP None
January NNP None
1988 CD None
and CC None
December NNP None
1992 CD None
, , None
231 CD Size
patients NNS None
with IN None
estrogen JJ None
receptor NN None
( ( None
ER NNP None
) ) None
-positive CD None
or CC None
ER-unknown JJ None
metastatic JJ None
breast NN None
cancer NN None
-DOCSTART- -X- N

septic JJ Condition
shock NN Condition
. . None
older JJR Age
people NNS None
septic JJ Condition
shock NN Condition
patients NNS None
. . None
Patients NNPS None
with IN None
septic JJ Condition
shock NN Condition
who WP None
were VBD None
enrolled VBN None
in IN None
the DT None
placebo NN None
limb NN None
of IN None
the DT None
North JJ None
American JJ None
Sepsis NNP None
Trial NNP None
( ( None
NORASEPT NNP None
II NNP None
) ) None
Nine NNP Size
hundred VBD Size
and CC Size
thirty JJ Size
patients NNS None
presenting VBG None
to TO None
hospital VB None
within IN None
12 CD None
hours NNS None
of IN None
the DT None
onset NN None
of IN None
septic JJ Condition
shock NN Condition
. . None
population NN None
was VBD None
broken VBN None
down RP None
into IN None
five CD None
age NN None
groups NNS None
as IN None
follows VBZ None
: : None
less JJR Age
than IN Age
50 CD Age
years NNS Age
( ( None
group NN None
one CD None
) ) None
, , None
50 CD Age
to TO Age
64 CD Age
years NNS Age
( ( None
group NN None
two CD None
) ) None
, , None
65 CD Age
to TO Age
74 CD Age
years NNS Age
( ( None
group NN None
three CD None
) ) None
, , None
75 CD Age
to TO Age
84 CD Age
years NNS Age
( ( None
group NN None
four CD None
) ) None
, , None
and CC None
85 CD Age
or CC Age
older JJR Age
( ( None
group NN None
five CD None
) ) None
. . None
930 CD Size
patients NNS None
. . None
patients NNS None
' POS None
mean JJ None
age NN None
( ( None
+/- JJ None
SD NNP None
) ) None
was VBD None
59 CD Age
+/- JJ Age
17 CD Age
years NNS Age
( ( None
range NN None
, , None
18 CD None
to TO None
102 CD None
) ) None
. . None
280 CD Size
patients NNS None
in IN None
group NN None
one CD None
, , None
242 CD Size
in IN None
group NN None
two CD None
, , None
210 CD Size
in IN None
group NN None
three CD None
, , None
150 CD Size
in IN None
group NN None
four CD None
, , None
and CC None
48 CD Size
in IN None
group NN None
five CD None
. . None
-DOCSTART- -X- N

post-stroke NN Condition
depressed JJ Condition
patients NNS None
. . None
post-stroke JJ None
patients NNS None
affected VBN None
by IN None
anxious JJ Condition
depression NN Condition
or CC None
retarded VBN Condition
depression NN Condition
. . None
Seventy-four JJ Size
post-stroke NN Condition
depressed JJ Condition
patients NNS None
patients NNS None
PSD NNP Condition
patients NNS None
-DOCSTART- -X- N

acute JJ None
hypertension NN None
13 CD None
patients NNS None
and CC None
the DT None
alpha-beta JJ None
adrenoceptor NN None
blocking VBG None
agent JJ None
labetalol NN None
in IN None
12 CD None
patients NNS None
were VBD None
compared VBN None
in IN None
46 CD None
severe JJ None
acute NN None
hypertensive JJ None
episodes NNS None
during IN None
haemodialysis NN None
. . None
diazoxide-treated JJ None
patients NNS None
patients NNS None
-DOCSTART- -X- N

proximal JJ Condition
interphalangeal NN Condition
joint NN Condition
in IN None
the DT None
horse NN None
Eight JJ Size
horses NNS None
-DOCSTART- -X- N

Parkinson NNP Condition
's POS Condition
disease NN Condition
. . None
Parkinson NNP Condition
's POS Condition
disease NN Condition
Parkinson NNP Condition
's POS Condition
disease NN Condition
subjects NNS None
and CC None
age-matched JJ None
controls NNS None
. . None
Parkinson NNP Condition
's POS Condition
disease NN Condition
patients NNS None
-DOCSTART- -X- N

Class NNP None
II NNP None
malocclusion NN None
. . None
Class NNP None
II NNP None
malocclusion NN None
. . None
Department NNP None
of IN None
Orthodontics NNP None
at IN None
the DT None
University NNP None
of IN None
Florida NNP None
between IN None
1990 CD None
and CC None
2003 CD None
. . None
86 CD None
subjects NNS None
were VBD None
treated VBN None
with IN None
a DT None
bionator NN None
, , None
93 CD None
were VBD None
treated VBN None
with IN None
headgear/biteplane NN None
81 CD None
served VBD None
as IN None
the DT None
observation NN None
group NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
hemodynamically RB Condition
decompensated VBN Condition
heart NN Condition
failure NN Condition
16 CD Size
decompensated JJ Condition
heart NN Condition
failure NN Condition
patients NNS None
-DOCSTART- -X- N

higher-functioning JJ Condition
autism NN Condition
adolescent JJ Condition
boys NNS Condition
. . Condition
higher-functioning JJ Condition
autism NN Condition
adolescent VB Condition
boys NNS Condition
Participants NNS None
were VBD None
seventh- JJ None
, , None
eighth- JJ None
and CC None
ninth-grade JJ None
students NNS None
( ( None
N NNP None
= NNP None
395 CD None
) ) None
from IN None
regular JJ None
classes NNS None
in IN None
a DT None
mainstream JJ None
school NN None
. . None
Two-eighth-grade JJ None
classes NNS None
were VBD None
for IN None
adolescent NN None
students NNS None
in IN None
inclusive JJ None
educational JJ None
environments NNS None
. . None
-DOCSTART- -X- N

[ JJ Condition
Metastatic NNP Condition
breast NN Condition
cancer NN Condition
: : None
Seventy-nine JJ Size
patients NNS None
with IN None
an DT None
histologically RB Condition
proven RB Condition
disseminated VBN Condition
breast NN Condition
cancer NN Condition
, , None
never RB Condition
treated VBN Condition
before IN Condition
with IN Condition
additive JJ Condition
hormonal JJ Condition
therapy NN Condition
, , None
entered VBD None
into IN None
a DT None
randomized JJ None
trial NN None
between IN None
june NN None
1981 CD None
and CC None
december VB None
1982 CD None
. . None
-DOCSTART- -X- N

Zambian JJ Condition
children NNS Age
with IN None
cryptosporidiosis NN Condition
: : None
Cryptosporidiosis NNP Condition
in IN None
children NNS Age
in IN None
developing VBG Condition
countries NNS Condition
Zambian JJ Condition
children NNS Age
with IN None
diarrhoea NN Condition
due JJ Condition
to TO Condition
Cryptosporidium NNP Condition
parvum NN Condition
. . None
Children NNP Age
with IN None
cryptosporidial JJ Condition
diarrhoea NNS Condition
who WP None
were VBD None
admitted VBN None
to TO None
the DT None
University NNP None
Teaching NNP None
Hospital NNP None
, , None
Lusaka NNP None
, , None
Zambia NNP None
, , None
between IN None
November NNP None
, , None
2000 CD None
, , None
and CC None
July NNP None
, , None
2001 CD None
, , None
and CC None
whose WP$ None
parents NNS None
consented VBD None
to TO None
their PRP$ None
having VBG None
an DT None
HIV JJ None
test NN None
were VBD None
randomly RB None
assigned VBN None
nitazoxanide RB None
( ( None
100 CD None
mg NN None
twice RB None
daily RB None
orally RB None
for IN None
3 CD None
days NNS None
) ) None
or CC None
placebo NN None
. . None
C NNP Condition
parvum NN Condition
or CC None
co-infected JJ None
at IN None
baseline NN None
. . None
50 CD Size
HIV-seropositive JJ None
and CC None
50 CD Size
HIV-seronegative JJ None
children NNS Age
-DOCSTART- -X- N

the DT None
60-year-old JJ Age
older JJR None
adults NNS None
( ( None
60 CD None
( ( None
SE NNP None
1 CD None
) ) None
years NNS None
; : None
BMI NNP None
26 CD None
( ( None
SE NNP None
1 CD None
) ) None
kg/m NN None
( ( None
2 CD None
) ) None
) ) None
60-year-old JJ None
subjects NNS None
-DOCSTART- -X- N

trained JJ None
men NNS None
Trained VBN None
men NNS None
( ( None
n JJ None
= VBZ None
41 CD None
; : None
34 CD None
+/- JJ None
5 CD None
y NN None
; : None
maximum JJ None
oxygen NN None
uptake JJ None
= JJ None
55 CD None
+/- JJ None
7 CD None
mL NN None
x NN None
kg NN None
( ( None
-1 NNP None
) ) None
x VBP None
min NN None
( ( None
-1 NNP None
) ) None
) ) None
from IN None
a DT None
homogenous JJ None
police NN None
Special JJ None
Forces NNS None
unit NN None
inadequate JJ None
mean JJ None
daily JJ None
fruit NN None
and CC None
vegetable JJ None
consumption NN None
( ( None
3.2 CD None
+/- JJ None
1.2 CD None
servings NNS None
) ) None
. . None
group NN None
of IN None
trained JJ None
men NNS None
over IN None
28 CD None
wk NNS None
. . None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Age
with IN None
minimal JJ None
verbal JJ None
language NN None
. . None
60 CD Size
minimally RB Condition
verbal JJ Condition
autistic JJ Condition
children NNS Condition
. . None
-DOCSTART- -X- N

salbutamol-treated JJ None
inpatients NNS None
with IN None
acute JJ None
bronchiolitis NN None
: : None
children NNS None
admitted VBN None
to TO None
the DT None
hospital NN None
with IN None
bronchiolitis NN None
treated VBN None
with IN None
nebulized JJ None
salbutamol NN None
. . None
participants NNS None
, , None
children NNS None
aged VBD None
6 CD None
weeks NNS None
to TO None
15 CD None
months NNS None
, , None
admitted VBN None
with IN None
first-time JJ None
wheezing NN None
, , None
were VBD None
eligible JJ None
if IN None
their PRP$ None
oxygen NN None
saturation NN None
was VBD None
less JJR None
than IN None
95 CD None
% NN None
on IN None
admission NN None
to TO None
the DT None
hospital NN None
and CC None
their PRP$ None
Respiratory NNP None
Distress NNP None
Assessment NNP None
Instrument NNP None
( ( None
RDAI NNP None
) ) None
score NN None
was VBD None
greater JJR None
than IN None
6 CD None
. . None
Patients NNS None
were VBD None
excluded VBN None
if IN None
they PRP None
had VBD None
any DT None
one CD None
of IN None
the DT None
following NN None
: : None
an DT None
underlying JJ None
disease NN None
that WDT None
might MD None
affect VB None
cardiopulmonary JJ None
status NN None
, , None
asthma NN None
, , None
recent JJ None
treatment NN None
with IN None
steroids NNS None
( ( None
within IN None
2 CD None
weeks NNS None
) ) None
, , None
or CC None
any DT None
history NN None
of IN None
adverse JJ None
reaction NN None
to TO None
steroids NNS None
. . None
children NNS None
hospitalized VBN None
with IN None
bronchiolitis NN None
-DOCSTART- -X- N

stroke NN None
patients NNS None
-- : None
results NNS None
stroke NN None
patients NNS None
in IN None
Latium NNP None
( ( None
Italy NNP None
) ) None
emergency NN None
system NN None
. . None
stroke JJ None
patient JJ None
referrals NNS None
by IN None
Emergency NNP None
Medical NNP None
Service NNP None
( ( None
EMS NNP None
) ) None
and CC None
Emergency NNP None
Room NNP None
( ( None
ER NNP None
) ) None
health NN None
professionals NNS None
trained VBN None
in IN None
the DT None
ECP NNP None
, , None
with IN None
those DT None
of IN None
non-trained JJ None
EMS NNP None
and CC None
ER NNP None
controls NNS None
. . None
eligible JJ None
( ( None
aged VBN None
< NNP None
/= $ None
80 CD None
and CC None
symptom JJ None
onset NN None
< NNP None
/= VBZ None
6 CD None
hours NNS None
) ) None
stroke VBD None
patients NNS None
referred VBN None
to TO None
a DT None
stroke NN None
unit NN None
( ( None
SU NNP None
) ) None
. . None
2656 CD None
patients NNS None
in IN None
the DT None
intervention NN None
arm NN None
and CC None
2239 CD None
in IN None
the DT None
control NN None
arm NN None
stroke NN None
patients NNS None
. . None
-DOCSTART- -X- N

either CC None
volunteers NNS None
or CC None
referred JJ None
subjects NNS None
. . None
this DT None
study NN None
prospectively RB None
evaluated VBD None
120 CD Size
sedentary JJ None
individuals NNS None
( ( None
60 CD Size
males NNS Sex
, , None
60 CD Size
females NNS Sex
, , None
aged VBD Age
20-80 CD Age
) ) None
, , None
randomly-selected JJ None
from IN None
> JJ None
8,000 CD None
subjects NNS None
. . None
sedentary JJ None
subjects NNS None
; : None
-DOCSTART- -X- N

patients NNS None
after IN Condition
myocardial JJ Condition
infarction NN Condition
male NN None
patients NNS None
after IN None
myocardial JJ None
infarction NN None
( ( None
MI NNP None
) ) None
aged VBD Age
between IN Age
38 CD Age
and CC Age
61 CD Age
. . None
the DT None
training NN Size
group NN Size
( ( Size
n JJ Size
= NNP Size
21 CD Size
) ) Size
, , None
staying VBG None
in IN None
Cardiac NNP None
Rehabilitation NNP None
Department NNP None
and CC None
the DT None
control NN Size
group NN Size
( ( Size
n JJ Size
= NNP Size
11 CD Size
) ) Size
The DT None
training NN None
group NN None
MI NNP None
patients NNS None
-DOCSTART- -X- N

after IN None
anal JJ None
fissure NN None
surgery NN None
. . None
patients NNS None
. . None
Between NNP None
July NNP None
1999 CD None
and CC None
December NNP None
2000 CD None
, , None
140 CD None
patients NNS None
undergoing JJ None
anal JJ None
sphincterotomy NN None
patients NNS None
who WP None
had VBD None
polyp NN None
and CC None
papilla NN None
removal NN None
-DOCSTART- -X- N

persons NNS None
with IN None
cystic JJ None
fibrosis NN None
and CC None
the DT None
G551D-CFTR NNP None
mutation NN None
. . None
39 CD None
adults NNS None
with IN None
cystic JJ None
fibrosis NN None
and CC None
at IN None
least JJS None
one CD None
G551D-CFTR JJ None
allele NN None
treat VB None
cystic JJ None
fibrosis NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
coronary JJ Condition
disease NN Condition
. . None
60 CD Size
patients NNS None
with IN None
documented JJ None
coronary JJ Condition
disease NN Condition
, , Condition
positive JJ None
exercise NN None
tests NNS None
, , None
and CC None
ischemic JJ None
episodes NNS None
on IN None
Holter NNP None
monitoring NN None
-DOCSTART- -X- N

737 CD None
patients NNS None
with IN None
aggressive JJ None
malignant JJ None
lymphoma NN None
. . None
From IN None
July NNP None
1984 CD None
to TO None
September NNP None
1987 CD None
, , None
737 CD None
patients NNS None
with IN None
aggressive JJ None
malignant JJ None
lymphoma NN None
( ( None
ML NNP None
) ) None
Four CD None
hundred VBD None
forty-two JJ None
patients NNS None
-DOCSTART- -X- N

recalcitrant JJ Condition
foot NN None
and CC None
hand NN None
warts NNS Condition
: : None
Recalcitrant NNP Condition
foot NN None
and CC None
hand NN None
warts NNS Condition
A NNP None
total NN None
of IN None
232 CD None
foot NN None
and CC None
hand NN None
warts NNS None
in IN None
45 CD Size
patients NNS None
were VBD None
entered VBN None
into IN None
the DT None
trial NN None
: : None
-DOCSTART- -X- N

adults NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
individuals NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
( ( None
a DT None
) ) None
215 CD None
supported VBN None
employees NNS None
who WP None
were VBD None
in IN None
sheltered JJ None
workshops NNS None
prior RB None
to TO None
entering VBG None
supported JJ None
employment NN None
and CC None
( ( None
b NN None
) ) None
215 CD None
supported VBN None
employees NNS None
who WP None
were VBD None
not RB None
in IN None
sheltered JJ None
workshops NNS None
. . None
individuals NNS None
with IN None
ASD NNP None
-DOCSTART- -X- N

shoulder NN None
arthroscopy NN None
] NNP None
Thirty-two JJ None
patients NNS None
with IN None
impingement JJ None
syndrome JJ None
underwent JJ None
subacromial JJ None
decompression NN None
in IN None
the DT None
course NN None
of IN None
arthroscopic JJ None
shoulder NN None
surgery NN None
. . None
-DOCSTART- -X- N

subjects NNS None
with IN None
asthma NN None
allergic JJ None
asthma NN None
. . None
27 CD None
patients NNS None
aged VBD None
18 CD None
to TO None
40 CD None
years NNS None
with IN None
positive JJ None
skin-prick JJ None
tests NNS None
and CC None
mild JJ None
asthma JJ None
in IN None
diseased JJ None
volunteers NNS None
-DOCSTART- -X- N

transplant NN None
recipients NNS None
and CC None
dialysis NN None
patients NNS None
transplant NN None
and CC None
dialysis NN None
patients NNS None
with IN None
different JJ None
levels NNS None
of IN None
renal JJ None
function NN None
. . None
23 CD Size
patients NNS Size
who WP None
were VBD None
either CC None
a DT None
recipient NN None
of IN None
an DT None
organ JJ None
transplant NN None
or CC None
on IN None
hemodialysis NN None
. . None
patients NNS None
with IN None
end-stage JJ Condition
renal JJ Condition
failure NN Condition
transplant JJ None
patients NNS None
human JJ Condition
immunodeficiency NN Condition
virus-infected JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
gallstones NNS Condition
: : None
24 CD Size
gallstone NN Condition
patients NNS None
24 CD Size
comparable JJ None
patients NNS None
on IN None
placebo NN None
treatment NN None
-DOCSTART- -X- N

1022 CD None
ovarian JJ Condition
cancers NNS Condition
ovarian JJ Condition
cancers NNS Condition
of IN None
stage NN Condition
1 CD Condition
and CC None
stage NN Condition
2 CD Condition
primarily RB None
inoperable JJ Condition
stage NN Condition
3 CD Condition
ovarian JJ Condition
cancers NNS Condition
-DOCSTART- -X- N

persons NNS None
with IN None
HIV/AIDS NNP None
. . None
persons NNS None
with IN None
human JJ None
immunodeficiency NN None
virus NN None
( ( None
HIV NNP None
) ) None
and CC None
acquired VBD None
immunodeficiency NN None
syndrome NN None
( ( None
AIDS NNP None
) ) None
. . None
11 CD Size
clinically RB None
stable JJ None
, , None
HIV-infected JJ None
adults NNS Age
had VBD None
been VBN None
treated VBN None
with IN None
highly RB None
active JJ None
, , None
antiretroviral JJ None
therapy NN None
and CC None
had VBD None
HIV NNP None
plasma NN None
RNA NNP None
levels NNS None
of IN None
less JJR None
than IN None
10 CD None
000 CD None
copies/mL NN None
. . None
persons NNS None
with IN None
HIV/AIDS NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
heart NN None
failure NN None
who WP None
were VBD None
in IN None
sinus NN None
rhythm NN None
and CC None
whose WP$ None
ejection NN None
fraction NN None
was VBD None
< JJ None
/=0.45 NNP None
. . None
a DT None
large JJ None
number NN None
of IN None
centers NNS None
( ( None
302 CD None
) ) None
in IN None
the DT None
United NNP None
States NNPS None
and CC None
Canada NNP None
, , None
many JJ None
of IN None
which WDT None
were VBD None
inexperienced VBN None
in IN None
research NN None
. . None
Of IN None
5602 CD None
postcards NNS None
distributed VBN None
, , None
5070 CD None
( ( None
90.5 CD None
% NN None
) ) None
were VBD None
completed VBN None
and CC None
returned VBN None
. . None
Of IN None
the DT None
total JJ None
7788 CD None
participants NNS None
entered VBD None
into IN None
the DT None
DIG NNP None
trial NN None
, , None
only RB None
97 CD None
participants NNS None
( ( None
1.2 CD None
% NN None
) ) None
could MD None
not RB None
have VB None
their PRP$ None
vital JJ None
status NN None
as IN None
of IN None
December NNP None
31 CD None
, , None
1995 CD None
determined VBD None
. . None
-DOCSTART- -X- N

Japanese JJ None
adult NN Age
healthy JJ Condition
subjects NNS None
: : None
Japanese JJ None
healthy JJ Condition
subjects NNS Condition
. . None
Forty-eight JJ Size
Japanese JJ None
healthy JJ Condition
subjects NNS Condition
( ( None
males NNS Sex
24 CD Size
; : None
females NNS Sex
24 CD Size
) ) None
single-center JJ None
, , None
double-blind JJ None
Japanese JJ None
subjects NNS None
; : None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ None
proximal JJ None
plantar NN None
fasciitis NN None
: : None
chronically RB None
painful JJ None
proximal JJ None
plantar NN None
fasciitis NN None
Forty-seven JJ None
patients NNS None
( ( None
49 CD None
feet NNS None
) ) None
with IN None
a DT None
previously RB None
unsuccessful JJ None
nonsurgical JJ None
treatment NN None
of IN None
at IN None
least JJS None
6 CD None
months NNS None
were VBD None
randomized VBN None
to TO None
two CD None
groups NNS None
. . None
Group NNP None
1 CD None
( ( None
25 CD None
heels NNS None
) ) None
group NN None
2 CD None
( ( None
24 CD None
heels NNS None
) ) None
-DOCSTART- -X- N

expression NN None
of IN None
p34 NN None
( ( None
cdc2 NN None
) ) None
and CC None
CyclinB1 NNP None
of IN None
germ JJ None
cells NNS None
of IN None
their PRP$ None
offspring NN None
in IN None
goats NNS Condition
. . None
goats NNS None
. . None
herd NN None
of IN None
119 CD Size
Taihang NNP None
Black NNP None
Goats NNP None
young JJ None
male NN None
goats NNS None
of IN None
-DOCSTART- -X- N

Sixty-two NNP None
( ( None
62 CD None
) ) None
community-recruited JJ None
patients NNS None
with IN None
fibromyalgia NN None
( ( None
FM NNP None
) ) None
Two CD None
homeopaths NNS None
jointly RB None
performed VBD None
case-taking JJ None
interviews NNS None
. . None
A DT None
conventional JJ None
medical JJ None
provider NN None
independently RB None
evaluated VBD None
patients NNS None
with IN None
a DT None
standardized JJ None
history NN None
and CC None
physical JJ None
examination NN None
. . None
-DOCSTART- -X- N

post-cholecystectomy JJ Condition
pain NN Condition
patients NNS None
suffering VBG None
from IN None
post-operative JJ Condition
pain NN Condition
after IN None
cholecystectomy NN Condition
99 CD Size
patients NNS None
with IN None
severe JJ Condition
pain NN Condition
following VBG Condition
surgery NN Condition
after IN Condition
surgery NN Condition
-DOCSTART- -X- N

Chinese JJ None
patients NNS None
with IN None
essential JJ None
hypertension NN None
. . None
105 CD None
patients NNS None
with IN None
mild JJ None
or CC None
moderate JJ None
essential JJ None
hypertension NN None
Only RB None
those DT None
patients NNS None
who WP None
have VBP None
finished VBN None
8 CD None
weeks NNS None
of IN None
active JJ None
treatment NN None
in IN None
both DT None
groups NNS None
were VBD None
included VBN None
into IN None
the DT None
final JJ None
analysis NN None
. . None
One CD None
hundred VBD None
one CD None
patients NNS None
( ( None
51 CD None
in IN None
enalapril NN None
group NN None
and CC None
50 CD None
in IN None
indapamide JJ None
group NN None
) ) None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
: : None
children NNS Age
with IN None
autism NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
40 CD Size
consecutive JJ None
children NNS Age
with IN None
autism NN Condition
, , None
whose WP$ None
ages NNS None
ranged VBD None
from IN None
2 CD Age
to TO Age
9 CD Age
years NNS None
, , None
who WP None
were VBD None
receiving VBG None
either CC None
risperidone NN None
or CC None
placebo VB None
given VBN None
orally RB None
at IN None
a DT None
dose NN None
of IN None
1 CD None
mg/day NN None
for IN None
6 CD None
months NNS None
. . None
40 CD Size
children NNS Age
enrolled VBD None
children NNS Age
with IN None
autism NN Condition
-DOCSTART- -X- N

prilocaine NN None
in IN None
volunteers NNS None
. . None
six CD Size
volunteers NNS None
. . None
-DOCSTART- -X- N

50 CD Size
consecutive JJ None
patients NNS None
. . None
Each DT None
patient NN None
98 CD Size
% NN Size
of IN None
patients NNS None
had VBD None
low JJ None
( ( None
< JJ None
15 CD None
J NNP None
) ) None
thresholds VBZ None
dual-coil JJ None
lead NN None
system NN None
88 CD Size
% NN Size
of IN None
patients NNS None
with IN None
the DT None
single-coil JJ None
configuration NN None
-DOCSTART- -X- N

chronic JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
patient NN None
] NN None
chronic JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
patient NN None
. . None
Three CD Size
hundred VBD Size
and CC Size
five CD Size
cases NNS None
chronic JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
patient NN None
-DOCSTART- -X- N

patients NNS None
with IN None
intracranial JJ Condition
arteriovenous JJ Condition
malformations NNS Condition
: : None
Thirty JJ Size
patients NNS None
undergoing VBG None
resection NN None
of IN None
arteriovenous JJ Condition
malformations NNS Condition
with IN None
deliberate JJ None
hypotension NN None
-DOCSTART- -X- N

osteonecrosis NN None
of IN None
the DT None
femoral JJ None
head NN None
. . None
37 CD None
hips NNS None
with IN None
early-stage JJ None
osteonecrosis NN None
( ( None
ON NNP None
) ) None
in IN None
33 CD None
patients NNS None
were VBD None
randomly RB None
assigned VBN None
early-stage NN None
ON NNP None
of IN None
the DT None
femoral JJ None
head NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
stable JJ None
COPD NNP None
. . None
27 CD None
patients NNS None
with IN None
stable JJ None
chronic JJ None
obstuctive JJ None
pulmonary JJ None
disease NN None
( ( None
COPD NNP None
) ) None
-DOCSTART- -X- N

peers NNS None
peers NNS None
Children NNP Age
( ( None
N NNP None
= NNP None
576 CD None
; : None
M NNP None
age NN None
= VBD None
10.06 CD None
) ) None
children NNS None
-DOCSTART- -X- N

mild JJ None
male JJ None
factor NN None
infertility NN None
: : None
mild JJ None
male JJ None
factor NN None
infertility NN None
. . None
The DT None
study NN None
was VBD None
performed VBN None
in IN None
the DT None
Assisted NNP None
Reproduction NNP None
Unit NNP None
of IN None
the DT None
2nd CD None
Department NNP None
of IN None
Obstetrics NNP None
and CC None
Gynecology NNP None
, , None
University NNP None
of IN None
Athens NNP None
, , None
Aretaieion NNP None
Hospital NNP None
, , None
Athens NNP None
, , None
Greece NNP None
, , None
and CC None
included VBD None
92 CD None
couples NNS None
who WP None
presented VBD None
with IN None
mild JJ None
male JJ None
factor NN None
infertility-all JJ None
candidates NNS None
for IN None
IUI NNP None
. . None
mild JJ None
male JJ None
infertility NN None
-DOCSTART- -X- N

90 CD Size
patients NNS None
with IN None
IgAN NNP Condition
of IN Condition
deficiency NN Condition
of IN Condition
Yin NNP Condition
with IN None
damp-heat JJ Condition
symptom NN Condition
-DOCSTART- -X- N

coronary JJ None
artery NN None
disease NN None
] NNP None
50patients CD Size
with IN None
chronic JJ Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
( ( Condition
CAD NNP Condition
) ) Condition
and CC None
51 CD Size
patients NNS None
with IN None
acute JJ Condition
coronary JJ Condition
syndrome NN Condition
. . None
patients NNS None
with IN None
various JJ None
CAD NNP None
forms NNS None
. . None
-DOCSTART- -X- N

subject NN Condition
's POS Condition
fist NN Condition
clenching NN Condition
20 CD None
female JJ None
and CC None
20 CD None
male JJ None
students NNS None
( ( None
ages NNS None
: : None
17-34 CD None
years NNS None
) ) None
-DOCSTART- -X- N

in IN None
patients NNS None
subjected VBN None
to TO None
craniotomy VB Condition
for IN None
cerebral JJ Condition
tumors NNS Condition
. . None
Twenty CD Size
patients NNS None
subjected VBN None
to TO None
craniotomy VB Condition
for IN None
supratentorial JJ Condition
cerebral JJ Condition
tumors NNS Condition
randomized VBN None
five CD Size
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
primary JJ Condition
coronary JJ Condition
surgery NN Condition
were VBD None
allocated VBN None
to TO None
the DT None
radial JJ None
artery NN None
( ( None
n JJ None
= NNP None
198 CD Size
) ) None
or CC None
free JJ None
right JJ None
internal JJ None
thoracic NN None
artery NN None
( ( None
n JJ None
= NNP None
196 CD Size
) ) None
if IN None
aged VBN None
less JJR None
than IN None
70 CD Age
years NNS None
( ( None
group NN None
1 CD None
) ) None
, , None
or CC None
radial JJ None
artery NN None
( ( None
n JJ None
= NNP None
113 CD Size
) ) None
or CC None
saphenous JJ None
vein NN None
( ( None
n JJ None
= NNP None
112 CD Size
) ) None
if IN None
aged VBN None
at IN None
least JJS None
70 CD Age
years NNS None
( ( None
group NN None
2 CD None
) ) None
. . None
All DT None
patients NNS None
received VBD None
a DT None
left JJ None
internal JJ None
thoracic NN None
artery NN None
to TO None
the DT None
left VBN None
anterior JJ None
descending NN None
in IN None
groups NNS None
1 CD None
and CC None
2 CD None
in IN None
237 CD Size
and CC None
113 CD Size
patients NNS None
, , None
respectively RB None
. . None
-DOCSTART- -X- N

overactive JJ None
bladder NN None
. . None
patients NNS None
with IN None
overactive JJ None
bladder NN None
( ( None
OAB NNP None
) ) None
. . None
patients NNS None
with IN None
continuous JJ None
OAB NNP None
symptoms NNS None
for IN None
? . None
3 CD None
months NNS None
, , None
daily JJ None
mean VBP None
voiding VBG None
frequency NN None
( ( None
DMVF NNP None
) ) None
? . None
8 CD None
, , None
and CC None
daily JJ None
mean JJ None
urgency NN None
or CC None
urgency NN None
incontinence NN None
frequency NN None
? . None
2 CD None
. . None
A DT None
-DOCSTART- -X- N

urogenital JJ Condition
atrophy NN Condition
in IN None
postmenopausal JJ Condition
women NNS Size
on IN Condition
hormone NN Condition
therapy NN Condition
. . None
27 CD Size
women NNS Size
with IN None
climacteric JJ Condition
symptoms NNS Condition
and CC None
atrophic JJ Condition
vaginitis NN Condition
receive VB None
HT NNP None
plus CC None
local JJ None
estriol NN None
or CC None
placebo NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
and CC None
high-normal JJ Condition
body NN Condition
lead JJ Condition
burdens NNS Condition
. . None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
University NNP None
medical JJ None
center NN None
; : None
50 CD None
patients NNS None
( ( None
serum JJ None
creatinine NN None
, , None
1.5-3.9 JJ None
mg/dL NN None
) ) None
with IN None
high-normal JJ None
body NN None
lead JJ None
burden NN None
( ( None
?80- JJ None
< NN None
600 CD None
?g NN None
) ) None
were VBD None
Chinese JJ None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
. . None
RESULTS NNP None
group NN None
. . None
17 CD None
( ( None
68 CD None
% NN None
control-group NN None
patients NNS None
and CC None
9 CD None
( ( None
36 CD None
% NN None
) ) None
treatment-group NN None
patients NNS None
achieved VBD None
nephropathy NN None
in IN None
type NN None
2 CD None
diabetic JJ None
patients NNS None
with IN None
high-normal JJ None
body NN None
lead JJ None
burdens NNS None
-DOCSTART- -X- N

asthmatic JJ None
children NNS None
: : None
asthmatic JJ None
children NNS None
. . None
paediatric JJ None
hospital NN None
located VBN None
on IN None
northeast NN None
of IN None
Brazil NNP None
with IN None
42 CD None
asthmatic JJ None
children NNS None
aged VBN None
? . None
36 CD None
months NNS None
. . None
The DT None
children NNS None
were VBD None
children NNS None
who WP None
received VBD None
the DT None
intervention NN None
proposed VBN None
-DOCSTART- -X- N

Subjects NNPS None
between IN None
the DT None
ages NNS None
of IN None
40-49 JJ Age
years NNS Age
were VBD None
randomly RB None
selected VBN None
from IN None
the DT None
lists NNS None
of IN None
36 CD None
primary JJ None
care NN None
centres NNS None
. . None
A DT None
total NN None
of IN None
32 CD Size
929 CD Size
subjects NNS None
were VBD None
invited VBN None
to TO None
attend VB None
, , None
8407 CD Size
were VBD None
evaluable JJ None
, , None
and CC None
2329 CD Size
( ( None
28 CD None
% NN None
) ) None
of IN None
these DT None
were VBD None
H. NNP None
pylori-positive JJ None
. . None
A DT None
total NN None
of IN None
1161 CD Size
subjects NNS None
dyspeptic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

of IN None
multiple JJ Condition
actinic JJ Condition
keratoses NNS Condition
. . None
A DT None
specialized JJ None
outpatient NN None
dermatology NN None
clinic NN None
within IN None
a DT None
state-funded JJ None
hospital NN None
in IN None
Germany NNP None
. . None
PATIENTS VB None
The DT None
study NN None
population NN None
was VBD None
aged VBN None
45 CD Age
to TO Age
85 CD Age
years NNS None
. . None
Of IN None
52 CD Size
patients NNS None
screened VBD None
, , None
36 CD None
men NNS Sex
and CC Sex
women NNS Sex
with IN None
AK NNP None
confirmed VBN None
by IN None
histological JJ None
diagnosis NN None
were VBD None
enrolled VBN None
. . None
Patients NNS None
were VBD None
excluded VBN None
from IN None
the DT None
study NN None
if IN None
they PRP None
did VBD None
not RB None
have VB None
a DT None
histological JJ None
diagnosis NN None
for IN None
AK NNP None
, , None
if IN None
they PRP None
were VBD None
older JJR None
than IN None
85 CD None
years NNS None
, , None
or CC None
if IN None
they PRP None
did VBD None
not RB None
comply VB None
with IN None
the DT None
protocol NN None
. . None
All DT None
patients NNS None
had VBD None
responded VBN None
to TO None
a DT None
notice NN None
asking VBG None
for IN None
volunteers NNS None
. . None
by IN None
patients NNS None
treated VBN None
with IN None
imiquimod NN None
-DOCSTART- -X- N

children NNS None
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
: : None
children NNS None
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
. . None
9 CD Size
Caucasian JJ Size
boys NNS None
, , None
3.8-8.1 CD Age
years NNS Age
old JJ None
, , None
with IN None
a DT None
DSM-IV JJ Condition
diagnosis NN Condition
of IN Condition
a DT Condition
pervasive JJ Condition
developmental NN Condition
disorder NN Condition
, , None
living VBG None
with IN None
their PRP$ None
families NNS None
, , None
receiving VBG None
no DT None
chronic JJ None
medications NNS None
, , None
and CC None
without IN None
significant JJ None
gastrointestinal JJ None
symptoms NNS None
. . None
Children NNP Age
with IN None
marked VBN None
stereotypy NN None
( ( None
meaningless NN None
, , None
repetitive JJ None
behaviors NNS None
) ) None
Our PRP$ None
subjects NNS None
did VBD None
not RB None
have VB None
prominent JJ None
gastrointestinal JJ None
symptoms NNS None
children NNS Age
with IN None
autistic JJ None
spectrum NN None
disorders NNS None
-DOCSTART- -X- N

adolescents NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . None
Anxiety NN None
is VBZ None
common JJ None
among IN None
adolescents NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP Condition
) ) None
in IN None
a DT None
sample NN None
of IN None
30 CD Size
adolescents NNS Age
with IN None
ASD NNP Condition
and CC Condition
anxiety NN Condition
symptoms NNS Condition
of IN None
moderate JJ None
or CC None
greater JJR None
severity NN None
. . None
-DOCSTART- -X- N

Wilms NNP Condition
' POS Condition
tumor NN Condition
. . Condition
National NNP None
Wilms NNP Condition
' POS Condition
Tumor NNP Condition
National NNP None
Wilms NNP None
' POS None
Tumor NNP None
low-risk JJ None
patients NNS None
those DT None
at IN None
high JJ None
risk NN None
for IN None
relapse NN None
. . None
Eligible JJ None
patients NNS None
( ( None
1439 CD Size
) ) None
stage NN None
( ( None
I-IV NNP None
) ) None
and CC None
histology NN None
( ( None
favorable JJ None
[ NN None
FH NNP None
] NNP None
or CC None
unfavorable JJ None
[ JJ None
UH NNP None
] NNP None
) ) None
, , None
and CC None
contributed VBD None
data NNS None
to TO None
survival VB None
and CC None
relapse-free JJ None
survival NN None
( ( None
RFS NNP None
) ) None
analyses VBZ None
. . None
Four-year JJ None
( ( None
postnephrectomy NN None
) ) None
survival NN None
percentages NNS None
high-risk JJ None
patients NNS None
-DOCSTART- -X- N

advanced JJ Condition
heart NN Condition
failure NN Condition
. . None
Heart NNP Condition
Failure NNP Condition
In IN None
patients NNS None
admitted VBN None
to TO None
the DT None
hospital NN None
with IN None
acute JJ Condition
HF NNP Condition
, , None
both DT None
ventricles NNS None
were VBD None
evaluated VBN None
by IN None
echocardiography NN None
on IN None
admission NN None
, , None
at IN None
discharge NN None
, , None
and CC None
at IN None
3 CD None
months NNS None
. . None
-DOCSTART- -X- N

Consecutive JJ Condition
procedural JJ Condition
angiograms NNS Condition
of IN Condition
patients NNS Condition
randomly RB Condition
assigned VBN Condition
to TO Condition
EES NNP Condition
( ( Condition
n=669 NN Condition
) ) Condition
or CC Condition
PES NNP Condition
( ( Condition
n=333 RB Condition
) ) Condition
were VBD Condition
analysed VBN Condition
by IN Condition
an DT Condition
independent JJ Condition
angiographic JJ Condition
core NN Condition
laboratory NN Condition
. . Condition
patients NNS None
receiving VBG None
EES NNP None
compared VBN None
to TO None
PES NNP None
Patients NNS None
treated VBD None
with IN None
EES NNP None
rather RB None
than IN None
PES NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
stable JJ Condition
angina JJ Condition
pectoris NN Condition
. . None
One CD Size
hundred VBD Size
hypertensive JJ Condition
patients NNS None
with IN None
stable JJ Condition
angina NNS Condition
pectoris NNS Condition
who WP None
underwent VBP None
elective JJ None
percutaneous JJ None
coronary JJ None
intervention NN None
in IN None
patients NNS None
with IN None
stable JJ None
angina NNS None
pectoris NN None
who WP None
received VBD None
-DOCSTART- -X- N

inguinal JJ Condition
herniorrhaphy NN Condition
. . Condition
hernia NN None
recurrence NN None
and CC None
complications NNS None
on IN None
PRO NNP None
for IN None
participants NNS None
in IN None
the DT None
Veterans NNP None
Affairs NNPS None
trial NN None
of IN None
Open NNP None
or CC None
Laparoscopic NNP None
Repair NNP None
of IN None
Inguinal NNP None
Hernia NNP None
. . None
1603 CD Size
patients NNS Size
with IN Size
PRO NNP Size
data NNS Size
, , Size
105 CD Size
had VBD Size
a DT Size
recurrence NN Size
and CC Size
342 CD Size
had VBD Size
a DT Size
complication NN Size
at IN Size
2 CD Size
years NNS Size
. . Size
-DOCSTART- -X- N

Helicobacter NNP Condition
pylori JJ Condition
eradication NN None
in IN None
children NNS Age
and CC None
adolescents NNS Age
children NNS Age
and CC None
adolescents NNS Age
. . None
Helicobacter NNP Condition
pylori NN Condition
infected VBD None
10-21 JJ Age
year NN None
olds NNS None
were VBD None
offered VBN None
treatment NN None
, , None
individuals NNS None
with IN None
abdominal JJ Condition
pain NN Condition
underwent JJ None
upper JJ None
endoscopy NN None
and CC None
those DT None
with IN None
peptic JJ Condition
ulcers NNS Condition
were VBD None
excluded VBN None
. . None
131 CD Size
individuals NNS None
were VBD None
randomized VBN None
, , None
of IN None
whom WP None
31 CD Size
( ( Size
24 CD Size
% NN Size
) ) Size
had VBD None
undergone JJ None
upper JJ None
endoscopy NN None
. . None
Full NNP None
compliance NN None
was VBD None
achieved VBN None
in IN None
93 CD None
% NN None
( ( None
122 CD None
of IN None
131 CD None
) ) None
. . None
children NNS Age
and CC None
adolescents NNS Age
. . None
children NNS Age
. . None
-DOCSTART- -X- N

During IN None
orthopaedic JJ Condition
surgery NN Condition
of IN None
the DT None
limb NN None
three CD None
parallel JJ None
groups NNS None
in IN None
30 CD Size
patients NNS None
-DOCSTART- -X- N

cardiac JJ Condition
arrhythmias NN Condition
in IN Condition
African-American JJ Condition
men NNS Condition
with IN Condition
systemic JJ Condition
hypertension NN Condition
and CC Condition
moderate VB Condition
to TO Condition
severe VB Condition
left JJ Condition
ventricular JJ Condition
hypertrophy NN Condition
. . None
45 CD None
hypertensive JJ None
African-American JJ None
men NNS None
with IN None
moderate JJ None
to TO None
severe VB None
left VBN None
ventricular JJ None
( ( None
LV NNP None
) ) None
hypertrophy NN None
. . None
subgroup NN None
of IN None
24 CD None
patients NNS None
. . None
hypertensive JJ None
African-American JJ None
men NNS None
with IN None
moderate JJ None
to TO None
severe VB None
LV NNP None
hypertrophy NN None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
glomerulonephritis NN Condition
. . None
patients NNS None
with IN None
chronic JJ Condition
glomerulonephritis NN Condition
( ( None
CGN NNP None
) ) None
40 CD Size
normotensive JJ None
hypercholesterolemic JJ Condition
patients NNS None
with IN None
CGN NNP Condition
Subjects NNS None
comprised VBD None
24 CD Size
men NNS Sex
and CC None
16 CD Size
women NNS Sex
, , None
with IN None
a DT None
mean JJ None
age NN None
of IN None
40.8+/-14.4 JJ Age
years NNS None
; : None
27 CD Size
had VBD None
IgA NNP Condition
nephropathy JJ Condition
and CC None
13 CD Size
had VBD None
non-IgA JJ Condition
proliferative JJ Condition
glomerulonephritis NN Condition
. . None
patients NNS None
with IN None
CGN NNP Condition
and CC None
hypercholesterolaemia NN Condition
. . None
-DOCSTART- -X- N

Therapist NNP None
Nine JJ None
therapists NNS None
were VBD None
studied VBN None
: : None
-DOCSTART- -X- N

ten JJ None
normotensive JJ None
and CC None
seven CD None
hypertensive JJ None
subjects NNS None
-DOCSTART- -X- N

postpartum NN None
Prague NNP None
Prague NNP None
50 CD Size
women NNS Size
with IN None
clinical JJ None
and CC None
lab JJ None
signs NNS None
of IN None
postpartal JJ Condition
anemia NN Condition
. . None
-DOCSTART- -X- N

after IN None
myocardial JJ Condition
infarction NN Condition
in IN None
patients NNS None
with IN None
left JJ Condition
ventricular JJ Condition
dysfunction NN Condition
. . None
Patients NNS None
patients NNS None
-DOCSTART- -X- N

ventricular JJ Condition
tachycardia NN Condition
before IN None
defibrillator NN Condition
implantation NN Condition
in IN None
patients NNS None
with IN None
coronary JJ Condition
heart NN Condition
disease NN Condition
( ( Condition
VTACH NNP Condition
) ) Condition
: : None
patients NNS None
with IN None
ventricular JJ Condition
tachycardia NN Condition
( ( Condition
VT NNP Condition
) ) Condition
and CC None
a DT None
history NN None
of IN None
myocardial JJ Condition
infarction NN Condition
The DT None
Ventricular NNP Condition
Tachycardia NNP Condition
Ablation NNP Condition
in IN Condition
Coronary NNP Condition
Heart NNP Condition
Disease NNP Condition
( ( Condition
VTACH NNP Condition
) ) Condition
study NN None
was VBD None
a DT None
prospective JJ None
, , None
open JJ None
, , None
randomised VBD None
controlled VBN None
trial NN None
, , None
undertaken VBN None
in IN None
16 CD None
centres NNS None
in IN None
four CD None
European JJ None
countries NNS None
. . None
Patients NNS None
aged VBN None
18-80 CD Age
years NNS Age
were VBD None
eligible JJ None
for IN None
enrolment NN None
if IN None
they PRP None
had VBD None
stable JJ Condition
VT NNP Condition
, , None
previous JJ Condition
myocardial JJ Condition
infarction NN Condition
, , None
and CC None
reduced VBD Condition
left-ventricular JJ Condition
ejection NN Condition
fraction NN Condition
( ( Condition
LVEF NNP Condition
; : Condition
< NNP Condition
or=50 IN Condition
% NN Condition
) ) Condition
. . None
110 CD Size
patients NNS None
were VBD None
randomly RB None
allocated VBN None
in IN None
a DT None
1:1 CD None
ratio NN None
107 CD Size
patients NNS None
were VBD None
included VBN None
in IN None
the DT None
ITT NNP None
population NN None
( ( None
ablation NN None
group NN None
, , None
n=52 RB None
; : None
control NN None
group NN None
, , None
n=55 RB None
) ) None
. . None
Nine JJ Size
patients NNS None
died VBD None
during IN None
the DT None
study NN None
( ( None
ablation NN None
group NN None
, , None
five CD None
; : None
control NN None
group NN None
, , None
four CD None
) ) None
. . None
patients NNS None
with IN None
stable JJ Condition
VT NNP Condition
, , None
previous JJ Condition
myocardial JJ Condition
infarction NN Condition
, , None
and CC None
reduced VBD Condition
LVEF NNP Condition
. . None
-DOCSTART- -X- N

nocturnal JJ None
sleep JJ None
disruption NN None
: : None
patients NNS None
with IN None
narcolepsy JJ None
. . None
narcolepsy JJ None
patients NNS None
228 CD None
adult NN None
patients NNS None
with IN None
narcolepsy/cataplexy NNS None
in IN None
the DT None
United NNP None
States NNPS None
, , None
Canada NNP None
, , None
and CC None
Europe NNP None
. . None
receiving VBG None
6 CD None
and CC None
9 CD None
g/night NN None
doses NNS None
-DOCSTART- -X- N

in IN None
AIDS NNP Condition
patients NNS None
in IN None
the DT None
Canadian NNP None
randomized VBD None
MAC NNP None
treatment NN None
trial NN None
. . None
HIV-positive JJ Condition
patients NNS None
with IN None
Mycobacterium NNP Condition
avium NN Condition
complex NN Condition
( ( Condition
MAC NNP Condition
) ) Condition
bacteremia NN Condition
. . None
Twenty-four JJ Size
hospital-based JJ None
HIV NNP None
clinics NNS None
in IN None
16 CD None
Canadian JJ None
cities NNS None
. . None
-DOCSTART- -X- N

male JJ None
mink NN None
( ( None
Neovison NNP None
vison NN None
) ) None
. . None
Eighty-six JJ None
male JJ None
mink NN None
were VBD None
exposed VBN None
to TO None
low VB None
( ( None
19 CD None
% NN None
of IN None
ME NNP None
from IN None
CP NNP None
; : None
crude JJ None
protein NN None
) ) None
or CC None
adequate JJ None
( ( None
31 CD None
% NN None
of IN None
ME NNP None
from IN None
CP NNP None
) ) None
protein NN None
provision NN None
in IN None
utero NN None
, , None
and CC None
to TO None
LP NNP None
( ( None
~20 CD None
% NN None
of IN None
ME NNP None
from IN None
CP NNP None
) ) None
or CC None
AP NNP None
( ( None
30-42 CD None
% NN None
of IN None
ME NNP None
from IN None
CP NNP None
) ) None
provision NN None
post-weaning NN None
. . None
mink NN None
-DOCSTART- -X- N

children NNS Condition
undergoing VBG Condition
laparoscopy NN Condition
. . Condition
50 CD Condition
children NNS Condition
undergoing JJ Condition
laparoscopy NN Condition
for IN Condition
diagnostic JJ Condition
and CC Condition
therapeutic JJ Condition
purposes NNS Condition
. . Condition
Their PRP$ None
ages NNS None
ranged VBN None
from IN None
3 CD None
to TO None
13 CD None
years NNS None
, , None
and CC None
all DT None
belonged VBD None
to TO None
American NNP None
Society NNP None
of IN None
Anesthesiologists NNP None
( ( None
ASA NNP None
) ) None
class NN None
I PRP None
or CC None
II NNP None
. . None
-DOCSTART- -X- N

head NN None
and CC None
neck NN None
cancer NN Condition
surgery NN None
: : None
patients NNS None
with IN None
head NN None
and CC None
neck NN None
cancer NN Condition
. . None
A DT None
population NN None
of IN None
44 CD Size
patients NNS Size
with IN None
oral JJ Condition
and CC Condition
laryngeal JJ Condition
cancer NN Condition
was VBD None
enrolled VBN None
in IN None
a DT None
randomized JJ None
trial NN None
. . None
head NN None
and CC None
neck NN None
cancer NN None
patients NNS None
. . None
-DOCSTART- -X- N

obese JJ Condition
patients NNS None
. . None
mildly RB Condition
or CC Condition
transiently RB Condition
hypertensive JJ Condition
nondiabetic JJ Condition
obese JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
. . None
healthy JJ None
volunteers NNS None
subjects NNS None
-DOCSTART- -X- N

methamphetamine NN Condition
craving NN Condition
. . None
population NN None
of IN None
methamphetamine NN Condition
users NNS Condition
. . None
-DOCSTART- -X- N

type NN None
II NNP None
diabetes VBZ None
mellitus NN None
. . None
somatostatin NN None
in IN None
10 CD None
normal JJ None
persons NNS None
( ( None
age NN None
26 CD None
+/- JJ None
3 CD None
years NNS None
, , None
relative JJ None
body NN None
weight VBD None
26 CD None
+/- JJ None
10 CD None
% NN None
according VBG None
to TO None
Broca NNP None
) ) None
-DOCSTART- -X- N

influenza NN None
type NN None
A DT None
or CC None
B NNP None
infection NN None
in IN None
25 CD None
patients NNS None
. . None
patients NNS None
with IN None
influenza NN None
A NNP None
or CC None
B NNP None
infection NN None
-DOCSTART- -X- N

children NNS None
vaccinated VBN None
with IN None
live JJ None
attenuated VBN None
influenza JJ None
vaccine NN None
. . None
children NNS None
vaccinated VBN None
with IN None
live JJ None
attenuated VBN None
influenza JJ None
vaccine NN None
( ( None
LAIV NNP None
) ) None
children NNS None
6-36 JJ None
months NNS None
of IN None
age NN None
. . None
-DOCSTART- -X- N

autism NN Condition
. . Condition
autistic JJ None
children NNS None
in IN None
residential JJ None
treatment NN None
. . None
Residential JJ None
school NN None
children NNS None
( ( None
N NNP None
= NNP None
18 CD None
) ) None
-DOCSTART- -X- N

German JJ None
Blackhead NNP None
mutton NN None
sheep NN None
. . None
shorn JJ None
and CC None
unshorn JJ None
sheep NN None
. . None
temperate JJ None
environmental JJ None
conditions NNS None
. . None
Fourteen NNP Size
nonlactating JJ Condition
German JJ None
Blackhead NNP None
mutton NN None
ewes NN None
in IN None
German JJ None
Blackhead NNP None
mutton NN None
sheep NN None
, , None
thus RB None
indicating VBG None
stress NN None
in IN None
fleeced JJ None
animals NNS None
, , None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ None
hepatic JJ None
disorders NNS None
] VBP None
494 CD None
patients NNS None
with IN None
chronic JJ None
hepatitis NN None
B NNP None
and CC None
C. NNP None
staying VBG None
in IN None
7 CD None
clinics NNS None
-DOCSTART- -X- N

young JJ None
patients NNS None
treated VBN None
with IN None
drospirenone-ethinylestradiol NN None
or CC None
contraceptive JJ None
vaginal JJ None
ring NN None
. . None
Bologna NNP None
University NNP None
School NNP None
of IN None
Medicine NNP None
. . None
Thirty-seven NNP None
women NNS None
with IN None
polycystic JJ None
ovary JJ None
syndrome NN None
( ( None
PCOS NNP None
) ) None
-DOCSTART- -X- N

surgical JJ None
trainees NNS None
learning VBG None
open JJ None
gastrectomy NN None
Thirty NNP None
residents NNS None
in IN None
general JJ None
surgery NN None
performed VBD None
2 CD None
open JJ None
partial JJ None
gastrectomy NN None
training VBG None
events NNS None
on IN None
a DT None
porcine JJ None
model NN None
. . None
-DOCSTART- -X- N

rats NNS None
. . None
controlled VBD None
animal JJ None
trial NN None
CCI NNP None
) ) None
rat VBP None
model NN None
of IN None
METHODS NNP None
Sprague-Dawley NNP None
rats NNS None
weighting VBG None
260 CD None
- : None
320 CD None
g NN None
vector NN None
) ) None
. . None
Rats NNPS None
Animals NNS None
were VBD None
sacrificed VBN None
and CC None
the DT None
L4-5 NNP None
lumbar NN None
segment NN None
of IN None
the DT None
spinal JJ None
cord NN None
was VBD None
removed VBN None
for IN None
determination NN None
of IN None
green JJ None
fluorescent NN None
protein NN None
( ( None
GFP NNP None
) ) None
expression NN None
. . None
Immunohistochemical JJ None
rats NNS None
-DOCSTART- -X- N

analgesia NN Condition
after IN Condition
craniotomy NN Condition
. . Condition
82 CD None
patients NNS None
undergoing JJ None
elective JJ None
craniotomies NNS None
. . None
-DOCSTART- -X- N

body NN None
fat JJ None
and CC None
blood NN None
lipid JJ None
profiles NNS None
of IN None
male JJ Sex
hypertriglyceridemic JJ Condition
subjects NNS None
. . None
body NN None
fat JJ None
and CC None
blood NN None
lipid JJ None
profiles NNS None
in IN None
hypertriglyceridemic JJ None
subjects NNS None
. . None
One-hundred-and-twelve JJ Size
subjects NNS None
50 CD Size
subjects NNS None
( ( None
34 CD Size
men NNS Sex
and CC None
16 CD Size
women NNS Sex
) ) None
, , None
while IN None
the DT None
MLCT NNP None
group NN None
consisted VBD None
of IN None
51 CD Size
subjects NNS None
( ( None
33 CD Size
men NNS Sex
and CC None
18 CD Size
women NNS Sex
) ) None
who WP None
completed VBD None
the DT None
study NN None
. . None
male JJ None
hypertriglyceridemic JJ None
subjects NNS None
. . None
-DOCSTART- -X- N

Twenty NNP Size
healthy JJ None
men NNS None
, , None
aged VBN None
18-55 CD Age
years NNS None
-DOCSTART- -X- N

childhood NN None
acute NN None
lymphoblastic JJ None
leukemia NN None
: : None
boys NNS None
with IN None
occult NN None
TL NNP None
494 CD None
boys NNS None
entered VBD None
on IN None
study NN None
263 CD None
boys NNS None
were VBD None
eligible JJ None
for IN None
testicular JJ None
biopsy NN None
. . None
Elective JJ None
testicular JJ None
biopsy NN None
was VBD None
performed VBN None
on IN None
235 CD None
( ( None
89.4 CD None
% NN None
) ) None
boys VBZ None
. . None
-DOCSTART- -X- N

[ JJ None
Obstetrical NNP None
analgesia NN None
23 CD None
normal JJ None
deliveries NNS None
. . None
group NN None
of IN None
normal JJ None
deliveries NNS None
in IN None
which WDT None
analgesia NN None
was VBD None
achieved VBN None
with IN None
pethidine NN None
. . None
-DOCSTART- -X- N

cervical JJ Condition
vertigo NN Condition
] NN None
cervical JJ Condition
vertigo NN Condition
January NNP None
2002 CD None
to TO None
May NNP None
2008 CD None
, , None
168 CD Size
patients NNS None
with IN None
cervical JJ None
vertigo NNS None
were VBD None
randomly RB None
divided VBN None
into IN None
treatment NN None
group NN None
( ( None
84 CD Size
cases NNS None
) ) None
and CC None
the DT None
control NN None
group NN None
( ( None
84 CD Size
cases NNS None
) ) None
, , None
22 CD Size
males NNS Sex
and CC None
62 CD Size
females NNS Sex
in IN None
treatment NN None
group NN None
; : None
24 CD Size
males NNS Sex
and CC None
60 CD Size
females NNS Sex
in IN None
control NN None
group NN None
. . None
cervical JJ None
vertigo NN None
vertebral JJ Condition
body NN Condition
displacement NN Condition
-DOCSTART- -X- N

after IN None
hip NN Condition
arthroplasty NN Condition
. . None
primary JJ Condition
total JJ Condition
hip NN Condition
arthroplasty NN Condition
186 CD Size
patients NNS None
received VBD None
either RB None
indomethacin JJ None
3 CD None
times NNS None
daily RB None
, , None
or CC None
rofecoxib VB None
twice RB None
, , None
and CC None
1 CD None
placebo NN None
, , None
daily RB None
for IN None
7 CD None
days NNS None
. . None
12 CD None
of IN None
the DT None
186 CD None
patients NNS None
included VBD None
discontinued VBN None
their PRP$ None
medication NN None
before IN None
the DT None
end NN None
of IN None
the DT None
trial NN None
due JJ None
to TO None
side VB None
effects NNS None
. . None
The DT None
remaining VBG None
174 CD Size
patients NNS None
were VBD None
included VBN None
in IN None
the DT None
analysis NN None
. . None
In IN None
the DT None
indomethacin NN None
group NN None
( ( None
n JJ None
= NNP None
89 CD Size
) ) None
, , None
77 CD None
patients NNS None
( ( None
87 CD None
% NN None
) ) None
showed VBD None
no DT None
HO NNP None
, , None
9 CD None
showed VBD None
HO NNP None
of IN None
grade NN None
1 CD None
and CC None
3 CD None
showed VBD None
HO NNP None
of IN None
grade NN None
2 CD None
according VBG None
to TO None
the DT None
Brooker NNP None
classification NN None
. . None
In IN None
the DT None
rofecoxib NN None
group NN None
( ( None
n JJ None
= NNP None
85 CD Size
) ) None
73 CD None
patients NNS None
( ( None
86 CD None
% NN None
) ) None
showed VBD None
no DT None
ossification NN None
, , None
9 CD None
showed VBD None
grade NN None
1 CD None
, , None
and CC None
3 CD None
showed VBD None
grade JJ None
2 CD None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
mellitus RB None
. . None
type NN None
2 CD None
diabetics NNS None
. . None
71 CD None
type NN None
2 CD None
diabetics NNS None
completed VBD None
the DT None
study NN None
. . None
diabetic JJ None
and CC None
hyperglycemic JJ None
patients NNS None
in IN None
need NN None
of IN None
nutritional JJ None
support NN None
. . None
-DOCSTART- -X- N

dairy NN None
cows NNS None
at IN None
parturition NN None
. . None
dairy VB None
cows NNS None
during IN None
the DT None
last JJ None
seven CD None
weeks NNS None
of IN None
pregnancy NN None
Ten CD None
monozygotic JJ None
twin NN None
pairs NNS None
of IN None
pregnant JJ None
cows NNS None
( ( None
five CD None
pairs NNS None
of IN None
parity NN None
1 CD None
or CC None
2 CD None
, , None
and CC None
five CD None
pairs NNS None
of IN None
parity NN None
3 CD None
or CC None
more JJR None
) ) None
cows NNS None
fed VBP None
the DT None
anion NN None
diet NN None
cows NNS None
fed VBP None
the DT None
cation NN None
diet NN None
. . None
-DOCSTART- -X- N

20 CD Size
men NNS Sex
with IN None
ventricular JJ Condition
tachycardia NN Condition
. . None
patient NN None
both DT None
with IN None
placebo NN Condition
and CC None
with IN None
active JJ Condition
pyridostigmine NN Condition
. . Condition
-DOCSTART- -X- N

chronic JJ Condition
stable JJ Condition
angina NN Condition
pectoris NN Condition
; : None
patients NNS None
with IN None
chronic JJ Condition
stable JJ Condition
angina NN Condition
in IN None
a DT None
large JJ None
scale NN None
, , None
international JJ None
Four CD None
hundred VBD None
patients NNS None
with IN None
chronic JJ None
stable JJ None
angina NN None
pectoris NN None
and CC None
a DT None
positive JJ None
treadmill NN None
exercise NN None
test NN None
were VBD None
randomized VBN None
198 CD None
patients NNS None
patients NNS None
with IN None
chronic JJ Condition
stable JJ Condition
angina NN Condition
treated VBN None
with IN None
regular JJ None
antianginal JJ None
background NN None
medication NN None
-DOCSTART- -X- N

Alzheimer NNP Condition
's POS Condition
caregiver NN None
health NN None
II NNP None
intervention NN None
. . None
CG NNP None
and CC None
care VB None
recipient NN None
( ( None
CR NNP None
) ) None
homes NNS None
in IN None
five CD None
U.S. NNP None
cities NNS None
. . None
Four CD Size
hundred CD Size
ninety-five JJ Size
dementia NN Condition
CG NNP Condition
and CC Condition
CR NNP Condition
dyads NNS Condition
( ( None
169 CD None
Hispanic NNP None
, , None
160 CD None
white JJ None
, , None
and CC None
166 CD None
African JJ None
American NNP None
) ) None
receiving VBG None
intervention NN None
and CC None
their PRP$ None
controls NNS None
. . None
racially RB None
and CC None
ethnically RB None
diverse JJ None
CGs NNP None
of IN None
people NNS None
with IN None
dementia NN Condition
. . None
-DOCSTART- -X- N

34 CD Size
, , None
lean JJ Condition
or CC None
overweight/obese JJ Condition
adults NNS Age
revealed VBD None
the DT None
obese JJ None
group NN None
the DT None
lean JJ None
and CC None
overweight JJ None
groups NNS None
overweight JJ None
and CC None
obese JJ None
individuals NNS None
. . None
-DOCSTART- -X- N

42 CD None
patients NNS None
Participants NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
treatment NN None
nursing NN None
modality NN None
for IN None
chronic JJ None
pain NN None
sufferers NNS None
. . None
-DOCSTART- -X- N

autistic JJ None
individuals NNS None
Eighteen NNP None
autistic JJ None
individuals NNS None
, , None
ranging VBG None
in IN None
age NN None
from IN None
7 CD None
to TO None
18 CD None
years NNS None
autistic JJ None
individuals NNS None
. . None
-DOCSTART- -X- N

Seventy-two JJ None
patients NNS None
with IN None
a DT None
carpal JJ None
tunnel NN None
syndrome NN None
were VBD None
individually RB None
randomized VBN None
into IN None
the DT None
trial NN None
( ( None
limited JJ None
incision NN None
CTR NNP None
) ) None
( ( None
n=36 JJ None
) ) None
and CC None
control NN None
group NN None
( ( None
traditional JJ None
technique NN None
CTR NNP None
) ) None
( ( None
n=36 JJ None
) ) None
. . None
In IN None
the DT None
trial NN None
group NN None
, , None
skin FW None
incision NN None
parallel NN None
to TO None
the DT None
thenar NN None
crease NN None
was VBD None
made VBN None
up RP None
to TO None
2.5 CD None
cm NN None
in IN None
length NN None
, , None
under IN None
an DT None
operating NN None
microscope NN None
and CC None
endoscopic JJ None
transillumination NN None
. . None
Skin NNP None
incision NN None
in IN None
the DT None
control NN None
group NN None
began VBD None
at IN None
the DT None
distal JJ None
border NN None
of IN None
the DT None
carpal JJ None
ligament NN None
, , None
followed VBD None
the DT None
longitudinal JJ None
crease NN None
of IN None
the DT None
palm NN None
, , None
and CC None
crossed VBD None
the DT None
base NN None
of IN None
the DT None
palm NN None
in IN None
a DT None
zigzag JJ None
fashion NN None
. . None
Three CD None
months NNS None
after IN None
surgery NN None
-DOCSTART- -X- N

nocturnal JJ None
asthma NN None
: : None
multicentre JJ None
French JJ None
Multicentre NNP None
Study NNP None
Group NNP None
. . None
Ninety NNP None
six CD None
patients NNS None
with IN None
nocturnal JJ None
asthma NN None
, , None
( ( None
forced JJ None
expiratory NN None
volume NN None
in IN None
one CD None
second NN None
( ( None
FEV1 NNP None
) ) None
60-90 CD None
% NN None
of IN None
predicted JJ None
value NN None
, , None
reversibility NN None
> NN None
or CC None
= VB None
15 CD None
% NN None
, , None
at IN None
least JJS None
two CD None
nocturnal JJ None
awakenings NNS None
per IN None
week NN None
) ) None
multicentre NN None
patients NNS None
with IN None
nocturnal JJ None
asthma NN None
. . None
-DOCSTART- -X- N

obese JJ Condition
patients NNS None
with IN None
chronic JJ Condition
arthropathy JJ Condition
] NN None
obese JJ Condition
patients NNS None
with IN None
an DT None
indication NN None
of IN None
replacement NN None
surgery NN None
for IN None
degenerative JJ None
osteoarthritis NN None
Thirty NNP Size
six CD Size
patients NNS None
were VBD None
randomized VBN None
Obese JJ Condition
patients NNS None
with IN None
chronic JJ Condition
osteoarthritis NN Condition
-DOCSTART- -X- N

Sensitivity NN None
to TO None
musical JJ None
structure NN None
in IN None
the DT None
human JJ None
brain NN None
. . None
brain-damaged JJ Condition
patients NNS None
individual-subject JJ None
fMRI NN None
analyses NNS None
-DOCSTART- -X- N

children NNS None
with IN None
pervasive JJ Condition
developmental NN Condition
disorders NNS Condition
. . None
children NNS None
with IN None
Pervasive NNP Condition
developmental NN Condition
disorders NNS Condition
( ( Condition
PDDs NNP Condition
) ) Condition
. . Condition
Subjects NNS None
( ( None
128 CD None
boys NNS None
, , None
21 CD None
girls NNS None
) ) None
had VBD None
a DT None
mean JJ None
age NN None
of IN None
9.3 CD None
( ( None
?3.12 NN None
) ) None
years NNS None
; : None
132 CD None
( ( None
88.6 CD None
% NN None
) ) None
were VBD None
diagnosed VBN None
with IN None
autistic JJ None
disorder NN None
( ( None
4.7 CD None
% NN None
with IN None
Asperger NNP None
's POS None
Disorder NNP None
; : None
6.7 CD None
% NN None
with IN None
PDD-not NNP None
otherwise RB None
specified VBD None
) ) None
. . None
Less JJR None
than IN None
half NN None
of IN None
the DT None
subjects NNS None
were VBD None
intellectually RB None
disabled VBN None
; : None
117 CD None
( ( None
78.5 CD None
% NN None
) ) None
were VBD None
rated VBN None
Moderate NNP None
or CC None
Marked VBN None
on IN None
the DT None
Clinical NNP None
Global NNP None
Impression NNP None
for IN None
Severity NNP None
. . None
Subjects NNS None
in IN None
this DT None
trial NN None
were VBD None
slightly RB None
older JJR None
and CC None
more RBR None
likely JJ None
to TO None
have VB None
complaints NNS None
of IN None
repetitive JJ None
behavior NN None
-DOCSTART- -X- N

patients NNS None
with IN None
atrial JJ None
fibrillation NN None
: : None
patiENTs NN None
with IN None
Atrial NNP None
fibrillation/atrial JJ None
flutter NN None
( ( None
ATHENA NNP None
) ) None
patients NNS None
with IN None
atrial JJ None
fibrillation NN None
( ( None
AF NNP None
) ) None
. . None
4628 CD None
patients NNS None
with IN None
a DT None
history NN None
of IN None
paroxysmal/persistent NN None
AF NNP None
and CC None
additional JJ None
risk NN None
factors NNS None
-DOCSTART- -X- N

nephrectomy JJ Condition
specimen NNS None
removed VBD None
for IN None
ipsilateral JJ Condition
renal JJ Condition
cell NN Condition
carcinoma NN Condition
. . None
nephrectomy JJ None
specimen NNS None
removed VBD None
for IN None
primary JJ None
renal JJ Condition
cell NN Condition
carcinoma NN Condition
primary JJ None
renal JJ Condition
cell NN Condition
carcinoma NN Condition
-DOCSTART- -X- N

children NNS Age
with IN None
an DT None
increased VBN None
risk NN None
of IN None
developing VBG None
hypertension NN Condition
-- : None
The DT None
children NNS Age
aged VBN None
9-11 CD Age
years NNS None
, , None
partly RB None
cross-sectionally RB None
and CC None
partly RB None
longitudinally RB None
after IN None
a DT None
physical JJ None
training NN None
programme NN None
. . None
Children NNP Age
from IN None
a DT None
hypertensive JJ Condition
subgroup NN None
comprising VBG None
the DT None
upper JJ None
5 CD None
% NN None
of IN None
the DT None
blood NN None
pressure NN None
distribution NN None
and CC None
children NNS None
from IN None
a DT None
randomly RB None
selected VBN None
normotensive JJ None
subgroup NN None
were VBD None
eligible JJ None
for IN None
the DT None
study NN None
. . None
In IN None
the DT None
cross-sectional JJ None
study NN None
40 CD Size
children NNS Age
from IN None
the DT None
hypertensive JJ Condition
subgroup NN None
and CC None
40 CD Size
children NNS None
from IN None
the DT None
normotensive JJ None
subgroup NN None
were VBD None
evaluated VBN None
. . None
10 CD Size
boys NNS None
from IN None
the DT None
hypertensive JJ Condition
subgroup NN None
and CC None
10 CD Size
boys NNS None
from IN None
the DT None
normotensive JJ None
subgroup NN None
children NNS Age
. . None
-DOCSTART- -X- N

One CD Condition
hundred CD Condition
and CC Condition
ten JJ Condition
patients NNS Condition
with IN None
a DT None
femoral JJ Condition
shaft NN Condition
fracture NN Condition
were VBD None
enrolled VBN None
in IN None
a DT None
prospective JJ None
, , None
randomized VBN None
study NN None
. . None
Fifty-four CD Size
patients NNS None
fifty-six JJ Size
-DOCSTART- -X- N

Leukocyte-depleted JJ None
reperfusion NN None
of IN None
transplanted JJ None
human JJ None
hearts NNS None
: : None
20 CD None
patients NNS None
were VBD None
enrolled VBN None
in IN None
a DT None
randomized JJ None
, , None
double-blind JJ None
clinical JJ None
trial NN None
to TO None
be VB None
treated VBN None
with IN None
either DT None
warm JJ None
whole NN None
blood NN None
reperfusion NN None
( ( None
group NN None
I PRP None
; : None
n CC None
= VB None
9 CD None
) ) None
( ( None
group NN None
II NNP None
; : None
n CC None
= VB None
11 CD None
) ) None
. . None
-DOCSTART- -X- N

rheumatoid JJ Condition
arthritis NN Condition
patients NNS None
treated VBN None
with IN None
etanercept JJ None
monotherapy NN None
: : None
etanercept-treated JJ None
patients NNS None
with IN None
rheumatoid JJ Condition
arthritis NN Condition
( ( Condition
RA NNP Condition
) ) Condition
. . None
Data NNP None
from IN None
an DT None
RCT NNP None
( ( None
Trial NNP None
of IN None
Etanercept NNP None
and CC None
Methotrexate NNP None
with IN None
Radiographic NNP None
Patient NNP None
Outcomes NNP None
[ NNP None
TEMPO NNP None
] NNP None
; : None
n=682 CC Size
) ) None
and CC None
an DT None
observational JJ None
registry NN None
( ( None
Rheumatoid NNP None
Arthritis NNP None
DMARD NNP None
Intervention NNP None
and CC None
Utilization NNP None
Study NNP None
[ NNP None
RADIUS NNP None
II NNP None
] NNP None
; : None
n=4341 CC None
) ) None
patients NNS None
initiating VBG None
etanercept NN None
( ( None
monotherapy NN None
or CC None
with IN None
methotrexate NN None
) ) None
. . None
RESULTS JJ None
Patients NNS None
from IN None
TEMPO NNP None
and CC None
RADIUS NNP None
II NNP None
who WP None
received VBD None
etanercept JJ None
monotherapy NN None
showed VBD None
patients NNS None
with IN None
lower JJR None
baseline NN None
CDAI NNP None
scores VBZ None
achieved VBN None
-DOCSTART- -X- N

stroke NN Condition
patients NNS None
16 CD Size
consecutive JJ None
patients NNS None
( ( None
median JJ None
age NN None
58.5 CD None
years NNS None
, , None
range VB None
40-83 JJ None
) ) None
Crying VBG Condition
history NN Condition
was VBD None
determined VBN None
from IN None
semistructured VBN None
interviews NNS None
and CC None
from IN None
diaries NNS None
kept VBN None
by IN None
the DT None
patients NNS None
. . None
13 CD Size
patients NNS None
in IN None
whom WP None
frequency NN None
of IN None
crying NN Condition
-DOCSTART- -X- N

Ninety-five JJ Size
primary JJ None
insomniacs NN Condition
, , None
32-64 CD Age
years NNS Age
old JJ Age
and CC Age
55 CD Age
age- JJ Age
and CC None
sex-matched JJ None
general JJ None
population-based JJ None
, , None
representative JJ None
controls NNS None
. . None
participants NNS None
with IN None
primary JJ Condition
insomnia NNS Condition
insomniacs NN None
-DOCSTART- -X- N

patients NNS None
with IN None
locally RB Condition
advanced JJ Condition
pancreatic JJ Condition
cancer NN Condition
-- : None
a DT None
multi-centre JJ None
locally RB Condition
advanced JJ Condition
pancreatic JJ Condition
cancer NN Condition
( ( None
LAPC NNP Condition
) ) None
95 CD Size
patients NNS None
with IN None
LAPC NNP Condition
-DOCSTART- -X- N

patients NNS None
with IN None
atrial JJ Condition
fibrillation NN Condition
. . None
after IN Condition
conversion NN Condition
to TO Condition
sinus VB Condition
rhythm NN Condition
. . None
patients NNS None
with IN None
atrial JJ Condition
fibrillation NN Condition
Patients NNPS None
who WP None
had VBD None
symptomatic JJ Condition
atrial JJ Condition
fibrillation NN Condition
for IN None
> $ None
48 CD None
hours NNS None
but CC None
< $ None
6 CD None
months NNS None
were VBD None
eligible JJ None
Patients NNS None
were VBD None
admitted VBN None
to TO None
a DT None
hospital NN None
randomly RB None
assigned VBN None
to TO None
receive VB None
either DT None
azimilide JJ None
125 CD None
mg NN None
or CC None
a DT None
matched JJ None
placebo NN None
twice RB None
daily RB None
for IN None
3 CD None
days NNS None
and CC None
then RB None
once RB None
daily JJ None
. . None
Patients NNS None
who WP None
were VBD None
in IN None
sinus NN None
rhythm NN None
spontaneously RB None
or CC None
had VBD None
sinus VBN None
rhythm NNS None
restored VBN None
by IN None
electric JJ None
cardioversion NN None
on IN None
day NN None
4 CD None
were VBD None
discharged VBN None
from IN None
the DT None
hospital NN None
. . None
patients NNS None
with IN None
structural JJ Condition
heart NN Condition
disease NN Condition
. . None
446 CD Size
patients NNS None
were VBD None
randomized VBN None
in IN None
the DT None
study NN None
; : None
314 CD Size
were VBD None
in IN None
the DT None
subgroup NN None
with IN None
structural JJ Condition
heart NN Condition
disease NN Condition
. . None
patients NNS None
with IN None
structural JJ Condition
heart NN Condition
disease NN Condition
who WP None
were VBD None
in IN None
atrial JJ Condition
fibrillation NN Condition
and CC None
converted VBD Condition
to TO Condition
sinus VB Condition
rhythm NN Condition
. . None
-DOCSTART- -X- N

gastroesophageal JJ Condition
malignancy NN Condition
. . None
300 CD Size
consecutive JJ None
patients NNS None
, , None
including VBG None
256 CD Size
with IN None
esophageal NN Condition
or CC Condition
gastric JJ Condition
carcinomas NN Condition
. . None
patients NNS None
with IN None
carcinoma NN Condition
-DOCSTART- -X- N

human JJ None
forearm NN None
. . None
human JJ None
forearm NN None
. . None
Subjects VBZ None
human JJ None
forearm NN None
of IN None
healthy JJ Condition
salt NN Condition
replete JJ Condition
subjects NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
epithelial JJ Condition
ovarian JJ Condition
carcinoma NN Condition
that WDT None
recurred VBD Condition
after IN Condition
or CC None
did VBD Condition
n't RB Condition
respond VB Condition
to TO Condition
first-line JJ Condition
, , Condition
platinum-based JJ Condition
chemotherapy NN Condition
Patients NNPS None
with IN None
measurable JJ None
and CC None
assessable JJ None
disease NN None
A DT None
total NN None
of IN None
474 CD Size
patients NNS None
-DOCSTART- -X- N

acromegalic JJ Condition
patients NNS Condition
with IN Condition
macroadenomas JJ Condition
newly RB Condition
diagnosed VBN Condition
acromegalic JJ Condition
patients NNS Condition
with IN Condition
macroadenomas NN Condition
. . None
pool NN None
of IN None
108 CD Size
patients NNS Size
49 CD Size
patients NNS Size
in IN Size
each DT Size
group NN Size
patients NNS Condition
with IN Condition
GH-secreting NNP Condition
pituitary JJ Condition
macroadenomas NN Condition
. . None
-DOCSTART- -X- N

Effects NNS None
of IN None
a DT None
common JJ None
variant NN None
in IN None
the DT None
CD38 NNP None
gene NN None
on IN None
social JJ None
processing NN None
One CD None
potential JJ None
candidate NN None
could MD None
be VB None
the DT None
CD38 NNP None
gene NN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
. . None
55 CD None
healthy JJ None
young JJ None
men NNS None
depending VBG None
on IN None
their PRP$ None
CD38 NNP None
gene NN None
variant NN None
Homozygotic JJ None
risk NN None
allele NN None
carriers NNS None
homozygotic JJ None
risk NN None
allele NN None
carriers NNS None
. . None
allele JJ None
groups NNS None
-DOCSTART- -X- N

elderly JJ Condition
persons NNS Condition
with IN Condition
minor JJ Condition
impairment NN Condition
of IN Condition
brain NN Condition
functions NNS Condition
. . Condition
10 CD Condition
volunteers NNS Condition
( ( Condition
61-78 CD Condition
years NNS Condition
) ) Condition
with IN Condition
minor JJ Condition
impairment NN Condition
of IN Condition
brain NN Condition
function NN Condition
geriatric JJ Condition
patients NNS Condition
-DOCSTART- -X- N

healthy JJ None
participants NNS None
: : None
major JJ None
depressive JJ None
disorder NN None
( ( None
MDD NNP None
) ) None
in IN None
adults NNS None
. . None
healthy JJ None
volunteers NNS None
. . None
healthy JJ None
subjects NNS None
healthy JJ None
adult NN None
participants NNS None
. . None
-DOCSTART- -X- N

chronic JJ Condition
tension-type JJ Condition
headache NN Condition
chronic JJ Condition
tension-type JJ Condition
headache NN Condition
( ( Condition
CTTH NNP Condition
) ) Condition
. . None
Two CD Size
hundred VBD Size
and CC Size
eighty-eight JJ Size
cases NNS Size
CTTH NNP Condition
-DOCSTART- -X- N

deceased-donor JJ None
kidney NN None
transplant NN None
recipients NNS None
at IN None
specified VBN None
risk NN None
of IN None
delayed JJ None
graft NN None
function NN None
: : None
multicenter NN None
Deceased-donor NNP None
kidney NN None
transplant NN None
patients NNS None
at IN None
protocol-specified JJ None
risk NN None
of IN None
DGF NNP None
in IN None
17 CD None
IE JJ None
patients NNS None
( ( None
in IN None
DGF-risk JJ None
patients NNS None
-DOCSTART- -X- N

glioma NN Condition
risk NN Condition
in IN None
Han NNP None
Chinese NNP None
. . None
glioma JJ None
susceptibility NN None
10 CD None
tag NN None
single JJ None
nucleotide JJ None
polymorphisms NN None
( ( None
tSNPs NN None
) ) None
in IN None
seven CD None
genes NNS None
associated VBN None
with IN None
glioma NN Condition
susceptibility NN None
in IN None
a DT None
Han NNP None
Chinese NNP None
population NN None
, , None
including VBG None
301 CD Size
glioma NN None
cases NNS None
and CC None
302 CD Size
controls NNS None
, , None
using VBG None
a DT None
multiplexed JJ None
single JJ None
nucleotide NN None
polymorphism NN None
( ( None
SNP NNP None
) ) None
MassEXTEND NNP None
assay NN None
. . None
-DOCSTART- -X- N

17 CD Size
metabolic JJ Condition
syndrome NN Condition
( ( None
MetS NNP Condition
) ) None
and CC None
15 CD Size
healthy JJ None
subjects NNS None
inhaled VBN None
filtered JJ None
air NN None
( ( None
FA NNP None
) ) None
or CC None
DE NNP None
exposure NN None
in IN None
two-hour JJ None
sessions NNS None
on IN None
different JJ None
days NNS None
with IN None
a DT None
minimum JJ None
2-week JJ None
washout NN None
period NN None
. . None
-DOCSTART- -X- N

10 CD None
healthy JJ None
subjects NNS None
-DOCSTART- -X- N

intrahepatic JJ Condition
cholestasis NN Condition
. . Condition
multicenter NN None
cholestatic JJ None
patients NNS None
with IN None
chronic JJ None
liver NN None
disease NN None
. . None
220 CD None
inpatients NNS None
( ( None
26 CD None
% NN None
chronic JJ None
active JJ None
hepatitis NN None
, , None
68 CD None
% NN None
cirrhosis NN None
, , None
6 CD None
% NN None
primary JJ None
biliary JJ None
cirrhosis NN None
) ) None
with IN None
stable JJ None
( ( None
1 CD None
month NN None
or CC None
more JJR None
) ) None
at IN None
least JJS None
twofold JJ None
increases NNS None
in IN None
serum JJ None
total NN None
and CC None
conjugated VBD None
bilirubin NN None
and CC None
alkaline JJ None
phosphatase NN None
volunteered VBD None
for IN None
the DT None
trial NN None
. . None
-DOCSTART- -X- N

airway NN None
responses NNS None
to TO None
allergen VB None
. . None
airway NN None
responses NNS None
to TO None
inhaled VB None
allergen NN None
. . None
Eight NNP Size
male NN Sex
volunteers NNS None
with IN None
allergic JJ Condition
asthma NN Condition
. . None
-DOCSTART- -X- N

preterm JJ Condition
infants NNS Age
. . None
Preterm NNP Condition
infants NNS Age
preterm NN Condition
infant NN Age
. . None
Two CD None
groups NNS None
of IN None
five CD Size
preterm JJ Condition
infants NNS Age
-DOCSTART- -X- N

criminal JJ None
suspects NNS None
short-sightedness NN None
during IN None
police NNS None
interrogation NN None
participants NNS None
( ( None
N NNP None
= NNP None
81 CD None
) ) None
criminal JJ None
and CC None
unethical JJ None
behaviors NNS None
Experiment JJ None
2 CD None
( ( None
N NNP None
= NNP None
143 CD None
) ) None
-DOCSTART- -X- N

migraine NN Condition
30 CD Size
children NNS Age
between IN Age
7 CD Age
and CC Age
17 CD Age
years NNS None
suffering VBG None
from IN None
at IN None
least JJS None
2 CD None
attacks/month NN None
of IN None
common JJ Condition
or CC Condition
classical JJ Condition
migraine NN Condition
since IN None
more JJR None
than IN None
1 CD None
year NN None
childhood NN Condition
migraine NN Condition
. . Condition
-DOCSTART- -X- N

new JJ None
non-urgent JJ None
rheumatology NN None
out-patient JJ None
referrals NNS None
. . None
patients NNS None
referred VBN None
for IN None
a DT None
non-urgent JJ None
rheumatology NN None
opinion NN None
. . None
a DT None
'fast JJ None
track NN None
' POS None
appointment NN None
with IN None
a DT None
6-week JJ None
target NN None
waiting VBG None
time NN None
against IN None
an DT None
'ordinary JJ None
' POS None
appointment NN None
in IN None
the DT None
main JJ None
city NN None
out-patient JJ None
clinic NN None
of IN None
the DT None
rheumatology NN None
service NN None
for IN None
the DT None
Lothian JJ None
and CC None
Borders NNPS None
region NN None
( ( None
population NN None
approximately RB None
1 CD None
million CD None
) ) None
. . None
-DOCSTART- -X- N

Seventy-two JJ Size
oncology NN Condition
nurses NNS Condition
-DOCSTART- -X- N

osteoarthritis NN Condition
of IN Condition
the DT Condition
knee NN Condition
. . None
osteoarthritis NN Condition
of IN Condition
the DT Condition
knee NN Condition
. . None
Outpatient NNP None
physical JJ None
therapy NN None
department NN None
of IN None
a DT None
large JJ None
military JJ None
medical JJ None
center NN None
. . None
83 CD Size
patients NNS None
with IN None
osteoarthritis NN Condition
of IN Condition
the DT Condition
knee NN Condition
who WP None
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
treatment NN None
( ( None
n JJ None
= VBZ None
42 CD Size
; : None
15 CD Size
men NNS Sex
and CC None
27 CD Size
women NNS Sex
[ JJ None
mean JJ None
age NN None
, , None
60 CD Age
+/- JJ Age
11 CD Age
years NNS None
] RB None
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= VBZ None
41 CD Size
; : None
19 CD Size
men NNS None
and CC None
22 CD Size
women NNS None
[ JJ None
mean JJ None
age NN None
, , None
62 CD Age
+/- JJ Age
10 CD Age
years NNS None
] RB None
) ) None
. . None
treatment NN None
group NN None
placebo NN None
group NN None
patients NNS None
with IN None
osteoarthritis NN Condition
of IN Condition
the DT Condition
knee NN Condition
-DOCSTART- -X- N

small JJ None
cell NN None
lung NN None
cancer NN None
patients NNS None
. . None
small JJ None
cell NN None
lung NN None
cancer NN None
( ( None
SCLC NNP None
) ) None
patients NNS None
11 CD None
patients NNS None
received VBD None
either RB None
standard JJ None
( ( None
four CD None
weekly RB None
) ) None
chemotherapy NN None
with IN None
ifosfamide NN None
, , None
carboplatin NN None
, , None
and CC None
etoposide RB None
( ( None
ICE NNP None
) ) None
or CC None
accelerated VBN None
( ( None
two CD None
weekly RB None
) ) None
ICE NNP None
with IN None
filgrastim NN None
( ( None
granulocyte JJ None
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
behavior NN None
. . None
13 CD Size
children NNS None
with IN None
autistic JJ Condition
behavior NN Condition
treated VBN None
with IN None
fenfluramine NN Condition
. . None
Six NNP None
children NNS None
( ( None
responders NNS None
) ) None
-DOCSTART- -X- N

Nine NNP None
healthy JJ Condition
volunteers NNS None
( ( None
age NN Age
, , Age
23.4 CD Age
+/- JJ Age
0.2 CD Age
years NNS Age
; : None
body NN None
mas VBZ None
index NN None
[ NNP None
BMI NNP None
] NNP None
, , None
23.5 CD None
+/- JJ None
1.6 CD None
kg/m NN None
( ( None
2 CD None
) ) None
) ) None
-DOCSTART- -X- N

Twelve NNP Age
healthy JJ Age
males NNS Age
with IN Age
a DT Age
mean JJ Age
age NN Age
of IN Age
35 CD Age
years NNS Age
-DOCSTART- -X- N

Oesophageal JJ Condition
intubation NN Condition
Forty NNP None
patients NNS None
had VBD None
both DT None
their PRP$ None
trachea NN None
and CC None
oesophagus NN None
intubated VBN None
anaesthetist NN Condition
's POS Condition
feeling NN None
when WRB None
he PRP None
squeezes VBZ None
the DT None
bag NN None
. . None
-DOCSTART- -X- N

human JJ None
skeletal JJ None
muscle NN None
. . None
Human NNP None
subjects VBZ None
-DOCSTART- -X- N

patients NNS None
receiving VBG Condition
sirolimus NN Condition
and CC Condition
corticosteroids NNS Condition
: : None
420 CD Size
de FW Condition
novo FW Condition
renal JJ Condition
allograft NN Condition
recipients NNS None
at IN None
49 CD None
European JJ None
transplant NN None
centers NNS None
. . None
357 CD Size
patients NNS None
-DOCSTART- -X- N

overweight NN Condition
and CC Condition
obese JJ Condition
women NNS Sex
. . None
overweight JJ Condition
and CC None
obese JJ Condition
women NNS Sex
Eighty-eight NNP Size
overweight NN Condition
and CC None
obese JJ Condition
women NNS Sex
participated VBD None
in IN None
this DT None
study NN None
. . None
-DOCSTART- -X- N

humans NNS None
: : None
exhaustive VBP None
cycling VBG None
exercise NN None
ten JJ None
fit JJ None
male NN None
human JJ None
subjects NNS None
. . None
-DOCSTART- -X- N

patients NNS None
after IN None
stoma NN Condition
surgery NN Condition
Eighteen JJ None
patients NNS None
who WP None
had VBD None
undergone JJ None
stoma NN Condition
surgery NN Condition
patients NNS None
after IN None
stoma NN Condition
surgery NN Condition
. . None
-DOCSTART- -X- N

black JJ None
MSM NNP None
: : None
black JJ None
MSM NNP None
New NNP None
York NNP None
City NNP None
Participants NNP None
( ( None
n JJ None
= NNP None
283 CD Size
) ) None
reporting NN None
at IN None
least JJS None
two CD None
sexual JJ None
partners NNS None
and CC None
unprotected JJ None
anal JJ None
intercourse NN None
with IN None
a DT None
man NN None
in IN None
the DT None
past JJ None
3 CD None
months NNS None
black JJ None
MSM NNP None
in IN None
the DT None
USA NNP None
-DOCSTART- -X- N

obese JJ Condition
adults NNS Age
. . None
obesity NN Condition
. . None
24 CD Size
obese JJ Condition
subjects NNS None
( ( None
22 CD Size
women NNS None
and CC None
2 CD Size
men NNS None
; : None
22-46 CD Age
years NNS Age
old JJ None
) ) None
obese JJ Condition
subjects NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( Condition
ASD NNP Condition
) ) Condition
. . None
Participants NNS None
( ( None
N NNP None
= NNP None
22 CD Size
) ) None
children NNS Age
with IN None
ASD NNP Condition
-DOCSTART- -X- N

healthy JJ Condition
and CC Condition
hypertensive JJ Condition
subjects NNS None
: : None
normal JJ Condition
humans NNS None
and CC None
patients NNS None
with IN None
essential JJ Condition
hypertension NN Condition
. . None
healthy JJ Condition
subjects NNS None
and CC None
in IN None
hypertensive JJ Condition
patients NNS None
11 CD Size
healthy JJ Condition
subjects NNS None
( ( None
controls NNS None
) ) None
and CC None
12 CD Size
hypertensive JJ None
inpatients NNS None
( ( None
mean JJ None
age NN None
, , None
38.9 CD Age
and CC None
40.4 CD Age
yr NN None
, , None
respectively RB None
) ) None
-DOCSTART- -X- N

patients NNS None
who WP None
had VBD None
a DT None
myocardial JJ None
infarction NN None
( ( None
MI NNP None
) ) None
. . None
203 CD None
patients NNS None
with IN None
a DT None
previous JJ None
MI NNP None
-DOCSTART- -X- N

in IN None
children NNS None
and CC None
adolescents NNS None
with IN None
AD NNP None
Autistic JJ None
Disorder NNP None
( ( None
AD NNP None
) ) None
A DT None
total NN None
of IN None
30 CD None
subjects NNS None
, , None
between IN None
the DT None
ages NNS None
of IN None
8 CD None
and CC None
18 CD None
with IN None
AD NNP None
based VBN None
on IN None
DSM NNP None
IV NNP None
criteria NNS None
, , None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
children NNS None
with IN None
AD NNP None
. . None
-DOCSTART- -X- N

impacted JJ None
third JJ None
molars NNS None
associated VBN None
with IN None
no DT None
gross JJ None
pathology NN None
. . None
patients NNS None
, , None
fully RB None
denate VB None
or CC None
with IN None
1 CD None
or CC None
2 CD None
teeth NNS None
missing VBG None
and CC None
older JJR None
than IN None
25 CD None
years NNS None
after IN None
surgical JJ None
removal NN None
of IN None
impacted JJ None
third JJ None
molars NNS None
( ( None
M3s NNP None
) ) None
associated VBN None
with IN None
no DT None
gross JJ None
pathology NN None
. . None
Five NNP None
hundred VBD None
sixty NN None
patients NNS None
, , None
fully RB None
dentate VB None
or CC None
with IN None
1 CD None
or CC None
2 CD None
teeth NNS None
missing VBG None
and CC None
older JJR None
than IN None
25 CD None
years NNS None
who WP None
had VBD None
no DT None
gross JJ None
pathology NN None
associated VBN None
with IN None
their PRP$ None
impacted VBN None
lower JJR None
M3s NNP None
patients NNS None
, , None
fully RB None
dentate VB None
or CC None
with IN None
1 CD None
or CC None
2 CD None
teeth NNS None
missing VBG None
and CC None
older JJR None
than IN None
25 CD None
years NNS None
who WP None
have VBP None
no DT None
jawbone NN None
atrophy NN None
and CC None
no DT None
systemic JJ None
problems NNS None
that WDT None
may MD None
impair VB None
bone NN None
strength NN None
-DOCSTART- -X- N

venous JJ Condition
thromboembolism NN Condition
. . Condition
Patients NNS None
with IN None
pulmonary JJ None
embolism NN None
or CC None
deep JJ None
venous JJ None
thrombosis NN None
patients NNS None
with IN None
an DT None
enhanced JJ None
risk NN None
of IN None
bleeding NN None
patients NNS None
without IN None
these DT None
risk NN None
factors NNS None
patients NNS Condition
receiving VBG Condition
continuous JJ Condition
heparin NN Condition
therapy NN Condition
. . Condition
patients NNS None
without IN None
risk NN None
factors NNS None
for IN None
bleeding NN None
patients NNS None
with IN None
a DT None
high JJ None
risk NN None
of IN None
bleeding NN None
-DOCSTART- -X- N

genital JJ Condition
herpes NNS Condition
. . None
chronic JJ Condition
recurrent NN Condition
genital JJ Condition
herpes NNS Condition
with IN Condition
high JJ Condition
incidence NN Condition
of IN Condition
relapses NNS Condition
. . None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Condition
. . Condition
autistic JJ None
children NNS None
who WP None
underwent VBP None
intrathecal JJ None
transplantation NN None
of IN None
stem NN None
cells NNS None
by IN None
lumbar NN None
puncture NN None
. . None
Forty NNP None
autistic JJ None
children NNS None
aged VBN None
2-12 CD None
, , None
who WP None
were VBD None
scheduled VBN None
for IN None
stem NN None
cell NN None
transplantation NN None
via IN None
lumbar NN None
puncture NN None
under IN None
anesthesia NN None
autistic JJ None
children NNS None
. . None
-DOCSTART- -X- N

poor JJ None
responder NN None
patients NNS None
. . None
poor JJ None
responder NN None
women NNS None
. . None
34 CD None
patients NNS None
undergoing JJ None
assisted JJ None
reproduction NN None
34 CD None
patients NNS None
poor JJ None
responder NN None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
symptomatic JJ Condition
paroxysmal JJ Condition
atrial JJ Condition
fibrillation NN Condition
and/or NN Condition
flutter NN Condition
monitored VBD None
with IN None
trans-telephonic JJ None
electrocardiography NN None
: : None
patients NNS None
with IN None
paroxysmal JJ Condition
atrial JJ Condition
fibrillation NN Condition
or CC Condition
flutter NN Condition
( ( Condition
PAF/PAFL NNP Condition
) ) Condition
experiencing VBG None
2 CD None
or CC None
more JJR None
episodes NNS None
of IN None
symptomatic JJ Condition
PAF/PAFL NNP Condition
during IN None
a DT None
28-day JJ None
observation NN None
period NN None
to TO None
determine VB None
the DT None
dose-response JJ None
effect NN None
and CC None
safety NN None
of IN None
flecainide NN None
. . None
143 CD Size
patients NNS None
at IN None
30 CD None
centers NNS None
123 CD Size
patients NNS None
patients NNS None
with IN None
PAF/PAFL NNP Condition
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
. . Condition
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
( ( None
CAD NNP None
) ) None
CAD NNP None
patients NNS None
with IN None
average JJ None
cholesterol NN None
levels NNS None
. . None
Twenty-eight NNP None
sedentary JJ None
male NN None
patients NNS None
with IN None
angiographically RB None
documented VBN None
CAD NNP None
and CC None
average JJ None
pretreatment JJ None
total NN None
plasma NN None
cholesterol NN None
levels NNS None
( ( None
5.1+/-0.9 JJ None
mmol/l NN None
) ) None
aged VBD None
42-75 CD None
years NNS None
were VBD None
included VBN None
. . None
patients NNS None
with IN None
CAD NNP None
and CC None
average JJ None
cholesterol NN None
levels NNS None
-DOCSTART- -X- N

total JJ None
knee NN None
arthroplasty NN None
( ( None
TKA NNP None
) ) None
patients NNS None
undergoing VBG None
minimally RB None
invasive JJ None
TKA NNP None
80 CD None
patients NNS None
-DOCSTART- -X- N

male NN Sex
, , None
obese JJ Condition
subjects NNS None
. . None
Twelve NNP Size
male NN None
, , None
obese JJ Condition
subjects NNS None
( ( None
age NN None
36.3+/-5.1 CD Age
y NN None
; : None
body NN None
weight VBD None
94.6+/-13.9 CD None
kg NN None
; : None
body NN None
mass NN None
index NN None
, , None
BMI NNP None
30.8+/-3.0 NNP None
kg/m2 NN None
) ) None
and CC None
in IN None
an DT None
additional JJ None
study NN None
15 CD None
lean JJ None
, , None
well-trained JJ None
subjects NNS None
( ( None
age NN None
36.2+/-7.2 CD Age
y NN None
; : None
body NN None
weight VBD None
72.2+/-5.9 JJ None
kg NN None
; : None
BMI NNP None
22.3+/-1.7 CD None
kg/m2 NN None
) ) None
participated VBD None
. . None
subjects NNS None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

smoking VBG None
cessation NN None
. . None
118 CD None
subjects NNS None
Mean NNP None
age NN None
of IN None
the DT None
study NN None
participants NNS None
was VBD None
37.6 CD None
+/- JJ None
12.4 CD None
years NNS None
; : None
they PRP None
smoked VBD None
an DT None
average NN None
of IN None
20.0 CD None
+/- JJ None
6.6 CD None
cigarettes NNS None
per IN None
day NN None
for IN None
20 CD None
+/- JJ None
12.1 CD None
years NNS None
. . None
The DT None
study NN None
dropout NN None
rate NN None
was VBD None
high JJ None
( ( None
43 CD None
% NN None
) ) None
. . None
tobacco NN None
dependence NN None
. . None
-DOCSTART- -X- N

young JJ None
nonverbal JJ Condition
children NNS Age
with IN None
autism NN Condition
Ten CD Size
young JJ None
, , None
nonverbal JJ Condition
children NNS Age
with IN None
autism NN Condition
mild JJ Condition
to TO Condition
moderate VB Condition
symptoms NNS Condition
of IN Condition
autism NN Condition
, , None
better JJR None
motor NN Condition
imitation NN Condition
skills NNS Condition
emerging VBG None
joint JJ Condition
attention NN Condition
skills NNS Condition
. . None
-DOCSTART- -X- N

osteoarthritis NN None
of IN None
the DT None
knee NN None
: : None
primary JJ None
osteoarthritis NN None
( ( None
OA NNP None
) ) None
of IN None
the DT None
knee NN None
total NN None
of IN None
622 CD None
men NNS None
and CC None
women NNS None
with IN None
radiological JJ None
evidence NN None
of IN None
primary JJ None
knee NN None
OA NNP None
and CC None
mild VB None
to TO None
severe VB None
symptoms NNS None
patients NNS None
with IN None
OA NNP None
-DOCSTART- -X- N

prostate NN Condition
cancer NN Condition
men NNS Sex
receiving VBG None
the DT None
dual JJ None
5alpha-reductase JJ None
inhibitor NN None
dutasteride NN None
. . None
A NNP None
total NN None
of IN None
2,802 CD Size
men NNS None
50 CD Age
years NNS Age
or CC Age
older JJR Age
with IN None
a DT None
clinical JJ None
diagnosis NN None
of IN None
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
, , None
no DT None
history NN None
of IN None
prostate NN None
cancer NN None
, , None
PSA NNP None
1.5 CD None
to TO None
10 CD None
ng/ml NNS None
, , None
prostate NN None
volume NN None
30 CD None
cc NN None
or CC None
greater JJR None
, , None
an DT None
American NNP None
Urological NNP None
Association NNP None
symptom VBD None
score NN None
of IN None
12 CD None
or CC None
greater JJR None
and CC None
peak JJ None
urinary JJ None
flow NN None
rate NN None
15 CD None
ml NN None
per IN None
second NN None
or CC None
less JJR None
were VBD None
randomized VBN None
to TO None
0.5 CD None
mg NNS None
dutasteride JJ None
daily RB None
or CC None
matching VBG None
placebo NN None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Condition
who WP Condition
had VBD Condition
received VBN Condition
alendronate JJ Condition
daily JJ Condition
or CC Condition
weekly JJ Condition
in IN Condition
tablets NNS Condition
with IN Condition
or CC Condition
without IN Condition
enteric JJ Condition
coating NN Condition
. . Condition
75 CD None
volunteers NNS None
, , None
aged VBD Age
45-58 JJ Age
with IN None
moderate JJ None
to TO None
severe VB None
osteopenia NN None
( ( None
T-score NNP None
lower JJR None
than IN None
-2 JJR None
SD NNP None
) ) None
assessed VBN None
by IN None
quantitative JJ None
ultrasound NN None
. . None
-DOCSTART- -X- N

malignant JJ Condition
pleural JJ Condition
and CC None
pericardial JJ Condition
effusion NN Condition
] NNP None
patients NNS None
with IN None
malignant JJ None
neoplasm NN None
. . None
( ( None
control NN None
group NN None
, , None
30 CD None
patients NNS None
) ) None
( ( None
N-CWS NNP None
group NN None
, , None
26 CD None
patients NNS None
) ) None
in IN None
55 CD None
patients NNS None
with IN None
malignant JJ Condition
pleural JJ Condition
effusion NN Condition
due JJ Condition
to TO Condition
primary JJ Condition
lung NN Condition
cancer NN Condition
. . None
Twenty-four JJ None
patients NNS None
with IN None
malignant JJ None
pericardial JJ None
effusion NN None
-DOCSTART- -X- N

Huntington NNP Condition
disease NN Condition
. . None
Huntington NNP Condition
disease NN Condition
( ( None
HD NNP Condition
) ) None
60 CD Size
HD NNP Condition
patients NNS None
HD NNP Condition
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
locally RB None
advanced JJ Condition
noninflammatory JJ Condition
breast NN Condition
cancer NN Condition
. . None
patients NNS None
with IN None
locally RB Condition
advanced JJ Condition
breast NN Condition
cancer NN Condition
treated VBN None
with IN None
chemotherapy NN None
and CC None
mastectomy NN None
. . None
Between NNP None
1985 CD None
and CC None
1989 CD None
, , None
200 CD Size
patients NNS None
with IN None
clinical JJ None
Stage NNP Condition
III NNP Condition
noninflammatory JJ Condition
breast NN Condition
cancer NN Condition
Of IN None
the DT None
179 CD Size
patients NNS None
treated VBN None
with IN None
mastectomy NN None
after IN None
neoadjuvant JJ None
chemotherapy NN None
, , None
108 CD Size
participated VBN None
-DOCSTART- -X- N

Subjects NNS None
with IN None
low JJ None
but CC None
normal JJ None
iron NN None
levels NNS None
In IN None
Study NNP None
1 CD None
( ( None
n=240 NN None
) ) None
, , None
125 CD None
mg NN None
was VBD None
infused VBN None
over IN None
10 CD None
minutes NNS None
. . None
In IN None
Study NNP None
2 CD None
( ( None
n=29 NN None
) ) None
, , None
62.5 CD None
mg NN None
was VBD None
infused VBN None
over IN None
30 CD None
minutes NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
retinitis NN Condition
pigmentosa NN Condition
receiving VBG None
vitamin IN None
A NNP None
treatment NN None
: : None
patients NNS None
with IN None
retinitis NN Condition
pigmentosa NN Condition
who WP None
are VBP None
receiving VBG None
vitamin IN None
A NNP None
. . None
208 CD Size
patients NNS None
with IN None
retinitis NN Condition
pigmentosa NN Condition
, , None
aged VBD None
18 CD Age
to TO Age
55 CD Age
years NNS None
Seventy NNP None
percent NN None
of IN None
the DT None
patients NNS None
in IN None
each DT None
group NN None
were VBD None
taking VBG None
vitamin NN None
A NNP None
, , None
15 CD None
000 CD None
IU/d NNP None
, , None
prior RB None
to TO None
entry NN None
. . None
patients NNS None
with IN None
retinitis NN Condition
pigmentosa NN Condition
patients NNS None
on IN None
vitamin NN None
A NN None
for IN None
at IN None
least JJS None
2 CD None
years NNS None
-DOCSTART- -X- N

high-risk JJ Condition
head NN Condition
and CC Condition
neck NN Condition
surgery NN Condition
: : None
Patients NNS None
who WP None
undergo VBP None
major JJ None
contaminated VBN None
surgery NN None
of IN None
the DT None
head NN None
and CC None
neck NN None
Patients NNS None
who WP None
were VBD None
identified VBN None
as IN None
requiring VBG None
pedicled VBD None
flap JJ None
reconstruction NN None
were VBD None
potential JJ None
candidates NNS None
for IN None
the DT None
study NN None
. . None
One CD Size
hundred VBD Size
nine CD Size
patients NNS None
were VBD None
evaluable JJ None
. . None
-DOCSTART- -X- N

area NN None
of IN None
low JJ Condition
malaria NNS Condition
transmission NN None
in IN None
Colombia NNP None
. . None
Patients NNPS None
> JJ Age
or CC Age
=1 JJ Age
year NN Age
of IN Age
age NN Age
with IN None
a DT None
parasite JJ None
density NN None
> NN None
or CC None
=1,000 CD None
asexual JJ None
parasites NNS None
per IN None
microliter NN None
were VBD None
enrolled VBN None
in IN None
this DT None
study NN None
. . None
Forty-four CD Size
percent NN None
( ( None
24 CD None
of IN None
54 CD None
) ) None
of IN None
the DT None
CQ-treated JJ None
patients NNS None
were VBD None
therapeutic JJ None
failures NNS None
, , None
including VBG None
7 CD None
early JJ None
treatment NN None
failures NNS None
( ( None
ETFs NNP None
) ) None
and CC None
17 CD None
late JJ None
treatment NN None
failures NNS None
( ( None
LTFs NNP None
) ) None
. . None
Four CD None
( ( None
6 CD None
% NN None
) ) None
of IN None
67 CD None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
solid JJ Condition
tumours NNS Condition
: : None
Patients NNP None
with IN None
advanced JJ Condition
solid JJ Condition
tumours NNS Condition
Twenty-seven JJ Size
patients NNS None
were VBD None
treated VBN None
; : None
detected VBN None
. . None
Four CD None
patients NNS None
achieved VBN None
partial JJ None
responses NNS None
and CC None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
non-small JJ Condition
cell NN Condition
lung NN Condition
cancer NN Condition
not RB Condition
suitable JJ Condition
for IN Condition
curative JJ Condition
therapy NN Condition
: : Condition
Patients NNPS None
were VBD None
eligible JJ None
if IN None
they PRP None
had VBD None
stage VBN None
I-IIIB NNP None
NSCLC NNP None
, , None
unsuitable JJ None
for IN None
curative JJ None
therapy NN None
, , None
or CC None
stage NN None
IV NNP None
with IN None
a DT None
PET-detected JJ None
extracranial JJ None
solitary JJ None
metastasis NN None
. . None
Eighty-four JJ None
patients NNS None
were VBD None
randomized VBN None
. . None
-DOCSTART- -X- N

menorrhagia NN Condition
. . None
Department NNP None
of IN None
Gynecology NNP None
of IN None
the DT None
University NNP None
of IN None
Naples NNP None
. . None
Eighty-two JJ Size
patients NNS None
who WP None
were VBD None
affected VBN None
by IN None
menorrhagia NN None
that WDT None
was VBD None
unresponsive JJ Condition
to TO Condition
medical JJ Condition
treatment NN Condition
menorrhagia NN None
-DOCSTART- -X- N

16 CD None
healthy JJ None
volunteers NNS None
0.31 CD None
) ) None
. . None
In IN None
Experiment JJ None
2 CD None
, , None
20 CD None
healthy JJ None
volunteers NNS None
underwent JJ None
-DOCSTART- -X- N

older JJR None
subjects NNS None
. . None
healthy JJ None
older JJR None
subjects NNS None
Twenty-two JJ None
volunteers NNS None
over IN None
60 CD None
years NNS None
of IN None
age NN None
an DT None
experimental JJ None
group NN None
of IN None
13 CD None
older JJR None
subjects NNS None
( ( None
3 CD None
men NNS None
and CC None
10 CD None
women NNS None
, , None
mean JJ None
age NN None
63.5 CD None
+/- JJ None
3 CD None
years NNS None
) ) None
while IN None
the DT None
remaining VBG None
9 CD None
subjects NNS None
( ( None
3 CD None
men NNS None
and CC None
6 CD None
women NNS None
, , None
mean JJ None
age NN None
64.2 CD None
+/- JJ None
4 CD None
years NNS None
) ) None
served VBD None
as IN None
inactive JJ None
control NN None
group NN None
. . None
healthy JJ None
elderly JJ None
people NNS None
. . None
-DOCSTART- -X- N

group NN None
A NNP None
patients NNS None
group NN None
B NNP None
patients NNS None
44 CD Size
patients NNS None
, , None
both DT None
male NN Sex
and CC None
female NN Sex
, , None
classified VBD None
as IN None
ASA NNP None
II NNP None
and CC None
III NNP None
. . None
group NN None
A NNP None
patients NNS None
-DOCSTART- -X- N

dyspnoeic JJ Condition
patients NNS None
100 CD Size
consecutive JJ None
patients NNS None
patients NNS None
with IN None
severe JJ Condition
pulmonary JJ Condition
disease NN Condition
-DOCSTART- -X- N

young JJ Age
children NNS Age
with IN None
autism NN Condition
Forty-seven JJ Size
children NNS Age
were VBD None
randomly RB None
assigned VBN None
to TO None
treatment NN None
and CC None
wait-list JJ None
control NN None
groups NNS None
. . None
-DOCSTART- -X- N

ozone-induced JJ Condition
lung NN Condition
injury NN Condition
in IN None
human JJ None
subjects NNS None
. . None
31 CD Size
healthy JJ None
nonsmoking VBG None
adults NNS None
( ( None
18 CD None
to TO None
35 CD None
yr NNS None
old JJ None
) ) None
-DOCSTART- -X- N

urinary JJ Condition
excretion NN Condition
of IN Condition
ferulic JJ Condition
acid NN Condition
in IN Condition
humans NNS Condition
Scandinavian JJ None
18 CD None
postmenopausal JJ None
women NNS None
after IN None
a DT None
dietary JJ None
intake NN None
of IN None
rye NN None
bran NN None
or CC None
an DT None
inert JJ None
wheat NN None
bran NN None
( ( None
control NN None
) ) None
in IN None
a DT None
crossover NN None
study NN None
( ( None
2 CD None
x RB None
6 CD None
weeks NNS None
with IN None
4 CD None
weeks NNS None
washout NN None
) ) None
-DOCSTART- -X- N

preterm JJ None
infants NNS None
. . None
preterm JJ None
infants NNS None
100 CD None
hospitalized JJ None
preterm NN None
infants NNS None
with IN None
birth JJ None
weights NNS None
of IN None
500 CD None
to TO None
1300 CD None
g NN None
-DOCSTART- -X- N

Sun NNP None
protection NN None
counseling VBG None
for IN None
children NNS None
: : None
clinicians NNS Condition
. . None
sun NN None
protection NN None
advice NN None
for IN None
children NNS None
Primary NNP None
care NN None
practices NNS None
caring VBG None
for IN None
children NNS None
in IN None
New NNP None
Hampshire NNP None
with IN None
special JJ None
attention NN None
to TO None
clinicians NNS None
serving VBG None
10 CD None
towns NNS None
that WDT None
were VBD None
involved VBN None
in IN None
a DT None
randomized NN None
controlled VBN None
trial NN None
of IN None
the DT None
multicomponent NN None
SunSafe NNP None
intervention NN None
involving VBG None
schools NNS None
, , None
recreation NN None
areas NNS None
, , None
and CC None
primary JJ None
care NN None
practices NNS None
. . None
all DT None
primary JJ Condition
care NN Condition
clinicians NNS Condition
serving VBG Condition
children NNS Condition
Clinicians NNPS None
in IN None
10 CD None
systematically RB None
selected VBN None
rural JJ None
towns NNS None
261 CD Size
eligible JJ Size
clinicians NNS Size
responding VBG None
to TO None
the DT None
statewide NN None
survey NN None
participating VBG None
clinicians NNS None
. . None
-DOCSTART- -X- N

very RB None
high-risk JJ None
childhood NN Age
acute NN Condition
lymphoblastic JJ Condition
leukemia NN Condition
. . None
childhood NN Age
acute NN Condition
lymphoblastic JJ Condition
leukemia NN Condition
( ( None
ALL DT Condition
) ) None
. . None
Sixty-seven NNP Size
children NNS Age
with IN None
very RB None
high-risk JJ Condition
ALL NNP Condition
high-risk JJ Condition
childhood NN Condition
ALL NNP Condition
-DOCSTART- -X- N

children NNS None
with IN None
cystic JJ Condition
fibrosis NN Condition
. . None
children NNS None
with IN None
cystic JJ Condition
fibrosis NN Condition
and CC None
pancreatic JJ Condition
insufficiency NN Condition
. . None
Cystic JJ None
fibrosis NN None
centers NNS None
in IN None
the DT None
eastern JJ None
, , None
midwestern JJ None
, , None
and CC None
southern JJ None
United NNP None
States NNPS None
. . None
Seventy-nine JJ Size
children NNS None
aged VBD Age
4 CD Age
to TO Age
12 CD Age
years NNS Age
below IN None
the DT None
40th CD None
percentile NN None
for IN None
weight NN None
for IN None
age NN None
were VBD None
recruited VBN None
. . None
-DOCSTART- -X- N

autistic JJ Condition
disorders NNS None
. . None
children NNS None
and CC None
adolescents NNS None
with IN None
autism NN Condition
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
. . None
Forty NNP None
children NNS None
and CC None
adolescents NNS None
met VBD None
diagnostic JJ None
criteria NNS None
for IN None
ASD NNP Condition
according VBG None
to TO None
DSM-IV NNP None
. . None
children NNS None
and CC None
adolescents NNS None
with IN None
ASD NNP Condition
. . None
-DOCSTART- -X- N

diffuse NN Condition
lung NN Condition
disease NN Condition
. . None
diffuse NN Condition
parenchymal JJ Condition
lung NN Condition
disease NN Condition
( ( Condition
DPLD NNP Condition
) ) None
. . None
95 CD Size
patients NNS None
who WP None
underwent VBP None
fluoroscopy NN None
guided VBD None
TBLB NNP None
over IN None
a DT None
two CD None
year NN None
period NN None
. . None
Patients NNS None
with IN None
a DT None
lung NN Condition
mass NN Condition
or CC None
solitary JJ None
lung NN Condition
nodule NN Condition
undergoing VBG None
TBLB NNP None
were VBD None
excluded VBN None
. . None
patients NNS None
with IN None
DPLD NNP Condition
74 CD Size
out IN None
of IN None
95 CD Size
patients NNS None
( ( None
78 CD None
% NN None
) ) None
Jumbo NNP None
forcep NN None
while IN None
the DT None
smaller JJR None
forcep NN None
was VBD None
diagnostic JJ None
in IN None
62 CD Size
out IN None
of IN None
95 CD Size
patients NNS None
( ( None
65 CD None
% NN None
) ) None
. . None
diffuse NN Condition
infiltrative JJ Condition
lung NN Condition
disease NN Condition
. . None
-DOCSTART- -X- N

induction NN None
of IN None
anaesthesia NN None
in IN None
200 CD None
unpremedicated JJ None
female NN None
patients NNS None
undergoing VBG None
elective JJ None
gynaecological JJ None
surgery NN None
. . None
-DOCSTART- -X- N

previously RB None
treated VBN None
patients NNS None
with IN None
refractory JJ Condition
advanced JJ Condition
non-small-cell JJ Condition
lung NN Condition
cancer NN Condition
: : None
patients NNS None
with IN None
locally RB Condition
advanced JJ Condition
or CC Condition
metastatic JJ Condition
non-small-cell JJ Condition
lung NN Condition
cancer NN Condition
. . None
1692 CD Size
patients NNS None
who WP None
were VBD None
refractory JJ Condition
to TO Condition
or CC Condition
intolerant VB Condition
of IN None
their PRP$ None
latest JJS Condition
chemotherapy NN Condition
regimen NNS None
1129 CD Size
patients NNS None
were VBD None
assigned VBN None
gefitinib NNS None
and CC None
563 CD Size
placebo NN None
. . None
812 CD Size
patients NNS None
with IN None
adenocarcinoma NN Condition
never-smokers NNS None
Asian JJ None
origin NN None
never-smokers NNS None
and CC None
patients NNS None
of IN None
Asian JJ None
origin NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
gastric JJ Condition
ulcer JJ Condition
100 CD Size
patients NNS None
with IN None
gastric JJ Condition
ulcer NNS Condition
aged VBN None
from IN None
16 CD Age
to TO Age
60 CD Age
years NNS Age
gastric JJ Condition
ulcer NN Condition
-DOCSTART- -X- N

exuding VBG None
wounds NNS None
. . None
exuding VBG None
wounds NNS None
greater JJR None
than IN None
2.5 CD None
x JJ None
2.5 CD None
cm NN None
. . None
target NN None
population NN None
was VBD None
300 CD None
control NN None
and CC None
300 CD None
test NN None
subjects NNS None
across IN None
three CD None
sites NNS None
in IN None
the DT None
UK NNP None
, , None
but CC None
recruitment JJ None
difficulties NNS None
resulted VBD None
in IN None
only RB None
125 CD None
patients NNS None
being VBG None
evaluable JJ None
. . None
-DOCSTART- -X- N

non-obstructive JJ None
mitral JJ None
mechanical JJ None
valve NN None
thrombosis NN None
. . None
Non-obstructive NNP None
prosthetic JJ Condition
valve NN Condition
thrombosis NN Condition
( ( Condition
PVT NNP Condition
) ) Condition
20 CD Size
consecutive JJ None
patients NNS None
were VBD None
found VBN None
by IN None
multiplane NN None
transesophageal NN None
echocardiography NN None
( ( None
TEE NNP None
) ) None
to TO None
have VB None
non-obstructive JJ Condition
PVT NNP Condition
. . Condition
-DOCSTART- -X- N

asthma NN Condition
asthma JJ Condition
79 CD None
asthma NN Condition
patients NNS Condition
requiring VBG None
high JJ None
doses NNS None
( ( None
1,500 CD None
microg/d NN None
or CC None
more JJR None
) ) None
of IN None
inhaled JJ Condition
beclomethasone NN Condition
dipropionate NN Condition
( ( None
BDI NNP None
) ) None
for IN None
clinical JJ None
control NN None
( ( None
duration NN None
of IN None
asthma NN None
, , None
11.0 CD None
+/- JJ None
3.1 CD None
yr NN None
; : None
duration NN None
of IN None
BDI NNP None
treatment NN None
, , None
0.5 CD None
+/- JJ None
0.3 CD None
yr NN None
; : None
FEV1 NNP None
percentage NN None
of IN None
predicted VBN None
, , None
80.7 CD None
+/- JJ None
2.0 CD None
% NN None
) ) None
. . None
asthma JJ Condition
-DOCSTART- -X- N

autistic JJ Condition
children NNS None
. . None
autistic JJ None
children NNS None
Forty-five JJ Size
children NNS None
, , None
2.02 CD Age
to TO Age
7.58 CD Age
years NNS None
old JJ None
( ( None
M NNP Age
= NNP Age
4.49 CD Age
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ Condition
ureteral JJ Condition
colic NN Condition
. . None
81 CD Size
patients NNS None
with IN None
acute JJ Condition
ureteral JJ Condition
colic NN Condition
and CC None
the DT None
confirmed JJ None
presence NN None
of IN None
a DT None
calculus NN None
. . None
randomized JJ None
double-blind JJ None
comparison NN None
of IN None
intramuscular JJ None
2 CD None
and CC None
4 CD None
mg. NN None
butorphanol NN None
and CC None
80 CD None
mg. NNS None
meperidine NN None
was VBD None
used VBN None
. . None
-DOCSTART- -X- N

small JJ Condition
cell NN Condition
lung NN Condition
cancer NN Condition
. . None
small JJ Condition
cell NN Condition
lung NN Condition
cancer NN Condition
. . None
-DOCSTART- -X- N

gingivitis NN None
in IN None
pregnancy NN None
. . None
gingival JJ Condition
inflammation NN Condition
during IN Condition
the DT Condition
fourth JJ Condition
and CC Condition
eighth JJ Condition
months NNS Condition
of IN Condition
pregnancy NN Condition
. . Condition
Thirty JJ None
women NNS None
gingival JJ None
health NN None
in IN None
pregnancy NN None
. . None
-DOCSTART- -X- N

head NN None
trauma NN None
patients NNS None
: : None
head NN None
trauma IN None
patients NNS None
inner-city JJ None
county NN None
trauma NN None
center NN None
with IN None
70,000 CD None
patient JJ None
visits NNS None
per IN None
year NN None
. . None
Sequential NNP None
adult NN Age
head NN None
trauma NN None
patients NNS None
requiring VBG None
rapid-sequence JJ None
intubation NN None
who WP None
had VBD None
no DT None
contraindications NNS None
to TO None
succinylcholine VB None
or CC None
pancuronium VB None
. . None
head NN None
trauma NN None
patient JJ None
46 CD Size
patients NNS None
head NN None
trauma NN None
patients NNS None
in IN None
an DT None
ED NNP None
setting NN None
. . None
-DOCSTART- -X- N

fiberoptic JJ Condition
bronchoscopy NN Condition
. . None
fiber-optic JJ Condition
bronchoscopy NN Condition
( ( Condition
FOB NNP Condition
) ) Condition
One-hundred JJ Size
twenty NN Size
patients NNS None
were VBD None
enrolled VBN None
. . None
Patients NNPS None
undergoing VBG None
FOB NNP Condition
-DOCSTART- -X- N

squamous JJ Condition
cell NN Condition
carcinomas NN Condition
of IN Condition
the DT Condition
head NN Condition
and CC Condition
neck NN Condition
squamous JJ Condition
cell NN Condition
carcinomas NN Condition
of IN Condition
the DT Condition
head NN Condition
and CC Condition
neck NN Condition
( ( Condition
HNSCC NNP Condition
) ) None
Eight NNP Size
hundred VBD Size
and CC Size
three CD Size
patients NNS Size
with IN None
representative JJ None
pretreatment NN None
tissue NN None
samples NNS None
from IN None
the DT None
randomized VBN None
DAHANCA NNP None
6 CD None
and CC None
7 CD None
study NN None
of IN None
5 CD None
vs. FW None
6 CD None
fx/wk NN None
of IN None
radiotherapy NN None
. . None
-DOCSTART- -X- N

disseminated JJ None
small JJ None
noncleaved-cell JJ None
lymphoma NN Condition
and CC None
B-cell NNP None
leukemia NN Condition
: : None
Children NNP None
's POS None
Cancer NNP None
Group NNP None
study NN None
. . None
patients NNS None
with IN None
disseminated JJ None
small JJ None
noncleaved-cell JJ None
lymphoma NN Condition
and CC None
B-cell NNP None
leukemia NN Condition
who WP None
were VBD None
treated VBN None
in IN None
four CD None
successive JJ None
Children NNP None
's POS None
Cancer NNP None
Group NNP None
trials NNS None
. . None
462 CD Size
patients NNS None
with IN None
disseminated JJ Condition
disease NN Condition
, , None
49 CD Size
( ( None
10.6 CD None
% NN None
) ) None
had VBD None
CNS NNP Condition
disease NN None
at IN None
diagnosis NN None
( ( None
CNS+ NNP Condition
) ) None
. . None
Of IN None
the DT None
CNS+ NNP Condition
patients NNS None
, , None
28 CD Size
had VBD None
M2 NNP None
( ( None
5 CD None
% NN None
to TO None
25 CD None
% NN None
blasts NNS None
) ) None
or CC None
M3 NNP None
( ( None
> VB None
25 CD None
% NN None
blasts NNS None
) ) None
bone NN None
marrow JJ None
involvement NN None
. . None
All DT Size
patients NNS None
received VBD None
protocol-based JJ None
systemic JJ None
and CC None
intrathecal JJ None
chemotherapy NN None
. . None
-DOCSTART- -X- N

assessing VBG None
theory NN None
of IN None
mind NN None
in IN None
normal JJ None
children NNS None
and CC None
children NNS None
with IN None
pervasive JJ Condition
developmental NN Condition
disorders NNS Condition
. . None
normal JJ None
children NNS None
and CC None
children NNS None
with IN None
pervasive JJ Condition
developmental NN Condition
disorders NNS Condition
( ( Condition
PDDs NNP Condition
) ) Condition
. . Condition
normal JJ None
children NNS None
( ( None
n JJ None
= NNP None
70 CD Size
) ) None
young JJ Age
children NNS Age
older JJR Age
children NNS Age
normal JJ None
children NNS Age
( ( None
n JJ None
= NNP None
12 CD Size
) ) None
sample NN None
of IN None
children NNS Age
with IN None
PDDs NNP Condition
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
children NNS Age
with IN None
PDDs NNP Condition
( ( None
n JJ None
= NNP None
20 CD Size
) ) None
children NNS Age
with IN None
other JJ None
psychiatric JJ Condition
disorders NNS Condition
( ( None
e.g. NN None
children NNS Age
with IN None
Attention-deficit NNP Condition
Hyperactivity NNP Condition
Disorder NNP Condition
; : None
n CC None
= VB None
32 CD Size
) ) None
-DOCSTART- -X- N

gastric JJ Condition
cancer NN Condition
patients NNS None
: : None
cancer NN Condition
patients NNS None
gastric JJ None
cancer NN None
patients NNS None
. . None
121 CD Size
gastric JJ Condition
cancer NN Condition
patients NNS None
attending VBG None
inpatient JJ None
rehabilitation NN None
after IN None
surgical JJ None
treatment NN None
-DOCSTART- -X- N

moderate JJ Condition
to TO Condition
severe VB Condition
COPD NNP Condition
. . None
subjects NNS None
with IN None
symptomatic JJ None
moderate NN None
to TO None
severe VB None
COPD NNP None
. . None
study NN None
. . None
Subjects VBZ None
40 CD None
years NNS None
or CC None
older JJR None
with IN None
cigarette NN None
smoking VBG None
history NN None
?10 JJ None
pack-years NNS None
and CC None
with IN None
the DT None
diagnosis NN None
of IN None
COPD NNP None
and CC None
post-bronchodilator NN None
FEV NNP None
( ( None
1 CD None
) ) None
?40 NN None
to TO None
? . None
80 CD None
% NN None
of IN None
predicted VBN None
normal JJ None
and CC None
FEV NNP None
( ( None
1 CD None
) ) None
/FVC NN None
of IN None
?0.70 NN None
were VBD None
enrolled VBN None
. . None
FSC NNP None
to TO None
subjects NNS None
with IN None
COPD NNP None
treated VBD None
-DOCSTART- -X- N

Adjuvant NNP None
subcutaneous JJ None
interleukin-2 NN None
in IN None
patients NNS None
with IN None
resected JJ None
renal JJ None
cell NN None
carcinoma NN None
: : None
patients NNS None
with IN None
resected JJ None
renal JJ None
cell NN None
carcinoma NN None
( ( None
RCC NNP None
) ) None
at IN None
high JJ None
risk NN None
for IN None
recurrent JJ None
disease NN None
( ( None
TNM NNP None
stages VBZ None
III NNP None
and CC None
IV NNP None
resected VBD None
distant JJ None
metastases NNS None
) ) None
. . None
Patients NNPS None
with IN None
surgically RB None
resected VBN None
locally RB None
advanced JJ None
( ( None
T3-4 CD None
or CC None
N1-2 NNP None
) ) None
or CC None
metastatic JJ None
RCC NNP None
Forty-one JJ None
patients NNS None
were VBD None
entered VBN None
in IN None
the DT None
study NN None
and CC None
40 CD None
were VBD None
evaluable JJ None
for IN None
toxicity NN None
. . None
patients NNS None
with IN None
surgically RB None
resected VBN None
RCC NNP None
at IN None
high JJ None
risk NN None
of IN None
recurrence NN None
. . None
-DOCSTART- -X- N

acne JJ None
vulgaris NN None
: : None
Eighty NNP Size
patients NNS None
( ( None
38 CD Size
males NNS Condition
and CC None
42 CD Size
females NNS Condition
, , None
mean JJ None
+/- JJ None
SD NNP None
age NN None
19.7 CD None
+/- JJ None
5.9 CD None
years NNS None
) ) None
-DOCSTART- -X- N

light-for-gestation NN Condition
infants NNS Age
in IN None
low-risk JJ Condition
pregnancies NNS Condition
. . None
2771 CD Size
pregnant JJ Condition
women NNS Sex
with IN None
gestational JJ None
age NN None
estimated VBN None
by IN None
ultrasound JJ None
measurement NN None
of IN None
the DT None
fetal JJ None
biparietal JJ None
diameter NN None
( ( None
BPD NNP None
) ) None
before IN None
the DT None
22nd CD None
week NN None
of IN None
gestation NN None
in IN None
the DT None
32nd CD Condition
and CC Condition
37th CD Condition
week NN Condition
of IN Condition
pregnancy NN Condition
186 CD None
uncomplicated JJ None
pregnancies NNS None
in IN None
which WDT None
there EX None
was VBD None
no DT None
clinical JJ None
suspicion NN None
of IN None
poor JJ None
intrauterine JJ None
growth NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
pervasive JJ Condition
developmental JJ Condition
disorders NNS Condition
: : None
children NNS Age
with IN None
pervasive JJ Condition
developmental NN Condition
disorders NNS Condition
. . None
Forty-four JJ Age
children NNS Age
, , Age
ages VBZ Age
8-11 CD Age
years NNS Age
, , None
were VBD None
randomly RB None
assigned VBN None
to TO None
treatment NN None
or CC None
wait JJ None
list NN None
. . None
Parents NNS Age
families NNS None
-DOCSTART- -X- N

anxiety NN None
and CC None
depression NN None
in IN None
patients NNS None
with IN None
cancer NN None
: : None
anxiety NN None
and CC None
depression NN None
in IN None
cancer NN None
patients NNS None
United NNP None
Kingdom NNP None
Two CD None
hundred VBD None
eighty-eight JJ None
cancer NN None
patients NNS None
, , None
referred VBD None
to TO None
complementary JJ None
therapy NN None
services NNS None
with IN None
clinical JJ None
anxiety NN None
and/or NN None
depression NN None
cancer NN None
patients NNS None
' POS None
-DOCSTART- -X- N

uremic JJ None
pericarditis NN None
. . None
24 CD None
patients NNS None
with IN None
endstage NN None
chronic JJ None
renal JJ None
failure NN None
and CC None
pericarditis NN None
randomly RB None
received VBD None
indomethacin JJ None
, , None
25 CD None
mg NN None
four CD None
times NNS None
daily RB None
, , None
( ( None
11 CD None
patients NNS None
) ) None
or CC None
a DT None
placebo NN None
( ( None
13 CD None
patients NNS None
) ) None
patients NNS None
received VBN None
peritoneal JJ None
or CC None
hemodialysis NN None
treatment NN None
concurrently RB None
-DOCSTART- -X- N

patients NNS None
with IN None
unresectable JJ None
stage NN None
IIIA NNP None
and CC None
B NNP None
non-small-cell JJ None
lung NN None
cancer NN None
. . None
Eligible JJ None
patients NNS None
were VBD None
treatment NN None
naive JJ None
, , None
and CC None
had VBD None
stage NN None
IIIA NNP None
and CC None
B NNP None
unresectable JJ None
non-small-cell JJ None
lung NN None
cancer NN None
, , None
Eastern NNP None
Cooperative NNP None
Oncology NNP None
Group NNP None
performance NN None
status NN None
0/1 CD None
, , None
and CC None
normal JJ None
organ JJ None
function NN None
. . None
total NN None
of IN None
388 CD None
patients NNS None
141 CD None
patients NNS None
enrolled VBD None
nine CD None
patients NNS None
-DOCSTART- -X- N

junior JJ None
high JJ None
school NN None
students NNS None
. . None
Fifty-nine JJ Size
junior JJ None
high JJ None
school NN None
students NNS None
who WP None
volunteered VBD None
to TO None
participate VB None
in IN None
treatment NN None
for IN None
interpersonal JJ None
anxiety NN Condition
( ( None
RET NNP None
) ) None
, , None
rational-emotive JJ None
therapy NN None
with IN None
imagery NN None
( ( None
REI NNP None
) ) None
, , None
relationship-oriented JJ None
counseling NN None
( ( None
ROC NNP None
) ) None
, , None
and CC None
waiting-list JJ None
control NN None
( ( None
WLC NNP None
) ) None
groups NNS None
. . None
-DOCSTART- -X- N

Treatment NN None
of IN None
hepatitis NN None
B NNP None
virus NN None
infection NN None
with IN None
interferon NN None
. . None
patients NNS None
with IN None
HBe NNP None
antigen-positive JJ None
disease NN None
acquired VBD None
in IN None
adult NN None
life NN None
Twenty-one CD None
pretreatment JJ None
variables NNS None
were VBD None
assessed VBN None
for IN None
their PRP$ None
significance NN None
in IN None
response NN None
prediction NN None
using VBG None
data NNS None
from IN None
114 CD None
patients NNS None
given VBN None
alpha-interferon NNS None
for IN None
chronic JJ None
hepatitis NN None
B NNP None
virus NN None
infection NN None
. . None
patients NNS None
-DOCSTART- -X- N

severe JJ None
persistent JJ Condition
depressions NNS Condition
in IN None
women NNS Sex
. . None
severely RB None
depressed JJ Condition
, , None
inpatient JJ None
women NNS Sex
who WP None
had VBD None
failed VBN None
to TO None
respond VB None
to TO None
various JJ None
conventional JJ None
treatments NNS None
of IN None
depression NN Condition
. . None
23 CD Size
premenopausal NN None
and CC None
postmenopausal JJ None
inpatient JJ None
women NNS None
. . None
17 CD Size
similar JJ None
patients NNS None
. . None
women NNS Size
receiving VBG None
high JJ None
doses NNS None
of IN None
estrogens NNS None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
Young NNP Age
children NNS Age
with IN None
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
7 CD Size
with IN None
autism NN Condition
, , None
8 CD Size
with IN None
pervasive JJ None
developmental JJ None
disorder NN None
not RB None
otherwise RB None
specified VBN None
-- : None
NOS NNP None
7 CD Size
with IN None
autism NN None
, , None
6 CD Size
with IN None
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
NOS NNP None
Children NNP Age
with IN None
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
. . None
Children NNP None
with IN None
autism NN None
young JJ None
children NNS None
with IN None
autism NN None
21 CD None
young JJ None
children NNS None
with IN None
autism NN None
. . None
-DOCSTART- -X- N

665 CD Size
patients NNS None
with IN None
a DT None
history NN None
of IN None
colorectal JJ Condition
adenomas NN Condition
to TO None
three CD None
treatment NN None
groups NNS None
23 CD Size
patients NNS None
died VBD None
, , None
15 CD Size
were VBD None
lost VBN None
to TO None
follow-up NN None
, , None
45 CD Size
refused VBD None
repeat NN None
colonoscopy NN None
, , None
and CC None
five CD Size
developed NNS None
severe JJ None
contraindications NNS None
to TO None
colonoscopy VB None
. . None
552 CD Size
participants NNS None
who WP None
completed VBD None
the DT None
follow-up JJ None
examination NN None
, , None
94 CD Size
stopped VBD None
treatment NN None
early RB None
. . None
28 CD Size
( ( None
15.9 CD None
% NN None
) ) None
of IN None
176 CD Size
patients NNS None
58 CD Size
( ( None
29.3 CD None
% NN None
) ) None
of IN None
198 CD Size
36 CD Size
( ( None
20.2 CD None
% NN None
) ) None
of IN None
178 CD Size
in IN None
the DT None
placebo NN None
group NN None
. . None
patients NNS None
with IN None
high JJ Condition
dietary JJ Condition
calcium NN Condition
intake NN Condition
. . None
-DOCSTART- -X- N

essential JJ None
hypertensive JJ None
patients NNS None
. . None
young JJ None
essential JJ None
hypertensive JJ None
patients NNS None
. . None
-DOCSTART- -X- N

parent NN None
toddlers NNS Age
at IN None
risk NN None
for IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
toddlers NNS None
at IN None
risk NN None
for IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( None
ASD NNP Condition
) ) None
aged VBD None
14 CD Age
to TO Age
24 CD Age
months NNS Age
and CC None
their PRP$ None
families NNS None
. . None
98 CD Size
children NNS None
and CC None
families NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
nonspecific JJ None
low JJ Condition
back RB Condition
pain NN Condition
. . None
patients NNS None
with IN None
low JJ Condition
back RB Condition
pain NN Condition
. . None
442 CD Size
patients NNS None
with IN None
low JJ Condition
back RB Condition
pain NN Condition
were VBD None
used VBN None
. . None
( ( None
sub NN None
) ) None
acute NN None
and CC None
chronic JJ None
patients NNS None
with IN None
low JJ Condition
back RB Condition
pain NN Condition
. . None
-DOCSTART- -X- N

models NNS None
of IN None
the DT None
hip NN None
seven CD None
a-p JJ None
hip NN None
radiographs NN None
21 CD None
femora NN None
was VBD None
built VBN None
and CC None
meshed VBN None
patient-specific JJ None
3D CD None
finite JJ None
element NN None
model NN None
-DOCSTART- -X- N

larger JJR None
patient JJ None
population NN None
. . None
Nine NNP None
hundred VBD None
patient JJ None
aged VBN None
< NN None
80 CD None
, , None
with IN None
diabetes NNS None
of IN None
> NN None
or CC None
=1 JJ None
year NN None
known VBN None
duration NN None
, , None
treated VBN None
by IN None
either DT None
diet JJ None
alone NN None
or CC None
diet JJ None
and CC None
oral JJ None
agents NNS None
, , None
will MD None
be VB None
recruited VBN None
in IN None
15 CD None
centres NNS None
and CC None
followed VBD None
for IN None
4 CD None
years NNS None
. . None
-DOCSTART- -X- N

normal JJ Condition
subjects NNS None
and CC None
postoperative JJ None
patients NNS None
. . None
Critically NNP Condition
ill JJ Condition
patients NNS None
seven CD Size
normal JJ Condition
, , Condition
healthy JJ Condition
male NN Sex
subjects NNS None
and CC None
eight CD Size
male NN Sex
patients NNS None
who WP None
had VBD None
undergone JJ None
upper JJ None
abdominal JJ None
surgery NN None
2-4 JJ None
days NNS None
previously RB None
-DOCSTART- -X- N

Intravenously RB None
administered VBN None
histamine NN None
increases NNS None
choroidal VBP None
but CC None
not RB None
retinal JJ None
blood NN None
flow NN None
. . None
humans NNS None
. . None
14 CD None
healthy JJ None
volunteers NNS None
. . None
-DOCSTART- -X- N

post-transplant JJ None
. . None
patients NNS None
achieving VBG None
tacrolimus JJ None
whole-blood JJ None
concentrations NNS None
of IN None
?10 NNP None
ng/mL NN None
within IN None
3 CD None
days NNS None
of IN None
kidney NN Condition
transplantation NN Condition
, , None
after IN None
randomization NN None
either RB None
to TO None
standard VB None
dosing VBG None
( ( None
control VB None
group NN None
) ) None
or CC None
post-transplantation NN None
dosing NN None
guided VBN None
by IN None
a DT None
2-hour JJ None
( ( None
C NNP None
( ( None
2 CD None
) ) None
) ) None
level NN None
following VBG None
a DT None
preoperative JJ None
tacrolimus NN None
dose NN None
( ( None
T2 NNP None
group NN None
) ) None
. . None
monitoring NN None
. . None
Participants NNS None
received VBD None
concomitant JJ None
mycophenolate NN None
mofetil NN None
and CC None
steroids NNS None
. . None
RESULTS NNP None
Ninety NNP None
patients NNS None
were VBD None
recruited VBN None
, , None
of IN None
which WDT None
84 CD None
were VBD None
included VBN None
in IN None
the DT None
analysis NN None
( ( None
control NN None
group NN None
n=43 VBD None
; : None
T2 NNP None
group NN None
n=41 NN None
) ) None
-DOCSTART- -X- N

pituitary JJ None
region NN None
lesions NNS None
Twelve CD None
patients NNS None
with IN None
known VBN None
or CC None
suspected VBN None
pituitary JJ None
lesions NNS None
Six CD None
of IN None
the DT None
patients NNS None
-DOCSTART- -X- N

gastric JJ Condition
cancer NN Condition
in IN None
gastric JJ Condition
cardia NN Condition
cancer NN Condition
( ( None
GCC NNP Condition
) ) None
and CC None
gastric JJ Condition
noncardia NN Condition
cancer NN Condition
( ( None
GNCC NNP Condition
) ) None
341 CD Size
incident JJ None
gastric JJ None
cancer NN None
cases NNS None
( ( None
86 CD None
cardia NN None
, , None
172 CD None
noncardia NN None
, , None
and CC None
83 CD None
nonspecified VBN None
) ) None
, , None
accrued VBN None
during IN None
22 CD None
years NNS None
of IN None
follow-up NN None
, , None
and CC None
341 CD Size
individually RB None
matched VBN None
controls NNS None
. . None
GNCC NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
pedunculated JJ Condition
and CC Condition
small JJ Condition
sessile NN Condition
tubular NN Condition
and CC Condition
tubulovillous JJ Condition
adenomas NN Condition
. . None
After IN None
initial JJ Condition
colonoscopic NN Condition
polypectomy NN Condition
patients NNS None
age NN None
above IN Age
60 CD Age
years NNS Age
and CC None
male JJ Sex
gender NN None
-DOCSTART- -X- N

Thirty-seven NNP None
healthy JJ None
volunteers NNS None
, , None
19 CD None
of IN None
whom WP None
had VBD None
consistently RB None
elevated VBN None
total JJ None
serum NN None
bilirubin NN None
( ( None
TSB NNP None
) ) None
concentrations NNS None
, , None
took VBD None
part NN None
volunteers NNS None
volunteers NNS None
volunteers NNS None
volunteers NNS None
-DOCSTART- -X- N

cancer-related JJ None
fatigue NN None
. . None
cancer NN None
patients NNS None
across IN None
diagnoses NNS None
during IN None
chemotherapy NN None
cancer NN None
patients NNS None
undergoing VBG None
chemotherapy NN None
. . None
213 CD None
cancer NN None
patients NNS None
with IN None
different JJ None
diagnoses NNS None
into IN None
CRF NNP None
in IN None
cancer NN None
patients NNS None
undergoing VBG None
chemotherapy NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
27 CD Size
young JJ Age
children NNS Age
with IN None
autism NN Condition
. . None
children NNS Age
with IN None
ASD NNP Condition
. . None
-DOCSTART- -X- N

acute JJ Condition
myocardial JJ Condition
infarction NN Condition
Patients NNPS None
with IN None
AMI NNP Size
who WP None
were VBD None
admitted VBN None
to TO None
76 CD None
acute NN None
care NN None
hospitals NNS None
in IN None
Quebec NNP None
that WDT None
treated VBD None
at IN None
least JJS None
30 CD None
AMI NNP None
patients NNS None
per IN None
year NN None
between IN None
April NNP None
1 CD None
, , None
1999 CD None
, , None
and CC None
March NNP None
31 CD None
, , None
2003 CD None
. . None
rapid JJ None
( ( None
immediate JJ None
; : None
n CC None
= $ None
38 CD None
hospitals NNS None
and CC None
2533 CD Size
patients NNS None
) ) None
or CC None
delayed VBN None
( ( None
14 CD None
months NNS None
; : None
n CC None
= $ None
38 CD None
hospitals NNS None
and CC None
3142 CD Size
patients NNS None
) ) None
patients NNS None
with IN None
AMI NNP None
. . None
-DOCSTART- -X- N

autism NN Condition
: : None
children NNS Age
Sixty-four JJ Size
children NNS None
with IN None
autism NN None
( ( None
ages VBZ None
2-7 CD None
years NNS None
; : None
55 CD Size
boys NNS Sex
and CC None
9 CD Size
girls NNS Sex
) ) None
with IN None
a DT None
range NN None
of IN None
intelligence NN None
quotient NN None
and CC None
verbal JJ None
ability NN None
children NNS None
with IN None
autism NN None
. . None
-DOCSTART- -X- N

Between NNP None
October NNP None
15 CD None
, , None
1996 CD None
, , None
and CC None
March NNP None
24 CD None
, , None
1999 CD None
, , None
104 CD Size
patients NNS None
at IN None
13 CD None
centers NNS None
were VBD None
prospectively RB None
randomized VBN None
cerebral JJ Condition
AVM NNP Condition
-DOCSTART- -X- N

sleep JJ None
need NN None
of IN None
sedentary JJ None
young JJ None
adults NNS None
. . None
sedentary JJ None
adults NNS None
Twelve NNP None
healthy JJ None
volunteers NNS None
( ( None
25.2 CD None
? . None
4.0 CD None
years NNS None
, , None
9 CD None
females NNS None
, , None
[ NNP None
Vdot NNP None
] NNP None
O NNP None
( ( None
2 CD None
) ) None
max NN None
35.4 CD None
? . None
8.8 CD None
ml? NN None
kg NN None
( ( None
-1 NN None
) ) None
? . None
min NN None
( ( None
-1 NNP None
) ) None
) ) None
were VBD None
-DOCSTART- -X- N

chronic JJ Condition
hepatic JJ Condition
encephalopathy NN Condition
. . None
The DT None
Italian JJ None
Multicenter NNP None
Study NNP None
Group NNP None
. . None
chronic JJ Condition
hepatic JJ Condition
encephalopathy NN Condition
in IN None
cirrhosis NN Condition
. . None
patients NNS None
were VBD None
administered VBN None
, , None
in IN None
addition NN None
to TO None
their PRP$ None
diet JJ None
, , None
branched-chain JJ None
amino NN None
acids NNS None
( ( None
0.24 CD None
g/kg NN None
, , None
30 CD None
patients NNS None
) ) None
or CC None
an DT None
equinitrogenous JJ Condition
amount NN None
of IN None
casein NN None
( ( None
34 CD None
patients NNS None
) ) None
. . None
cirrhotic JJ None
patients NNS None
with IN None
chronic JJ Condition
encephalopathy NN Condition
. . None
-DOCSTART- -X- N

short-term JJ Condition
memory NN Condition
random NN None
interval JJ None
repetition NN None
central JJ None
executive NN None
-DOCSTART- -X- N

children NNS None
with IN None
autistic JJ None
disorder NN None
: : None
Twelve NNP None
children NNS None
, , None
all DT None
boys NNS None
, , None
aged VBD None
4 CD None
to TO None
7 CD None
years NNS None
, , None
with IN None
a DT None
diagnosis NN None
of IN None
autistic JJ None
disorder NN None
and CC None
low JJ None
concentrations NNS None
of IN None
spinal JJ None
6R-l-erythro-5,6,7,8-tetrahydrobiopterin JJ None
( ( None
tetrahydrobiopterin NN None
) ) None
-DOCSTART- -X- N

enteric JJ None
microflora NNS None
in IN None
low-birth-weight JJ None
neonates NNS None
. . None
neonatal JJ None
gut NN None
function NN None
. . None
neonatal JJ None
gut NN None
71 CD None
preterm JJ None
infants NNS None
of IN None
less JJR None
than IN None
2000 CD None
g JJ None
birth NN None
weight NN None
. . None
Infants VBZ None
less JJR None
than IN None
1500 CD None
g NN None
infants NNS None
weighing VBG None
1500 CD None
to TO None
1999 CD None
g NN None
infants NNS None
weighing VBG None
less JJR None
than IN None
1500 CD None
g NN None
infants NNS None
weighing VBG None
less JJR None
than IN None
1500 CD None
g NN None
at IN None
birth NN None
-DOCSTART- -X- N

chronic JJ None
immune NN None
thrombocytopenia NN None
patients NNS None
with IN None
chronic JJ None
immune JJ None
thrombocytopenia NN None
adults NNS None
with IN None
previously RB None
treated VBN None
immune JJ None
thrombocytopenia NN None
of IN None
more JJR None
than IN None
6 CD None
months NNS None
' POS None
duration NN None
who WP None
had VBD None
baseline NN None
platelet NN None
counts VBZ None
lower JJR None
than IN None
30,000 CD None
per IN None
?L NN None
Between NNP None
Nov NNP None
22 CD None
, , None
2006 CD None
, , None
and CC None
July NNP None
31 CD None
, , None
2007 CD None
, , None
197 CD None
patients NNS None
-DOCSTART- -X- N

Brain NNP Condition
activity NN Condition
correlates VBZ Condition
differentially RB None
with IN None
increasing VBG None
temporal JJ None
complexity NN None
of IN None
rhythms NN None
during IN None
initialisation NN None
, , None
synchronisation NN None
, , None
and CC None
continuation NN None
phases NNS None
of IN None
paced JJ Condition
finger NN Condition
tapping VBG Condition
. . None
parts NNS None
of IN None
the DT None
human JJ None
motor NN None
system NN None
-DOCSTART- -X- N

schizophrenia NN None
: : None
in IN None
schizophrenia NN None
. . None
in IN None
schizophrenia NN None
patients NNS None
with IN None
negative JJ None
symptoms NNS None
who WP None
were VBD None
receiving VBG None
second JJ None
generation NN None
antipsychotics NNS None
. . None
Forty-three JJ None
subjects NNS None
-DOCSTART- -X- N

transient JJ Condition
renal JJ Condition
dysfunction NN Condition
Nineteen JJ None
patients NNS None
with IN None
normal JJ None
preoperative JJ None
creatinine NN None
clearances NNS None
who WP None
were VBD None
scheduled VBN None
for IN None
reconstructive JJ None
aortic JJ None
surgery NN None
-DOCSTART- -X- N

children NNS None
with IN None
autistic JJ None
spectrum NN None
disorders NNS None
. . None
parents NNS None
of IN None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
. . None
Data NNP None
from IN None
diet JJ None
diaries NNS None
of IN None
children NNS None
( ( None
3-8 CD None
years NNS None
) ) None
with IN None
ASD NNP None
( ( None
n JJ None
= NNP None
62 CD None
) ) None
were VBD None
analyzed VBN None
children NNS None
-DOCSTART- -X- N

children NNS Age
treated VBN None
in IN None
the DT None
Medical NNP None
Research NNP None
Council NNP None
AML NNP None
10 CD None
and CC None
12 CD None
trials NNS None
for IN None
acute JJ Condition
myeloid NN Condition
leukemia NN Condition
. . None
Between NNP None
May NNP None
1988 CD None
and CC None
June NNP None
2000 CD None
, , None
698 CD Size
children NNS Age
were VBD None
treated VBN None
in IN None
the DT None
Medical NNP None
Research NNP None
Council NNP None
acute VBZ Condition
myeloid JJ Condition
leukemia NN Condition
10 CD None
and CC None
12 CD None
trials NNS None
. . None
-DOCSTART- -X- N

hormone-sensitive JJ None
advanced JJ None
or CC None
metastatic JJ None
breast NN Condition
cancer NN Condition
patients NNS None
. . None
women NNS Condition
with IN None
advanced JJ None
breast NN None
cancer NN None
. . None
Ninety-two NNP Size
patients NNS None
with IN None
advanced JJ None
breast NN None
cancer NN None
received VBD None
arzoxifene JJ None
20 CD None
or CC None
50 CD None
mg/day NN None
. . None
-DOCSTART- -X- N

breast NN Condition
cancer NN Condition
patients NNS None
investigated VBD None
a DT None
cohort NN None
of IN None
278 CD None
patients NNS None
from IN None
the DT None
GeparTrio NNP None
trial NN None
-DOCSTART- -X- N

isochronous JJ Condition
tapping NN Condition
: : None
Isochronous JJ Condition
serial JJ Condition
interval NN Condition
production NN Condition
( ( Condition
ISIP NNP Condition
) ) None
Men NNP Sex
and CC None
women NNS Sex
, , None
22-36 JJ Age
years NNS Age
old JJ None
-DOCSTART- -X- N

interferon NN Condition
alpha NN Condition
monotherapy NN Condition
relapsers NNS Condition
with IN None
chronic JJ Condition
hepatitis NN Condition
C. NNP Condition
interferon NN Condition
monotherapy NN Condition
relapsers NNS Condition
with IN None
chronic JJ Condition
hepatitis NN Condition
C. NNP Condition
Interferon NNP Condition
alpha NN Condition
monotherapy NN Condition
relapsers NNS Condition
with IN None
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
Only JJ None
patients NNS None
with IN None
negative JJ Condition
HCV NNP Condition
RNA NNP Condition
at IN None
week NN None
10 CD None
continued VBD None
treatment NN None
. . None
Thirty-seven JJ Size
patients NNS None
were VBD None
enrolled VBN None
, , None
19 CD Size
( ( None
6 CD Size
females NNS Age
, , None
median JJ None
age NN None
43 CD Age
) ) None
in IN None
the DT None
24 CD None
week NN None
and CC None
18 CD Size
( ( None
5 CD Size
females NNS Age
, , None
median JJ None
age NN None
40 CD Age
) ) None
in IN None
the DT None
48 CD None
week NN None
treatment NN None
arm NN None
. . None
Baseline JJ None
characteristics NNS None
were VBD None
similar JJ None
in IN None
both DT None
groups NNS None
. . None
Three CD Size
patients NNS None
discontinued VBN None
treatment NN None
early JJ None
( ( None
two CD None
due JJ None
to TO None
moderate VB None
adverse JJ None
events NNS None
, , None
one CD None
due JJ None
to TO None
non-compliance NN None
) ) None
. . None
relapsers NNS Condition
with IN Condition
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
-DOCSTART- -X- N

children NNS None
and CC None
young JJ None
adults NNS None
receiving VBG None
hematopoietic JJ None
stem-cell JJ None
transplantation NN None
hematopoietic JJ None
stem-cell JJ None
transplantation NN None
( ( None
HSCT NNP None
) ) None
recipients NNS None
. . None
178 CD None
patients NNS None
( ( None
89 CD None
in IN None
each DT None
arm NN None
) ) None
, , None
receiving VBG None
unmanipulated JJ None
HSCT NNP None
from IN None
either CC None
a DT None
relative NN None
or CC None
an DT None
unrelated JJ None
donor NN None
-DOCSTART- -X- N

glaucoma NN Condition
patients NNS None
undergoing JJ None
cataract JJ None
extraction NN None
with IN None
posterior JJ Condition
chamber NN Condition
lens NNS Condition
implant VBP Condition
. . None
glaucoma NN None
patients NNS None
. . None
Thirty NNP Size
six CD Size
patients NNS None
with IN None
glaucoma JJ None
undergoing JJ None
cataract NN None
extraction NN None
and CC None
posterior JJ None
chamber NN None
lens VBZ None
implantation NN None
glaucoma NN None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
the DT None
acquired JJ Condition
immunodeficiency NN Condition
syndrome NN Condition
. . None
310 CD Size
adults NNS Age
with IN None
AIDS NNP Condition
who WP None
had VBD None
recently RB None
recovered VBN None
from IN None
an DT None
initial JJ None
episode NN None
of IN None
PCP NNP Condition
and CC None
had VBD None
no DT None
treatment-limiting JJ None
toxic NN None
effects NNS None
of IN None
trimethoprim-sulfamethoxazole JJ None
or CC None
pentamidine NN None
. . None
patients NNS None
with IN None
AIDS NNP Condition
who WP None
are VBP None
receiving VBG None
zidovudine NN None
-DOCSTART- -X- N

adult NN None
infants NNS Age
' POS None
10-month-old JJ Age
infants NNS None
. . None
infants NNS None
-DOCSTART- -X- N

randomized NN None
, , None
blinded VBD None
trial NN None
in IN None
217 CD Size
postmenopausal JJ Condition
women NNS Sex
with IN None
hot JJ Condition
flushes NNS Condition
randomized VBD None
to TO None
5 CD None
or CC None
10 CD None
g/day NN None
of IN None
MF101 NNP None
or CC None
placebo NN None
for IN None
12 CD None
weeks NNS None
. . None
-DOCSTART- -X- N

NSCLC NNP None
high JJ None
performance NN None
status NN None
patients NNS None
who WP None
have VBP None
relapsed VBN None
after IN None
their PRP$ None
first-line JJ None
chemotherapy NN None
. . None
300 CD None
patients NNS None
will MD None
be VB None
randomized VBN None
-DOCSTART- -X- N

children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
and CC None
abnormal JJ None
results NNS None
on IN None
transcranial JJ None
Doppler NNP None
ultrasonography NN None
. . None
children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
who WP None
were VBD None
at IN None
high JJ None
risk NN None
for IN None
stroke NN Condition
children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
and CC None
no DT None
history NN None
of IN None
stroke NN Condition
had VBD None
to TO None
have VB None
undergone JJ None
two CD None
transcranial JJ None
Doppler NNP None
studies NNS None
that WDT None
showed VBD None
that IN None
the DT None
time-averaged JJ None
mean JJ None
blood-flow JJ None
velocity NN None
in IN None
the DT None
internal JJ None
carotid NN None
or CC None
middle JJ None
cerebral JJ None
artery NN None
was VBD None
200 CD None
cm JJ None
per IN None
second NN None
or CC None
higher JJR None
. . None
patients NNS None
130 CD Size
children NNS None
( ( None
mean JJ None
[ NNP None
+/-SD NN None
] NNP None
age NN None
, , None
8.3+/-3.3 CD None
years NNS None
) ) None
were VBD None
enrolled VBN None
; : None
63 CD Size
children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
who WP None
have VBP None
abnormal JJ None
results NNS None
on IN None
transcranial JJ None
Doppler NNP None
ultrasonography NN None
. . None
-DOCSTART- -X- N

muscle NN Condition
fatigue NN Condition
. . None
Seven NNP Size
paraplegic JJ None
subjects NNS None
participated VBN None
-DOCSTART- -X- N

in IN None
Chinese JJ None
women NNS Sex
. . None
Chinese JJ None
women NNS None
196 CD Size
Chinese JJ Condition
women NNS Sex
( ( None
52 CD Size
premenopausal NN Condition
with IN None
ages NNS Age
ranging VBG Age
from IN Age
18 CD Age
to TO Age
40 CD Age
years NNS Age
, , None
57 CD Size
perimenopausal NN Condition
from IN None
41 CD Age
to TO Age
60 CD Age
years NNS Age
, , None
and CC None
87 CD Size
postmenopausal NN Condition
from IN None
61 CD Age
to TO Age
81 CD Age
years NNS Age
) ) None
. . None
women NNS None
around IN None
the DT None
menopausal NN None
-DOCSTART- -X- N

emergency NN None
physicians NNS None
( ( None
EPs NNP None
) ) None
Ninety-five JJ Size
physicians NNS None
were VBD None
randomized VBN None
. . None
Eighty-two JJ Size
physicians NNS None
completed VBD None
the DT None
experiment NN None
, , None
for IN None
a DT None
response NN None
rate NN None
of IN None
86 CD None
% NN None
. . None
Physicians NNPS None
-DOCSTART- -X- N

strength NN None
of IN None
the DT None
radius NN None
Fifty NNP Size
pairs NN None
of IN None
sheep JJ None
tibiae NN None
were VBD None
utilized VBN None
Five CD Size
pairs NNS None
were VBD None
used VBN None
in IN None
a DT None
pilot NN None
study NN None
and CC None
45 CD Size
pairs NNS None
were VBD None
used VBN None
in IN None
the DT None
main JJ None
experiment NN None
. . None
Five CD Size
pairs NNS None
of IN None
human JJ None
radii NN None
were VBD None
used VBN None
for IN None
the DT None
control NN None
in IN None
the DT None
pilot NN None
study NN None
. . None
control NN None
group NN None
( ( None
group NN None
1 CD None
) ) None
had VBD None
no DT None
alteration NN None
to TO None
the DT None
bone NN None
. . None
-DOCSTART- -X- N

ovarian JJ Condition
cancer NN Condition
: : None
Women NNP Sex
with IN None
newly-diagnosed JJ Condition
epithelial JJ Condition
OC NNP Condition
recruitment NN None
. . None
Seventy-seven JJ None
women NNS Sex
were VBD None
evaluable JJ None
for IN None
the DT None
primary JJ None
outcome NN None
. . None
women NNS None
receiving VBG None
CT NNP None
for IN None
newly-diagnosed JJ None
epithelial JJ None
OC NNP None
. . None
-DOCSTART- -X- N

HIV-infected JJ Condition
subjects NNS None
with IN None
prior JJ None
nucleoside JJ None
analog NN None
experience NN None
. . None
283 CD Size
nucleoside-experienced JJ None
HIV-infected JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

healthy JJ Condition
institutionalized VBN None
elderly JJ Age
humans NNS None
. . None
elderly JJ Age
healthy JJ None
institutionalized JJ None
elderly RB None
. . None
62 CD Size
subjects NNS None
aged VBN None
65-96 CD Age
years NNS None
healthy JJ Condition
elderly JJ Age
subjects NNS None
. . None
healthy JJ Condition
elderly JJ Age
people NNS None
. . None
-DOCSTART- -X- N

nonverbal JJ Condition
children NNS Age
with IN None
autism NN Condition
. . None
nonverbal JJ Condition
children NNS None
with IN None
autism NN Condition
. . None
Participants NNS None
were VBD None
12 CD Size
nonverbal JJ Condition
children NNS Condition
with IN None
autism NN Condition
ages NNS Age
5 CD Age
through IN Age
7 CD Age
randomly RB None
assigned VBN None
to TO None
either DT None
treatment NN None
group NN None
. . None
children NNS Age
with IN None
autism NN Condition
. . None
-DOCSTART- -X- N

human JJ None
treatment NN Condition
of IN Condition
de FW Condition
novo FW Condition
coronary JJ Condition
lesions NNS Condition
. . None
A NNP None
total NN None
of IN None
122 CD Size
( ( None
qDES JJ Size
66 CD Size
, , None
BMS NNP Size
56 CD Size
) ) None
patients NNS None
atherosclerotic JJ Condition
disease NN Condition
. . None
-DOCSTART- -X- N

advanced JJ Condition
breast NN Condition
cancer NN Condition
600 CD None
cases NNS None
advanced JJ Condition
breast NN Condition
cancers NNS Condition
French JJ None
603 CD None
patients NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
. . None
31 CD None
children NNS None
with IN None
autistic JJ None
spectrum NN None
disorders NNS None
in IN None
an DT None
8-week JJ None
, , None
double-blinded JJ None
study NN None
-DOCSTART- -X- N

surgery NN None
in IN None
patients NNS None
with IN None
angina NN Condition
. . None
patients NNS None
undergoing VBG None
coronary JJ Condition
arteriography NN Condition
at IN None
the DT None
fourteen JJ None
participating VBG None
centres NNS None
Patients NNS None
with IN None
arteriographically RB Condition
proven JJ Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
are VBP None
considered VBN None
for IN None
the DT None
trial NN None
The DT None
trial NN None
will MD None
recruit VB None
at IN None
least JJS None
1000 CD Size
patients NNS None
who WP None
will MD None
be VB None
followed VBN None
for IN None
five CD None
years NNS None
. . None
-DOCSTART- -X- N

idiopathic JJ None
pulmonary JJ None
fibrosis NN None
( ( None
IPF NNP None
) ) None
patients NNS None
with IN None
IPF NNP None
. . None
subjects NNS None
with IN None
IPF NNP None
who WP None
completed VBD None
the DT None
6MWT CD None
, , None
Saint NNP None
George NNP None
's POS None
Respiratory NNP None
Questionnaire NNP None
( ( None
SGRQ NNP None
) ) None
and CC None
forced VBN None
vital JJ None
capacity NN None
( ( None
FVC NNP None
) ) None
123 CD None
subjects NNS None
alive JJ None
and CC None
able JJ None
to TO None
complete VB None
the DT None
6MWT CD None
at IN None
both DT None
follow-up JJ None
time NN None
points NNS None
patients NNS None
with IN None
IPF NNP None
with IN None
moderate JJ None
physiological JJ None
impairment NN None
patient JJ None
population NN None
. . None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS None
. . None
healthy JJ None
, , None
non-drug-abusing JJ Condition
volunteers NNS None
. . None
Ten NNP None
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

sheep JJ None
fed NN None
on IN None
finger NN None
millet NN None
straw NN None
( ( None
Eleucine NNP None
coracana NN None
) ) None
-based VBD None
diet JJ None
Nellore NNP None
rams NNS None
fed VBP None
on IN None
a DT None
finger NN None
millet NN None
straw NN None
( ( None
FMS NNP None
) ) None
-based VBD None
diet JJ None
. . None
Thirty-six JJ None
Nellore NNP None
sheep NN None
sheep JJ None
fed NN None
on IN None
an DT None
FMS-based JJ None
diet NN None
. . None
-DOCSTART- -X- N

severely RB None
neutropenic JJ None
patients NNS None
. . None
fever NN None
in IN None
neutropenic JJ None
patients NNS None
. . None
patients NNS None
who WP None
experienced VBD None
a DT None
total NN None
of IN None
247 CD None
febrile JJ None
episodes NNS None
All DT None
247 CD None
episodes NNS None
were VBD None
evaluable JJ None
febrile JJ None
neutropenic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

canine JJ None
Canine NNP Condition
parvoviral JJ Condition
enteritis NN Condition
dogs NNS None
parvoviral JJ Condition
enteritis NN Condition
in IN Condition
dogs NNS Condition
. . None
beagle NN None
pups NNS None
( ( Age
8-9 JJ Age
weeks NNS None
) ) None
; : None
Fourteen JJ Size
animals NNS None
were VBD None
inoculated VBN None
with IN None
virulent JJ None
canine NN None
parvovirus NN None
; : None
10 CD Size
animals NNS None
that WDT None
developed VBD None
clinical JJ None
signs NNS None
thereby RB None
meeting VBG None
the DT None
inclusion NN None
criteria NNS None
were VBD None
admitted VBN None
to TO None
the DT None
treatment NN None
phase NN None
dogs NNS None
with IN None
parvoviral JJ Condition
enteritis NN Condition
-DOCSTART- -X- N

autistic JJ Condition
disorder NN Condition
: : Condition
infantile JJ Condition
autism NN Condition
. . None
Children NNP Age
between IN Age
the DT Age
ages NNS Age
3 CD Age
and CC Age
11 CD Age
years NNS Age
( ( None
inclusive JJ None
) ) None
with IN None
a DT None
DSM NNP Condition
IV NNP Condition
clinical JJ Condition
diagnosis NN Condition
of IN Condition
autism NN Condition
and CC None
who WP None
were VBD None
outpatients NNS Condition
from IN None
a DT None
specialty NN None
clinic NN None
for IN None
children NNS None
at IN None
Roozbeh NNP None
Psychiatric NNP None
Teaching NNP None
Hospital NNP None
were VBD None
recruited VBN None
. . None
children NNS Age
presented VBN None
with IN None
a DT None
chief JJ None
complaint NN None
of IN None
severely RB None
disruptive JJ None
symptoms NNS None
related VBN None
to TO None
autistic JJ Condition
disorder NN Condition
. . None
children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
. . None
-DOCSTART- -X- N

advanced JJ Condition
breast NN Condition
cancer NN Condition
: : None
From IN None
January NNP None
1985 CD None
to TO None
September NNP None
1988 CD None
, , None
60 CD Size
women NNS Sex
with IN None
advanced JJ Condition
breast NN Condition
cancer NN Condition
were VBD None
randomized VBN None
in IN None
two CD None
arms NNS None
All DT None
patients NNS None
were VBD None
post-menopausal JJ Condition
, , None
previously RB None
untreated VBN None
with IN None
hormone NN None
therapy NN None
, , None
and CC None
with IN None
tumor NN None
receptor NN None
status NN None
determined VBD None
immediately RB None
before IN None
randomization NN None
; : None
all DT None
had VBD None
objectively RB None
evaluable JJ Condition
lesions NNS Condition
. . None
Thirty-one NN Size
and CC None
29 CD Size
patients NNS None
were VBD None
included VBN None
respectively RB None
in IN None
arms NNS None
A NNP None
and CC None
B NNP None
. . None
-DOCSTART- -X- N

autism NN Condition
: : None
children NNS Age
children NNS Age
children NNS None
autistic JJ Condition
children NNS Age
-DOCSTART- -X- N

63 CD Size
patients NNS None
undergoing JJ None
deep JJ Condition
anterior JJ Condition
resection NN Condition
of IN Condition
the DT Condition
rectum NN Condition
, , None
39 CD Size
patients NNS None
received VBD None
a DT None
straight JJ None
colo-anal JJ None
anastomosis NN None
-DOCSTART- -X- N

premenopausal JJ Condition
women NNS Sex
women NNS None
36 CD Size
premenopausal JJ Sex
women NNS Sex
, , None
20 CD Size
of IN Size
whom WP Size
used VBD Size
OC NNP Size
premenopausal NN Size
OC NNP Size
non-OC JJ Size
users NNS Size
-DOCSTART- -X- N

patients NNS None
with IN None
epithelial JJ Condition
ovarian JJ Condition
cancer NN Condition
and CC None
relation NN None
to TO None
TP53 NNP None
gene NN None
status NN None
. . None
45 CD Size
ovarian JJ Condition
cancer NN Condition
patients NNS None
randomized VBN None
to TO None
treatment NN None
38 CD Size
patients NNS None
with IN None
clinically RB None
evaluable JJ None
disease NN None
after IN None
initial JJ None
surgery NN None
. . None
-DOCSTART- -X- N

studied VBN None
in IN None
67 CD Size
patients NNS None
undergoing JJ None
colorectal JJ Condition
surgery NN Condition
under IN None
continuous JJ Condition
epidural JJ Condition
anaesthesia NN Condition
and CC None
light JJ Condition
general JJ Condition
anaesthesia NN Condition
using VBG None
propofol NN None
, , None
halothane NN None
, , None
and CC None
midazolam/fentanyl NN None
. . None
-DOCSTART- -X- N

coronary JJ Condition
artery NN Condition
bypass NN Condition
graft NN Condition
patency NN None
. . None
610 CD Size
patients NNS None
undergoing JJ None
coronary JJ Condition
artery NN Condition
bypass NN Condition
grafting VBG Condition
All DT None
patients NNS None
received VBD None
antithrombotic JJ Condition
treatment NN Condition
, , None
either CC None
aspirin NN None
or CC None
warfarin NN None
. . None
patients NNS None
undergoing VBG None
coronary JJ Condition
artery NN Condition
bypass NN Condition
grafting NN Condition
-DOCSTART- -X- N

cervical JJ None
high-risk JJ None
human JJ None
papilloma NN None
virus NN None
infection NN None
patients NNS None
] VBP None
cervical JJ Condition
high-risk JJ Condition
human JJ Condition
papilloma NN Condition
virus NN Condition
( ( Condition
HR-HPV NNP Condition
) ) Condition
infection NN Condition
. . Condition
Totally RB None
HR-HPV NNP None
infection NN None
70 CD None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
gynecologic JJ Condition
malignancies NNS Condition
. . None
patients NNS None
with IN None
gynecologic JJ Condition
malignancies NNS Condition
. . None
Ninety-three JJ Size
consecutive JJ None
patients NNS None
with IN None
gynecologic JJ Condition
pelvic JJ Condition
malignancies NNS Condition
who WP None
underwent VBP None
surgery NN None
including VBG None
pelvic NN None
or CC None
pelvic NN None
and CC None
paraaortic JJ None
lymphadenectomy NN None
93 CD Size
patients NNS None
-DOCSTART- -X- N

essential JJ Condition
hypertension NN Condition
. . None
446 CD None
hypertensive JJ Condition
patients NNS None
( ( None
mean JJ Age
age NN Age
: : Age
55.8 CD Age
+/- JJ Age
11.0 CD Age
years NNS Age
) ) None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
and CC None
developmental JJ Condition
delay NN Condition
children NNS Age
with IN None
developmental JJ Condition
problems NNS Condition
. . None
Participants VBZ None
A DT None
total NN None
of IN None
59 CD Size
children NNS None
, , None
aged VBN None
3-5 CD Age
years NNS None
, , None
attending VBG None
two CD None
early JJ None
childhood NN None
intervention NN None
centres NNS None
in IN None
Melbourne NNP None
, , None
Australia NNP None
. . None
Half NNP None
of IN None
the DT None
subjects NNS None
Fifty-four JJ Size
children NNS Age
-DOCSTART- -X- N

lunar JJ Condition
stent NN Condition
MOONLIGHT NNP None
( ( None
Multicenter NNP None
Objective NNP None
ObservatioNal NNP None
Lunar NNP None
Iridiumoxide NNP None
intimal JJ None
GrowtH NNP None
Trial NNP None
) ) None
study NN None
Between IN None
March NNP None
2001 CD None
and CC None
November NNP None
2001 CD None
, , None
87 CD Size
patients NNS None
with IN None
99 CD None
lesions NNS Condition
were VBD None
enrolled VBN None
in IN None
this DT None
study NN None
-DOCSTART- -X- N

lateral JJ Condition
epicondylitis NN Condition
. . Condition
tennis NN None
elbow NN None
. . None
tennis NN None
elbow NN None
Fifty NNP None
patients NNS None
who WP None
had VBD None
tennis NN None
elbow NN None
participated VBD None
in IN None
the DT None
study NN None
-DOCSTART- -X- N

class NN Condition
II NNP Condition
furcation NN Condition
defects NNS Condition
. . None
Class NNP None
II NNP None
furcation NN None
defects NNS None
Nine NNP Size
patients NNS None
, , None
with IN None
two CD None
comparable JJ None
Class NNP Condition
II NNP Condition
furcation NN Condition
defects NNS Condition
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
GTR-group NNP Condition
or CC Condition
OFD-group NNP Condition
. . None
-DOCSTART- -X- N

epidemiologic JJ None
control NN None
group NN None
. . None
self-administered JJ None
questionnaire NN None
was VBD None
sent VBN None
to TO None
parents NNS None
in IN None
the DT None
municipality NN None
of IN None
Stockholm NNP None
, , None
Sweden NNP None
, , None
who WP None
were VBD None
to TO None
be VB None
used VBN None
as IN None
a DT None
control NN None
group NN None
in IN None
a DT None
study NN None
addressing VBG None
stress NN None
in IN None
parents NNS None
of IN None
children NNS Age
with IN None
cancer NN Condition
. . None
450 CD Size
parents NNS None
respondents NNS None
-DOCSTART- -X- N

third-party JJ None
blood NN None
transfusion NN None
protocol NN None
Antigen NNP None
pre-treatment NN None
in IN None
animals NNS None
pre-transplantation NN None
blood NN None
transfusions NNS None
planned JJ None
programme NN None
of IN None
third-party JJ None
blood NN None
transfusions NNS None
24 CD None
patients NNS None
were VBD None
recruited VBN None
to TO None
the DT None
study NN None
; : None
ten CC None
received VBD None
cyclosporin NNS None
with IN None
blood NN None
transfusions NNS None
( ( None
BT NNP None
) ) None
( ( None
group NN None
1 CD None
) ) None
, , None
14 CD None
received VBD None
BT NNP None
alone RB None
( ( None
group NN None
2 CD None
) ) None
-DOCSTART- -X- N

South JJ None
African JJ None
population NN None
. . None
women NNS Sex
with IN None
pregnancy-related JJ Condition
low JJ Condition
back RB Condition
pain NN Condition
. . None
Fifty NNP Size
women NNS None
between IN None
16 CD None
and CC None
24 CD None
weeks NNS None
of IN None
pregnancy NN None
were VBD None
recruited VBN None
at IN None
Tygerberg NNP None
and CC None
Paarl NNP None
Hospitals NNP None
, , None
Western NNP None
Cape NNP None
, , None
South NNP None
Africa NNP None
. . None
Twenty-six JJ Size
women NNS None
were VBD None
randomized VBN None
to TO None
a DT None
10-week JJ None
exercise NN None
program NN None
and CC None
24 CD None
were VBD None
randomized VBN None
as IN None
controls NNS None
. . None
pregnancy NN None
in IN None
South JJ None
African JJ None
women NNS None
with IN None
lumbar NN Condition
and CC Condition
pelvic JJ Condition
girdle NN Condition
pain NN Condition
. . None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Condition
. . Condition
autistic JJ None
children NNS None
. . None
-DOCSTART- -X- N

patients NNS None
and CC None
in IN None
dogs NNS None
with IN None
experimentally RB None
induced JJ None
heart NN None
failure NN None
( ( None
HF NNP None
) ) None
both DT None
patients NNS None
and CC None
dogs NNS None
with IN None
chronic JJ None
HF NNP None
. . None
Six NNP None
dogs NNS None
with IN None
microembolizations-induced JJ None
HF NNP None
and CC None
9 CD None
HF NNP None
patients NNS None
underwent JJ None
CCM NNP None
leads NNS None
and CC None
generator NN None
( ( None
OPTIMIZER NNP None
II NNP None
) ) None
implantation NN None
. . None
-DOCSTART- -X- N

Hematologic NNP Condition
patients NNS None
' POS None
clinical JJ None
and CC None
psychosocial JJ None
experiences NNS None
with IN None
implanted JJ None
long-term JJ None
central JJ Condition
venous JJ Condition
catheter NN Condition
: : None
hematologic JJ Condition
patients NNS None
. . None
Eighty-two JJ Size
patients NNS None
with IN None
tunneled JJ None
CVCs NNP Condition
-DOCSTART- -X- N

orthognathic JJ Condition
surgery NN None
. . None
temporomandibular JJ Condition
joint NN Condition
( ( Condition
TMJ NNP Condition
) ) Condition
after IN None
bilateral JJ Condition
sagittal JJ Condition
split NN Condition
osteotomy NN Condition
of IN None
the DT None
mandible JJ None
for IN None
orthognathic JJ Condition
surgery NN None
A NNP None
total NN None
of IN None
28 CD Size
patients NNS None
with IN None
mandibular JJ Condition
retrognathism NN Condition
had VBD None
bilateral JJ Condition
sagittal JJ Condition
split NN Condition
osteotomies NNS Condition
for IN None
mandibular JJ None
advancement NN None
. . None
14 CD Size
patients NNS None
( ( None
28 CD Size
TMJ NNP Condition
) ) None
15/28 CD Size
TMJs NNP Condition
( ( None
54 CD None
% NN None
) ) None
that WDT None
had VBD None
not RB None
been VBN None
positioned VBN None
changed VBD None
28 CD Size
that WDT None
had VBD None
been VBN None
positioned VBN None
, , None
changes NNS None
were VBD None
found VBN None
in IN None
only RB None
3 CD Size
TMJs NNP Condition
( ( None
11 CD None
% NN None
) ) None
postoperatively RB None
. . None
-DOCSTART- -X- N

geriatric JJ Condition
depression NN Condition
Thirty-eight JJ Size
patients NNS None
treatment NN None
of IN None
late-life JJ Condition
depression NN Condition
. . None
small JJ None
and CC None
predominantly RB None
White NNP None
sample NN None
. . None
-DOCSTART- -X- N

postoperative JJ None
disease NN None
management NN None
of IN None
moderate JJ Condition
to TO Condition
severe JJ Condition
endometriosis NN Condition
. . None
patients NNS None
treated VBN None
with IN None
triptorelin NN None
every DT None
6 CD None
weeks NNS None
. . None
Kwong NNP None
Wah NNP None
Hospital NNP None
, , None
a DT None
large JJ None
public JJ None
hospital NN None
in IN None
an DT None
urban JJ None
location NN None
( ( None
Hong NNP None
Kong NNP None
) ) None
. . None
Forty NNP Size
patients NNS None
after IN None
their PRP$ None
first JJ None
conservative JJ None
operation NN None
for IN None
endometriosis NN None
, , None
with IN None
surgical JJ None
confirmation NN None
of IN None
revised VBN None
AFS NNP Condition
stage NN Condition
III NNP Condition
or CC Condition
IV NNP Condition
endometriosis NN Condition
. . None
-DOCSTART- -X- N

HIV NNP Condition
infection NN Condition
. . Condition
HIV-infected JJ Condition
patients NNS None
. . None
HIV-infected JJ Condition
patients NNS None
. . None
Twenty-one CD Size
HIV-seropositive JJ Condition
patients NNS None
HIV-infected JJ Condition
patients NNS None
. . None
HIV-infected JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

atrial JJ None
DFTs NNP None
in IN None
33 CD None
patients NNS None
. . None
-DOCSTART- -X- N

stroke NN Condition
patients NNS Condition
post-acute JJ None
hemiparetic JJ None
patients NNS None
Twenty-six JJ None
patients NNS None
within IN None
3 CD None
months NNS None
of IN None
onset NN None
of IN None
stroke NN None
-DOCSTART- -X- N

Rett NNP None
syndrome NN None
: : None
female JJ None
patients NNS None
. . None
35 CD None
subjects NNS None
. . None
patients NNS None
with IN None
Rett NNP None
syndrome NN None
. . None
-DOCSTART- -X- N

patients NNS None
who WP None
underwent JJ Condition
hysterectomy NN Condition
Forty NNP None
patients NNS None
were VBD None
divided VBN None
into IN None
four CD None
groups NNS None
of IN None
ten NN None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
pancreatic JJ Condition
adenocarcinoma NN Condition
previously RB None
untreated VBN None
with IN None
systemic JJ None
therapy NN None
. . None
Six NNP Size
hundred VBD Size
eighty-eight JJ Size
patients NNS None
were VBD None
enrolled VBN None
. . None
-DOCSTART- -X- N

brown-egg NN None
laying NN None
hens NNS None
. . None
total NN None
of IN None
five CD Size
hundred JJ Size
forty NN Size
19-wk-old JJ Age
HyLine NNP None
Brown NNP None
hens NNS None
were VBD None
used VBN None
to TO None
study VB None
-DOCSTART- -X- N

healthy JJ Condition
neonates NNS Age
10 CD Size
term NN None
infants NNS Age
-DOCSTART- -X- N

metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
. . None
metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
813 CD Size
patients NNS None
with IN None
previously RB None
untreated VBN None
metastatic JJ Condition
colorectal NN Condition
cancer NN Condition
patients NNS None
with IN None
metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
. . Condition
-DOCSTART- -X- N

outpatient JJ Condition
anesthesia NN Condition
. . None
outpatients NNS None
undergoing VBG None
procedures NNS Condition
greater JJR Condition
than IN Condition
2 CD Condition
hours NNS Condition
in IN Condition
length NN Condition
. . None
Thirty-three JJ Size
patients NNS None
aged VBD None
18 CD Age
to TO Age
70 CD Age
years NNS None
Patients NNS None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
dementia NN None
and CC None
depression NN None
. . None
patients NNS None
with IN None
dementia NN None
and CC None
mild JJ None
depression NN None
( ( None
DSM-III-R NNP None
290.21 CD None
) ) None
127 CD None
patients NNS None
-DOCSTART- -X- N

locally RB None
advanced JJ None
non-small JJ None
cell NN None
lung NN None
cancer NN None
: : None
Patients NNPS None
with IN None
stages NNS None
II NNP None
and CC None
IIIA/B NNP None
non-small-cell JJ None
lung NN None
cancer NN None
RESULTS VB None
243 CD None
patients NNS None
( ( None
pts NNS None
) ) None
were VBD None
enrolled VBN None
; : None
120 CD None
received VBD None
AM NNP None
, , None
123 CD None
received VBD None
no-AM JJ None
. . None
Two CD None
pts NNS None
on IN None
each DT None
arm NN None
were VBD None
found VBN None
ineligible JJ None
. . None
Overall JJ None
, , None
85 CD None
% NN None
of IN None
patients NNS None
were VBD None
?70 JJ None
years NNS None
; : None
75 CD None
% NN None
had VBD None
a DT None
KPS NNP None
?90 NNP None
. . None
34 CD None
% NN None
had VBD None
squamous JJ None
histology NN None
. . None
With IN None
-DOCSTART- -X- N

patients NNS None
with IN None
diabetes NNS Condition
mellitus NNS Condition
( ( None
DM NNP None
) ) None
type NN None
2 CD None
and CC None
chronic JJ Condition
CME NNP Condition
without IN None
evident JJ None
vitreomacular JJ None
traction NN None
. . None
Forty NNP Size
eyes NNS None
with IN None
attached JJ None
posterior JJ None
hyaloid NN None
patients NNS None
with IN None
DM NNP None
type NN None
2 CD None
and CC None
cystoid JJ None
diabetic JJ None
macular NN None
edema NN None
without IN None
evident JJ None
vitreoretinal JJ None
traction NN None
. . None
ILM NNP None
eyes NNS None
with IN None
preexisting VBG None
PVD NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
squamous JJ None
cell NN None
carcinoma NN None
of IN None
the DT None
head NN None
and CC None
neck NN None
. . None
Eighty-three JJ None
patients NNS None
with IN None
advanced JJ None
disease NN None
were VBD None
entered VBN None
into IN None
the DT None
first JJ None
study NN None
( ( None
43/chemotherapy CD None
; : None
40/control CD None
) ) None
, , None
and CC None
60 CD None
into IN None
the DT None
second JJ None
Patient JJ None
randomization NN None
was VBD None
stratified VBN None
by IN None
stage NN None
( ( None
III/IV NNP None
) ) None
and CC None
site NN None
-DOCSTART- -X- N

proliferative JJ None
diabetic JJ None
retinopathy NN None
: : None
80 CD None
eyes NNS None
of IN None
40 CD None
high-risk JJ None
characteristic JJ None
proliferative JJ None
diabetic JJ None
retinopathy NN None
type NN None
II NNP None
diabetics NNS None
. . None
The DT None
median JJ None
age NN None
was VBD None
52 CD None
years NNS None
( ( None
range NN None
: : None
39-68 JJ None
) ) None
and CC None
30 CD None
% NN None
of IN None
the DT None
participants NNS None
were VBD None
male JJ None
. . None
-DOCSTART- -X- N

after IN Condition
end-to-side JJ Condition
neurorrhaphy NN Condition
. . Condition
after IN None
end-to-side JJ None
neurorrhaphy NN None
Four CD None
groups NNS None
( ( None
n=4 JJ None
for IN None
each DT None
group NN None
) ) None
were VBD None
used VBN None
: : None
end-to-end JJ None
coaptation NN None
( ( None
six CD None
months NNS None
postoperatively RB None
) ) None
, , None
end-to-side JJ None
coaptation NN None
( ( None
four CD None
months NNS None
and CC None
six CD None
months NNS None
postoperatively RB None
) ) None
and CC None
normal JJ None
control NN None
. . None
-DOCSTART- -X- N

subjects NNS Condition
with IN Condition
mild-to-moderate JJ Condition
asthma NN Condition
. . Condition
subjects NNS None
with IN None
mild-to-moderate JJ None
asthma NN None
, , None
three CD None
groups NNS None
of IN None
11 CD None
patients NNS None
-DOCSTART- -X- N

Thirty-four CD Size
healthy JJ Condition
young JJ Age
women NNS Age
normal JJ Condition
women NNS Sex
. . None
-DOCSTART- -X- N

non-diabetic JJ Condition
chronic JJ Condition
kidney NN Condition
disease NN Condition
: : None
patients NNS None
with IN None
non-diabetic JJ None
chronic JJ None
kidney NN None
disease NN None
. . None
14 CD None
patients NNS None
with IN None
nondiabetic JJ None
chronic JJ None
kidney NN None
disease NN None
with IN None
24-h JJ None
mean JJ None
proteinuria NN None
of IN None
2.01 CD None
g NN None
( ( None
95 CD None
% NN None
CI NNP None
, , None
1.36?2.66 CD None
) ) None
and CC None
estimated VBN None
creatinine JJ None
clearance NN None
of IN None
93?6.8 CD None
ml/min NN None
. . None
The DT None
of IN None
patients NNS None
with IN None
chronic JJ None
proteinuric JJ None
non-diabetic JJ None
kidney NN None
disease NN None
. . None
-DOCSTART- -X- N

elective JJ Condition
hip NN Condition
surgery NN Condition
. . None
patients NNS None
undergoing JJ None
total JJ Condition
hip NN Condition
replacement NN Condition
120 CD None
patients NNS None
enrolled VBD None
, , None
112 CD None
completed VBD None
-DOCSTART- -X- N

tetralogy NN None
of IN None
Fallot NNP None
( ( None
TOF NNP None
) ) None
. . None
TOF NNP None
patients NNS None
receiving VBG None
cardioplegia NN None
. . None
From IN None
January NNP None
2008 CD None
to TO None
June NNP None
2010 CD None
, , None
80 CD None
consecutive JJ None
children NNS None
undergoing VBG None
correction NN None
of IN None
TOF NNP None
in IN None
children NNS None
undergoing VBG None
correction NN None
of IN None
tetralogy NN None
of IN None
Fallot NNP None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
mild JJ Condition
or CC Condition
borderline JJ Condition
hypertension NN Condition
: : Condition
A DT None
total NN None
of IN None
18 CD None
hypertensive JJ None
and CC None
hyperinsulinemic JJ None
( ( None
= JJ None
10 CD None
U/mL NNP None
or CC None
more JJR None
) ) None
men NNS None
and CC None
women NNS None
completed VBD None
the DT None
trial NN None
. . None
patients NNS None
with IN None
hypertension NN None
-DOCSTART- -X- N

the DT None
Japan NNP None
Morning NNP None
Surge NNP None
1 CD None
study NN None
. . None
434 CD Size
treated JJ None
hypertensive JJ Condition
patients NNS Condition
whose WP$ None
home NN None
systolic NN Condition
blood NN Condition
pressure NN Condition
was VBD Condition
135 CD Condition
mmHg NN Condition
or CC Condition
higher JJR Condition
. . None
They PRP None
-DOCSTART- -X- N

intracerebral JJ Condition
hemorrhage NN Condition
evacuation NN None
( ( None
MISTIE NNP None
) ) None
younger JJR Age
patients NNS None
, , None
and CC None
produces VBZ None
relatively RB None
small JJ None
initial JJ None
injury NN None
to TO None
cerebral JJ None
tissues NNS None
-- : None
all DT None
factors NNS None
suggesting VBG None
that IN None
interventional JJ None
amelioration NN None
is VBZ None
possible JJ None
. . None
Subjects NNS None
in IN None
both DT None
groups NNS None
medically RB None
managed VBN None
according VBG None
to TO None
standard JJ None
ICU NNP None
protocols NNS None
. . None
-DOCSTART- -X- N

children NNS None
undergoing VBG None
myringotomy NN None
. . None
70 CD None
% NN None
of IN None
children NNS None
bilateral JJ None
myringotomy NNS None
and CC None
tube VB None
placement NN None
( ( None
BM NNP None
& CC None
T NNP None
) ) None
. . None
Forty NNP None
three CD None
ASA NNP None
I PRP None
or CC None
II NNP None
children NNS None
age NN None
six CD None
months NNS None
or CC None
older JJR None
scheduled VBN None
for IN None
elective JJ None
BM NNP None
& CC None
T NNP None
children NNS None
receiving VBG None
rescue NN None
analgesia NN None
. . None
children NNS None
undergoing VBG None
BM NNP None
& CC None
T NNP None
. . None
-DOCSTART- -X- N

in IN None
patients NNS None
with IN None
gastroesophageal JJ Condition
reflux JJ Condition
disease NN Condition
. . None
patients NNS None
with IN None
gastroesophageal JJ Condition
reflux NN Condition
disease NN Condition
( ( Condition
GERD NNP Condition
) ) Condition
. . Condition
39 CD Size
patients NNS None
with IN None
delayed JJ Condition
gastric NN Condition
emptying NN Condition
( ( Condition
DGE NNP Condition
) ) Condition
from IN None
2 CD None
studies NNS None
( ( None
n JJ Size
= NNP Size
84 CD Size
) ) None
All PDT None
the DT None
84 CD Size
patients NNS None
were VBD None
classified VBN None
at IN None
baseline NN None
with IN None
DGE NNP Condition
( ( None
gastric JJ None
retention NN None
> VBD None
6.3 CD None
% NN None
at IN None
4 CD None
hours NNS None
) ) None
or CC None
normal JJ Condition
gastric JJ Condition
emptying NN Condition
. . None
subgroup NN None
of IN None
diabetic JJ Condition
patients NNS None
with IN None
DGE NNP Condition
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
patients NNS None
with IN None
GERD NNP Condition
with IN None
DGE NNP Condition
. . None
-DOCSTART- -X- N

dysfunctional JJ None
uterine JJ None
bleeding NN None
among IN None
women NNS None
agreeing VBG None
to TO None
obtain VB None
surgical JJ None
treatment NN None
. . None
dysfunctional JJ None
uterine JJ None
bleeding NN None
( ( None
DUB NNP None
) ) None
of IN None
women NNS None
who WP None
agreed VBD None
to TO None
obtain VB None
surgical JJ None
treatment NN None
; : None
We PRP None
collected VBD None
baseline NN None
data NNS None
on IN None
DUB NNP None
symptoms NNS None
and CC None
aspects NNS None
of IN None
the DT None
financial JJ None
and CC None
quality-of-life JJ None
burden NN None
for IN None
237 CD None
women NNS None
agreeing VBG None
to TO None
surgery VB None
for IN None
DUB NNP None
in IN None
a DT None
randomized JJ None
trial NN None
comparing VBG None
hysterectomy NN None
with IN None
endometrial JJ None
ablation NN None
. . None
-DOCSTART- -X- N

various JJ None
nasal JJ Condition
pathologies NNS Condition
: : None
patients NNS None
with IN None
allergic JJ Condition
rhinitis NN Condition
, , None
acute JJ Condition
sinusitis NN Condition
and CC None
chronic JJ Condition
sinusitis NN Condition
. . None
132 CD Size
adults NNS Age
Patient JJ None
numbers NNS None
were VBD None
as IN None
follows VBZ None
: : None
controls NNS Size
, , Size
45 CD Size
; : None
allergic JJ Size
rhinitis NN Size
, , Size
21 CD Size
; : None
acute JJ Size
sinusitis NN Size
, , Size
24 CD Size
; : None
and CC None
chronic JJ Size
sinusitis NN Size
, , Size
42 CD Size
. . None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS None
. . None
23 CD Size
healthy JJ Condition
male NN Sex
volunteers NNS None
-DOCSTART- -X- N

children NNS None
with IN None
autistic JJ Condition
disorder NN Condition
: : None
children NNS None
with IN None
autism NN Condition
. . None
Children NNP None
with IN None
autism NN Condition
-DOCSTART- -X- N

drug-free JJ None
adults NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
drug-free JJ None
adult NN None
patients NNS None
with IN None
autistic JJ Condition
disorder NN Condition
Twenty NNP None
drug-free JJ None
adults NNS None
with IN None
autistic JJ Condition
disorder NN Condition
( ( None
16 CD None
men NNS None
and CC None
4 CD None
women NNS None
) ) None
( ( None
mean JJ None
[ NNP None
+/- NN None
SD NNP None
] NNP None
age NN None
, , None
30.5 CD None
+/- JJ None
8.5 CD None
years NNS None
) ) None
patients NNS None
with IN None
autism NN None
autistic JJ None
disorder NN None
-DOCSTART- -X- N

endosseous JJ None
implants NNS None
up IN None
to TO None
and CC None
including VBG None
stage NN None
II NNP None
surgery NN None
: : None
a DT None
study NN None
of IN None
2,641 CD Size
implants NNS None
. . None
endosseous JJ None
implants NNS None
-DOCSTART- -X- N

hypertensive JJ Condition
patients NNS None
treated VBN None
with IN None
cilazapril NN None
. . None
twenty JJ Size
patients NNS None
with IN None
essential JJ Condition
hypertension NN Condition
-DOCSTART- -X- N

African-American JJ None
renal JJ Condition
transplant NN Condition
patients NNS None
. . None
African-American JJ None
renal JJ None
transplant NN None
patients NNS None
African-American JJ None
renal JJ None
transplant NN None
patients NNS None
who WP None
did VBD None
not RB None
have VB None
clinical JJ None
pharmacy NN None
services NNS None
. . None
Renal NNP Size
transplant NN Size
patients NNS Size
( ( None
N NNP None
= NNP None
13 CD Size
) ) None
( ( None
N NNP None
= NNP None
10 CD Size
) ) None
African-American JJ None
renal JJ None
transplant NN None
patients NNS None
. . None
-DOCSTART- -X- N

pediatric JJ None
asthma NN Condition
. . None
children NNS None
with IN None
asthma NN Condition
are VBP None
able JJ None
to TO None
acquire VB None
the DT None
asthma NN Condition
knowledge NN None
and CC None
skills NNS None
presented VBN None
in IN None
a DT None
self-management JJ None
training NN None
program NN None
conducted VBN None
by IN None
the DT None
American NNP None
Lung NNP None
Association NNP None
of IN None
Utah NNP None
preschool NN None
( ( None
ages VBZ None
2-5 CD None
) ) None
one CD None
or CC None
both DT None
parents NNS None
child NN None
and CC None
parent NN None
( ( None
s NN None
) ) None
. . None
( ( None
ages IN None
6-14 NN None
) ) None
child NN None
and CC None
parent NN None
( ( None
s PRP None
) ) None
Private JJ None
physicians NNS None
referred VBD None
21 CD Size
preschool NN None
children NNS None
and CC None
38 CD None
school-age JJ None
children NNS None
into IN None
the DT None
program NN None
. . None
school-age JJ None
children NNS None
preschool NN None
children NNS None
-DOCSTART- -X- N

pediatric JJ None
cardiac JJ None
patients NNS None
. . None
pediatric JJ None
cardiac JJ None
surgery NN None
. . None
50 CD None
pediatric JJ None
patients NNS None
( ( None
18 CD None
girls NNS None
, , None
32 CD None
boys NNS None
) ) None
, , None
aged VBD None
4 CD None
months NNS None
to TO None
15 CD None
years NNS None
, , None
undergoing VBG None
elective JJ None
repair NN None
of IN None
congenital JJ None
heart NN None
disease NN None
. . None
-DOCSTART- -X- N

post-operative JJ None
infective JJ None
complications NNS None
following VBG None
emergency NN None
abdominal JJ Condition
surgery NN Condition
. . None
57 CD Size
patients NNS None
undergoing JJ None
emergency NN None
abdominal JJ None
surgery NN None
, , None
prospectively RB None
a DT None
further JJ None
63 CD Size
patients NNS None
undergoing JJ None
emergency NN None
abdominal JJ None
surgery NN None
The DT None
total NN None
of IN None
120 CD Size
patients NNS None
studied VBN None
-DOCSTART- -X- N

360 CD Size
ASA NNP Condition
physical JJ Condition
status NN Condition
I-III NNP Condition
patients NNS None
undergoing VBG None
total JJ None
abdominal JJ None
hysterectomy NN None
( ( None
TAH NNP None
) ) None
-DOCSTART- -X- N

hookworm NN None
infection NN None
. . None
participants NNS None
with IN None
allergic JJ None
rhinitis NN None
. . None
participants NNS None
were VBD None
sensitized VBN None
-DOCSTART- -X- N

in IN None
man NN Sex
. . None
Eighteen NNP Size
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

asthmatics NNS Condition
8 CD Size
asthmatics NNS Condition
. . None
Subjects NNS None
-DOCSTART- -X- N

nasal JJ Condition
allergen JJ Condition
17 CD Size
patients NNS None
with IN None
anamnestic JJ None
known VBN None
rhinokonjunktivitis NN Condition
( ( None
6 CD None
f NN None
, , None
11 CD None
m NN None
) ) None
had VBD None
a DT None
pricktest NN None
and CC None
then RB None
a DT None
nasal JJ None
provocation NN None
testing VBG None
with IN None
an DT None
allergen NN None
which WDT None
provoked VBD None
a DT None
reaction NN None
on IN None
the DT None
skin NN None
. . None
7 CD Size
patients NNS None
a DT None
positive JJ None
reaction NN None
, , None
within IN None
7 CD None
patient NN None
a DT None
negative JJ None
reaction NN None
, , None
3 CD None
patients NNS None
had VBD None
a DT None
unspecific JJ None
nasal NN None
hyperreactivity NN None
. . None
6 CD None
of IN None
the DT None
7 CD None
patients NNS None
with IN None
positive JJ None
reaction NN None
in IN None
aR NN None
of IN None
the DT None
7 CD None
results NNS None
with IN None
negative JJ None
reaction NN None
-DOCSTART- -X- N

postoperative JJ Condition
pain NN Condition
relief NN None
after IN None
total JJ Condition
knee NN Condition
arthroplasty NN Condition
. . None
total JJ None
knee NN None
arthroplasty NN None
. . None
Patients NNS None
were VBD None
randomly RB None
enrolled VBN None
into IN None
patient-controlled JJ None
anesthesia NN None
( ( None
PCA NNP None
) ) None
alone RB None
, , None
PCA NNP None
plus CC None
TENS NNP None
, , None
or CC None
PCA NNP None
plus CC None
sham JJ None
TENS NNP None
. . None
-DOCSTART- -X- N

treatment NN None
of IN None
pyoderma NN None
in IN None
Bamako NNP None
, , None
Mali NNP None
: : None
Pyoderma NNP None
( ( None
bacterial JJ None
superficial NN None
skin NN None
infection NN None
) ) None
tropical JJ None
developing VBG None
countries NNS None
. . None
In IN None
Bamako NNP None
, , None
132 CD None
patients NNS None
with IN None
pyoderma NN None
, , None
diagnosed VBN None
and CC None
graded VBN None
as IN None
severe JJ None
on IN None
clinical JJ None
grounds NNS None
severe JJ None
pyoderma NN None
in IN None
Mali NNP None
. . None
-DOCSTART- -X- N

granulocytopenic JJ Condition
patients NNS None
. . None
granulocytopenic JJ Condition
patients NNS None
. . None
Patients NNS None
were VBD None
stratified VBN None
into IN None
two CD Size
groups NNS None
: : None
favorable-prognosis NN None
, , None
group NN Size
1 CD Size
( ( None
carcinoma NN Condition
, , None
lymphoma NN Condition
, , None
multiple JJ Condition
myeloma NN Condition
) ) None
, , None
or CC None
unfavorable-prognosis NN None
, , None
group NN Size
2 CD Size
( ( None
acute JJ Condition
leukemia NN Condition
, , None
bone NN Condition
marrow NN Condition
transplantation NN Condition
) ) None
, , None
based VBN None
on IN None
anticipated JJ None
duration NN None
of IN None
granulocytopenia NN Condition
. . None
-DOCSTART- -X- N

young JJ Age
children NNS Age
with IN Age
autism NN Age
sensory JJ None
impairment NN None
in IN None
young JJ None
children NNS None
Thirteen NNP None
children NNS None
with IN None
autism NN None
between IN Age
the DT Age
ages NNS Age
of IN Age
three CD Age
and CC Age
six CD Age
children NNS None
with IN None
bowel NN None
and CC None
sleep JJ None
abnormalities NNS None
-DOCSTART- -X- N

CPAP NNP None
therapy NN None
in IN None
a DT None
cool JJ None
sleeping NN None
environment NN None
. . None
patients NNS None
with IN None
obstructive JJ None
sleep JJ None
apnoea NN None
syndrome NN None
( ( None
OSAS NNP None
) ) None
. . None
19 CD None
patients NNS None
with IN None
a DT None
first-ever JJ None
diagnosis NN None
of IN None
OSAS NNP None
-DOCSTART- -X- N

atrial JJ Condition
fibrillation NN Condition
or CC None
flutter NN Condition
( ( Condition
AFF NNP Condition
) ) Condition
over IN None
450 CD Size
patients NNS None
. . None
Seventy-eight JJ Size
patients NNS None
with IN None
AFF NNP Condition
and CC None
a DT None
ventricular JJ None
rate NN None
of IN None
> NNP None
/= NNP None
120 CD None
beats NNS None
per IN None
minute NN None
were VBD None
enrolled VBN None
. . None
One CD Size
patient NN None
in IN None
the DT None
placebo NN None
group NN None
-DOCSTART- -X- N

schoolchildren NNS None
: : None
middle-income JJ None
students NNS None
children NNS None
from IN None
a DT None
semi-urban JJ None
population NN None
near IN None
Hyderabad NNP None
, , None
India NNP None
. . None
Included NNP None
were VBD None
869 CD None
children NNS None
who WP None
were VBD None
6 CD None
to TO None
16 CD None
y NN None
of IN None
age NN None
in IN None
grades NNS None
1 CD None
to TO None
10 CD None
. . None
number NN None
of IN None
children NNS None
per IN None
treatment NN None
group NN None
ranged VBD None
from IN None
32 CD None
in IN None
the DT None
case NN None
of IN None
bone NN None
heath NN None
to TO None
177 CD None
for IN None
body NN None
weight NN None
. . None
-DOCSTART- -X- N

33 CD Size
patients NNS None
with IN None
pulmonary JJ Condition
hypertension NN Condition
. . None
33 CD Size
age- JJ None
and CC None
sex-matched JJ None
control NN None
subjects NNS None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
: : None
community NN None
day-care NN None
centers NNS None
. . None
children NNS None
with IN None
autism NN None
in IN None
community NN None
day-care NN None
centers NNS None
. . None
Thirty-five JJ None
preschool NN None
children NNS None
with IN None
a DT None
DSM NNP None
III-R NNP None
diagnosis NN None
of IN None
autism NN None
or CC None
pervasive JJ None
developmental JJ None
disorder NN None
-DOCSTART- -X- N

seasonal JJ None
allergic JJ None
rhinitis NN None
Ontario NNP None
, , None
Quebec NNP None
and CC None
Manitoba NNP None
Two CD None
hundred VBD None
and CC None
eighty-four JJ None
out-patients NNS None
with IN None
SAR NNP None
, , None
who WP None
were VBD None
symptomatic JJ None
during IN None
the DT None
ragweed NN None
season NN None
, , None
volunteered VBD None
for IN None
enrolment NN None
( ( None
243 CD None
randomized VBN None
) ) None
SAR NNP None
-DOCSTART- -X- N

elderly JJ None
100 CD None
elderly JJ None
patients NNS None
with IN None
signs NNS None
of IN None
cerebro-vascular JJ None
impairment NN None
demonstrated VBN None
by IN None
psychometric JJ None
testing VBG None
-DOCSTART- -X- N

laparoscopic NN Condition
adrenalectomy NN Condition
( ( Condition
LA NNP Condition
) ) Condition
From IN None
January NNP None
2004 CD None
to TO None
January NNP None
2006 CD None
, , None
50 CD None
patients NNS None
( ( None
pts NNS None
) ) None
undergoing VBG None
LA NNP None
-DOCSTART- -X- N

humans NNS None
on IN None
a DT None
modified JJ None
temporal JJ None
generalization NN None
task NN None
with IN None
1 CD None
, , None
3 CD None
, , None
or CC None
5 CD None
presentations NNS None
of IN None
the DT None
standard JJ None
duration NN None
. . None
-DOCSTART- -X- N

retinopathy NN None
of IN None
prematurity NN None
: : None
one CD None
randomly NN None
selected VBN None
eye NN None
172 CD None
infants NNS None
had VBD None
been VBN None
examined VBN None
3 CD None
months NNS None
after IN None
randomization NN None
. . None
-DOCSTART- -X- N

focal JJ Condition
hand NN Condition
dystonia NN Condition
. . None
Patients NNS None
with IN None
writer NN Condition
's POS Condition
cramp NN Condition
patients NNS None
with IN None
dystonia NN Condition
patients NNS None
with IN None
writer NN Condition
's POS Condition
cramp NN Condition
. . None
Fourteen JJ Size
patients NNS None
affected VBN None
by IN None
writer NN None
's POS None
cramp NN None
in IN None
the DT None
right JJ None
hand NN None
and CC None
17 CD Size
age- JJ None
and CC None
gender-matched JJ None
healthy JJ None
subjects NNS None
were VBD None
recruited VBN None
for IN None
the DT None
study NN None
. . None
Patients NNS None
with IN None
writer NN Condition
's POS Condition
cramp NN Condition
-DOCSTART- -X- N

postoperative JJ Condition
dental NN Condition
pain NN Condition
. . None
pain NN Condition
resulting VBG None
from IN None
extraction NN None
of IN None
impacted JJ None
third JJ None
molar JJ None
teeth NN None
. . None
patients NNS None
with IN None
moderate JJ Condition
or CC Condition
severe JJ Condition
pain NN Condition
within IN None
8 CD None
hours NNS None
of IN None
extraction NN None
of IN None
impacted JJ None
third JJ None
molars NNS None
. . None
postoperative NN None
pain NN None
-DOCSTART- -X- N

adding VBG None
highly RB None
dissimilar JJ None
fillers NNS None
increases VBZ None
confidence NN None
lineup JJ None
identifications NNS None
. . None
witness NN None
's POS None
identified VBN None
( ( None
non-dud JJ None
) ) None
lineup NN None
member NN None
Four CD None
studies NNS None
( ( None
N NNP None
witnesses NNS None
' POS None
dissimilar JJ None
lineup NN None
members NNS None
witnesses NNS None
' POS None
-DOCSTART- -X- N

cadaver JJ Condition
femoral JJ Condition
osteotomy NN Condition
. . None
46 CD Size
femoral JJ Condition
shaft NN Condition
fractures NNS Condition
were VBD None
randomized VBN None
to TO None
treatment NN None
with IN None
Gross-Kempf NNP None
nails NNS None
, , None
24 CD Size
with IN None
slotted VBN Condition
nails NNS Condition
and CC None
22 CD Size
with IN None
non-slotted JJ Condition
nails NNS Condition
. . None
femoral JJ Condition
fractures NNS Condition
. . None
-DOCSTART- -X- N

traumatic JJ Condition
hyphema NN Condition
. . None
One CD Size
hundred VBD Size
twelve NN Size
patients NNS None
who WP None
sustained VBD None
hyphema NN Condition
after IN Condition
blunt NN Condition
trauma NN Condition
were VBD None
enrolled VBN None
Blacks NNS None
comprised VBD None
53 CD None
% NN None
of IN None
the DT None
study NN None
population NN None
, , None
and CC None
the DT None
mean JJ None
age NN None
of IN None
the DT None
patients NNS None
was VBD None
23.5 CD Age
years NNS None
. . None
-DOCSTART- -X- N

ST-elevation NNP None
myocardial JJ None
infarction NN None
patients NNS None
with IN None
ST-elevation NNP None
myocardial JJ None
infarction NN None
( ( None
STEMI NNP None
) ) None
living NN None
in IN None
rural JJ None
areas NNS None
with IN None
long JJ None
transfer NN None
delays NNS None
to TO None
percutaneous JJ None
coronary JJ None
intervention NN None
( ( None
PCI NNP None
) ) None
. . None
The DT None
NORwegian JJ None
study NN None
on IN None
DIstrict NNP None
treatment NN None
of IN None
STEMI NNP None
( ( None
NORDISTEMI NNP None
) ) None
patients NNS None
with IN None
STEMI NNP None
of IN None
less JJR None
than IN None
6 CD None
hours NNS None
of IN None
duration NN None
and CC None
more JJR None
than IN None
90 CD None
minutes NNS None
expected VBD None
time NN None
delay NN None
to TO None
PCI NNP None
A NNP None
total NN None
of IN None
266 CD None
patients NNS None
April NNP None
2006 CD None
, , None
109 CD None
patients NNS None
-DOCSTART- -X- N

clozapine-treated JJ None
patients NNS None
with IN None
schizophrenia NN Condition
: : None
clozapine-treated JJ None
patients NNS None
with IN None
schizophrenia NN None
. . None
In IN None
trial NN None
, , None
clozapine-treated JJ None
patients NNS None
with IN None
schizophrenia NN None
were VBD None
eight CD None
. . None
Nineteen JJ None
patients NNS None
completed VBD None
the DT None
study NN None
. . None
There EX None
rosiglitazone NN None
group NN None
( ( None
n=9 CC None
) ) None
and CC None
the DT None
placebo NN None
group NN None
( ( None
n=10 RB None
) ) None
. . None
When WRB None
clozapine-treated JJ None
patients NNS None
with IN None
schizophrenia NN None
. . None
Future JJ None
patients NNS None
with IN None
schizophrenia NN None
. . None
-DOCSTART- -X- N

adults NNS Age
with IN None
soft JJ Condition
tissue NN Condition
sarcomas NN Condition
of IN Condition
the DT Condition
head NN Condition
and CC Condition
neck NN Condition
, , Condition
breast NN Condition
, , Condition
and CC Condition
trunk NN Condition
. . None
Since IN None
1977 CD None
, , None
31 CD None
patients NNS None
were VBD None
entered VBN None
in IN None
a DT None
randomized JJ None
, , None
prospective JJ None
study NN None
testing VBG None
the DT None
efficacy NN None
of IN None
adjuvant JJ None
chemotherapy NN None
after IN None
aggressive JJ None
local JJ None
treatment NN None
of IN None
high-grade JJ None
sarcomas NN None
of IN None
the DT None
head NN None
, , None
neck NN None
, , None
breast NN None
, , None
and CC None
trunk NN None
( ( None
excluding VBG None
retroperitoneal VB None
sarcomas NN None
) ) None
. . None
All DT None
patients NNS None
had VBD None
complete JJ None
resection NN None
of IN None
gross JJ None
tumor NN None
and CC None
underwent JJ None
postoperative JJ None
radiotherapy NN None
( ( None
6000-6300 JJ None
rads NNS None
over IN None
7-8 JJ None
weeks NNS None
) ) None
. . None
Seventeen JJ None
patients NNS None
received VBD None
adjuvant JJ None
chemotherapy NN None
An DT None
additional JJ None
26 CD None
patients NNS None
entire JJ None
group NN None
of IN None
57 CD Size
patients NNS None
The DT None
subgroup NN Size
of IN Size
patients NNS Size
with IN Size
sarcomas NN Size
of IN Size
the DT Size
trunk NN Size
( ( Size
39 CD Size
patients NNS Size
) ) Size
-DOCSTART- -X- N

Syphacia NNP None
muris NNP None
infection NN None
in IN None
laboratory NN None
rats NNS None
. . None
naturally RB None
acquired VBN None
S. NNP None
muris JJ None
infections NNS None
rats NNS None
. . None
Fourty-eight JJ Size
S. NNP None
muris-positive JJ None
rats NNS None
male NN None
and CC None
female JJ None
rats NNS None
-DOCSTART- -X- N

hypertensive JJ Condition
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
hypertensive JJ Condition
type-2 JJ Condition
diabetic JJ Condition
patients NNS None
hypertensive JJ Condition
type-2 JJ Condition
diabetic JJ Condition
patients NNS None
. . None
Forty NNP Size
type-2 JJ Condition
diabetic JJ Condition
patients NNS None
with IN None
never-treated JJ None
hypertension NN Condition
-DOCSTART- -X- N

We PRP None
used VBD None
data NNS None
from IN None
EORTC NNP None
22881-10882 JJ None
trial NN None
, , None
with IN None
median JJ None
follow-up NN None
of IN None
77.4 CD None
months NNS None
. . None
Patients NNS None
receiving VBG None
BCT NNP Condition
and CC Condition
50Gy CD Condition
whole JJ Condition
breast NN Condition
irradiation NN Condition
were VBD None
randomized VBN None
to TO None
no DT None
boost NN None
and CC None
16Gy CD None
boost NN None
younger JJR Age
patients NNS Age
8.4 CD None
% NN None
of IN None
the DT None
study NN None
population NN None
would MD None
receive VB None
67 CD None
% NN None
of IN None
the DT None
study NN None
population NN None
younger JJR None
patients NNS None
-DOCSTART- -X- N

cocaine-abusing JJ Condition
homeless JJ None
persons NNS None
: : None
cocaine-dependent JJ Condition
homeless NN None
persons NNS None
who WP None
participated VBD None
in IN None
a DT None
clinical JJ None
trial NN None
that WDT None
compared VBN None
day NN None
treatment NN None
only RB None
( ( None
DT NNP None
, , None
n JJ None
= NNP None
69 CD Size
) ) None
with IN None
day NN None
treatment NN None
plus CC None
abstinent-contingent JJ None
housing NN None
and CC None
work NN None
( ( None
DT+ NNP None
, , None
n JJ None
= NNP None
72 CD Size
) ) Size
. . None
-DOCSTART- -X- N

chronic JJ Condition
stable JJ Condition
angina NN Condition
: : None
chronic JJ Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
. . None
Twelve VB Size
male NN Sex
patients NNS None
with IN None
stable JJ Condition
effort NN Condition
angina NN Condition
and CC None
without IN None
previous JJ None
myocardial JJ Condition
infarction NN Condition
were VBD None
studied VBN None
. . None
-DOCSTART- -X- N

adults NNS None
with IN None
both DT None
autism NN Condition
and CC None
mental JJ Condition
retardation NN Condition
. . None
6 CD None
adults NNS None
with IN None
both DT None
autism NN Condition
and CC None
moderate VB None
to TO None
profound VB None
mental JJ Condition
retardation NN Condition
. . None
6 CD None
participants NNS None
adults NNS None
with IN None
both DT None
autism NN Condition
and CC None
mental JJ Condition
retardation NN Condition
-DOCSTART- -X- N

external JJ Condition
genital NN Condition
and CC Condition
perianal JJ Condition
warts NNS Condition
in IN None
different JJ None
patient JJ None
populations NNS None
. . None
patients NNS None
' POS None
demographic JJ None
variables NNS None
external JJ Condition
genital NN Condition
and CC Condition
perianal JJ Condition
warts NNS Condition
. . None
Male NNP Sex
and CC None
female JJ Sex
immunocompetent NN Condition
patients NNS None
subgroups NNS None
based VBN None
on IN None
variables NNS None
of IN None
gender NN None
, , None
baseline JJ None
wart NN Condition
area NN None
, , None
duration NN None
of IN None
current JJ None
outbreak NN None
of IN None
warts NNS Condition
, , None
previous JJ None
wart NN None
treatment NN None
, , None
and CC None
tobacco NN None
use NN None
. . None
external JJ None
genital NN Condition
and CC Condition
perianal JJ Condition
warts NNS Condition
-DOCSTART- -X- N

high JJ None
autism NN None
spectrum JJ None
quotient NN None
adult NN None
of IN None
normal JJ None
intelligence NN None
low- JJ None
and CC None
high-scoring JJ None
individuals NNS None
on IN None
the DT None
Autism NNP None
Spectrum NNP None
Quotient NNP None
Fifteen NNP None
low-scoring JJ None
individuals NNS None
and CC None
14 CD None
high-scoring JJ None
individuals NNS None
derived VBN None
from IN None
a DT None
normal JJ None
population NN None
participated VBD None
in IN None
the DT None
study NN None
. . None
Autism NNP None
Spectrum NNP None
Quotient NNP None
autistic JJ None
individuals NNS None
-DOCSTART- -X- N

Postoperative JJ None
Fifty NNP Size
ASA NNP Condition
I-II JJ Condition
patients NNS Condition
after IN Condition
spinal JJ Condition
anaesthesia NN Condition
. . None
-DOCSTART- -X- N

Collaborative NNP None
Initial NNP None
Glaucoma NNP None
Treatment NNP None
Study NNP None
Six NNP None
hundred VBD None
seven CD None
newly RB None
diagnosed VBN None
glaucoma NN None
patients NNS None
. . None
607 CD None
subjects NNS None
with IN None
newly RB None
diagnosed VBN None
open-angle JJ None
glaucoma NN None
subjects NNS None
with IN None
advanced JJ None
VF NNP None
loss NN None
at IN None
baseline NN None
subjects NNS None
with IN None
diabetes NNS None
subjects NNS None
with IN None
more RBR None
advanced JJ None
VF NNP None
loss NN None
at IN None
presentation NN None
patients NNS None
with IN None
diabetes NNS None
-DOCSTART- -X- N

One CD Size
hundred CD Size
and CC Size
twenty JJ Size
patients NNS None
presenting VBG None
at IN None
Macquarie NNP None
Hospital NNP None
for IN None
admission NN None
psychiatric JJ Condition
patients NNS None
-DOCSTART- -X- N

patients NNS None
receiving VBG None
intravenous JJ None
antibiotics NNS None
: : None
specific JJ None
for IN None
a DT None
patient NN Size
group NN Size
receiving VBG None
prolonged JJ None
courses NNS None
of IN None
i.v NN None
. . None
antibiotics NNS None
. . None
Patients NNPS None
with IN None
cystic JJ None
fibrosis NN None
receiving VBG None
intermittent JJ None
i.v NN None
. . None
antibiotics NNS None
patients NNS None
requiring VBG None
longer JJR None
term NN None
i.v NN None
. . None
access NN None
. . None
-DOCSTART- -X- N

asthmatics NNS Condition
. . None
13 CD Size
asthmatic JJ Condition
patients NNS None
after IN None
single JJ None
and CC None
multiple JJ None
oral JJ None
dosage NN None
of IN None
a DT None
microcrystalline JJ None
theophylline NN None
tablet NN None
( ( None
Nuelin NNP None
) ) None
and CC None
a DT None
sustained-release JJ None
preparation NN None
( ( None
Nuelin NNP None
Retard NNP None
) ) None
-DOCSTART- -X- N

inguinal JJ Condition
herniorrhaphy NN Condition
patients NNS None
. . None
patients NNS None
undergoing JJ None
inguinal JJ Condition
herniorrhaphy NN Condition
adults NNS Age
undergoing VBG None
elective JJ None
, , None
outpatient JJ None
, , None
unilateral JJ Condition
inguinal JJ Condition
herniorrhaphy NN Condition
. . None
Fifty-five JJ Size
subjects NNS None
completed VBD None
the DT None
study NN None
. . None
outpatient JJ Condition
inguinal JJ Condition
hernia NN Condition
repair NN None
. . None
-DOCSTART- -X- N

critically RB Condition
ill JJ Condition
children NNS None
. . None
Twenty-five JJ None
percent NN None
of IN None
the DT None
children NNS None
with IN None
IIT NNP None
experienced VBD None
hypoglycemia NN Condition
We PRP None
studied VBD None
369 CD Size
patients NNS None
who WP None
stayed VBD None
in IN None
PICU NNP None
for IN None
at IN None
least JJS None
3 CD None
d NN None
( ( None
study VB None
1 CD None
) ) None
and CC None
126 CD Size
patients NNS None
in IN None
a DT None
nested JJ None
case-control NN None
study NN None
( ( None
study VB None
2 CD None
) ) None
. . None
-DOCSTART- -X- N

infertile JJ Condition
patients NNS None
: : None
One CD Size
hundred VBN Size
eighty-nine JJ Size
infertile JJ Condition
women NNS Sex
undergoing VBG None
outpatient JJ None
hysteroscopy NN None
. . None
group NN None
B NNP None
group NN None
A NNP None
. . None
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
large JJ None
condylomata NNS None
acuminata NNS None
after IN None
laser NN None
therapy NN None
. . None
clinical JJ None
patients NNS None
after IN None
laser NN None
therapy NN None
. . None
52 CD Size
patients NNS None
-DOCSTART- -X- N

chronic JJ None
pancreatitis NN None
patients NNS None
with IN None
pain NN None
Sixty NNP None
chronic JJ None
pancreatitis NN None
patients NNS None
were VBD None
compared VBN None
to TO None
15 CD None
healthy JJ None
controls NNS None
. . None
patients NNS None
patients NNS None
-DOCSTART- -X- N

childhood NN Age
acute NN Condition
lymphoblastic JJ Condition
leukaemia NN Condition
. . None
127 CD Size
children NNS Age
undergoing JJ None
treatment NN None
for IN None
childhood NN None
non-T JJ None
acute JJ Condition
lymphoblastic JJ Condition
leukaemia NN Condition
( ( Condition
ALL NNP Condition
) ) Condition
childhood NN None
ALL NNP Condition
. . None
-DOCSTART- -X- N

1232 CD None
middleaged VBD None
, , None
normotensive JJ None
, , None
healthy JJ None
men NNS None
. . None
-DOCSTART- -X- N

anterior JJ Condition
segment NN Condition
surgery NN Condition
. . None
local JJ None
anesthesia NN None
in IN None
ophthalmic JJ Condition
surgery NN Condition
Patients NNS None
undergoing VBG None
various JJ None
anterior JJ Condition
segment NN Condition
surgery NN Condition
300 CD Size
were VBD None
operated VBN None
with IN None
1-quadrant JJ Condition
sub-Tenon NN Condition
's POS Condition
anesthesia NN Condition
( ( Condition
1-QST JJ Condition
) ) Condition
and CC None
the DT None
results NNS None
were VBD None
compared VBN None
with IN None
270 CD Size
patients NNS Size
operated VBN None
with IN None
retrobulbar NN Condition
anesthesia NN Condition
. . None
Patients NNS None
undergoing VBG None
various JJ None
anterior JJ Condition
segment NN Condition
surgery NN Condition
procedures NNS None
-DOCSTART- -X- N

adults NNS Age
with IN None
autism NN Condition
adults NNS None
with IN None
autism NN None
adults NNS None
with IN None
autism NN None
-DOCSTART- -X- N

150 CD None
consecutive JJ None
adult NN None
patients NNS None
undergoing VBG None
tonsillectomy NN None
. . None
Indications NNS None
included VBD None
chronic JJ Condition
tonsillitis NN Condition
and CC None
obstructive JJ Condition
sleep NN Condition
apnea NN Condition
syndrome NN Condition
. . Condition
Exclusion NN None
criteria NNS None
included VBD None
peritonsillar JJ Condition
abscess NN Condition
history NN None
, , None
bleeding VBG Condition
disorders NNS Condition
, , None
and CC None
any DT None
other JJ None
procedure NN None
together RB None
with IN None
tonsillectomy NN Condition
. . None
-DOCSTART- -X- N

teacher NN None
teacher VB None
teachers NNS None
teachers NNS None
teacher JJ None
-DOCSTART- -X- N

human JJ None
embryo JJ None
culture NN None
. . None
Pronuclear-stage JJ None
human JJ None
embryos NN None
Human JJ None
embryos NN None
from IN None
seven CD Size
patients NNS None
Murine NNP None
embryos JJ None
Human NNP None
embryos NN None
-DOCSTART- -X- N

recipients NNS None
of IN None
extended JJ None
criteria NNS None
donor JJ None
kidneys NNS None
. . None
Patients NNS None
in IN None
the DT None
BENEFIT-EXT NNP None
study NN None
received VBD None
extended JJ None
criteria NNS None
donor JJ None
kidneys NNS None
Patients NNS None
who WP None
remained VBD None
on IN None
assigned JJ None
therapy NN None
through IN None
year NN None
3 CD None
were VBD None
eligible JJ None
to TO None
enter VB None
a DT None
long-term JJ None
extension NN None
( ( None
LTE NNP None
) ) None
study NN None
. . None
Three CD None
hundred VBD None
four CD None
patients NNS None
entered VBD None
the DT None
LTE NNP None
( ( None
n JJ None
= $ None
104 CD None
MI NNP None
; : None
n CC None
= $ None
113 CD None
LI NNP None
; : None
n CC None
= $ None
87 CD None
CsA NNP None
) ) None
, , None
and CC None
260 CD None
continued VBD None
treatment NN None
through IN None
year NN None
5 CD None
( ( None
n JJ None
= $ None
69 CD None
CsA NNP None
) ) None
. . None
Twenty CD None
patients NNS None
who WP None
were VBD None
seronegative JJ None
for IN None
Epstein-Barr NNP None
virus NN None
( ( None
EBV NNP None
( ( None
- : None
) ) None
) ) None
at IN None
transplantation NN None
-DOCSTART- -X- N

neurally RB Condition
mediated VBN Condition
syncope NN Condition
. . None
subjects NNS Condition
susceptible JJ Condition
to TO Condition
tilt-induced JJ Condition
syncope NN Condition
. . None
Eight NNP Size
previously RB None
characterized VBD None
patients NNS None
with IN None
recurrent JJ None
NMS NNP None
( ( None
five CD Size
females NNS Sex
and CC None
three CD Size
males NNS Sex
; : None
34+/-2 JJ Age
yr NN Age
) ) None
were VBD None
recruited VBN None
from IN None
the DT None
Vanderbilt NNP None
Syncope NNP None
Unit NNP None
eight CD Size
age-matched JJ Age
controls NNS Condition
NMS NNP None
patients NNS None
. . None
patients NNS None
with IN None
NMS NNP None
-DOCSTART- -X- N

random JJ None
blood NN None
samples NNS None
various JJ None
ethnic JJ None
groups NNS None
in IN None
KwaZulu-Natal NNP None
, , None
South NNP None
Africa NNP None
, , None
and CC None
with IN None
samples NNS None
of IN None
selected VBN None
red JJ None
cell NN None
phenotypes NNS None
. . None
-DOCSTART- -X- N

bronchial JJ Condition
hyperreactivity NN Condition
bronchial JJ Condition
hyperresponsiveness NN Condition
evaluation NN None
model NN None
bronchial JJ Condition
hyperresponsiveness NN Condition
. . Condition
-DOCSTART- -X- N

Colorectal JJ Condition
carcinoma NN Condition
colorectal JJ Condition
cancer NN Condition
patients NNS Condition
and CC None
healthy JJ Condition
control NN Condition
subjects VBZ Condition
colorectal JJ Condition
cancer NN Condition
patients NNS None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
standard JJ None
versus NN None
extended VBD None
lymphadenectomy NN None
in IN None
radical JJ Condition
PD NNP Condition
for IN None
pancreatic JJ Condition
cancer NN Condition
March NNP None
2000 CD None
to TO None
May NNP None
2003 CD None
, , None
112 CD Size
patients NNS None
with IN None
potentially RB None
curable JJ None
pancreatic JJ Condition
head NN Condition
cancer NN Condition
were VBD None
enrolled VBN None
and CC None
intraoperatively RB None
randomized VBN None
to TO None
a DT None
standard NN None
or CC None
extended JJ None
lymphadenectomy NN None
group NN None
. . None
A DT Size
hundred CD Size
and CC Size
one CD Size
eligible JJ None
patients NNS None
were VBD None
analyzed VBN None
. . None
Demographic NNP None
and CC None
histopathological JJ None
characteristics NNS None
of IN None
the DT None
two CD None
groups NNS None
were VBD None
similar JJ None
. . None
patients NNS None
with IN None
resectable JJ Condition
pancreatic JJ Condition
head NN Condition
cancer NN Condition
-DOCSTART- -X- N

Forty-six JJ Size
patients NNS None
with IN None
systemic JJ Condition
poisoning NN Condition
by IN Condition
this DT Condition
snake NN Condition
23 CD Size
patients NNS None
in IN None
one CD None
group NN None
-DOCSTART- -X- N

Gastric JJ Condition
ulcer NN Condition
treatment NN None
( ( None
67/86 CD Size
) ) None
patients NNS None
receiving VBG None
6 CD None
micrograms NNS None
EGF NNP None
intravenously RB None
twice RB None
a DT None
week NN None
rat NN None
gastric JJ Condition
ulcers NNS Condition
-DOCSTART- -X- N

autistic JJ Condition
syndromes NNS Condition
. . Condition
children NNS Age
with IN None
autistic JJ Condition
syndromes NNS Condition
and CC None
urinary JJ Condition
peptide NN Condition
abnormalities NNS Condition
. . Condition
diet JJ None
and CC None
control NN None
group NN None
with IN None
10 CD Size
children NNS Age
in IN None
each DT None
group NN None
participated VBD None
. . None
-DOCSTART- -X- N

acute JJ Condition
extremity NN Condition
pain NN Condition
after IN None
emergency NN None
department NN None
discharge NN None
. . None
patients NNS None
discharged VBN None
from IN None
the DT None
emergency NN None
department NN None
( ( None
ED NNP None
) ) None
. . None
patients NNS None
with IN None
acute JJ None
extremity NN None
pain NN None
who WP None
were VBD None
discharged VBN None
home NN None
from IN None
the DT None
ED NNP None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
cardiac JJ None
surgery NN None
: : None
patients NNS None
who WP None
achieved VBD None
hemostasis NN None
at IN None
the DT None
primary JJ None
treatment NN None
site NN None
within IN None
5 CD None
min NN None
, , None
and CC None
maintained VBD None
hemostasis NN None
until IN None
surgical JJ None
closure NN None
. . None
patients NNS None
undergoing JJ None
cardiac JJ None
surgery NN None
. . None
-DOCSTART- -X- N

new JJ Condition
mothers NNS Condition
' POS None
low-income JJ None
, , None
first-time JJ None
mothers NNS None
' POS None
safety NN None
practices NNS None
during IN None
their PRP$ None
child NN None
's POS None
first JJ None
18 CD None
months NNS None
. . None
Primiparous JJ Condition
women NNS Sex
( ( None
n JJ None
= NNP None
167 CD Size
) ) None
-DOCSTART- -X- N

deep-vein JJ Condition
thrombosis NN Condition
and CC None
swelling NN None
after IN None
hemiarthroplasty NN Condition
for IN Condition
hip NN Condition
fracture NN Condition
. . None
82 CD Size
patients NNS None
treated VBN Condition
by IN Condition
hemiarthroplasty NN Condition
for IN Condition
subcapital JJ Condition
fracture NN Condition
of IN Condition
the DT Condition
femoral JJ Condition
neck NN Condition
. . None
-DOCSTART- -X- N

therapists NNS None
therapists NNS None
disclosing VBG None
personal JJ None
information NN None
during IN None
psychotherapy NN None
. . None
therapists NNS None
at IN None
a DT None
university NN None
counseling NN None
center NN None
one CD None
client NN None
another DT None
client NN None
. . None
quality NN None
of IN None
the DT None
therapeutic JJ None
relationship NN None
and CC None
the DT None
outcome NN None
of IN None
treatment NN None
. . None
-DOCSTART- -X- N

non-metastatic JJ Condition
breast NN Condition
cancer NN Condition
. . None
women NNS Sex
diagnosed VBN None
with IN None
breast NN Condition
cancer NN Condition
. . None
36 CD Size
consecutive JJ None
patients NNS None
with IN None
non-metastatic JJ Condition
breast NN Condition
cancer NN Condition
assigned VBD None
to TO None
surgery VB None
and CC None
systemic VB None
chemotherapy NN None
-DOCSTART- -X- N

plantar NN Condition
fasciitis NN Condition
. . None
One CD Size
hundred VBD Size
three CD Size
subjects NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
one CD None
of IN None
three CD None
treatment NN None
categories NNS None
: : None
anti-inflammatory NN None
, , None
accommodative JJ None
, , None
or CC None
mechanical JJ None
. . None
Subjects NNS None
85 CD Size
patients NNS None
who WP None
completed VBD None
the DT None
study NN None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS None
. . None
healthy JJ None
male NN Sex
volunteers NNS None
two CD None
groups NNS None
of IN None
subjects NNS None
( ( None
each DT None
containing VBG None
six CD Size
subjects NNS None
taking VBG None
the DT None
drug NN None
and CC None
three CD Size
taking VBG None
placebo NN None
) ) None
receiving VBG None
3 CD None
, , None
60 CD None
and CC None
300 CD None
mg NN None
or CC None
15 CD None
, , None
60 CD None
and CC None
450 CD None
mg NN None
YM17E NNP None
, , None
respectively RB None
. . None
small JJ None
number NN None
of IN None
subjects NNS None
-DOCSTART- -X- N

autistic JJ Condition
disorder NN Condition
: : None
Twenty-eight JJ Size
children NNS Age
( ( None
27 CD Size
boys NNS Sex
) ) None
ages VBZ Age
3 CD Age
to TO Age
11 CD Age
years NNS Age
( ( None
M NNP None
= NNP None
5.8 CD None
) ) None
with IN None
a DT None
primary JJ Condition
diagnosis NN Condition
of IN Condition
autistic JJ Condition
disorder NN Condition
received VBD None
either CC None
placebo NN None
or CC None
lamotrigine JJ None
twice JJ None
daily RB None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
rheumatoid JJ Condition
arthritis NN Condition
. . None
patients NNS None
with IN None
rheumatoid JJ Condition
arthritis NN Condition
( ( Condition
RA NNP Condition
) ) Condition
. . None
patients NNS None
with IN None
RA NNP None
. . None
Patients NNPS None
( ( None
n JJ None
= NNP None
48 CD Size
) ) None
enrolled VBN None
at IN None
the DT None
beginning NN None
of IN None
our PRP$ None
study NN None
patients NNS None
with IN None
RA NNP Condition
patients NNS None
with IN None
RA NNP Condition
. . None
-DOCSTART- -X- N

human JJ Condition
inferior JJ Condition
alveolar JJ Condition
nerve NN Condition
block NN Condition
. . None
30 CD Size
subjects NNS None
randomly RB None
received VBD None
an DT None
inferior JJ None
alveolar JJ None
injection NN None
at IN None
three CD None
successive JJ None
appointments NNS None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
malignant JJ Condition
diseases NNS Condition
. . None
children NNS None
with IN None
malignant JJ Condition
diseases NNS Condition
. . None
Twenty CD Size
children NNS None
were VBD None
included VBN None
in IN None
the DT None
study NN None
but CC None
four CD Size
( ( None
two CD Size
in IN None
each DT None
group NN None
) ) None
had VBD None
to TO None
be VB None
excluded VBN None
; : None
three CD Size
because IN None
the DT None
entry NN None
criteria NNS None
turned VBD None
out RP None
not RB None
to TO None
be VB None
fulfilled VBN None
and CC None
one CD Size
because NN None
of IN None
lack NN None
of IN None
data NNS None
. . None
children NNS None
with IN None
malignant JJ Condition
diseases NNS Condition
. . None
-DOCSTART- -X- N

chronic JJ Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
] NNP None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
with IN None
liver JJ Condition
fibrosis NN Condition
. . None
57 CD Size
chronic NN Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
with IN None
liver JJ Condition
fibrosis NN Condition
liver JJ Condition
fibrosis NN Condition
in IN None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
-DOCSTART- -X- N

Helicobacter NNP Condition
pylori JJ Condition
eradication NN Condition
: : None
Korea NNP None
. . None
After IN None
upper JJ Condition
gastrointestinal JJ Condition
endoscopy NN Condition
, , None
H. NNP None
pylori-infected JJ None
patients NNS None
with IN None
a DT None
gastric JJ Condition
ulcer NN Condition
and/or VBZ Condition
a DT Condition
duodenal JJ Condition
ulcer NN Condition
total NN None
of IN None
598 CD Size
patients NNS None
were VBD None
enrolled VBN None
; : None
H. NNP None
pylori NN None
in IN None
Korea NNP None
. . None
-DOCSTART- -X- N

snoring NN None
: : None
Patients NNS None
who WP None
had VBD None
been VBN None
referred VBN None
for IN None
investigation NN None
and CC None
treatment NN None
of IN None
their PRP$ None
snoring NN Condition
were VBD None
randomly RB None
allocated VBN None
to TO None
receive VB None
either DT None
UPPP NNP None
or CC None
LAUP NNP None
. . None
Forty-seven JJ Size
patients NNS None
with IN None
confirmed JJ Condition
palatal JJ Condition
flutter NN Condition
had VBD Condition
surgery NN Condition
and CC None
all DT None
of IN None
them PRP None
had VBD None
a DT None
preoperative JJ None
and CC None
postoperative JJ None
objective JJ None
assessment NN None
of IN None
their PRP$ None
snoring NN None
loudness NN None
and CC None
duration NN None
in IN None
the DT None
home NN None
. . None
-DOCSTART- -X- N

alcohol NN Condition
withdrawal NN Condition
syndrome NN Condition
in IN None
a DT None
medical JJ None
intensive JJ None
care NN None
unit NN None
: : None
alcohol NN Condition
withdrawal NN Condition
syndrome NN Condition
( ( None
AWS NNP Condition
) ) None
. . None
Twenty-six NNP Size
alcoholic JJ None
patients NNS None
with IN None
severe JJ None
AWS NNP None
and CC None
concomitant JJ None
medical JJ None
diseases NNS None
were VBD None
randomally RB None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

64 CD None
Gy NNP None
vs NN None
70 CD None
Gy NNP None
salvage NN None
RT NNP None
Thirty NNP Size
European JJ None
centers NNS None
participated VBD None
, , None
43 CD None
% NN None
of IN None
which WDT None
were VBD None
using VBG None
3-dimensional JJ None
conformal JJ None
RT NNP None
( ( None
3D-CRT JJ None
) ) None
, , None
with IN None
the DT None
remaining VBG None
centers NNS None
using VBG None
intensity NN None
modulated VBN None
RT NNP None
( ( None
IMRT NNP None
) ) None
or CC None
volumetric JJ None
modulated VBN None
arc NN None
technique NN None
( ( None
VMAT NNP None
) ) None
. . None
5 CD None
centers NNS None
completed VBD None
the DT None
DR NNP None
successfully RB None
-DOCSTART- -X- N

clomipramine NN Condition
and CC None
haloperidol NN Condition
in IN Condition
autism NN Condition
. . None
8 CD Size
subjects NNS None
, , None
mean JJ None
age NN None
5.62 CD Age
years NNS Age
, , None
who WP None
met VBD None
criteria NNS None
for IN None
autism NN None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
Parkinson NNP Condition
's POS Condition
disease NN Condition
. . None
two CD None
groups NNS None
of IN None
patients NNS Condition
with IN Condition
Parkinson NNP Condition
's POS Condition
disease NN Condition
. . None
10 CD Size
patients NNS Condition
with IN Condition
a DT Condition
moderate JJ Condition
motor NN Condition
impairment NN Condition
insufficiently RB Condition
controlled VBN Condition
by IN Condition
monotherapy NN Condition
with IN Condition
bromocriptine NN Condition
. . None
eight CD Size
patients NNS Condition
with IN Condition
L-dopa-induced JJ Condition
peak-dose JJ Condition
dyskinesia NN Condition
. . None
-DOCSTART- -X- N

One CD None
hundred VBD None
forty-two JJ None
patients NNS None
-DOCSTART- -X- N

one CD None
eye NN None
of IN None
each DT None
of IN None
48 CD Size
patients NNS None
with IN None
ocular JJ Condition
hypertension NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
peripheral JJ None
arterial JJ None
bypass NN None
procedures NNS None
: : None
patients NNS None
with IN None
lower JJR None
extremity NN None
arterial JJ None
bypass NN None
surgery NN None
. . None
831 CD None
patients NNS None
who WP None
underwent JJ None
peripheral JJ None
arterial JJ None
bypass NN None
surgery NN None
long-term JJ None
treatment NN None
program NN None
of IN None
WASA NNP None
-DOCSTART- -X- N

autism NN Condition
-DOCSTART- -X- N

hemodialysis NN Condition
patients NNS None
. . None
80 CD Size
stable JJ None
chronic JJ Condition
hemodialysis NN Condition
patients NNS None
selected VBN None
on IN None
the DT None
basis NN None
of IN None
their PRP$ None
acceptable JJ None
control NN None
of IN None
serum NN None
phosphorus NN None
( ( None
P NNP None
) ) None
levels NNS None
with IN None
aluminum NN None
hydroxide NN None
( ( None
AH NNP None
) ) None
. . None
patients NNS None
were VBD None
dialyzed VBN None
against IN None
the DT None
same JJ None
calcium NN None
dialyzate NN None
-DOCSTART- -X- N

adult NN None
asthma NN None
: : None
Sixteen NNP None
young JJ None
adult NN None
sufferers NNS None
from IN None
extrinsic JJ None
paroxysmal JJ None
asthma NN None
with IN None
pollen JJ None
hypersensitivity NN None
took VBD None
part NN None
in IN None
a DT None
therapeutic JJ None
trial NN None
of IN None
the DT None
synthetic JJ None
anticholinergic NN None
agent NN None
oxitropium NN None
bromide NN None
administered VBN None
by IN None
a DT None
metered VBN None
dose NN None
inhaler NN None
. . None
-DOCSTART- -X- N

chronic JJ Condition
lymphocytic JJ Condition
leukemia NN Condition
. . None
patient JJ None
outcomes NNS None
in IN None
chronic JJ Condition
lymphocytic JJ Condition
leukemia NN Condition
( ( None
CLL NNP Condition
) ) None
. . None
patients NNS None
who WP None
will MD None
benefit VB None
from IN None
immunochemotherapy NN None
over IN None
chemotherapy NN None
alone RB None
has VBZ None
not RB None
been VBN None
determined VBN None
. . None
We PRP None
assessed VBD None
genome-wide JJ None
expression NN None
of IN None
300 CD Size
pretreatment NN None
specimens NNS None
from IN None
a DT None
subset NN None
of IN None
552 CD Size
patients NNS None
in IN None
REACH NNP None
, , None
a DT None
study NN None
of IN None
FC NNP None
or CC None
R-FC NNP None
in IN None
relapsed JJ None
CLL NNP Condition
. . None
An DT None
independent JJ None
test NN None
set NN None
was VBD None
derived VBN None
from IN None
282 CD None
pretreatment NN None
specimens NNS None
from IN None
CLL8 NNP None
, , None
a DT None
study NN None
of IN None
FC NNP None
or CC None
R-FC NNP None
in IN None
treatment-na?ve JJ None
patients NNS None
. . None
for IN None
CLL NNP None
patients NNS None
-DOCSTART- -X- N

stem NN Condition
cell NN Condition
transplant NN Condition
patients NNS None
. . None
117 CD Size
patients NNS None
who WP None
had VBD None
undergone JJ Condition
stem NN Condition
cell NN Condition
transplantation NN Condition
( ( None
SCT NNP Condition
) ) None
. . None
subgroup NN None
of IN None
allogeneic JJ Condition
SCT NNP Condition
patients NNS Condition
autologous JJ Condition
SCT NNP Condition
patients NNS Condition
with IN Condition
breast JJ Condition
cancer NN Condition
SCT NNP Condition
patients NNS Condition
-DOCSTART- -X- N

evidence-based JJ None
prescription NN None
drug NN None
label NN None
on IN None
actual JJ None
medication NN None
use NN None
. . None
randomly VB None
sampled VBN None
patients NNS Condition
who WP Condition
receive VBP Condition
their PRP$ Condition
care NN Condition
from IN Condition
free JJ Condition
clinics NNS Condition
, , Condition
mobile JJ Condition
vans NNS Condition
and CC Condition
federally RB Condition
qualified JJ Condition
health NN Condition
centers NNS Condition
( ( None
FQHCs NNP None
) ) None
in IN None
Northern NNP None
Virginia NNP None
. . None
patients NNS Condition
with IN Condition
diabetes NNS Condition
or CC Condition
hypertension NN Condition
; : None
-DOCSTART- -X- N

borderline JJ None
hypertensive JJ None
patients NNS None
with IN None
IDDM-type NNP None
diabetes NNS None
mellitus NN None
Twenty-nine JJ None
IDDM NNP None
patients NNS None
with IN None
borderline JJ None
hypertension NN None
diabetic JJ None
patients NNS None
with IN None
borderline JJ None
hypertension NN None
-DOCSTART- -X- N

prostate NN Condition
carcinoma NN Condition
. . None
25 CD Size
matched JJ None
primary NN Condition
and CC Condition
metastatic JJ Condition
prostate NN Condition
tumors NNS Condition
. . Condition
Twenty-five JJ Size
cases NNS None
were VBD None
selected VBN None
from IN None
the DT None
surgical JJ None
pathology NN None
files NNS None
of IN None
the DT None
Mayo NNP None
Clinic NNP None
from IN None
patients NNS None
who WP None
had VBD None
undergone JJ None
radical JJ None
retropubic NN None
prostatectomy NN None
and CC None
bilateral JJ None
lymphadenectomy NN None
between IN None
1987-1991 JJ None
. . None
All DT None
patients NNS None
had VBD None
regional JJ Condition
lymph NN Condition
node NN Condition
metastases NNS Condition
at IN None
the DT None
time NN None
of IN None
surgery NN None
. . None
24 CD Size
informative JJ None
cases NNS None
-DOCSTART- -X- N

grade NN None
1 CD None
and CC None
2 CD None
hemorrhoids NNS Condition
. . None
80 CD Size
patients NNS None
with IN None
first JJ None
and CC None
second JJ None
degree NN None
hemorrhoids NNS None
; : None
first JJ None
and CC None
second JJ None
degree NN None
hemorrhoids NNS None
-DOCSTART- -X- N

paroxysmal JJ None
atrial JJ None
fibrillation NN None
-- : None
a DT None
atrial JJ None
fibrillation NN None
Eligible JJ None
patients NNS None
will MD None
present VB None
AF NNP None
lasting VBG None
less JJR None
than IN None
43 CD None
hours NNS None
, , None
will MD None
be VB None
in IN None
stable JJ None
cardio-pulmonary JJ None
condition NN None
and CC None
will MD None
have VB None
no DT None
prior JJ None
history NN None
of IN None
advanced JJ None
heart NN None
failure NN None
or CC None
significant JJ None
valvular JJ None
disease NN None
. . None
sample JJ None
size NN None
of IN None
80 CD None
patients NNS None
was VBD None
calculated VBN None
-DOCSTART- -X- N

healthy JJ None
men NNS None
. . None
healthy JJ None
young JJ None
male NN None
volunteers NNS None
. . None
Eight CD None
participants NNS None
( ( None
mean JJ None
age NN None
+/- JJ None
standard NN None
deviation NN None
, , None
22 CD None
+/- JJ None
0.9 CD None
years NNS None
) ) None
healthy JJ None
young JJ None
male JJ None
subjects NNS None
-DOCSTART- -X- N

hypertensive JJ Condition
patients NNS None
. . None
four CD None
groups NNS None
of IN None
patients NNS None
with IN None
essential JJ Condition
hypertension NN Condition
( ( None
six CD Size
patients NNS None
for IN None
each DT None
group NN None
) ) None
. . None
-DOCSTART- -X- N

subjects NNS None
with IN None
prehypertension NN None
. . None
untreated JJ None
hypertensive JJ None
patients NNS None
and CC None
high-risk JJ None
pregnant JJ None
women NNS None
. . None
prehypertension NN None
. . None
244 CD None
subjects NNS None
with IN None
prehypertension NN None
, , None
43.0 CD None
+/- JJ None
13.0 CD None
years NNS None
of IN None
age NN None
prehypertensive JJ None
subjects NNS None
. . None
subjects NNS None
at IN None
elevated JJ None
risk NN None
of IN None
developing VBG None
hypertension NN None
. . None
-DOCSTART- -X- N

type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
during IN None
ophthalmic JJ Condition
surgery NN None
. . None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
. . None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
-DOCSTART- -X- N

perioperative JJ None
radial JJ None
arterial JJ None
catheter NN None
Two-hundred JJ None
patients NNS None
presence NN None
of IN None
hematoma NN None
at IN None
the DT None
puncture NN None
site NN None
after IN None
decannulation NN None
long JJ None
duration NN None
of IN None
cannulation NN None
age NN None
< VBP None
65 CD None
yr NN None
-DOCSTART- -X- N

severe VB Condition
atopic NN Condition
dermatitis NN Condition
in IN Condition
adults NNS Condition
: : Condition
59 CD Condition
patients NNS Condition
with IN Condition
moderate JJ Condition
to TO Condition
severe VB Condition
atopic NN Condition
dermatitis NN Condition
Forty-seven JJ Condition
patients NNS Condition
completed VBD Condition
the DT Condition
study NN Condition
. . Condition
-DOCSTART- -X- N

40 CD None
children NNS None
with IN None
severe JJ None
and CC None
persistent JJ None
soiling NN None
and CC None
often RB None
with IN None
a DT None
history NN None
of IN None
faecal JJ None
retention NN None
. . None
-DOCSTART- -X- N

glass NN None
ionomer NN None
cement NN None
Human NNP Condition
maxillary JJ Condition
central JJ Condition
incisors NNS Condition
( ( None
n JJ None
= NNP None
70 CD Size
) ) None
root JJ Condition
end NN Condition
cavities NNS Condition
root NN Condition
slices NNS Condition
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
disseminated JJ Condition
testicular JJ Condition
tumors NNS Condition
] VBP Condition
patients NNS None
with IN None
disseminated JJ None
testicular JJ None
tumors NNS None
. . None
Of IN None
34 CD None
patients NNS None
registered VBD None
, , None
10 CD None
patients NNS None
were VBD None
with IN None
minimal JJ None
disease NN None
in IN None
stages NNS None
IIA NNP None
, , None
IIIO NNP None
and CC None
IIIA NNP None
and CC None
24 CD None
with IN None
extensive JJ None
disease NN None
in IN None
IIB NNP None
, , None
IIIB2 NNP None
and CC None
IIIC NNP None
. . None
Seminomas NNP None
were VBD None
found VBN None
in IN None
10 CD None
patients NNS None
, , None
while IN None
non-seminomatous JJ None
tumors NNS None
in IN None
24 CD None
. . None
-DOCSTART- -X- N

iron NN None
deficiency NN None
anemia NN Condition
in IN None
heavy JJ None
uterine JJ Condition
bleeding NN Condition
: : None
477 CD Size
women NNS Sex
with IN None
anemia NN Condition
, , Condition
iron NN Condition
deficiency NN Condition
, , Condition
and CC Condition
heavy JJ Condition
uterine JJ Condition
bleeding NN Condition
were VBD None
assigned VBN None
patients NNS None
with IN None
iron NN None
deficiency NN None
anemia NN None
due JJ None
to TO None
heavy JJ None
uterine JJ None
bleeding NN None
-DOCSTART- -X- N

children NNS None
with IN None
Asperger NNP None
's POS None
syndrome NN None
: : None
Asperger NNP None
's POS None
and CC None
typically RB None
developed JJ None
children NNS None
Asperger NNP None
children NNS None
-DOCSTART- -X- N

ear JJ Condition
surgery NN Condition
ear JJ None
microsurgical JJ None
operations NNS None
Simple JJ None
mastoidectomies NNS None
, , None
radical JJ None
mastoidectomies NNS None
and CC None
tympano NN None
plastics NNS None
were VBD None
carried VBN None
out IN None
in IN None
49 CD None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
newly RB None
diagnosed VBN None
or CC None
recurrent JJ None
epilepsy NN None
. . None
patients NNS None
with IN None
untreated JJ None
, , None
newly RB None
diagnosed VBN None
or CC None
recurrent JJ None
partial JJ None
and/or NN None
generalised VBD None
tonic-clonic JJ None
seizures NNS None
patients NNS None
on IN None
CBZ NNP None
600 CD None
-DOCSTART- -X- N

high-risk JJ Condition
patients NNS None
for IN None
percutaneous JJ Condition
intervention NN Condition
and CC None
bypass NN Condition
surgery NN Condition
: : None
high-risk JJ Condition
patients NNS Condition
patients NNS None
with IN None
main-stem JJ Condition
and CC Condition
main-stem-equivalent JJ Condition
stenosis NN Condition
patients NNS None
with IN None
high JJ None
risk NN None
for IN None
both DT None
treatments NNS None
. . None
patients NNS None
with IN None
symptomatic JJ None
main-stem NN None
and CC None
main-stem-equivalent JJ None
lesions NNS None
with IN None
substantially RB None
increased VBN None
risk NN None
for IN None
bypass NN None
surgery NN None
. . None
( ( None
n JJ None
= NNP None
23 CD Size
) ) None
( ( None
n JJ None
= NNP None
21 CD Size
) ) None
. . None
Patients NNS None
of IN None
the DT None
stent NN None
group NN None
and CC None
the DT None
bypass NN None
group NN None
did VBD None
not RB None
differ VB None
in IN None
baseline NN None
characteristics NNS None
, , None
including VBG None
Parsonnet NNP None
score NN None
and CC None
quality-of-life JJ None
score NN None
. . None
high-risk JJ Condition
patients NNS Condition
for IN Condition
stent JJ Condition
implantation NN Condition
and CC None
bypass NN Condition
surgery NN Condition
-DOCSTART- -X- N

anorexia JJ None
nervosa NN None
and CC None
bulimia NN None
nervosa NN None
. . None
Eighty JJ Size
patients NNS None
( ( None
57 CD Size
with IN None
anorexia JJ Condition
nervosa NN Condition
; : None
23 CD Size
with IN None
bulimia NN Condition
nervosa NN Condition
) ) None
were VBD None
first RB None
admitted VBN None
to TO None
a DT None
specialized JJ None
unit NN None
to TO None
restore VB None
their PRP$ None
weight NN None
to TO None
normal JJ None
. . None
patients NNS None
whose WP$ None
illness NN None
was VBD None
not RB None
chronic JJ None
and CC None
had VBD None
begun VBN None
before IN None
the DT None
age NN None
of IN None
19 CD None
years NNS None
. . None
older JJR None
patients NNS None
. . None
-DOCSTART- -X- N

men NNS Sex
treated VBN None
for IN None
symptomatic JJ Condition
benign NN Condition
prostatic JJ Condition
hyperplasia NN Condition
. . None
men NNS None
with IN None
lower JJR Condition
urinary JJ Condition
tract NN Condition
symptoms NNS Condition
associated VBN None
with IN None
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
( ( None
BPH NNP Condition
) ) None
. . None
men NNS None
aged VBN None
> NN Age
or CC Age
= $ Age
50 CD Age
years NNS None
372 CD Size
patients NNS None
355 CD Size
completing VBG None
the DT None
study NN None
. . None
At IN None
baseline NN None
, , None
64 CD None
% NN None
of IN None
the DT None
patients NNS None
reported VBD None
erectile JJ Condition
dysfunction NN Condition
( ( None
ED NNP Condition
) ) None
and CC None
63 CD None
% NN None
reported VBD None
ejaculatory JJ Condition
dysfunction NN Condition
( ( None
EjD NNP Condition
) ) None
. . None
-DOCSTART- -X- N

during IN None
transesophageal JJ Condition
echocardiography NN Condition
: : None
Patients NNS None
with IN None
ischemic JJ Condition
stroke NN Condition
or CC Condition
transient JJ Condition
ischemic JJ Condition
attack NN Condition
undergoing JJ None
TEE NNP None
because IN None
of IN None
presumed JJ None
cardioembolic JJ None
origin NN None
in IN None
a DT None
specialized JJ None
stroke NN None
unit NN None
of IN None
the DT None
Johann NNP None
Wolfgang NNP None
Goethe-University NNP None
, , None
Frankfurt/Main NNP None
, , None
Germany NNP None
. . None
Forty-one CD Size
( ( Size
41 CD Size
) ) Size
patients NNS None
were VBD None
studied VBN None
. . None
-DOCSTART- -X- N

subjects NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
. . None
type NN None
2 CD None
diabetes NNS None
mellitus FW None
( ( None
T2DM NNP None
) ) None
General NNP None
Clinical NNP None
Research NNP None
Centers NNPS None
at IN None
two CD None
University NNP None
Hospitals NNP None
. . None
Forty-one JJ None
subjects NNS None
with IN None
T2DM NNP None
-DOCSTART- -X- N

toddlers NNS Age
with IN None
autism NN Condition
. . None
parent NN None
children NNS Age
with IN None
autism NN Condition
based VBN None
on IN None
the DT None
TEACCH NNP None
model NN None
. . None
Twenty JJ Size
families NNS Size
child NN Age
and CC None
parent NN None
-DOCSTART- -X- N

advanced JJ Condition
gastric NN Condition
or CC Condition
gastroesophageal NN Condition
cancer NN Condition
adenocarcinoma NN Condition
: : None
For IN None
patients NNS None
with IN None
advanced JJ Condition
gastric NN Condition
or CC Condition
gastroesophageal NN Condition
cancer NN Condition
( ( Condition
AGGEC NNP Condition
) ) Condition
In IN None
a DT None
multinational JJ None
trial NN None
( ( None
V325 NNP None
) ) None
, , None
445 CD Size
patients NNS None
were VBD None
randomly RB None
assigned VBN None
and CC None
treated VBN None
-DOCSTART- -X- N

64 CD None
healthy JJ None
right-handed JJ None
human JJ None
subjects NNS None
covering VBG None
a DT None
wide JJ None
range NN None
of IN None
the DT None
adult NN None
lifespan NN None
( ( None
age NN None
range NN None
20-88 CD None
years NNS None
, , None
mean VB None
47.6 CD None
? . None
20.7 CD None
, , None
34 CD None
female NN None
) ) None
. . None
-DOCSTART- -X- N

54 CD Size
healthy JJ None
volunteers NNS None
to TO None
Persons NNPS None
with IN None
one CD None
or CC None
two CD None
long JJ None
( ( None
l NN None
) ) None
5HTTLPR CD Condition
alleles NNS Condition
5HTTLPR CD Condition
genotype NN Condition
. . None
-DOCSTART- -X- N

aortic JJ Condition
valve NN Condition
replacement NN Condition
. . None
Stentless NNP None
( ( None
Freestyle NNP None
, , None
Toronto NNP None
, , None
n RB None
= VBZ None
106 CD Size
) ) None
or CC None
conventional JJ None
biological JJ None
aortic JJ None
valves NNS None
( ( None
Carpentier-Edwards NNP None
, , None
n JJ None
= NNP None
74 CD Size
) ) None
were VBD None
evaluated VBN None
patients NNS None
after IN None
aortic JJ Condition
valve NN Condition
replacement NN Condition
. . None
-DOCSTART- -X- N

youth NN Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
youth NN Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( Condition
ASD NNP Condition
) ) Condition
youth NN Age
with IN None
ASD NNP Condition
between IN None
the DT None
ages NNS None
of IN None
18-21 JJ Age
years NNS None
of IN None
age NN None
. . None
24 CD Size
( ( None
87.5 CD None
% NN None
) ) None
treatment NN None
group NN None
participants NNS None
16 CD Size
( ( None
6.25 CD None
% NN None
) ) None
of IN None
control NN None
group NN None
participants NNS None
-DOCSTART- -X- N

patients NNS None
presenting VBG None
with IN None
combined JJ None
pathology NN None
: : None
dyscirculatory NN None
encephalopathy NN None
and CC None
climacteric JJ None
syndrome NN None
] NN None
. . None
rehabilitation NN None
of IN None
women NNS None
presenting VBG None
with IN None
combined JJ None
pathology NN None
: : None
dyscirculatory NN None
encephalopathy NN None
and CC None
climacteric JJ None
syndrome NN None
. . None
-DOCSTART- -X- N

adults NNS Age
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
Individuals NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
29 CD Size
high-functioning JJ Size
adults NNS Size
with IN Size
ASD NNP Size
and CC None
matched VBD None
controls NNS None
. . None
Adults NNS Age
with IN None
ASD NNP None
-DOCSTART- -X- N

small JJ Condition
cell NN Condition
lung NN Condition
cancer NN Condition
Eighty-three JJ None
patients NNS None
with IN None
small JJ None
cell NN None
lung NN None
cancer NN None
74 CD None
patients NNS None
solid JJ None
cancer NN None
patients NNS None
-DOCSTART- -X- N

Twenty-six NNP Size
patients NNS None
with IN None
knee NN Condition
disorders NNS Condition
requiring VBG Condition
arthroscopy NN Condition
-DOCSTART- -X- N

Forty NNP Size
patients NNS None
scheduled VBN None
to TO None
undergo VB None
thoracotomy NN Condition
-DOCSTART- -X- N

migraine NN Condition
pain NN None
. . None
migraineurs NNS None
. . None
23 CD Condition
migraineurs NNS None
showing VBG None
pain NN None
at IN None
pressure NN None
on IN None
scalp NN None
arteries NNS None
patients NNS None
experiencing VBG None
scalp JJ None
arterial JJ None
tenderness NN None
. . None
-DOCSTART- -X- N

duodenal JJ Condition
ulcer NN Condition
283 CD Size
patients NNS None
with IN None
active JJ None
duodenal JJ Condition
ulcer NN Condition
to TO None
compare VB None
possible JJ None
factors NNS None
that WDT None
may MD None
affect VB None
healing NN None
and CC None
relapse NN None
in IN None
patients NNS None
treated VBN None
with IN None
a DT None
potent JJ None
antisecretory NN None
agent NN None
, , None
cimetidine NN None
, , None
or CC None
a DT None
site-protective JJ None
and CC None
cytoprotective JJ None
agent NN None
, , None
sucralfate NN None
. . None
both DT None
groups NNS None
patients NNS None
with IN None
healed JJ None
ulcers NNS Condition
, , None
238 CD Size
participated VBN None
patients NNS None
-DOCSTART- -X- N

depression NN None
among IN None
low-income JJ None
patients NNS None
with IN None
cancer NN None
. . None
Patients NNPS None
With IN None
Cancer NNP None
Study NNP None
patients NNS None
included VBD None
472 CD None
low-income JJ None
, , None
predominantly RB None
female JJ None
Hispanic JJ None
patients NNS None
with IN None
cancer NN None
age NN None
> VBD None
or= JJ None
18 CD None
years NNS None
with IN None
major JJ None
depression NN None
( ( None
49 CD None
% NN None
) ) None
, , None
dysthymia NN None
( ( None
5 CD None
% NN None
) ) None
, , None
or CC None
both DT None
( ( None
46 CD None
% NN None
) ) None
. . None
Patients NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
intervention NN None
( ( None
n JJ None
= NNP None
242 CD None
) ) None
or CC None
enhanced VBN None
usual JJ None
care NN None
( ( None
EUC NNP None
; : None
n CC None
= VB None
230 CD None
) ) None
. . None
patients NNS None
with IN None
depressive JJ None
disorders NNS None
in IN None
a DT None
low-income JJ None
, , None
predominantly RB None
Hispanic JJ None
population NN None
in IN None
public JJ None
sector NN None
oncology NN None
clinics NNS None
. . None
-DOCSTART- -X- N

autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
children NNS None
with IN None
Autism NNP Condition
Spectrum NNP Condition
Disorder NNP Condition
. . Condition
43 CD Size
children NNS None
, , None
aged VBN None
3-8 CD None
years NNS None
. . None
-DOCSTART- -X- N

early JJ None
rheumatoid NN Condition
arthritis NN Condition
. . Condition
Fifty-seven JJ None
patients NNS None
younger JJR None
than IN None
65 CD None
years NNS None
with IN None
early JJ None
, , None
nonerosive JJ Condition
RA NNP Condition
7 CD Size
of IN Size
the DT Size
57 CD Size
patients NNS Size
( ( None
12.3 CD None
% NN None
) ) None
withdrew NN None
early JJ Condition
RA NNP Condition
. . None
-DOCSTART- -X- N

Healthy NNP None
men NNS None
( ( None
20-33 CD None
years NNS None
old JJ None
) ) None
-DOCSTART- -X- N

90 CD None
patients NNS None
who WP None
had VBD None
aortic JJ None
, , None
mitral JJ None
, , None
and/or JJ None
tricuspid JJ None
valve FW None
replacement NN None
with IN None
Sorin NNP None
Bicarbon NNP None
or CC None
CarboMedics NNPS None
bileaflet NN None
prostheses NNS None
-DOCSTART- -X- N

Patients NNPS None
undergoing VBG None
mini-incision JJ Condition
thyroidectomy NN Condition
under IN None
local JJ None
anesthesia NN None
Recruitment NNP None
led VBD None
to TO None
22 CD Size
patients NNS None
in IN None
group NN None
1 CD None
and CC None
25 CD Size
patients NNS None
in IN None
group NN None
2 CD None
. . None
-DOCSTART- -X- N

low-risk JJ None
trabeculectomy NN Condition
. . None
population NN None
of IN None
low-risk JJ None
glaucoma NN Condition
patients NNS None
in IN None
whom WP None
antimetabolites NNS None
might MD None
not RB None
be VB None
indicated VBN None
. . None
65 CD Size
eyes NNS None
was VBD None
designed VBN None
, , None
with IN None
31 CD Size
eyes NNS None
receiving VBG None
750 CD None
rads NNS None
of IN None
intraoperative JJ None
beta NN None
radiation NN None
( ( None
group NN None
1 CD None
) ) None
, , None
and CC None
34 CD Size
eyes NNS None
receiving VBG None
no DT None
supplementation NN None
( ( None
group NN None
2 CD None
) ) None
. . None
low-risk JJ Condition
patients NNS Condition
-DOCSTART- -X- N

laparoscopic JJ Condition
cholecystectomy NN Condition
. . Condition
laparoscopic JJ None
cholecystectomy NN None
. . None
patients NNS None
undergoing VBG None
laparoscopic JJ None
cholecystectomy NN None
. . None
30 CD None
patients NNS None
in IN None
each DT None
group NN None
: : None
patients NNS None
undergoing VBG None
laparoscopic JJ None
cholecystectomy NN None
laparoscopic JJ None
cholecystectomy NN None
. . None
-DOCSTART- -X- N

European JJ Condition
pre-hospital JJ None
thrombolysis NN None
. . None
patients NNS None
with IN None
suspected JJ None
myocardial JJ None
infarction NN None
patients NNS None
with IN None
suspected JJ None
myocardial JJ None
infarction NN None
total NN None
of IN None
5469 CD None
patients NNS None
in IN None
16 CD None
countries NNS None
were VBD None
randomised VBN None
by IN None
198 CD None
mobile JJ None
emergency NN None
units NNS None
to TO None
receive VB None
either DT None
pre-hospital JJ None
treatment NN None
with IN None
anistreplase NN None
, , None
the DT None
thrombolytic JJ None
agent NN None
used VBN None
, , None
followed VBN None
by IN None
placebo NN None
after IN None
hospital JJ None
admission NN None
( ( None
pre-hospital JJ None
group NN None
; : None
2750 CD None
patients NNS None
) ) None
, , None
or CC None
placebo NN None
followed VBN None
by IN None
anistreplase NN None
( ( None
hospital JJ None
group NN None
; : None
2719 CD None
patients NNS None
) ) None
. . None
patients NNS None
with IN None
suspected JJ None
myocardial JJ None
infarction NN None
-DOCSTART- -X- N

maintenance NN None
phase NN None
of IN None
renal JJ Condition
anaemia NN Condition
treatment NN None
. . None
patients NNS None
with IN None
anaemia NN Condition
and CC None
chronic JJ Condition
kidney NN Condition
disease NN Condition
( ( Condition
CKD NNP Condition
) ) Condition
maintained VBD None
on IN None
haemodialysis NN None
. . None
Eligible JJ None
patients NNS None
were VBD None
18-75 CD Age
years NNS Age
old JJ Age
with IN None
CKD NNP Condition
stage NN Condition
5 CD Condition
maintained VBN None
on IN None
haemodialysis NN None
. . None
In IN None
total JJ None
, , None
313 CD Size
patients NNS Size
were VBD None
randomized VBN None
patients NNS None
with IN None
renal JJ Condition
anaemia NN Condition
. . None
-DOCSTART- -X- N

skeletally RB Condition
matured VBN Condition
non-syndromal JJ Condition
patients NNS Condition
with IN Condition
transverse JJ Condition
maxillary JJ Condition
hypoplasia NN Condition
. . Condition
23 CD Size
bone-borne JJ None
and CC None
19 CD Size
tooth-borne JJ None
patients NNS None
were VBD None
analyzed VBN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
liver JJ None
metastases NNS None
from IN None
colorectal JJ None
cancer NN None
150 CD None
patients NNS None
will MD None
be VB None
included VBN None
and CC None
randomized VBN None
intraoperatively RB None
after IN None
surgical JJ None
exploration NN None
just RB None
prior RB None
to TO None
resection NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
spontaneous JJ Condition
breathing NN Condition
after IN None
abdominal JJ None
surgery NN None
. . None
-DOCSTART- -X- N

metastatic JJ None
breast NN None
cancer NN None
patients NNS None
with IN None
metastatic JJ None
breast NN None
cancer NN None
( ( None
MBC NNP None
) ) None
patients NNS None
-DOCSTART- -X- N

postmenopausal JJ Condition
osteoporotic JJ Condition
women NNS Sex
. . None
paired JJ None
biopsies NNS None
of IN None
osteoporotic JJ Condition
women NNS Sex
treated VBN None
with IN None
either DT None
strontium NN None
ranelate NN None
or CC None
a DT None
placebo NN None
for IN None
36 CD None
months NNS None
paired JJ None
biopsies NNS None
of IN None
osteoporotic JJ Condition
women NNS Sex
treated VBN None
with IN None
either DT None
strontium NN None
ranelate NN None
( ( None
SrRan NNP None
) ) None
or CC None
a DT None
placebo NN None
for IN None
36 CD None
months NNS None
. . None
ten NN Size
paired JJ None
biopsies NNS None
-DOCSTART- -X- N

outpatient JJ None
youth NN None
with IN None
autistic JJ None
disorder NN None
: : None
youth NN None
with IN None
developmental JJ None
disabilities NNS None
. . None
eight CD None
outpatients NNS None
who WP None
participated VBD None
in IN None
an DT None
ongoing JJ None
placebo-controlled JJ None
study NN None
of IN None
valproate NN None
for IN None
aggression NN None
in IN None
autism NN None
. . None
-DOCSTART- -X- N

normal JJ Condition
subjects NNS Condition
and CC Condition
patients NNS Condition
with IN Condition
type JJ Condition
1 CD Condition
diabetes NNS Condition
. . Condition
seven CD None
normal JJ None
men NNS None
and CC None
nine CD None
insulin-dependent NN None
( ( None
type JJ None
1 CD None
) ) None
diabetic JJ None
patients NNS None
. . None
normal JJ None
men NNS None
diabetic JJ None
patients NNS None
normal JJ None
men NNS None
insulin-dependent JJ None
diabetic JJ None
patients NNS None
-DOCSTART- -X- N

participants NNS Condition
were VBD Condition
required VBN Condition
to TO Condition
locomote VB Condition
in IN Condition
the DT Condition
dark NN Condition
to TO Condition
a DT Condition
lit NN Condition
target NN Condition
in IN Condition
three CD Condition
different JJ Condition
conditions NNS Condition
: : Condition
monocular JJ Condition
vision/target NN Condition
with IN Condition
image NN Condition
size NN Condition
, , Condition
binocular JJ Condition
vision/target NN Condition
with IN Condition
image NN Condition
size NN Condition
, , Condition
and CC Condition
binocular JJ Condition
vision/point-light JJ Condition
target NN Condition
( ( Condition
without IN Condition
image NN Condition
size NN Condition
) ) Condition
. . Condition
participants NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
. . Condition
Sixty NNP Size
subjects VBZ None
with IN None
autism NN Condition
-DOCSTART- -X- N

risperidone-treated JJ None
youths NNS None
with IN None
autism NN None
: : None
63 CD None
children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
treated VBN None
with IN None
risperidone NN None
for IN None
6 CD None
months NNS None
. . None
-DOCSTART- -X- N

recent JJ None
onset NN None
rheumatoid NN Condition
arthritis NN Condition
patients NNS None
with IN None
recently RB None
diagnosed VBN None
rheumatoid NN Condition
arthritis NN Condition
( ( Condition
RA NNP Condition
) ) Condition
Twenty-two JJ Size
patients NNS None
with IN None
a DT None
history NN None
of IN None
recently RB None
diagnosed VBN None
RA NNP Condition
of IN None
less JJR None
than IN None
2 CD None
years NNS None
22 CD Size
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ None
coronary JJ None
syndrome NN None
in IN None
the DT None
PROVE NNP None
IT-TIMI NNP None
22 CD None
trial NN None
. . None
large JJ None
cohort NN None
of IN None
patients NNS None
presenting VBG None
across IN None
the DT None
spectrum NN None
of IN None
ACS NNP None
. . None
( ( None
n JJ None
= NNP None
3,761 CD None
) ) None
patients NNS Condition
randomized VBN Condition
to TO Condition
atorvastatin VB Condition
80 CD Condition
mg NN Condition
or CC Condition
pravastatin NN Condition
40 CD Condition
mg NN Condition
after IN Condition
ACS NNP Condition
in IN Condition
patients NNS None
with IN None
elevated JJ None
baseline NN None
PlGF NNP None
-DOCSTART- -X- N

obesity NN Condition
. . Condition
Subjects NNS None
were VBD None
1,504 CD Size
police NNS None
trainees NNS None
( ( None
85 CD None
% NN None
male NN Sex
, , None
15 CD None
% NN None
female NN Sex
) ) None
with IN None
an DT None
ethnic JJ None
distribution NN None
of IN None
82 CD None
% NN None
white JJ None
, , None
16 CD None
% NN None
African JJ None
American NNP None
, , None
and CC None
2 CD None
% NN None
other JJ None
. . None
Data NNS None
were VBD None
collected VBN None
at IN None
25 CD None
sites NNS None
across IN None
the DT None
state NN None
of IN None
North NNP None
Carolina NNP None
. . None
-DOCSTART- -X- N

breast NN Condition
cancer NN Condition
-- : Condition
long-term JJ Condition
Oslo NNP None
study NN None
. . None
the DT None
effect NN None
of IN None
postoperative JJ None
radiotherapy NN None
as IN None
an DT None
adjuvant NN None
to TO None
radical JJ None
mastectomy NN None
are VBP None
presented VBN None
. . None
1115 CD None
patients NNS None
including VBG None
27 CD None
protocol JJ None
deviants NNS None
. . None
-DOCSTART- -X- N

hypertensive JJ Condition
patients NNS None
Diagnosed VBD None
hypertensive JJ Condition
patients NNS None
Five CD Size
hundred VBD Size
participants NNS None
were VBD None
enrolled VBN None
and CC None
baseline JJ None
characteristics NNS None
include VBP None
a DT None
mean JJ None
age NN None
of IN None
60.0 CD Age
years NNS Age
; : None
57.6 CD None
% NN None
female NN Sex
; : None
and CC None
77.6 CD None
% NN None
white JJ None
. . None
37.7 CD None
% NN None
participants NNS None
had VBD None
uncontrolled VBN Condition
blood NN Condition
pressure NN Condition
; : None
the DT None
mean NN None
body NN None
mass NN None
index NN None
( ( None
BMI NNP None
) ) None
was VBD None
in IN None
the DT None
obese JJ None
range NN None
( ( None
32.4 CD None
) ) None
and CC None
21.8 CD None
% NN None
had VBD None
diabetes NNS Condition
. . None
-DOCSTART- -X- N

three-centre JJ Condition
study NN Condition
investigated VBD Condition
the DT Condition
preference NN Condition
of IN Condition
cystic JJ Condition
fibrosis NN Condition
( ( Condition
CF NNP Condition
) ) Condition
patients NNS Condition
Fifty-nine JJ None
patients NNS None
with IN None
a DT None
mean JJ None
age NN None
10 CD None
years NNS None
( ( None
range VB None
3-17 NNP None
) ) None
51 CD None
of IN None
54 CD None
patients NNS None
who WP None
completed VBD None
the DT None
study NN None
CF NNP None
children NNS None
-DOCSTART- -X- N

low JJ Condition
back RB Condition
pain NN Condition
low JJ None
back RB None
pain NN None
( ( None
LBP NNP None
) ) None
and CC None
disability NN None
. . None
Middle-aged JJ None
working VBG None
men NNS None
with IN None
recent JJ None
LBP NNP None
but CC None
without IN None
severe JJ None
disability NN None
training NN None
LBP NNP None
and CC None
disability NN None
among IN None
middle JJ None
aged VBN None
working VBG None
men NNS None
. . None
-DOCSTART- -X- N

Canadian JJ None
lactating VBG None
women NNS Sex
exposed VBN None
to TO None
high JJ None
levels NNS None
of IN None
folate NN Condition
Canada NNP None
reproducing VBG None
women NNS Sex
. . None
women NNS Sex
with IN None
high JJ Condition
blood NN Condition
folate NN Condition
values NNS Condition
well-educated JJ None
lactating VBG None
Canadian JJ None
women NNS Sex
exposed VBN None
to TO None
high JJ None
levels NNS None
of IN None
synthetic JJ None
folate NN None
. . None
sample NN None
of IN None
predominantly RB None
university-educated JJ None
lactating VBG None
women NNS Sex
( ( Age
32 CD Age
+/- JJ Age
4 CD Age
yr NN None
) ) None
at IN None
4- JJ None
( ( None
n JJ None
= NNP None
53 CD Size
) ) None
and CC None
16-wk JJ None
postpartum NN None
( ( None
n JJ None
= NNP None
55 CD Size
) ) None
. . None
-DOCSTART- -X- N

Thirty-two NNP None
healthy JJ None
, , None
opioid-naive JJ None
adults NNS None
-DOCSTART- -X- N

myocardial JJ Condition
infarction NN Condition
: : None
Patients NNPS None
with IN None
left JJ Condition
ventricular JJ Condition
ejection NN Condition
fraction NN Condition
less JJR Condition
than IN Condition
45 CD Condition
% NN Condition
after IN Condition
AMI NNP Condition
were VBD None
randomly RB None
assigned VBN None
stem NN None
cell NN None
delivery NN None
via IN None
intramyocardial JJ None
injection NN None
and CC None
intracoronary JJ None
infusion NN None
3-6 JJ None
weeks NNS None
or CC None
3-4 JJ None
months NNS None
after IN None
AMI NNP None
. . None
A DT None
total NN None
of IN None
60 CD Size
patients NNS None
were VBD None
treated VBN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
lower JJR Condition
urinary JJ Condition
tract NN Condition
symptoms NNS Condition
associated VBN None
with IN None
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
. . None
Patient JJ None
preference NN None
for IN None
benign JJ None
prostatic JJ None
hyperplasia NN None
( ( None
BPH NNP None
) ) None
treatment NN None
with IN None
the DT None
? . None
( ( None
1 CD None
) ) None
-blockers NNS None
, , None
tamsulosin NN None
or CC None
silodosin NN None
, , None
Japanese JJ None
patients NNS None
with IN None
lower JJR Condition
urinary JJ Condition
tract NN Condition
symptoms NNS None
associated VBN None
with IN None
BPH NNP None
102 CD None
patients NNS None
( ( None
mean JJ Age
age NN Age
70.3 CD Age
years NNS Age
) ) None
were VBD None
enrolled VBN None
and CC None
84 CD None
( ( None
n JJ None
= $ None
42 CD None
per IN None
group NN None
) ) None
completed VBD None
the DT None
study NN None
. . None
that IN None
patients NNS None
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS Condition
. . None
10 CD None
healthy JJ None
men NNS None
-DOCSTART- -X- N

653 CD None
patients NNS None
with IN None
dermatophytoses NNS None
653 CD None
patients NNS None
included VBN None
in IN None
the DT None
trial NN None
-DOCSTART- -X- N

Fifty NNP Size
patients NNS None
with IN None
blepharitis NN Condition
, , None
conjuctivitis NN Condition
, , None
or CC None
blepharoconjunctivitis NN Condition
-DOCSTART- -X- N

women NNS None
from IN None
breast NN None
cancer NN None
. . None
A DT None
total NN None
of IN None
266 CD None
064 CD None
women NNS None
( ( None
age NN None
of IN None
30 CD None
to TO None
64 CD None
years NNS None
) ) None
associated VBD None
with IN None
519 CD None
textile NN None
factories NNS None
in IN None
Shanghai NNP None
had VBD None
been VBN None
randomly RB None
assigned VBN None
to TO None
a DT None
BSE NNP None
group NN None
( ( None
132 CD None
979 CD None
women NNS None
) ) None
or CC None
a DT None
control NN None
group NN None
( ( None
133 CD None
085 CD None
women NNS None
) ) None
since IN None
1989 CD None
. . None
-DOCSTART- -X- N

tinnitus NN Condition
: : None
tinnitus NN Condition
patients NNS None
. . None
116 CD Size
patients NNS None
with IN None
chronic JJ None
tinnitus NN Condition
-DOCSTART- -X- N

BRAF NNP None
mutation NN None
in IN None
stage NN Condition
III NNP Condition
colon NN Condition
cancer NN Condition
: : None
colorectal JJ Condition
carcinogenesis NN Condition
. . None
patients NNS Condition
with IN Condition
stage NN Condition
III NNP Condition
colon NN Condition
cancer NN Condition
. . None
506 CD Size
stage NN Condition
III NNP Condition
colon NN Condition
cancer NN Condition
patients NNS None
enrolled VBN None
in IN None
a DT None
randomized JJ None
adjuvant NN None
chemotherapy NN None
trial NN None
75 CD Size
BRAF-mutated JJ None
patients NNS None
stage NN Condition
III NNP Condition
colon NN Condition
cancer NN Condition
. . None
-DOCSTART- -X- N

108 CD None
patients NNS None
diagnosed VBN None
as IN None
having VBG None
mild NN None
to TO None
moderate VB None
hypertension NN None
. . None
-DOCSTART- -X- N

coronary JJ None
artery NN None
surgery NN None
. . None
coronary JJ Condition
artery JJ Condition
bypass NN Condition
grafting NN Condition
45 CD Size
hypertensive JJ Condition
coronary JJ Condition
bypass NN Condition
patients NNS None
-DOCSTART- -X- N

during IN None
starvation NN None
in IN None
humans NNS None
. . None
starving VBG Condition
subjects NNS Condition
. . None
28 CD None
normal JJ Condition
men NNS None
( ( None
age NN None
27-35 CD None
years NNS None
) ) None
within IN None
10 CD None
% NN None
of IN None
their PRP$ None
ideal NN None
body NN None
weight NN None
. . None
They PRP None
were VBD None
randomly RB None
divided VBN None
into IN None
4 CD None
groups NNS None
of IN None
7 CD None
. . None
-DOCSTART- -X- N

opioid JJ Condition
physical JJ Condition
dependence NN Condition
in IN None
heroin NN Condition
addicts NNS Condition
. . None
long-term JJ None
heroin NN Condition
addicts NNS Condition
Patients NNS None
who WP None
received VBD None
placebo NN None
( ( None
n JJ None
= NNP None
18 CD Size
) ) None
Patients NNS None
who WP None
received VBD None
naloxone NN None
( ( None
n JJ None
= NNP None
58 CD Size
) ) None
-DOCSTART- -X- N

hypertensive JJ Condition
patients NNS None
in IN None
a DT None
rural JJ None
setting NN None
. . None
patients NNS None
who WP None
were VBD None
monitored VBN None
by IN None
specially RB None
trained VBN None
community NN None
pharmacists NNS None
in IN None
a DT None
group NN None
medical JJ None
practice NN None
. . None
25 CD Size
patients NNS None
control NN None
group NN None
of IN None
26 CD Size
patients NNS None
-DOCSTART- -X- N

ovarian JJ None
stimulation NN None
for IN None
IVF NNP None
. . None
prior RB None
to TO None
IVF NNP None
in IN None
1509 CD None
patients NNS None
. . None
1509 CD None
patients NNS None
were VBD None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( None
ASD NNP Condition
) ) None
. . None
Children NNP Age
ages VBZ Age
6-12 NN Age
with IN Age
ASD NNP None
children NNS Age
with IN None
ASD NNP Condition
. . None
-DOCSTART- -X- N

congestive JJ Condition
heart NN Condition
failure NN Condition
associated VBN None
with IN None
renal JJ Condition
insufficiency NN Condition
: : None
critically RB Condition
ill JJ Condition
patients NNS None
with IN None
oliguria NNS Condition
or CC None
acute JJ Condition
renal JJ Condition
failure NN Condition
. . None
20 CD Size
study NN None
patients NNS None
( ( None
mean JJ Age
age NN Age
74.3 CD Age
+/- JJ Age
15 CD Age
years NNS Age
) ) None
with IN None
severe JJ Condition
CHF NNP Condition
, , None
10 CD Size
( ( None
Group NNP None
A NNP None
) ) None
-DOCSTART- -X- N

homeless JJ None
women NNS Sex
. . None
325 CD Size
women NNS Sex
who WP None
resided VBD None
in IN None
emergency NN None
or CC None
sober-living NN None
shelters NNS None
and CC None
their PRP$ None
308 CD Size
intimate JJ None
sexual JJ None
partners NNS None
. . None
homeless JJ Condition
participants NNS None
impoverished JJ Condition
populations NNS None
-DOCSTART- -X- N

post-ERCP JJ None
pancreatitis NN None
: : None
post-ERCP JJ None
pancreatitis NN None
. . None
Patients NNPS None
A DT None
total NN None
of IN None
246 CD None
patients NNS None
were VBD None
randomized VBN None
( ( None
116 CD None
pure-cut JJ None
current JJ None
, , None
130 CD None
blend NN None
current JJ None
) ) None
. . None
-DOCSTART- -X- N

Forty-five JJ Size
( ( None
45 CD Size
) ) None
female NN Sex
subjects NNS None
, , None
between IN None
the DT None
ages NNS None
of IN None
18 CD Age
and CC Age
40 CD Age
years NNS Age
no-treatment JJ None
control NN None
, , None
the DT None
treatment-control NN None
( ( None
table JJ None
stabilization NN None
) ) None
, , None
and CC None
the DT None
experimental JJ None
( ( None
PostureJac NNP None
) ) None
group NN None
. . None
PostureJac NNP None
group NN None
no-treatment JJ None
control NN None
( ( None
p=.001 NN None
) ) None
and CC None
the DT None
treatment-control NN None
( ( None
p=.004 NN None
) ) None
groups NNS None
-DOCSTART- -X- N

poisoning NN Condition
with IN Condition
acetaminophen NN Condition
: : None
Ten NNP Size
healthy JJ None
adult NN Age
volunteers NNS Age
victims NNS None
of IN None
acetaminophen NN Condition
overdose NN Condition
. . None
-DOCSTART- -X- N

dentinal JJ Condition
cold JJ Condition
sensitivity NN Condition
. . None
Postoperative NNP Condition
cold VBD Condition
sensitivity NN Condition
after IN None
the DT None
cementation NN None
of IN None
indirect JJ None
restorations NNS None
with IN None
composite JJ None
cements NNS None
The DT None
hypersensitive JJ None
root NN None
surfaces NNS None
of IN None
selected VBN None
teeth NNS None
sample JJ Size
size NN Size
was VBD Size
22 CD Size
. . None
-DOCSTART- -X- N

extended VBN None
wear NN None
rigid JJ None
gas NN None
permeable JJ None
contact NN None
lenses NNS None
. . None
single-center JJ None
, , None
controlled VBN None
, , None
double-masked JJ None
study NN None
of IN None
39 CD None
RGP NNP None
lens VBZ None
wearers NNS None
. . None
RGP NNP None
lenses VBZ None
-DOCSTART- -X- N

older JJR Condition
sarcopenic JJ Condition
obese JJ Condition
New NNP Condition
Zealanders NNP Condition
. . Condition
older JJR None
adults NNS None
. . None
Osteoporosis NN None
was VBD None
prevalent JJ None
in IN None
low JJ None
muscle NN None
mass NN None
participants NNS None
and CC None
related VBN None
to TO None
gait VB None
and CC None
balance VB None
deficits NNS None
. . None
One CD None
hundred VBD None
eighty-three JJ None
older NN None
adults NNS None
( ( None
age NN None
72.7 CD None
+/- JJ None
6 CD None
years NNS None
, , None
range VBP None
56-93 JJ None
; : None
body NN None
mass NN None
index NN None
28.2 CD None
+/- JJ None
4.9 CD None
, , None
range VBP None
16.6-46.0 JJ None
) ) None
were VBD None
recruited VBN None
from IN None
a DT None
New NNP None
Zealand NNP None
falls VBZ None
prevention NN None
intervention NN None
trial NN None
. . None
Total JJ None
and CC None
appendicular JJ None
skeletal JJ None
muscle NN None
mass NN None
( ( None
ASM NNP None
) ) None
, , None
percent JJ None
fat NN None
, , None
and CC None
bone NN None
mineralization NN None
were VBD None
assessed VBN None
by IN None
dual JJ None
energy NN None
X-ray JJ None
absorptiometry NN None
and CC None
used VBD None
to TO None
characterize VB None
normal JJ None
lean JJ None
( ( None
NL NNP None
, , None
n JJ None
= NNP None
51 CD None
) ) None
, , None
sarcopenic JJ None
( ( None
SS NNP None
, , None
n JJ None
= NNP None
18 CD None
) ) None
, , None
sarcopenic JJ None
obese NN None
( ( None
SO NNP None
, , None
n JJ None
= NNP None
29 CD None
) ) None
, , None
and CC None
obese JJ None
( ( None
OO NNP None
, , None
n JJ None
= NNP None
85 CD None
) ) None
phenotypes NNS None
. . None
low JJ None
ASM NNP None
groups NNS None
-DOCSTART- -X- N

renal JJ None
transplant NN None
recipients NNS None
with IN None
tacrolimus-based JJ None
immunosuppression NN None
. . None
renal JJ Condition
transplant NN Condition
recipients NNS Condition
. . None
15 CD None
centers NNS None
in IN None
France NNP None
and CC None
1 CD None
center NN None
in IN None
Belgium NNP None
; : None
309 CD None
patients NNS None
were VBD None
randomized VBN None
to TO None
receive VB None
either DT None
induction NN None
therapy NN None
with IN None
ATG NNP None
( ( None
n=151 NN None
) ) None
followed VBN None
by IN None
initiation NN None
of IN None
tacrolimus NN None
on IN None
day NN None
9 CD None
or CC None
immediate JJ None
tacrolimus-based JJ None
triple NN None
therapy NN None
( ( None
n=158 JJ None
) ) None
. . None
-DOCSTART- -X- N

HER2-positive JJ Condition
breast NN Condition
cancer NN Condition
: : Condition
patients NNS None
who WP None
will MD None
benefit VB None
from IN None
targeted JJ None
anticancer NN None
therapies NNS None
. . None
455 CD None
women NNS None
with IN None
invasive JJ None
human JJ None
epidermal JJ None
growth NN None
factor NN None
receptor NN None
2 CD None
( ( None
HER2 NNP None
) ) None
-positive VBP None
breast NN None
cancer NN None
assessed VBN None
in IN None
a DT None
subset NN None
of IN None
patients NNS None
. . None
Eighty-six JJ Size
patients NNS Size
underwent JJ Size
( ( Size
18 CD Size
) ) Size
F-FDG CD Size
PET/CT NNP Size
-DOCSTART- -X- N

Sixty NNP None
women NNS None
with IN None
climacteric JJ None
complaints NNS None
who WP None
had VBD None
not RB None
menstruated VBN None
for IN None
at IN None
least JJS None
1 CD None
year NN None
climacteric JJ None
complaints NNS None
in IN None
postmenopausal JJ None
women NNS None
-DOCSTART- -X- N

of IN None
overweight/obesity NN None
among IN None
children NNS None
among IN None
elementary JJ None
school NN None
students NNS None
. . None
in IN None
elementary JJ None
schools NNS None
in IN None
Forsyth NNP None
County NNP None
, , None
North NNP None
Carolina NNP None
, , None
METHODS NNP None
The DT None
study NN None
included VBD None
third- JJ None
through IN None
fifth-grade JJ None
classrooms NNS None
in IN None
eight CD None
elementary JJ None
schools NNS None
. . None
among IN None
elementary JJ None
school NN None
children NNS None
. . None
-DOCSTART- -X- N

nodular JJ Condition
basal NN Condition
cell NN Condition
carcinoma NN Condition
. . None
nodular JJ Condition
basal NN Condition
cell NN Condition
carcinoma NN Condition
( ( None
BCC NNP Condition
) ) None
. . None
patients NNS None
with IN None
nodular JJ Condition
BCC NNP Condition
. . None
Twenty NNP Size
patients NNS None
Twenty NNP Size
patients NNS None
imiquimod NN None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
vehicle NN None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
-DOCSTART- -X- N

treatment NN None
of IN None
periodontitis NN Condition
: : None
subjects NNS None
with IN None
chronic JJ Condition
periodontitis NN Condition
30 CD Size
subjects NNS None
with IN None
moderate JJ None
to TO None
advanced JJ None
periodontitis NN Condition
13 CD Size
test NN Size
and CC None
15 CD Size
control NN Size
subjects NNS None
subjects NNS None
with IN None
moderate JJ None
to TO None
advanced JJ None
periodontitis NN Condition
. . None
-DOCSTART- -X- N

hypertensive JJ None
patients NNS None
: : None
36 CD None
never-treated JJ None
mild NN None
to TO None
moderate VB None
hypertensive JJ None
patients NNS None
. . None
-DOCSTART- -X- N

luminal NN Condition
A NNP Condition
breast NN Condition
cancer NN Condition
subgroup NN None
two CD None
primary JJ None
breast NN None
cancer NN None
cohorts NNS None
( ( None
n JJ None
= NN None
144 CD None
and CC None
n JJ None
= NNP None
564 CD None
) ) None
and CC None
mRNA JJ None
expression NN None
of IN None
YAP1 NNP None
was VBD None
evaluated VBN None
in IN None
a DT None
gene NN None
expression NN None
dataset NN None
( ( None
n JJ None
= NN None
1107 CD None
) ) None
ER+ NNP None
( ( None
Estrogen NNP None
Receptor NNP None
? . None
positive JJ None
) ) None
subgroup NN None
the DT None
ER- NNP None
( ( None
Estrogen NNP None
Receptor NNP None
? . None
negative JJ None
) ) None
subgroup NN None
YAP1 NNP None
aggressive JJ None
luminal NN None
A NNP None
breast NN None
cancer NN None
subgroup NN None
, , None
-DOCSTART- -X- N

malignant JJ Condition
melanoma NN Condition
. . None
malignant JJ None
melanoma NN None
. . None
patients NNS None
with IN None
high-risk JJ None
melanoma NN None
the DT None
patients NNS None
had VBD None
lesions NNS None
greater JJR None
than IN None
1.70 CD None
mm JJ None
thick NN None
and CC None
TNM NNP None
stage NN None
IB NNP None
or CC None
stage NN None
II NNP None
disease NN None
. . None
coumarin-treated JJ None
group NN None
of IN None
13 CD None
patients NNS None
, , None
and CC None
10 CD None
recurrences NNS None
in IN None
the DT None
placebo-treated JJ None
group NN None
of IN None
14 CD None
patients NNS None
-DOCSTART- -X- N

HIV-infected JJ Condition
patients NNS None
with IN None
painful JJ Condition
peripheral JJ Condition
neuropathy NN Condition
: : None
HIV-related NNP Condition
painful JJ Condition
peripheral JJ Condition
neuropathy NN Condition
( ( Condition
PPN NNP Condition
) ) None
22 CD Size
patients NNS None
19 CD Size
patients NNS None
who WP None
received VBD None
at IN None
least JJS None
2 CD None
weeks NNS None
of IN None
the DT None
drug NN None
, , None
16 CD Size
of IN None
whom WP None
were VBD None
crossed-over RB None
to TO None
receive VB None
the DT None
alternate NN None
agent NN None
. . None
-DOCSTART- -X- N

manic JJ None
patients NNS None
who WP None
did VBD None
not RB None
respond VB None
to TO None
an DT None
initial JJ None
adequate JJ None
trial NN None
of IN None
lithium NN None
. . None
( ( None
n JJ None
= NNP None
45 CD None
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
nasal JJ Condition
polyposis NN Condition
Forty NNP Size
consecutive JJ None
patients NNS None
without IN None
laboratory NN None
or CC None
other JJ None
clinical JJ None
signs NNS None
of IN None
allergy NN None
but CC None
with IN None
severe JJ Condition
nasal JJ Condition
polyposis NN Condition
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
Twenty CD Size
patients NNS None
were VBD None
treated VBN None
with IN None
intranasal JJ Condition
Bdp NNP Condition
and CC None
twenty JJ Size
patients NNS None
received VBD None
no DT None
treatment NN None
after IN None
polypectomy NN Condition
. . None
patients NNS None
were VBD None
followed VBN None
for IN None
at IN None
least JJS None
2.5 CD None
years NNS None
. . None
-DOCSTART- -X- N

pityriasis NN Condition
versicolor NN Condition
. . None
pityriasis NN Condition
versicolor NN Condition
; : None
pityriasis NN Condition
versicolor NN Condition
. . None
pityriasis NN Condition
versicolor NN Condition
. . None
Eighty NNP Size
patients NNS None
suffering VBG None
from IN None
pityriasis NN Condition
versicolor NN Condition
pityriasis NN Condition
versicolor NN Condition
. . None
-DOCSTART- -X- N

Preschoolers NNS Age
twenty-two JJ Size
3- JJ Age
to TO Age
4-year-olds NNS Age
children NNS Age
thirty-two JJ Size
4- JJ Age
to TO Age
5-year-olds NNS Age
children NNS Age
-DOCSTART- -X- N

coronary JJ None
atherosclerosis NN None
diabetic JJ None
patients NNS None
360 CD None
diabetic JJ None
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
diabetic JJ None
patients NNS None
diabetic JJ None
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
-DOCSTART- -X- N

University NNP None
research NN None
laboratory NN None
. . None
Twenty-seven NNP Size
healthy JJ Condition
volunteers NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
untreated JJ None
acute NN None
myeloid NN None
leukemia NN None
. . None
In IN None
1996 CD None
, , None
survival NN None
data NNS None
were VBD None
updated VBN None
from IN None
three CD None
prospective JJ None
, , None
randomized JJ None
comparisons NNS None
of IN None
idarubicin NN None
and CC None
daunorubicin NN None
that WDT None
began VBD None
in IN None
1984 CD None
and CC None
1985 CD None
. . None
These DT None
were VBD None
trials NNS None
of IN None
the DT None
Memorial NNP None
Sloan-Kettering NNP None
Cancer NNP None
Center NNP None
( ( None
MSKCC NNP None
) ) None
, , None
the DT None
U.S. NNP None
Multicenter NNP None
Study NNP None
Group NNP None
, , None
and CC None
the DT None
Southeastern NNP None
Cancer NNP None
Study NNP None
Group NNP None
( ( None
SEG NNP None
) ) None
. . None
-DOCSTART- -X- N

manikin JJ None
model NN None
. . None
modified JJ None
resuscitation NN None
manikin NN None
Thirty-six NNP None
experienced VBD None
practitioners NNS None
-DOCSTART- -X- N

invasive JJ None
aspergillosis NN None
in IN None
high-risk JJ None
haematology NN None
patients NNS None
: : None
haematology NN None
patients NNS None
at IN None
high JJ None
risk NN None
of IN None
invasive JJ None
aspergillosis NN None
. . None
eligible JJ None
patients NNS None
were VBD None
adults NNS None
undergoing VBG None
allogeneic JJ None
stem-cell JJ None
transplantation NN None
or CC None
chemotherapy NN None
for IN None
acute JJ None
leukaemia NN None
, , None
with IN None
no DT None
history NN None
of IN None
invasive JJ None
fungal JJ None
disease NN None
. . None
240 CD None
eligible JJ None
patients NNS None
were VBD None
recruited VBN None
from IN None
six CD None
Australian JJ None
centres NNS None
between IN None
Sept NNP None
30 CD None
, , None
2005 CD None
, , None
and CC None
Nov NNP None
19 CD None
, , None
2009 CD None
. . None
high-risk JJ None
haematology NN None
patients NNS None
. . None
FUNDING NNP None
-DOCSTART- -X- N

people NNS None
with IN None
schizophrenia NN Condition
in IN None
Beijing NNP None
, , None
China NNP None
: : None
people NNS None
with IN None
schizophrenia NN None
and CC None
their PRP$ None
families NNS None
sample NN None
of IN None
Chinese JJ None
people NNS None
with IN None
schizophrenia NN None
. . None
large JJ None
hospital NN None
with IN None
a DT None
sample NN None
of IN None
101 CD Size
patients NNS None
with IN None
schizophrenia NN None
and CC None
their PRP$ None
families NNS None
. . None
-DOCSTART- -X- N

elderly JJ None
patient NN None
. . None
elderly JJ None
by IN None
recruiting VBG None
13 CD None
subjects NNS None
> JJ Age
75 CD Age
years NNS Age
of IN Age
age NN Age
, , None
already RB None
fitted VBN None
with IN None
a DT None
physiological JJ None
pacing NN None
system NN None
. . None
All DT None
had VBD None
been VBN None
paced VBN None
for IN None
complete JJ None
or CC None
Mobitz NNP None
II NNP None
heart NN None
block NN None
. . None
-DOCSTART- -X- N

smokers NNS None
. . None
Four CD None
hundred VBD None
seventy-nine JJ None
smokers NNS None
Genotyping VBG None
used VBN None
Affymetrix NNP None
arrays NNS None
( ( None
Santa NNP None
Clara NNP None
, , None
CA NNP None
, , None
USA NNP None
) ) None
. . None
smokers NNS None
-DOCSTART- -X- N

chorioptic JJ Condition
mange NN Condition
in IN None
alpacas NN None
. . None
naturally RB None
infested VBN None
alpacas NN None
Thirty NNP Size
alpacas NN None
, , None
all DT None
positive JJ None
for IN None
Chorioptes NNP None
sp NN None
. . None
mite NN None
, , None
were VBD None
randomly RB None
allocated VBN None
to TO None
two CD None
treatment NN None
groups NNS None
in IN None
Study NNP None
1 CD None
. . None
In IN None
Study NNP None
2 CD None
, , None
one CD None
group NN None
of IN None
19 CD Size
alpacas NNS None
received VBD None
four CD None
administrations NNS None
at IN None
weekly JJ None
interval NN None
of IN None
topical JJ None
eprinomectin NN None
at IN None
the DT None
dose JJ None
rate NN None
of IN None
500mug/kg CD None
, , None
and CC None
response NN None
to TO None
treatment NN None
was VBD None
monitored VBN None
by IN None
mite JJ None
counts NNS None
. . None
Chorioptes NNPS Condition
mite JJ Condition
burden NN Condition
in IN None
alpacas NN None
. . None
-DOCSTART- -X- N

smoking VBG Condition
cessation NN Condition
among IN None
cancer NN Condition
patients NNS None
enrolled VBN None
in IN None
a DT None
smoking NN None
cessation NN None
program NN None
. . None
cancer NN None
patients NNS None
Data NNP None
from IN None
246 CD Size
cancer NN Condition
patients NNS None
participating VBG None
in IN None
a DT None
randomized JJ None
placebo-controlled JJ None
smoking NN None
cessation NN None
clinical JJ None
trial NN None
Patients NNS None
with IN None
tobacco-related JJ None
cancers NNS None
and CC None
female JJ Sex
patients NNS None
cancer NN None
patients NNS None
. . None
-DOCSTART- -X- N

toddlers NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
. . None
young JJ None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
. . None
toddlers NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
. . None
-DOCSTART- -X- N

unstable JJ None
angina NN Condition
] NNP None
patients NNS None
with IN None
unstable JJ Condition
angina JJ Condition
pectoris NN Condition
. . None
total NN None
of IN None
213 CD Size
eligible JJ None
patients NNS None
were VBD None
enrolled VBN None
. . None
patients NNS None
with IN None
unstable JJ None
angina JJ None
pectoris NN None
. . None
-DOCSTART- -X- N

Global JJ None
contour NN None
saliency NN None
Our PRP$ None
visual JJ None
system NN None
can MD None
link VB None
components NNS None
of IN None
contours NNS None
and CC None
segregate JJ None
contours NNS None
from IN None
complex JJ None
backgrounds NNS None
based VBN None
on IN None
geometric JJ None
grouping NN None
rules NNS None
. . None
This DT None
is VBZ None
an DT None
important JJ None
intermediate JJ None
step NN None
in IN None
object JJ None
recognition NN None
. . None
The DT None
substrate NN None
for IN None
contour JJ None
integration NN None
may MD None
be VB None
based VBN None
on IN None
contextual JJ None
interactions NNS None
and CC None
intrinsic JJ None
horizontal NN None
connections NNS None
seen VBN None
in IN None
primary JJ None
visual JJ None
cortex NN None
( ( None
V1 NNP None
) ) None
. . None
We PRP None
examined VBD None
the DT None
perceptual JJ None
rules NNS None
governing VBG None
contour NN None
saliency NN None
to TO None
determine VB None
whether IN None
the DT None
spatial JJ None
extents NNS None
of IN None
contextual JJ None
interactions NNS None
and CC None
horizontal JJ None
connections NNS None
match VBP None
those DT None
mediating JJ None
saliency NN None
. . None
To TO None
quantify VB None
these DT None
rules NNS None
, , None
we PRP None
used VBD None
stimuli NNS None
composed VBN None
of IN None
randomly RB None
oriented VBN None
nonoverlapping JJ None
line NN None
segments NNS None
. . None
Salient NN None
contours NN None
within IN None
this DT None
complex JJ None
background NN None
were VBD None
formed VBN None
by IN None
colinear JJ None
alignment NN None
of IN None
nearby JJ None
segments NNS None
. . None
Contour NNP None
detectability NN None
was VBD None
measured VBN None
using VBG None
a DT None
2-interval-forced-choice JJ None
design NN None
. . None
-DOCSTART- -X- N

during IN None
routine JJ None
surgeries NNS None
One CD Size
hundred VBD Size
patients NNS None
aged VBN None
5-88 CD Age
years NNS Age
( ( None
56 CD Size
patients NNS Size
with IN None
a DT None
history NN None
of IN None
chronic JJ Condition
respiratory NN Condition
complaints NNS Condition
and CC None
44 CD Size
patients NNS Size
without IN None
) ) None
entered VBD None
Phase NNP None
1 CD None
, , None
and CC None
100 CD Size
patients NNS Size
aged VBN None
6-82 JJ Age
years NNS Age
( ( None
62 CD Size
patients NNS Size
with IN None
a DT None
history NN None
of IN None
chronic JJ Condition
respiratory NN Condition
complaints NNS Condition
and CC None
38 CD Size
patients NNS Size
without IN None
) ) None
entered VBD None
Phase NNP None
2 CD None
. . None
-DOCSTART- -X- N

Households NNS None
with IN None
young JJ Age
children NNS Age
and CC None
use NN None
of IN None
freely RB None
distributed VBN None
bednets NNS None
in IN None
rural JJ None
Madagascar NNP None
. . None
children NNS Age
in IN None
Madagascar NNP None
. . None
bednet NN None
distribution NN None
programs NNS None
young JJ Age
children NNS Age
. . None
free JJ None
bednet NN None
distribution NN None
program NN None
in IN None
Madagascar NNP None
from IN None
2007-2008 JJ None
. . None
children NNS None
560 CD Size
households NNS None
in IN None
the DT None
study NN None
child NN None
under IN Age
5 CD Age
years NNS Age
of IN None
age NN None
children NNS None
-DOCSTART- -X- N

outpatient JJ Condition
anesthesia NN Condition
: : None
postoperative JJ None
recovery NN None
of IN None
patients NNS None
following VBG None
the DT None
use NN None
of IN None
either DT None
propofol-nitrous JJ None
oxide NN None
( ( None
N2O NNP None
) ) None
or CC None
enflurane-N2O JJ None
for IN None
maintenance NN None
of IN None
outpatient JJ Condition
anesthesia NN Condition
. . None
University NNP None
hospital NN None
outpatient NN Condition
surgery NN None
center NN None
. . None
61 CD Size
ASA NNP Condition
physical JJ Condition
status NN Condition
I PRP Condition
and CC Condition
II NNP Condition
, , None
healthy JJ Condition
female NN Sex
outpatients NNS Condition
undergoing VBG None
laparoscopic NN Condition
surgery NN Condition
. . None
-DOCSTART- -X- N

multi-centre JJ None
studies NNS None
. . None
West NNP None
Germany NNP None
and CC None
involving VBG None
80 CD Size
patients NNS None
serious JJ Condition
systemic JJ Condition
infections NNS Condition
. . None
large JJ None
collaborative NN None
study NN None
involving VBG None
15 CD None
centres NNS None
, , None
254 CD Size
patients NNS None
were VBD None
enrolled VBN None
. . None
-DOCSTART- -X- N

fentanyl-induced JJ None
cough NN None
during IN None
general JJ None
anesthesia JJ None
induction NN None
: : None
total NN None
of IN None
120 CD None
patients NNS None
, , None
American NNP None
Society NNP None
of IN None
Anesthesiologists NNP None
( ( None
ASA NNP None
) ) None
physical JJ None
status NN None
I-II NNP None
, , None
were VBD None
randomized VBN None
into IN None
two CD None
equally RB None
sized JJ None
groups NNS None
( ( None
n JJ None
= NNP None
60 CD None
) ) None
. . None
RESULTS NNP None
No NNP None
patient NN None
in IN None
the DT None
dezocine NN None
group NN None
and CC None
42 CD None
patients NNS None
in IN None
the DT None
control NN None
group NN None
suppressing VBG None
fentanyl-induced JJ None
cough NN None
in IN None
our PRP$ None
patients NNS None
. . None
-DOCSTART- -X- N

episiotomy/laceration NN Condition
. . None
Ninety NN Size
patients NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
one CD None
of IN None
three CD None
treatment NN None
groups NNS None
. . None
30 CD Size
subjects NNS None
applying VBG None
a DT None
warm JJ None
perineal NN None
pack NN None
, , None
30 CD Size
applying VBG None
a DT None
cold JJ None
perineal NN None
pack NN None
, , None
and CC None
30 CD Size
taking VBG None
a DT None
warm JJ None
sitz NN None
bath NN None
. . None
-DOCSTART- -X- N

ondelayed-onset JJ None
muscle NN None
soreness NN None
. . None
Ten CD Size
healthy JJ None
males NNS Condition
and CC None
ten VB None
healthy JJ None
females NNS Condition
aged VBD None
21.5 CD None
+/- JJ None
3.2 CD None
years NNS None
( ( None
mean JJ None
+/- NNP None
s NN None
) ) None
participated VBD None
in IN None
the DT None
study NN None
delayed-onset JJ None
muscle NN None
soreness NN None
( ( None
DOMS NNP None
) ) None
. . None
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
. . None
healthy JJ None
volunteers NNS None
. . None
A DT None
university NN None
medical JJ None
center NN None
. . None
Seven NNP Size
healthy JJ None
men NNS Sex
and CC None
women NNS Sex
. . None
Six NNP None
subjects NNS None
( ( None
86 CD None
% NN None
) ) None
completed VBD None
the DT None
study NN None
; : None
one CD None
was VBD None
removed VBN None
due JJ None
to TO None
the DT None
development NN None
of IN None
a DT None
rash NN None
. . None
-DOCSTART- -X- N

chronic JJ Condition
schizophrenia NN Condition
. . None
chronic JJ Condition
schizophrenia NN Condition
in-patients NNS None
( ( None
n=35 NN Size
) ) None
Patients NNS None
stable JJ Condition
antipsychotic JJ Condition
treatment NN Condition
chronic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

39 CD Size
patients NNS None
with IN None
marginal JJ Condition
zone NN Condition
B NNP Condition
cell NN Condition
lymphoma NN Condition
( ( Condition
MZBCL NNP Condition
) ) Condition
of IN None
the DT None
parotid NN None
glands NNS None
( ( None
stages NNS None
I PRP None
or CC None
II NNP None
) ) None
were VBD None
studied VBN None
. . None
-DOCSTART- -X- N

overweight JJ Condition
Latina NNP None
adolescents NNS Age
. . None
overweight JJ None
Latina NNP None
adolescent NN None
females NNS Sex
. . None
41 CD Size
overweight JJ Condition
Latina NNP None
girls NNS Sex
( ( None
15.2 CD Age
+/- JJ Age
1.1 CD Age
yr NN Age
) ) None
overweight JJ Condition
Latina NNP None
girls NNS Sex
. . None
-DOCSTART- -X- N

463 CD Size
women NNS Sex
. . None
400 CD Size
women NNS Sex
in IN None
each DT None
arm NN None
of IN None
the DT None
trial NN None
. . None
Participating VBG None
general JJ None
practices NNS None
and CC None
a DT None
district NN None
general JJ None
teaching NN None
hospital NN None
. . None
Women NNP Sex
attending VBG None
their PRP$ None
general JJ None
practitioner NN None
in IN None
the DT None
first JJ Condition
trimester NN Condition
to TO None
confirm VB None
pregnancy NN Condition
, , None
in IN None
whom WP None
a DT None
first JJ None
trimester NN None
ultrasound JJ None
scan NN None
was VBD None
not RB None
indicated VBN None
. . None
463 CD Size
women NNS Sex
had VBD None
been VBN None
enrolled VBN None
. . None
-DOCSTART- -X- N

sensory JJ Condition
problems NNS Condition
for IN None
children NNS None
with IN None
autism NN Condition
. . None
children NNS None
with IN None
autism NN Condition
. . None
Trakya NNP None
University NNP None
Training NNP None
and CC None
Research NNP None
Center NNP None
for IN None
Mentally NNP None
and CC None
Physically NNP None
Handicapped NNP None
Children NNP None
in IN None
Turkey NNP None
. . None
comprising VBG None
15 CD Size
children NNS None
between IN None
7 CD None
and CC None
11 CD None
years NNS None
of IN None
age NN None
with IN None
autism NN Condition
, , None
according VBG None
to TO None
DSM-IV NNP None
criteria NNS None
. . None
-DOCSTART- -X- N

Mefloquine NNP None
kinetics NNS None
in IN None
cured JJ None
and CC None
recrudescent JJ None
patients NNS None
with IN None
acute JJ None
falciparum NN None
malaria NN None
and CC None
in IN None
healthy JJ None
volunteers NNS None
. . None
clinical JJ None
trial NN None
in IN None
Thailand NNP None
among IN None
patients NNS None
with IN None
malaria NNS None
and CC None
healthy JJ None
volunteers NNS None
. . None
administered VBN None
to TO None
11 CD None
patients NNS None
and CC None
5 CD None
volunteers NNS None
and CC None
750 CD None
mg NN None
was VBD None
given VBN None
to TO None
16 CD None
patients NNS None
and CC None
5 CD None
volunteers NNS None
. . None
cured JJ None
patients NNS None
taking VBG None
750 CD None
mg JJ None
mefloquine NN None
, , None
peak JJ None
plasma JJ None
drug NN None
concentration NN None
( ( None
Cmax NNP None
) ) None
and CC None
area NN None
under IN None
the DT None
plasma JJ None
concentration-time JJ None
curve NN None
( ( None
AUC NNP None
) ) None
patients NNS None
with IN None
malaria NNS None
and CC None
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

humans NNS None
human JJ None
subjects NNS None
-DOCSTART- -X- N

cocaine NN Condition
dependence NN Condition
. . None
Subjects NNS None
were VBD None
54 CD Size
outpatients NNS None
who WP None
met VBD None
DSM NNP None
III-R NNP None
criteria NNS None
for IN None
active JJ None
cocaine NN None
dependence NN None
and CC None
who WP None
completed VBD None
a DT None
minimum NN None
of IN None
2 CD None
weeks NNS None
of IN None
treatment NN None
. . None
did VBD None
not RB None
differ VB None
for IN None
lifetime NN None
cocaine NN None
use NN None
, , None
lifetime JJ None
histories NNS None
of IN None
psychopathology NN None
, , None
admission NN None
scores NNS None
on IN None
psychometric JJ None
assessments NNS None
, , None
and CC None
sociodemographics NNS None
. . None
-DOCSTART- -X- N

Ten CD None
ceramic JJ None
blocks NNS None
( ( None
6x6x6 CD None
mm NN None
) ) None
were VBD None
fabricated VBN None
and CC None
randomly RB None
assigned VBN None
to TO None
2 CD None
groups NNS None
( ( None
n=5 NN None
) ) None
, , None
according VBG None
to TO None
the DT None
conditioning NN None
method NN None
: : None
G1- JJ None
10 CD None
% NN None
hydrofluoric JJ None
acid NN None
application NN None
for IN None
2 CD None
min NN None
plus CC None
rinsing NN None
and CC None
drying NN None
, , None
followed VBN None
by IN None
silane NN None
application NN None
for IN None
30 CD None
s NNS None
; : None
G2- NNP None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . None
adults NNS Age
and CC None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( Condition
ASD NNP Condition
) ) Condition
children NNS Age
with IN None
ASD NNP Condition
Twenty-one CD Size
children NNS None
with IN None
ASD NNP Condition
( ( None
9-16 CD Age
years NNS Age
) ) None
were VBD None
compared VBN None
to TO None
typically RB None
developing VBG None
matched VBN None
groups NNS None
. . None
children NNS Age
with IN None
ASD NNP Condition
typically RB None
matched VBD None
groups NNS None
children NNS Age
with IN None
ASD NNP Condition
. . None
children NNS Age
with IN None
ASD NNP Condition
-DOCSTART- -X- N

condylomata NNS Condition
acuminata NNS Condition
following VBG Condition
cryotherapy NN Condition
97 CD None
patients NNS None
with IN None
recurrent JJ None
condylomata NN None
acuminata NN None
. . Condition
36 CD None
and CC None
37 CD None
patients NNS None
, , None
respectively RB None
, , None
completed VBD None
the DT None
study NN None
population NN None
of IN None
patients NNS None
with IN None
recurrent JJ None
condylomata NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
severe JJ None
injuries NNS None
. . None
patients NNS None
sustaining VBG None
severe JJ None
injury NN None
. . None
patients NNS None
with IN None
major JJ None
infection NN None
on IN None
day NN None
60 CD None
. . None
Nine JJ None
university-affiliated JJ None
level NN None
1 CD None
trauma NN None
centers NNS None
. . None
Four CD None
hundred JJ None
sixteen JJ None
patients NNS None
with IN None
severe JJ None
injuries NNS None
, , None
assessed VBN None
by IN None
Injury NNP None
Severity NNP None
Score NNP None
and CC None
degree NN None
of IN None
contamination NN None
. . None
patients NNS None
treated VBN None
with IN None
interferon NN None
gamma NN None
. . None
-DOCSTART- -X- N

outpatient JJ Condition
surgical JJ Condition
procedures NNS Condition
. . None
under IN None
general JJ Condition
anaesthesia NN Condition
. . None
One CD Size
hundred VBD Size
ASA NNP Condition
I-II NNP Condition
patients NNS Condition
, , None
aged VBN None
18-60 JJ Age
yr NN Age
undergoing VBG None
elective JJ Condition
minor JJ Condition
surgery NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
metabolic JJ None
syndrome JJ None
receiving VBG None
low-dose JJ None
aspirin NN None
. . None
Patients NNS None
who WP None
had VBD None
metabolic JJ None
syndrome NN None
-DOCSTART- -X- N

Prostate NNP None
, , None
Lung NNP None
, , None
Colorectal NNP None
and CC None
Ovarian NNP None
( ( None
PLCO NNP None
) ) None
Trial NNP None
all DT None
cancers NNS None
showing VBG None
a DT None
positive JJ None
screen NN None
result NN None
earlier RBR None
with IN None
ROCA NNP None
than IN None
under IN None
the DT None
PLCO NNP None
such JJ None
women NNS None
132 CD None
intervention NN None
arm NN None
ovarian JJ None
cancer NN None
deaths NNS None
versus VBP None
119 CD None
in IN None
usual JJ None
care NN None
-DOCSTART- -X- N

early-stage JJ Condition
breast NN Condition
cancer NN Condition
. . None
women NNS Sex
with IN None
early-stage JJ Condition
breast NN Condition
cancer NN Condition
was VBD None
tested VBN None
a DT None
three-group JJ None
, , None
three-phase JJ None
randomized JJ None
clinical JJ None
trial NN None
of IN None
a DT None
sample NN None
of IN None
125 CD Size
women NNS Sex
. . None
-DOCSTART- -X- N

type NN None
2 CD None
diabetes NNS None
: : None
type VB None
2 CD None
diabetes NNS None
subjects NNS None
8 CD None
patients NNS None
, , None
5 CD None
of IN None
whom WP None
were VBD None
insulin-requiring JJ None
. . None
type NN None
2 CD None
diabetes NNS None
group NN None
normal JJ None
nondiabetic JJ None
subjects NNS None
-DOCSTART- -X- N

healthy JJ None
male NN None
and CC None
female JJ None
volunteers NNS None
: : None
male NN None
and CC None
female JJ None
healthy JJ None
volunteers NNS None
. . None
Ten CD Size
males NNS Sex
and CC None
nine CD Size
females NNS Sex
( ( None
age NN None
range NN None
20-33 CD None
years NNS None
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
primary JJ None
hypertension NN None
] NN None
patients NNS None
with IN None
primary JJ None
hypertension NN None
. . None
40 CD None
patients NNS None
with IN None
hypertension NN None
. . None
An DT None
additional JJ None
twenty NN None
healthy JJ None
people NNS None
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
( ( None
normal JJ None
group NN None
) ) None
. . None
hypertension NN None
patient NN None
hypertension NN None
patients NNS None
-DOCSTART- -X- N

50 CD Size
cirrhotic JJ Condition
patients NNS None
. . None
esophageal JJ Condition
varices NNS Condition
. . Condition
41 CD Size
patients NNS None
. . None
Nine CD Size
patients NNS None
showed VBD None
negative JJ Condition
MRA NNP Condition
results NNS Condition
. . Condition
-DOCSTART- -X- N

cataract NN None
extraction NN None
with IN None
lens JJ None
implantation NN None
. . None
participation NN None
of IN None
medical JJ None
statisticians NNS None
A DT None
total NN None
of IN None
190 CD None
patients NNS None
with IN None
ICCE NNP None
and CC None
ACL NNP None
and CC None
170 CD None
patients NNS None
with IN None
ECCE NNP None
and CC None
PCL NNP None
were VBD None
followed VBN None
up RP None
for IN None
2 CD None
years NNS None
. . None
patients NNS None
with IN None
an DT None
intact JJ None
iris JJ None
diaphragm NN None
. . None
-DOCSTART- -X- N

infants NNS Age
younger JJR Age
than IN Age
6 CD Age
months NNS Age
of IN Age
age NN Age
. . None
Young NNP Age
children NNS Age
children NNS Age
< $ Age
6 CD Age
months NNS Age
of IN Age
age NN Age
. . None
children NNS None
. . None
healthy JJ Condition
children NNS Age
6 CD Age
to TO Age
< VB Age
24 CD Age
weeks NNS Age
of IN Age
age NN Age
. . None
Healthy NNP Condition
infants NNS Age
aged VBD Age
6 CD Age
to TO Age
< VB Age
16 CD Age
weeks NNS Age
and CC Age
16 CD Age
to TO Age
< VB Age
24 CD Age
weeks NNS Age
infants NNS None
aged VBD None
6 CD Age
to TO Age
< VB Age
16 CD Age
weeks NNS Age
those DT None
aged VBN None
16 CD Age
to TO Age
< VB Age
24 CD Age
weeks NNS Age
children NNS None
6 CD Age
to TO Age
< VB Age
16 CD Age
weeks NNS Age
of IN None
age NN None
infants NNS None
6 CD Age
to TO Age
< VB Age
24 CD Age
weeks NNS Age
of IN None
age NN None
. . None
infants NNS None
< VBP None
6 CD Age
months NNS Age
of IN None
age NN None
. . None
-DOCSTART- -X- N

autism NN None
in IN None
children NNS None
. . None
Sixty NNP None
children NNS None
with IN None
autism NN None
or CC None
Asperger NNP None
syndrome VBP None
( ( None
3-11 CD None
years NNS None
old JJ None
) ) None
-DOCSTART- -X- N

eyelid JJ Condition
skin NN Condition
following VBG None
trichloroacetic JJ None
acid JJ None
chemical NN None
peel NN None
. . None
phenol-peeled JJ Condition
patients NNS None
patients NNS None
undergoing JJ None
deep JJ Condition
eyelid NN Condition
peel NN Condition
in IN None
conjunction NN None
with IN None
a DT None
blepharoplasty NN None
10 CD Size
patients NNS None
standard JJ None
upper-eyelid JJ None
blepharoplasty NN None
. . None
-DOCSTART- -X- N

infants NNS Age
after IN None
revaccinated VBN None
hepatitis NN None
B NNP None
vaccine NN None
] NN None
Non-and-low JJ None
response NN None
infants NNS Age
born VBN None
in IN None
2004 CD Age
2005 CD Age
administered VBD None
3 CD None
doses NNS None
of IN None
HepB NNP None
at IN None
0 CD None
, , None
1 CD None
, , None
6 CD None
months NNS None
in IN None
Guangzhou NNP None
, , None
Beijing NNP None
and CC None
Zhejiang NNP None
non-and-low JJ None
response NN None
children NNS None
103 CD Size
non-and-low JJ None
response NN None
children NNS Age
-DOCSTART- -X- N

female JJ Condition
women NNS None
without IN None
previous JJ None
sexual JJ None
dysfunction NN None
. . None
Forty-nine JJ None
women NNS None
were VBD None
included VBN None
in IN None
the DT None
EE30/LNG150 NNP None
group NN None
and CC None
48 CD None
in IN None
the DT None
EE20/LNG100 NNP None
group NN None
. . None
-DOCSTART- -X- N

women NNS Sex
with IN None
coronary JJ Condition
disease NN Condition
: : None
coronary JJ Condition
heart NN Condition
disease NN Condition
in IN None
women NNS None
. . None
women NNS None
women NNS None
coronary JJ None
patients NNS None
. . None
Two CD Size
hundred VBD Size
thirty-seven JJ Size
consecutive JJ None
women NNS None
patients NNS None
, , None
aged VBD None
75 CD Age
years NNS Age
or CC None
younger JJR None
, , None
hospitalized VBN None
for IN None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
, , None
coronary JJ Condition
artery NN Condition
bypass NN Condition
grafting NN Condition
, , None
or CC None
percutaneous JJ Condition
coronary JJ Condition
intervention NN Condition
women NNS None
with IN None
coronary JJ Condition
heart NN Condition
disease NN Condition
-DOCSTART- -X- N

early JJ None
preintrusive JJ None
atherosclerosis NN None
. . None
nonsmoking VBG None
40- JJ None
to TO None
59-year-old JJ None
men NNS None
with IN None
previous JJ None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
146 CD None
subjects NNS None
subjects NNS None
not RB None
treated VBN None
with IN None
lipid-lowering JJ None
drugs NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
metastatic JJ None
gastric JJ None
cancer NN None
. . None
patients NNS None
with IN None
metastatic JJ None
gastric JJ None
adenocarcinoma NN None
. . None
134 CD None
eligible JJ None
patients NNS None
-DOCSTART- -X- N

schizophrenia NN Condition
patients NNS None
. . None
20 CD Condition
schizophrenia NN Condition
patients NNS None
-DOCSTART- -X- N

volunteers NNS None
. . None
Single NNP None
university NN None
hospital NN None
. . None
Ten CD None
male NN None
volunteers NNS None
aged VBN None
18-28 JJ None
( ( None
mean JJ None
22 CD None
) ) None
years NNS None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
noncardiac JJ None
surgery NN None
. . None
noncardiac JJ None
surgery NN None
. . None
patients NNS None
with IN None
, , None
or CC None
at IN None
risk NN None
for IN None
, , None
atherosclerotic JJ None
disease NN None
who WP None
were VBD None
undergoing VBG None
noncardiac JJ None
surgery NN None
. . None
10,010 CD None
patients NNS None
at IN None
135 CD None
centers NNS None
in IN None
23 CD None
countries NNS None
were VBD None
enrolled VBN None
. . None
329 CD None
patients NNS None
patients NNS None
undergoing JJ None
noncardiac JJ None
surgery NN None
-DOCSTART- -X- N

population-based JJ None
cancer NN Condition
registry NN None
United NNP None
States NNPS None
population-based JJ None
registries NNS None
postmenopausal JJ Condition
women NNS None
with IN None
node JJ Condition
negative JJ Condition
breast NN Condition
cancer NN Condition
. . Condition
140 CD Size
subjects NNS None
in IN None
this DT None
single JJ None
institution NN None
study NN None
, , None
the DT None
Wisconsin NNP None
Cancer NNP Condition
Reporting NNP None
System NNP None
( ( None
WCRS NNP None
) ) None
, , None
a DT None
population-based JJ None
cancer NN Condition
registry NN None
, , None
was VBD None
used VBN None
. . None
3,585 CD None
women NNS None
who WP None
met VBD None
the DT None
study NN None
criteria NNS None
with IN None
respect NN None
to TO None
age NN None
, , None
stage NN None
, , None
and CC None
previous JJ None
therapy NN None
. . None
women NNS Sex
eligible JJ None
and CC None
interested JJ None
women NNS None
. . None
140 CD Size
women NNS None
were VBD None
entered VBN None
on IN None
study NN None
. . None
population-based JJ None
cancer NN Condition
registry NN None
-DOCSTART- -X- N

patients NNS None
with IN None
HCC NNP Condition
smaller JJR None
than IN None
4 CD None
cm NN None
. . None
hepatocellular JJ Condition
carcinoma NN Condition
( ( None
HCC NNP None
) ) None
? . None
4 CD None
cm NN None
, , None
in IN None
patients NNS None
with IN None
liver JJ Condition
cirrhosis NN Condition
. . None
METHODS NNP None
Thirty NNP None
patients NNS None
with IN None
single JJ None
HCC NNP None
? . None
4 CD None
cm NN None
in IN None
diameter NN None
were VBD None
randomly RB None
assigned VBN None
to TO None
one CD None
of IN None
two CD None
treatments NNS None
: : None
15 CD None
patients NNS None
were VBD None
treated VBN None
with IN None
PLA NNP None
source NN None
; : None
15 CD None
patients NNS None
were VBD None
treated VBN None
with IN None
RFA NNP None
electrode NN None
. . None
Patients NNS None
documented VBN None
in IN None
13 CD None
patients NNS None
( ( None
1 CD None
PLA NNP None
-DOCSTART- -X- N

outdoor JJ None
workers NNS None
' POS None
Outdoor NNP None
workers NNS None
outdoor JJ None
workers NNS None
. . None
Outdoor NNP None
workers NNS None
were VBD None
randomly RB None
allocated VBN None
to TO None
an DT None
intervention NN None
( ( None
n JJ None
= NNP None
65 CD Size
) ) None
or CC None
control VB None
group NN None
( ( None
n JJ None
= NNP None
77 CD Size
) ) None
. . None
outdoor JJ None
workers NNS None
. . None
-DOCSTART- -X- N

retinal JJ None
angiomatous JJ None
proliferation NN None
: : None
retinal JJ None
angiomatous JJ None
proliferation NN None
( ( None
RAP NNP None
) ) None
Thirty-four JJ None
patients NNS None
with IN None
RAP NNP None
with IN None
any DT None
stage NN None
of IN None
neovascularization NN None
patients NNS None
with IN None
RAP NNP None
. . None
-DOCSTART- -X- N

vascular JJ Condition
dementia NN Condition
: : None
patients NNS None
with IN None
vascular JJ None
dementia NN None
( ( None
VaD NNP None
) ) None
Patients NNPS None
( ( None
n=603 JJ Size
; : None
mean JJ Age
age NN Age
, , Age
73.9 CD Age
years NNS Age
; : None
55.2 CD None
% NN None
men NNS Sex
) ) None
with IN None
probable JJ None
( ( None
70.5 CD None
% NN None
) ) None
or CC None
possible JJ None
( ( None
29.5 CD None
% NN None
) ) None
VaD NNP None
, , None
according VBG None
to TO None
criteria NNS None
of IN None
the DT None
National NNP None
Institute NNP None
of IN None
Neurological NNP None
Disorders NNP None
and CC None
Stroke NNP None
( ( None
NINDS NNP None
) ) None
and CC None
the DT None
Association NNP None
Internationale NNP None
pour VBP None
la NN None
Recherche NNP None
et CC None
l'Enseignement JJ None
en NN None
Neurosciences NNP None
( ( None
AIREN NNP None
) ) None
-DOCSTART- -X- N

humans NNS None
. . None
20 CD None
healthy JJ None
, , None
nondiabetic JJ None
Caucasian NNP None
male NN None
volunteers NNS None
[ VBP None
27 CD None
+/- JJ None
5 CD None
( ( None
SD NNP None
) ) None
yr NN None
, , None
72 CD None
+/- JJ None
9 CD None
kg NN None
, , None
20 CD None
+/- JJ None
7 CD None
% NN None
body NN None
fat JJ None
] NNP None
-DOCSTART- -X- N

enamel JJ Condition
subsurface NN Condition
lesions NNS Condition
remineralized VBN None
by IN None
a DT None
sugar-free JJ None
chewing NN None
gum NN None
containing VBG None
casein JJ None
phosphopeptide-amorphous JJ None
calcium NN None
phosphate NN None
. . None
enamel JJ Condition
lesions NNS Condition
remineralized VBN None
in IN None
situ NN None
by IN None
a DT None
sugar-free JJ None
chewing NN None
gum NN None
containing VBG None
casein JJ None
phosphopeptide-amorphous JJ None
calcium NN None
phosphate NN None
nanocomplexes NNS None
( ( None
CPP-ACP JJ None
: : None
Recaldent NN None
) ) None
. . None
Subjects NNS None
wore RBR None
removable JJ None
palatal JJ None
appliances NNS None
with IN None
insets NNS None
of IN None
human JJ None
enamel NN None
containing VBG None
demineralized JJ None
subsurface NN Condition
lesions NNS Condition
and CC None
chewed VBD None
the DT None
gum NN None
for IN None
20 CD None
min NN None
4 CD None
times NNS None
per IN None
day NN None
for IN None
14 CD None
days NNS None
. . None
-DOCSTART- -X- N

elderly JJ Age
adults NNS Age
with IN None
newly RB None
diagnosed VBN None
acute RB Condition
myelogenous JJ Condition
leukemia NN Condition
. . None
elderly JJ Age
adults NNS Age
with IN None
newly RB None
diagnosed VBN None
acute RB None
myelogenous JJ None
leukemia NN None
( ( None
AML NNP Condition
) ) None
. . None
84 CD Size
adults NNS Age
( ( None
age NN None
range NN None
, , None
70-90 JJ Age
years NNS Age
; : None
median JJ Age
, , Age
76 CD Age
years NNS Age
) ) None
who WP None
were VBD None
not RB None
candidates NNS None
for IN None
conventional JJ None
chemotherapy NN None
. . None
40 CD None
patients NNS None
treated VBN None
-DOCSTART- -X- N

Out-patients NNS None
scheduled VBN None
for IN None
endoscopic NN None
ultrasonography NN None
were VBD None
randomly RB None
assigned VBN None
to TO None
oral JJ None
pre-medication NN None
with IN None
the DT None
anti-foam JJ None
agent NN None
, , None
dimethylpolysiloxane NN None
, , None
alone RB None
( ( None
treatment NN None
A NNP None
; : None
n JJ None
= NNP None
29 CD None
) ) None
, , None
with IN None
dimethylpolysiloxane JJ None
plus CC None
sodium JJ None
bicarbonate NN None
( ( None
treatment NN None
B NNP None
; : None
n CC None
= VB None
29 CD None
) ) None
or CC None
with IN None
dimethylpolysiloxane NN None
, , None
sodium NN None
bicarbonate NN None
and CC None
pronase NN None
( ( None
treatment NN None
C NNP None
; : None
n CC None
= VB None
29 CD None
) ) None
. . None
-DOCSTART- -X- N

acute NN None
exacerbated VBD None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
patients NNS None
] VBP None
acute NN None
exacerbated VBD None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
( ( None
COPD NNP None
) ) None
patients NNS None
. . None
Seventy-nine JJ None
patients NNS None
with IN None
acute JJ None
exacerbated VBN None
COPD NNP None
acute NN None
exacerbated VBN None
COPD NNP None
patients NNS None
. . None
-DOCSTART- -X- N

3790 CD None
heterosexual JJ None
HIV-1-serodiscordant JJ None
couples NNS None
participating VBG None
in IN None
two CD None
longitudinal JJ None
studies NNS None
of IN None
HIV-1 NNP None
incidence NN None
in IN None
seven CD None
African JJ None
countries NNS None
1314 CD None
couples NNS None
in IN None
which WDT None
the DT None
HIV-1-seronegative JJ None
partner NN None
was VBD None
female JJ None
couples NNS None
in IN None
which WDT None
the DT None
HIV-1-seronegative JJ None
partner NN None
was VBD None
male JJ None
-DOCSTART- -X- N

patients NNS None
with IN None
head NN None
and CC None
neck NN None
cancer NN None
: : None
124 CD None
patients NNS None
with IN None
histologically RB None
proven VBN None
locally RB None
advanced JJ None
non-nasopharyngeal JJ None
head NN None
and CC None
neck NN None
cancer NN None
( ( None
HNC NNP None
) ) None
patients NNS None
with IN None
locally RB None
advanced JJ None
HNC NNP None
-DOCSTART- -X- N

locally RB Condition
advanced JJ Condition
squamous JJ Condition
cell NN Condition
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
. . None
locally RB None
advanced JJ None
squamous JJ None
cell NN None
carcinoma NN None
of IN None
the DT None
head NN None
and CC None
neck NN None
. . None
One CD Size
hundred CD Size
and CC Size
fifty-three JJ Size
patients NNS None
( ( None
all DT None
of IN None
whom WP None
had VBD None
stage NN None
III NNP None
or CC None
IV NNP None
unresectable JJ Condition
disease NN Condition
with IN None
no DT None
distant JJ None
metastases NNS None
and CC None
who WP None
had VBD None
received VBN None
two CD None
cycles NNS None
of IN None
taxol NN None
and CC None
cisplatin NN None
chemotherapy NN None
) ) None
patients NNS None
with IN None
locally RB Condition
advanced VBN Condition
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
. . None
Forty NNP Size
children NNS Age
between IN None
the DT None
ages NNS None
4 CD Age
and CC Age
12 CD Age
years NNS None
with IN None
a DT None
DSM NNP None
IV-TR NNP None
clinical JJ None
diagnosis NN None
of IN None
autism NN Condition
were VBD None
recruited VBN None
. . None
The DT None
children NNS Age
presented VBN None
with IN None
a DT None
chief JJ None
complaint NN None
of IN None
severely RB None
disruptive JJ None
symptoms NNS None
related VBN None
to TO None
autistic JJ Condition
disorder NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
. . None
-DOCSTART- -X- N

in IN None
humans NNS None
with IN None
naloxone NN None
, , None
the DT None
opioid JJ None
antagonist NN None
. . None
12 CD Size
healthy JJ None
male NN Size
volunteers NNS None
were VBD None
included VBN None
human JJ None
volunteers NNS None
-DOCSTART- -X- N

502 CD Size
adults NNS None
with IN None
seasonal JJ Condition
allergic JJ Condition
rhinitis NN Condition
of IN None
at IN None
least JJS None
2 CD None
years NNS None
' POS None
duration NN None
. . None
patients NNS None
underwent VBP None
between IN None
one CD None
and CC None
five CD None
priming NN None
sessions NNS None
with IN None
exposure NN None
to TO None
3,500 CD None
grains/m NN None
( ( None
3 CD None
) ) None
( ( None
+/-500 JJ None
) ) None
of IN None
ragweed NN None
pollen NN None
in IN None
an DT None
environmental JJ None
exposure NN None
chamber NN None
. . None
Patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
unresectable JJ None
pancreatic JJ None
adenocarcinoma NN None
. . None
Advanced NNP None
pancreatic JJ None
cancer NN None
Patients NNS None
with IN None
histological/cytological JJ None
proven NN None
inoperable JJ None
adenocarcinoma NN None
of IN None
the DT None
head NN None
of IN None
pancreas NNS None
were VBD None
randomised VBN None
to TO None
receive VB None
KAb NNP None
201 CD None
Between NNP None
February NNP None
2003 CD None
and CC None
July NNP None
2005 CD None
, , None
25 CD None
patients NNS None
were VBD None
enrolled VBN None
. . None
Nineteen JJ None
patients NNS None
were VBD None
randomised VBN None
, , None
9 CD None
to TO None
the DT None
intravenous JJ None
and CC None
10 CD None
to TO None
the DT None
intra-arterial JJ None
arms NNS None
. . None
-DOCSTART- -X- N

three CD None
power NN None
toothbrushes NNS None
. . None
After IN None
refraining VBG None
from IN None
all DT None
oral JJ None
hygiene NN None
procedures NNS None
for IN None
23-25 JJ None
hours NNS None
, , None
subjects NNS None
received VBD None
an DT None
oral JJ None
tissue NN None
examination NN None
A DT None
total NN None
of IN None
79 CD Size
subjects NNS None
( ( None
28 CD Size
males NNS Sex
and CC None
51 CD Size
females NNS Sex
) ) None
were VBD None
enrolled VBN None
and CC None
completed VBN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

allogeneic JJ None
marrow NN None
transplantation NN None
compared VBN None
with IN None
blood NN None
stem NN None
cell NN None
transplantation NN None
. . None
recipients NNS None
of IN None
blood NN None
stem NN None
cells NNS None
recipients NNS None
of IN None
marrow NN None
. . None
115 CD None
patients NNS None
randomly RB None
assigned VBN None
to TO None
receive VB None
either DT None
allogeneic JJ None
marrow NN None
or CC None
filgrastim-mobilized JJ None
blood NN None
stem NN None
cell NN None
transplantation NN None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
relapsing-remitting JJ Condition
multiple JJ Condition
sclerosis NN Condition
: : Condition
a DT Condition
multicentre NN Condition
patients NNS None
with IN None
relapsing-remitting JJ None
multiple JJ None
sclerosis NN None
The DT None
study NN None
was VBD None
done VBN None
in IN None
51 CD None
centres NNS None
in IN None
nine CD None
countries NNS None
. . None
Inclusion NN None
criteria NNS None
were VBD None
one CD None
or CC None
more JJR None
relapses NNS None
in IN None
the DT None
year NN None
before IN None
entry NN None
and CC None
at IN None
least JJS None
one CD None
gadolinium NN None
enhancing NN None
( ( None
GdE NNP None
) ) None
lesion NN None
on IN None
screening VBG None
MRI NNP None
. . None
Of IN None
720 CD None
patients NNS None
screened VBD None
, , None
306 CD Size
eligible JJ None
patients NNS None
were VBD None
enrolled VBN None
. . None
Patients NNS None
, , None
aged VBN None
18-50 CD Age
years NNS None
In IN None
patients NNS None
with IN None
relapsing-remitting JJ None
multiple JJ None
sclerosis NN None
-DOCSTART- -X- N

healthy JJ Condition
adult NN Age
subjects NNS None
multiple JJ None
protease NN None
inhibitor NN None
( ( None
PI NNP None
) ) None
-experienced VBD None
patients NNS None
infected VBN None
with IN None
human JJ None
immunodeficiency NN None
virus NN None
type NN None
1 CD None
. . None
Forty-two NNP Size
healthy JJ Condition
adult NN Age
subjects NNS None
were VBD None
enrolled VBN None
-DOCSTART- -X- N

hypertension NN Condition
emergencies NNS Condition
] VBP None
hypertensive JJ Condition
emergencies NNS Condition
. . None
During IN None
hypertensive JJ Condition
crises NNS Condition
( ( Condition
systolic JJ Condition
blood NN Condition
pressure NN Condition
exceeding VBG Condition
200 CD Condition
mmHg NN Condition
and CC Condition
diastolic JJ Condition
blood NN Condition
pressure NN Condition
exceeding VBG Condition
115 CD Condition
mmHg NN Condition
) ) None
forty NN Size
hypertensive JJ Condition
patients NNS None
hypertensive JJ Condition
emergencies NNS Condition
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
high-risk JJ Condition
coronary JJ Condition
artery NN Condition
bypass NN Condition
graft NN Condition
surgery NN Condition
: : None
patients NNS None
with IN None
obstructive JJ Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
; : None
high-risk JJ None
patients NNS None
High-risk JJ Condition
patients NNS Condition
undergoing VBG Condition
CABG NNP Condition
surgery NN Condition
3023 CD Size
patients NNS None
were VBD None
enrolled VBN None
at IN None
130 CD None
sites NNS None
in IN None
Canada NNP None
, , None
the DT None
United NNP None
States NNPS None
, , None
and CC None
Germany NNP None
between IN None
October NNP None
2006 CD None
and CC None
September NNP None
2007 CD None
, , None
with IN None
results NNS None
anticipated VBN None
shortly RB None
after IN None
completion NN None
of IN None
90-day JJ None
follow-up NN None
in IN None
March NNP None
2008 CD None
. . None
-DOCSTART- -X- N

obese JJ Condition
patients NNS Condition
Sixty NNP Condition
obese JJ Condition
women NNS Condition
were VBD Condition
included VBN Condition
in IN Condition
the DT Condition
study NN Condition
. . Condition
were VBD None
divided VBN None
into IN None
2 CD None
equal JJ None
groups-the JJ None
-DOCSTART- -X- N

status NN None
of IN None
infants NNS None
fed VBN None
soy-based JJ None
formulas NNS None
with IN None
or CC None
without IN None
added JJ None
nucleotides NNS None
for IN None
1 CD None
year NN None
: : None
Infants NNPS None
fed VBD None
a DT None
soy JJ None
protein NN None
isolate-based JJ None
formula NN None
soy-fed JJ None
infants NNS None
infants NNS None
fed VBN None
soy JJ None
protein NN None
isolate NN None
formulas NNS None
with IN None
and CC None
without IN None
added VBN None
nucleotides NNS None
for IN None
1 CD None
year NN None
. . None
Newborn NNP None
, , None
term NN None
infants NNS None
studied VBN None
in IN None
a DT None
masked JJ None
12-month JJ None
feeding VBG None
trial NN None
( ( None
n JJ None
= NN None
94 CD None
, , None
n RB None
= VBZ None
92 CD None
) ) None
. . None
nonrandomized JJ None
human JJ None
milk/formula-fed JJ None
cohort NN None
( ( None
n JJ None
= NNP None
81 CD None
) ) None
soy JJ None
formula NN None
and CC None
human JJ None
milk/formula-fed JJ None
infants NNS None
infants NNS None
fed VBN None
soy JJ None
formula NN None
Infants NNPS None
fed VBD None
this DT None
commercial JJ None
soy NN None
formula NN None
human JJ None
milk/formula-fed JJ None
infants NNS None
-DOCSTART- -X- N

12 CD None
healthy JJ None
male NN None
volunteers NNS None
Six CD None
participants NNS None
-DOCSTART- -X- N

FIGO NNP Condition
stage NN Condition
I PRP Condition
endometrial JJ Condition
carcinoma NN Condition
with IN None
myometrial JJ Condition
invasion NN Condition
. . None
FIGO NNP Condition
stage NN Condition
I PRP Condition
endometrial JJ Condition
carcinoma NN Condition
with IN None
myometrial JJ Condition
invasion NN Condition
patients NNS None
62 CD Size
patients NNS None
who WP None
entered VBD None
the DT None
study NN None
Five CD None
patients NNS None
had VBD None
a DT None
relapse NN None
: : None
FIGO NNP Condition
stage NN Condition
I PRP Condition
endometrial JJ Condition
carcinoma NN Condition
with IN None
myometrial JJ Condition
invasion NN Condition
. . None
-DOCSTART- -X- N

25 CD None
eyes NNS None
of IN None
25 CD None
patients NNS None
suffering VBG None
from IN None
bilateral JJ None
primary JJ None
open-angle JJ None
glaucoma NN None
( ( None
POAG NNP None
) ) None
before IN None
and CC None
after IN None
argon-laser JJ None
trabeculoplasty NN None
. . None
-DOCSTART- -X- N

cognition NN None
in IN None
the DT None
elderly JJ None
: : None
Participants NNS None
in IN None
the DT None
Age-Related JJ None
Eye NNP None
Disease NNP None
Study NNP None
2,166 CD None
elderly JJ None
persons NNS None
after IN None
a DT None
median NN None
of IN None
6.9 CD None
years NNS None
of IN None
treatment NN None
. . None
-DOCSTART- -X- N

autism NN None
preschool NN Age
children NNS Age
with IN Age
autism NN Age
Participants NNS None
were VBD None
58 CD None
children NNS None
( ( None
46 CD None
boys NNS None
) ) None
with IN None
autism NN None
between IN None
3 CD None
and CC None
4 CD None
years NNS None
of IN None
age NN None
. . None
young JJ None
children NNS None
with IN None
autism NN None
-DOCSTART- -X- N

Treatment NN None
of IN None
renal JJ Condition
failure NN Condition
associated VBN None
with IN None
multiple JJ Condition
myeloma NN Condition
. . None
patients NNS None
with IN None
multiple JJ None
myeloma NN None
Twenty-one CD Size
patients NNS None
with IN None
active JJ None
myeloma NN Condition
and CC None
progressive JJ None
renal JJ None
failure NN None
Of IN None
5 CD Size
patients NNS None
who WP None
were VBD None
oliguric JJ None
and CC None
undergoing JJ None
dialysis NN None
at IN None
presentation NN None
Of IN None
16 CD Size
polyuric JJ None
patients NNS None
-DOCSTART- -X- N

fresh JJ Age
scars NNS Age
after IN Age
thoracic NN Age
surgery NN Age
in IN Age
children NNS Age
and CC Age
adolescents NNS Age
. . Age
45 CD None
young JJ None
patients NNS None
who WP None
had VBD None
undergone JJ None
thoracic NN None
surgery NN None
. . None
scar NN None
treatment NN None
after IN None
thoracic NN None
surgery NN None
. . None
-DOCSTART- -X- N

after IN None
pediatric JJ None
umbilical JJ None
hernia NN None
repair NN None
. . None
Tertiary-referral JJ None
urban JJ None
children NNS None
's POS None
hospital NN None
. . None
Eligible JJ None
children NNS None
3 CD None
to TO None
12 CD None
years NNS None
of IN None
age NN None
undergoing JJ None
elective JJ None
umbilical JJ None
hernia NN None
repair NN None
from IN None
November NNP None
16 CD None
, , None
2009 CD None
, , None
through IN None
May NNP None
31 CD None
, , None
2011 CD None
. . None
-DOCSTART- -X- N

chronic JJ None
hepatitis NN None
B NNP None
patients NNS None
chronic JJ None
hepatitis NN None
B NNP None
patients NNS None
treated VBD None
with IN None
different JJ None
doses NNS None
of IN None
recombinant JJ None
hepatitis NN None
B NNP None
vaccine NN None
. . None
Seventy-two NNP None
chronic JJ None
hepatitis NN None
B NNP None
patients NNS None
who WP None
did VBD None
not RB None
use VB None
any DT None
anti-HBV JJ None
drugs NNS None
within IN None
6 CD None
months NNS None
The DT None
patients NNS None
in IN None
different JJ None
groups NNS None
were VBD None
treated VBN None
with IN None
different JJ None
doses NNS None
of IN None
recombinant JJ None
hepatitis NN None
B NNP None
vaccine NN None
patients NNS None
who WP None
were VBD None
ELISPOT NNP None
positive JJ None
patients NNS None
with IN None
chronic JJ None
hepatitis NN None
B NNP None
. . None
-DOCSTART- -X- N

occlusal JJ None
surfaces NNS None
Thirty NNP Size
premolars NNS None
cavities NNS None
-DOCSTART- -X- N

September NNP None
1996 CD None
to TO None
October NNP None
1998 CD None
, , None
we PRP None
randomly RB None
allocated VBD None
49 CD None
legs NNS None
to TO None
compression VB None
sclerotherapy NN None
and CC None
49 CD None
legs NNS None
to TO None
ambulatory JJ None
phlebectomy NN None
. . None
Eighty-two JJ None
patients NNS None
were VBD None
included VBN None
, , None
of IN None
whom WP None
16 CD None
were VBD None
included VBN None
with IN None
both DT None
of IN None
their PRP$ None
legs NNS None
. . None
The DT None
number NN None
of IN None
treated JJ None
legs NN None
was VBD None
therefore RB None
98 CD None
two CD None
patients NNS None
-DOCSTART- -X- N

postmenopausal NN None
patients NNS None
with IN None
metastatic JJ Condition
breast NN Condition
carcinoma NN Condition
: : None
Breast NNP Condition
cancer NN Condition
patients NNS None
with IN Condition
prior JJ Condition
response NN Condition
to TO Condition
endocrine VB Condition
therapy NN Condition
post NN None
menopausal NN None
patients NNS None
who WP None
had VBD None
disease NN None
progression NN None
after IN None
receiving VBG None
antiestrogen NN None
therapy NN None
either DT None
for IN None
metastatic JJ None
disease NN None
or CC None
as IN None
adjuvant JJ None
therapy NN None
. . None
In IN None
2 CD None
multiinstitutional JJ None
prospective JJ None
trials NNS None
, , None
683 CD Size
postmenopausal NN None
patients NNS None
postmenopausal NN None
patients NNS None
with IN None
metastatic JJ None
breast NN None
carcinoma NN None
-DOCSTART- -X- N

prostate NN Condition
disease NN Condition
. . None
Benign NNP Condition
Prostatic NNP Condition
Hyperplasia NNP Condition
approximately RB None
20 CD None
% NN None
of IN None
patients NNS None
-DOCSTART- -X- N

Bovine NNP Condition
carotid NN Condition
artery NN Condition
heterografts NNS Condition
versus VBP None
polytetrafluoroethylene JJ Condition
grafts NNS None
. . None
diabetic JJ Condition
patients NNS None
nondiabetic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

76 CD Size
patients NNS None
undergoing JJ None
primary JJ Condition
total JJ Condition
knee NN Condition
arthroplasty NN Condition
were VBD None
assigned VBN None
-DOCSTART- -X- N

surgical JJ None
patients NNS None
with IN None
serious JJ Condition
systemic JJ Condition
infection NN Condition
. . None
patients NNS None
with IN None
serious JJ Condition
systemic JJ Condition
infection NN Condition
. . None
Thirty-seven JJ Size
surgical JJ None
patients NNS None
were VBD None
evaluated VBN None
for IN None
efficacy NN None
and CC None
46 CD Size
patients NNS None
were VBD None
evaluated VBN None
for IN None
toxicity NN None
. . None
patients NNS None
who WP None
have VBP None
serious JJ Condition
infections NNS Condition
after IN None
surgery NN None
. . None
-DOCSTART- -X- N

mild NN Condition
to TO Condition
moderate VB Condition
essential JJ Condition
hypertensive JJ Condition
black JJ Condition
patients NNS Condition
. . Condition
mild VB None
to TO None
moderate VB None
essential JJ None
hypertensive JJ None
black JJ None
patients NNS None
. . None
mild NN None
to TO None
moderate VB None
essential JJ None
hypertensive JJ None
black JJ None
patients NNS None
-DOCSTART- -X- N

infants NNS None
at IN None
risk NN None
of IN None
allergic JJ None
disease NN None
. . None
Sixty-one JJ None
mother-infant JJ None
pairs NNS None
were VBD None
included VBN None
, , None
special JJ None
emphasis NN None
being VBG None
placed VBN None
on IN None
the DT None
maternal JJ None
allergic NN None
status NN None
. . None
infants NNS None
of IN None
allergic NN None
, , None
atopic NN None
mothers NNS None
Allergic NNP None
mothers NNS None
-DOCSTART- -X- N

The DT None
Central NNP None
Medical NNP None
Unit NNP None
( ( None
CMU NNP None
) ) None
-- : None
a DT None
freestanding JJ None
primary NN None
care NN None
medical JJ None
clinic NN None
staffed VBN None
by IN None
physicians NNS None
and CC None
nurse JJ None
practitioners NNS None
. . None
Injection NNP None
drug NN None
users NNS None
( ( None
IDUs NNP None
) ) None
seeking VBG None
substance NN Condition
abuse NN Condition
treatment NN None
between IN None
the DT None
ages NNS None
of IN None
18 CD Age
and CC Age
50 CD Age
years NNS Age
who WP None
were VBD None
addicted VBN None
to TO None
opioids NNS None
( ( None
e.g. NN None
heroin NN None
) ) None
and CC None
not RB None
currently RB None
in IN None
drug NN None
treatment NN None
. . None
One CD Size
hundred VBD Size
forty JJ Size
opioid-addicted JJ None
IDUs NNP None
were VBD None
referred VBN None
to TO None
the DT None
medical JJ None
clinic NN None
for IN None
AOD NNP None
. . None
Among IN None
the DT None
125 CD Size
patients NNS None
who WP None
enrolled VBD None
in IN None
the DT None
study NN None
, , None
57 CD Size
selected VBN None
clonidine NN None
and CC None
68 CD Size
selected VBN None
clonidine/naltrexone NN None
. . None
IDUs NNP None
who WP None
are VBP None
addicted VBN Condition
to TO Condition
opioids NNS Condition
. . None
-DOCSTART- -X- N

cardiovascular JJ None
and CC None
cardiorespiratory JJ None
cardiovascular NN None
and CC None
cardiorespiratory NN None
adaptations NNS None
in IN None
college NN None
athletes NNS None
and CC None
compared VBN None
two CD None
concurrent JJ None
exercise NN None
( ( None
CE NNP None
) ) None
protocols NNS None
. . None
performed VBN None
on IN None
30 CD Size
women NNS Age
( ( None
mean JJ None
age NN None
19.6 CD Age
years NNS None
) ) None
and CC None
20 CD Size
men NNS Age
( ( None
20.4 CD Age
years NNS None
) ) None
. . None
-DOCSTART- -X- N

apical JJ None
hypertrophic JJ None
cardiomyopathy NN None
: : None
Thirteen JJ None
patients NNS None
who WP None
had VBD None
predominant JJ None
hypertrophy NN None
( ( None
> CD None
or CC None
= VB None
15 CD None
mm NN None
) ) None
at IN None
the DT None
apical JJ None
level NN None
without IN None
the DT None
spadelike NN None
configuration NN None
underwent JJ None
NMR NNP None
imaging VBG None
twice RB None
before RB None
and CC None
after IN None
54+/-10 JJ None
months NNS None
' POS None
follow-up NN None
. . None
-DOCSTART- -X- N

randomised VBD None
multicentre JJ None
trial NN None
with IN None
the DT None
birth NN None
trainer NN None
perineal JJ Condition
trauma NN Condition
. . Condition
Randomised VBD None
, , None
single-blind JJ Condition
multicentre NN None
trial NN None
in IN None
four CD None
university NN None
hospitals NNS None
in IN None
Germany NNP None
including VBG None
276 CD Size
primigravidae NN None
. . None
two CD None
groups NNS None
-DOCSTART- -X- N

menopausal NN None
symptoms NNS None
in IN None
women NNS None
treated VBN None
with IN None
soy JJ None
isoflavones NNS None
. . None
women NNS None
who WP None
do VBP None
and CC None
who WP None
do VBP None
not RB None
produce VB None
equol NN None
96 CD None
healthy JJ None
menopausal NN None
women NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
malignant JJ None
pleural JJ None
mesothelioma NN None
( ( None
MS01 NNP None
) ) None
: : None
409 CD None
patients NNS None
with IN None
malignant JJ None
pleural JJ None
mesothelioma NN None
, , None
from IN None
76 CD None
centres NNS None
in IN None
the DT None
UK NNP None
and CC None
two CD None
in IN None
Australia NNP None
-DOCSTART- -X- N

periodontal JJ None
infections NNS None
with IN None
systemic JJ None
antimicrobial JJ None
agents NNS None
Patients NNS None
who WP None
had VBD None
high JJ None
proportions NNS None
of IN None
spirochetes NNS None
, , None
i.e. FW None
> FW None
20 CD None
% NN None
, , None
in IN None
plaques NNS None
removed VBN None
from IN None
diseased JJ None
periodontal NN None
sites NNS None
18 CD Size
patients NNS None
-DOCSTART- -X- N

microvascular JJ None
complications NNS None
of IN None
type NN Condition
1 CD Condition
diabetes NNS Condition
mellitus RB Condition
. . None
microvascular JJ None
complications NNS None
of IN None
type NN Condition
1 CD Condition
diabetes NNS Condition
mellitus RB Condition
. . None
type NN None
1 CD None
diabetes NNS None
mellitus NN None
-DOCSTART- -X- N

psychosis NN Condition
first JJ Condition
episode NN Condition
psychosis NN Condition
. . None
untreated JJ None
psychosis NN None
( ( None
DUP NNP None
) ) None
First NNP None
Episode NNP None
Psychosis NNP None
( ( None
FEP NNP None
) ) None
patients NNS None
Seventy-seven NNP Size
consecutively RB None
admitted VBD None
, , None
drug-na?ve JJ None
patients NNS None
with IN None
FEP NNP None
of IN None
untreated JJ None
negative JJ None
symptoms NNS None
( ( None
DUNS NNP None
) ) None
or CC None
a DT None
short JJ None
duration NN None
of IN None
untreated JJ None
positive JJ None
symptoms NNS None
( ( None
DUPS NNP None
) ) None
of IN None
FEP NNP None
patients NNS None
. . None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Age
's POS Age
behavior NN None
. . None
behavioral JJ None
and CC None
emotional JJ None
disturbances NNS None
in IN None
Thai NNP None
autistic JJ None
children NNS None
. . None
The DT None
study NN None
was VBD None
conducted VBN None
at IN None
the DT None
Rehabilitation NNP None
Centre NNP None
of IN None
the DT None
Thai NNP None
Red NNP None
Cross NNP None
Society NNP None
. . None
A NNP None
total NN None
of IN None
60 CD Size
autistic JJ Condition
children NNS None
between IN None
the DT None
ages NNS None
of IN None
3 CD Age
and CC Age
10 CD Age
completed VBD None
this DT None
study NN None
. . None
Sixty NNP Size
( ( Size
60 CD Size
) ) Size
autistic JJ None
children NNS None
, , None
mean JJ None
age NN None
4.67 CD Age
+/- JJ Age
1.82 CD Age
, , None
were VBD None
recruited VBN None
. . None
Thailand NNP None
. . None
-DOCSTART- -X- N

robot-assisted JJ None
endoscopic NN None
thyroidectomy NN None
Postoperative NNP Condition
pain NN Condition
following VBG Condition
endoscopic NN Condition
thyroidectomy NN Condition
124 CD Size
women NNS Size
21-60 CD None
years NNS None
of IN None
age NN None
who WP None
were VBD None
scheduled VBN None
for IN None
elective JJ None
gasless NN None
robot-assisted JJ None
endoscopic NN None
thyroidectomy NN None
via IN None
the DT None
transaxillary JJ None
approach NN None
. . None
pain NN None
management NN None
in IN None
patients NNS None
with IN None
moderate JJ Condition
to TO Condition
severe VB Condition
postoperative JJ Condition
pain NN Condition
after IN None
gasless JJ None
robot-assisted JJ None
endoscopic NN None
thyroidectomy NN None
performed VBD None
via IN None
the DT None
transaxillary JJ None
approach NN None
. . None
-DOCSTART- -X- N

post NN None
thrombotic JJ None
syndrome NN None
. . None
acute JJ None
deep JJ None
venous JJ None
thrombosis NN None
( ( None
DVT NNP None
) ) None
Sixty-nine JJ None
consecutive JJ None
patients NNS None
with IN None
acute JJ None
DVT NNP None
documented VBN None
by IN None
duplex JJ None
ultrasonography NN None
Patients NNS None
were VBD None
followed VBN None
clinically RB None
at IN None
months NNS None
1 CD None
, , None
3 CD None
, , None
6 CD None
, , None
12 CD None
, , None
18 CD None
, , None
and CC None
24 CD None
after IN None
the DT None
diagnosis NN None
of IN None
DVT NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
relapsed JJ None
multiple JJ None
myeloma NN None
. . None
59 CD Size
patients NNS None
with IN None
relapsed JJ None
multiple JJ None
myeloma NN None
control NN None
and CC None
interferon NN None
patients NNS None
. . None
-DOCSTART- -X- N

hypoxemia NN Condition
we PRP None
studied VBD None
20 CD Size
healthy JJ None
men NNS Sex
, , None
aged VBD None
20 CD Age
to TO Age
34 CD Age
years NNS None
, , None
using VBG None
a DT None
tight-fitting JJ None
face NN None
mask NN None
and CC None
an DT None
isocapnic JJ None
partial NN None
rebreathing NN None
system NN None
( ( None
a DT None
modified VBN None
anesthesia NN None
machine NN None
) ) None
-DOCSTART- -X- N

ASA NNP Condition
Class NNP Condition
I-III NNP Condition
female JJ Sex
patients NNS Condition
about IN Condition
to TO Condition
undergo VB Condition
major JJ Condition
abdominal JJ Condition
gynaecological JJ Condition
surgery NN Condition
or CC Condition
vaginal JJ Condition
hysterectomy NN Condition
. . None
-DOCSTART- -X- N

population-based JJ None
screening NN None
study NN None
. . None
prostate NN Condition
cancer NN Condition
and CC Condition
benign JJ Condition
conditions NNS Condition
of IN Condition
the DT Condition
prostate NN Condition
( ( None
Rotterdam NNP None
section NN None
of IN None
the DT None
European NNP None
Randomized NNP None
Study NNP None
of IN None
Screening NNP None
for IN None
Prostate NNP None
Cancer NNP None
) ) None
10,865 CD Size
men NNS None
have VBP None
been VBN None
screened VBN None
biopsy NN None
results NNS None
of IN None
1202 CD Size
men NNS None
with IN None
PSA NNP Condition
levels NNS Condition
of IN Condition
4 CD Condition
ng/mL NNS Condition
or CC Condition
more JJR Condition
1202 CD Size
men NNS None
studied VBD None
, , None
361 CD Size
cases NNS None
of IN None
prostate NN None
cancer NN None
-DOCSTART- -X- N

Eastern NNP None
Cooperative NNP None
Oncology NNP None
Group NNP None
patients NNS None
with IN None
metastatic JJ Condition
breast NN Condition
cancer NN Condition
. . None
162 CD Size
women NNS None
( ( None
90 CD Size
premenopausal NN Condition
and CC None
72 CD Size
postmenopausal NN Condition
) ) None
with IN None
metastatic JJ Condition
breast NN Condition
cancer NN Condition
Eastern JJ None
Cooperative NNP None
Oncology NNP None
Group NNP None
( ( None
ECOG NNP None
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
inflammatory JJ Condition
bowel NN Condition
disease NN Condition
Fifty-six JJ Size
outpatients NNS None
Thirty-nine JJ Size
subjects NNS None
completed VBD None
the DT None
study NN None
IBD NNP None
patients NNS None
-DOCSTART- -X- N

injection NN None
comfort NN None
cohesive JJ None
hyaluronic JJ None
acid NN None
filler NN None
three CD None
centers NNS None
enrolled VBD None
60 CD Size
subjects NNS None
, , None
injected VBN None
with IN None
both DT None
products NNS None
, , None
randomly RB None
assigned VBN None
to TO None
left VBD None
or CC None
right JJ None
nasolabial JJ None
fold NN None
. . None
Subjects NNS None
used VBD None
a DT None
visual JJ None
analog NN None
scale NN None
( ( None
0-10 JJ None
) ) None
for IN None
pain NN None
assessment NN None
. . None
-DOCSTART- -X- N

boys NNS Sex
with IN None
fragile JJ Condition
x JJ Condition
syndrome NN Condition
: : None
boys NNS Sex
with IN None
fragile JJ Condition
X NNP Condition
syndrome NN Condition
. . None
Twenty NNP Size
boys VBZ Age
with IN None
fragile JJ Condition
X NNP Condition
syndrome NN Condition
-DOCSTART- -X- N

Deep JJ Condition
vein NN Condition
thrombosis NN Condition
after IN None
major JJ Condition
reconstructive JJ Condition
spinal NN Condition
surgery NN Condition
. . None
deep JJ Condition
vein NN Condition
thrombosis NN Condition
after IN None
major JJ Condition
adult NN Condition
spinal JJ Condition
surgery NN Condition
major JJ Condition
adult NN Condition
spinal JJ Condition
surgery NN Condition
. . None
Three CD Size
hundred VBD Size
twenty-nine JJ Size
patients NNS None
One CD Size
hundred VBD Size
ten JJ Size
patients NNS None
-DOCSTART- -X- N

second-degree JJ Condition
burns NNS Condition
. . None
burn NN Condition
patients NNS Condition
second-degree JJ Condition
burn NN Condition
wounds NNS Condition
. . None
Seventy-two JJ Size
cases NNS None
of IN None
patients NNS None
with IN None
acute JJ Condition
second-degree JJ Condition
burns NNS Condition
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
patients NNS None
with IN None
less JJR None
than IN None
30 CD None
% NN None
TBSA NNP None
covered VBD None
with IN None
xenogenic JJ None
acellular JJ None
dermal NN None
matrix NN None
. . None
patients NNS None
with IN None
less JJR None
than IN None
30 CD None
% NN None
TBSA NNP None
covered VBD None
with IN None
betadine JJ None
ointment NN None
gauzes NNS None
. . None
patients NNS None
with IN None
more JJR None
than IN None
30 CD None
% NN None
TBSA NNP None
covered VBD None
with IN None
porcine JJ None
acellular JJ None
dermal NN None
matrix NN None
. . None
patients NNS None
with IN None
more JJR None
than IN None
30 CD None
% NN None
TBSA NNP None
covered VBD None
with IN None
betadine JJ None
ointment NN None
gauzes NNS None
. . None
second-degree JJ Condition
burn NN Condition
wound NN Condition
-DOCSTART- -X- N

after IN None
matched VBN None
donor NN Condition
allogeneic NN Condition
HCT NNP Condition
. . None
matched VBN None
, , None
related VBN None
donor NN None
( ( None
MRD NNP None
) ) None
allogeneic VBZ None
hematopoietic JJ None
cell NN None
transplantation NN None
( ( None
HCT NNP None
) ) None
recipients NNS None
. . None
304 CD None
randomized JJ None
subjects NNS None
. . None
after IN None
MRD NNP None
HCT NNP None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN Condition
: : None
childhood VB None
neurodevelopmental JJ Condition
disorders NNS Condition
. . Condition
13 CD Size
children NNS None
( ( None
aged VBN Age
5 CD Age
to TO Age
17 CD Age
years NNS Age
) ) None
with IN None
autistic JJ None
disorders NNS None
accompanied VBN None
by IN None
severe JJ Condition
tantrums NNS Condition
, , Condition
aggression NN Condition
, , Condition
or CC Condition
self-injurious JJ Condition
behavior NN Condition
. . None
children NNS None
with IN None
autism NN None
. . None
-DOCSTART- -X- N

proliferative JJ Condition
diabetic JJ Condition
retinopathy NN Condition
or CC Condition
severe JJ Condition
nonproliferative JJ Condition
diabetic JJ Condition
retinopathy NN Condition
Sixty JJ None
patients NNS None
with IN None
bilaterally RB None
symmetrical JJ None
proliferative JJ None
diabetic JJ None
retinopathy NN None
or CC None
severe JJ None
nonproliferative JJ None
diabetic JJ None
retinopathy NN None
-DOCSTART- -X- N

medical JJ Condition
intensive JJ Condition
care NN Condition
unit NN Condition
patients NNS Condition
. . Condition
critically RB None
ill JJ None
patients NNS None
; : None
The DT None
medical JJ None
intensive JJ None
care NN None
unit NN None
( ( None
ICU NNP None
) ) None
of IN None
a DT None
university NN None
hospital NN None
located VBN None
in IN None
a DT None
large JJ None
metropolitan JJ None
area NN None
. . None
A DT None
total NN None
of IN None
100 CD None
patients NNS None
who WP None
were VBD None
admitted VBN None
to TO None
the DT None
medical JJ None
ICU NNP None
, , None
required VBD None
arterial JJ None
line NN None
monitoring NN None
for IN None
clinical JJ None
purposes NNS None
, , None
and CC None
were VBD None
managed VBN None
by IN None
the DT None
ICU NNP None
medical JJ None
service NN None
. . None
Exclusion NNP None
criteria NNS None
included VBD None
active JJ None
bleeding NN None
or CC None
chronic JJ None
renal JJ None
failure NN None
at IN None
the DT None
time NN None
of IN None
ICU NNP None
admission NN None
. . None
critically RB None
ill JJ None
patients NNS None
critically RB None
ill JJ None
patients NNS None
-DOCSTART- -X- N

nasal JJ None
CPAP NNP None
. . None
( ( None
CPAP NNP None
) ) None
therapy NN None
Fifteen NNP None
patients NNS None
with IN None
mouth JJ None
leak JJ None
complaining NN None
of IN None
mouth NN None
dryness NN None
and CC None
nasal JJ None
obstruction NN None
six CD None
patients NNS None
. . None
-DOCSTART- -X- N

dermoid JJ Condition
cysts NNS Condition
-- : None
a DT None
ovarian JJ Condition
dermoid NN Condition
cysts NNS Condition
. . None
Thirty-eight JJ Size
women NNS Sex
with IN None
benign JJ Condition
ovarian JJ Condition
dermoid NN Condition
cyst NN Condition
dermoid JJ Condition
ovarian JJ Condition
cysts NNS Condition
-DOCSTART- -X- N

children NNS Age
and CC None
adolescents NNS Age
with IN None
GH NNP Condition
and CC Condition
cortisol JJ Condition
insufficiency NN Condition
. . None
young JJ Age
GH NNP Condition
deficient NN Condition
patients NNS None
children NNS Age
and CC None
adolescents NNS Age
with IN None
GH NNP Condition
and/or VBP Condition
cortisol JJ Condition
deficiency NN Condition
. . None
A NNP None
total NN None
of IN None
20 CD Size
patients NNS Size
( ( None
2-18 CD Age
years NNS Age
) ) None
fasted VBD None
for IN None
14 CD None
h NN None
( ( None
22.00-12.00 JJ None
h NN None
) ) None
on IN None
two CD None
occasions NNS None
Fourteen NNP Age
had VBD None
pituitary JJ Condition
hormone NN Condition
deficiency NN Condition
( ( Condition
PHD NNP Condition
) ) Condition
including VBG None
GH NNP Condition
deficiency NN Condition
( ( Condition
GHD NNP Condition
) ) Condition
. . None
Of IN None
the DT None
14 CD Size
patients NNS None
, , None
seven CD Size
were VBD None
ACTH NNP None
sufficient NN None
( ( None
PHDC+ NNP None
) ) None
and CC None
seven CD None
ACTH NNP Condition
deficient NN Condition
( ( Condition
PHDC- NNP Condition
) ) Condition
. . None
Six NNP Size
had VBD None
primary JJ Condition
adrenal JJ Condition
failure NN Condition
( ( Condition
PAF NNP Condition
) ) Condition
. . None
patients NNS None
with IN None
PHDC- NNP Condition
. . None
children NNS Age
and CC None
adolescents NNS Age
Patients NNS None
with IN None
PHD NNP Condition
-DOCSTART- -X- N

Histamine NNP Condition
intolerance-like NN Condition
symptoms NNS Condition
in IN None
healthy JJ Condition
volunteers NNS None
10 CD Size
healthy JJ None
females NNS Sex
( ( None
age NN None
range NN None
22-36 CD Age
years NNS Age
, , None
mean JJ None
29.1 CD None
+/- JJ None
5.4 CD None
) ) None
who WP None
were VBD None
hospitalized VBN None
and CC None
challenged VBN None
on IN None
two CD None
consecutive JJ None
days NNS None
with IN None
placebo NN None
( ( None
peppermint JJ None
tea NN None
) ) None
or CC None
75 CD None
mg NN None
of IN None
pure JJ None
histamine NN None
( ( None
equaling VBG None
124 CD None
mg JJ None
histamine NN None
dihydrochloride NN None
, , None
dissolved VBN None
in IN None
peppermint NN None
tea NN None
) ) None
. . None
healthy JJ None
females NNS Sex
without IN None
a DT None
history NN None
of IN None
food NN None
intolerance NN None
. . None
-DOCSTART- -X- N

Endotracheal NNP None
cuff NN None
pressure NN None
and CC None
tracheal NN None
mucosal NN None
blood NN None
flow NN None
: : None
four CD None
large JJ None
volume NN None
cuffs NNS None
. . None
Low JJ None
pressure NN None
cuffs NNS None
40 CD Size
patients NNS Condition
undergoing JJ Condition
surgery NN Condition
-DOCSTART- -X- N

premolars NNS None
restored VBN None
using VBG None
two CD None
dowel-and-core JJ None
systems NNS None
. . None
endodontically-treated JJ None
teeth NNS None
restored VBN None
with IN None
two CD None
dowel-core JJ None
systems NNS None
. . None
Thirty-two NNP Size
extracted VBD None
mandibular JJ None
first JJ None
premolars NNS None
root NN Condition
fractures NNS Condition
. . None
-DOCSTART- -X- N

laryngectomy NN Condition
female JJ Sex
laryngectomees NNS Condition
and/or VBP None
laryngectomees NNS Condition
with IN Condition
a DT Condition
hypotonic JJ Condition
pharyngoesophageal NN Condition
( ( Condition
PE NNP Condition
) ) Condition
segment NN Condition
six CD Size
laryngectomees NNS Condition
. . None
speech JJ Condition
intelligibility NN Condition
measurements NNS Condition
with IN None
12 CD None
listeners NNS None
female JJ Condition
laryngectomees NNS Condition
with IN Condition
a DT Condition
hypotonic JJ Condition
PE NNP Condition
segment NN Condition
male NN Condition
laryngectomees NNS Condition
-DOCSTART- -X- N

20 CD Size
heparinized JJ Condition
dogs NNS None
-DOCSTART- -X- N

standard-risk JJ None
patients NNS None
high-risk JJ None
patients NNS None
. . None
standard-risk JJ None
( ( None
SR NNP None
) ) None
patients NNS None
high-risk NN None
( ( None
HR NNP None
) ) None
patients NNS None
. . None
SR NNP None
patients NNS None
( ( None
localized JJ None
tumors NNS None
, , None
volume NN None
< VBD None
100 CD None
mL NN None
) ) None
HR $ None
patients NNS None
( ( None
volume NN None
> NNP None
or=100 VBZ None
mL NN None
or CC None
metastases NNS None
) ) None
total NN None
of IN None
647 CD None
patients NNS None
were VBD None
randomly RB None
assigned VBN None
: : None
79 CD None
SR NNP None
patients NNS None
were VBD None
assigned VBN None
to TO None
VAIA NNP None
, , None
76 CD None
SR NN None
patients NNS None
were VBD None
assigned VBN None
to TO None
VACA NNP None
, , None
240 CD None
HR NNP None
were VBD None
assigned VBN None
to TO None
VAIA NNP None
, , None
and CC None
252 CD None
HR NNP None
patients NNS None
were VBD None
assigned VBN None
to TO None
EVAIA NNP None
. . None
SR NNP None
group NN None
HR NNP None
group NN None
SR NNP None
patients NNS None
HR NNP None
patients NNS None
-DOCSTART- -X- N

children NNS None
with IN None
acute JJ Condition
diarrhoea NN Condition
. . None
children NNS None
with IN None
heavy JJ None
economic JJ None
burden NN None
for IN None
families NNS None
and CC None
society NN None
. . None
children NNS None
with IN None
acute JJ Condition
diarrhoea NN Condition
. . None
children NNS None
( ( None
age NN Age
3-36 CD Age
m NN Age
) ) None
with IN None
acute JJ None
diarrhoea NNS None
55 CD Size
children NNS None
in IN None
placebo NN None
group NN None
and CC None
52 CD Size
in IN None
synbiotic JJ None
group NN None
. . None
The DT None
two CD None
groups NNS None
were VBD None
similar JJ None
for IN None
demographic JJ None
and CC None
clinical JJ None
characteristics NNS None
. . None
-DOCSTART- -X- N

tuberculosis NN None
in IN None
an DT None
immigrant JJ None
population NN None
. . None
Immigrants NNS Condition
with IN None
LTBI NNP Condition
. . None
in IN None
Barcelona NNP None
, , None
Spain NNP None
, , None
from IN None
April NNP None
2001 CD None
to TO None
April NNP None
2005 CD None
. . None
590 CD Size
subjects NNS None
enrolled VBN None
-DOCSTART- -X- N

acute JJ None
appendicitis NN None
in IN None
women NNS None
of IN None
reproductive JJ None
age NN None
. . None
acute JJ None
appendicitis NN None
in IN None
women NNS None
of IN None
reproductive JJ None
age NN None
1991-1992 JJ None
. . None
Female JJ None
patients NNS None
between IN None
16 CD None
and CC None
45 CD None
years NNS None
suspected JJ None
acute JJ None
appendicitis NN None
. . None
-DOCSTART- -X- N

40 CD None
patients NNS None
were VBD None
allocated VBN None
specific JJ None
immunotherapy NN None
( ( None
hyposensitization NN None
) ) None
with IN None
partially RB None
purified VBN None
timothy JJ None
extract NN None
or CC None
two CD None
timothy JJ None
major JJ None
allergens NNS None
19 CD None
, , None
25 CD None
. . None
All DT None
patients NNS None
had VBD None
typical JJ None
grass NN None
pollen NN None
hay NN None
fever NN None
, , None
in IN None
27 CD None
% NN None
associated VBN None
with IN None
grass NN None
pollen NN None
asthma NN None
and CC None
in IN None
13 CD None
% NN None
with IN None
birch NN None
pollen NN None
allergy NN None
. . None
dithiothreitol JJ None
treatment NN None
. . None
IgG NNP None
anti-IgG JJ None
titres NNS None
greater JJR None
than IN None
or CC None
equal JJ None
to TO None
9 CD None
were VBD None
demonstrated VBN None
in IN None
45 CD None
% NN None
of IN None
the DT None
patients NNS None
. . None
-DOCSTART- -X- N

severe JJ None
head NN None
injury NN None
: : None
patients NNS None
admitted VBN None
to TO None
the DT None
intensive JJ None
care NN None
unit NN None
after IN None
severe JJ None
head NN None
injury NN None
. . None
university NN None
Level NNP None
I PRP None
trauma VBP None
center NN None
. . None
Twenty NNP None
patients NNS None
admitted VBD None
with IN None
a DT None
Glasgow NNP None
Coma NNP None
Scale NNP None
score NN None
of IN None
< $ None
10 CD None
patients NNS None
after IN None
head JJ None
injury NN None
. . None
-DOCSTART- -X- N

critically RB Condition
ill JJ Condition
patients NNS Condition
critically RB None
ill JJ None
patients NNS None
, , None
especially RB None
those DT None
with IN None
severe JJ None
sepsis NN None
. . None
-DOCSTART- -X- N

patients NNS Condition
receiving VBG Condition
chemotherapy NN Condition
. . None
Patients NNS None
with IN None
newly RB Condition
diagnosed VBN Condition
small-cell NN Condition
lung NN Condition
cancer NN Condition
( ( Condition
SCLC NNP Condition
) ) Condition
-DOCSTART- -X- N

Adults NNS Age
with IN None
systolic JJ Condition
BP NNP Condition
120-159 JJ Condition
mm NN Condition
Hg NNP Condition
and CC Condition
diastolic JJ Condition
BP NNP Condition
80-95 JJ Condition
mm NN Condition
Hg NNP Condition
subjects NNS None
with IN None
hypertension NN Condition
at IN None
baseline NN None
-DOCSTART- -X- N

78 CD None
randomized VBD None
patients NNS None
with IN None
either DT None
Bj?rk-Shiley NNP None
( ( None
B-S NNP None
) ) None
or CC None
Lillehei-Kaster JJ None
( ( None
L-K NNP None
) ) None
aortic JJ None
disc NN None
valve NN None
prostheses NNS None
were VBD None
re-admitted JJ None
for IN None
clinical JJ None
and CC None
haemodynamic JJ None
evaluation NN None
. . None
The DT None
patients NNS None
were VBD None
selected VBN None
that IN None
those DT None
with IN None
narrow JJ None
aortic JJ None
roots NNS None
were VBD None
over-represented JJ None
. . None
75 CD None
patients NNS None
and CC None
left VBD None
ventricular JJ None
catheterisation NN None
via IN None
the DT None
transseptal JJ None
approach NN None
was VBD None
performed VBN None
in IN None
42 CD None
. . None
-DOCSTART- -X- N

sensory/motor-based JJ None
functional JJ None
knowledge NN None
of IN None
man-made JJ None
objects NNS None
: : None
participants NNS None
Participants NNS None
participants NNS None
' POS None
Participants NNS None
Participants NNS None
-DOCSTART- -X- N

finasteride-treated JJ None
subjects NNS None
and CC None
male JJ None
pseudohermaphrodites NNS Condition
with IN None
inherited JJ Condition
5 CD Condition
alpha-reductase JJ Condition
deficiency NN Condition
. . None
Male JJ Condition
pseudohermaphrodites NNS Condition
( ( Condition
MPHs NNP Condition
) ) Condition
with IN Condition
inherited JJ Condition
5 CD Condition
alpha-reductase JJ Condition
deficiency NN Condition
and CC Condition
decreased VBD Condition
dihydrotestosterone NN Condition
production NN Condition
The DT None
5 CD None
alpha-steroid JJ None
metabolite NN None
profile NN None
in IN None
the DT None
MPHs NNP None
was VBD None
compared VBN None
with IN None
that DT None
of IN None
men NNS Condition
with IN Condition
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
-DOCSTART- -X- N

eye NN None
surgery NN None
. . None
105 CD Size
patients NNS None
admitted VBN None
for IN None
cataract NN Condition
surgery NN None
control NN None
group NN None
( ( None
n JJ None
= NNP None
99 CD Size
) ) None
-DOCSTART- -X- N

uncomplicated JJ Condition
falciparum NN Condition
malaria NN Condition
. . Condition
multicentre JJ None
study NN None
, , None
conducted VBN None
in IN None
Senegal NNP None
and CC None
in IN None
Cameroon NNP None
in IN None
2005 CD None
any DT None
subject JJ None
weighting NN None
more JJR None
than IN None
10 CD None
kg NNS None
, , None
presenting VBG None
with IN None
a DT None
malaria NN None
paroxysm NN None
confirmed VBN None
by IN None
parasitaemia NN None
> NN None
or CC None
= $ None
1,000/microl CD None
, , None
after IN None
informed JJ None
consent NN None
. . None
Three-hundred JJ Size
and CC Size
sixteen JJ Size
patients NNS None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

102 CD Size
tension-free JJ None
hernioplasties NNS Condition
with IN None
implantation NN None
of IN None
a DT None
prolene NN None
mesh NN None
in IN None
all DT None
groin NN Condition
hernias VBD Condition
to TO None
53 CD Size
Cooper NNP None
ligament NN None
repairs NNS None
in IN None
direct JJ Condition
hernias NN Condition
and CC None
53 CD Size
abdominal JJ None
ring NN None
repairs NNS None
in IN None
indirect JJ Condition
hernias NN Condition
. . None
tension-free JJ Condition
herniotomies NNS Condition
-DOCSTART- -X- N

after IN None
hip NN Condition
fracture NN Condition
surgery NN None
. . None
139 CD Condition
nondepressed JJ None
elderly JJ Age
patients NNS None
( ( None
> JJ Age
60 CD Age
years NNS Age
) ) None
hospitalized VBD None
for IN None
hip NN Condition
fracture NN Condition
surgery NN None
nondepressed JJ None
patients NNS None
after IN None
hip-fracture JJ Condition
surgery NN None
. . None
-DOCSTART- -X- N

ovarian JJ Condition
cancer NN Condition
patients NNS None
. . None
8 CD Size
patients NNS None
( ( None
age NN None
43-65 CD None
years NNS None
) ) None
with IN None
ovarian JJ None
cancer NN None
. . None
-DOCSTART- -X- N

in IN None
healthy JJ None
subjects NNS None
. . None
to TO None
patients NNS None
with IN None
hemophilia NNS None
and CC None
inhibitors NNS None
. . None
of IN None
N7-GP NNP None
in IN None
healthy JJ None
men NNS None
. . None
METHODS VB None
A DT None
randomized JJ None
, , None
placebo-controlled JJ None
, , None
dose-escalation JJ None
trial NN None
with IN None
five CD None
cohorts NNS None
( ( None
N7-GP NNP None
dose NN None
of IN None
12.5-100 JJ None
?g NNP None
kg NN None
( ( None
-1 NNP None
) ) None
) ) None
was VBD None
performed VBN None
. . None
In IN None
each DT None
cohort NN None
, , None
eight CD None
subjects NNS None
were VBD None
randomized VBN None
to TO None
patients NNS None
with IN None
hemophilia NNS None
and CC None
inhibitors NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
alcoholic JJ Condition
liver NN Size
disease NN Size
patients NNS None
with IN None
alcoholic JJ Condition
liver NN Condition
disease NN Condition
Fifty JJ Size
patients NNS None
with IN None
alcoholic JJ Condition
liver NN Condition
disease NN Condition
( ( None
27 CD Size
with IN None
cirrhosis NN Condition
, , None
23 CD Size
without IN None
cirrhosis NN Condition
) ) None
15 CD Size
healthy JJ Condition
controls NNS None
patients NNS None
with IN None
alcoholic JJ Condition
liver NN Condition
disease NN Condition
-DOCSTART- -X- N

postmenopausal JJ None
osteoporosis NN None
: : None
postmenopausal JJ None
women NNS None
with IN None
osteoporosis NN None
. . None
61 CD None
postmenopausal JJ None
women NNS None
with IN None
osteoporosis NN None
. . None
-DOCSTART- -X- N

antiretroviral-naive JJ Condition
adults NNS None
with IN None
HIV NNP Condition
infection NN Condition
: : None
554 CD Size
antiretroviral-naive JJ None
human JJ Condition
immunodeficiency NN Condition
virus-infected JJ Condition
adults NNS None
( ( None
plasma JJ None
HIV NNP None
type NN None
1 CD None
[ JJ None
HIV-1 NNP None
] NNP None
RNA NNP None
level NN None
, , None
> NNP None
or=400 VBZ None
copies/mL NN None
; : None
CD4 NNP None
( ( None
+ NNP None
) ) None
cell NN None
count NN None
, , None
> VBZ None
100 CD None
cells/mm NN None
( ( None
3 CD None
) ) None
) ) None
and CC None
compared VBN None
a DT None
300-mg JJ None
once-daily JJ None
( ( None
q.d JJ None
. . None
) ) None
regimen NNS None
of IN None
lamivudine NN None
( ( None
3TC CD None
) ) None
versus NN None
a DT None
150-mg JJ None
twice-daily JJ None
( ( None
b.i.d NN None
. . None
) ) None
regimen NNS None
of IN None
3TC CD None
, , None
combined VBN None
with IN None
zidovudine NN None
( ( None
300 CD None
mg NN None
b.i.d NN None
. . None
) ) None
and CC None
efavirenz $ None
( ( None
600 CD None
mg NN None
q.d NN None
. . None
) ) None
, , None
during IN None
a DT None
48-week JJ None
period NN None
. . None
-DOCSTART- -X- N

aphakic JJ None
retinal JJ None
detachment NN None
. . None
84 CD None
patients NNS None
with IN None
aphakic JJ None
retinal JJ None
detachment NN None
were VBD None
treated VBN None
either RB None
by IN None
local JJ None
scleral JJ None
buckling VBG None
alone RB None
or CC None
combined VBN None
with IN None
an DT None
encirclement NN None
. . None
-DOCSTART- -X- N

841 CD Size
women NNS Sex
at IN None
risk NN Condition
for IN Condition
pregnancy NN Condition
. . None
subset NN None
of IN None
42 CD Size
women NNS Size
at IN None
one CD None
site NN None
underwent JJ None
colposcopy NN Condition
. . None
women NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
parents NNS None
of IN None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( Condition
ASD NNP Condition
) ) Condition
Eighty NNP None
children NNS None
, , None
ages VBZ None
2-10 CD None
years NNS None
, , None
with IN None
ASD NNP None
and CC None
sleep JJ None
onset NN None
delay NN None
completed VBD None
the DT None
study NN None
. . None
ASD NNP None
. . None
-DOCSTART- -X- N

first-degree JJ None
relatives NNS None
of IN None
breast NN Condition
cancer NN Condition
patients NNS None
. . None
women NNS Sex
at IN None
moderate JJ None
risk NN None
for IN None
breast NN Condition
cancer NN Condition
55 CD None
% NN None
of IN None
women NNS Sex
were VBD None
regularly RB None
active JJ None
. . None
women NNS Sex
at IN None
moderate JJ None
risk NN None
for IN None
breast NN Condition
cancer NN Condition
-DOCSTART- -X- N

mastectomy JJ None
patients NNS None
. . None
60 CD None
group NN None
I-II NNP None
( ( None
American JJ None
Society NNP None
of IN None
Anesthesiology NNP None
criteria NNS None
) ) None
mastectomy NN None
patients NNS None
, , None
20 CD None
in IN None
each DT None
group NN None
. . None
-DOCSTART- -X- N

in IN None
hypertensive JJ Condition
subjects NNS None
. . None
double-blind NN None
, , None
placebo NN None
controlled VBD None
, , None
parallel FW None
group NN None
two CD Size
appropriate JJ None
groups NNS None
. . None
-DOCSTART- -X- N

4 CD Size
psychologically RB None
and CC None
physically RB None
healthy JJ Condition
hallucinogen-using NN Condition
adults NNS None
. . None
pressure NN None
. . None
Participant NNP None
narratives VBZ None
-DOCSTART- -X- N

remission NN None
induction NN None
therapy NN None
for IN None
acute JJ Condition
leukemia NN Condition
patients NNS None
undergoing JJ None
remission NN None
induction NN None
therapy NN None
for IN None
acute JJ Condition
leukemia NN Condition
. . None
Adults NNP None
with IN None
acute JJ None
leukemia NN None
undergoing VBG None
remission NN None
induction NN None
chemotherapy NN None
36 CD Size
patients NNS Size
41 CD Size
patients NNS Size
patients NNS None
undergoing JJ None
remission NN None
induction NN None
chemotherapy NN None
for IN None
acute JJ None
leukemia NN None
. . None
-DOCSTART- -X- N

elderly JJ Age
patients NNS Age
60 CD Age
elderly JJ Age
patients NNS Age
-DOCSTART- -X- N

randomly RB None
selected VBN None
subjects NNS None
for IN None
cavity NN None
preparation NN None
with IN None
conventional JJ None
air NN None
turbine/bur IN None
dental JJ None
surgery NN None
or CC None
an DT None
Er NNP None
, , None
Cr NNP None
: : None
YSGG PRP$ None
laser-powered JJ None
system NN None
using VBG None
a DT None
split-mouth JJ None
design NN None
. . None
Sixty-seven JJ None
subjects NNS None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

Children NNP Age
with IN None
persistent JJ Condition
conduct NN Condition
problems NNS Condition
who WP None
dropout VBP None
of IN None
treatment NN None
. . None
child NN None
and CC None
adolescent JJ None
mental JJ None
health NN None
service NN None
. . None
children NNS None
with IN None
persistent JJ None
conduct NN None
problems NNS None
presenting VBG None
to TO None
a DT None
community NN None
mental JJ None
health NN None
service NN None
first JJ None
study NN None
included VBD None
32 CD Size
children NNS None
mothers NNS None
who WP None
were VBD None
younger JJR None
and CC None
less RBR None
educated VBN None
Forty-six JJ None
children NNS None
were VBD None
included VBN None
. . None
children NNS None
who WP None
defaulted VBD None
-DOCSTART- -X- N

Nine NNP None
trained JJ None
cyclists NNS None
-DOCSTART- -X- N

Eskimo NNP Condition
diet NN Condition
. . None
Healthy JJ None
men NNS Sex
and CC Sex
women NNS Sex
( ( None
134 CD None
) ) None
-DOCSTART- -X- N

bronchial JJ None
provocation NN None
with IN None
methacholine JJ None
] NN None
A DT None
bronchial JJ None
provocation NN None
challenge NN None
test NN None
was VBD None
conducted VBN None
with IN None
30 CD Size
subjects NNS Condition
using VBG None
metacholin NN None
. . None
-DOCSTART- -X- N

venous JJ Condition
thromboembolism NN Condition
in IN None
cancer NN Condition
patients NNS None
. . None
patients NNS None
with IN None
venous JJ Condition
thromboembolism NN Condition
patients NNS None
on IN None
long-term JJ None
therapy NN None
for IN None
acute JJ Condition
venous JJ Condition
thromboembolism NN Condition
who WP None
have VBP None
active JJ Condition
cancer NN Condition
. . None
Consecutive JJ None
consenting VBG None
patients NNS None
from IN None
one CD None
center NN None
in IN None
a DT None
multicenter NN None
trial NN None
24 CD Size
patients NNS Size
who WP None
had VBD None
anti-Xa JJ Condition
levels NNS Condition
patients NNS None
with IN None
active JJ Condition
cancer NN Condition
-DOCSTART- -X- N

individuals NNS None
with IN None
serious JJ Condition
mental JJ Condition
illness NN Condition
( ( None
SMI NNP Condition
) ) None
receiving VBG None
antipsychotic JJ None
drug NN None
therapy NN None
. . None
individuals NNS None
with IN None
SMI NNP None
over IN None
8 CD None
weeks NNS None
. . None
30 CD None
individuals NNS None
( ( None
BMI NNP None
? . None
28 CD None
kg/m NN None
( ( None
2 CD None
) ) None
) ) None
were VBD None
for IN None
individuals NNS None
with IN None
SMI NNP None
and CC None
patients NNS None
taking VBG None
antipsychotic JJ None
medications NNS None
; : None
financial JJ None
-DOCSTART- -X- N

children NNS Age
. . None
80 CD Size
school NN None
children NNS Age
with IN None
blood NN Condition
pressures NNS Condition
above IN Condition
the DT Condition
95th CD Condition
percentile NN Condition
for IN Condition
age NN Condition
and CC Condition
sex NN Condition
but CC Condition
below IN Condition
130/90 CD Condition
mm NN Condition
Hg NNP Condition
at IN None
school NN None
screening VBG None
Twenty NNP Size
children NNS Age
aged VBD Age
6 CD Age
to TO Age
9 CD Age
years NNS Age
and CC None
their PRP$ None
families NNS None
-DOCSTART- -X- N

hepatocellular JJ Condition
carcinomas NN Condition
. . None
85 CD Size
HCC NNP None
patients NNS None
after IN None
transcatheter JJ None
arterial JJ None
chemoembolization NN None
and CC None
radiofrequency NN None
ablation NN None
therapy NN None
were VBD None
randomized VBN None
to TO None
immunotherapy VB None
group NN None
and CC None
no DT None
adjuvant JJ None
therapy NN None
group NN None
. . None
All DT None
patients NNS None
were VBD None
screened VBN None
by IN None
computed JJ None
tomography NN None
every DT None
2 CD None
months NNS None
to TO None
observe VB None
the DT None
tumor NN None
recurrent NN None
conditions NNS None
. . None
HCC NNP None
patients NNS None
-DOCSTART- -X- N

healthy JJ Condition
men NNS Sex
. . None
Twenty-four CD Size
healthy JJ None
males NNS Sex
( ( None
age NN None
, , None
35-48 CD None
years NNS None
) ) None
participated VBD None
in IN None
the DT None
study NN None
. . None
healthy JJ None
men NNS Sex
-DOCSTART- -X- N

patients NNS None
with IN None
liver JJ Condition
failure NN Condition
] NNP Condition
. . None
subjects NNS None
with IN None
liver JJ None
failure NN None
174 CD None
MARS NNP None
treatment NN None
sessions NNS None
for IN None
146 CD None
patients NNS None
with IN None
liver JJ None
failure NN None
and CC None
prothrombin JJ None
time NN None
activity NN None
percentage NN None
( ( None
PTA NNP None
) ) None
? . None
40 CD None
% NN None
were VBD None
randomly RB None
divided VBN None
into IN None
2 CD None
groups NNS None
: : None
92 CD None
MARS NNP None
treatment NN None
sessions NNS None
in IN None
the DT None
heparin-free JJ None
group NN None
and CC None
82 CD None
in IN None
the DT None
low-dose JJ None
heparin NN None
group NN None
. . None
-DOCSTART- -X- N

patient NN None
A NNP None
total NN None
of IN None
214 CD None
patients NNS None
( ( None
mean JJ None
age NN None
: : None
54.1 CD None
years NNS None
; : None
120 CD None
male NN None
, , None
94 CD None
female NN None
) ) None
from IN None
four CD None
university NN None
hospitals NNS None
( ( None
106 CD None
patients NNS None
) ) None
-DOCSTART- -X- N

acute NN None
and CC None
prolonged JJ Condition
diarrhoea NN Condition
in IN None
children NNS Age
: : None
a DT None
community-based JJ None
trial NN None
in IN None
rural JJ None
Bangladesh NNP None
. . None
acute NN None
( ( None
< JJ None
7 CD None
days NNS None
) ) None
or CC None
prolonged VBN None
( ( None
? . None
7 CD None
days NNS None
) ) None
diarrhoea VBP None
at IN None
among IN None
2968 CD Size
Bangladeshi NNP None
rural JJ None
children NNS None
6-36 JJ Age
months NNS Age
old JJ Age
. . None
diarrhoeal JJ None
children NNS None
. . None
acute NN None
and CC None
prolonged VBD None
childhood NN None
diarrhoea NN None
managed VBD None
-DOCSTART- -X- N

self-face JJ None
representations NNS None
participants NNS None
participants NNS None
in IN None
the DT None
self-face JJ None
prime JJ None
condition NN None
higher JJR None
autism NN Condition
traits NNS None
neurocognitively RB Condition
healthy JJ Condition
sample NN Condition
) ) None
participants NNS None
with IN None
high JJ Condition
autism NN Condition
traits NNS Condition
performed VBN None
as RB None
well RB None
as IN None
those DT None
with IN None
low JJ Condition
autism NN Condition
traits NNS Condition
. . None
-DOCSTART- -X- N

minimally RB None
verbal JJ None
children NNS None
with IN None
autism NN None
: : None
3 CD None
to TO None
5 CD None
year NN None
old JJ None
, , None
minimally RB None
verbal JJ None
children NNS None
with IN None
autism NN None
who WP None
were VBD None
attending VBG None
a DT None
non-public JJ None
preschool NN None
. . None
deficits NNS None
in IN None
minimally RB None
verbal JJ None
children NNS None
with IN None
ASD NNP None
-DOCSTART- -X- N

pregnant JJ Condition
Pakistani NNP Condition
women NNS Sex
in IN None
Oslo NNP None
. . None
pregnant JJ Condition
Pakistani NNP None
immigrant NN None
women NNS Sex
group NN None
of IN None
Norwegian JJ Condition
women NNS Sex
. . None
women NNS Sex
in IN None
the DT None
18th CD Condition
week NN Condition
of IN Condition
pregnancy NN Condition
. . None
Women NNP Sex
referred VBD None
to TO None
routine VB None
ultrasound JJ None
examination NN None
at IN None
Aker NNP None
and CC None
Ullev?l NNP None
Hospitals NNP None
in IN None
Norway NNP None
. . None
SUBJECTS NNP None
All NNP None
( ( None
58 CD None
) ) None
healthy JJ None
women NNS None
of IN None
Pakistani NNP None
origin NN None
referred VBD None
from IN None
October NNP None
of IN None
1991 CD None
to TO None
January NNP None
of IN None
1992 CD None
were VBD None
included VBN None
, , None
of IN None
whom WP None
38 CD None
( ( None
66 CD None
% NN None
) ) None
participated VBD None
. . None
Forty-five JJ None
Norwegian JJ None
women NNS None
were VBD None
randomly RB None
included VBN None
in IN None
the DT None
same JJ None
period NN None
and CC None
38 CD None
( ( None
84 CD None
% NN None
) ) None
of IN None
these DT None
women NNS None
participated VBD None
. . None
-DOCSTART- -X- N

teachers NNS None
of IN None
young JJ None
children NNS None
with IN None
autism NN None
: : None
young JJ None
children NNS None
with IN None
autism NN None
in IN None
self-contained JJ None
special JJ None
education NN None
classrooms NNS None
. . None
Thirty-three JJ None
children NNS None
with IN None
autism NN None
between IN None
the DT None
ages NNS None
of IN None
3 CD None
and CC None
6 CD None
years NNS None
participated VBN None
in IN None
the DT None
study NN None
with IN None
their PRP$ None
classroom NN None
teachers NNS None
( ( None
n JJ None
= NNP None
14 CD None
) ) None
. . None
14 CD None
preschool NN None
special JJ None
education NN None
teachers NNS None
young JJ None
children NNS None
with IN None
autism NN None
in IN None
their PRP$ None
classrooms NNS None
. . None
young JJ None
children NNS None
with IN None
autism NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
rheumatoid JJ Condition
arthritis NN Condition
and CC None
an DT None
inadequate JJ None
response NN None
to TO None
1 CD None
or CC None
more JJR None
tumor JJ None
necrosis NN None
factor NN None
inhibitors NNS None
: : None
patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
( ( None
RA NNP Condition
) ) None
who WP None
had VBD None
an DT None
inadequate JJ None
response NN None
to TO None
tumor VB None
necrosis NN None
factor NN None
( ( None
TNF NNP None
) ) None
inhibitors NNS None
. . None
Patients NNPS None
in IN None
REFLEX NNP None
PBO-randomized JJ None
patients NNS None
480 CD None
patients NNS None
received VBN None
? . None
1 CD None
RTX NNP None
course NN None
. . None
-DOCSTART- -X- N

adults NNS Age
with IN None
asperger JJ Condition
syndrome NN Condition
. . None
healthy JJ None
men NNS None
. . None
individuals NNS None
with IN None
Asperger NNP None
syndrome NN None
( ( None
AS IN None
) ) None
adults NNS None
with IN None
AS NNP None
individuals NNS None
with IN None
AS NNP None
. . None
-DOCSTART- -X- N

chronic JJ Condition
osteomyelitis NN Condition
. . None
Twenty-seven JJ Size
patients NNS None
had VBD None
documented VBN None
infections NNS Condition
with IN Condition
quinolone-sensitive JJ Condition
organisms NNS Condition
-DOCSTART- -X- N

diabetic JJ None
patients NNS None
undergoing VBG None
percutaneous JJ None
coronary JJ None
intervention NN None
: : None
diabetic JJ None
patients NNS None
undergoing VBG None
percutaneous JJ None
coronary JJ None
intervention NN None
( ( None
PCI NNP None
) ) None
. . None
In IN None
18 CD None
countries NNS None
, , None
4809 CD None
patients NNS None
undergoing VBG None
PCI NNP None
with IN None
stent JJ None
implantation NN None
diabetic JJ None
patients NNS None
undergoing VBG None
PCI NNP None
diabetic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

pregnant VB Condition
and CC None
non-pregnant JJ Condition
women NNS Sex
. . None
nine CD Size
non-pregnant JJ Condition
and CC None
36 CD Size
pregnant JJ Condition
women NNS Sex
. . None
36 CD Size
pregnant JJ Condition
women NNS Sex
non-pregnant JJ Condition
and CC None
pregnant JJ Condition
women NNS Sex
-DOCSTART- -X- N

women NNS Sex
with IN None
locally RB Condition
advanced JJ Condition
breast NN Condition
cancer NN Condition
: : None
patients NNS None
with IN None
breast JJ Condition
cancer NN Condition
. . None
women NNS Sex
undergoing VBG None
neoadjuvant JJ Condition
chemotherapy NN Condition
for IN None
breast NN Condition
cancer NN Condition
. . None
open-label JJ None
, , None
phase VB None
2 CD None
randomised JJ None
trial NN None
between IN None
March NNP None
17 CD None
, , None
2003 CD None
, , None
and CC None
May NNP None
19 CD None
, , None
2006 CD None
, , None
at IN None
a DT None
single JJ None
centre NN None
. . None
Eligible JJ None
patients NNS None
had VBD None
clinical JJ Condition
stage NN Condition
II-III NNP Condition
( ( Condition
> CD Condition
or CC Condition
= VB Condition
T2 NNP Condition
and/or JJ Condition
> NN Condition
or CC Condition
= VB Condition
N1 NNP Condition
) ) Condition
newly RB Condition
diagnosed VBN Condition
breast NN Condition
cancer NN Condition
, , None
Eastern NNP None
Cooperative NNP None
Oncology NNP None
Group NNP None
performance NN None
status NN None
of IN None
0 CD None
or CC None
1 CD None
, , None
and CC None
normal JJ None
cardiac NN None
, , None
renal JJ None
, , None
and CC None
liver JJ None
function NN None
. . None
120 CD Size
women NNS Sex
were VBD None
randomly RB None
assigned VBN None
120 CD Size
patients NNS None
initially RB None
enrolled VBD None
, , None
one CD Size
withdrew NN None
after IN None
signing VBG None
consent NN None
and CC None
one CD Size
patient NN None
's POS None
baseline NN None
bone NN None
marrow NN None
was VBD None
not RB None
available JJ None
. . None
109 CD Size
bone-marrow NN None
samples NNS None
were VBD None
available JJ None
-DOCSTART- -X- N

children NNS None
with IN None
disorders NNS Condition
of IN Condition
the DT Condition
autism NN Condition
spectrum NN Condition
. . None
children NNS None
with IN None
Autism NNP None
Spectrum NNP None
Disorders NNP None
21 CD None
children NNS None
with IN None
Autism NNP None
Spectrum NNP Condition
Disorder NNP None
diagnoses NNS None
-DOCSTART- -X- N

typhoid JJ Condition
fever NN Condition
in IN None
children NNS Age
. . None
Dong NNP None
Nai NNP None
Pediatric NNP None
Center NNP None
patients NNS None
with IN None
multidrug-resistant JJ Condition
typhoid NN Condition
fever NN Condition
in IN None
Vietnam NNP None
. . None
In IN None
an DT None
open JJ None
trial NN None
children NNS Age
with IN None
suspected JJ None
typhoid NN Condition
fever NN Condition
82 CD Size
patients NNS None
( ( None
44 CD None
in IN None
the DT None
cefixime NN None
group NN None
, , None
38 CD None
in IN None
the DT None
ofloxacin JJ None
group NN None
) ) None
and CC None
70 CD Size
( ( None
85 CD None
% NN None
) ) None
of IN None
the DT None
isolates NNS None
were VBD None
multidrug-resistant JJ None
. . None
cefixime-treated JJ None
patients NNS None
uncomplicated JJ Condition
typhoid NN Condition
fever NN Condition
in IN None
children NNS Age
-DOCSTART- -X- N

patients NNS None
affected VBN None
by IN None
acne NN Condition
and CC None
polycystic JJ Condition
ovary JJ Condition
syndrome NN Condition
: : Condition
few JJ None
patients NNS None
, , None
especially RB None
women NNS Sex
In IN None
women NNS Sex
with IN None
acne NN Condition
and CC None
proven JJ None
PCOS NNP None
therapy NN None
with IN None
estroprogestins NNS None
( ( None
EPs NNP None
) ) None
women NNS Sex
affected VBN None
by IN None
mild NN Condition
to TO Condition
severe VB Condition
acne NN Condition
and CC None
polycystic JJ Condition
ovary JJ Condition
syndrome NN Condition
( ( Condition
PCOS NNP Condition
) ) Condition
. . None
Fifty-nine JJ Size
women NNS Sex
were VBD None
randomized VBN None
women NNS Sex
with IN None
acne NN None
-DOCSTART- -X- N

severely RB Condition
burned JJ Condition
children NNS Age
. . None
Thirty-five JJ Size
children NNS Age
with IN None
> NN None
or CC None
=40 CD None
% NN None
total JJ None
body NN None
surface NN None
area NN None
burns NNS None
were VBD None
randomized VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
. . None
patients NNS None
with IN None
metastatic JJ None
colorectal JJ None
cancer NN None
. . None
Patients NNPS None
with IN None
metastatic JJ None
colorectal JJ None
cancer NN None
patients NNS None
without IN None
disease JJ None
progression NN None
One CD Size
hundred VBD Size
eighteen JJ Size
patients NNS None
patients NNS None
with IN None
metastatic JJ None
colorectal JJ None
cancer NN None
. . None
-DOCSTART- -X- N

tibial JJ None
fractures NNS None
patients NNS None
with IN None
tibial JJ None
shaft NN None
fractures NNS None
. . None
Level NNP None
1 CD None
trauma NN None
center NN None
. . None
Forty-five JJ None
patients NNS None
with IN None
displaced NNS None
closed VBD None
and CC None
open JJ None
Gustilo NNP None
type NN None
I-IIIA NNP None
fractures NNS None
of IN None
the DT None
central JJ None
two CD None
thirds NNS None
of IN None
the DT None
tibia NN None
. . None
patients NNS None
with IN None
tibial JJ None
shaft NN None
fractures NNS None
-DOCSTART- -X- N

cancer NN None
patients NNS None
. . None
cancer NN None
patients NNS None
with IN None
dysfunctional JJ None
fear NN None
of IN None
progression NN None
. . None
cancer NN None
patients NNS None
receiving VBG None
inpatient JJ None
rehabilitation NN None
. . None
A DT None
total NN None
of IN None
174 CD None
patients NNS None
were VBD None
included VBN None
in IN None
the DT None
economic JJ None
evaluation NN None
. . None
cancer NN None
patients NNS None
with IN None
high JJ None
levels NNS None
of IN None
anxiety NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
child NN Age
responsiveness NN None
in IN None
children NNS Age
with IN None
autism NN Condition
during IN None
joint JJ None
engagement NN None
episodes NNS None
. . None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
children NNS Age
with IN None
autism NN Condition
. . None
-DOCSTART- -X- N

Each DT None
of IN None
nine CD None
normal-hearing JJ None
pilot NN None
subjects NNS None
were VBD None
placed VBN None
BO-105 JJ None
helicopter NN None
. . None
-DOCSTART- -X- N

weightlifters NNS None
. . None
Thirteen NNP Size
experienced VBD None
male JJ Sex
weightlifters NNS None
taking VBG None
high-protein JJ None
diets NNS None
and CC None
regular JJ None
exercise NN None
-DOCSTART- -X- N

patients NNS None
with IN None
cirrhosis NN Condition
and CC Condition
ascites NNS Condition
. . None
seven CD Size
patients NNS None
with IN None
cirrhosis NN None
and CC None
tense NN None
ascites NNS None
. . None
Patients NNS None
patients NNS None
with IN None
cirrhosis NN Condition
and CC Condition
ascites NNS Condition
. . None
-DOCSTART- -X- N

14,916 CD None
men NNS None
initially RB None
free JJ None
of IN None
diagnosed JJ None
cancer NN None
, , None
we PRP None
identified VBD None
1,066 CD None
men NNS None
with IN None
incident JJ None
prostate NN None
cancer NN None
( ( None
including VBG None
496 CD None
with IN None
aggressive JJ None
disease NN None
, , None
defined VBD None
as IN None
stage NN None
C NNP None
or CC None
D NNP None
, , None
Gleason NNP None
7-10 CD None
, , None
metastatic JJ None
, , None
and CC None
fatal JJ None
prostate NN None
cancer NN None
) ) None
and CC None
1,618 CD None
cancer-free JJ None
, , None
age- JJ None
and CC None
smoking-matched JJ None
control NN None
participants NNS None
in IN None
the DT None
Physicians NNPS None
' POS None
Health NNP None
Study NNP None
. . None
men NNS None
with IN None
plasma NN None
25 CD None
( ( None
OH NNP None
) ) None
D NNP None
levels NNS None
above IN None
the DT None
median NN None
-DOCSTART- -X- N

children NNS None
and CC None
adolescents NNS None
with IN None
autistic JJ None
disorder NN None
children NNS None
and CC None
adolescents NNS None
with IN None
autistic JJ None
disorders NNS None
patients NNS None
( ( None
5-17 JJ None
years NNS None
of IN None
age NN None
, , None
who WP None
completed VBD None
the DT None
previous JJ None
fixed-dose JJ None
, , None
6 CD None
week NN None
, , None
double-blind JJ None
[ NNP None
DB NNP None
] NNP None
phase NN None
Fifty-six NNP None
( ( None
71 CD None
% NN None
) ) None
out IN None
of IN None
79 CD None
enrolled JJ None
patients NNS None
completed VBD None
the DT None
OLE NNP None
-DOCSTART- -X- N

150 CD Size
patients NNS None
with IN None
gallbladder JJ Condition
lithiasis NN Condition
who WP None
underwent JJ None
laparoscopy NN Condition
-DOCSTART- -X- N

Thirty-four JJ Size
patients NNS None
undergoing VBG None
elective JJ Condition
shoulder NN Condition
surgery NN Condition
were VBD None
randomized VBN None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
in IN None
Hong NNP None
Kong NNP None
. . None
children NNS Age
with IN None
autism NN Condition
Twenty-four JJ Size
children NNS Size
diagnosed VBN None
with IN None
autism NN Condition
from IN None
Kowloon NNP None
, , None
Hong NNP None
Kong NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
breast JJ Condition
cancer NN Condition
. . None
?-?A JJ None
) ) None
in IN None
breast NN Condition
cancer NN Condition
patients NNS None
during IN None
chemotherapy NN None
. . None
PATIENTS NNP None
series NN None
of IN None
30 CD Size
breast NN Condition
cancer NN Condition
patients NNS None
who WP None
underwent VBP None
standardised VBN None
chemotherapy NN None
were VBD None
-DOCSTART- -X- N

school-aged JJ None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
: : None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
. . None
participants NNS None
. . None
Six CD None
children NNS None
children NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

insula NN None
and CC None
amygdala JJ None
brain NN None
areas NNS None
activated VBN None
by IN None
misleading VBG None
information NN None
during IN None
an DT None
expectancy NN None
period NN None
rostral JJ None
anterior JJ None
cingulate NN None
cortex NN None
( ( None
rACC NN None
) ) None
, , None
orbitofrontal JJ None
cortex NN None
( ( None
OFC NNP None
) ) None
, , None
and CC None
dorsolateral JJ None
prefrontal NN None
cortex NN None
-DOCSTART- -X- N

patients NNS None
with IN None
BPH NNP Condition
: : None
94 CD None
patients NNS None
patients NNS None
with IN None
symptoms NNS None
of IN None
I-II NNP None
stages NNS None
benign VBP Condition
prostatic JJ Condition
hyperplasia NN Condition
( ( Condition
BPH NNP Condition
) ) Condition
. . None
-DOCSTART- -X- N

positron NN None
emission NN None
tomography-negative JJ None
stage NN None
I/II NNP None
Hodgkin NNP None
lymphoma NN None
patients NNS None
with IN None
clinical JJ Condition
stage NN Condition
I/II NNP Condition
Hodgkin NNP Condition
lymphoma NN Condition
( ( Condition
HL NNP Condition
) ) Condition
. . None
patients NNS None
attaining VBG None
a DT None
negative JJ None
early JJ None
PET NNP None
scan NN None
after IN None
two CD None
cycles NNS None
of IN None
ABVD NNP None
Patients NNP None
age NN Age
15 CD Age
to TO Age
70 CD Age
years NNS Age
with IN None
untreated JJ Condition
clinical JJ Condition
stage NN Condition
I/II NNP Condition
HL NNP Condition
were VBD None
eligible JJ None
. . None
The DT None
analysis NN None
included VBD None
1,137 CD Size
patients NNS None
. . None
favorable JJ Size
subgroup NN Size
unfavorable JJ Size
subgroup NN Size
-DOCSTART- -X- N

type NN None
1 CD None
diabetes NNS None
type JJ None
1 CD None
diabetes NNS None
( ( None
T1D NNP None
) ) None
24 CD None
patients NNS None
, , None
8-18 CD None
years NNS None
old JJ None
, , None
with IN None
newly RB None
diagnosed VBN None
T1D NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
heart NN Condition
failure NN Condition
: : None
patients NNS None
with IN None
chronic JJ None
heart NN None
failure NN None
. . None
Nineteen NNP Size
patients NNS None
entered VBD None
the DT None
study NN None
. . None
Three CD Size
patients NNS None
had VBD None
ischemic JJ Condition
heart NN Condition
disease NN Condition
, , None
13 CD None
had VBD None
dilated VBN Condition
cardiomyopathy NN Condition
, , None
and CC None
three CD None
had VBD None
valvular JJ Condition
disease NN Condition
; : Condition
16 CD None
patients NNS None
were VBD None
in IN None
New NNP None
York NNP None
Heart NNP None
Association NNP None
class NN None
II NNP None
, , None
and CC None
three CD None
patients NNS None
were VBD None
in IN None
New NNP None
York NNP None
Heart NNP None
Association NNP None
class NN None
III NNP None
. . None
patients NNS None
with IN None
atrial JJ Condition
fibrillation NN Condition
patients NNS None
with IN None
sinus JJ Condition
rhythm NN Condition
. . None
Patients NNS None
with IN None
mild-to-moderate JJ Condition
heart NN Condition
failure NN Condition
with IN None
sinus NN Condition
rhythm NN Condition
those DT None
with IN None
atrial JJ Condition
fibrillation NN Condition
because IN None
of IN None
its PRP$ None
frequent JJ None
induction NN None
of IN None
tachycardia NN Condition
-DOCSTART- -X- N

Twenty-eight JJ Size
newly RB None
diagnosed VBN None
patients NNS None
with IN None
small JJ Condition
cell NN Condition
lung NN Condition
cancer NN Condition
patients NNS None
with IN None
extensive JJ None
disease NN None
; : None
-DOCSTART- -X- N

chemotherapy-naive JJ None
patients NNS None
with IN None
colorectal JJ Condition
cancer NN Condition
. . None
Forty-eight NNP Size
patients NNS None
were VBD None
randomized VBN None
Forty-five JJ Size
patients NNS None
were VBD None
assessable JJ None
for IN None
response NN None
: : None
-DOCSTART- -X- N

recurrent NN None
gastric JJ Condition
carcinoma NN Condition
. . None
cancer NN Condition
patients NNS None
a DT None
group NN None
of IN None
patients NNS None
with IN None
recurrent JJ None
gastric JJ None
cancer NN None
1 CD None
) ) None
Intradermal NNP None
group NN None
( ( None
ID NNP None
Group NNP None
) ) None
, , None
42 CD Size
patients NNS None
given VBN None
an DT None
intradermal JJ None
injections NNS None
of IN None
OK-432 NNP None
. . None
2 CD None
) ) None
Intramuscular NNP None
group NN None
( ( None
IM NNP None
Group NNP None
) ) None
, , None
40 CD Size
patients NNS None
given VBN None
an DT None
intramuscular JJ None
injections NNS None
of IN None
OK-432 NNP None
. . None
3 CD None
) ) None
Control NNP None
group NN None
( ( None
C NNP None
Group NNP None
) ) None
, , None
39 CD Size
patients NNS None
not RB None
given VBN None
injections NNS None
. . None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS Condition
. . Condition
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
breast JJ None
reconstruction NN None
with IN None
the DT None
abdominal JJ None
wall NN None
. . None
breast NN None
reconstruction NN None
by IN None
transposition NN None
of IN None
rectus NN None
abdominis NN None
myocutaneous JJ None
flap NN None
From IN None
October NNP None
1990 CD None
to TO None
March NNP None
1992 CD None
38 CD None
patients NNS None
were VBD None
recruited VBN None
: : None
20 CD None
patients NNS None
in IN None
the DT None
antibiotic JJ None
prophylaxis NN None
arm NN None
and CC None
18 CD None
patients NNS None
in IN None
the DT None
control NN None
group NN None
. . None
-DOCSTART- -X- N

knee NN Condition
arthroplasty NN Condition
. . None
after IN Condition
knee NN Condition
arthroplasty NN Condition
. . None
8 CD None
university NN None
hospitals NNS None
. . None
670 CD Size
consecutive JJ None
patients NNS None
who WP None
had VBD None
knee VBN Condition
arthroplasty RB Condition
. . None
patients NNS None
with IN None
adequate JJ Condition
bilateral JJ Condition
venograms NNS Condition
; : None
417 CD Size
patients NNS None
with IN None
adequate JJ Condition
venograms NNS Condition
after IN Condition
knee NN Condition
arthroplasty NN Condition
. . None
-DOCSTART- -X- N

functionally RB Condition
impaired JJ Condition
older JJR Condition
adults NNS Condition
older JJR None
people NNS None
. . None
Community-dwelling JJ None
people NNS None
aged VBN None
? . None
65 CD None
years NNS None
with IN None
functional JJ None
impairment NN None
were VBD None
RESULTS VB None
A DT None
total NN None
of IN None
170 CD None
participants NNS None
( ( None
n JJ None
= $ None
86 CD None
perindopril NN None
, , None
n JJ None
= FW None
84 CD None
placebo NN None
) ) None
were VBD None
randomized VBN None
. . None
Mean JJ None
age NN None
was VBD None
75.7 CD None
( ( None
standard JJ None
deviation NN None
[ NNP None
SD NNP None
] NNP None
6.8 CD None
) ) None
years NNS None
. . None
functionally RB None
impaired JJ None
older JJR None
people NNS None
. . None
-DOCSTART- -X- N

multi-site JJ None
swine NN None
production NN None
system NN None
during IN None
an DT None
outbreak NN None
of IN None
systemic JJ None
porcine NN None
circovirus NN None
associated VBN None
disease NN None
. . None
2 CD Size
cohorts NNS Size
of IN None
finisher NN Age
pigs NNS Age
in IN None
a DT None
multi-site JJ None
swine NN None
production NN None
system NN None
located VBN None
in IN None
southern JJ None
Ontario NNP None
. . None
2 CD None
cohorts NNS None
. . None
pigs NNS None
herd NN None
experiencing VBG None
an DT None
outbreak NN None
of IN None
PCVAD NNP None
-DOCSTART- -X- N

screening VBG None
normally RB Condition
intelligent JJ Condition
persons NNS None
with IN None
pervasive JJ Condition
developmental NN Condition
disorders NNS Condition
. . None
25 CD Condition
normally RB Condition
intelligent JJ Condition
high-functioning JJ Condition
pervasive JJ Condition
developmental NN Condition
disorder NN Condition
( ( None
HPDD NNP Condition
) ) None
patients NNS None
( ( None
mean JJ None
age NN None
, , None
24.2 CD Age
years NNS Age
; : None
24 CD Condition
male NN Age
, , None
one CD Condition
female NN Age
) ) None
and CC None
215 CD Condition
controls NNS None
( ( None
mean JJ None
age NN None
, , None
30.4 CD Age
years NNS Age
; : None
86 CD Condition
male NN Age
, , None
129 CD Condition
female NN Age
) ) None
randomly RB None
selected VBN None
from IN None
the DT None
general JJ None
population NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
Alzheimer NNP None
's POS None
disease NN None
. . None
patients NNS None
with IN None
Alzheimer NNP None
's POS None
disease NN None
( ( None
AD NNP None
) ) None
AD NNP None
patients NNS None
as IN None
compared VBN None
to TO None
age-matched JJ None
controls NNS None
. . None
AD NNP None
patients NNS None
AD NNP None
patients NNS None
. . None
AD NNP None
patients NNS None
-DOCSTART- -X- N

vegetarians NNS None
7 CD None
vegetarians NNS None
( ( None
VEG NNP None
) ) None
and CC None
nonvegetarians NNS None
( ( None
NVEG NNP None
) ) None
vegetarianism NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
sick JJ Condition
sinus NN Condition
syndrome NN Condition
. . None
patients NNS None
with IN None
sick JJ Condition
sinus NN Condition
syndrome NN Condition
patients NNS None
with IN None
sick JJ Condition
sinus NN Condition
syndrome NN Condition
. . None
Two CD Size
hundred VBD Size
twenty-five JJ Size
consecutive JJ None
patients NNS None
with IN None
sick JJ Condition
sinus NN Condition
syndrome NN Condition
and CC None
intact JJ None
AV NNP None
conduction NN None
patients NNS None
patients NNS None
with IN None
sick JJ Condition
sinus NN Condition
syndrome NN Condition
-DOCSTART- -X- N

in IN None
HIV-HCV-coinfected JJ None
patients NNS None
: : None
in IN None
HIV-HCV-coinfected JJ None
patients NNS None
. . None
METHODS NNP None
HIV NNP None
and CC None
HCV NNP None
genotype VBP None
1- JJ None
and CC None
4-coinfected JJ None
subjects NNS None
RESULTS VB None
A DT None
total NN None
of IN None
67 CD None
patients NNS None
were VBD None
included VBN None
; : None
33 CD None
in IN None
-DOCSTART- -X- N

patients NNS None
with IN None
severe JJ Condition
chronic JJ Condition
congestive JJ Condition
heart NN Condition
failure NN Condition
: : None
patients NNS None
with IN None
moderate JJ Condition
to TO Condition
severe VB Condition
congestive JJ Condition
heart NN Condition
failure NN Condition
. . None
1,068 CD Condition
patients NNS Condition
enrolled VBN None
in IN None
a DT None
survival NN None
study NN None
of IN None
class NN Condition
III NNP Condition
or CC Condition
IV NNP Condition
heart NN Condition
failure NN Condition
at IN None
the DT None
time NN None
of IN None
double-blind JJ None
randomization NN None
to TO None
milrinone VB None
, , None
a DT None
phosphodiesterase NN None
inhibitor NN None
, , None
or CC None
placebo NN None
. . None
-DOCSTART- -X- N

LDL NNP None
oxidation NN None
. . None
atherogenesis NN None
. . None
healthy JJ None
persons NNS None
79 CD None
healthy JJ None
subjects NNS None
. . None
-DOCSTART- -X- N

treatment NN None
of IN None
bone NN None
infections NNS None
] NNP None
33 CD None
patients NNS None
suffering VBG None
from IN None
osteomyelitis NN None
. . None
17 CD None
patients NNS None
, , None
a DT None
through IN None
drainage NN None
with IN None
sterile JJ None
physiologic JJ None
solution NN None
was VBD None
applied VBN None
, , None
while IN None
in IN None
the DT None
second JJ None
group NN None
, , None
16 CD None
patients NNS None
, , None
antibiotic JJ None
was VBD None
added VBN None
to TO None
the DT None
sterile JJ None
physiologic JJ None
solution NN None
. . None
-DOCSTART- -X- N

A DT None
total NN None
of IN None
119 CD Size
patients NNS Condition
, , None
aged VBN None
61-86 CD Age
years NNS Age
, , None
underwent JJ None
cataract NN Condition
surgery NN Condition
with IN None
phacoemulsification NN None
performed VBN None
by IN None
a DT None
single JJ None
surgeon NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
overactive JJ Condition
bladder NN Condition
associated VBN Condition
with IN Condition
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
: : None
total NN None
of IN None
100 CD Size
patients NNS None
with IN None
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
( ( Condition
BPH NNP Condition
) ) Condition
and CC Condition
overactive JJ Condition
bladder NN Condition
( ( Condition
OAB NNP Condition
) ) Condition
symptoms NNS None
( ( None
BPH/OAB NNP None
) ) None
, , None
enrolled VBN None
between IN None
June NNP None
2006 CD None
to TO None
March NNP None
2008 CD None
-DOCSTART- -X- N

total JJ None
knee JJ None
arthroplasty NN None
. . None
after IN None
primary JJ None
total JJ None
knee NN None
arthroplasty NN None
( ( None
TKA NNP None
) ) None
. . None
One CD None
hundred CD None
and CC None
ten VB None
consecutive JJ None
TKA NNP None
patients NNS None
-DOCSTART- -X- N

toddlers NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
: : None
toddlers NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
. . None
Fifty NNP None
toddlers NNS None
with IN None
ASD NNP None
, , None
ages VBZ None
21 CD None
to TO None
33 CD None
months NNS None
toddlers NNS None
toddlers NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

web-based JJ None
tailored JJ None
smoking NN Condition
cessation NN Condition
advice NN None
reports NNS None
Participants NNS None
were VBD None
allocated VBN None
randomly RB None
to TO None
one CD None
of IN None
two CD None
groups NNS None
Participants NNS None
( ( None
n IN None
= NNP None
1758 CD None
) ) None
were VBD None
visitors NNS None
to TO None
the DT None
QUIT NNP None
website NN None
who WP None
were VBD None
based VBN None
in IN None
the DT None
United NNP None
Kingdom NNP None
, , None
aged VBD None
18 CD Age
years NNS Age
or CC Age
over RB Age
and CC None
who WP None
smoked VBD None
cigarettes NNS None
or CC None
hand-rolled JJ None
tobacco NN None
. . None
MEASUREMENTS NNP None
intervention NN None
group NN None
did VBD None
control NN None
group NN None
on IN None
. . None
Intervention NN None
participants NNS None
gave VBD None
more RBR None
materials NNS None
than IN None
control NN None
participants NNS None
. . None
CONCLUSIONS VB None
-DOCSTART- -X- N

patients NNS None
with IN None
birch NN Condition
pollen NN Condition
allergy NN Condition
. . None
thirty-seven JJ None
adult NN None
patients NNS None
were VBD None
exposed VBN None
for IN None
eight CD None
hours NNS None
in IN None
an DT None
environmental JJ None
exposure NN None
chamber NN None
( ( None
EEC NNP None
) ) None
to TO None
birch VB None
pollen NN None
at IN None
an DT None
average JJ None
concentration NN None
of IN None
3500 CD None
? . None
500 CD None
grains/m NN None
( ( None
3 CD None
) ) None
RESULTS NNP None
Thirty-six JJ None
patients NNS None
were VBD None
immunotherapy NN None
in IN None
birch NN None
pollen NN None
allergic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

autism NN None
. . None
children NNS None
with IN None
and CC None
without IN None
autism NN None
The DT Condition
children NNS Condition
with IN Condition
autism NN Condition
individuals NNS None
with IN None
autism NN None
-DOCSTART- -X- N

benign JJ Condition
thyroid JJ Condition
nodules NNS Condition
. . None
subjects NNS None
with IN None
compressive JJ None
symptoms NNS None
due JJ None
to TO None
benign VB Condition
thyroid JJ Condition
nodules NNS Condition
and/or VBP None
at IN None
high JJ None
surgical JJ None
risk NN None
. . None
Twenty NNP Size
six CD Size
subjects NNS None
were VBD None
randomized VBN None
to TO None
the DT None
intervention NN None
( ( None
no DT None
. . None
13 CD None
, , None
age NN None
68+/-3 JJ Age
yr NN Age
, , None
mean+/-SEM NN None
) ) None
or CC None
observation NN None
( ( None
no DT None
. . None
13 CD None
, , None
age NN None
71+/-2 JJ Age
yr NN Age
) ) None
groups NNS None
. . None
benign JJ Condition
thyroid JJ Condition
nodules NNS Condition
in IN None
patients NNS None
at IN None
high JJ None
surgical JJ None
risk NN None
. . None
-DOCSTART- -X- N

Economic JJ None
evaluation NN None
of IN None
a DT None
nursing-led JJ None
inpatient JJ None
unit NN None
: : None
transfer NN None
to TO None
a DT None
nursing-led JJ None
inpatient NN None
unit NN None
for IN None
intermediate JJ None
care NN None
nursing-led JJ None
inpatient JJ None
units NNS None
sample JJ None
size NN None
of IN None
175 CD None
, , None
of IN None
which WDT None
89 CD None
were VBD None
in IN None
the DT None
nursing-led JJ None
inpatient NN None
unit NN None
arm NN None
and CC None
86 CD None
in IN None
the DT None
control NN None
arm NN None
. . None
-DOCSTART- -X- N

98 CD Condition
patients NNS Condition
affected VBN Condition
by IN Condition
a DT Condition
dirty NN Condition
wound NN Condition
. . Condition
The DT None
study NN None
included VBD None
98 CD None
patients NNS None
who WP None
underwent VBP None
intestinal JJ None
recanalization NN None
procedures NNS None
between IN None
December NNP None
2003 CD None
and CC None
December NNP None
2008 CD None
, , None
with IN None
the DT None
stoma NN None
as IN None
the DT None
surgical JJ None
site NN None
. . None
-DOCSTART- -X- N

locally RB None
advanced JJ None
prostatic JJ None
cancer NN None
. . None
151 CD Size
patients NNS None
with IN None
locally RB None
advanced JJ None
prostatic JJ None
cancer NN None
( ( None
T3-4 NNP None
M0 NNP None
) ) None
, , None
representing VBG None
38 CD None
% NN None
of IN None
the DT None
404 CD None
cancer NN None
patients NNS None
in IN None
a DT None
Finnish JJ None
multicenter NN None
study NN None
-DOCSTART- -X- N

anemia NN Condition
of IN None
chronic JJ Condition
renal JJ Condition
disease NN Condition
: : None
iron-replete JJ None
hemodialysis NN None
patients NNS None
4 CD Size
androgen-treated JJ None
patients NNS None
chronic JJ None
hemodialysis NN None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
knee JJ None
osteoarthritis NN None
. . None
patients NNS None
with IN None
knee JJ None
joint JJ None
OA NNP None
. . None
Fifty NNP None
patients NNS None
( ( None
19 CD None
males NNS None
and CC None
31 CD None
females NNS None
) ) None
with IN None
a DT None
mean JJ None
age NN None
of IN None
53.6 CD None
+/- JJ None
8.9 CD None
years NNS None
patients NNS None
with IN None
OA NNP None
of IN None
the DT None
knee NN None
. . None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS None
. . None
males NNS Sex
and CC None
females NNS Sex
males NNS Sex
and CC None
females NNS Sex
-DOCSTART- -X- N

Hodgkin NNP Condition
's POS Condition
disease NN Condition
. . None
chemotherapy NN Condition
in IN None
nonbulky JJ None
involved JJ None
field NN None
( ( None
IF/BF NNP None
) ) None
and CC None
noninvolved VBN None
extended-field NN None
( ( None
EF/IF NNP None
) ) None
sites VBZ None
in IN None
patients NNS None
with IN None
intermediate-stage JJ None
Hodgkin NNP Condition
's POS Condition
disease NN Condition
( ( None
HD NNP None
) ) None
. . None
HD NNP Condition
patients NNS None
in IN None
stage NN Condition
I PRP Condition
to TO Condition
IIIA NNP Condition
with IN None
a DT None
large JJ Condition
mediastinal JJ Condition
mass NN Condition
, , None
E NNP Condition
stage NN Condition
, , None
or CC None
massive JJ Condition
spleen JJ Condition
involvement NN Condition
146 CD Size
patients NNS None
who WP None
responded VBD None
to TO None
chemotherapy VB Condition
were VBD None
randomized VBN None
to TO None
receive VB None
20 CD None
Gy NNP None
( ( None
70 CD Size
patients NNS None
) ) None
or CC None
40 CD None
Gy NNP None
( ( None
76 CD Size
patients NNS None
) ) None
of IN None
EF NNP None
irradiation NN None
in IN None
all DT None
fields NNS None
outside IN None
bulky JJ None
disease NN None
sites NNS None
. . None
A DT None
cohort NN None
of IN None
111 CD Size
patients NNS None
who WP None
fulfilled VBD None
the DT None
same JJ None
inclusion NN None
criteria NNS None
in IN None
the DT None
subsequent JJ None
trial NN None
HD5 NNP None
( ( None
1988 CD None
to TO None
1993 CD None
) ) None
were VBD None
treated VBN None
with IN None
30 CD None
Gy NNP None
. . None
modern JJ None
polychemotherapy NN Condition
in IN None
patients NNS None
with IN None
intermediate-stage JJ Condition
HD NNP Condition
. . None
-DOCSTART- -X- N

12 CD Size
young JJ Age
healthy JJ Condition
male NN None
volunteers NNS None
. . None
-DOCSTART- -X- N

101 CD None
anxious JJ Condition
outpatients NNS Condition
symptoms NNS None
of IN None
anxiety NN None
patients NNS None
on IN None
ketazolam NN None
dropped VBD None
out IN None
of IN None
the DT None
study NN None
-DOCSTART- -X- N

Twenty NNP None
patients NNS None
with IN None
seborrhoeic JJ None
dermatitis NN None
were VBD None
included VBN None
in IN None
this DT None
study NN None
, , None
11 CD None
patients NNS None
in IN None
the DT None
pimecrolimus JJ None
1 CD None
% NN None
cream NN None
group NN None
and CC None
nine CD None
patients NNS None
in IN None
the DT None
betamethasone NN None
17-valerate JJ None
0.1 CD None
% NN None
cream NN None
group NN None
. . None
-DOCSTART- -X- N

adults NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
11 CD None
adults NNS None
with IN None
autism NN None
or CC None
Aspergers NNS None
disorder VBP None
and CC None
8 CD None
age- JJ None
and CC None
gender-matched JJ None
healthy JJ None
controls NNS None
via IN None
randomized VBN None
double-blind NN None
, , None
m-CPP JJ None
and CC None
placebo JJ None
challenges NNS None
. . None
Patients NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
subjects VBZ None
with IN None
autism NN None
spectrum NN None
disorders NNS None
-DOCSTART- -X- N

gastroesophageal JJ None
reflux NN None
. . None
23 CD Size
patients NNS Size
with IN None
gastroesophageal JJ Condition
reflux NN Condition
. . None
Group NNP None
I PRP None
patients NNS None
with IN None
delayed JJ None
or CC None
normal JJ None
GE NNP None
-DOCSTART- -X- N

toothbrushes NNS None
periodontal JJ Condition
diseases NNS Condition
. . None
Twenty NNP Size
patients NNS None
had VBD None
one CD None
side NN None
of IN None
their PRP$ None
mouths NNS None
brushed VBN None
with IN None
a DT None
toothbrush NN None
containing VBG None
the DT None
antimicrobial JJ None
agent NN None
( ( None
experimental JJ None
side NN None
) ) None
, , None
and CC None
the DT None
other JJ None
side NN None
with IN None
a DT None
toothbrush NN None
containing VBG None
no DT None
agent NN None
( ( None
control NN None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
autistic JJ Condition
disorder NN Condition
. . None
About IN None
40 CD Size
children NNS Age
between IN None
the DT None
ages NNS None
three CD Age
and CC Age
11 CD Age
years NNS Age
( ( None
inclusive JJ None
) ) None
with IN None
a DT None
DSM NNP None
IV NNP None
clinical JJ None
diagnosis NN None
of IN None
autism NN Condition
and CC None
who WP None
were VBD None
outpatients NNS None
from IN None
a DT None
specialty NN None
clinic NN None
for IN None
children NNS None
were VBD None
recruited VBN None
. . None
children NNS Age
presented VBN None
with IN None
a DT None
chief JJ None
complaint NN None
of IN None
severely RB None
disruptive JJ None
symptoms NNS None
related VBN None
to TO None
autistic JJ Condition
disorder NN Condition
. . None
-DOCSTART- -X- N

dogs NNS None
. . None
dogs NNS None
undergoing VBG None
elective JJ None
orchiectomy NN None
or CC None
ovariohysterectomy NN None
. . None
46 CD Size
dogs NNS Size
housed VBN None
in IN None
animal NN None
shelters NNS None
and CC None
undergoing VBG None
elective JJ None
orchiectomy NN None
or CC None
ovariohysterectomy NN None
. . None
dogs NNS None
undergoing VBG None
surgery NN None
. . None
-DOCSTART- -X- N

in IN None
vitro JJ None
fertilization NN None
( ( None
IVF NNP None
) ) None
Forty-eight JJ None
patients NNS None
having VBG None
IVF NNP None
for IN None
the DT None
first JJ None
time NN None
patients NNS None
undergoing VBG None
IVF NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
alcoholic JJ None
cirrhosis NN None
and CC None
massive JJ None
ascites NNS None
. . None
patients NNS None
with IN None
alcoholic JJ None
cirrhosis NN None
299 CD None
men NNS None
with IN None
alcoholic JJ None
cirrhosis NN None
, , None
who WP None
had VBD None
persistent NN None
or CC None
recurrent NN None
severe JJ None
ascites VBZ None
despite IN None
a DT None
standard JJ None
medical JJ None
regimen NNS None
, , None
to TO None
receive VB None
either RB None
intensive JJ None
medical JJ None
treatment NN None
or CC None
peritoneovenous JJ None
( ( None
LeVeen NNP None
) ) None
shunting VBG None
. . None
Group NNP None
1 CD None
had VBD None
normal JJ None
or CC None
mildly RB None
abnormal JJ None
results NNS None
on IN None
liver-function NN None
tests NNS None
, , None
Group NNP None
2 CD None
had VBD None
more RBR None
severe JJ None
liver NN None
dysfunction NN None
or CC None
previous JJ None
complications NNS None
, , None
and CC None
Group NNP None
3 CD None
had VBD None
severe JJ None
prerenal JJ None
azotemia NN None
without IN None
kidney NN None
disease NN None
. . None
medical JJ None
patients NNS None
surgical JJ None
patients NNS None
medical JJ None
and CC None
surgical JJ None
patients NNS None
. . None
-DOCSTART- -X- N

women NNS Sex
taking VBG Condition
estradiol/trimegestone NN Condition
or CC Condition
estradiol/dydrogesterone NN Condition
. . None
184 CD Size
healthy JJ None
post-menopausal JJ None
women NNS Sex
-DOCSTART- -X- N

following VBG None
acute JJ None
coronary JJ None
syndromes NNS None
. . None
489 CD Size
black JJ None
and CC None
6,890 CD Size
non-black JJ None
patients NNS None
with IN None
acute JJ None
coronary JJ Condition
syndromes NNS Condition
black JJ None
patients NNS None
non-black JJ None
patients NNS None
-DOCSTART- -X- N

Sixteen JJ Size
patients NNS None
scheduled VBN None
for IN None
gastrectomy NN Condition
were VBD None
studied VBN None
. . None
patients NNS None
receiving VBG None
intraoperative JJ None
epidural JJ None
block NN None
. . None
-DOCSTART- -X- N

advanced JJ Condition
urothelial JJ Condition
carcinoma NN Condition
: : None
Japanese JJ None
Urothelial JJ Condition
Cancer NNP Condition
Research NNP None
Group NNP None
. . None
patients NNS None
with IN None
T3b NNP Condition
, , Condition
T4 NNP Condition
or CC Condition
metastatic JJ Condition
urothelial JJ Condition
carcinoma NN Condition
treated VBN None
with IN None
MEC NNP None
or CC None
M-VAC NNP None
chemotherapy NN None
From IN None
1991 CD None
to TO None
1995 CD None
, , None
89 CD Size
patients NNS None
with IN None
T3b NNP Condition
, , Condition
T4 NNP Condition
or CC Condition
metastatic JJ Condition
urothelial JJ Condition
carcinoma NN Condition
-DOCSTART- -X- N

membrane NN Condition
leads NNS Condition
. . None
multicenter NN None
ventricular JJ Condition
leads NNS Condition
: : None
Twenty-three CD Size
of IN None
the DT None
81 CD Size
patients NNS None
were VBD None
women NNS Sex
; : None
the DT None
mean JJ None
age NN None
for IN None
all DT None
patients NNS None
was VBD None
74 CD Age
+/- JJ Age
10 CD Age
years NNS Age
. . None
-DOCSTART- -X- N

children NNS None
with IN None
cystic JJ Condition
fibrosis NN Condition
. . None
11 CD None
malnourished JJ Condition
children NNS None
( ( None
age NN None
10 CD None
to TO None
17 CD None
years NNS None
) ) None
with IN None
cystic JJ Condition
fibrosis NN Condition
, , None
before IN None
and CC None
after IN None
improvement NN None
of IN None
nutritional JJ None
status NN None
with IN None
supplemental JJ None
parenteral JJ None
nutrients NNS None
for IN None
1 CD None
month NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
recurrent NN None
or CC None
metastatic JJ None
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
: : None
Recurrent NNP None
or CC None
metastatic JJ None
squamous JJ Condition
cell NN Condition
carcinoma NN Condition
of IN None
the DT None
head NN None
and CC None
neck NN None
( ( None
SCCHN NNP None
) ) None
patients NNS None
with IN None
recurrent NN None
or CC None
metastatic JJ None
SCCHN NNP Condition
and CC None
no DT None
prior JJ None
systemic JJ None
therapy NN None
for IN None
metastatic JJ None
disease NN None
were VBD None
randomized VBN None
to TO None
pemetrexed VB None
( ( None
500 CD None
mg/m NN None
( ( None
2 CD None
) ) None
) ) None
plus CC None
cisplatin NN None
( ( None
75 CD None
mg/m NN None
( ( None
2 CD None
) ) None
; : None
n CC None
= VB None
398 CD None
) ) None
or CC None
placebo JJ None
plus CC None
cisplatin NN None
( ( None
75 CD None
mg/m NN None
( ( None
2 CD None
) ) None
; : None
n CC None
= VB None
397 CD None
) ) None
patients NNS None
with IN None
oropharyngeal JJ Condition
cancers NNS Condition
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
outpatient JJ Condition
gynecological JJ Condition
laparoscopy NN Condition
. . None
90 CD None
ASA NNP None
grade NN None
I PRP None
or CC None
11 CD None
women NNS Sex
undergoing VBG None
outpatient JJ None
gynecological JJ None
laparoscopy NN None
. . None
-DOCSTART- -X- N

GH-deficient NNP Condition
adults NNS Age
Sixty-eight JJ Size
patients NNS None
( ( None
44 CD Size
men NNS Sex
and CC None
24 CD Size
women NNS Size
) ) None
with IN None
a DT None
mean JJ None
age NN None
of IN None
44.3 CD Age
( ( Age
1.2 CD Age
) ) Age
yr NN Age
and CC None
verified VBD None
GH NNP Condition
deficiency NN Condition
participated VBD None
in IN None
a DT None
2-phase JJ None
treatment NN None
trial NN None
patients NNS None
12 CD None
months NNS None
of IN None
GH NNP None
treatment NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
different JJ None
degrees NNS None
of IN None
immunosuppression NN None
] NNP None
patients NNS None
with IN None
different JJ None
degrees NNS None
of IN None
immunodepression NN None
-DOCSTART- -X- N

infections NNS Condition
in IN Condition
hospitalized JJ Condition
patients NNS Condition
. . None
121 CD Size
hospitalized JJ Condition
patients NNS None
. . None
Eighteen JJ Size
patients NNS None
were VBD None
then RB None
withdrawn VBN None
from IN None
the DT None
study NN None
. . None
patients NNS None
( ( None
n JJ None
= NNP None
103 CD Size
) ) None
-DOCSTART- -X- N

randomised VBN None
trials NNS None
childhood NN None
acute NN None
lymphoblastic JJ None
leukaemia NN None
( ( None
UKALL NNP None
X NNP None
) ) None
randomised VBD None
patients NNS None
aged VBN None
0-14 CD None
years NNS None
inclusive JJ None
with IN None
an DT None
initial JJ None
white JJ None
blood NN None
count NN None
of IN None
less JJR None
than IN None
100 CD None
x JJ None
10 CD None
( ( None
9 CD None
) ) None
/l NN None
to TO None
receive VB None
an DT None
early JJ None
intensification NN None
block NN None
, , None
a DT None
late JJ None
intensification NN None
block NN None
, , None
both DT None
, , None
or CC None
neither RB None
. . None
UKALL NNP None
XI NNP None
, , None
for IN None
children NNS None
aged VBN None
1-14 CD None
years NNS None
all DT None
patients NNS None
were VBD None
also RB None
randomised VBN None
between IN None
late JJ None
intensification NN None
alone RB None
and CC None
both DT None
early JJ None
plus NN None
late JJ None
blocks NNS None
. . None
-DOCSTART- -X- N

surgery NN None
of IN None
the DT None
abdominal JJ None
aorta NN None
] NNP None
Twenty-five JJ None
patients NNS None
undergoing VBG None
excision NN None
of IN None
an DT None
aortic JJ None
abdominal JJ None
aneurysm NN None
-DOCSTART- -X- N

in IN None
sedentary JJ None
postmenopausal JJ None
women NNS None
postmenopausal JJ None
women NNS None
post-menopausal JJ None
women NNS None
supine JJ None
resting VBG None
HRV NNP None
in IN None
373 CD None
post-menopausal JJ None
women NNS None
( ( None
45-75 JJ None
y NN None
) ) None
after IN None
6-months CD None
of IN None
randomly NN None
assigned VBN None
sedentary JJ None
postmenopausal NN None
women NNS None
-DOCSTART- -X- N

treatment NN None
of IN None
chronic JJ Condition
pain NN Condition
. . None
469 CD Size
patients NNS None
469 CD Size
patients NNS None
, , None
255 CD Size
( ( None
54.4 CD None
% NN None
) ) None
were VBD None
female JJ Sex
and CC None
214 CD Size
( ( None
45.6 CD None
% NN None
) ) None
were VBD None
male JJ Sex
. . None
mean JJ None
age NN None
was VBD None
51.1 CD Age
years NNS Age
. . None
Types NNS None
of IN None
chronic NN Condition
pain NN Condition
included VBD None
back RB Condition
( ( None
214 CD None
; : None
45.6 CD None
% NN None
) ) None
, , None
arthritic JJ Condition
( ( None
145 CD None
; : None
30.9 CD None
% NN None
) ) None
, , None
other JJ Condition
musculoskeletal NN Condition
( ( None
65 CD None
; : None
13.9 CD None
% NN None
) ) None
, , None
cancer NN Condition
( ( None
6 CD None
; : None
1.3 CD None
% NN None
) ) None
, , None
diabetic JJ Condition
neuropathic NN Condition
( ( None
3 CD None
; : None
0.6 CD None
% NN None
) ) None
, , None
postherpetic JJ Condition
neuralgic NN Condition
( ( None
5 CD None
; : None
1.1 CD None
% NN None
) ) None
, , None
other JJ Condition
neurologic NN Condition
( ( None
21 CD None
; : None
4.5 CD None
% NN None
) ) None
, , None
and CC None
other JJ None
unclassified JJ Condition
chronic JJ Condition
pain NN Condition
( ( None
10 CD None
; : None
2.1 CD None
% NN None
) ) None
-DOCSTART- -X- N

40 CD None
women NNS None
with IN None
laparoscopically RB None
confirmed VBN None
endometriosis NN None
. . None
The DT None
trial NN None
was VBD None
conducted VBN None
at IN None
a DT None
private JJ None
CHM NNP None
clinic NN None
in IN None
Hove NNP None
( ( None
U.K. NNP None
) ) None
and CC None
at IN None
a DT None
National NNP None
Health NNP None
Service NNP None
outpatient NN None
clinic NN None
in IN None
London NNP None
( ( None
U.K. NNP None
) ) None
. . None
Twenty-eight NNP None
( ( None
28 CD None
) ) None
women NNS None
completed VBD None
the DT None
trial NN None
. . None
-DOCSTART- -X- N

postoperative JJ Condition
wound NN Condition
infection NN Condition
in IN None
elective JJ None
colon NN None
surgery NN None
. . None
-DOCSTART- -X- N

knee NN Condition
joint JJ Condition
osteoarthritis NN Condition
: : None
knee NN Condition
osteoarthritis NN Condition
140 CD Size
community NN None
volunteers NNS None
with IN None
knee NN Condition
osteoarthritis NN Condition
participated VBD None
and CC None
119 CD Size
completed VBD None
the DT None
trial NN None
. . None
physiotherapy NN None
and CC None
placebo NN None
groups NNS None
-DOCSTART- -X- N

left JJ None
ventricular JJ None
function NN None
. . None
hypertensives NNS None
with IN None
incipient JJ Condition
heart NN Condition
failure NN Condition
. . None
left VBD None
ventricular JJ None
function NN None
-DOCSTART- -X- N

sensory JJ None
and CC None
self-regulation JJ None
problems NNS None
in IN None
young JJ Age
children NNS Age
with IN None
autism NN Condition
: : None
46 CD Size
children NNS Age
with IN None
autism NN Condition
< NNP None
age NN Age
6 CD Age
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
initial JJ None
symptoms NNS None
of IN None
prostatic JJ None
adenoma NN None
and CC None
risk NN None
of IN None
its PRP$ None
progression NN None
] NN None
multicenter NN None
, , None
open-population NN None
50 CD Size
patients NNS Size
with IN None
initial JJ None
symptoms NNS None
of IN None
prostatic JJ Condition
adenoma NN Condition
( ( Condition
PA NNP Condition
) ) Condition
in IN None
comparison NN None
with IN None
50 CD Size
matched JJ Size
controls NNS Size
. . None
-DOCSTART- -X- N

Women NNP Condition
undergoing VBG None
controlled JJ None
ovarian JJ Condition
stimulation NN Condition
for IN None
assisted JJ None
conception NN None
-DOCSTART- -X- N

4159 CD Size
patients NNS None
with IN None
myocardial JJ None
infarction NN None
and CC None
average JJ None
LDL NNP None
concentrations NNS None
at IN None
baseline NN None
( ( None
115 CD None
to TO None
174 CD None
mg/dL NNS None
, , None
mean VBP None
139 CD None
mg/dL NN None
) ) None
. . None
patients NNS None
who WP None
had VBD None
either CC None
a DT None
myocardial JJ Condition
infarction NN Condition
or CC None
coronary JJ Condition
death NN Condition
( ( None
cases NNS None
, , None
n=418 NN Size
) ) None
patients NNS None
who WP None
did VBD None
not RB None
have VB None
a DT None
cardiovascular JJ None
event NN None
( ( None
control NN None
subjects VBZ None
, , None
n=370 NN Size
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
scleroderma NN Condition
( ( Condition
SSc NNP Condition
) ) Condition
. . None
41 CD Size
patients NNS None
with IN None
SSc NNP None
. . None
-DOCSTART- -X- N

after IN None
radiation NN None
therapy NN None
for IN None
breast NN None
cancer NN None
. . None
519 CD None
disease-free JJ None
breast NN None
cancer NN None
patients NNS None
7 CD None
to TO None
12 CD None
years NNS None
after IN None
primary JJ None
treatment NN None
. . None
-DOCSTART- -X- N

The DT None
root NN None
canals NNS None
of IN None
30 CD Size
human JJ None
incisors NNS None
and CC None
canines NNS None
-DOCSTART- -X- N

operable JJ None
breast NN Condition
cancer NN Condition
: : None
Patients NNS None
with IN None
involved JJ Condition
axillary JJ Condition
lymph NN Condition
nodes NNS Condition
. . None
of IN None
569 CD Size
patients NNS None
with IN None
cancer NN Condition
of IN Condition
the DT Condition
breast NN Condition
and CC None
involvement NN Condition
of IN Condition
axillary JJ Condition
lymph NN Condition
nodes NNS Condition
were VBD None
randomised VBN None
, , None
after IN None
simple JJ None
mastectomy NN None
with IN None
axillary JJ None
sampling NN None
premenopausal NN Condition
post-menopausal JJ Condition
-DOCSTART- -X- N

fat JJ None
intake NN None
in IN None
rats NNS None
. . None
subjects NNS None
with IN None
a DT None
preference NN None
for IN None
a DT None
high-fat JJ None
diet NN None
. . None
nine CD Size
female NN Sex
and CC None
three CD Size
male NN Sex
healthy JJ None
subjects NNS None
( ( None
age NN Age
34 CD Age
( ( Age
sd VB Age
11 CD Age
) ) Age
years NNS None
, , None
BMI NNP None
24.5 CD None
( ( None
sd VB None
2.5 CD None
) ) None
kg/m NN None
( ( None
2 CD None
) ) None
) ) None
with IN None
a DT None
preference NN None
for IN None
a DT None
high-fat JJ None
diet NN None
ingested VBN None
ENT NNP None
( ( None
3 CD None
x RB None
15 CD None
mg/d NN None
) ) None
or CC None
placebo NN None
( ( None
PLA NNP None
) ) None
while IN None
consuming VBG None
a DT None
high-fat JJ None
diet JJ None
ad NN None
libitum NN None
for IN None
4 CD None
d. NNS None
Eight JJ None
subjects NNS None
subjects NNS None
with IN None
a DT None
preference NN None
for IN None
a DT None
high-fat JJ None
diet JJ None
-DOCSTART- -X- N

persons NNS None
with IN None
developmental JJ Condition
disabilities NNS Condition
. . None
2 CD Size
persons NNS None
with IN None
developmental JJ None
disabilities NNS None
-DOCSTART- -X- N

Eleven JJ None
patients NNS None
with IN None
12 CD None
traumatic JJ None
femur NN None
fractures NNS None
-DOCSTART- -X- N

preterm JJ Condition
labour NN Condition
. . None
pregnant JJ Condition
women NNS Sex
4122 CD Size
women NNS None
at IN None
27-31 JJ None
weeks NNS None
' POS None
gestation NN None
69 CD None
women NNS None
. . None
pregnant JJ Condition
women NNS None
with IN None
group-B JJ Condition
streptococci NN Condition
in IN None
the DT None
urine NN None
-DOCSTART- -X- N

20 CD Size
patients NNS None
with IN None
leukaemia JJ Condition
receiving VBG None
human JJ None
recombinant JJ None
granulocyte NN None
macrophage NN None
colony NN None
stimulating VBG None
factor NN None
( ( None
GM NNP None
CSF NNP None
) ) None
, , None
with IN None
20 CD Size
patients NNS None
receiving VBG None
placebo NN None
both DT None
patient JJ None
groups NNS None
. . None
-DOCSTART- -X- N

nonvalvular JJ None
atrial JJ None
fibrillation NN None
. . None
patients NNS None
with IN None
atrial JJ None
fibrillation NN None
double-blind JJ None
trial NN None
, , None
we PRP None
randomly VBP None
assigned VBD None
14,264 CD None
patients NNS None
with IN None
nonvalvular JJ None
atrial JJ None
fibrillation NN None
who WP None
were VBD None
at IN None
increased VBN None
risk NN None
for IN None
stroke NN None
-DOCSTART- -X- N

post-tonsillectomy NN None
. . None
Thirty-seven JJ None
patients NNS None
from IN None
5 CD None
to TO None
14 CD None
years NNS None
old JJ None
undergoing JJ None
electrocautery NN None
tonsillectomy NN None
mouth NN None
rinse NN None
water NN None
rinse NN None
( ( None
control NN None
) ) None
treatment NN None
group NN None
control NN None
group NN None
. . None
-DOCSTART- -X- N

individual JJ None
Smith-Lemli-Opitz JJ None
patients NNS None
. . None
Smith-Lemli-Opitz NNP Condition
syndrome NN Condition
( ( Condition
SLOS NNP Condition
) ) Condition
23 CD Size
children NNS None
( ( None
aged VBN Age
4-17 CD Age
years NNS Age
) ) None
. . None
13 CD None
subjects NNS None
( ( None
57 CD None
% NN None
) ) None
, , None
whereas $ None
9 CD None
subjects NNS None
( ( None
39 CD None
% NN None
) ) None
had VBD None
EEGs NNP None
consistently RB None
free JJ None
of IN None
IEDs NNP None
. . None
-DOCSTART- -X- N

cetuximab-associated JJ Condition
acnelike JJ Condition
eruption NN Condition
. . None
cetuximab-related JJ Condition
facial JJ Condition
rash NN Condition
. . Condition
In IN None
all DT None
, , None
24 CD Size
patients NNS None
with IN None
metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
with IN Condition
cetuximab JJ Condition
facial JJ Condition
rash NN Condition
patients NNS None
with IN None
cetuximab-related JJ Condition
facial JJ Condition
rash NN Condition
. . None
-DOCSTART- -X- N

dental JJ Condition
pain NN Condition
. . None
120 CD Size
patients NNS None
suffering VBG None
from IN None
pain NN None
as IN None
a DT None
result NN None
of IN None
oral JJ None
surgery NN None
-DOCSTART- -X- N

patients NNS Condition
in IN Condition
state NN Condition
hospitals NNS Condition
. . None
long-term JJ Condition
state NN Condition
hospital NN Condition
inpatients NNS Condition
in IN None
Connecticut NNP None
. . None
people NNS Condition
experiencing VBG Condition
lengthy JJ Condition
hospitalizations NNS Condition
. . None
Long-stay JJ Condition
patients NNS Condition
with IN None
schizophrenia NN Condition
in IN Condition
a DT Condition
state NN Condition
hospital NN Condition
were VBD None
randomly RB None
assigned VBN None
to TO None
begin VB None
open-label JJ None
clozapine NN None
( ( None
n JJ None
= NNP None
138 CD Size
) ) None
or CC None
to TO None
continue VB None
receiving VBG None
conventional JJ None
antipsychotic JJ None
medications NNS None
( ( None
n JJ None
= NNP None
89 CD Size
) ) None
. . None
-DOCSTART- -X- N

sublingual JJ Condition
and CC Condition
vaginal JJ Condition
misoprostol NN Condition
in IN Condition
second JJ Condition
trimester NN Condition
termination NN Condition
of IN Condition
pregnancy NN Condition
. . Condition
second JJ None
trimester NN None
medical JJ None
abortion NN None
. . None
Tertiary JJ None
referral JJ None
unit NN None
and CC None
a DT None
teaching JJ None
hospital NN None
. . None
Two CD None
hundred VBD None
and CC None
twenty-four JJ None
women NNS None
at IN None
12 CD None
to TO None
20 CD None
weeks NNS None
of IN None
gestation NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
newly RB None
diagnosed VBN None
type NN Condition
1 CD Condition
diabetes NNS Condition
mellitus RB Condition
. . Condition
18 CD Size
patients NNS None
with IN None
Type NNP Condition
1 CD Condition
diabetes NNS Condition
mellitus RB Condition
. . None
All DT None
were VBD None
participating VBG None
in IN None
the DT None
Canadian-European JJ None
randomized JJ None
placebo-controlled JJ None
cyclosporin NN None
trial NN None
in IN None
newly RB None
diagnosed VBN None
Type NNP None
1 CD Condition
diabetic JJ Condition
patients NNS None
-DOCSTART- -X- N

transradial JJ Condition
artery NN Condition
catheterization NN Condition
. . None
patients NNS None
undergoing VBG None
transradial JJ Condition
coronary JJ Condition
angiography NN Condition
. . None
A NNP None
total NN None
of IN None
379 CD Size
patients NNS Size
undergoing VBG None
the DT None
procedure NN None
were VBD None
randomly RB None
enrolled VBN None
-DOCSTART- -X- N

hypertensive JJ None
and CC None
hypercholesterolaemic JJ None
patients NNS None
patients NNS None
who WP None
were VBD None
also RB None
encouraged VBN None
to TO None
improve VB None
their PRP$ None
lifestyle NN None
. . None
Fifty-four JJ None
general JJ None
practice NN None
surgeries NNS None
in IN None
Norway NNP None
. . None
Hypertensive JJ None
patients NNS None
, , None
210 CD None
females NNS None
and CC None
160 CD None
males NNS None
, , None
treated VBD None
or CC None
untreated JJ None
with IN None
antihypertensive JJ None
drugs NNS None
with IN None
a DT None
sitting VBG None
diastolic JJ None
blood NN None
pressure NN None
between IN None
95 CD None
and CC None
115 CD None
mmHg NN None
and CC None
a DT None
serum JJ None
total NN None
cholesterol NN None
between IN None
6.5 CD None
mmol/l NNS None
( ( None
7.0 CD None
for IN None
those DT None
age NN None
60-67 JJ None
years NNS None
) ) None
and CC None
9.0 CD None
mmol/l NN None
. . None
hypertensive JJ None
and CC None
hypercholesterolaemic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

people NNS None
with IN None
autism NN Condition
or CC None
Asperger NNP Condition
syndrome VBP Condition
people NNS None
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
Two CD None
groups NNS None
of IN None
11 CD Size
children NNS Age
( ( None
age NN Age
12-18 CD Age
) ) None
with IN None
autism NN None
or CC None
Asperger NNP None
syndrome VBP None
at IN None
two CD None
special JJ None
schools NNS None
participated VBD None
: : None
-DOCSTART- -X- N

community-based JJ None
substance NN None
abuse NN None
clinicians NNS None
Motivational NNP None
Interviewing NNP None
( ( None
MI NNP None
) ) None
. . None
13 CD None
clinicians NNS None
received VBD None
live JJ None
supervision NN None
via IN None
telephone NN None
during IN None
5 CD None
counseling VBG None
sessions NNS None
conducted VBN None
at IN None
their PRP$ None
community NN None
treatment NN None
facilities NNS None
. . None
MI NNP None
community NN None
clinicians NNS None
-DOCSTART- -X- N

a DT None
report NN None
on IN None
218 CD Size
patients NNS None
with IN None
a DT None
median JJ None
follow-up NN None
of IN None
eight CD None
years NNS None
. . None
patients NNS None
with IN None
advanced JJ Condition
stage NN Condition
Hodgkin NNP Condition
's POS Condition
disease NN Condition
( ( Condition
HD NNP Condition
) ) Condition
, , None
as RB None
well RB None
as IN None
in IN None
early JJ Condition
stage NN Condition
patients NNS Condition
with IN Condition
systemic JJ Condition
symptoms NNS Condition
and/or VBP Condition
bulky JJ Condition
disease NN Condition
. . None
218 CD Size
patients NNS None
with IN None
previously RB None
untreated VBN None
HD NNP Condition
entered VBD None
this DT None
study NN None
: : None
106 CD Size
patients NNS Size
in IN None
arm NN Condition
A NNP Condition
( ( Condition
ABVD/MOPP NNP Condition
) ) None
and CC None
112 CD Size
in IN None
arm NN Condition
B NNP Condition
( ( Condition
ABVD/OPP NNP Condition
) ) Condition
. . None
patients NNS None
who WP None
entered VBD None
the DT None
ABVD/MOPP NNP None
arm NN None
. . None
-DOCSTART- -X- N

adults NNS Age
with IN None
autistic JJ Condition
disorder NN None
Thirty NNP Size
adults NNS None
with IN None
autistic JJ Condition
disorder NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ Condition
cardiogenic JJ Condition
pulmonary JJ Condition
edema NN Condition
. . Condition
From IN None
1985 CD None
to TO None
1987 CD None
80 CD Size
patients NNS None
with IN None
acute JJ Condition
cardiogenic JJ Condition
pulmonary JJ Condition
edema NN Condition
only RB None
55 CD Size
patients NNS None
were VBD None
included VBN None
-DOCSTART- -X- N

inner-city JJ None
children NNS None
with IN None
asthma NN Condition
. . None
5- JJ Age
to TO Age
11-year-old JJ Age
children NNS None
( ( None
n JJ None
= NNP None
937 CD Size
) ) None
with IN None
moderate JJ None
to TO None
severe VB None
asthma RB None
receiving VBG None
health NN None
care NN None
in IN None
hospital- JJ None
and CC None
community-based JJ None
clinics NNS None
and CC None
private JJ None
practices NNS None
in IN None
7 CD None
inner-city JJ None
urban JJ None
areas NNS None
. . None
caretaker NN None
of IN None
each DT None
child NN None
-DOCSTART- -X- N

hormone-resistant JJ None
metastatic JJ None
prostate NN None
carcinoma NN None
. . None
51 CD None
patients NNS None
with IN None
stage JJ None
D NNP None
hormone-resistant JJ None
prostatic JJ None
carcinoma NN None
poor JJ None
initial JJ None
performance NN None
status NN None
or CC None
liver VB None
involvement NN None
essentially RB None
geriatric JJ None
population NN None
. . None
-DOCSTART- -X- N

intravenous JJ None
infusion NN None
due JJ None
to TO None
phlebitis VB Condition
and CC Condition
extravasation NN Condition
. . None
skin NN None
of IN None
patients NNS None
patients NNS None
with IN None
active JJ None
patches NNS None
-DOCSTART- -X- N

Sixty NNP None
roots NNS None
of IN None
maxillary JJ None
central JJ None
incisors NNS None
Each DT None
tooth NN None
-DOCSTART- -X- N

for IN None
teens NNS None
with IN None
ASD NNP None
. . None
parent-assisted JJ None
social JJ None
skills NNS None
training VBG None
for IN None
teens NNS None
with IN None
ASD NNP None
. . None
Korean NNP None
and CC None
reviewed VBN None
by IN None
21 CD None
child JJ None
mental JJ None
health NN None
professionals NNS None
. . None
Items NNP None
surveyed VBN None
by IN None
447 CD None
middle JJ None
school NN None
students NNS None
, , None
and CC None
accordingly RB None
. . None
Participants NNS None
included VBD None
47 CD None
teens NNS None
between IN None
12 CD None
and CC None
18 CD None
years NNS None
of IN None
age NN None
with IN None
a DT None
diagnosis NN None
of IN None
ASD NNP None
and CC None
a DT None
verbal JJ None
intelligence NN None
quotient NN None
( ( None
IQ NNP None
) ) None
? . None
65 CD None
efficacious JJ None
for IN None
teens NNS None
with IN None
ASD NNP None
in IN None
Korea NNP None
adolescents NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

displaced JJ Condition
midshaft NN Condition
clavicular JJ Condition
fractures-a JJ Condition
fully RB None
displaced VBN None
midshaft NN None
clavicular NN None
fractures NNS None
in IN None
adults NNS None
. . None
Level NNP Condition
1 CD Condition
trauma NN Condition
center NN None
. . None
Sixty NNP Size
patients NNS None
between IN None
18 CD Age
and CC Age
65 CD Age
years NNS Age
of IN None
age NN None
participated VBN None
and CC None
completed VBN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN Condition
and CC Condition
without IN Condition
autism NN Condition
. . None
children NNS None
with IN None
and CC None
without IN None
autism NN None
Children NNP None
with IN None
autism NN None
and CC None
typically RB None
developed JJ None
children NNS None
participated VBN None
Children NNP None
with IN None
autism NN None
typically RB None
developed JJ None
children NNS None
children NNS None
with IN None
autism NN None
children NNS None
with IN None
autism NN None
. . None
-DOCSTART- -X- N

robot-assisted JJ None
motor NN None
training NN None
after IN None
chronic JJ Condition
stroke NN Condition
: : None
robot-assisted JJ None
reaching NN None
programs NNS None
robot-assisted JJ None
training VBG None
out IN None
of IN None
the DT None
horizontal JJ None
plane NN None
Adults NNP Age
( ( None
N=62 NNP Size
) ) None
with IN None
chronic JJ Condition
, , Condition
stroke-related JJ Condition
arm NN Condition
weakness NN Condition
stratified VBN None
by IN None
impairment JJ None
severity NN None
using VBG None
baseline JJ None
UE NNP None
motor NN None
assessments NNS None
. . None
1.40-4.47 JJ None
) ) None
. . None
Participants NNS None
with IN None
greater JJR None
motor NN None
impairment NN None
( ( None
n=41 JJ None
) ) None
demonstrated VBD None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
unstable JJ Condition
angina NN Condition
. . Condition
Fifty-six JJ None
patients NNS None
with IN None
unstable JJ None
angina NN None
, , None
mean JJ None
age NN None
of IN None
55.4 CD None
+/- JJ None
8.5 CD None
, , None
41 CD None
men NNS None
and CC None
15 CD None
women NNS None
-DOCSTART- -X- N

eleven RB None
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

bone NN None
marrow NN None
of IN None
patients NNS None
with IN None
acute JJ None
myeloid NN None
leukemia NN None
. . None
In IN None
32 CD None
patients NNS None
with IN None
newly RB None
diagnosed VBN None
untreated JJ None
AML NNP None
10 CD None
control NN None
patients NNS None
-DOCSTART- -X- N

young JJ Sex
children NNS Sex
with IN None
autism NN Condition
. . None
young JJ Age
children NNS Age
with IN None
autism NN Condition
. . None
Twenty-four JJ Size
children NNS Age
with IN None
autism NN Condition
, , None
3.0 CD Age
to TO Age
8.3 CD Age
years NNS Age
old JJ Age
( ( None
mean JJ None
5.1 CD Age
) ) None
who WP None
were VBD None
living VBG None
at IN None
home NN None
and CC None
attending VBG None
appropriate JJ None
school NN None
programs NNS None
-DOCSTART- -X- N

Guatemalan NNP None
adults NNS None
. . None
1424 CD None
Guatemalan NNP None
individuals NNS None
( ( None
aged VBN None
25-42 CD None
years NNS None
) ) None
between IN None
2002 CD None
and CC None
2004 CD None
. . None
accounted VBD None
for IN None
60 CD None
% NN None
of IN None
the DT None
2392 CD None
children NNS None
( ( None
aged VBN None
0-7 CD None
years NNS None
) ) None
who WP None
had VBD None
been VBN None
enrolled VBN None
in IN None
a DT None
nutrition NN None
intervention NN None
study NN None
during IN None
1969-77 JJ None
. . None
-DOCSTART- -X- N

two CD None
studies NNS None
of IN None
aripiprazole NN None
in IN None
the DT None
treatment NN None
of IN None
irritability NN Condition
associated VBN None
with IN None
autistic JJ Condition
disorder NN Condition
. . None
two CD None
8-week JJ None
, , None
randomized VBN None
, , None
double-blind JJ None
, , None
multicenter JJ None
trials NNS None
children NNS None
and CC None
adolescents NNS None
with IN None
autistic JJ Condition
disorder NN Condition
-DOCSTART- -X- N

non-invasive JJ None
positive-pressure NN None
ventilation NN None
( ( None
NPPV NNP None
) ) None
Fourteen NNP Size
patients NNS None
with IN None
stable JJ Condition
hypercapnic JJ Condition
COPD NN Condition
who WP None
were VBD None
receiving VBG None
long-term JJ None
NPPV NNP None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

patients NNS None
treated VBN None
for IN None
a DT None
hematological JJ Condition
malignancy NN Condition
. . None
febrile JJ Condition
neutropenic JJ Condition
patients NNS None
. . None
patients NNS None
with IN None
prolonged JJ Condition
neutropenia NN Condition
the DT None
clinician NN None
's POS None
compliance NN None
with IN None
these DT None
rules NNS None
in IN None
1951 CD None
febrile NN None
neutropenic JJ None
episodes NNS None
was VBD None
the DT None
subject NN None
of IN None
the DT None
present JJ None
analysis NN None
. . None
-DOCSTART- -X- N

Menopausal NNP None
menopause-related JJ None
women NNS None
with IN None
vasomotor NN None
symptoms NNS None
. . None
Peri- NN None
and CC None
postmenopausal JJ None
women NNS None
, , None
40-62 JJ None
years NNS None
old JJ None
, , None
RESULTS NNP None
Among IN None
355 CD None
randomly NNS None
assigned VBN None
women NNS None
who WP None
average VBP None
age NN None
was VBD None
54.7 CD None
years NNS None
, , None
338 CD None
women NNS None
( ( None
95 CD None
% NN None
) ) None
completed VBD None
12-week JJ None
assessments NNS None
. . None
among IN None
healthy JJ None
sedentary JJ None
menopausal NN None
women NNS None
, , None
-DOCSTART- -X- N

chronic JJ None
midportion NN None
Achilles NNP None
tendinopathy NN Condition
: : None
chronic JJ Condition
midportion NN Condition
Achilles NNP Condition
tendinopathy NN Condition
. . None
Sports NNP None
Medical NNP None
Department NNP None
, , None
The DT None
Hague NNP None
Medical NNP None
Centre NNP None
, , None
The DT None
Netherlands NNP None
. . None
Inclusion NNP None
criteria NNS None
were VBD None
: : None
age NN None
18-70 CD Age
years NNS Age
, , None
active JJ Condition
participation NN Condition
in IN Condition
sports NNS Condition
, , None
and CC None
tendon VB Condition
pain NN Condition
localised VBN Condition
at IN Condition
2-7 JJ Condition
cm NN Condition
from IN Condition
distal JJ Condition
insertion NN Condition
. . None
Exclusion NN None
criteria NNS None
were VBD None
: : None
insertional JJ None
disorders NNS None
, , None
partial JJ None
or CC None
complete JJ None
ruptures NNS None
, , None
or CC None
systemic JJ None
illness NN None
. . None
70 CD None
tendons NNS None
were VBD None
included VBN None
eccentric JJ None
group NN None
from IN None
50.1 CD None
to TO None
68.8 CD None
( ( None
p NN None
= RB None
0.001 CD None
) ) None
night NN None
splint NN None
group NN None
from IN None
49.4 CD None
to TO None
67.0 CD None
( ( None
p NN None
< RB None
0.001 CD None
) ) None
. . None
-DOCSTART- -X- N

scaphoid NN Condition
fractures NNS Condition
fractures NNS Condition
of IN Condition
the DT Condition
carpal JJ Condition
scaphoid NN Condition
. . None
392 CD Size
fresh JJ None
fractures NNS None
292 CD Size
fractures NNS None
-DOCSTART- -X- N

registered JJ None
nurses NNS None
. . None
health NN None
care NN None
professionals NNS None
. . None
mail NN None
and CC None
telephone NN None
survey NN None
of IN None
49,605 CD None
registered JJ None
nurses NNS None
for IN None
the DT None
2000 CD None
National NNP None
Sample NNP None
Survey NNP None
of IN None
Registered NNP None
Nurses NNP None
-DOCSTART- -X- N

urban JJ None
and CC None
rural JJ None
older JJR None
, , None
long-term JJ Condition
survivors NNS Condition
of IN Condition
breast NN Condition
, , Condition
prostate NN Condition
, , Condition
and CC Condition
colorectal JJ Condition
cancer NN Condition
Older NNP None
adult NN None
cancer NN None
survivors NNS None
urban JJ None
and CC None
rural JJ None
cancer NN None
survivors NNS None
cancer NN None
. . None
Survivors NNS None
in IN None
the DT None
present JJ None
analysis NN None
( ( None
n=729 JJ None
) ) None
underwent JJ None
Among IN None
rural JJ None
survivors NNS None
, , None
-DOCSTART- -X- N

women NNS Sex
with IN None
abnormal JJ Condition
cervical JJ Condition
smears NNS Condition
. . None
Colposcopy NNP None
clinic NN None
at IN None
Aberdeen NNP None
Royal NNP None
Infirmary NNP None
. . None
100 CD Size
women NNS Sex
with IN None
abnormal JJ Condition
cervical JJ Condition
smears NNS Condition
selected VBN None
for IN None
cone NN None
biopsy NN None
according VBG None
to TO None
current JJ None
colposcopy NN None
criteria NNS None
. . None
-DOCSTART- -X- N

rats NNS None
. . None
rat NN None
. . None
Thirty-seven NNP Size
male NN Sex
Wistar NNP None
rats NNS None
-DOCSTART- -X- N

The DT None
nonsmoking JJ None
participants NNS None
, , None
ages VBZ None
18-30 CD None
years NNS None
, , None
included VBD None
42 CD None
women NNS None
and CC None
31 CD None
men NNS None
who WP None
reported VBD None
demographic JJ None
information NN None
and CC None
measures NNS None
of IN None
external JJ None
temperature NN None
and CC None
heart NN None
rate NN None
were VBD None
taken VBN None
prior RB None
to TO None
introduction NN None
of IN None
an DT None
anxiety-eliciting JJ None
task NN None
and CC None
exposure NN None
to TO None
lavender VB None
, , None
rosemary JJ None
, , None
or CC None
water NN None
scents NNS None
. . None
-DOCSTART- -X- N

3 CD None
groups NNS None
of IN None
healthy JJ Condition
male JJ Sex
patients NNS None
: : None
Control NNP None
( ( None
n JJ None
= NNP None
35 CD Size
) ) None
, , None
2.5 CD None
microg/kg NN None
Clonidine NNP None
( ( None
n JJ None
= NNP None
36 CD Size
) ) None
, , None
and CC None
5.0 CD None
microg/kg NNS None
Clonidine NNP None
( ( None
n JJ None
= NNP None
36 CD Size
) ) None
groups NNS None
. . None
-DOCSTART- -X- N

healthy JJ Condition
young JJ Condition
subjects NNS Condition
Five NNP None
groups NNS None
of IN None
8 CD None
subjects NNS None
each DT None
-DOCSTART- -X- N

symptomatic JJ None
and CC None
asymptomatic JJ None
episodes NNS None
of IN None
ST NNP Condition
segment NN Condition
depression NN Condition
occurring VBG None
during IN None
daily JJ None
life NN None
and CC None
during IN None
exercise NN None
. . None
patients NNS None
with IN None
coronary JJ Condition
disease NN Condition
; : None
Sixty NNP Size
patients NNS None
with IN None
stable JJ None
coronary JJ None
artery NN None
disease NN None
, , None
a DT None
positive JJ None
treadmill NN None
exercise NN None
test NN None
and CC None
asymptomatic JJ None
ST NNP Condition
segment NN Condition
depression NN Condition
on IN None
ambulatory JJ None
electrocardiographic JJ None
recording VBG None
were VBD None
assessed VBN None
in IN None
a DT None
multicenter NN None
, , None
double-blind JJ None
, , None
placebo-controlled JJ None
, , None
cross-over JJ None
trial NN None
. . None
patients NNS None
with IN None
stable JJ None
coronary JJ None
artery NN None
disease NN None
. . None
-DOCSTART- -X- N

Women NNP Condition
's POS Condition
responses NNS Condition
to TO Condition
information NN Condition
on IN Condition
mammographic JJ Condition
breast NN Condition
density NN Condition
. . Condition
participants NNS Condition
of IN Condition
a DT Condition
screening JJ Condition
program NN Condition
. . Condition
sample NN None
of IN None
618 CD None
women NNS None
50 CD None
years NNS None
or CC None
older JJR None
with IN None
MBD NNP None
greater JJR None
than IN None
50 CD None
% NN None
of IN None
breast NN None
volume NN None
. . None
-DOCSTART- -X- N

Eleven NNP None
healthy JJ None
subjects NNS None
-DOCSTART- -X- N

recurrent JJ None
herpetic JJ None
ocular JJ None
infection NN None
. . None
Twenty NNP None
patients NNS None
with IN None
herpes NNS None
simplex JJ None
virus IN None
1-related JJ None
recurrent NN None
keratitis/keratouveitis NN None
-DOCSTART- -X- N

social JJ None
behavior NN None
in IN None
children NNS Age
with IN None
autism NN Condition
. . None
4- JJ None
to TO None
12-year-old JJ None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
; : None
N NNP None
= NNP None
24 CD None
) ) None
during IN None
-DOCSTART- -X- N

low-income JJ None
urban JJ None
children NNS None
: : None
low-income JJ None
urban JJ None
population NN None
in IN None
Seattle/King NNP None
County NNP None
, , None
Washington NNP None
, , None
as RB None
well RB None
as IN None
caregiver NN None
knowledge NN None
caretakers NNS None
of IN None
children NNS None
aged VBN None
4-12 CD None
years NNS None
with IN None
persistent JJ None
asthma NN Condition
living NN None
in IN None
households NNS None
with IN None
incomes NNS None
less JJR None
than IN None
200 CD None
% NN None
of IN None
poverty NN None
. . None
children NNS None
and CC None
their PRP$ None
caregivers NNS None
are VBP None
participants NNS None
in IN None
the DT None
ongoing JJ None
Seattle-King JJ None
County NNP None
Healthy NNP None
Homes NNP None
Project NNP None
, , None
a DT None
randomized VBN None
controlled JJ None
trial NN None
of IN None
an DT None
intervention NN None
to TO None
empower VB None
low-income JJ None
families NNS None
to TO None
reduce VB None
exposure NN None
to TO None
indoor VB None
asthma JJ Condition
triggers NNS None
. . None
the DT None
first JJ None
112 CD Size
enrolled JJ None
households NNS None
. . None
low-income JJ None
urban JJ None
children NNS None
with IN None
asthma NN Condition
-DOCSTART- -X- N

restricting- JJ None
and CC None
restricting-purging-type JJ None
anorexia NN None
nervosa NN None
. . None
35 CD None
patients NNS None
with IN None
restricting-type JJ None
anorexia NN None
nervosa NN None
. . None
Anorexics NNS None
patients NNS None
with IN None
anorexia JJ None
nervosa NN None
-DOCSTART- -X- N

subcutaneous JJ None
heparin NN None
injection NN None
on IN None
bruising NN None
and CC None
pain NN None
. . None
50 CD Size
patients NNS None
to TO None
whom WP None
subcutaneous JJ Condition
heparin NN Condition
was VBD None
administered VBN None
. . None
-DOCSTART- -X- N

Sports NNP None
Medical NNP None
Department NNP None
of IN None
the DT None
Hague NNP None
Medical NNP None
Centre NNP None
. . None
Twenty-six JJ Size
tendons NNS None
from IN None
patients NNS None
with IN None
chronic JJ Condition
midportion NN Condition
Achilles NNP Condition
tendinopathy NN Condition
were VBD None
included VBN None
. . None
26 CD Size
asymptomatic JJ None
tendons NNS None
. . None
-DOCSTART- -X- N

acute JJ Condition
myocardial JJ Condition
infarction NN Condition
395 CD Size
patients NNS None
with IN None
acute JJ None
myocardial JJ None
infarction NN None
( ( None
AMI NNP Condition
) ) None
138 CD Size
patients NNS None
with IN None
anterior JJ None
wall NN None
AMI NNP None
257 CD Size
patients NNS None
with IN None
nonanterior JJ None
wall NN None
AMI NNP None
patients NNS None
with IN None
anterior JJ None
wall NN None
AMI NNP None
-DOCSTART- -X- N

minimally RB None
invasive JJ None
mitral-valve JJ Condition
operations NNS Condition
. . None
patients NNS None
with IN None
peripheral JJ None
vessel NN None
disease NN None
. . None
20 CD Size
patients NNS None
were VBD None
prospectively RB None
randomized VBN None
into IN None
2 CD None
groups NNS None
, , None
to TO None
undergo VB None
either RB None
standard JJ None
femoral NN None
( ( None
group NN None
A NNP None
) ) None
or CC None
direct JJ None
aortic JJ None
cannulation NN None
( ( None
group NN None
B NNP None
) ) None
. . None
-DOCSTART- -X- N

competitive JJ None
swimmers NNS None
. . None
18 CD None
male NN None
and CC None
female JJ None
junior JJ None
competitive JJ None
swimmers NNS None
9 CD None
days NNS None
during IN None
training NN None
. . None
-DOCSTART- -X- N

chronic JJ None
myeloid NN None
leukemia NN None
blast NN None
phase NN None
. . None
Seventy-three JJ None
eligible JJ None
patients NNS None
-DOCSTART- -X- N

older JJR Age
adults NNS Age
with IN None
insomnia NN Condition
. . None
Seventeen NNP None
sedentary JJ None
adults NNS None
aged VBN None
> JJ Age
or=55 CD Age
years NNS Age
with IN None
insomnia NN None
( ( None
mean JJ None
age NN None
61.6 CD None
[ NN None
SD?4.3 NNP None
] NNP None
years NNS None
; : None
16 CD None
female NN None
) ) None
participated VBD None
included VBD None
primary JJ None
insomnia NN None
for IN None
at IN None
least JJS None
3 CD None
months NNS None
, , None
habitual JJ None
sleep NN None
duration NN None
< POS None
6.5h CD None
and CC None
a DT None
Pittsburgh NNP None
Sleep NNP None
Quality NNP None
Index NNP None
( ( None
PSQI NNP None
) ) None
score VBD None
> JJ None
5 CD None
. . None
in IN None
older JJR Age
adults NNS Age
with IN None
chronic JJ None
insomnia NN None
. . None
-DOCSTART- -X- N

age-associated JJ Condition
memory NN Condition
impairment NN Condition
. . None
age-associated JJ None
memory NN None
impairment NN None
( ( None
AAMI NNP None
) ) None
patients NNS None
. . None
AAMI NNP None
patients NNS None
-DOCSTART- -X- N

Wuchereria NNP Condition
bancrofti JJ Condition
infection NN Condition
in IN None
human JJ None
beings NNS None
and CC None
mosquitoes NNS None
. . None
14 CD None
communities NNS None
in IN None
matched JJ None
pairs NNS None
. . None
People NNS None
aged VBD None
5 CD Age
years NNS None
or CC None
older JJR None
in IN None
seven CD None
communities NNS None
received VBD None
randomly RB None
assigned VBN None
diethylcarbamazine NN None
6 CD None
mg/kg NN None
and CC None
people NNS None
in IN None
the DT None
other JJ None
seven CD None
communities NNS None
five CD None
communities NNS None
2219 CD Size
( ( None
87.6 CD None
% NN None
) ) None
of IN None
2534 CD Size
eligible JJ None
people NNS None
received VBD None
treatment NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
extrahepatic JJ Condition
portal NN Condition
venous JJ Condition
obstruction NN Condition
. . None
adult NN None
patients NNS None
with IN None
cirrhosis NN None
. . None
49 CD Size
children NNS None
with IN None
extrahepatic JJ None
portal NN None
venous JJ None
obstruction NN None
who WP None
had VBD None
proven VBN None
bleeding VBG None
from IN None
esophageal JJ None
varices NNS None
. . None
Twenty-four CD Size
patients NNS None
were VBD None
treated VBN None
with IN None
sclerotherapy NN None
and CC None
25 CD Size
with IN None
band NN None
ligation NN None
. . None
children NNS Age
-DOCSTART- -X- N

tuberculosis NN None
in IN None
HIV NNP None
infection NN None
: : None
tuberculin JJ None
skin JJ None
test-positive JJ None
and CC None
negative JJ None
individuals NNS None
with IN None
HIV NNP None
infection NN None
. . None
Seven NNP None
trials NNS None
from IN None
Mexico NNP None
, , None
Haiti NNP None
, , None
the DT None
United NNP None
States NNPS None
, , None
Zambia NNP None
, , None
Uganda NNP None
and CC None
Kenya NNP None
. . None
Individuals NNP None
free JJ None
from IN None
tuberculosis NN None
, , None
2367 CD None
persons NNS None
in IN None
the DT None
intervention NN None
and CC None
2162 CD None
in IN None
the DT None
control NN None
groups NNS None
. . None
isoniazid JJ None
prophylaxis NN None
in IN None
HIV-infected JJ None
persons NNS None
. . None
persons NNS None
with IN None
HIV NNP None
infection NN None
. . None
restricted VBN None
to TO None
tuberculin VB None
skin JJ None
test-positive JJ None
persons NNS None
. . None
-DOCSTART- -X- N

Sinemet NNP None
CR NNP None
in IN None
Parkinson NNP None
's POS None
disease NN None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
total JJ None
mastectomy NN None
. . None
128 CD Size
women NNS None
undergoing VBG Condition
total JJ Condition
mastectomy NN Condition
. . None
patients NNS None
undergoing JJ Condition
total JJ Condition
mastectomy NN Condition
-DOCSTART- -X- N

IPPB NNP None
for IN None
the DT None
treatment NN None
of IN None
croup NN None
: : None
Twenty CD None
patients NNS None
( ( None
aged VBN None
4 CD None
months NNS None
to TO None
5 CD None
years NNS None
) ) None
hospitalized VBD None
with IN None
acute JJ None
croup NN None
and CC None
persistent JJ None
inspiratory NN None
stridor NN None
at IN None
rest NN None
acute JJ None
signs NNS None
of IN None
croup NN None
. . None
-DOCSTART- -X- N

Plasmodium NNP None
falciparum NN None
malaria NN None
to TO None
mefloquine VB None
in IN None
African JJ None
children NNS None
85 CD Size
children NNS Age
suffering VBG None
from IN None
acute JJ Condition
symptomatic JJ Condition
falciparum NN Condition
malaria NN Condition
. . Condition
children NNS None
with IN None
hyperparasitaemia NN Condition
those DT None
without IN None
hyperparasitaemia NN None
-DOCSTART- -X- N

40 CD None
lesions NNS None
of IN None
actinic JJ Condition
keratosis NN Condition
in IN None
Japanese JJ None
patients NNS None
. . None
12 CD None
, , None
15 CD None
and CC None
13 CD None
Japanese JJ None
actinic JJ Condition
keratosis NN Condition
( ( Condition
AK NNP Condition
) ) Condition
lesions NNS None
Most JJS None
Japanese JJ None
AK NNP None
lesions NNS None
can MD None
-DOCSTART- -X- N

treatment NN None
of IN None
prostates NNS Condition
larger JJR Condition
than IN Condition
40 CD Condition
grams NNS Condition
: : None
men NNS Sex
with IN None
bladder NN Condition
outflow JJ Condition
obstruction NN Condition
( ( Condition
BOO NNP Condition
) ) Condition
secondary VBP None
to TO None
benign VB Condition
prostatic JJ Condition
hyperplasia NN Condition
with IN None
a DT None
minimum NN None
of IN None
24-month JJ None
follow-up JJ None
. . None
Sixty-one CD Size
patients NNS None
All DT None
patients NNS None
had VBD None
BOO NNP Condition
proven RB None
on IN None
urodynamic JJ None
studies NNS None
pre-operatively RB None
( ( None
prostate JJ Condition
size NN Condition
40-200 JJ Condition
g NN Condition
) ) None
. . None
30 CD None
patients NNS None
in IN None
each DT None
group NN None
. . None
-DOCSTART- -X- N

home-based JJ None
telehealth NN None
intervention NN None
nurse JJ None
and CC None
patient JJ None
Subjects NNPS None
randomized NN None
controlled VBD None
clinical JJ None
trial NN None
Telephone NNP None
( ( None
n=14 NN Size
) ) None
and CC None
videophone NN None
( ( None
n=14 JJ Size
) ) None
interactions NNS None
Nurses NNPS None
Patients NNS None
-DOCSTART- -X- N

heart NN None
failure NN None
patients NNS None
. . None
heart NN None
failure NN None
patients NNS None
patients NNS None
surviving VBG None
myocardial JJ None
infarction NN None
. . None
humans NNS None
. . None
Patients NNPS None
with IN None
post-myocardial JJ None
infarction NN None
left VBD None
ventricular JJ None
dysfunction NN None
patients NNS None
with IN None
stable JJ None
congestive JJ None
heart NN None
failure NN None
. . None
-DOCSTART- -X- N

acute JJ None
hematogenous JJ Condition
bone NN None
and CC None
joint JJ None
infection NN None
in IN None
children NNS Age
: : None
Thirty-three JJ Size
cases NNS None
of IN None
acute JJ None
hematogenous JJ None
bone NN None
or CC None
joint JJ None
infection NN None
in IN None
children NNS None
children NNS None
with IN None
blood-borne JJ None
musculoskeletal JJ Condition
infection NN Condition
. . None
-DOCSTART- -X- N

20 CD Size
healthy JJ Condition
male NN Sex
volunteers NNS None
. . None
One CD Size
subject NN None
was VBD None
identified VBN None
to TO None
be VB None
a DT None
poor JJ Condition
metabolizer NN Condition
. . None
-DOCSTART- -X- N

hypertensive JJ Condition
pregnancy NN Condition
. . None
21 CD Size
normotensive JJ Condition
and CC None
36 CD Size
hypertensive JJ Condition
patients NNS None
during IN None
the DT None
last JJ None
trimester NN None
of IN None
pregnancy NN None
. . None
hypertensive JJ Condition
patients NNS None
normotensive JJ Condition
and CC None
hypertensive JJ Condition
patients NNS None
. . None
hypertensive JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

COPD NNP None
patients NNS None
. . None
Participants NNS None
can MD None
use VB None
any DT None
background NN None
treatment NN None
for IN None
COPD NNP None
except IN None
inhaled JJ None
anticholinergic JJ None
agents NNS None
. . None
The DT None
study NN None
encompasses VBZ None
a DT None
wide JJ None
range NN None
of IN None
COPD NNP None
patients NNS None
, , None
e.g FW None
. . None
patients NNS None
with IN None
stable JJ None
cardiac JJ None
diseases NNS None
including VBG None
arrhythmia NN None
can MD None
be VB None
included VBN None
. . None
Clinical JJ None
sites NNS None
are VBP None
international JJ None
and CC None
include VBP None
both DT None
primary JJ None
care NN None
as RB None
well RB None
as IN None
specialists NNS None
. . None
RESULTS NNP None
To TO None
date NN None
, , None
over IN None
17,000 CD None
participants NNS None
have VBP None
been VBN None
randomized VBN None
from IN None
over IN None
1200 CD None
sites NNS None
in IN None
50 CD None
countries NNS None
with IN None
-DOCSTART- -X- N

autistic JJ None
children NNS None
. . None
autistic JJ None
children NNS None
-DOCSTART- -X- N

students NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
Forty-two JJ None
students NNS None
with IN None
autism NN None
, , None
varying VBG None
in IN None
age NN None
and CC None
expressive JJ None
communication NN None
ability NN None
, , None
were VBD None
randomly RB None
assigned VBN None
to TO None
the DT None
experimental JJ None
conditions NNS None
. . None
-DOCSTART- -X- N

in IN None
a DT None
dental JJ None
school NN None
setting VBG None
. . None
patients NNS None
Fifty NNP Size
patients NNS None
were VBD None
recruited VBN None
in IN None
the DT None
school NN None
's POS None
Urgent NNP None
Care NNP None
Clinic NNP None
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
small JJ None
choroidal NNS None
melanoma NN None
. . None
patients NNS None
with IN None
small JJ None
choroidal NNS None
melanoma NN None
. . None
From IN None
December NNP None
1986 CD None
to TO None
August NNP None
1989 CD None
, , None
patients NNS None
with IN None
small JJ None
choroidal NN None
melanoma NN None
, , None
not RB None
large JJ None
enough RB None
to TO None
be VB None
eligible JJ None
for IN None
the DT None
COMS NNP None
clinical JJ None
trials NNS None
A DT None
total NN None
of IN None
204 CD None
patients NNS None
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
Otherwise NNP None
healthy JJ None
patients NNS None
, , None
average JJ None
age NN None
of IN None
60 CD None
years NNS None
, , None
without IN None
a DT None
previous JJ None
diagnosis NN None
of IN None
malignant JJ None
disease NN None
who WP None
have VBP None
small JJ None
choroidal JJ None
lesions NNS None
judged VBD None
to TO None
be VB None
melanoma VBN None
-DOCSTART- -X- N

One CD Size
hundred VBD Size
seventy-seven JJ Size
women NNS Sex
aged VBD None
41 CD Age
+/- JJ Age
8 CD Age
( ( None
mean JJ None
+/- NNP None
SD NNP None
) ) None
years NNS None
, , None
referred VBD None
for IN None
evaluation NN None
of IN None
excessive JJ Condition
uterine JJ Condition
bleeding NN Condition
, , None
were VBD None
enrolled VBN None
hysteroscopy NN None
in IN None
an DT None
outpatient JJ None
population NN None
. . None
premenopausal JJ Age
women NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
cystic JJ Condition
fibrosis NN Condition
children NNS Age
and CC Age
adolescents NNS Age
with IN None
CF NNP Condition
. . None
44 CD Size
CF NNP None
patients NNS None
( ( None
aged VBN Age
7-19 CD Age
y NN Age
; : None
20 CD Sex
males NNS Sex
) ) None
who WP None
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
magnesium NN None
( ( None
n JJ None
= VBZ None
22 CD Size
; : None
300 CD None
mg/d NN None
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= NNP None
22 CD Size
) ) None
for IN None
8 CD None
wk NN None
with IN None
a DT None
4-wk JJ None
washout NN None
period NN None
between IN None
trials NNS None
. . None
-DOCSTART- -X- N

Between IN None
November NNP None
1973 CD None
and CC None
July NNP None
1982 CD None
, , None
123 CD Size
women NNS Sex
younger JJR Age
than IN Age
70 CD Age
years NNS Age
of IN Age
age NN Age
and CC None
at IN None
clinical JJ Condition
Stages NNP Condition
I PRP Condition
and CC Condition
II NNP Condition
were VBD None
enrolled VBN None
. . None
112 CD Size
were VBD None
treated VBN None
by IN None
the DT None
same JJ None
surgeon NN None
and CC None
confirmed VBD None
pathologically RB None
as IN None
having VBG None
invasive JJ Condition
mammary JJ Condition
carcinoma NN Condition
. . None
patients NNS None
with IN None
lateral JJ Condition
tumors NNS Condition
patients NNS None
treated VBD None
between IN None
1960 CD None
and CC None
1978 CD None
-DOCSTART- -X- N

transurethral JJ None
procedures NNS None
. . None
elderly JJ Age
males NNS Age
undergoing VBG None
elective JJ Condition
transurethral JJ Condition
resection NN Condition
of IN Condition
the DT Condition
prostate NN Condition
. . None
Teaching NNP None
hospital NN None
. . None
21 CD Size
ASA NNP None
physical JJ None
status NN None
I PRP None
, , None
II NNP None
, , None
and CC None
III NNP None
patients NNS None
at IN Age
least JJS Age
18 CD Age
years NNS None
of IN None
age NN None
, , None
undergoing VBG None
transurethral JJ None
surgery NN None
. . None
-DOCSTART- -X- N

rural JJ None
and CC None
urban JJ None
Chinese JJ None
population NN None
in IN None
Qingdao NNP None
. . None
rural JJ None
and CC None
urban JJ None
Chinese JJ None
population NN None
. . None
Qingdao NNP None
, , None
China NNP None
in IN None
2006 CD None
with IN None
6100 CD None
Chinese JJ None
aged VBN None
35-74 JJ None
yr NN None
invited VBN None
and CC None
5355 CD None
who WP None
attended VBD None
; : None
3357 CD None
subjects NNS None
, , None
1562 CD None
urban NN None
( ( None
46.5 CD None
% NN None
) ) None
and CC None
1795 CD None
rural JJ None
residents NNS None
( ( None
53.5 CD None
% NN None
) ) None
met VBD None
the DT None
inclusion NN None
criteria NNS None
for IN None
the DT None
current JJ None
data NN None
analysis NN None
. . None
adult JJ None
Chinese NNPS None
in IN None
both DT None
rural JJ None
and CC None
urban JJ None
areas NNS None
in IN None
Qingdao NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
heart NN Condition
failure NN Condition
. . None
patients NNS None
with IN None
chronic JJ None
heart NN None
failure NN None
and CC None
decreased JJ None
ejection NN None
fraction NN None
. . None
66 CD Size
patients NNS None
were VBD None
examined VBN None
patients NNS None
with IN None
chronic JJ None
heart NN None
failure NN None
and CC None
decreased JJ None
ejection NN None
fraction NN None
. . None
-DOCSTART- -X- N

porcine JJ None
model NN None
of IN None
lavage-induced JJ Condition
acute NN Condition
lung NN Condition
injury NN Condition
: : None
lavage-induced JJ None
porcine NN None
lung NN None
injury NN None
33 CD Size
healthy JJ None
female NN Sex
pigs NNS None
, , None
weighing VBG None
52 CD None
+/- JJ None
4.1 CD None
kg NN None
( ( None
mean JJ None
+/- NNP None
SD NNP None
) ) None
four CD None
groups NNS None
: : None
group NN None
1 CD None
group NN None
2 CD None
group NN None
3 CD None
group NN None
4 CD None
-DOCSTART- -X- N

young JJ Age
children NNS Age
with IN None
autism NN Condition
. . None
Children NNP None
with IN None
autism NN None
three CD Size
young JJ None
children NNS None
with IN None
autism NN None
and CC None
their PRP$ None
mothers NNS None
. . None
young JJ None
children NNS None
with IN None
autism NN None
parents NNS None
. . None
-DOCSTART- -X- N

trial NN None
in IN None
adults NNS None
. . None
Sixty NNP Size
and CC Size
59 CD Size
healthy JJ Condition
young JJ None
adults NNS None
previously RB Condition
immunized VBN Condition
against IN Condition
tetanus NN Condition
( ( Condition
T NNP Condition
) ) Condition
and CC Condition
diphtheria NN Condition
( ( Condition
D NNP Condition
) ) Condition
were VBD None
randomized VBN None
to TO None
receive VB None
intramuscularly RB None
either DT None
Td NNP None
vaccine NN None
alone RB None
( ( None
group NN None
1 CD None
) ) None
or CC None
Td NNP None
vaccine NN None
plus CC None
500 CD None
IU NNP None
of IN None
TIG NNP None
( ( None
group NN None
2 CD None
) ) None
simultaneously RB None
. . None
-DOCSTART- -X- N

families NNS None
in IN None
challenging VBG None
contexts NN None
: : None
France NNP None
children NNS None
being VBG None
referred VBN None
for IN None
mental JJ None
health NN None
problems NNS None
. . None
families NNS None
living VBG None
in IN None
vulnerable JJ None
contexts NN None
. . None
440 CD None
women NNS None
and CC None
their PRP$ None
families NNS None
, , None
took VBD None
place NN None
in IN None
Paris NNP None
and CC None
its PRP$ None
inner JJ None
suburbs NNS None
from IN None
2006 CD None
to TO None
2011 CD None
. . None
To TO None
be VB None
eligible JJ None
for IN None
inclusion NN None
, , None
women NNS None
had VBD None
to TO None
be VB None
( ( None
i NN None
) ) None
under IN None
26 CD None
years NNS None
old JJ None
, , None
( ( None
ii NN None
) ) None
less JJR None
that IN None
27 CD None
weeks NNS None
pregnant JJ None
, , None
( ( None
iii NN None
) ) None
sufficiently RB None
fluent VBN None
in IN None
French JJ None
to TO None
give VB None
truly NN None
informed JJ None
consent NN None
to TO None
participate VB None
in IN None
the DT None
study NN None
and CC None
benefit NN None
from IN None
the DT None
intervention NN None
and CC None
( ( None
iv NN None
) ) None
presenting VBG None
with IN None
one CD None
or CC None
more JJR None
of IN None
the DT None
following JJ None
social JJ None
vulnerability NN None
factors NNS None
: : None
low JJ None
income NN None
, , None
low JJ None
educational JJ None
level NN None
, , None
and/or RB None
intending VBG None
to TO None
bring VB None
up RP None
the DT None
child NN None
without IN None
the DT None
child NN None
's POS None
father NN None
. . None
-DOCSTART- -X- N

nurse JJ None
run NN None
clinics NNS None
for IN None
patients NNS None
with IN None
epilepsy NN Condition
in IN None
general JJ None
practice NN None
: : None
nurse JJ None
run NN None
epilepsy NN Condition
clinics NNS None
in IN None
primary JJ None
care NN None
. . None
nurse JJ None
run NN None
clinics NNS None
versus VBP None
usual JJ None
care NN None
. . None
Six NNP None
general JJ None
practices NNS None
in IN None
the DT None
South NNP None
Thames NNPS None
region NN None
. . None
251 CD Size
patients NNS None
aged VBN None
over IN None
15 CD None
years NNS None
who WP None
were VBD None
taking VBG None
anti-epileptic JJ None
drugs NNS None
or CC None
had VBD None
a DT None
diagnosis NN None
of IN None
epilepsy NN Condition
and CC None
an DT None
attack NN None
in IN None
the DT None
past JJ None
two CD None
years NNS None
who WP None
met VBD None
specified VBN None
inclusion NN None
criteria NNS None
and CC None
had VBD None
responded VBN None
to TO None
a DT None
questionnaire NN None
. . None
127 CD Size
patients NNS None
Nurse NNP None
run VBP None
clinics NNS None
for IN None
patients NNS None
with IN None
epilepsy NN Condition
-DOCSTART- -X- N

women NNS None
with IN None
and CC None
without IN None
heart NN None
disease NN None
: : None
women NNS None
with IN None
a DT None
history NN None
of IN None
coronary JJ None
heart NN None
disease NN None
( ( None
CHD NNP None
) ) None
. . None
women NNS None
with IN None
and CC None
without IN None
CHD NNP None
13 CD None
388 CD None
women NNS None
at IN None
increased VBN None
risk NN None
for IN None
breast NN None
cancer NN None
Cardiovascular JJ None
follow-up NN None
was VBD None
available JJ None
for IN None
13 CD None
194 CD None
women NNS None
, , None
1048 CD None
of IN None
whom WP None
had VBD None
prior RB None
clinical JJ None
CHD NNP None
. . None
women NNS None
with IN None
or CC None
without IN None
heart NN None
disease NN None
-DOCSTART- -X- N

autologous JJ None
transplantation NN None
. . None
134 CD Size
patients NNS None
with IN None
cancer NN Condition
undergoing VBG None
high-dose JJ None
chemotherapy NN None
and CC None
autologous JJ None
PBPC NNP None
transplantation NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
HIV-1 NNP Condition
infection NN Condition
in IN None
12 CD Size
patients NNS None
with IN None
human JJ Condition
immunodeficiency NN Condition
virus NN Condition
type-1 NN Condition
( ( None
HIV-1 NNP Condition
) ) None
infection NN None
3-12 JJ None
months NNS None
after IN None
initiation NN None
of IN None
antiretroviral JJ None
therapy NN None
. . None
HIV-1 NNP Condition
infection NN None
. . None
-DOCSTART- -X- N

two CD None
intensive JJ None
care NN None
units NNS None
in IN None
two CD None
adult NN None
acute NN None
care NN None
hospitals NNS None
. . None
Thirty NNP Size
patients NNS None
admitted VBD None
to TO None
the DT None
intensive JJ None
care NN None
unit NN None
who WP None
had VBD None
a DT None
thermodilution NN None
pulmonary JJ None
artery NN None
catheter NN None
in IN None
place NN None
. . None
Ages NNS None
ranged VBD None
from IN None
39 CD Age
to TO Age
80 CD Age
years NNS None
( ( None
mean NN None
of IN None
66.4 CD None
+/- JJ None
11.3 CD None
years NNS None
) ) None
. . None
-DOCSTART- -X- N

posterior JJ Condition
blepharitis NN Condition
. . None
blepharitis NN Condition
, , None
an DT None
inflammatory JJ Condition
disease NN Condition
of IN None
the DT None
eyelid JJ None
with IN None
abnormal JJ None
eyelid JJ None
flora NN None
as IN None
an DT None
etiologic JJ None
determinant NN None
. . None
Twenty-one CD Size
patients NNS None
diagnosed VBN None
with IN None
posterior JJ Condition
blepharitis NN Condition
Twenty NNP Size
patients NNS None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
breast NN Condition
cancer NN Condition
. . None
62 CD Size
patients NNS None
with IN None
advanced JJ None
breast NN None
cancer NN None
-DOCSTART- -X- N

irritability NN Condition
in IN None
children NNS None
with IN None
autistic JJ Condition
disorder NN Condition
: : None
autistic JJ Condition
disorders NNS Condition
. . None
irritability NN Condition
in IN None
autistic JJ Condition
children NNS None
who WP None
were VBD None
not RB None
optimally RB None
responding VBG None
male NN None
and CC None
female JJ None
outpatients NNS None
aged VBN None
5-12 CD None
years NNS None
with IN None
a DT None
diagnosis NN None
of IN None
autistic JJ None
disorder NN None
based VBN None
on IN None
the DT None
DSM-IV-TR NNP None
criteria NNS None
and CC None
a DT None
score NN None
of IN None
?12 NN None
on IN None
the DT None
Aberrant NNP None
Behavior NNP None
Checklist-Community NNP None
( ( None
ABC-C NNP None
) ) None
irritability NN None
subscale NN None
who WP None
had VBD None
discontinued VBN None
other JJ None
medications NNS None
because IN None
of IN None
a DT None
lack NN None
of IN None
efficacy NN None
. . None
INTERVENTIONS NNP None
RESULTS NNP None
Forty-nine JJ None
patients NNS None
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
, , None
and CC None
forty JJ None
children NNS None
completed VBD None
the DT None
trial NN None
-DOCSTART- -X- N

metabolically RB None
obese JJ None
, , None
normal-weight JJ None
individuals NNS None
: : None
metabolically RB None
obese JJ None
, , None
normal-weight JJ None
( ( None
MONW NNP None
) ) None
individuals NNS None
. . None
A NNP None
total NN None
of IN None
47 CD None
MONW NNP None
individuals NNS None
with IN None
hypomagnesemia NN None
were VBD None
enrolled VBN None
of IN None
MONW NNP None
individuals NNS None
. . None
-DOCSTART- -X- N

42 CD None
cases NNS None
of IN None
autism NN Condition
] NNP None
autism NN Condition
. . None
Eighty-four JJ Size
children NNS Age
of IN None
autism NN Condition
were VBD None
randomly RB None
divided VBN None
into IN None
a DT None
tongue JJ None
acupuncture NN None
group NN None
( ( None
group NN None
A NNP None
) ) None
and CC None
a DT None
conventional JJ None
training NN None
group NN None
( ( None
group NN None
B NNP None
) ) None
, , None
42 CD None
cases NNS None
in IN None
each DT None
group NN None
. . None
autism NN Condition
. . None
-DOCSTART- -X- N

both DT None
forearms NNS None
of IN None
eight CD None
healthy JJ None
males NNS None
who WP None
received VBD None
unilateral JJ None
brachial JJ None
artery NN None
infusions NNS None
of IN None
the DT None
endothelium-dependent JJ None
vasodilators NNS None
substance NN None
P NNP None
( ( None
2 CD None
to TO None
8 CD None
pmol/min NN None
) ) None
and CC None
bradykinin NN None
( ( None
100 CD None
to TO None
1,000 CD None
pmol/min NN None
) ) None
, , None
and CC None
the DT None
endothelium-independent JJ None
vasodilator NN None
sodium NN None
nitroprusside NN None
( ( None
2 CD None
to TO None
8 CD None
microg/min NN None
) ) None
. . None
-DOCSTART- -X- N

ureteric JJ None
calculi NN None
. . None
ureteric JJ None
calculi NN None
. . None
One NNP None
hundred VBD None
and CC None
six CD None
consecutive JJ None
patients NNS None
with IN None
ureteric JJ None
calculi NNS None
at IN None
different JJ None
levels NNS None
-DOCSTART- -X- N

symptomatic JJ Condition
malignant JJ Condition
pleural JJ Condition
effusion NN Condition
. . None
malignant JJ Condition
pleural JJ Condition
effusion NN Condition
. . None
From IN None
September NNP None
1993 CD None
to TO None
November NNP None
1995 CD None
, , None
57 CD Size
patients NNS None
Patients NNS None
with IN None
poor JJ Condition
general JJ Condition
condition NN Condition
( ( None
Karnofsky NNP None
score RB None
less JJR None
than IN None
30 CD None
% NN None
) ) None
, , None
poor JJ Condition
pulmonary JJ Condition
function NN Condition
( ( None
forced JJ None
expiratory NN None
volume NN None
in IN None
1 CD None
second NN None
less JJR None
than IN None
0.5 CD None
L NNP None
) ) None
, , None
or CC None
trapped VBN Condition
lungs NNS Condition
were VBD None
excluded VBN None
from IN None
this DT None
study NN None
. . None
patients NNS None
who WP None
do VBP None
not RB None
have VB None
trapped VBN Condition
lungs NNS Condition
. . None
-DOCSTART- -X- N

nasopharyngeal JJ Condition
carcinoma NN Condition
] NNP None
terminal JJ Condition
nasopharyngeal JJ Condition
carcinoma NN Condition
( ( None
NPC NNP Condition
) ) None
. . None
180 CD Size
patients NNS None
with IN None
NPC NNP Condition
terminal JJ Condition
NPC NNP Condition
-DOCSTART- -X- N

chronic JJ Condition
stage NN Condition
II NNP Condition
and CC None
stage NN Condition
III NNP Condition
decubitus NN Condition
ulcers NNS Condition
. . None
stage NN Condition
II NNP Condition
and CC None
stage NN Condition
III NNP Condition
chronic JJ Condition
decubitus NN Condition
ulcers NNS Condition
. . None
Seventy-four JJ Size
ulcers NNS Condition
were VBD None
treated VBN None
in IN None
four CD None
centers NNS None
. . None
Forty-three JJ Size
patients NNS None
were VBD None
selected VBN None
for IN None
the DT None
experimental JJ None
group NN None
, , None
and CC None
31 CD None
control NN None
subjects NNS None
used VBD None
the DT None
sham JJ None
instrument NN None
( ( None
placebo JJ None
group NN None
) ) None
. . None
-DOCSTART- -X- N

tinea NN None
pedis NNS None
interdigital JJ None
tinea NN None
pedis NN None
. . None
Half-side NNP None
comparative NN None
study NN Condition
on IN Condition
subjects NNS Condition
with IN Condition
symmetric JJ Condition
, , Condition
bilateral JJ Condition
interdigital JJ Condition
tinea NN Condition
pedis NN Condition
. . Condition
40 CD None
participants NNS None
( ( None
mean JJ None
age NN None
52.5 CD None
years NNS None
, , None
60 CD None
% NN None
male NN None
) ) None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

patients NNS None
without IN Condition
erosive JJ Condition
oesophagitis NN Condition
. . None
Patients NNPS None
with IN None
chronic JJ None
heartburn NN None
but CC None
with IN None
no DT None
endoscopic JJ None
evidence NN None
of IN None
erosive JJ None
oesophagitis NN None
require NN None
gastric JJ None
acid JJ None
suppression NN None
to TO None
relieve VB None
symptoms NNS None
. . None
patients NNS None
with IN None
frequent JJ Condition
heartburn NN Condition
for IN Condition
> NN Condition
or CC Condition
= $ Condition
6 CD Condition
months NNS Condition
and CC None
no DT None
evidence NN None
of IN None
erosive JJ None
oesophagitis NN None
on IN None
endoscopy NN None
. . None
40 CD None
mg NN None
( ( None
n JJ None
= NNP None
241 CD None
) ) None
or CC None
20 CD None
mg NN None
( ( None
n JJ None
= NNP None
234 CD None
) ) None
, , None
with IN None
placebo NN None
( ( None
n JJ None
= NNP None
242 CD None
) ) None
patients NNS None
without IN None
erosive JJ None
oesophagitis NN None
. . None
-DOCSTART- -X- N

hypertension NN Condition
patients NNS None
] VBP None
85 CD Size
females NNS Sex
with IN None
borderline JJ Condition
mental JJ Condition
disorders NNS Condition
in IN None
essential JJ Condition
hypertension NN Condition
-DOCSTART- -X- N

1319 CD Size
children NNS None
aged VBN None
11-13 CD Age
years NNS Age
. . None
children NNS None
the DT None
MFP NNP None
test NN None
group NN None
( ( Size
444 CD Size
children NNS None
) ) None
and CC None
the DT None
MFP NNP None
control NN None
group NN None
( ( None
450 CD Size
children NNS None
) ) None
TMP NNP None
test NN None
group NN None
( ( None
425 CD Size
children NNS None
) ) None
three CD None
groups NNS None
of IN None
children NNS None
-DOCSTART- -X- N

breast NN Condition
cancer NN Condition
women NNS Condition
receiving VBG None
adjuvant JJ Condition
chemotherapy NN Condition
or CC Condition
radiation NN Condition
therapy NN Condition
for IN None
newly RB None
diagnosed VBN None
breast NN None
cancer NN None
Fifty-two NNP Size
patients NNS None
with IN None
newly RB None
diagnosed VBN None
breast NN None
cancer NN None
women NNS None
Women NNS None
-DOCSTART- -X- N

elderly JJ None
patients NNS None
in IN None
older JJR None
patients NNS None
older JJR None
adults NNS None
Old NNP None
Patients NNPS None
with IN None
Hypertension NNP None
older JJR None
patients NNS None
( ( None
> JJ None
60 CD None
years NNS None
) ) None
with IN None
both DT None
diastolic JJ None
and CC None
isolated JJ None
systolic JJ None
hypertension NN None
older JJR None
individuals NNS None
with IN None
hypertension NN None
-DOCSTART- -X- N

renal JJ None
haemodynamics NNS None
and CC None
natriuresis NN None
in IN None
man NN None
. . None
eight CD Condition
normal JJ None
male JJ Condition
subjects NNS None
both DT None
prior JJ None
to TO None
and CC None
following VBG None
administration NN None
of IN None
intravenous JJ None
frusemide NN None
( ( None
20 CD None
mg NN None
) ) None
. . None
man NN None
-DOCSTART- -X- N

tinea NN Condition
pedis NN Condition
. . None
Twenty-nine JJ Size
patients NNS None
with IN None
mycologically RB None
proven VBN None
tinea NN Condition
pedis NNS Condition
-DOCSTART- -X- N

patients NNS None
with IN None
hypertension NN Condition
. . None
borderline JJ Condition
hypertension NN Condition
in IN None
Tecumseh NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
interstitial JJ Condition
cystitis NN Condition
( ( Condition
IC NNP Condition
) ) Condition
. . Condition
Thirteen NNP Size
female JJ None
patients NNS None
( ( None
6 CD Size
in IN None
the DT None
United NNP None
States NNPS None
and CC None
7 CD Size
in IN None
Poland NNP None
) ) None
with IN None
IC NNP None
according VBG None
to TO None
the DT None
criteria NNS None
of IN None
the DT None
National NNP None
Institute NNP None
of IN None
Diabetes NNP None
, , None
Digestive NNP None
and CC None
Kidney NNP None
Disease NNP None
were VBD None
included VBN None
. . None
100 CD Condition
to TO Condition
200 CD Condition
U NNP Condition
of IN Condition
Dysport NNP Condition
( ( None
Polish JJ None
patients NNS None
) ) None
or CC None
Botox NNP Condition
( ( None
U.S. NNP None
patients NNS None
) ) None
Polish JJ None
patients NNS None
-DOCSTART- -X- N

congestive JJ Condition
heart NN Condition
failure NN Condition
patients NNS None
with IN None
moderate JJ None
to TO None
severe VB None
congestive JJ None
heart NN None
failure NN None
Seventeen JJ None
patients NNS None
on IN None
chronic JJ None
digitalis NN None
and CC None
diuretic JJ None
therapy NN None
patients NNS None
with IN None
moderate JJ None
to TO None
severe VB None
chronic JJ None
heart NN None
failure NN None
-DOCSTART- -X- N

rheumatoid JJ Condition
arthritis NN Condition
: : Condition
rheumatoid NN Condition
arthritis NN Condition
( ( Condition
RA NNP Condition
) ) Condition
28 CD None
joints NNS None
( ( None
DAS28 NNP None
) ) None
patients NNS None
with IN None
RA NNP None
in IN None
whom WP None
disease NN None
had VBD None
remained VBN None
active JJ None
despite IN None
treatment NN None
with IN None
disease-modifying JJ None
antirheumatic JJ None
drugs NNS None
. . None
-DOCSTART- -X- N

2079 CD Size
men NNS Sex
and CC None
women NNS Sex
who WP None
were VBD None
35 CD Age
years NNS None
of IN None
age NN None
or CC None
older JJR None
and CC None
who WP None
had VBD None
had VBN None
one CD None
or CC None
more JJR None
histologically RB None
confirmed VBN None
colorectal JJ Condition
adenomas NN Condition
removed VBD None
within IN None
six CD None
months NNS None
before IN None
randomization NN None
A DT None
total NN None
of IN None
1905 CD Size
of IN None
the DT None
randomized JJ None
subjects NNS None
( ( None
91.6 CD None
percent NN None
) ) None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

autism NN None
spectrum NN None
disorder NN None
children NNS None
with IN None
ASD NNP None
high JJ None
functioning NN None
children NNS None
with IN None
ASD NNP None
. . None
children NNS None
with IN None
autism NN None
-DOCSTART- -X- N

acute JJ Condition
myelogenous JJ Condition
leukemia NN Condition
. . Condition
Twenty-seven JJ None
patients NNS None
receiving VBG None
a DT None
standard JJ None
cytosine NN None
arabinoside NN None
and CC None
daunorubicin JJ None
regimen NNS None
as IN None
induction NN None
of IN None
reinduction NN None
therapy NN None
of IN None
acute JJ None
myelogenous JJ None
leukemia NN None
Treatment NN None
groups NNS None
were VBD None
comparable JJ None
with IN None
respect NN None
to TO None
age NN None
and CC None
baseline NN None
granulocyte NN None
counts NNS None
. . None
-DOCSTART- -X- N

COPD NNP Condition
patients NNS Condition
: : Condition
subjects NNS None
with IN None
COPD NNP None
participants NNS None
with IN None
mild-to-moderate JJ None
COPD NNP None
. . None
1,116 CD None
participants NNS None
in IN None
10 CD None
centers NNS None
over IN None
> $ None
3.5 CD None
to TO None
4.5 CD None
years NNS None
. . None
A DT None
total NN None
of IN None
1,116 CD None
smokers NNS None
or CC None
recent JJ None
ex-smokers NNS None
with IN None
mild-to-moderate JJ None
COPD NNP None
( ( None
age NN None
range NN None
, , None
40 CD None
to TO None
69 CD None
years NNS None
; : None
mean JJ None
age NN None
, , None
56.3 CD None
years NNS None
; : None
37.2 CD None
% NN None
female NN None
) ) None
. . None
Older JJR None
men NNS None
middle-aged JJ None
to TO None
elderly JJ None
persons NNS None
with IN None
COPD NNP None
. . None
-DOCSTART- -X- N

advanced JJ None
epithelial JJ None
ovarian JJ None
carcinoma NN None
patients NNS None
with IN None
advanced JJ None
epithelial JJ None
ovarian JJ None
cancer NN None
who WP None
had VBD None
failed VBN None
one CD None
prior JJ None
platinum-based JJ None
regimen NNS None
Patients NNPS None
with IN None
bidimensionally RB None
measurable JJ None
disease NN None
A DT None
total NN None
of IN None
226 CD None
patients NNS None
relapse NN None
of IN None
ovarian JJ None
cancer NN None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
or CC None
asthma NN Condition
and CC None
other JJ None
special JJ Condition
health NN Condition
care NN Condition
needs NNS Condition
: : None
parents NNS None
of IN None
children NNS Age
with IN None
autism NN Condition
compared VBN None
with IN None
parents NNS None
of IN None
children NNS Age
with IN None
asthma NN Condition
or CC None
other JJ None
special JJ Condition
health NN Condition
care NN Condition
needs VBZ Condition
Parents NNPS None
of IN None
495 CD Size
children NNS Age
with IN None
autism NN Condition
, , None
parents NNS None
of IN None
6716 CD Size
children NNS Age
with IN None
asthma NN Condition
, , None
and CC None
parents NNS None
of IN None
11,403 CD Size
children NNS None
with IN None
other JJ None
special JJ Condition
health NN Condition
care NN Condition
needs VBZ Condition
without IN None
asthma NN Condition
. . None
-DOCSTART- -X- N

immune NN Condition
system NN Condition
36 CD Size
healthy JJ None
volunteers NNS None
utilising VBG None
quantitative JJ None
multi-parameter NN None
flow NN None
cytometry NN None
with IN None
monoclonal JJ None
antibodies NNS None
directed VBN None
against IN None
specific JJ None
surface NN None
markers NNS None
of IN None
human JJ None
lymphocyte JJ None
subsets NNS None
. . None
-DOCSTART- -X- N

drug NN None
preferences NNS None
: : None
normal JJ Condition
volunteers NNS None
'non-choosers NNS None
' POS None
never RB None
chose JJ None
drug NN None
, , None
whereas IN None
'choosers NNS None
' POS None
always RB None
chose JJ None
drug NN None
. . None
males NNS Sex
and/or IN None
full-time JJ None
students NNS None
-DOCSTART- -X- N

migraine NN Condition
in IN None
adolescents NNS Age
: : None
adolescent JJ None
migraineurs NNS None
. . None
Patients NNS None
aged VBD None
12 CD Age
to TO Age
17 CD Age
years NNS Age
received VBD None
rizatriptan JJ None
5 CD None
mg NN None
( ( None
n JJ None
= NNP None
149 CD Size
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= NNP None
147 CD Size
) ) None
adolescents NNS None
for IN None
the DT None
treatment NN None
of IN None
a DT None
migraine JJ None
attack NN Condition
. . None
-DOCSTART- -X- N

High NNP None
schools NNS None
( ( None
N=24 NNP None
) ) None
paired VBD None
on IN None
enrollment NN None
size NN None
, , None
racial JJ None
composition NN None
, , None
urban JJ None
or CC None
rural JJ None
location NN None
, , None
and CC None
class NN None
structure NN None
were VBD None
randomized VBN None
into IN None
control NN None
( ( None
N=12 NNP None
) ) None
or CC None
experimental JJ None
( ( None
N=12 NNP None
) ) None
groups NNS None
. . None
Of IN None
the DT None
4044 CD Size
girls NNS Sex
enrolled VBD None
and CC None
eligible JJ None
, , None
2087 CD Size
( ( Size
51.6 CD Size
% NN Size
) ) None
participated VBD None
in IN None
the DT None
measurement JJ None
component NN None
of IN None
the DT None
study NN None
. . None
1038 CD Size
girls NNS Sex
in IN None
the DT None
control NN None
group NN None
and CC None
1049 CD Size
girls NNS Sex
in IN None
the DT None
experimental JJ None
group NN None
. . None
black JJ None
and CC None
white JJ None
adolescent JJ Age
girls NNS Sex
. . None
black JJ None
and CC None
white JJ None
adolescent JJ Age
girls NNS Sex
. . None
-DOCSTART- -X- N

Nine NNP None
male NN None
and CC None
six CD None
female JJ None
healthy JJ None
subjects NNS None
were VBD None
studied VBN None
during IN None
supine JJ None
bicycle NN None
exercise NN None
at IN None
workloads NNS None
of IN None
12 CD None
and CC None
37 CD None
W NNP None
; : None
pedalling VBG None
rates NNS None
varied VBD None
between IN None
30 CD None
and CC None
50 CD None
cycles/min NN None
at IN None
each DT None
workload NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
asthma NN Condition
. . None
patients NNS None
with IN None
a DT None
diagnosis NN None
of IN None
asthma NN Condition
. . None
Adult NNP Age
asthma JJ Condition
patients NNS None
undergoing VBG None
treatment NN None
with IN None
budesonide JJ None
400 CD None
microg NN None
b.i.d NN None
. . None
and CC None
salbutamol JJ None
200 CD None
microg NN None
p.r.n NN None
. . None
less JJR None
than IN None
twice RB None
weekly JJ None
were VBD None
studied VBN None
. . None
Arm VB None
A NNP None
( ( None
16 CD Size
males/six NN Sex
females NNS Sex
, , None
aged VBD None
48 CD Age
+/- JJ Age
16 CD Age
yrs NN None
) ) None
received VBD None
clarithromycin JJ None
250 CD None
mg NN None
b.i.d NN None
. . None
for IN None
8 CD None
weeks NNS None
, , None
arm NN None
B NNP None
( ( None
eight CD Size
males/12 NN Sex
females NNS Sex
, , None
aged VBD None
42 CD None
+/- JJ None
12 CD None
yrs NN None
) ) None
clarithromycin-treated JJ Condition
patients NNS None
. . None
patients NNS None
with IN None
asthma NN Condition
. . None
-DOCSTART- -X- N

gastroesophageal NN Condition
reflux NN Condition
( ( Condition
GER NNP Condition
) ) Condition
patients NNS Condition
undergoing VBG Condition
thoracotomy NN Condition
in IN Condition
the DT Condition
lateral JJ Condition
position NN Condition
80 CD Size
adult NN None
patients NNS None
undergoing VBG None
thoracotomy NN None
. . None
Patients NNS None
at IN None
high JJ None
risk NN None
of IN None
GER NNP None
were VBD None
excluded VBN None
from IN None
the DT None
study NN None
. . None
Patients NNS None
undergoing JJ None
thoracotomy NNS None
-DOCSTART- -X- N

informal JJ None
caregivers NNS None
of IN None
heart NN Condition
failure NN Condition
patients NNS Condition
. . None
informal JJ None
caregivers NNS None
of IN None
patients NNS None
with IN None
heart NN None
failure NN None
. . None
60 CD Size
caregiver/patient NN Size
dyads NNS Size
in IN None
a DT None
cross-sectional JJ None
design NN None
. . None
Patients NNS None
with IN None
chronic JJ Condition
stable JJ Condition
heart NN Condition
failure NN Condition
were VBD None
recruited VBN None
from IN None
out-patient JJ None
clinics NNS None
. . None
informal JJ None
caregivers NNS None
of IN None
heart NN None
failure NN None
patients NNS None
. . None
-DOCSTART- -X- N

acute JJ Condition
migraine NN Condition
attacks NNS Condition
. . None
multicenter NN None
296 CD Size
patients NNS None
fulfilling VBG None
the DT None
International NNP None
Headache NNP None
Society NNP None
diagnostic JJ None
criteria NNS None
for IN None
migraine NN Condition
were VBD None
enrolled VBN None
. . None
-DOCSTART- -X- N

neuropathic JJ Condition
pain NN Condition
patients NNS None
: : None
60 CD Size
patients NNS None
with IN None
neuropathic JJ Condition
pain NN Condition
for IN None
8 CD None
weeks NNS None
. . None
RESULTS VB None
A DT None
total NN None
of IN None
55 CD Size
patients NNS None
completed VBD None
the DT None
study NN None
. . None
groups NNS None
regarding VBG None
pain NN None
intensity NN None
and CC None
escape NN None
medication NN None
. . None
-DOCSTART- -X- N

healthy JJ None
children NNS None
undergoing VBG None
ambulatory NN Condition
surgery NN Condition
. . None
healthy JJ None
children NNS None
. . None
69 CD Size
ambulatory JJ Condition
surgical JJ Condition
patients NNS None
( ( None
1 CD Age
mo NN Age
to TO Age
< VB Age
17 CD Age
yr NNP Age
old JJ Age
) ) None
pediatric JJ None
ambulatory JJ Condition
surgical JJ Condition
patients NNS None
. . None
pediatric JJ None
ambulatory JJ Condition
surgical JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

heart NN Condition
failure NN Condition
patients NNS None
with IN None
obstructive JJ Condition
sleep NN Condition
apnea NN Condition
heart NN Condition
failure NN Condition
( ( None
HF NNP Condition
) ) None
patients NNS None
HF NNP Condition
patients NNS None
with IN None
coexisting VBG None
OSA NNP Condition
. . None
medically RB None
treated VBN None
HF NNP Condition
patients NNS None
( ( None
EF NNP None
< RB None
45 CD None
% NN None
) ) None
and CC None
OSA NNP Condition
( ( None
apnea-hypopnea JJ None
index NN None
> VBD None
or CC None
=20/h CD None
of IN None
sleep NN None
) ) None
In IN None
nine CD Size
control NN None
patients NNS None
8 CD Size
CPAP-treated JJ None
patients NNS None
Treatment NNP None
of IN None
coexisting VBG None
OSA NNP Condition
by IN None
CPAP NNP None
in IN None
HF NNP Condition
patients NNS None
HF NNP Condition
patients NNS None
with IN None
moderate JJ None
to TO None
severe VB None
OSA NNP Condition
. . None
-DOCSTART- -X- N

pregnancy-related JJ None
mortality NN None
and CC None
infant JJ None
mortality NN None
in IN None
rural JJ None
Bangladesh NNP None
: : None
pregnancy-related JJ None
and CC None
infant JJ None
mortality NN None
. . None
pregnant JJ None
women NNS None
13 CD None
to TO None
45 CD None
years NNS None
of IN None
age NN None
and CC None
their PRP$ None
live-born JJ None
infants NNS None
to TO None
12 CD None
weeks NNS None
( ( None
84 CD None
days NNS None
) ) None
postpartum VBP None
in IN None
rural JJ None
northern JJ None
Bangladesh NNP None
between IN None
2001 CD None
and CC None
2007 CD None
. . None
Five CD None
hundred VBD None
ninety-six JJ None
community NN None
clusters NNS None
( ( None
study NN None
sectors NNS None
) ) None
were VBD None
randomized VBN None
for IN None
pregnant JJ None
women NNS None
Married JJ None
women NNS None
( ( None
n JJ None
= NNP None
125,257 CD None
) ) None
carotene NN None
in IN None
pregnant JJ None
women NNS None
in IN None
Bangladesh NNP None
, , None
compared VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
oligospermia JJ None
] NN None
patients NNS None
with IN None
oligospermia NN None
( ( None
OSM NNP None
) ) None
. . None
Seventy-two JJ None
OSM NNP None
patients NNS None
patients NNS None
with IN None
OSM NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
coronary JJ None
heart NN None
disease NN None
( ( None
CHD NNP None
) ) None
and CC None
its PRP$ None
equivalents NNS None
. . None
One CD None
hundred CD None
and CC None
ten JJ None
patients NNS None
with IN None
CHD NNP None
and CC None
its PRP$ None
equivalents NNS None
with IN None
serum JJ None
total JJ None
cholesterol NN None
( ( None
TC NNP None
) ) None
> VBD None
or CC None
= $ None
3.5 CD None
mmol/L NN None
-DOCSTART- -X- N

metastatic JJ Condition
breast NN Condition
cancer NN Condition
. . None
first-line JJ Condition
treatment NN Condition
of IN Condition
women NNS Condition
with IN Condition
metastatic JJ Condition
breast NN Condition
cancer NN Condition
( ( Condition
MBC NNP Condition
) ) Condition
. . Condition
Women NNP None
( ( None
n=509 JJ None
) ) None
with IN None
MBC NNP Condition
and CC Condition
normal JJ Condition
cardiac JJ Condition
function NN Condition
were VBD None
randomized VBN None
-DOCSTART- -X- N

acute JJ None
epicondylitis NN Condition
. . None
pain NN None
of IN None
medial NN None
or CC None
lateral JJ None
epicondylitis NN Condition
( ( None
tennis IN Condition
elbow NN Condition
) ) None
. . None
patients NNS None
with IN None
medial JJ None
or CC None
lateral JJ None
elbow NN None
epicondylitis NN Condition
. . None
199 CD None
patients NNS None
with IN None
elbow JJ None
epicondylitis NN Condition
-DOCSTART- -X- N

transurethral JJ None
resection NN None
of IN None
superficial JJ None
bladder NN None
cancer NN None
] NNP None
prophylactic JJ None
intravesical JJ None
instillation NN None
of IN None
pirarubicin NN None
( ( None
THP NNP None
) ) None
prior RB None
to TO None
transurethral JJ None
resection NN None
( ( None
TUR NNP None
) ) None
of IN None
superficial JJ None
bladder NN None
cancer NN None
. . None
63 CD None
patients NNS None
superficial JJ None
bladder NN None
cancer NN None
. . None
-DOCSTART- -X- N

snowshoe JJ None
training NN None
. . None
healthy JJ Condition
males NNS Sex
and CC None
females NNS Sex
between IN None
the DT None
ages NNS None
of IN None
19 CD Age
and CC Age
24 CD Age
. . None
These DT None
subjects NNS None
were VBD None
recruited VBN None
from IN None
the DT None
University NNP None
of IN None
Vermont NNP None
population NN None
and CC None
surrounding VBG None
community NN None
. . None
17 CD Size
subjects NNS None
( ( None
10 CD None
snowshoers NNS None
and CC None
7 CD None
runners NNS None
) ) None
participated VBD None
-DOCSTART- -X- N

anal JJ None
fissures NNS None
90 CD Size
patients NNS None
with IN None
anal JJ Condition
fissure NN Condition
were VBD None
recruited VBN None
. . None
-DOCSTART- -X- N

subarachnoid JJ Condition
hemorrhage NN Condition
: : None
patients NNS None
with IN None
acute JJ Condition
nontraumatic JJ Condition
subarachnoid NN Condition
hemorrhage NN Condition
( ( Condition
SAH NNP Condition
) ) Condition
42 CD Size
patients NNS None
participating VBG None
in IN None
the DT None
enoxaparin JJ None
trial NN None
for IN None
acute NN Condition
aneurysmal JJ Condition
SAH NNP Condition
at IN None
four CD None
time NN None
points NNS None
: : None
1 CD None
) ) None
at IN None
hospital JJ None
admission NN None
; : None
2 CD None
) ) None
12 CD None
to TO None
24 CD None
hours NNS None
after IN None
aneurysm JJ None
surgery NN None
but CC None
before IN None
initiation NN None
of IN None
enoxaparin JJ None
therapy NN None
; : None
3 CD None
) ) None
3 CD None
hours NNS None
after IN None
the DT None
first JJ None
dose NN None
; : None
and CC None
4 CD None
) ) None
at IN None
the DT None
conclusion NN None
of IN None
treatment NN None
. . None
-DOCSTART- -X- N

hypertonus NN Condition
. . Condition
Ten CD Size
adults NNS Age
with IN None
hypertonic JJ Condition
wrist NN None
flexors NNS None
volunteered VBD None
as IN None
subjects NNS None
hypertonus NN Condition
. . Condition
older JJR Age
subjects NNS None
younger JJR Age
adults NNS Age
-DOCSTART- -X- N

299 CD Sex
older JJR Sex
men NNS Sex
-DOCSTART- -X- N

adults NNS None
with IN None
chronic JJ None
spinal JJ None
cord NN None
injury NN None
. . None
untrained JJ None
adults NNS None
with IN None
chronic JJ None
spinal JJ None
cord NN None
injury NN None
( ( None
SCI NNP None
) ) None
. . None
Male NNP None
adults NNS None
with IN None
complete JJ None
SCI NNP None
at IN None
or CC None
below IN None
the DT None
fifth JJ None
thoracic NN None
level NN None
( ( None
T5 NNP None
) ) None
( ( None
N=17 NNP None
) ) None
volunteered VBD None
for IN None
this DT None
study NN None
. . None
intervention NN None
( ( None
n=9 JJ None
) ) None
or CC None
control NN None
( ( None
n=8 JJ None
) ) None
group NN None
antioxidant NN None
defense NN None
system NN None
in IN None
adults NNS None
with IN None
chronic JJ None
SCI NNP None
-DOCSTART- -X- N

rectal JJ Condition
cancer NN Condition
: : None
patients NNS None
with IN None
rectal JJ None
cancer NN None
treated VBN None
by IN None
abdominoperineal NN None
or CC None
anterior JJ None
resection NN None
, , None
with IN None
or CC None
without IN None
preoperative JJ None
radiotherapy NN None
1292 CD Size
patients NNS None
included VBN None
in IN None
two CD None
consecutive JJ None
controlled VBN None
randomized JJ None
trials NNS None
of IN None
preoperative JJ None
radiotherapy NN None
in IN None
operable JJ None
rectal JJ None
carcinoma NN None
. . None
rectal JJ None
cancer NN None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
GERD NNP Condition
: : None
patients NNS None
with IN None
gastroesophageal JJ None
reflux NN None
disease NN None
( ( None
GERD NNP None
) ) None
. . None
adults NNS Age
with IN None
GERD-associated JJ Condition
sleep JJ Condition
disturbances NNS Condition
and CC Condition
moderate-to-severe JJ Condition
nighttime JJ Condition
heartburn NN Condition
( ( None
recorded VBN None
by IN None
patient JJ None
diary JJ None
during IN None
screening VBG None
) ) None
. . None
Patients NNS None
received VBD None
oral JJ None
esomeprazole JJ None
40 CD None
mg NN None
( ( None
n JJ None
= NNP None
220 CD None
) ) None
or CC None
20 CD None
mg NN None
( ( None
n JJ None
= NNP None
226 CD None
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= NNP None
229 CD None
) ) None
once RB None
daily JJ None
for IN None
4 CD None
wk NN None
. . None
-DOCSTART- -X- N

chronic JJ None
hemodialysis NN Condition
patients NNS None
. . None
14 CD Size
chronic JJ Condition
uremic JJ Condition
patients NNS Condition
on IN Condition
regular JJ Condition
hemodialysis NN Condition
treatment NN None
. . None
Nine JJ Size
patients NNS None
with IN None
chronic JJ Condition
renal JJ Condition
anemia NN Condition
on IN Condition
maintenance NN Condition
hemodialysis NN Condition
patients NNS None
had VBD None
chronic JJ None
hemodialysis NN None
patients NNS None
-DOCSTART- -X- N

laryngeal JJ None
cancer NN None
. . None
120 CD None
newly RB None
identified VBN None
cases NNS None
of IN None
laryngeal JJ None
squamous JJ None
cell NN None
carcinoma NN None
who WP None
were VBD None
registered VBN None
at IN None
10 CD None
participating VBG None
institutions NNS None
between IN None
November NNP None
1984 CD None
and CC None
October NNP None
1989 CD None
. . None
Of IN None
the DT None
initial JJ None
120 CD None
cases NNS None
, , None
11 CD None
cases NNS None
were VBD None
disqualified VBN None
( ( None
3 CD None
cases NNS None
of IN None
double JJ None
cancer NN None
and CC None
8 CD None
of IN None
incomplete JJ None
primary JJ None
therapy NN None
) ) None
and CC None
the DT None
remaining VBG None
109 CD None
were VBD None
used VBN None
for IN None
evaluation NN None
. . None
-DOCSTART- -X- N

Cutaneous NNP Condition
Lymphoma NNP Condition
Task NNP None
Force NNP None
phase NN None
III NNP None
randomized VBD None
clinical JJ None
trial NN None
early JJ None
stages NNS None
of IN None
mycosis NN Condition
fungoides NNS Condition
. . None
patients NNS None
treated VBN None
with IN None
PUVA NNP None
alone RB None
or CC None
PUVA NNP None
and CC None
bexarotene NN None
. . None
in IN None
patients NNS None
with IN None
stage NN None
IB NNP None
and CC None
IIA NNP None
mycosis NN None
fungoides NNS None
( ( None
MF NNP None
) ) None
. . None
after IN None
93 CD None
of IN None
145 CD None
required JJ None
patients NNS None
the DT None
93 CD None
randomized JJ None
patients NNS None
, , None
87 CD None
started VBD None
treatment NN None
, , None
41 CD None
received VBD None
PUVA NNP None
and CC None
46 CD None
received VBD None
PUVA NNP None
+ NNP None
bexarotene NN None
. . None
-DOCSTART- -X- N

20 CD None
patients NNS None
undergoing JJ None
craniotomy NN None
for IN None
supratentorial JJ None
cerebral JJ None
tumours NNS None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
: : None
children NNS None
with IN None
an DT None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
. . None
children NNS None
with IN None
ASD NNP None
. . None
children NNS None
with IN None
ASD NNP None
. . None
One CD None
hundred VBD None
children NNS None
with IN None
ASD NNP None
, , None
aged VBD None
7 CD None
to TO None
12 CD None
years NNS None
will MD None
be VB None
children NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

cervicitis NN Condition
of IN None
unknown JJ None
etiology NN None
. . None
women NNS None
with IN None
cervicitis NN None
of IN None
unknown JJ None
etiology NN None
Five CD Size
hundred VBD Size
seventy-seven JJ Size
women NNS None
were VBD None
screened VBN None
for IN None
MPC NNP Condition
. . Condition
Women NNP None
with IN None
MPC NNP None
One CD Size
hundred VBD Size
thirty-one NN Size
( ( None
23 CD None
% NN None
[ CC None
131/577 CD None
] NN None
) ) None
screened VBD None
women NNS None
Eighty-seven NNP Size
were VBD None
enrolled VBN None
-DOCSTART- -X- N

trauma NN Condition
patients NNS None
] VBP None
50 CD Size
posttraumatic JJ Condition
intensive-care JJ Condition
patients NNS None
with IN None
medium NN None
grade NN None
lesions NNS Condition
( ( None
ISS NNP Condition
criteria NNS Condition
) ) None
, , None
the DT None
patients NNS None
who WP None
are VBP None
at IN None
particularly RB None
high JJ None
infection NN None
exposure NN None
risk NN None
, , None
e.g NN None
. . None
through IN None
reintervention NN None
surgery NN None
, , None
haemorrhage NN None
complications NNS None
or CC None
extensive JJ None
diagnostic JJ None
interventions NNS None
. . None
-DOCSTART- -X- N

241 CD Size
consecutive JJ None
patients NNS None
undergoing VBG None
elective JJ None
coronary JJ Condition
artery NN Condition
bypass NN Condition
grafting VBG None
were VBD None
randomly RB None
allocated VBN None
into IN None
three CD None
groups NNS None
. . None
Group1 NNP Size
( ( Size
n=77 NN Size
) ) Size
Group NNP Size
2 CD Size
( ( Size
n=72 NN Size
) ) Size
Group NNP Size
3 CD Size
( ( Size
n=92 NN Size
) ) Size
-DOCSTART- -X- N

general JJ None
surgical JJ None
adult NN None
patient JJ None
population NN None
. . None
surgical JJ None
patients NNS None
A NNP None
total NN None
of IN None
700 CD None
adult NN None
surgical JJ None
patients NNS None
who WP None
planned VBD None
to TO None
have VB None
surgery NN None
under IN None
general JJ None
anesthesia NN None
general JJ None
surgical JJ None
adult NN None
patient JJ None
population NN None
. . None
-DOCSTART- -X- N

polyarteritis NN Condition
nodosa NN Condition
and CC None
Churg-Strauss JJ Condition
syndrome NN Condition
: : None
polyarteritis NN Condition
nodosa NN Condition
( ( None
PAN NNP Condition
) ) None
and CC None
Churg-Strauss JJ Condition
syndrome NN Condition
( ( None
CSS NNP Condition
) ) None
236 CD Size
patients NNS None
71 CD Size
patients NNS None
( ( None
1981-1983 JJ None
) ) None
compared VBN None
the DT None
association NN None
of IN None
CYC NNP None
with IN None
corticosteroids NNS None
( ( None
CS NNP None
) ) None
and CC None
PE NNP None
to TO None
CS NNP None
and CC None
PE NNP None
, , None
in IN None
order NN None
to TO None
evaluate VB None
the DT None
efficacy NN None
of IN None
CYC NNP None
given VBN None
as IN None
the DT None
first-line JJ None
treatment NN None
to TO None
control VB None
disease NN None
activity NN None
and CC None
subsequent JJ None
survival NN None
of IN None
PAN NNP None
and CC None
CSS NNP None
patients NNS None
. . None
December NNP None
1983 CD None
and CC None
December NNP None
1988 CD None
at IN None
patients NNS None
without IN Condition
HBV NNP Condition
markers NNS Condition
and CC None
the DT None
second JJ None
at IN None
patients NNS None
with IN Condition
HBV NNP Condition
markers NNS Condition
. . None
78 CD Size
patients NNS None
without IN Condition
HBV NNP Condition
markers NNS Condition
33 CD Size
patients NNS None
with IN None
PAN NNP Condition
related VBD None
to TO None
HBV NNP Condition
56 CD Size
patients NNS None
and CC None
addressed VBD None
to TO None
severe VB Condition
PAN NNP Condition
without IN Condition
HBV NNP Condition
markers NNS Condition
or CC None
CSS NNP None
PAN NNP Condition
related VBD None
to TO None
HBV NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
ST-segment JJ Condition
elevation NN Condition
acute IN Condition
myocardial JJ Condition
infarction NN Condition
] NNP None
ST-segment JJ Condition
elevation NN Condition
acute IN Condition
myocardial JJ Condition
infarction NN Condition
( ( Condition
STEMI NNP Condition
) ) Condition
patients NNS None
undergoing VBG None
emergency NN Condition
percutaneous JJ Condition
coronary JJ Condition
intervention NN Condition
( ( Condition
PCI NNP Condition
) ) Condition
. . None
STEMI NNP Condition
patients NNS None
undergoing VBG None
emergency NN Condition
PCI NNP Condition
in IN None
affiliated JJ None
hospital NN None
of IN None
Beihua NNP None
University NNP None
between IN None
October NNP None
2006 CD None
and CC None
January NNP None
2009 CD None
the DT None
control NN None
group NN None
( ( None
n JJ None
= NNP None
34 CD Condition
) ) None
postconditioning NN None
group NN None
( ( None
n JJ None
= NNP None
30 CD Condition
) ) None
injury NN None
in IN None
patients NNS None
with IN None
STEMI NNP None
. . None
-DOCSTART- -X- N

laryngopharyngeal JJ Condition
epidermoid JJ Condition
carcinoma NN Condition
. . Condition
Twenty-four CD None
patients NNS None
, , None
with IN None
a DT None
biopsy-proven JJ None
laryngeal NN None
or CC None
hypopharyngeal NN None
carcinoma NN None
healthy JJ None
control-group NN None
. . None
patients NNS None
with IN None
laryngo-pharyngeal JJ None
cancer NN None
-DOCSTART- -X- N

acute VB Condition
stroke NN Condition
patients NNS None
. . None
stroke VB Condition
patients NNS None
-DOCSTART- -X- N

recurrent NN None
or CC None
metastasised VBN None
colorectal JJ None
cancer NN None
( ( None
mCRC NN None
) ) None
Tumour NNP None
tissue NN None
was VBD None
obtained VBN None
from IN None
168 CD None
patients NNS None
with IN None
mCRC NN None
for IN None
relative JJ None
thymidylate NN None
synthase NN None
( ( None
TS NNP None
) ) None
mRNA NN None
quantitation NN None
. . None
patients NNS None
with IN None
primarily RB None
non-resectable JJ None
mCRC NN None
. . None
-DOCSTART- -X- N

total JJ Condition
hip NN Condition
replacement NN Condition
with IN Condition
resurfacing VBG Condition
Metal-on-metal NNP Condition
( ( Condition
MOM NNP Condition
) ) Condition
total JJ None
hip NN None
arthroplasties NNS None
52 CD None
hips NNS None
in IN None
52 CD Size
patients NNS None
( ( None
median JJ None
age NN None
60 CD None
( ( None
51-64 JJ None
) ) None
years NNS None
, , None
30 CD None
women NNS Age
) ) None
-DOCSTART- -X- N

healthy JJ None
male NN Sex
volunteers NNS None
( ( None
n=12 NN None
) ) None
. . None
subjects VBZ None
received VBN None
a DT None
single JJ None
dose NN None
of IN None
either CC None
donepezil JJ None
HCl NNP None
( ( None
5 CD None
mg NN None
) ) None
, , None
digoxin NN None
( ( None
0.25 CD None
mg NN None
) ) None
, , None
or CC None
a DT None
combination NN None
of IN None
both DT None
drugs NNS None
. . None
12 CD Size
volunteers NNS None
-DOCSTART- -X- N

total JJ Condition
hip JJ Condition
replacement NN Condition
: : None
a DT None
randomized JJ None
prospective JJ None
study NN None
. . None
From IN None
2004 CD None
to TO None
2008 CD None
, , None
81 CD Size
patients NNS None
seeking VBG None
elective JJ None
THRs NNP None
were VBD None
randomly RB None
assigned VBN None
into IN None
a DT None
standard JJ None
rehabilitation NN None
group NN None
or CC None
an DT None
early JJ None
rehabilitation NN None
group NN None
. . None
standard JJ None
group NN None
included VBD None
restrictions NNS None
to TO None
avoid VB None
hip NN None
flexion NN None
> VBD None
90 CD None
degrees NNS None
and CC None
avoidance NN None
of IN None
riding VBG None
in IN None
a DT None
car NN None
for IN None
the DT None
first JJ None
postoperative JJ None
month NN None
. . None
The DT None
early JJ None
group NN None
had VBD None
no DT None
flexion NN None
or CC None
car NN None
riding NN None
restrictions NNS None
. . None
Forty-three JJ Size
patients NNS None
were VBD None
in IN None
the DT None
standard JJ None
group NN None
and CC None
38 CD Size
patients NNS None
were VBD None
in IN None
the DT None
early JJ None
group NN None
. . None
no DT None
significant JJ None
demographic JJ None
differences NNS None
between IN None
the DT None
2 CD None
groups NNS None
. . None
-DOCSTART- -X- N

97 CD Size
cases NNS None
of IN None
SCD NNP Condition
among IN None
apparently RB None
healthy JJ None
men NNS Sex
enrolled VBN None
in IN None
the DT None
Physician NNP None
's POS None
Health NNP None
Study NNP None
. . None
apparently RB None
healthy JJ None
men NNS None
who WP None
are VBP None
at IN None
an DT None
increased VBN None
long-term JJ Condition
risk NN Condition
of IN Condition
SCD NNP Condition
. . None
-DOCSTART- -X- N

essential JJ None
hypertension NN None
. . None
19 CD None
ambulatory JJ None
men NNS None
with IN None
moderated VBN None
essential JJ None
hypertension NN None
( ( None
supine JJ None
diastolic NN None
blood NN None
pressure NN None
[ NNP None
DPB NNP None
] NNP None
, , None
100 CD None
to TO None
120 CD None
mm NNS None
Hg NNP None
after IN None
receiving VBG None
placebo NN None
for IN None
two CD None
weeks NNS None
) ) None
whose WP$ None
sodium JJ None
intake NN None
was VBD None
unrestricted VBN None
. . None
The DT None
captopril NN None
group NN None
included VBD None
12 CD None
patients NNS None
and CC None
the DT None
propranolol NN None
group NN None
seven CD None
. . None
moderate JJ None
essential JJ None
hypertension NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
chronic JJ Condition
kidney NN Condition
disease NN Condition
. . None
patients NNS None
with IN None
chronic JJ Condition
kidney NN Condition
disease NN Condition
( ( Condition
CKD NNP Condition
) ) None
. . None
patients NNS None
with IN None
mild JJ Condition
CKD NNP Condition
. . None
Thirty NNP Condition
CKD NNP Condition
patients NNS Condition
with IN None
mild JJ Condition
to TO Condition
moderate VB Condition
renal JJ Condition
insufficiency NN Condition
( ( None
20 CD Sex
men NNS Sex
and CC None
10 CD Sex
women NNS Sex
; : None
mean JJ None
age NN None
, , None
37 CD Age
years NNS Age
; : None
estimated VBN None
glomerular JJ Condition
filtration NN Condition
rate NN Condition
( ( None
eGFR NN None
) ) None
> VBZ None
60 CD None
mL NN None
min NN None
( ( None
-1 NNP None
) ) None
and CC None
blood NN None
pressure NN None
> VBZ None
130/85 CD None
mmHg NN None
) ) None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
coronary JJ Condition
artery NN Condition
disease NN Condition
. . None
University NNP None
Hospital NNP None
, , None
cardiac JJ None
surgical JJ None
operative NN None
theatre NN None
. . None
42 CD None
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
, , None
scheduled VBN None
to TO None
undergo VB None
coronary JJ None
surgery NN None
. . None
INCLUSION NNP None
CRITERIA NNP None
severe JJ Condition
coronary JJ Condition
stenosis NN Condition
of IN Condition
anterior JJ Condition
descending VBG Condition
coronary JJ Condition
artery NN Condition
; : None
no DT Condition
collateral NN Condition
flow NN Condition
on IN Condition
angiography NN Condition
; : None
at IN Condition
least JJS Condition
two CD Condition
normokinetic JJ Condition
segments NNS Condition
in IN Condition
the DT Condition
myocardial JJ Condition
region NN Condition
supplied VBN Condition
by IN Condition
the DT Condition
vessel NN Condition
being VBG Condition
bypassed VBN Condition
. . None
-DOCSTART- -X- N

long-standing JJ None
adductor-related JJ Condition
groin NN Condition
pain NN Condition
in IN None
athletes NNS Condition
: : None
adductor-related JJ Condition
groin NN Condition
pain NN Condition
. . None
adductor-related JJ None
groin NN None
pain NN None
in IN None
athletes NNS None
. . None
68 CD Size
athletes NNS None
with IN None
long-standing JJ None
( ( None
median JJ None
40 CD None
weeks NNS None
) ) None
adductor-related JJ Condition
groin NN Condition
pain NN Condition
-- : None
after IN None
examination NN None
according VBG None
to TO None
a DT None
standardised VBN None
protocol NN None
-- : None
were VBD None
randomly RB None
assigned VBN None
to TO None
AT NNP None
or CC None
PT NNP None
. . None
23 CD None
patients NNS None
in IN None
the DT None
AT NNP None
group NN None
and CC None
four CD None
in IN None
the DT None
PT NNP None
group NN None
returned VBD None
to TO None
sports NNS None
without IN None
groin NN None
pain NN None
( ( None
odds NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
osteoporosis NN Condition
: : None
80 CD Size
postmenopausal JJ Condition
women NNS None
with IN None
osteoporosis NN Condition
postmenopausal JJ Condition
women NNS None
Eighty NNP Size
postmenopausal JJ Condition
women NNS None
with IN None
osteoporosis NN Condition
were VBD None
randomly RB None
assigned VBN None
to TO None
a DT None
control NN None
group NN None
( ( None
n JJ None
= NNP None
38 CD Size
) ) None
or CC None
an DT None
exercise NN None
group NN None
( ( None
n JJ None
= NNP None
42 CD Size
) ) None
. . None
patients NNS None
with IN None
osteoporosis NN None
. . None
-DOCSTART- -X- N

autism NN Condition
. . None
individuals NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP Condition
) ) None
individuals NNS None
with IN None
autism NN None
13 CD Size
individuals NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

in IN None
man NN None
animals NNS None
and CC None
man NN None
. . None
animals NNS None
in IN None
man NN None
-DOCSTART- -X- N

pregnant JJ None
gilts NNS None
in IN None
their PRP$ None
offspring NN None
. . None
pregnant JJ None
gilts NNS None
in IN None
their PRP$ None
offspring NN None
. . None
33 CD None
German JJ None
Landrace NNP None
gilts NNS None
of IN None
the DT None
sows NNS None
The DT None
offspring VBG None
were VBD None
cross-fostered JJ None
offspring NN None
piglets NNS None
pigs NNS None
-DOCSTART- -X- N

flexible JJ None
nasendoscopy NN None
98 CD Size
patients NNS None
flexible JJ None
nasendoscopy NN None
flexible JJ None
nasendoscopy NN None
-DOCSTART- -X- N

umbilical JJ None
cord NN None
complications NNS None
] VBP None
A NNP None
low-risk JJ None
population NN None
of IN None
4196 CD None
cases NNS None
was VBD None
selected VBN None
in IN None
which WDT None
cord NN None
complications NNS None
have VBP None
been VBN None
recognized VBN None
in IN None
34.3 CD None
% NN None
. . None
Cases VBZ None
with IN None
cord NN None
complications NNS None
and CC None
controls NNS None
were VBD None
paired VBN None
25 CD None
pairs NNS None
were VBD None
randomly RB None
selected VBN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ None
non-small-cell JJ None
lung NN None
cancer NN None
: : None
quality NN None
of IN None
life NN None
directed VBN None
phase NN None
II NNP None
randomized VBD None
trial NN None
of IN None
Gruppo NNP None
Oncologico NNP None
Italia NNP None
Meridionale NNP None
. . None
metastatic JJ None
non-small-cell JJ None
lung NN None
cancer NN None
Patients NNPS None
37 CD None
pts NNS None
( ( None
88 CD None
% NN None
) ) None
in IN None
the DT None
DCT/CDDP NNP None
arm NN None
39 CD None
pts NNS None
( ( None
87 CD None
% NN None
) ) None
in IN None
the DT None
VNR/CDDP NNP None
one NN None
. . None
pts NNS None
with IN None
advanced JJ None
non-small-cell JJ None
lung NN None
cancer NN None
-DOCSTART- -X- N

postexercise NN Condition
hypotension NN Condition
in IN None
humans NNS None
. . None
blood NN None
pressure NN None
that WDT None
occurs VBZ None
after IN None
exercise NN None
in IN None
humans NNS None
. . None
Eight NNP Size
healthy JJ None
subjects NNS None
humans NNS None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
. . None
risperidone NN None
in IN None
children NNS Age
ages NNS None
5 CD Age
to TO Age
17 CD Age
years NNS Age
with IN None
autism NN Condition
accompanied VBN None
by IN None
severe JJ None
tantrums NNS None
, , None
aggression NN None
, , None
and/or JJ None
self-injurious JJ None
behavior NN None
who WP None
showed VBD None
a DT None
positive JJ None
response NN None
in IN None
an DT None
earlier JJR None
8-week JJ None
trial NN None
. . None
Part NNP None
I PRP None
included VBD None
63 CD Size
children NNS None
. . None
Part NNP None
II NNP None
included VBD None
32 CD Size
patients NNS None
. . None
children NNS None
with IN None
autism NN None
characterized VBN None
by IN None
tantrums NNS None
, , None
aggression NN None
, , None
and/or JJ None
self-injurious JJ None
behavior NN None
. . None
-DOCSTART- -X- N

premenopausal NN Condition
patients NNS None
with IN None
advanced JJ Condition
breast NN Condition
cancer NN Condition
. . None
122 CD Size
premenopausal JJ Condition
women NNS Sex
54 CD Size
evaluable JJ None
women NNS Sex
treated VBN None
with IN None
tamoxifen NN None
, , None
24 CD None
% NN None
had VBD None
an DT None
objective JJ None
response NN None
, , None
as IN None
compared VBN None
with IN None
21 CD None
% NN None
of IN None
53 CD Size
women NNS Sex
having VBG None
an DT None
oophorectomy NN None
58 CD Size
patients NNS None
premenopausal JJ Condition
women NNS Sex
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
treated VBD None
with IN None
interferon-alpha JJ None
and CC None
ribavirin NN None
: : None
patients NNS None
with IN None
chronic JJ None
hepatitis NN None
C NNP None
during IN None
and CC None
after IN None
treatment NN None
with IN None
interferon-alpha JJ None
( ( None
IFN-alpha NNP None
) ) None
and CC None
ribavirin NN None
. . None
previously RB None
untreated JJ None
patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
patients NNS None
in IN None
the DT None
control NN None
and CC None
the DT None
amantadine NN None
group NN None
. . None
-DOCSTART- -X- N

hairy NN Condition
cell NN Condition
leukemia NN Condition
. . None
cohort NN None
of IN None
69 CD Size
patients NNS None
treated VBN None
from IN None
1983 CD None
to TO None
1986 CD None
. . None
69 CD Size
hairy NN Condition
cell NN Condition
leukemia NN Condition
( ( Condition
HCL NNP Condition
) ) Condition
patients NNS None
treated VBN None
with IN None
interferon JJ None
alfa-2b NN None
( ( None
IFN NNP None
) ) None
as IN None
primary JJ None
treatment NN None
from IN None
1983 CD None
to TO None
1986 CD None
. . None
-DOCSTART- -X- N

second-grade JJ Size
general JJ None
education NN None
students NNS None
with IN None
difficulty NN None
attending VBG None
. . None
Ten CD Size
participants NNS None
from IN None
nine CD None
elementary JJ None
schools NNS None
in IN None
a DT None
suburban JJ None
Texas NNP None
school NN None
district NN None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
duodenal JJ Condition
ulcer NN Condition
( ( Condition
Du NNP Condition
) ) Condition
upon IN None
190 CD Size
patients NNS None
with IN None
DU NNP Condition
. . None
Seventy NNP Size
three CD Size
patients NNS None
two CD None
groups NNS None
31 CD Size
patients NNS None
42 CD Size
patients NNS None
with IN None
H. NNP None
pylori FW None
patients NNS None
with IN None
DU NNP Condition
-DOCSTART- -X- N

Home-based JJ None
reach-to-grasp JJ None
training NN None
for IN None
people NNS None
after IN Condition
stroke NN Condition
: : None
study NN None
protocol NN None
people NNS None
with IN None
stroke NN Condition
50 CD Size
individuals NNS None
with IN None
upper-limb JJ Condition
motor NN Condition
impairment NN Condition
after IN None
stroke NN Condition
. . None
Participants NNS None
will MD None
be VB None
recruited VBN None
after IN Condition
discharge NN Condition
from IN Condition
hospital NN Condition
and CC Condition
up RB Condition
to TO Condition
12 CD Condition
months NNS Condition
post-stroke RB Condition
from IN None
hospital NN None
stroke NN Condition
services NNS None
and CC None
community NN None
therapy-provider NN None
services NNS None
. . None
Participants NNS None
Participants NNS None
Participants NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
. . None
children NNS Age
with IN None
Autistic NNP None
Spectrum NNP None
Disorders NNP None
( ( None
ASD NNP Condition
) ) None
. . None
Thirty-two JJ Size
children NNS Age
with IN None
ASD NNP Condition
treatment NN None
group NN None
control NN None
group NN None
children NNS Age
with IN None
ASD NNP Condition
. . None
-DOCSTART- -X- N

Twenty-six JJ None
postmenopausal JJ None
women NNS None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS Condition
Thirty NNP None
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

people NNS None
at IN None
normal JJ Condition
risk NN Condition
for IN Condition
colorectal JJ Condition
cancer NN Condition
. . None
healthy JJ Condition
volunteers NNS None
. . None
30 CD Size
subjects NNS None
for IN None
28 CD None
days NNS None
. . None
-DOCSTART- -X- N

children NNS None
, , None
adolescents NNS None
and CC None
adults NNS None
with IN None
mental JJ None
retardation NN None
. . None
destructive JJ None
Forty NNP None
subjects NNS None
, , None
aged VBN None
8-56 CD None
years NNS None
( ( None
mean=22 NN None
) ) None
, , None
all DT None
with IN None
mental JJ None
retardation NN None
and CC None
36 CD None
with IN None
autism NN None
spectrum NN None
disorders NNS None
participated VBD None
-DOCSTART- -X- N

osteoarthritis NN Condition
( ( None
OA NNP Condition
) ) None
of IN None
the DT None
hip NN None
or CC None
knee NN None
Fifty NNP Size
patients NNS None
, , None
demographically RB None
balanced VBN None
, , None
with IN None
radiographically RB None
proven JJ None
primary JJ None
hip NN None
or CC None
knee NN None
OA NNP Condition
completed VBD None
the DT None
classical JJ None
paper NN None
and CC None
the DT None
new JJ None
computerized JJ None
WOMAC NNP None
version NN None
. . None
-DOCSTART- -X- N

rhythmical JJ None
arm NN None
swing NN None
in IN None
humans NNS None
. . None
rhythmic JJ None
arm NN None
swing NN None
in IN None
humans NNS None
. . None
subjects NNS None
swung VBP None
their PRP$ None
ipsilateral JJ None
arms NNS None
or CC None
both DT None
arms NNS None
reciprocally RB None
during IN None
testing VBG None
. . None
-DOCSTART- -X- N

480 CD None
subjects NNS None
with IN None
a DT None
history NN None
of IN None
repeated VBN None
parasuicide NN None
Most JJS None
patients NNS None
had VBD None
significant JJ None
anxiety NN None
and CC None
depressive JJ None
disturbance NN None
with IN None
42 CD None
% NN None
having VBG None
a DT None
personality NN None
disorder NN None
. . None
-DOCSTART- -X- N

linear JJ None
surgical JJ None
incisions NNS None
: : None
Patients NNPS None
undergoing VBG None
Wise-pattern JJ Condition
breast NN Condition
reduction NN Condition
or CC Condition
abdominal JJ Condition
procedures NNS Condition
Of IN None
59 CD Size
patients NNS None
, , None
eight CD None
were VBD None
excluded VBN None
from IN None
randomization NN None
Fifty-one CD Size
patients NNS None
( ( None
breast NN None
, , None
n JJ None
= VBP None
24 CD None
; : None
abdomen NNS None
, , None
n JJ None
= NNP None
27 CD None
) ) None
-DOCSTART- -X- N

lambs NNS Condition
and CC None
steers NNS Condition
fed VBP Condition
to TO Condition
meet VB Condition
requirements NNS Condition
of IN Condition
natural JJ Condition
markets NNS Condition
. . None
lambs NNS None
and CC None
cattle NNS None
destined VBD None
for IN None
all DT None
natural JJ None
markets NNS None
. . None
1 CD None
, , None
48 CD None
Dorset NNP None
? . None
Hampshire NNP None
lambs NN None
( ( None
initial JJ None
BW NNP None
29.4 CD None
? . None
0.1 CD None
kg NN None
) ) None
were VBD None
characteristics NNS None
. . None
Lambs NNP None
were VBD None
allotted VBN None
to TO None
12 CD None
pens NNS None
( ( None
4 CD None
lambs NNS None
per IN None
pen NN None
) ) None
, , None
and CC None
blocked VBN None
by IN None
sex NN None
and CC None
BW NNP None
. . None
Exp NNP None
. . None
2 CD None
168 CD None
crossbred VBD None
steers NNS None
( ( None
initial JJ None
BW NNP None
300 CD None
? . None
0.7 CD None
kg NN None
) ) None
were VBD None
lambs NN None
and CC None
steers NNS None
fed VBP None
-DOCSTART- -X- N

hypertension NN Condition
. . None
59 CD Size
mild NN Condition
to TO Condition
moderate VB Condition
hypertensives NNS Condition
-DOCSTART- -X- N

toddlers NNS None
with IN None
early JJ None
autism NN None
symptoms NNS None
. . None
Sixty-two JJ None
children NNS None
( ( None
51 CD None
boys NNS None
and CC None
11 CD None
girls NNS None
; : None
M NNP None
age NN None
= VBD None
20 CD None
months NNS None
; : None
SD NNP None
= NNP None
2.6 CD None
) ) None
who WP None
met VBD None
criteria NNS None
for IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
and CC None
their PRP$ None
parents NNS None
participated VBN None
in IN None
the DT None
study NN None
. . None
Parents NNS None
of IN None
children NNS None
who WP None
evidence NN None
higher JJR None
object JJ None
interest NN None
-DOCSTART- -X- N

transrectal JJ Condition
ultrasound NN Condition
guided VBD Condition
prostate NN Condition
biopsy NN Condition
100 CD Size
consecutive JJ None
patients NNS None
with IN None
sterile JJ Condition
urine JJ Condition
cultures NNS Condition
underwent JJ None
transrectal JJ Condition
ultrasound NN Condition
guided VBD Condition
prostate NN Condition
biopsy NN Condition
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
arterial JJ Condition
occlusive JJ Condition
disease NN Condition
of IN Condition
the DT Condition
lower JJR Condition
extremities NNS Condition
] VBP Condition
patients NNS None
with IN None
advanced JJ None
atherosclerosis NN None
manifested VBN None
by IN None
arterial JJ None
occlusion NN None
in IN None
the DT None
lower JJR None
extremities NNS None
without IN None
a DT None
baseline NN None
blood NN None
lipid JJ None
disorder NN None
statin NN None
treatment NN None
comparable JJ None
control NN None
group NN None
without IN None
statins VBZ None
patients NNS None
with IN None
arterial JJ None
occlusion NN None
of IN None
the DT None
lower JJR None
extremities NNS None
with IN None
baseline NN None
dyslipidaemia NN None
-DOCSTART- -X- N

children NNS None
with IN None
ASD NNP None
, , None
ADHD NNP None
and CC None
ASD+ADHD NNP None
. . None
Children NNP None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
and CC None
attention NN None
deficit NN None
hyperactivity NN None
disorder NN None
( ( None
ADHD NNP None
) ) None
Children NNP None
with IN None
ASD NNP None
( ( None
n=19 NN None
) ) None
, , None
ADHD NNP None
( ( None
n=18 NN None
) ) None
, , None
comorbid JJ None
ASD+ADHD NNP None
( ( None
n=29 NN None
) ) None
and CC None
typically RB None
developing VBG None
( ( None
TD NNP None
) ) None
controls NNS None
( ( None
n=26 NN None
) ) None
children NNS None
with IN None
ASD NNP None
( ( None
ASD/ASD+ADHD NNP None
) ) None
children NNS None
with IN None
ASD NNP None
children NNS None
with IN None
ADHD NNP None
( ( None
ADHD/ASD+ADHD NNP None
) ) None
children NNS None
with IN None
ASD NNP None
children NNS None
with IN None
ADHD NNP None
Children NNP None
with IN None
ASD+ADHD NNP None
-DOCSTART- -X- N

arthrography NN Condition
of IN None
the DT None
knee NN None
. . None
double JJ None
contrast NN None
knee NN None
arthrography NN Condition
, , None
190 CD Size
and CC None
184 CD Size
patients NNS None
each DT None
. . None
-DOCSTART- -X- N

autism NN None
. . None
unfamiliar JJ None
child NN None
with IN None
autism NN None
. . None
Children NNP None
( ( None
N=296 NNP None
; : None
M NNP None
age=10.21 IN None
years NNS None
) ) None
unfamiliar JJ None
child NN None
with IN None
autism NN None
teacher NN None
hypothetical JJ None
mother NN None
hypothetical JJ None
father NN None
hypothetical JJ None
doctor NN None
. . None
Fifth-graders NNS None
-DOCSTART- -X- N

in IN None
alcohol NN Condition
dependence NN Condition
: : None
on IN None
alcohol NN None
drinking NN None
indices NNS None
. . None
Seventy-one CD Condition
alcohol-dependent JJ None
subjects NNS None
in IN None
patients NNS None
reporting VBG None
a DT None
comorbid NN Condition
psychiatric JJ Condition
disorder NN Condition
. . None
-DOCSTART- -X- N

multinational JJ Age
postmenopausal JJ Condition
women NNS Condition
with IN Condition
HR+ NNP Condition
breast NN Condition
cancer NN Condition
ineligible JJ Condition
for IN Condition
breast-conserving JJ Condition
surgery NN Condition
. . Condition
postmenopausal JJ None
women NNS None
with IN None
HR+ NNP None
locally RB None
advanced VBD None
breast NN None
cancer NN None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
elective JJ Condition
craniotomy NN Condition
for IN None
supratentorial JJ Condition
mass NN Condition
lesions NNS Condition
. . None
Ninety-one JJ Size
patients NNS None
-DOCSTART- -X- N

uncomplicated JJ Condition
malaria NNS Condition
: : None
sub-Saharan JJ None
Africa NNP None
. . None
children NNS Age
from IN None
Kampala NNP None
, , None
Uganda NNP None
. . None
healthy JJ None
children NNS None
aged VBD None
6 CD Age
months NNS Age
to TO Age
5 CD Age
years NNS Age
316 CD Size
participants NNS None
-DOCSTART- -X- N

herpes NNS Condition
simplex JJ Condition
labialis NN Condition
( ( None
HSL NNP None
) ) None
. . None
2437 CD Size
patients NNS None
with IN None
a DT None
history NN Condition
of IN Condition
HSL NNP Condition
1443 CD None
patients NNS None
experienced VBD None
a DT None
recurrence NN None
35 CD None
% NN None
of IN None
patients NNS None
-DOCSTART- -X- N

post-cesarean JJ Condition
section NN Condition
( ( Condition
CS NNP Condition
) ) Condition
morphine VB None
self-administered JJ None
by IN None
the DT None
patient NN None
via IN None
the DT None
patient-controlled JJ None
analgesia NN None
device NN None
( ( None
PCA NNP None
) ) None
Forty-two JJ None
patients NNS None
scheduled VBN None
for IN None
elective JJ None
CS NNP None
All DT Condition
patients NNS Condition
received VBD Condition
-DOCSTART- -X- N

people NNS None
with IN None
multiple JJ Condition
sclerosis NN Condition
. . None
people NNS None
with IN None
multiple JJ Condition
sclerosis NN Condition
multiple JJ Condition
sclerosis NN Condition
. . None
In IN None
phase NN None
1 CD None
, , None
36 CD Size
participants NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
experimental VB None
and CC None
control VB None
groups NNS None
. . None
phase NN None
2 CD None
, , None
the DT None
control NN None
group NN None
people NNS None
with IN None
multiple JJ Condition
sclerosis NN Condition
( ( None
MS NNP Condition
) ) None
-DOCSTART- -X- N

210 CD Size
ASA NNP None
I PRP None
or CC None
II NNP None
patients NNS None
undergoing VBG None
cesarean JJ None
delivery NN None
, , None
who WP None
were VBD None
randomly RB None
assigned VBN None
to TO None
six CD None
groups NNS None
. . None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Sex
with IN None
advanced JJ Condition
breast NN Condition
cancer NN Condition
. . None
Eighty-eight JJ Size
postmenopausal JJ None
women NNS None
with IN None
metastatic JJ None
breast NN None
cancer NN None
, , None
in IN None
whom WP None
estrogen NN None
receptors NNS None
( ( None
ER NNP None
) ) None
were VBD None
positive JJ None
or CC None
unknown JJ None
Patients NNS Condition
with IN Condition
known JJ Condition
ER NNP Condition
negative JJ Condition
status NN Condition
were VBD Condition
not RB Condition
studied VBN Condition
. . None
postmenopausal NN None
patients NNS None
with IN None
advanced JJ None
breast NN None
cancer NN None
. . None
-DOCSTART- -X- N

families NNS None
with IN None
a DT None
handicapped JJ Condition
child NN Age
, , None
which WDT None
has VBZ None
already RB None
been VBN None
successfully RB None
evaluated VBN None
in IN None
its PRP$ None
country NN None
of IN None
origin NN None
, , None
Australia NNP None
. . None
several JJ None
Social NNP None
Pediatric NNP None
Centers NNP None
( ( None
SPCs NNP None
) ) None
and CC None
further JJ None
clinics/institutions NNS None
in IN None
Germany NNP None
( ( None
3-7 JJ None
families NNS None
per IN None
training NN None
) ) None
-DOCSTART- -X- N

chronic JJ None
depression NN None
among IN None
women NNS None
in IN None
an DT None
inner JJ None
city NN None
. . None
remission NN None
from IN None
depression NN None
. . None
remission NN Condition
of IN Condition
chronic JJ Condition
depression NN Condition
-DOCSTART- -X- N

Children NNP None
's POS None
attitudes NNS None
and CC None
behavioral JJ None
intentions NNS None
toward IN None
a DT None
peer NN None
with IN None
autistic JJ None
behaviors NNS None
: : None
children NNS None
's POS None
ratings NNS None
of IN None
attitudes NNS None
and CC None
behavioral JJ None
intentions NNS None
toward IN None
a DT None
peer NN None
presented VBN None
with IN None
or CC None
without IN None
autistic JJ None
behaviors NNS None
. . None
Third- CD None
and CC None
sixth-grade JJ None
children NNS None
( ( None
N NNP None
= NNP None
233 CD None
) ) None
-DOCSTART- -X- N

patients NNS None
of IN None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
undergoing VBG None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
. . None
patients NNS None
with IN None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
who WP None
undergo VBP None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
Forty-five JJ Size
patients NNS None
posted VBD None
for IN None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
-DOCSTART- -X- N

patients NNS None
with IN None
congestive JJ Condition
heart NN Condition
failure NN Condition
. . None
60 CD Size
patients NNS None
with IN None
mild JJ Condition
to TO None
moderate VB Condition
( ( Condition
II NNP Condition
and CC Condition
III NNP Condition
NYHA NNP Condition
class NN Condition
) ) Condition
congestive JJ Condition
heart NN Condition
failure NN Condition
. . None
The DT None
group NN None
was VBD None
made VBN None
up IN None
of IN None
men NNS Sex
and CC None
women NNS Sex
aged VBD None
between IN Age
48 CD Age
and CC Age
73 CD Age
years NNS Age
in IN None
chronic JJ Condition
treatment NN Condition
with IN None
digitalis NN None
and CC None
diuretics NNS None
for IN None
at IN None
least JJS None
3 CD None
months NNS None
and CC None
who WP None
still RB None
displayed VBD None
symptoms NNS None
. . None
patients NNS None
with IN None
congestive JJ Condition
heart NN Condition
failure NN Condition
-DOCSTART- -X- N

type NN Condition
2 CD Condition
diabetic JJ Condition
subjects NNS None
: : None
type NN None
2 CD None
diabetic JJ None
individuals NNS None
. . None
Twenty-four JJ Size
participants NNS None
with IN None
type NN Condition
2 CD Condition
diabetes NNS Condition
( ( None
mean JJ Age
age NN Age
58 CD Age
years NNS Age
; : None
14 CD Size
women NNS Sex
and CC None
10 CD Size
men NNS Sex
) ) None
-DOCSTART- -X- N

cystoid JJ None
macular JJ None
edema NN None
in IN None
branch JJ None
retinal JJ None
vein NN None
occlusion NN None
. . None
patients NNS None
with IN None
perfused JJ None
branch NN None
retinal JJ None
vein NN None
occlusion NN None
. . None
Thirty NNP None
eyes NNS None
of IN None
30 CD None
consecutive JJ None
patients NNS None
with IN None
cystoid JJ None
macular JJ None
edema NN None
secondary JJ None
to TO None
nonischemic JJ None
branch NN None
retinal JJ None
vein NN None
occlusion NN None
were VBD None
assigned VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
or CC Condition
recurrent JJ Condition
breast NN Condition
cancer NN Condition
. . None
patients NNS None
with IN None
advanced JJ Condition
or CC Condition
recurrent JJ Condition
breast NN Condition
cancer NN Condition
. . None
221 CD Size
patients NNS None
were VBD None
assessable JJ None
. . None
patients NNS None
who WP None
were VBD None
premenopausal NN Condition
, , None
had VBD None
no DT Condition
prior JJ Condition
therapy NN Condition
, , None
and CC None
were VBD None
stage NN None
IV NNP None
at IN None
diagnosis NN None
with IN None
an DT None
intact JJ Condition
primary JJ Condition
tumor NN Condition
. . None
patients NNS None
who WP None
had VBD None
not RB Condition
received VBN Condition
prior JJ Condition
therapy NN Condition
. . None
-DOCSTART- -X- N

Electrical JJ None
cardioversion NN None
( ( None
ECV NNP None
) ) None
of IN None
atrial JJ None
fibrillation NN None
( ( None
AF NNP None
) ) None
60 CD None
patients NNS None
attending VBG None
for IN None
ECV NNP None
of IN None
persistent JJ None
AF NNP None
to TO None
a DT None
transesophageal NN None
or CC None
a DT None
transthoracic JJ None
approach NN None
. . None
-DOCSTART- -X- N

Shigella NNP None
sonnei NN None
: : None
guinea NN None
pig NN None
model NN None
. . None
Phase NNP None
I PRP None
study VBP None
, , None
10 CD None
evaluable JJ None
subjects NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
severe JJ Condition
acute NN Condition
pancreatitis NN Condition
. . None
patients NNS None
with IN None
severe JJ Condition
acute NN Condition
pancreatitis NN Condition
( ( Condition
SAP NNP Condition
) ) Condition
. . None
71 CD Condition
patients NNS Condition
with IN None
confirmed VBN None
severe JJ Condition
acute NN Condition
pancreatitis NN Condition
from IN None
March NNP None
2009 CD None
to TO None
September NNP None
2011 CD None
in IN None
the DT None
Department NNP None
of IN None
Critical NNP None
Care NNP None
Medicine NNP None
of IN None
Huizhou NNP None
Municipal NNP None
Central NNP None
Hospital NNP None
, , None
Guangdong NNP None
, , None
China NNP None
patients NNS None
with IN None
severe JJ Condition
acute NN Condition
pancreatitis NN Condition
. . None
-DOCSTART- -X- N

twelve JJ None
insulin-dependent JJ None
diabetes NNS None
( ( None
IDDM NNP None
) ) None
patients NNS None
. . None
-DOCSTART- -X- N

End-expiratory JJ Condition
lung NN Condition
volume NN Condition
20 CD None
patients NNS None
postcardiac JJ None
surgery NN None
. . None
-DOCSTART- -X- N

20 CD Size
patients NNS None
undergoing JJ None
oral JJ Condition
surgery NN Condition
with IN None
intravenous JJ None
midazolam NNS None
sedation NN Condition
. . None
-DOCSTART- -X- N

35 CD Size
consecutive JJ None
patients NNS None
presenting VBG None
with IN None
acute NN Condition
thrombosed VBN Condition
circumferential JJ Condition
prolapsed JJ Condition
haemorrhoids NNS Condition
. . None
Thirty NNP Size
patients NNS None
patients NNS None
stapled JJ None
group NN None
patients NNS None
More JJR None
patients NNS None
in IN None
the DT None
conventional JJ Condition
group NN Condition
complained VBD None
of IN None
persistent JJ None
symptoms NNS None
of IN None
pain NN None
, , None
bleeding NN None
and CC None
discharge NN None
at IN None
2 CD None
week NN None
and CC None
6 CD None
week NN None
review NN None
with IN None
20 CD None
% NN None
requiring VBG None
readmission NN None
compared VBN None
with IN None
none NN None
in IN None
the DT None
stapled JJ None
group NN None
. . None
two CD None
patients NNS None
from IN None
each DT None
group NN None
had VBD None
ultrasonic JJ None
evidence NN None
-DOCSTART- -X- N

pre-eclampsia NN Condition
. . Condition
Pre-Eclampsia NNP None
of IN None
Pregnancy NNP None
. . None
group NN None
of IN None
primiparous JJ None
and CC None
multiparous JJ None
pregnant JJ None
women NNS None
. . None
Some DT Condition
of IN Condition
these DT Condition
women NNS Condition
had VBD Condition
personal JJ Condition
or CC Condition
family NN Condition
histories NNS Condition
of IN Condition
hypertension NN Condition
( ( Condition
21 CD Condition
% NN Condition
) ) Condition
. . Condition
Only RB None
those DT None
patients NNS None
who WP None
received VBD None
prenatal JJ None
care NN None
at IN None
the DT None
Central NNP None
Maternity NNP None
Hospital NNP None
for IN None
Luanda NNP None
hypertension NN None
of IN None
pregnancy NN None
. . None
eclampsia NN None
-DOCSTART- -X- N

hirsutism NN None
. . None
hirsutism NN None
. . None
Women NNP None
with IN None
hirsutism NN None
, , None
as IN None
defined VBN None
by IN None
a DT None
minimum JJ None
Ferriman-Gallwey JJ None
score NN None
of IN None
10 CD None
47 CD None
women NNS None
enrolled VBD None
hirsutism NN None
. . None
-DOCSTART- -X- N

total JJ None
hip NN None
replacement NN None
. . None
total JJ None
hip NN None
replacement NN None
patients NNS None
in IN None
the DT None
bupivacaine NN None
only RB None
group NN None
bupivacaine-morphine JJ None
group NN None
-DOCSTART- -X- N

military JJ None
paratroopers NNS None
' POS None
Army NNP None
paratrooper IN None
training NN None
. . None
777 CD Size
volunteers NNS None
from IN None
the DT None
U.S. NNP None
Army NNP None
Airborne NNP None
School NNP None
, , None
Fort NNP None
Benning NNP None
, , None
Ga. NNP None
745 CD None
completed VBD None
all DT None
study NN None
requirements NNS None
( ( None
369 CD None
brace-wearers NNS None
and CC None
376 CD None
non-brace-wearers NNS None
) ) None
. . None
during IN None
parachute JJ None
training NN None
-DOCSTART- -X- N

Human NNP None
primary JJ None
visual JJ None
cortex NN None
( ( None
V1 NNP None
) ) None
is VBZ None
selective JJ None
for IN None
second-order JJ None
spatial JJ None
frequency NN None
. . None
Human NNP None
primary JJ None
visual JJ None
cortex NN None
( ( None
V1 NNP None
) ) None
early JJ None
visual JJ None
cortex NN None
human JJ None
visual JJ None
cortex NN None
-DOCSTART- -X- N

chronic JJ Condition
low JJ Condition
back RB Condition
pain NN Condition
: : None
A NNP None
total NN None
of IN None
210 CD Condition
participants NNS None
with IN None
low JJ Condition
back RB Condition
pain NN Condition
lasting NN None
at IN None
least JJS None
3 CD None
months NNS None
will MD None
be VB None
recruited VBN None
from IN None
primary JJ None
care NN None
clinics NNS None
of IN None
a DT None
large JJ None
healthcare NN None
system NN None
based VBN None
in IN None
Seattle NNP None
. . None
chronic JJ Condition
back RB Condition
pain NN Condition
-DOCSTART- -X- N

children NNS None
with IN None
Developmental NNP Condition
Coordination NNP Condition
Disorder NNP Condition
: : None
parents NNS None
and CC None
teachers NNS None
. . None
Children NNP None
with IN None
Developmental NNP Condition
Coordination NNP Condition
Disorder NNP Condition
( ( Condition
DCD NNP Condition
) ) Condition
parents NNS None
and CC None
teachers NNS None
children NNS None
with IN None
DCD NNP None
; : None
children NNS None
with IN None
DCD NNP None
Thirty-one CD Size
children NNS None
with IN None
DCD NNP None
aged VBD None
7 CD Age
to TO Age
9 CD Age
years NNS Age
participated VBN None
in IN None
the DT None
study NN None
. . None
teachers NNS None
and CC None
parents NNS None
27 CD Size
children NNS None
teachers NNS None
and CC None
parents NNS None
-DOCSTART- -X- N

Smokers NNP Condition
recruited VBD None
from IN None
among IN None
the DT None
health NN None
centre NN None
users NNS None
through IN None
the DT None
preventive JJ None
activities NNS None
and CC None
health NN None
promotion NN None
programme NN None
. . None
54 CD Size
patients NNS None
were VBD None
included VBN None
, , None
with IN None
6 CD Size
losses NNS None
. . None
21 CD Size
MI NNP None
group NN None
27 CD Size
AI NNP None
group NN None
. . None
-DOCSTART- -X- N

metastatic JJ Condition
renal NN Condition
cell NN Condition
cancer NN Condition
. . Condition
metastatic JJ Condition
renal NN Condition
cell NN Condition
cancer NN Condition
Patients NNS None
One CD None
hundred CD None
and CC None
eighty-three JJ None
patients NNS None
were VBD None
enrolled VBN None
between IN None
January NNP None
1998 CD None
and CC None
November NNP None
2003 CD None
. . None
-DOCSTART- -X- N

Dural NNP Condition
Arteriovenous NNP Condition
Fistula NNP Condition
. . Condition
dural JJ None
arteriovenous JJ None
fistula NN None
( ( None
DAVF NNP None
) ) None
in IN None
the DT None
transverse NN None
sinus NN None
. . None
Nine NNP None
patients NNS None
underwent JJ Condition
NCE NNP Condition
4D CD Condition
MRA NNP Condition
All DT None
patients NNS None
also RB None
underwent JJ None
digital JJ None
subtraction NN None
angiography NN None
( ( None
DSA NNP None
) ) None
Among IN None
seven CD None
patients NNS None
with IN None
patent NN None
DAVFs NNP None
, , None
of IN None
three CD None
patients NNS None
with IN None
CVR NNP None
. . None
-DOCSTART- -X- N

young JJ Condition
children NNS Age
with IN Condition
autism NN Condition
Children NNP None
with IN None
autism NN None
young JJ None
children NNS None
with IN None
autism NN None
and CC None
co-morbid JJ None
ID NNP None
young JJ None
children NNS None
with IN None
autism NN None
with IN None
a DT None
range NN None
of IN None
intellectual JJ None
ability NN None
Participants NNPS None
were VBD None
55 CD Size
children NNS None
with IN None
autistic JJ None
disorder NN None
, , None
aged VBN None
4-7 CD None
years NNS None
( ( None
FSIQ NNP None
42-107 CD None
) ) None
young JJ None
children NNS None
with IN None
autism NN None
young JJ None
children NNS None
with IN None
autism NN None
-DOCSTART- -X- N

benign JJ None
prostatic JJ None
hyperplasia NN None
: : None
patients NNS None
with IN None
benign JJ None
prostatic JJ None
hyperplasia NN None
618 CD None
patients NNS None
, , None
418 CD None
( ( None
68 CD None
% NN None
) ) None
target NN None
BPH NNP None
population NN None
-DOCSTART- -X- N

miosis NN None
during IN None
vitrectomy NN None
. . None
Fifty NNP None
consecutive JJ None
patients NNS None
undergoing VBG None
vitrectomy NN None
-DOCSTART- -X- N

acute JJ Condition
seasonal JJ Condition
allergic JJ Condition
conjunctivitis NN Condition
. . Condition
Eighteen JJ None
subjects NNS None
( ( None
mean JJ None
age NN None
, , None
29.5?11.0 CD None
years NNS None
) ) None
allergic VBP None
to TO None
grass VB None
pollen NN None
. . None
of IN None
allergic JJ None
conjunctivitis NN None
. . None
A DT None
CC NNP None
enhanced VBD None
Signs NNP None
of IN None
allergic JJ None
conjunctivitis NN None
generally RB None
were VBD None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
spinal JJ None
anesthesia NN None
. . None
Sixty NNP Size
ASA NNP None
class NN None
I PRP None
patients NNS None
scheduled VBN None
for IN None
herniorrhapy NN None
under IN None
spinal JJ None
anesthesia NN None
Group NNP None
1 CD None
= NN None
patients NNS None
Group NNP None
2 CD None
= NN None
patients NNS None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Age
: : None
childhood NN Age
autism NN Condition
subjects NNS None
with IN None
autism NN Condition
Forty-five JJ Size
subjects NNS None
diagnosed VBN None
with IN None
autism NN Condition
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
boiled VBN None
CM NNP None
for IN None
group NN None
I PRP None
( ( None
n JJ None
= NNP None
15 CD None
) ) None
, , None
raw JJ None
CM NNP None
for IN None
group NN None
II NNP None
( ( None
n JJ None
= NNP None
15 CD None
) ) None
, , None
and CC None
placebo NN None
for IN None
group NN None
III NNP None
( ( None
n JJ None
= NNP None
15 CD None
) ) None
for IN None
2 CD None
wk NN None
. . None
autistic JJ None
children NNS None
, , None
-DOCSTART- -X- N

prostate NN Condition
cancer NN Condition
men NNS Sex
's POS Sex
( ( None
45-70 CD Age
years NNS None
) ) None
Internet NNP None
access NN None
and CC None
their PRP$ None
willingness NN None
to TO None
use VB None
a DT None
web- JJ None
vs. FW None
a DT None
print-based JJ None
tool NN None
. . None
men NNS None
's POS None
informed VBN None
decision NN None
making VBG None
-DOCSTART- -X- N

Cooperative NNP None
Group NNP None
of IN None
Study NNP None
and CC None
Treatment NNP None
of IN None
Multiple NNP Condition
Myeloma NNP Condition
. . None
Patients NNS None
with IN None
untreated JJ Condition
stage NN Condition
I PRP Condition
MM NNP Condition
( ( None
defined VBN None
according VBG None
to TO None
Durie NNP None
and CC None
Salmon NNP None
) ) None
stage NN None
II NNP None
patients NNS None
stage NN None
III NNP None
patients NNS None
-DOCSTART- -X- N

UK NNP Condition
genetic JJ Condition
risk NN Condition
counselling NN Condition
services NNS Condition
for IN Condition
familial JJ Condition
cancer NN Condition
: : Condition
50 CD None
new JJ None
clinic JJ None
attendees NNS None
, , None
referred VBD None
for IN None
cancer NN None
genetic JJ None
counselling NN None
to TO None
five CD None
UK NNP None
centres NNS None
. . None
The DT None
centres NNS None
represented VBD None
England NNP None
, , None
Scotland NNP None
and CC None
Wales NNP None
, , None
and CC None
were VBD None
randomly RB None
selected VBN None
from IN None
groups NNS None
ranked VBN None
by IN None
different JJ None
levels NNS None
of IN None
clinical JJ None
activity NN None
in IN None
cancer NN None
genetics NNS None
practice NN None
. . None
A DT None
total NN None
of IN None
256 CD None
unaffected JJ None
adults NNS None
fulfilled VBD None
the DT None
study NN None
criteria NNS None
. . None
-DOCSTART- -X- N

healthy JJ None
male NN None
volunteers NNS None
. . None
-DOCSTART- -X- N

wound NN None
closure NN None
dermal JJ Condition
closure NN Condition
of IN Condition
the DT Condition
Pfannenstiel NNP Condition
incision NN Condition
during IN None
nonemergent JJ None
cesarean JJ Condition
delivery NN None
surgery NN None
produces VBZ None
enrolled VBD None
195 CD Size
patients NNS None
, , None
of IN None
whom WP None
188 CD Size
were VBD None
eligible JJ None
for IN None
analysis NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
muscle-invasive JJ Condition
bladder NN Condition
cancer NN Condition
improved VBD None
local JJ None
control NN None
or CC None
survival NN None
. . None
Ninety-nine NNP Size
eligible JJ None
patients NNS None
with IN None
T2 NNP Condition
to TO Condition
T4b NNP Condition
transitional JJ Condition
cell NN Condition
bladder NN Condition
cancer NN Condition
participated VBD None
, , None
64 CD Size
% NN Size
with IN None
cT3b NN None
or CC None
cT4 NN None
. . None
-DOCSTART- -X- N

pediatric JJ Age
patients NNS None
with IN None
irritability NN Condition
associated VBN None
with IN None
autistic JJ Condition
disorder NN Condition
. . None
autistic JJ Condition
disorder NN Condition
in IN None
pediatric JJ Age
patients NNS None
. . None
patients NNS None
( ( None
6-17 CD None
years NNS None
) ) None
who WP None
met VBD None
the DT None
current JJ None
Diagnostic NNP None
and CC None
Statistical NNP None
Manual NNP None
of IN None
Mental NNP None
Disorders NNP None
, , None
Fourth NNP None
Edition NNP None
, , None
Text NNP None
Revision NNP None
( ( None
DMS-IV-TR NNP None
) ) None
criteria NN None
for IN None
autistic JJ Condition
disorder NN Condition
and CC None
who WP None
also RB None
had VBD None
serious JJ Condition
behavioral JJ Condition
problems NNS Condition
( ( None
ie VB None
, , None
tantrums NNS None
, , None
aggression NN None
, , None
self-injurious JJ None
behavior NN None
, , None
or CC None
a DT None
combination NN None
of IN None
these DT None
behavioral JJ None
problems NNS None
) ) None
between IN None
March NNP None
2011 CD None
and CC None
June NNP None
2012 CD None
. . None
Patients NNS None
with IN None
a DT None
stable JJ None
response NN None
( ( None
? . None
25 CD None
% NN None
decrease NN None
in IN None
Aberrant NNP None
Behavior NNP None
Checklist-irritability NNP None
subscale NN None
score NN None
and CC None
a DT None
rating NN None
of IN None
much JJ None
improved VBN None
or CC None
very RB None
much JJ None
improved VBN None
on IN None
the DT None
Clinical JJ None
Global NNP None
Impressions-Improvement NNP None
scale NN None
) ) None
for IN None
12 CD None
consecutive JJ None
weeks NNS None
were VBD None
RESULTS NNP None
Eighty-five JJ None
patients NNS None
were VBD None
randomized VBN None
in IN None
phase NN None
2 CD None
-DOCSTART- -X- N

home-visit JJ None
invitation NN None
increase NN None
Pap NNP None
smear JJ None
screening NN None
in IN None
Samliem NNP None
, , None
Khon NNP None
Kaen NNP None
, , None
Thailand NNP None
cervical JJ Condition
cancer NN Condition
screening VBG Condition
in IN None
women NNS Sex
between IN None
35 CD Age
and CC Age
60 CD Age
years NNS None
of IN None
age NN None
. . None
randomly RB None
recruited VBD None
304 CD Size
women NNS None
from IN None
the DT None
Samliem NNP None
inner-city NN None
community NN None
, , None
Khon NNP None
Kaen NNP None
, , None
Northeast NNP None
Thailand NNP None
, , None
and CC None
assigned VBD None
participants NNS None
58 CD None
of IN None
158 CD Size
women NNS None
in IN None
the DT None
intervention NN None
zone NN None
and CC None
46 CD None
of IN None
146 CD Size
in IN None
the DT None
control NN None
zone NN None
were VBD None
excluded VBN None
from IN None
the DT None
study NN None
because IN None
of IN None
having VBG None
had VBD None
a DT None
Pap NNP None
smear NN None
within IN None
5 CD None
years NNS None
, , None
but CC None
these DT None
were VBD None
included VBN None
in IN None
the DT None
final JJ None
analysis NN None
. . None
100 CD None
women NNS None
in IN None
the DT None
intervention NN None
group NN None
100 CD None
women NNS None
in IN None
the DT None
control NN None
group NN None
-DOCSTART- -X- N

asthmatic JJ Condition
patients NNS None
. . None
asthmatic JJ Condition
patients NNS None
. . None
Patients NNS None
severe JJ None
asthmatic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

56 CD Size
old JJ Age
subjects NNS None
randomized VBN None
into IN None
3 CD None
groups NNS None
. . None
-DOCSTART- -X- N

infants NNS None
with IN None
gastrointestinal JJ Condition
diseases NNS Condition
infants NNS Age
with IN None
different JJ None
gastrointestinal JJ None
diseases NNS None
21 CD Size
patients NNS None
( ( None
age NN None
0-2 CD Age
months NNS Age
) ) None
and CC None
40 CD Size
healthy JJ None
infants NNS None
( ( None
age NN None
0-2 CD Age
months NNS Age
) ) None
patients NNS None
suffered VBD None
from IN None
partial JJ None
or CC None
total JJ None
intestinal JJ None
obstruction NN None
, , None
necrotizing VBG None
enterocolitis NN None
or CC None
pyloric JJ None
stenosis.All NN None
infants NNS None
were VBD None
fasting VBG None
-DOCSTART- -X- N

unstable JJ None
trochanteric JJ None
hip NN None
fractures NNS None
: : None
analysis NN None
of IN None
218 CD None
fractures NNS None
. . None
retrospective JJ None
radiographic JJ None
review NN None
of IN None
218 CD None
unstable JJ None
fractures NNS None
-DOCSTART- -X- N

children NNS Age
receiving VBG None
combined JJ None
cancer NN Condition
chemotherapy NN Condition
. . None
adults NNS Age
and CC None
children NNS Age
receiving VBG None
cancer NN Condition
chemotherapy NN Condition
. . None
children NNS None
receiving VBG None
highly RB Condition
emetogenic JJ Condition
chemotherapy NN Condition
for IN None
various JJ None
malignancies NNS Condition
. . None
total NN None
of IN None
51 CD Size
children NNS None
( ( None
mean JJ None
age NN None
: : None
7.7 CD Age
+/- NN Age
4.8 CD Age
year NN Age
) ) None
were VBD None
studied VBN None
children NNS Age
receiving VBG None
highly RB Condition
emetogenic JJ Condition
chemotherapy NN Condition
. . None
-DOCSTART- -X- N

22 CD None
patients NNS None
with IN None
alopecia JJ None
areata NNS None
to TO None
whom WP None
either DT None
DNCB NNP None
or CC None
croton VB None
oil NN None
was VBD None
applied VBN None
topically RB None
. . None
-DOCSTART- -X- N

catamenial JJ Condition
epilepsy NN Condition
. . None
14 CD Size
of IN None
18 CD Size
patients NNS None
who WP None
received VBD None
both DT None
treatments NNS None
-DOCSTART- -X- N

unselected JJ None
hypertensive JJ Condition
population NN None
. . None
One CD Size
hundred VBD Size
nineteen JJ Size
patients NNS None
with IN None
essential JJ Condition
hypertension NN Condition
( ( None
96 CD Size
completing VBG None
six CD None
months NNS None
and CC None
92 CD Size
a DT None
one CD None
year NN None
study NN None
period NN None
) ) None
all DT None
groups NNS None
smallest JJS None
patients NNS None
-DOCSTART- -X- N

low JJ Condition
self-esteem NNS Condition
in IN None
patients NNS None
with IN None
depressive JJ Condition
disorders NNS Condition
: : None
Sixty-one JJ Size
patients NNS None
with IN None
depressive JJ None
disorders NNS None
who WP None
were VBD None
already RB None
in IN None
therapy NN None
in IN None
an DT None
outpatient JJ None
mental JJ None
health NN None
institution NN None
assigned VBN None
-DOCSTART- -X- N

childhood/adolescent JJ Age
pervasive JJ Condition
developmental NN Condition
disorder NN Condition
. . None
Eleven NNP Size
patients NNS None
with IN None
a DT None
diagnosis NN None
of IN None
either DT None
autism NN Condition
, , None
Asperger NNP Condition
's POS Condition
syndrome NN Condition
, , None
or CC None
PDD NNP Condition
not RB None
otherwise RB None
specified VBN None
( ( None
PDD-NOS NNP None
) ) None
and CC None
aged VBN None
6-14 CD Age
years NNS Age
-DOCSTART- -X- N

mental JJ Condition
rotation NN Condition
task NN Condition
. . None
Forty-six JJ Size
females NNS None
and CC None
46 CD Size
males NNS None
-DOCSTART- -X- N

in IN None
cats NNS None
naturally RB None
infected VBN None
with IN None
feline JJ None
leukaemia NN None
virus NN None
. . None
in IN None
domestic JJ None
cats NNS None
. . None
trial NN None
. . None
Fourty-four CD None
FeLV-infected JJ None
cats NNS None
in IN None
which WDT None
free JJ None
FeLV NNP None
p27 NN None
antigen NN None
was VBD None
detected VBN None
in IN None
serum NN None
by IN None
enzyme-linked JJ None
immunosorbent JJ None
assay NN None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
Cats NNS None
-DOCSTART- -X- N

men NNS Sex
. . None
Fourteen NNP None
young JJ None
healthy JJ None
men NNS None
( ( None
height NN None
: : None
177.0 CD None
? . None
2.1 CD None
cm NN None
, , None
weight NN None
: : None
85.8 CD None
? . None
5.5 CD None
kg NN None
, , None
age NN None
: : None
24.6 CD None
? . None
1.1 CD None
yr NN None
) ) None
performed VBD None
-DOCSTART- -X- N

'preschoolers NNS None
with IN None
autism NN None
' '' None
: : None
young JJ None
children NNS None
with IN None
autistic JJ None
disorder NN None
. . None
young JJ None
children NNS None
with IN None
autistic JJ None
disorder NN None
. . None
Two CD None
rural JJ None
and CC None
two CD None
metropolitan JJ None
regions NNS None
were VBD None
randomly RB None
allocated VBN None
to TO None
intervention NN None
groups NNS None
( ( None
n JJ None
= NNP None
70 CD None
) ) None
or CC None
control NN None
( ( None
n JJ None
= NNP None
35 CD None
) ) None
. . None
Parents NNS None
from IN None
autism NN None
assessment NN None
services NNS None
in IN None
the DT None
intervention NN None
regions NNS None
parents NNS None
of IN None
young JJ None
children NNS None
with IN None
autistic JJ None
disorder NN None
low-functioning JJ None
children NNS None
. . None
-DOCSTART- -X- N

129 CD None
clinicians NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
heart NN Condition
failure NN Condition
after IN None
myocardial JJ Condition
infarction NN Condition
patients NNS None
with IN None
heart NN Condition
failure NN Condition
( ( Condition
HF NNP Condition
) ) Condition
patients NNS None
with IN None
class NN Condition
II NNP Condition
to TO Condition
IV NNP Condition
HF NNP Condition
and CC None
ejection NN None
fraction NN None
< VBD None
35 CD None
% NN None
Of IN None
330 CD Size
patients NNS None
intended VBN None
for IN None
enrollment NN None
, , None
23 CD Size
were VBD None
randomized VBN None
( ( None
MARVEL-1 NNP None
) ) None
before IN None
stopping VBG None
the DT None
study NN None
for IN None
financial JJ None
reasons NNS None
HF NNP None
patients NNS None
with IN None
chronic JJ None
postinfarction NN None
cardiomyopathy NN None
HF NNP None
patients NNS None
with IN None
postinfarction NN None
cardiomyopathy NN None
-DOCSTART- -X- N

lower JJR None
oesophageal JJ None
sphincter NN None
pressure NN None
. . None
12 CD Size
healthy JJ Condition
volunteers NNS None
using VBG None
oesophageal JJ None
pressure NN None
transducers NNS None
. . None
-DOCSTART- -X- N

hospitalized JJ None
elderly JJ Age
patients NNS Age
-- : None
a DT None
elderly JJ Age
hospitalized JJ None
patients NNS None
. . None
patients NNS None
aged VBN None
75 CD Age
years NNS Age
and CC Age
older JJR Age
on IN None
four CD None
or CC None
more JJR None
medicines NNS None
who WP None
had VBD None
been VBN None
discharged VBN None
from IN None
three CD None
acute JJ None
general JJ None
and CC None
one CD None
long-stay JJ None
hospital NN None
to TO None
a DT None
pharmacy NN None
intervention NN None
or CC None
usual JJ None
care NN None
. . None
we PRP None
recruited VBD None
362 CD None
patients NNS None
, , None
of IN None
whom WP None
181 CD None
were VBD None
randomized VBN None
to TO None
each DT None
group NN None
. . None
We PRP None
collected VBD None
hospital NN None
and CC None
general JJ None
practice NN None
data NNS None
on IN None
at IN None
least JJS None
91 CD None
and CC None
72 CD None
% NN None
of IN None
patients NNS None
respectively RB None
at IN None
each DT None
follow-up JJ None
point NN None
and CC None
interviewed VBD None
between IN None
43 CD None
and CC None
90 CD None
% NN None
of IN None
the DT None
study NN None
subjects NNS None
. . None
-DOCSTART- -X- N

Autism NNP None
spectrum NN None
disorders NNS None
. . None
individuals NNS None
with IN None
an DT None
Autism NNP None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
adolescents NNS None
with IN None
ASDs NNP None
individuals NNS None
with IN None
Autism NNP None
adolescents NNS None
with IN None
ASDs NNP None
to TO None
controls VB None
matched VBN None
on IN None
sex NN None
, , None
age NN None
and CC None
IQ NNP None
individuals NNS None
with IN None
ASDs NNP None
individuals NNS None
with IN None
ASDs NNP None
ASDs NNP None
-DOCSTART- -X- N

drainage NN None
of IN None
subretinal JJ Condition
fluid NN Condition
: : None
50 CD Size
consecutive JJ None
eyes NNS None
-DOCSTART- -X- N

women NNS None
319 CD Size
women NNS Sex
presenting VBG None
at IN None
term NN None
, , None
seeking VBG None
analgesia NN None
for IN None
continuous JJ Condition
severe JJ Condition
lower JJR Condition
back RB Condition
pain NN Condition
during IN Condition
labour NN Condition
. . None
Participants NNS None
will MD None
be VB None
recruited VBN None
from IN None
two CD None
major JJ None
maternity NN None
hospitals NNS None
in IN None
Australia NNP None
. . None
labouring VBG None
women NNS None
. . None
-DOCSTART- -X- N

surgery NN None
of IN None
the DT None
thyroid JJ None
gland NN None
. . None
76 CD Size
consecutive JJ None
patients NNS None
who WP None
came VBD None
for IN None
scheduled VBN None
thyroid NN Condition
surgery NN None
. . None
patients NNS None
in IN None
the DT None
treatment NN None
group NN None
( ( None
n JJ None
= NNP None
39 CD None
) ) None
and CC None
control NN None
group NN None
( ( None
n JJ None
= NNP None
37 CD None
) ) None
-DOCSTART- -X- N

healthy JJ Condition
male JJ Condition
subjects NNS Condition
. . Condition
12 CD None
healthy JJ None
male NN None
volunteers NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
ischemic JJ Condition
heart NN Condition
disease NN Condition
. . None
14 CD Size
randomized JJ None
patients NNS None
with IN None
stable JJ None
ischemic JJ None
heart NN None
disease NN None
-DOCSTART- -X- N

apparently RB None
healthy JJ None
individuals NNS None
. . None
survivors NNS None
of IN None
acute JJ None
myocardial JJ None
infarction NN None
. . None
Patients NNS None
aged VBD None
75 CD None
years NNS None
or CC None
less JJR None
A DT None
total NN None
of IN None
1918 CD Size
patients NNS None
were VBD None
screened VBN None
for IN None
participation NN None
; : None
1214 CD Size
were VBD None
recruited VBN None
. . None
-DOCSTART- -X- N

20 CD Size
male JJ Sex
subjects NNS None
-DOCSTART- -X- N

Outpatient NNP None
management NN None
of IN None
asthma NN None
patients NNS Condition
with IN Condition
chronic JJ Condition
asthma NN Condition
. . None
130 CD Size
nonsteroid-dependent JJ Condition
patients NNS Condition
were VBD None
randomized VBN None
chronic JJ None
asthma NN None
. . None
-DOCSTART- -X- N

pulmonary JJ Condition
vascular NN Condition
bed NN Condition
in IN None
man NN Sex
. . None
oedema NNS Condition
in IN None
patients NNS None
with IN None
hypoxic JJ Condition
cor NN Condition
pulmonale NN Condition
. . None
Eight NNP Size
normal JJ None
volunteers NNS None
were VBD None
studied VBN None
-DOCSTART- -X- N

basal NN None
cell NN None
carcinoma NN None
. . None
basal NN None
cell NN None
carcinoma NN None
Subjects NNP None
applied VBD None
study NN None
cream NN None
to TO None
one CD None
biopsy-confirmed JJ None
basal NN None
cell NN None
carcinoma NN None
tumor NN None
vehicle-controlled JJ None
, , None
double-blind JJ None
study NN None
. . None
basal NN None
cell NN None
carcinoma NN None
before IN None
Mohs NNP None
micrographic JJ None
surgery NN None
. . None
-DOCSTART- -X- N

treatment NN Condition
in IN Condition
an DT Condition
IVF NNP Condition
programme NN Condition
. . Condition
IVF NNP None
programme NN None
HCG NNP None
( ( None
193 CD None
transfers NNS None
) ) None
against IN None
placebo NN None
( ( None
194 CD None
transfers NNS None
) ) None
. . None
IVF NNP Condition
programme NN Condition
. . Condition
-DOCSTART- -X- N

treated JJ None
hypertensive JJ Condition
patients NNS None
hypertensive JJ None
patients NNS None
receiving VBG None
drug NN None
treatment NN None
people NNS None
with IN None
one CD None
or CC None
more JJR None
cardiovascular JJ Condition
risk NN Condition
factors NNS Condition
Fifteen NNP None
Italian JJ None
hypertension NN None
units NNS None
studied VBD None
142 CD Size
hypertensive JJ None
patients NNS None
( ( None
76 CD Size
men NNS Sex
, , None
66 CD Size
women NNS Sex
; : None
mean JJ None
age NN None
59 CD Age
+/- JJ Age
5.9 CD Age
years NNS Age
) ) None
treated VBD None
with IN None
different JJ None
antihypertensive JJ None
drugs NNS None
-DOCSTART- -X- N

adults NNS Age
with IN None
established VBN None
rheumatoid NN Condition
arthritis NN Condition
: : Condition
patients NNS None
with IN None
disease NN None
modifying VBG None
antirheumatic JJ None
drug NN None
( ( None
DMARD NNP None
) ) None
refractory NN Condition
rheumatoid JJ Condition
arthritis NN Condition
( ( Condition
RA NNP Condition
) ) Condition
. . None
714 CD Size
patients NNS None
who WP None
received VBD None
etanercept RB None
in IN None
one CD None
of IN None
7 CD None
initial JJ None
trials NNS None
or CC None
a DT None
longterm JJ None
extension NN None
. . None
581 CD Size
patients NNS None
who WP None
enrolled VBD None
in IN None
the DT None
extension NN None
. . None
714 CD Size
patients NNS None
enrolled VBN None
in IN None
the DT None
initial JJ None
trials NNS None
, , None
581 CD Size
( ( None
81 CD None
% NN None
) ) None
enrolled VBN None
in IN None
the DT None
extension NN None
, , None
and CC None
388 CD Size
( ( None
54 CD None
% NN None
) ) None
patients NNS None
are VBP None
continuing VBG None
to TO None
receive VB None
etanercept JJ None
therapy NN None
. . None
356 CD Size
patients NNS None
who WP None
completed VBD None
6 CD None
years NNS None
of IN None
etanercept JJ None
treatment NN None
167 CD Size
patients NNS None
who WP None
completed VBD None
Year NNP None
7 CD None
. . None
patients NNS None
with IN None
RA NNP Condition
in IN None
general JJ None
. . None
-DOCSTART- -X- N

stable JJ None
patients NNS None
with IN None
moderate-to-severe JJ None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
. . None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
( ( None
COPD NNP Condition
) ) None
114 CD Size
patients NNS None
with IN None
COPD NNP Condition
of IN None
moderate-to-severe JJ None
degree NN None
. . None
moderate-to-severe JJ Condition
COPD NNP Condition
patients NNS None
. . None
-DOCSTART- -X- N

Persistent JJ Condition
phenothiazine NN Condition
dyskinesia NN Condition
Six CD Size
patients NNS None
with IN None
persistent JJ Condition
phenothiazine NN Condition
dyskinesia NN Condition
-DOCSTART- -X- N

after IN None
cardiac JJ None
catheterization NN None
: : None
450 CD None
patients NNS None
-DOCSTART- -X- N

very RB None
preterm JJ Condition
infants NNS Age
to TO None
term NN None
equivalent JJ None
age NN None
. . None
neuromotor NN None
function NN None
in IN None
very RB None
preterm JJ None
infants NNS Age
123 CD Size
very RB None
preterm JJ Condition
infants NNS Age
was VBD None
conducted VBN None
in IN None
the DT None
neonatal JJ None
intensive JJ None
care NN None
unit NN None
of IN None
the DT None
sole JJ None
tertiary JJ None
referral JJ None
centre NN None
in IN None
Western JJ None
Australia NNP None
. . None
Infants NNS Age
were VBD None
stratified VBN None
by IN None
gestational JJ None
age NN None
( ( None
< JJ None
29 CD Age
weeks NNS Age
or CC Age
29-30 JJ Age
weeks NNS Age
) ) None
-DOCSTART- -X- N

the DT None
elderly JJ None
in IN None
elderly JJ None
patients NNS None
Eighty-five JJ None
ASA NNP None
grade NN None
I PRP None
or CC None
II NNP None
patients NNS None
( ( None
aged VBN None
60-89 CD None
yr NN None
) ) None
for IN None
elective JJ None
total JJ None
hip NN None
replacement NN None
elderly JJ None
patients NNS None
undergoing VBG None
elective JJ None
procedures NNS None
-DOCSTART- -X- N

splanchnic JJ Condition
oxygenation NN Condition
in IN None
humans NNS None
. . None
20 CD Size
ASA NNP None
physical JJ None
status NN None
I PRP None
, , None
II NNP None
, , None
and CC None
III NNP None
adults NNS Age
, , None
who WP None
underwent VBD None
major JJ None
abdominal JJ None
surgery NN None
requiring VBG None
mechanical JJ None
ventilation NN None
a DT None
few JJ None
hours NNS None
postoperatively RB None
. . None
-DOCSTART- -X- N

student NN None
actors NNS None
' POS None
Twelve NNP None
student NN None
actors NNS None
( ( Condition
6 CD Condition
males NNS Condition
, , Condition
6 CD Condition
females NNS Condition
) ) Condition
students NNS None
( ( None
3 CD None
males NNS None
, , None
3 CD None
females NNS None
) ) None
-DOCSTART- -X- N

first-year JJ None
pharmacy NN None
students NNS None
. . None
pharmacy NN None
student NN None
first-year JJ None
students NNS None
Students NNS None
students NNS None
-DOCSTART- -X- N

ulcerative JJ Condition
colitis NN Condition
. . None
patients NNS None
with IN None
poor JJ Condition
pouch JJ Condition
function NN Condition
Twenty NNP Size
ulcerative JJ Condition
colitis NN Condition
patients NNS None
with IN None
poor JJ Condition
pouch JJ Condition
function NN Condition
( ( None
score NN None
> VBZ None
4 CD None
on IN None
a DT None
12-point JJ None
score NN None
) ) None
total NN None
of IN None
16 CD Size
patients NNS None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

fleas NNS None
on IN None
cats NNS None
. . None
cats NNS None
Eighty NNP Size
cats NNS None
were VBD None
randomly RB None
allocated VBN None
Kansas NNP Condition
1 CD Condition
flea NN Condition
strain NN None
. . None
cats NN None
cats NNS None
-DOCSTART- -X- N

adults NNS Age
with IN None
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
: : None
adults NNS Age
with IN None
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
( ( None
ALL DT Condition
) ) None
patients NNS None
with IN None
Philadelphia NNP Condition
chromosome NN Condition
( ( Condition
Ph NNP Condition
) ) Condition
-positive VBP Condition
ALL NNP None
. . None
accrued VBD None
patients NNS None
from IN None
August NNP None
1996 CD None
to TO None
October NNP None
2004 CD None
. . None
median JJ None
patient NN None
age NN None
was VBD None
43 CD Age
years NNS None
. . None
Responses NNS None
were VBD None
evaluated VBN None
in IN None
164 CD Size
patients NNS None
. . None
patients NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
ages VBZ None
3-8 CD None
years NNS None
. . None
Phase NNP None
1 CD None
involved VBD None
65 CD Size
children NNS Age
who WP None
received VBD None
one CD None
round NN None
of IN None
DMSA NNP None
( ( None
3 CD None
days NNS None
) ) None
. . None
Participants NNS None
who WP None
had VBD None
high JJ Condition
urinary JJ Condition
excretion NN Condition
of IN Condition
toxic JJ Condition
metals NNS Condition
phase NN None
2 CD Size
, , Size
49 CD Size
participants NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
previous JJ None
coronary JJ None
artery NN None
bypass NN None
grafting NN None
( ( None
from IN None
the DT None
j-Cypher JJ None
Registry NNP None
) ) None
. . None
patients NNS None
who WP None
had VBD None
previously RB None
undergone JJ None
coronary JJ None
artery NN None
bypass NN None
grafting NN None
( ( None
CABG NNP None
) ) None
in IN None
the DT None
drug-eluting JJ None
stent NN None
era NN None
. . None
12,812 CD None
patients NNS None
who WP None
had VBD None
undergone JJ None
sirolimus-eluting JJ None
stent NN None
implantation NN None
in IN None
the DT None
j-Cypher JJ None
registry NN None
, , None
919 CD None
( ( None
7.2 CD None
% NN None
) ) None
had VBD None
a DT None
history NN None
of IN None
CABG NNP None
and CC None
had VBD None
significantly RB None
higher JJR None
crude JJ None
5-year JJ None
mortality NN None
( ( None
19.9 CD None
% NN None
vs JJ None
14.0 CD None
% NN None
, , None
p NN None
< NNP None
0.001 CD None
) ) None
. . None
patients NNS None
with IN None
previous JJ None
CABG NNP None
than IN None
patients NNS None
with IN None
previous JJ None
CABG NNP None
, , None
those DT None
the DT None
patients NNS None
with IN None
previous JJ None
CABG NNP None
, , None
those DT None
-DOCSTART- -X- N

arterial JJ Condition
hypertensive JJ Condition
patients NNS None
. . None
49 CD Size
hypertensive JJ Condition
patients NNS None
( ( None
WHO NNP None
I-II NNP None
) ) None
, , None
divided VBD None
into IN None
three CD Size
parallel JJ None
randomized VBN None
groups NNS None
, , None
were VBD None
studied VBN None
over IN None
a DT None
6 CD None
months NNS None
period NN None
. . None
hypertensive JJ Condition
subjects NNS None
with IN None
metabolic JJ Condition
coronary JJ Condition
risk NN Condition
factors NNS None
. . None
-DOCSTART- -X- N

two CD None
groups NNS None
of IN None
hyperprolactinaemic JJ None
subjects NNS None
. . None
normal JJ None
postpartum JJ None
women NNS None
patients NNS None
with IN None
chlorpromazine-induced JJ None
hyperprolactinaemia NN None
and CC None
galactorrhoea NN None
In IN None
neither DT None
group NN None
was VBD None
milk VBN None
production NN None
suppressed VBN None
. . None
-DOCSTART- -X- N

antihistaminic NN None
( ( None
H1 NNP None
) ) None
effect NN None
of IN None
bilastine NN None
. . None
studies NNS None
in IN None
healthy JJ Condition
adult NN None
subjects NNS None
. . None
In IN None
the DT None
single-dose JJ None
studies NNS None
, , None
a DT None
total NN None
of IN None
183 CD Size
subjects NNS None
received VBD None
oral JJ None
doses NNS None
of IN None
bilastine NN None
In IN None
the DT None
multiple-dose JJ None
studies NNS None
, , None
127 CD Size
healthy JJ Condition
subjects NNS None
received VBD None
bilastine JJ None
-DOCSTART- -X- N

children NNS None
with IN None
Autism NNP Condition
Spectrum NNP Condition
Disorders NNP Condition
( ( Condition
ASD NNP Condition
) ) None
. . None
two CD None
groups NNS None
of IN None
children NNS None
children NNS None
with IN None
ASD NNP Condition
-DOCSTART- -X- N

management NN None
of IN None
atrial JJ Condition
fibrillation NN Condition
complicating VBG None
coronary JJ None
artery NN None
bypass NN None
grafting NN None
: : None
management NN None
of IN None
atrial JJ None
fibrillation NN None
( ( None
AF NNP Condition
) ) None
complicating VBG None
coronary JJ None
artery NN None
bypass NN None
grafting NN None
( ( None
CABG NNP None
) ) None
post-CABG JJ None
AF NNP None
in IN None
the DT None
PREVENT-IV NNP None
trial NN None
geographic JJ None
region NN None
type NN None
of IN None
site NN None
. . None
patients NNS None
who WP None
developed VBD None
post-CABG JJ Condition
AF NNP Condition
( ( None
663 CD Size
) ) None
with IN None
those DT None
who WP None
did VBD None
not RB None
( ( None
2,131 CD Size
) ) None
. . None
patients NNS None
with IN None
post-CABG JJ None
patients NNS None
without IN None
AF NNP None
patients NNS None
with IN None
AF NNP None
-DOCSTART- -X- N

in IN None
patients NNS None
undergoing JJ None
chemotherapy NN Condition
. . None
patients NNS None
undergoing JJ None
chemotherapy NN Condition
. . None
patients NNS None
undergoing JJ None
chemotherapy NN Condition
. . None
patients NNS None
undergoing JJ None
chemotherapy NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
amyotrophic JJ Condition
lateral JJ Condition
sclerosis NN Condition
. . None
ALS NNP None
. . None
-DOCSTART- -X- N

radiocontrast-induced JJ None
nephropathy NN None
. . None
patients NNS None
undergoing VBG None
coronary JJ None
procedures NNS None
. . None
single-center JJ None
patients NNS Condition
undergoing VBG Condition
cardiovascular JJ Condition
procedures NNS Condition
. . Condition
We PRP None
prospectively RB None
enrolled VBD None
264 CD None
patients NNS None
who WP None
were VBD None
scheduled VBN None
for IN None
cardiovascular JJ None
procedures NNS None
and CC None
had VBD None
a DT None
baseline JJ None
creatinine NN None
level NN None
> VBD None
1.2 CD None
mg/dL NN None
. . None
-DOCSTART- -X- N

[ JJ None
Complaints NNS None
in IN None
the DT None
postoperative JJ None
phase NN None
related VBN None
to TO None
anesthetics NNS Condition
] NNP None
headache NN None
, , None
nausea NN None
, , None
vomiting NN None
, , None
and CC None
analgesic JJ None
requirement NN None
during IN None
the DT None
first JJ None
postoperative JJ None
24 CD None
h NN None
women NNS None
men NNS None
. . None
patients NNS None
in IN None
the DT None
postoperative JJ Condition
phase NN Condition
-DOCSTART- -X- N

autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
subjects NNS None
diagnosed VBN None
with IN None
an DT None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( Condition
ASD NNP Condition
) ) Condition
subjects NNS None
diagnosed VBN None
with IN None
an DT None
ASD NNP Condition
subjects NNS None
diagnosed VBN None
with IN None
an DT None
ASD NNP Condition
. . None
trial NN None
using VBG None
oral JJ None
lipoceutical JJ None
glutathione NN None
( ( None
n=13 JJ Size
) ) None
or CC None
transdermal JJ None
glutathione NN None
( ( None
n=13 JJ Size
) ) None
in IN None
children NNS Age
, , None
3-13 CD Age
years NNS None
of IN None
age NN None
, , None
with IN None
a DT None
diagnosis NN None
of IN None
an DT None
ASD NNP Condition
. . None
Subjects NNPS None
underwent JJ None
pre- JJ None
and CC None
post-treatment JJ None
lab NN None
testing VBG None
oral JJ None
and CC None
transdermal JJ None
treatment NN None
groups NNS None
subjects NNS None
diagnosed VBN None
with IN None
an DT None
ASD NNP Condition
-DOCSTART- -X- N

relieving VBG None
neuroendocrino-immunological JJ Condition
effect NN Condition
65 CD Size
patients NNS None
took VBD None
prednisone NN None
, , None
and CC None
were VBD None
randomly RB None
divided VBN None
into IN None
Fufang NNP None
prednisone NN None
group NN None
( ( None
mixture NN None
of IN None
prednisone NN None
and CC None
EB NNP None
) ) None
and CC None
prednisone NN None
group NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
atrial JJ Condition
fibrillation NN Condition
715 CD Size
patients NNS None
aged VBN None
75 CD Age
years NNS Age
or CC Age
less JJR Age
and CC None
385 CD Size
patients NNS None
older JJR Age
than IN Age
75 CD Age
; : None
-DOCSTART- -X- N

bradycardia NN Condition
and CC None
emetic JJ Condition
symptoms NNS Condition
in IN None
otoplasty NN None
. . None
Fifty NNP Size
otoplasty JJ Condition
patients NNS None
were VBD None
studied VBN None
; : None
-DOCSTART- -X- N

readers NNS None
with IN None
autism NN Condition
Individuals NNS None
with IN None
autism NN None
16 CD Condition
normally RB Condition
developing VBG Condition
adolescents NNS None
and CC None
16 CD Condition
adolescents NNS None
with IN None
autism NN Condition
readers NNS None
with IN None
autism NN Condition
-DOCSTART- -X- N

judo NN None
athletes NNS None
' POS None
judo NN None
athletes NNS None
in IN None
a DT None
top JJ None
10 CD None
national-ranked JJ None
team NN None
. . None
18 CD Size
athletes NNS Size
of IN None
both DT Sex
sexes NNS Sex
from IN None
a DT None
judo NN None
team NN None
currently RB None
competing VBG None
on IN None
a DT None
national JJ None
level NN None
. . None
national JJ None
level NN None
judo NN None
athletes NNS None
-DOCSTART- -X- N

Austrain NNP None
Czech JJ None
German NNP None
gastric NN None
cancer NN None
subgroup NN None
of IN None
individuals NNS None
with IN None
an DT None
increased VBN None
risk NN None
for IN None
this DT None
fatal JJ None
disease NN None
. . None
Men NN None
between IN None
55 CD None
and CC None
65 CD None
years NNS None
of IN None
age NN None
with IN None
a DT None
gastric JJ None
cancer NN None
phenotype NN None
of IN None
Helicobacter NNP None
pylori FW None
gastritis NN None
are VBP None
randomized VBN None
Since IN None
March NNP None
1998 CD None
, , None
1524 CD None
target NN None
patients NNS None
have VBP None
been VBN None
screened VBN None
, , None
279 CD None
patients NNS None
( ( None
18.3 CD None
% NN None
) ) None
had VBD None
a DT None
corpus NN None
dominant JJ None
type NN None
of IN None
H. NNP None
pylori FW None
gastritis NN None
, , None
and CC None
167 CD None
of IN None
those DT None
were VBD None
randomized VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
postoperative JJ Condition
dental NN Condition
pain NN Condition
. . None
One CD Size
hundred CD Size
and CC Size
fifty JJ Size
fit NN None
, , None
young JJ Age
adults NNS Age
participated VBD None
Patients NNS None
suffering VBG None
from IN None
moderate JJ Condition
to TO Condition
severe VB Condition
pain NN Condition
following VBG None
surgery NN None
were VBD None
monitored VBN None
for IN None
up RB None
to TO None
8 CD None
hours NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
xerostomia NN Condition
following VBG None
treatment NN None
of IN None
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
. . None
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
chronic JJ Condition
xerostomia NN Condition
total NN None
of IN None
145 CD Size
patients NNS None
with IN None
chronic JJ Condition
radiation-induced JJ Condition
xerostomia NN Condition
> $ None
18 CD None
months NNS None
after IN None
treatments NNS None
were VBD None
recruited VBN None
from IN None
seven CD None
UK NNP None
cancer NN None
centres NNS None
. . None
patients NNS None
suffering VBG None
from IN None
chronic JJ Condition
radiation-induced JJ Condition
xerostomia NN Condition
. . Condition
-DOCSTART- -X- N

Wegener NNP None
's POS None
granulomatosis NN None
. . None
patients NNS None
with IN None
Wegener NNP None
's POS None
granulomatosis NN None
have VBP None
disease NN None
flares NNS None
after IN None
conventional JJ None
medications NNS None
are VBP None
tapered VBN None
. . None
in IN None
180 CD None
patients NNS None
with IN None
Wegener NNP None
's POS None
granulomatosis NN None
. . None
Of IN None
the DT None
174 CD None
patients NNS None
who WP None
could MD None
be VB None
evaluated VBN None
, , None
126 CD None
( ( None
72.4 CD None
percent NN None
) ) None
had VBD None
a DT None
sustained VBN None
remission NN None
, , None
but CC None
only RB None
86 CD None
( ( None
49.4 CD None
percent NN None
) ) None
remained VBD None
in IN None
remission NN None
for IN None
the DT None
remainder NN None
of IN None
the DT None
trial NN None
. . None
maintenance NN None
of IN None
remission NN None
in IN None
patients NNS None
with IN None
Wegener NNP None
's POS None
granulomatosis NN None
. . None
-DOCSTART- -X- N

Caregivers NNP None
( ( None
n JJ None
= NNP None
77 CD Size
) ) Size
of IN None
the DT None
cognitively RB Condition
impaired JJ Condition
living NN None
at IN None
home NN None
-DOCSTART- -X- N

Treatment-seeking JJ None
, , None
alcohol-dependent JJ Condition
individuals NNS None
entering VBG None
the DT None
Combining NNP None
Pharmacotherapies NNPS None
and CC None
Behavioral NNP None
Interventions NNP None
for IN None
Alcohol NNP None
Dependence NNP None
( ( None
COMBINE NNP None
) ) None
Study NNP None
( ( None
N NNP None
= NNP None
1,372 CD Size
; : None
69 CD Size
% NN Size
men NNS None
) ) None
treatment-seeking JJ None
individuals NNS None
with IN None
DSM-IV NNP None
alcohol NN None
dependence NN None
. . None
-DOCSTART- -X- N

African-Americans NNPS None
. . None
African-American JJ None
patients NNS None
attending VBG None
a DT None
primary-care JJ None
provider NN None
visit NN None
to TO None
compare VB None
efficacy NN None
of IN None
a DT None
computer-delivered JJ None
tailored JJ None
intervention NN None
to TO None
increase VB None
colorectal JJ None
cancer NN None
( ( None
CRC NNP None
) ) None
screening NN None
( ( None
n JJ None
= NNP None
273 CD None
) ) None
with IN None
non-tailored JJ None
print NN None
material-an JJ None
American JJ None
Cancer NNP None
Society NNP None
brochure NN None
on IN None
CRC NNP None
screening NN None
( ( None
n JJ None
= NNP None
283 CD None
) ) None
. . None
-DOCSTART- -X- N

individuals NNS None
in IN None
an DT None
RCT NNP None
of IN None
pharmacotherapy NN None
and CC None
counseling VBG None
for IN None
smoking VBG None
cessation NN None
individuals NNS None
enrolled VBN None
in IN None
a DT None
comparative JJ None
effectiveness NN None
trial NN None
of IN None
cessation NN None
therapies NNS None
between IN None
October NNP None
2005 CD None
and CC None
May NNP None
2007 CD None
( ( None
1346 CD None
total NN None
participants NNS None
; : None
1338 CD None
with IN None
requisite JJ None
data NNS None
for IN None
further JJ None
analysis NN None
) ) None
. . None
-DOCSTART- -X- N

localized JJ None
non-Hodgkin NN None
's POS None
lymphoma NN None
in IN None
children NNS None
: : None
73 CD None
children NNS None
with IN None
previously RB None
untreated VBN None
localized JJ None
non-Hodgkin NN None
's POS None
lymphoma NN None
-DOCSTART- -X- N

nausea NN None
, , None
vomiting VBG None
and CC None
appetite JJ None
loss NN None
in IN None
remission NN None
induction NN None
chemotherapy NN None
of IN None
acute JJ None
myeloid NN None
leukemia NN None
-- : None
a DT None
acute JJ None
myeloid NN None
leukemia NN None
granisetron NN None
alone RB None
and CC None
combination NN None
with IN None
granisetron NN None
plus CC None
methylprednisolone NN None
. . None
combination NN None
group NN None
. . None
The DT None
single JJ None
and CC None
combination NN None
groups NNS None
comprised VBD None
14 CD None
and CC None
13 CD None
patients NNS None
, , None
respectively RB None
, , None
and CC None
there EX None
was VBD None
no DT None
significant JJ None
difference NN None
between IN None
the DT None
background NN None
of IN None
both DT None
groups NNS None
. . None
-DOCSTART- -X- N

endometrial JJ None
polyps NNS None
121 CD None
women NNS None
were VBD None
randomly RB None
allocated VBN None
to TO None
polyp VB None
removal NN None
-DOCSTART- -X- N

normotensive JJ Condition
patients NNS None
. . None
Sixty-six JJ Size
patients NNS None
with IN None
American JJ None
Society NNP None
of IN None
Anesthesiologists NNP None
( ( Condition
ASA NNP Condition
) ) Condition
physical JJ Condition
status NN Condition
class NN Condition
I PRP Condition
who WP None
required VBD None
tracheal JJ Condition
intubation NN Condition
for IN None
elective JJ None
surgery NN None
-DOCSTART- -X- N

healthy JJ None
men NNS None
: : None
GHD NNP Age
adults NNS Age
healthy JJ Sex
nonobese JJ Sex
males NNS Sex
-DOCSTART- -X- N

hyperphosphatemic JJ Condition
patients NNS Condition
with IN Condition
end-stage JJ Condition
renal JJ Condition
disease NN Condition
. . Condition
patients NNS Condition
receiving VBG Condition
long-term JJ Condition
dialysis NN Condition
treatment NN Condition
. . Condition
patients NNS Condition
with IN Condition
end-stage JJ Condition
renal JJ Condition
disease NN Condition
( ( Condition
ESRD NNP Condition
) ) Condition
. . Condition
Chinese JJ None
patients NNS None
with IN None
ESRD NNP None
. . None
male NN Sex
and CC Sex
female JJ Sex
hemodialysis NN Sex
patients NNS Sex
n=73 CC None
) ) None
n=30 CC None
) ) None
n=31 CC None
; : None
Chinese JJ Condition
patients NNS Condition
with IN Condition
ESRD NNP Condition
. . Condition
-DOCSTART- -X- N

high-risk JJ Condition
cardiac JJ Condition
surgery NN Condition
patients NNS Condition
] VBP None
EuroSCORE-stratified JJ None
high-risk JJ None
cardiac NN None
surgery NN None
patients NNS None
with IN None
a DT None
score NN None
?8 NN None
. . None
with IN None
104 CD None
patients NNS None
either CC None
without IN None
prophylactic JJ None
IABP NNP None
insertion NN None
( ( None
group NN None
A NNP None
, , None
n=52 NN None
) ) None
or CC None
with IN None
IABP NNP None
( ( None
group NN None
B NNP None
, , None
n=52 NN None
) ) None
was VBD None
RESULTS VB None
The DT None
median JJ None
age NN None
of IN None
the DT None
patients NNS None
was VBD None
74 CD None
years NNS None
and CC None
43 CD None
% NN None
of IN None
participants NNS None
were VBD None
females NNS None
. . None
The DT None
EuroSCORE-stratified JJ None
high-risk JJ None
patients NNS None
is VBZ None
-DOCSTART- -X- N

infants NNS None
with IN None
acute JJ None
wheezing NN None
: : None
Twenty-eight JJ None
infants NNS None
admitted VBN None
to TO None
Exequiel NNP None
Gonz?lez NNP None
Cortes NNP None
Children NNP None
's POS None
Hospital NNP None
because IN None
of IN None
acute NN None
wheezing NN None
( ( None
AW NNP None
) ) None
in IN None
infants NNS None
with IN None
AW NNP None
-DOCSTART- -X- N

peripheral JJ Condition
pulmonary JJ Condition
lesions NNS Condition
: : Condition
Two CD None
hundred VBD None
two CD None
patients NNS None
with IN None
PPLs NNP None
and CC None
positive JJ None
EBUS NNP None
findings NNS None
were VBD None
enrolled VBN None
. . None
A DT None
total NN None
of IN None
182 CD None
patients NNS None
( ( None
94 CD None
in IN None
the DT None
EBUS NNP None
CDPs NNP None
group NN None
and CC None
88 CD None
in IN None
the DT None
EBUS-TBNA JJ None
plus CC None
CDPs NNP None
group NN None
) ) None
were VBD None
analyzed VBN None
. . None
-DOCSTART- -X- N

Sixty NNP Size
adult NN Age
patients NNS None
, , None
ASA NNP None
Classes NNP None
I PRP None
& CC None
II NNP None
-DOCSTART- -X- N

IHD NNP None
. . None
Ischemic NNP None
Heart NNP None
disease NN None
. . None
Ischemic NNP None
Heart NNP None
Disease NNP None
patients NNS None
with IN None
a DT None
previous JJ None
myocardial JJ None
infarction NN None
or CC None
unstable JJ None
angina-ischemic JJ None
heart NN None
disease NN None
( ( None
IHD NNP None
) ) None
. . None
9014 CD None
patients NNS None
from IN None
85 CD None
centers NNS None
in IN None
Australia NNP None
and CC None
New NNP None
Zealand NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
cirrhosis NN Condition
and CC Condition
variceal NN Condition
hemorrhage NN Condition
cirrhotic JJ Condition
patients NNS None
with IN None
medium/large NN None
varices NNS None
Three CD Size
hundred VBD Size
fourteen JJ Size
patients NNS None
with IN None
grades NNS None
2 CD None
or CC None
3 CD None
esophageal JJ None
varices NNS None
( ( None
Child VB None
A DT None
and CC None
B/C NNP None
: : None
218 CD None
and CC None
96 CD None
) ) None
One CD None
hundred VBD None
seventy-three JJ None
patients NNS None
had VBD None
no DT None
previous JJ None
history NN None
of IN None
variceal NN None
bleeding NN None
. . None
245 CD Size
patients NNS None
( ( None
100 CD None
% NN None
of IN None
patients NNS None
with IN None
prior JJ None
variceal NN None
hemorrhage NN None
, , None
61 CD None
% NN None
of IN None
patients NNS None
without IN None
prior JJ None
hemorrhage NN None
) ) None
were VBD None
receiving VBG None
some DT None
form NN None
of IN None
prophylactic JJ None
therapy NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
centrally RB None
reviewed VBN None
low-grade JJ Condition
gliomas NN Condition
treated VBN None
with IN None
chemotherapy NN Condition
with IN Condition
or CC Condition
without IN Condition
radiotherapy NN Condition
children NNS Age
who WP None
were VBD None
treated VBN None
with IN None
chemotherapy NN Condition
and CC None
radiotherapy NN Condition
on IN None
the DT None
Children NNP None
's POS None
Cancer NNP None
Group NNP None
( ( None
CCG NNP None
) ) None
high-grade NN Condition
glioma NN Condition
protocol NN None
( ( None
CCG-945 NNP None
) ) None
who WP None
were VBD None
diagnosed VBN None
with IN None
low-grade JJ Condition
gliomas NN Condition
on IN None
post NN None
hoc JJ None
central JJ Condition
pathologic NN Condition
review NN Condition
Between NNP None
1985 CD None
and CC None
1991 CD None
, , None
250 CD Size
children NNS Age
with IN None
institutionally RB None
classified VBN None
high-grade JJ Condition
gliomas NNS Condition
were VBD None
enrolled VBN None
on IN None
CCG-945 NNP None
. . None
Patients NNS None
older JJR None
than IN None
24 CD Age
months NNS Age
with IN None
intracranial JJ Condition
lesions NNS Condition
younger JJR Age
patients NNS None
and CC None
those DT None
with IN None
primary JJ Condition
spinal JJ Condition
cord NN Condition
tumors NNS Condition
low-grade JJ Condition
glioma NN Condition
in IN None
70 CD Size
patients NNS None
, , None
who WP None
were VBD None
the DT None
focus NN None
of IN None
the DT None
current JJ None
study NN None
. . None
42 CD Size
males NNS None
and CC None
28 CD Size
females NNS None
( ( None
median JJ None
age NN None
, , None
7.7 CD Age
years NNS Age
) ) None
with IN None
a DT None
median JJ None
follow-up NN None
of IN None
10.4 CD Age
years NNS Age
. . None
-DOCSTART- -X- N

normal JJ Condition
human JJ Condition
facial JJ Condition
skin NN Condition
flora NN Condition
. . None
Eighteen JJ Size
volunteers NNS None
-DOCSTART- -X- N

oral JJ None
ketoprofen NN None
. . None
8 CD Size
healthy JJ Condition
male NN Sex
volunteers NNS None
, , None
mean JJ None
age NN None
27.2 CD Age
years NNS None
14 CD None
blood NN None
and CC None
4 CD None
urine JJ None
samples NNS None
-DOCSTART- -X- N

hypertensive JJ Condition
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
and CC None
microalbuminuria NNS Condition
. . None
Patients NNPS None
with IN None
diabetes NNS Condition
complicated VBN None
by IN None
hypertension NN Condition
and CC None
microalbuminuria NNS Condition
Patients NNPS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
, , None
mild-to-moderate JJ None
hypertension NN Condition
( ( None
diastolic JJ None
blood NN None
pressure NN None
85-105 JJ None
mmHg NN None
, , None
systolic JJ None
blood NN None
pressure NN None
< VBZ None
160 CD None
mmHg NN None
, , None
and CC None
24-hour JJ None
mean JJ None
systolic JJ None
blood NN None
pressure NN None
> VBZ None
130 CD None
mmHg NN None
) ) None
, , None
and CC None
microalbuminuria NNS Condition
-DOCSTART- -X- N

upper JJ None
abdominal JJ None
cancer NN None
patients NNS None
: : None
Sixty NNP None
patients NNS None
aged VBD None
18 CD None
years NNS None
or CC None
older JJR None
with IN None
unresectable JJ None
upper JJ None
abdominal JJ None
cancers NNS None
-DOCSTART- -X- N

acne JJ Condition
vulgaris NN Condition
: : None
moderate JJ Condition
acne NNS Condition
vulgaris NNS Condition
( ( None
240 CD Size
patients NNS None
) ) None
in IN None
both DT None
intention-to-treat JJ None
and CC None
per-protocol JJ None
populations NNS None
. . None
moderate JJ Condition
acne NN Condition
vulgaris NN Condition
-DOCSTART- -X- N

Percutaneous JJ None
Nephrolithotomy NNP None
( ( None
PCNL NNP None
) ) None
60 CD Size
patients NNS None
undergoing JJ None
PCNL NNP Condition
. . None
Cases NNS Condition
of IN Condition
renal JJ Condition
stone NN Condition
regardless NN None
of IN None
stone NN None
size NN None
and CC None
configuration NN None
, , None
having VBG None
pre-operative JJ None
negative JJ None
urine JJ None
culture NN None
, , None
no DT None
coagulopathy NN None
, , None
and CC None
no DT None
visible JJ None
residual JJ None
stone NN None
in IN None
intra-operative JJ None
fluoroscopy NN None
, , None
were VBD None
included VBN None
. . None
Mean NNP None
age NN Age
of IN Age
cases NNS Age
were VBD Age
43.2 CD Age
( ( Age
25-70 JJ Age
) ) Age
, , Age
40.1 CD Age
( ( Age
25-73 JJ Age
) ) Age
, , Age
and CC Age
44 CD Age
( ( Age
25-70 JJ Age
) ) Age
years NNS Age
in IN None
groups NNS None
A NNP None
, , None
B NNP None
and CC None
C NNP None
, , None
respectively RB None
-DOCSTART- -X- N

tonsillar JJ None
and CC None
dental JJ None
focal JJ None
infections NNS None
. . None
Twenty CD Size
patients NNS None
with IN None
palmoplantar JJ Condition
pustulosis NN Condition
( ( Condition
PPP NNP Condition
) ) Condition
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS Condition
. . Condition
healthy JJ None
volunteers NNS None
. . None
-DOCSTART- -X- N

dialysis NN Condition
patients NNS None
. . None
28 CD Size
patients NNS None
were VBD None
randomized VBN None
to TO None
maintenance NN None
of IN None
Cndi NNP None
at IN None
13.6 CD None
mS/cm NNS None
( ( None
equivalent JJ None
to TO None
135 CD None
mmol/L NN None
of IN None
Na+ NNP None
) ) None
or CC None
serial JJ None
reduction NN None
of IN None
Cndi NNP None
in IN None
steps NNS None
of IN None
0.2 CD None
mS/cm NNS None
, , None
guided VBN None
by IN None
symptoms NNS None
and CC None
blood NN None
pressure NN None
. . None
-DOCSTART- -X- N

healthy JJ None
women NNS Sex
were VBD None
randomized VBN None
to TO None
EE VB None
20 CD None
microg/DRSP NN None
3 CD None
mg NN None
or CC None
EE NNP None
20 CD None
microg/DSG NN None
150 CD None
microg NN None
for IN None
seven CD None
cycles NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
. . None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
( ( None
COPD NNP Condition
) ) None
patients NNS None
with IN None
symptomatic JJ Condition
, , Condition
smoking-related JJ Condition
COPD NNP Condition
patients NNS None
with IN None
severe JJ Condition
COPD NNP Condition
( ( Condition
stage NN Condition
III NNP Condition
) ) Condition
than IN None
mild NN Condition
( ( Condition
stage NN Condition
I PRP Condition
) ) Condition
elderly JJ Age
patients NNS None
-DOCSTART- -X- N

Streptococcus NNP None
mutans NNS None
and CC None
approximal JJ None
dental JJ None
caries NNS None
. . None
Streptococcus NNP None
mutants NNS None
and CC None
approximal JJ None
dental JJ None
caries NNS None
One CD None
hundred CD None
and CC None
eighty-seven JJ None
13-year-old JJ None
individuals NNS None
with IN None
high JJ None
levels NNS None
of IN None
salivary JJ None
S. NNP None
mutans NNS None
( ( None
greater JJR None
than IN None
10 CD None
( ( None
6 CD None
) ) None
/mL NN None
) ) None
were VBD None
selected VBN None
. . None
-DOCSTART- -X- N

single JJ None
dose NN None
of IN None
1,000 CD None
mg NN None
of IN None
levetiracetam NN None
on IN None
essential JJ None
tremor NN None
24 CD None
patients NNS None
in IN None
a DT None
double-blind JJ None
, , None
placebo-controlled JJ None
trial NN None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
overactive JJ Condition
bladder NN Condition
. . Condition
patients NNS None
with IN None
overactive JJ None
bladder NN None
( ( None
OAB NNP None
) ) None
symptoms NNS None
. . None
patients NNS None
with IN None
OAB NNP None
symptoms NNS None
. . None
Twenty-six JJ None
patients NNS None
The DT None
mean JJ None
age NN None
was VBD None
67 CD None
years NNS None
and CC None
mean JJ None
BMI NNP None
was VBD None
28.3 CD None
kg/m NN None
( ( None
2 CD None
) ) None
. . None
patients NNS None
with IN None
OAB NNP None
-DOCSTART- -X- N

Parenting VBG Condition
stress NN Condition
in IN None
the DT None
infant JJ None
aphakia NN None
treatment NN None
parenting VBG Condition
stress NN Condition
following VBG None
infants NNS Age
' POS None
cataract NN None
extraction NN None
surgery NN None
Caregivers NNPS None
caregiver NN None
stress NN None
during IN None
infancy NN Age
-DOCSTART- -X- N

glomerular JJ Condition
diseases NNS None
: : None
glomerulonephritis NN Condition
29 CD Size
GN NNP None
patients NNS None
with IN None
normal JJ Condition
renal JJ Condition
function NN Condition
( ( None
17 CD Size
membranoproliferative NN None
GN NNP None
, , None
12 CD Size
IgA NNP None
GN NNP None
) ) None
-DOCSTART- -X- N

social JJ Condition
impairment NN Condition
in IN Condition
individuals NNS Condition
with IN Condition
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : Condition
ARA NNP None
added VBD None
to TO None
DHA NNP None
( ( None
n JJ None
= NNP None
7 CD None
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= NNP None
6 CD None
) ) None
in IN None
13 CD None
participants NNS None
( ( None
mean JJ None
age NN None
, , None
14.6 CD None
[ NN None
SD NNP None
, , None
5.9 CD None
] CD None
years NNS None
) ) None
. . None
individuals NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Age
: : None
autistic JJ Condition
children NNS None
18 CD Size
children NNS Age
, , None
ages VBZ None
3.08 CD Age
to TO None
7.99 CD Age
years NNS None
, , None
who WP None
completed VBD None
this DT None
ongoing JJ None
study NN None
. . None
older JJR None
children NNS None
. . None
-DOCSTART- -X- N

myocardial JJ Condition
infarction NN Condition
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
( ( Condition
MI NNP Condition
) ) Condition
patients NNS None
on IN None
thrombolytic JJ None
therapy NN None
( ( None
TLT NNP None
) ) None
106 CD Size
males NNS Sex
with IN None
Q-MI NNP Condition
entered VBD None
the DT None
study NN None
-DOCSTART- -X- N

participants NNS None
performed VBD None
a DT None
self-timed JJ None
30 CD None
minute NN None
brisk NN Condition
walk VBP Condition
in IN None
two CD None
different JJ None
environments NNS None
, , None
park NN None
and CC None
urban JJ None
sample NN None
of IN None
40 CD None
healthy JJ None
adults NNS None
was VBD None
recruited VBN None
: : None
16 CD None
males NNS None
, , None
24 CD None
females NNS None
, , None
mean JJ None
age NN None
22.9 CD None
( ( None
5.5 CD None
) ) None
years NNS None
. . None
The DT None
steps/min NN None
. . None
Participants NNS None
accumulated VBD None
-DOCSTART- -X- N

Saint-Fran?ois JJ None
d'Assise NN None
Hospital NNP None
, , None
Qu?bec NNP None
, , None
Canada NNP None
. . None
sixty-five JJ None
middle-aged JJ None
women NNS None
who WP None
participated VBD None
in IN None
a DT None
randomized JJ None
clinical JJ None
trial NN None
. . None
among IN None
middle-aged JJ None
women NNS None
with IN None
low JJ None
consumption NN None
of IN None
marine NN None
food NN None
products NNS None
( ( None
< $ None
3 CD None
servings/week NN None
) ) None
, , None
-DOCSTART- -X- N

type NN None
2 CD None
diabetic JJ None
patients NNS None
under IN None
good JJ None
glycemic JJ None
control NN None
. . None
type NN None
2 CD None
diabetes NNS None
type NN None
2 CD None
diabetic JJ None
patients NNS None
who WP None
were VBD None
already RB None
under IN None
good JJ None
glycemic JJ None
control NN None
. . None
78 CD None
drug-naive JJ None
type NN None
2 CD None
diabetic JJ None
patients NNS None
whose WP$ None
HbA1c NNP None
was VBD None
less JJR None
than IN None
6.5 CD None
% NN None
. . None
Thirty-eight JJ None
patients NNS None
type NN None
2 CD None
diabetic JJ None
patients NNS None
with IN None
good JJ None
glycemic NNS None
control NN None
-DOCSTART- -X- N

tutors NNS None
of IN None
children NNS Age
with IN None
autism NN Condition
. . None
trained JJ None
tutors NNS None
. . None
novice JJ None
tutors NNS None
of IN None
children NNS Age
with IN None
autism NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ None
myocardial JJ None
infarction NN None
47 CD None
Italian JJ None
coronary JJ None
care NN None
units NNS None
. . None
757 CD None
patients NNS None
from IN None
the DT None
GISSI-3 NNP None
echo NN None
substudy NN None
population NN None
with IN None
their PRP$ None
first JJ None
acute JJ None
myocardial JJ None
infarct NN None
were VBD None
studied VBN None
-DOCSTART- -X- N

infants NNS Age
healthy JJ Condition
infants NNS Age
. . None
The DT None
Pa NNP None
group NN None
( ( None
n JJ None
= NNP None
101 CD Size
) ) None
had VBD None
a DT None
clearly RB None
lower JJR None
incidence NN None
of IN None
both DT None
local JJ Condition
and CC Condition
systemic JJ Condition
adverse JJ Condition
events NNS Condition
than IN None
the DT None
Pw NNP None
group NN None
( ( None
n JJ None
= NNP None
100 CD Size
) ) None
. . None
-DOCSTART- -X- N

Thirty NN Size
patients NNS None
undergoing VBG None
elective JJ None
cholecystectomy NN Condition
were VBD None
allocated VBN None
patients NNS None
who WP None
received VBD None
the DT None
infusion NN None
of IN None
morphine NN None
. . None
-DOCSTART- -X- N

internet NN None
use NN None
Korean JJ None
adolescents NNS Age
: : None
57,857 CD Size
middle JJ None
and CC None
high JJ None
school NN None
students NNS None
( ( None
13-18 CD Age
year NN Age
olds NNS Age
) ) None
from IN None
a DT None
Korean NNP None
nationally RB None
representative JJ None
survey NN None
, , None
which WDT None
was VBD None
surveyed VBN None
in IN None
2009 CD None
. . None
Female JJ None
students NNS None
in IN None
girls NNS None
' POS None
schools NNS None
adolescents NNS Age
-DOCSTART- -X- N

septate JJ Condition
uterus NN Condition
: : None
Endoscopic NNP None
gynecology NN None
units NNS None
at IN None
tertiary JJ None
care NN None
university NN None
hospitals NNS None
. . None
One CD Size
hundred-sixty JJ Size
patients NNS None
with IN None
septate JJ None
uterus NNS None
and CC None
a DT None
history NN None
of IN None
recurrent JJ None
abortion NN None
or CC None
primary JJ None
infertility NN Condition
undergoing VBG None
hysteroscopic NN None
metroplasty NN None
from IN None
2001 CD None
to TO None
2005 CD None
. . None
-DOCSTART- -X- N

frequency NN None
discrimination NN None
. . None
frequency NN None
discrimination NN None
listeners NNS None
three CD None
listeners NNS None
-DOCSTART- -X- N

falls NNS None
among IN None
at-risk JJ None
elders NNS None
. . None
elderly JJ None
persons NNS None
incidence NN None
of IN None
falls NNS None
and CC None
the DT None
time NN None
to TO None
first VB None
fall NN None
among IN None
a DT None
clinically RB None
defined JJ None
population NN None
of IN None
elderly JJ None
men NNS None
and CC None
women NNS None
. . None
The DT None
participants NNS None
were VBD None
294 CD None
men NNS None
and CC None
women NNS None
, , None
aged VBD None
60 CD None
years NNS None
or CC None
older JJR None
, , None
who WP None
had VBD None
either CC None
a DT None
hospital JJ None
admission NN None
or CC None
bed NN None
rest NN None
for IN None
2 CD None
days NNS None
or CC None
more JJR None
within IN None
the DT None
previous JJ None
month NN None
. . None
among IN None
elderly JJ None
men NNS None
and CC None
women NNS None
recovering VBG None
from IN None
recent JJ None
hospitalizations NNS None
, , None
bed VBD None
rest NN None
, , None
or CC None
both DT None
who WP None
have VBP None
low JJ None
levels NNS None
of IN None
physical JJ None
functioning NN None
. . None
-DOCSTART- -X- N

school-aged JJ Age
children NNS Age
school-aged JJ None
children NNS None
30 CD Size
healthy JJ Condition
children NNS None
children NNS Age
children NNS None
-DOCSTART- -X- N

patients NNS None
suffering VBG None
from IN None
severe JJ None
acute NN None
pancreatitis NN None
] NNP None
patients NNS None
with IN None
severe JJ None
acute NN None
pancreatitis NN None
( ( None
ASP NNP None
) ) None
. . None
Seventy NNP None
SAP NNP None
cases NNS None
admitted VBD None
from IN None
January NNP None
2005 CD None
to TO None
October NNP None
2012 CD None
were VBD None
randomly RB None
assigned VBN None
parenteral JJ None
nutrition NN None
( ( None
PN NNP None
) ) None
group NN None
( ( None
n=22 NN None
) ) None
, , None
EN NNP None
group NN None
( ( None
n=25 CC None
) ) None
and CC None
bifidobacterium NN None
added VBD None
EN NNP None
( ( None
P+EN NNP None
) ) None
group NN None
( ( None
n=23 RB None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
H. NNP None
pylori JJ None
eradication NN None
. . None
One CD Size
hundred CD Size
and CC Size
ninety-three JJ Size
( ( Size
193 CD Size
) ) Size
H. NNP None
pylori-positive JJ None
patients NNS None
Group NNP None
A NNP None
( ( None
N NNP None
= NNP None
64 CD Size
) ) None
: : None
Group NNP Condition
B NNP Condition
( ( None
N NNP None
= NNP None
64 CD Size
) ) Size
: : None
Group NNP None
C NNP None
( ( None
N NNP None
= NNP None
65 CD Size
) ) None
: : None
All DT None
patients NNS None
One CD None
hundred CD None
and CC None
eighty-eight JJ None
out IN None
of IN None
the DT None
193 CD None
H. NNP None
pylori-positive JJ None
patients NNS None
( ( None
96 CD None
% NN None
) ) None
completed VBD None
therapy NN None
. . None
193 CD None
enrolled JJ None
subjects NNS None
-DOCSTART- -X- N

threshold JJ None
retinopathy NN Condition
of IN Condition
prematurity NN Condition
. . None
retinopathy NN Condition
of IN Condition
prematurity NN Condition
( ( None
ROP NNP Condition
) ) None
Patients NNPS None
Nineteen JJ Size
infants NNS None
( ( None
33 CD Size
eyes NNS None
) ) None
were VBD None
treated VBN None
, , None
ranging VBG None
from IN None
485 CD None
to TO None
863 CD None
g NNS None
birth JJ None
weight NN None
( ( None
23 CD None
to TO None
27 CD None
weeks NNS None
gestational JJ None
age NN None
) ) None
; : None
18 CD Size
patients NNS None
( ( None
32 CD Size
eyes NNS None
) ) None
Four CD Size
patients NNS None
( ( None
8 CD Size
eyes NNS None
) ) None
had VBD None
bilateral JJ None
zone CD None
1 CD None
disease NN None
. . None
Postconceptional JJ None
age NN None
was VBD None
36 CD Age
to TO Age
45 CD Age
weeks NNS None
at IN None
the DT None
time NN None
of IN None
treatment NN None
. . None
-DOCSTART- -X- N

early JJ None
haemorrhoids NNS None
. . None
early JJ None
hemorrhoids NNS None
102 CD Size
patients NNS Size
were VBD None
included VBN None
at IN None
the DT None
POF NNP None
Hospital NNP None
, , None
Wah NNP None
Cantt NNP None
from IN None
October NNP None
2004 CD None
to TO None
June NNP None
2005 CD None
. . None
The DT Age
mean JJ Age
age NN Age
of IN Age
the DT Age
patients NNS Age
was VBD Age
44 CD Age
years NNS Age
, , None
86 CD None
were VBD None
males NNS Sex
and CC None
16 CD None
were VBD None
females NNS None
. . None
24.5 CD None
% NN None
of IN None
the DT None
patients NNS None
had VBD None
a DT None
positive JJ Condition
family NN Condition
history NN Condition
of IN Condition
haemorrhoids NNS Condition
. . None
-DOCSTART- -X- N

stapled JJ None
versus NN None
open JJ None
hemorrhoidectomy NN Condition
. . None
hemorrhoids NNS Condition
Milligan NNP None
Morgan NNP None
hemorrhoidectomy NN None
. . None
84 CD Size
patients NNS None
were VBD None
randomly RB None
allocated VBN None
to TO None
the DT None
stapled VBN None
( ( None
n JJ None
= NNP None
42 CD Size
) ) None
or CC None
open JJ None
group NN None
( ( None
n JJ None
= NNP None
42 CD Size
) ) None
. . None
All DT None
patients NNS None
were VBD None
operated VBN None
on IN None
under IN None
spinal JJ None
anesthesia NN None
. . None
mean JJ None
age NN None
of IN None
patients NNS None
was VBD None
46.02 CD Age
years NNS None
( ( None
SD NNP None
, , None
12.33 CD None
) ) None
in IN None
the DT None
stapled JJ None
group NN None
and CC None
48.64 CD Age
years NNS None
( ( None
14.57 CD None
) ) None
in IN None
the DT None
open JJ None
group NN None
. . None
Grade NNP Condition
III NNP Condition
or CC Condition
IV NNP Condition
hemorrhoids NNS Condition
were VBD None
more JJR None
common JJ None
in IN None
men NNS None
( ( None
ie NN None
, , None
80.9 CD None
% NN None
and CC None
85.7 CD None
% NN None
in IN None
the DT None
stapled JJ None
and CC None
open JJ None
group NN None
, , None
respectively RB None
) ) None
. . None
grade NN Condition
III NNP Condition
and CC Condition
grade VBD Condition
IV NNP Condition
hemorrhoids NNS Condition
. . None
-DOCSTART- -X- N

overweight JJ Condition
children NNS None
children NNS Age
. . None
18 CD None
sedentary JJ None
, , None
overweight JJ None
( ( None
BMI?85th NNP None
percentile NN None
) ) None
8- CD None
to TO None
11-year-old JJ None
children NNS None
( ( None
94 CD None
% NN None
Black NNP None
) ) None
, , None
-DOCSTART- -X- N

gastritis NN None
due JJ None
to TO None
Campylobacter NNP None
pylori NN None
. . None
Fifty JJ None
patients NNS None
gastritis NN None
associated VBN None
with IN None
Campylobacter NNP None
pylori NN None
. . None
18 CD None
patients NNS None
-DOCSTART- -X- N

children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
: : None
children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
and CC None
prominent JJ None
repetitive JJ None
behavior NN None
. . None
149 CD None
children NNS None
and CC None
adolescents NNS None
5 CD None
to TO None
17 CD None
years NNS None
of IN None
age NN None
( ( None
mean JJ None
[ NNP None
SD NNP None
] NNP None
age NN None
, , None
9.4 CD None
[ NN None
3.1 CD None
] CD None
years NNS None
) ) None
from IN None
6 CD None
academic JJ None
centers NNS None
Participants NNS None
had VBD None
autistic JJ None
disorder NN None
, , None
Asperger NNP None
syndrome NN None
, , None
or CC None
pervasive JJ None
developmental JJ None
disorder NN None
, , None
not RB None
otherwise RB None
specified VBN None
; : None
had VBD None
illness JJ None
severity NN None
ratings NNS None
that WDT None
were VBD None
moderate JJ None
or CC None
more JJR None
than IN None
moderate VB None
on IN None
the DT None
Clinical JJ None
Global NNP None
Impression-Severity NNP None
scale NN None
; : None
and CC None
scored VBD None
moderate JJ None
or CC None
more JJR None
than IN None
moderate VB None
on IN None
compulsive JJ None
behaviors NNS None
measured VBN None
with IN None
the DT None
modified JJ None
Children NNP None
's POS None
Yale-Brown JJ None
Obsessive-Compulsive JJ None
Scale NNP None
. . None
children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
-DOCSTART- -X- N

methadone-maintained JJ None
cocaine NN None
abusers NNS None
patients NNS None
in IN None
methadone JJ None
maintenance NN None
. . None
methadone-maintained JJ None
, , None
cocaine-dependent JJ None
patients NNS None
( ( None
N NNP None
= NNP None
193 CD None
) ) None
with IN None
and CC None
without IN None
concurrent JJ None
AD NNP None
Patients NNS None
with IN None
and CC None
without IN None
concurrent JJ None
AD NNP None
cocaine-using JJ None
methadone NN None
patients NNS None
-DOCSTART- -X- N

ischemic JJ None
stroke NN None
: : None
acute JJ None
ischemic JJ None
stroke NN None
patients NNS None
. . None
From IN None
215 CD None
patients NNS None
admitted VBD None
within IN None
24 CD None
hours NNS None
of IN None
a DT None
hemispheric JJ None
ischemic JJ None
stroke NN None
, , None
89 CD None
patients NNS None
on IN None
chronic JJ None
statin NN None
treatment NN None
were VBD None
randomly RB None
assigned VBN None
Patients NNS None
with IN None
statin NN None
withdrawal NN None
patients NNS None
without IN None
previous JJ None
treatment NN None
with IN None
statins NNS None
-DOCSTART- -X- N

40 CD Condition
open-angle JJ Condition
patients NNS Condition
treated VBN Condition
with IN Condition
the DT Condition
long JJ Condition
acting JJ Condition
pilocarpine-complex NN Condition
for IN Condition
120 CD Condition
days NNS Condition
. . Condition
-DOCSTART- -X- N

impoverished JJ Condition
relational-encoding NN Condition
and CC None
distinctiveness NN Condition
heuristic JJ Condition
accounts NNS Condition
. . None
participants NNS None
were VBD None
given VBN None
inclusion NN Condition
recall NN Condition
instructions NNS Condition
to TO None
report VB None
studied JJ None
items NNS None
as RB None
well RB None
as IN None
related JJ None
items NNS None
-DOCSTART- -X- N

skin JJ Condition
cancers NNS Condition
among IN None
beachgoers NNS None
in IN None
southeastern JJ None
New NNP None
England NNP None
. . None
representative JJ None
sample NN None
( ( None
N NNP None
= NNP None
2,324 CD Size
) ) None
of IN None
beachgoers NNS None
in IN None
Southeastern NNP None
New NNP None
England NNP None
during IN None
the DT None
summer NN None
of IN None
1995 CD None
. . None
-DOCSTART- -X- N

gastric JJ Condition
acid JJ Condition
secretion NN Condition
and CC None
gastrin NN Condition
release NN Condition
in IN None
man NN Sex
. . None
man NN None
. . None
normal JJ None
volunteers NNS None
single JJ None
patient NN None
with IN None
Zollinger-Ellison NNP Condition
syndrome NN Condition
. . None
pentagastrin NN Condition
stimulated VBD Condition
acid JJ Condition
secretion NN Condition
in IN None
man NN None
. . None
-DOCSTART- -X- N

COPD NNP None
. . None
22 CD Size
patients NNS None
with IN None
stable JJ Condition
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
( ( None
FEV1 NNP Condition
less JJR Condition
than IN Condition
70 CD Condition
percent NN Condition
predicted VBN Condition
) ) None
. . None
-DOCSTART- -X- N

atrial JJ Condition
fibrillation NN Condition
or CC None
atrial JJ None
flutter NN None
. . None
45 CD Size
patients NNS None
with IN None
atrial JJ None
fibrillation NN None
or CC None
atrial JJ None
flutter NN None
, , None
in IN None
a DT None
randomized JJ None
, , None
parallel JJ None
, , None
open-label JJ None
study NN None
. . None
Patients NNS None
with IN None
either DT None
new JJ None
onset NN None
( ( None
less JJR None
than IN None
48 CD None
hours NNS None
, , None
n JJ None
= NNP None
31 CD Size
) ) None
or CC None
old JJ None
onset NN None
( ( None
greater JJR None
than IN None
48 CD None
hours NNS None
, , None
n JJ None
= NNP None
14 CD Size
) ) None
of IN None
atrial JJ None
fibrillation NN None
or CC None
flutter NN None
with IN None
rapid JJ None
ventricular JJ None
rate NN None
were VBD None
stratified VBN None
-DOCSTART- -X- N

assessment NN None
of IN None
catheter-tip JJ Condition
PO2 NNP None
sensor NN None
: : None
standard JJ None
catheters NNS Condition
catheter NN Condition
surface NN None
. . None
success NN None
rate NN None
for IN None
catheter NN Condition
insertion NN None
is VBZ None
57 CD None
% NN None
for IN None
138 CD Size
standard NN Size
and CC None
50 CD None
% NN None
for IN None
74 CD Size
laser-cut JJ Size
catheters NNS Condition
studied VBN None
. . None
-DOCSTART- -X- N

autism NN None
: : None
autism NN None
15 CD None
children NNS None
aged VBN None
2-16 CD None
years NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
. . None
-DOCSTART- -X- N

Eleven NNP None
chronic JJ None
renal JJ None
failure NN None
patients NNS None
and CC None
11 CD None
matched JJ None
controls NNS None
the DT None
uremic JJ None
patients NNS None
Uremic JJ None
patients NNS None
chronic JJ None
renal JJ None
failure NN None
patients NNS None
different JJ None
group NN None
of IN None
seven CD None
uremic JJ None
patients NNS None
uremic JJ None
patients NNS None
-DOCSTART- -X- N

cancer NN Condition
pain NN Condition
. . None
Chronic NNP Condition
cancer NN Condition
pain NN Condition
patients NNS None
( ( None
n=25 JJ Size
) ) None
were VBD None
randomized VBN None
to TO None
OAD NNP None
morphine NN None
( ( None
mean JJ None
238 CD None
+/- JJ None
319 CD None
mg NN None
q24h NN None
) ) None
or CC None
twice-daily JJ None
-DOCSTART- -X- N

patients NNS None
with IN None
transient JJ None
ischemic JJ None
attack NN None
or CC None
stroke NN None
caused VBN None
by IN None
angiographically RB None
verified VBN None
50 CD None
to TO None
99 CD None
percent NN None
stenosis NN None
of IN None
a DT None
major JJ None
intracranial JJ None
artery NN None
After IN None
569 CD None
patients NNS None
had VBD None
undergone JJ None
randomization NN None
, , None
enrollment NN None
was VBD None
stopped VBN None
because IN None
of IN None
concerns NNS None
about IN None
the DT None
safety NN None
of IN None
the DT None
patients NNS None
who WP None
had VBD None
been VBN None
assigned VBN None
to TO None
receive VB None
warfarin NN None
. . None
patients NNS None
with IN None
intracranial JJ None
arterial JJ None
stenosis NN None
. . None
-DOCSTART- -X- N

stable JJ Condition
angina NN Condition
. . None
149 CD Size
men NNS None
with IN None
stable JJ Condition
angina NN Condition
. . None
-DOCSTART- -X- N

relapsed JJ Condition
smokers NNS Condition
low JJ None
income NN None
smokers NNS Condition
who WP None
had VBD None
previously RB None
used VBN None
quitline NN None
( ( None
QL NNP None
) ) None
support NN None
A NNP None
sample NN None
of IN None
2985 CD Size
previous JJ None
QL NNP None
callers NNS None
smokers NNS Condition
with IN None
previous JJ None
QL NNP None
treatment NN None
-DOCSTART- -X- N

shivering VBG Condition
threshold NN Condition
in IN Condition
humans NNS Condition
. . Condition
nine CD None
healthy JJ None
male NN None
volunteers NNS None
( ( None
18-40 JJ None
yr NN None
) ) None
on IN None
two CD None
randomly NNS None
assigned VBN None
treatment NN None
days NNS None
: : None
-DOCSTART- -X- N

Bitewing NNP None
film NN None
quality NN None
: : None
Four NNP None
bitewing VBG None
films NNS None
right NN None
and CC None
left VBD None
premolar JJ None
and CC None
molar JJ None
regions NNS None
of IN None
45 CD Size
dental JJ None
students NNS None
360 CD None
films NNS None
-DOCSTART- -X- N

children NNS Age
of IN None
non-severe JJ Condition
pneumonia NN Condition
with IN None
wheeze NN Condition
: : None
developing NN None
countries NNS None
. . None
children NNS Age
presenting VBG None
with IN None
non-severe JJ Condition
pneumonia NN Condition
with IN None
wheeze NN Condition
, , None
who WP None
have VBP None
persistent VBN None
fast RB None
breathing NN None
after IN None
nebulisation NN None
with IN None
salbutamol NN None
, , None
and CC None
have VBP None
normal JJ None
chest NN None
radiograph NN None
. . None
eight CD None
government NN None
hospitals NNS None
in IN None
India NNP None
. . None
Participants NNS None
were VBD None
children NNS Age
aged VBN None
2-59 JJ Age
months NNS None
of IN None
age NN None
836 CD Size
cases NNS None
in IN None
placebo NN None
and CC None
835 CD Size
in IN None
amoxycillin NN None
group NN None
. . None
children NNS Age
with IN None
non-severe JJ Condition
pneumonia NN Condition
and CC None
wheeze NN Condition
-DOCSTART- -X- N

patients NNS Condition
undergoing VBG Condition
cholecystectomy NN Condition
. . None
24 CD Size
patients NNS None
undergoing JJ None
cholecystectomy NN None
. . None
Ten CD None
patients NNS None
The DT None
placebo NN None
group NN None
patients NNS None
cholecystectomized JJ None
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
poor JJ Condition
prognoses NNS Condition
, , Condition
to TO Condition
determine VB Condition
risk NN Condition
factors NNS Condition
for IN Condition
surgical JJ Condition
failure NN Condition
and CC Condition
to TO Condition
examine VB Condition
the DT Condition
relationship NN Condition
of IN Condition
intraocular JJ Condition
pressure NN Condition
and CC Condition
visual JJ Condition
function NN Condition
. . Condition
213 CD None
patients NNS None
with IN None
previous JJ None
cataract NN None
surgery NN None
or CC None
previous JJ None
failed VBD None
filtering VBG None
surgery NN None
eyes NNS None
after IN None
previous JJ None
cataract NN None
surgery NN None
or CC None
unsuccessful JJ None
filtering NN None
surgery NN None
-DOCSTART- -X- N

multiple JJ Condition
sclerosis NN Condition
: : None
multiple JJ None
sclerosis NN None
201 CD Size
patients NNS None
with IN None
clinically RB None
definite JJ None
multiple JJ None
sclerosis NN None
-DOCSTART- -X- N

autistic JJ None
children NNS None
: : None
14 CD None
autistic JJ None
children NNS None
autistic JJ None
children NNS None
-DOCSTART- -X- N

phacoemulsification NN Condition
. . None
80 CD Size
American JJ None
Society NNP None
of IN None
Anesthesiology NNP None
grade VBD None
I-II NNP None
patients NNS None
who WP None
underwent JJ None
phacoemulsification NN None
with IN None
local JJ None
anesthesia NN None
under IN None
sedation NN None
. . None
four CD None
groups NNS None
( ( None
20 CD Size
patients NNS None
for IN None
each DT None
) ) None
: : None
-DOCSTART- -X- N

Twenty-two NNP Size
healthy JJ Condition
female NN Sex
volunteers NNS None
extra JJ None
1 CD None
group NN None
-DOCSTART- -X- N

open JJ Condition
heart NN Condition
surgery NN Condition
Fifty-two JJ None
patients NNS None
undergoing VBG None
coronary JJ None
artery NN None
bypass NN None
on IN None
cardiopulmonary JJ None
bypass NN None
-DOCSTART- -X- N

iron-deficiency NN Condition
anemia NN Condition
( ( None
IDA NNP None
) ) None
Patients NNPS None
with IN None
IDA NNP Condition
the DT None
treated VBN None
group NN None
and CC None
the DT None
control NN None
group NN None
, , None
50 CD Size
in IN None
each DT None
group NN None
. . None
-DOCSTART- -X- N

speech NN None
Humans NNS None
people NNS None
-DOCSTART- -X- N

104 CD Size
patients NNS None
with IN None
H. NNP None
pylori FW None
infection NN None
and CC None
recurrent JJ Condition
duodenal JJ Condition
ulcer NN Condition
52 CD Size
patients NNS None
given VBN None
antibiotics NNS None
patients NNS None
with IN None
recurrent JJ Condition
duodenal JJ Condition
ulcer NN Condition
-DOCSTART- -X- N

preterm JJ Condition
infants NNS None
fed VBN None
standard JJ None
infant NN None
formulas NN None
. . None
preterm JJ Condition
infants NNS None
fed VBN None
standard JJ None
infant NN None
formulas NNS None
, , None
Similac NNP None
With IN None
Iron NNP None
and CC None
Similac NNP None
With IN None
Whey NNP None
+ NNP None
Iron NNP None
. . None
rapidly RB None
growing VBG None
preterm JJ Condition
infant NN Age
-DOCSTART- -X- N

after IN None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
using VBG None
cardiopulmonary JJ None
bypass NN None
. . None
Consecutively RB None
listed VBD None
candidates NNS None
for IN None
elective JJ None
bypass NN None
( ( None
n JJ None
= NNP None
107 CD None
) ) None
-DOCSTART- -X- N

chemotherapy NN Condition
for IN Condition
advanced JJ Condition
solid JJ Condition
tumors NNS Condition
: : Condition
227 CD None
patients NNS None
with IN None
breast NN None
, , None
colorectal NN None
, , None
lung NN None
and CC None
other JJ None
solid JJ None
forms NNS None
of IN None
cancer NN None
. . None
MPA NNP None
( ( None
117 CD None
patients NNS None
) ) None
placebo NN None
( ( None
110 CD None
patients NNS None
) ) None
. . None
-DOCSTART- -X- N

CAPD NNP Condition
peritonitis NN Condition
. . None
Fifty-one CD Size
patients NNS Size
were VBD None
included VBN None
CAPD NNP Condition
peritonitis NN Condition
. . None
-DOCSTART- -X- N

chronic JJ Condition
kidney NN Condition
disease NN Condition
with IN None
outcomes NNS None
in IN None
chronic JJ Condition
heart NN Condition
failure NN Condition
: : None
patients NNS None
with IN None
heart NN Condition
failure NN Condition
( ( None
HF NNP Condition
) ) None
. . None
HF NNP Condition
patients NNS None
Of IN None
7788 CD Size
patients NNS None
in IN None
the DT None
Digitalis NNP None
Investigation NNP None
Group NNP None
trial NN None
, , None
3527 CD Size
had VBD None
CKD NNP Condition
, , None
defined VBN None
by IN None
an DT None
estimated VBN None
glomerular JJ None
filtration NN None
rate NN None
( ( None
GFR NNP None
) ) None
< VBD None
60 CD None
ml/min/1.73 NNS None
m NN None
( ( None
2 CD None
) ) None
body NN None
surface JJ None
area NN None
( ( None
BSA NNP None
) ) None
. . None
ambulatory JJ None
patients NNS None
with IN None
chronic JJ Condition
HF NNP Condition
-DOCSTART- -X- N

mild VB Condition
inflammation NN Condition
. . Condition
19 CD Condition
subjects NNS None
received VBD None
the DT None
influenza JJ None
vaccine NN None
, , None
20 CD Condition
subjects NNS None
the DT None
combination NN None
of IN None
influenza NN None
and CC None
pneumococcal JJ None
vaccine NN None
. . None
-DOCSTART- -X- N

chronic JJ Condition
central JJ Condition
serous JJ Condition
chorioretinopathy NN Condition
: : Condition
Thirty-four JJ None
eyes NNS None
of IN None
32 CD None
patients NNS None
with IN None
chronic JJ None
CSC NNP None
with IN None
> NNP None
6 CD None
months NNS None
' POS None
duration NN None
of IN None
symptoms NNS None
or CC None
recurrent JJ None
CSC NNP None
were VBD None
randomly RB None
placed VBN None
into IN None
the DT None
low-fluence JJ None
PDT NNP None
group NN None
( ( None
n JJ None
= NNP None
18 CD None
) ) None
or CC None
the DT None
ranibizumab NN None
group NN None
( ( None
n JJ None
= NNP None
16 CD None
) ) None
. . None
16 CD None
eyes NNS None
2 CD None
eyes NNS None
-DOCSTART- -X- N

parents NNS None
of IN None
children NNS None
with IN None
autism NN None
: : None
a DT None
parent NN None
children NNS None
with IN None
autism NN None
. . None
parents NNS None
of IN None
young JJ None
children NNS None
on IN None
the DT None
autism NN None
spectrum NN None
Parents NNS None
Parents NNS None
young JJ None
children NNS None
with IN None
autism NN None
. . None
-DOCSTART- -X- N

white JJ None
and CC None
black JJ None
normotensive JJ None
subjects NNS None
: : None
Twelve NNP None
normotensive JJ None
white JJ None
and CC None
12 CD None
normotensive JJ None
black JJ None
men NNS None
whites NNS None
blacks NNS None
. . None
salt-sensitive JJ None
hypertension NN None
in IN None
blacks NNS None
. . None
-DOCSTART- -X- N

psychotic JJ Condition
depression NN Condition
patients NNS None
with IN None
major JJ Condition
depression NN Condition
. . None
major JJ Condition
depression NN Condition
with IN None
psychotic JJ Condition
features NNS Condition
( ( Condition
MDpsy NNP Condition
) ) Condition
. . None
MDpsy NNP Condition
in IN None
patients NNS None
who WP None
participated VBD None
in IN None
the DT None
STOPD-PD NNP None
study NN None
, , None
a DT None
randomized VBN None
, , None
double-blind JJ None
, , None
clinical JJ None
trial NN None
comparing VBG None
a DT None
subjects NNS None
with IN None
a DT None
history NN None
of IN None
no DT None
prior JJ None
treatment NN None
or CC None
inadequate JJ None
treatment NN None
who WP None
were VBD None
treated VBN None
with IN None
a DT None
combination NN None
of IN None
olanzapine NN None
and CC None
sertraline NN None
. . None
subjects NNS None
who WP None
had VBD None
previously RB None
failed VBN None
to TO None
respond VB None
to TO None
an DT None
antidepressant JJ None
alone NN None
and CC None
who WP None
were VBD None
treated VBN None
with IN None
olanzapine JJ None
monotherapy NN None
. . None
subjects NNS None
who WP None
had VBD None
previously RB None
failed VBN None
to TO None
respond VB None
to TO None
a DT None
combination NN None
of IN None
an DT None
antipsychotic JJ None
and CC None
an DT None
antidepressant NN None
. . None
patients NNS None
with IN None
MDpsy NNP Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
common JJ None
cancers NNS Condition
involving VBG None
bone NN None
receiving VBG None
intravenous JJ None
bisphosphonate NN None
therapy NN None
Enrolled NNP None
in IN None
the DT None
study NN None
were VBD None
184 CD Size
patients NNS None
12 CD Size
% NN Size
of IN None
eligible JJ None
patients NNS None
( ( None
16/138 CD None
) ) None
Cancer NNP None
patients NNS None
-DOCSTART- -X- N

exchange NN None
transfusions NNS None
. . None
42 CD None
hyperbilirubinemic JJ None
infants NNS None
who WP None
required VBD None
exchange NN None
transfusions NNS None
15 CD None
infants NNS None
infants NNS None
with IN None
low JJ None
RABC NNP None
-DOCSTART- -X- N

coronary JJ Condition
artery NN Condition
bypass NN Condition
graft NN None
surgery NN None
: : None
Forty CD Size
patients NNS None
were VBD None
randomized VBN None
-DOCSTART- -X- N

obese JJ None
patients NNS None
. . None
One CD None
hundred CD None
and CC None
five CD None
obese JJ None
[ NN None
Body NNP None
Mass NNP None
Index NNP None
( ( None
BMI NNP None
) ) None
> VBD None
or CC None
= $ None
30 CD None
] JJ None
patients NNS None
participated VBN None
in IN None
the DT None
study NN None
. . None
62 CD None
took VBD None
part NN None
in IN None
the DT None
treatment NN None
program NN None
and CC None
43 CD None
served VBD None
as IN None
controls NNS None
. . None
obesity NN None
unit NN None
's POS None
waiting VBG None
list NN None
Fifty-seven NNP None
( ( None
92 CD None
% NN None
) ) None
patients NNS None
completed VBN None
treatment NN None
. . None
-DOCSTART- -X- N

patients NNS None
suffering VBG None
a DT None
suspected JJ None
acute JJ Condition
coronary JJ Condition
syndrome NN Condition
: : None
multi-centre NN None
pain NN None
and CC None
discomfort NN None
among IN None
patients NNS Condition
who WP Condition
suffer VBP Condition
from IN Condition
acute JJ Condition
coronary JJ Condition
syndrome NN Condition
( ( Condition
ACS NNP Condition
) ) Condition
multi-centre NN None
all DT None
, , None
890 CD Size
patients NNS Size
were VBD None
randomised VBN None
to TO None
-DOCSTART- -X- N

patients NNS None
with IN None
the DT None
chronic JJ Condition
fatigue NN Condition
syndrome NN Condition
. . None
chronic JJ Condition
fatigue NN Condition
syndrome NN Condition
. . None
66 CD Size
patients NNS None
with IN None
the DT None
chronic JJ Condition
fatigue NN Condition
syndrome NN Condition
who WP None
had VBD None
neither CC None
a DT None
psychiatric JJ Condition
disorder NN Condition
nor CC None
appreciable JJ Condition
sleep JJ Condition
disturbance NN Condition
. . None
patients NNS None
with IN None
the DT None
chronic JJ Condition
fatigue NN Condition
syndrome NN Condition
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
. . None
autistic JJ Condition
disorder NN Condition
. . None
Forty NNP Size
children NNS None
between IN None
the DT None
ages NNS Age
of IN Age
4 CD Age
and CC Age
12 CD Age
years NNS Age
with IN None
a DT None
DSM NNP Condition
IV NNP Condition
clinical JJ Condition
diagnosis NN Condition
of IN Condition
autism NN Condition
who WP None
were VBD None
outpatients NNS None
from IN None
a DT None
specialty NN None
clinic NN None
for IN None
children NNS None
were VBD None
recruited VBN None
. . None
children NNS None
severely RB Condition
disruptive JJ Condition
symptoms NNS Condition
related VBN None
to TO None
autistic JJ Condition
disorder NN Condition
. . None
children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
. . None
-DOCSTART- -X- N

in IN None
children NNS None
with IN None
high-functioning JJ None
autism NN None
and CC None
concurrent JJ None
anxiety NN None
disorders NNS None
. . None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
Forty NNP None
children NNS None
with IN None
ASD NNP None
( ( None
7-11 CD None
years NNS None
) ) None
and CC None
their PRP$ None
primary JJ None
caregiver NN None
children NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

adults NNS Age
with IN None
autistic JJ Condition
and CC Condition
Asperger NNP Condition
's POS Condition
disorders NNS Condition
. . None
autism NN Condition
spectrum NN Condition
patients NNS None
. . None
15 CD None
adults NNS None
with IN None
autism NN None
or CC None
Asperger NNP None
's POS None
disorder NN None
-DOCSTART- -X- N

antipsychotic JJ None
drugs NNS None
risperidone NN Condition
( ( None
N=16 NNP Condition
) ) None
, , None
olanzapine JJ Condition
( ( None
N=18 NNP Condition
) ) None
and CC None
low JJ None
doses NNS None
of IN None
haloperidol NN Condition
( ( None
N=18 NNP Condition
) ) None
large JJ None
and CC None
heterogeneous JJ None
sample NN None
of IN None
schizophrenia NN Condition
spectrum NN Condition
patients NNS None
. . None
group NN None
of IN None
45 CD Condition
healthy JJ Condition
volunteers NNS None
was VBD None
also RB None
longitudinally RB None
evaluated VBN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
Forty-two NNP Size
diabetic JJ Condition
patients NNS None
-DOCSTART- -X- N

mild JJ None
pneumonia NN Condition
. . None
Eighty-six JJ Size
male JJ Sex
patients NNS None
, , None
doing VBG None
their PRP$ None
obligatory JJ None
military JJ None
service NN None
, , None
ranging VBG None
between IN None
19 CD Age
and CC Age
24 CD Age
years NNS Age
of IN None
age NN None
( ( None
mean JJ None
20 CD None
) ) None
Seventy-eight JJ Size
patients NNS None
were VBD None
able JJ None
to TO None
be VB None
evaluated VBN None
for IN None
efficacy NN None
-DOCSTART- -X- N

Children NNP Age
and CC None
Teenagers NNP Age
with IN None
Cancer NNP Condition
children NNS None
have VBP None
reduced VBN None
contact NN None
with IN None
their PRP$ None
social JJ None
network NN None
of IN None
friends NNS None
, , None
and CC None
have VBP None
limited VBN None
participation NN None
in IN None
education NN None
, , None
sports NNS None
, , None
and CC None
leisure NN None
activities NNS None
. . None
children NNS Age
nationwide JJ None
children NNS Age
aged VBN None
6-18 CD Age
years NNS Age
newly RB None
diagnosed VBN None
with IN None
cancer NN Condition
in IN None
eastern JJ None
Denmark NNP None
( ( None
n=120 NN Size
) ) None
and CC None
a DT None
matched JJ None
control NN None
group NN None
in IN None
western JJ None
Denmark NNP None
( ( None
n=120 NN Size
) ) None
. . None
includes VBZ None
Danish-speaking NNP None
children NNS Age
diagnosed VBD None
with IN None
cancer NN Condition
and CC None
treated VBN None
at IN None
pediatric JJ None
oncology NN None
units NNS None
in IN None
Denmark NNP None
. . None
child NN Age
with IN None
cancer NN Condition
Children NNP Age
with IN None
cancer NN Condition
child NN Age
with IN None
cancer NN Condition
patients NNS None
children NNS Age
with IN None
cancer NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
mild JJ Condition
obstructive JJ Condition
sleep NN Condition
apnea NN Condition
. . None
cardiovascular JJ Condition
diseases NNS Condition
in IN None
obstructive JJ Condition
sleep NN Condition
apnea NN Condition
( ( Condition
OSA NNP Condition
) ) Condition
overweight JJ Condition
patients NNS None
with IN None
mild JJ Condition
OSA NNP Condition
. . Condition
Patients NNPS None
were VBD None
randomized VBN None
to TO None
supervised VBN None
intensive JJ None
lifestyle JJ None
intervention NN None
group NN None
( ( None
N=28 NNP Size
) ) None
or CC None
to TO None
control VB None
group NN None
( ( None
N=31 NNP Size
) ) None
, , None
which WDT None
received VBD None
routine JJ None
lifestyle JJ None
advices NNS None
. . None
overweight JJ Condition
patients NNS None
with IN None
mild JJ Condition
OSA NNP Condition
OSA NNP Condition
patients NNS None
-DOCSTART- -X- N

acute JJ None
bronchiolitis NN None
One CD None
hundred CD None
and CC None
fifty-six JJ None
infants NNS None
aged VBN None
between IN None
7 CD None
weeks NNS None
and CC None
24 CD None
months NNS None
who WP None
had VBD None
had VBN None
an DT None
episode NN None
of IN None
wheezing NN None
and CC None
other JJ None
signs NNS None
and CC None
symptoms NNS None
of IN None
bronchiolitis NN None
-DOCSTART- -X- N

esthesioneuroblastoma NN Condition
poorly RB None
differentiated VBN None
tumors NNS None
arising VBG None
in IN None
the DT None
sinonasal NN None
tract NN None
. . None
high-grade JJ None
esthesioneuroblastomas NN None
other JJ None
poorly RB None
differentiated VBN None
tumors NNS None
arising VBG None
in IN None
the DT None
nasal JJ None
cavity NN None
24 CD None
frozen JJ None
cases NNS None
of IN None
esthesioneuroblastoma NN None
and CC None
poorly RB None
differentiated VBN None
tumors NNS None
. . None
poorly RB None
differentiated VBN None
tumors NNS None
of IN None
the DT None
sinonasal JJ None
region NN None
. . None
-DOCSTART- -X- N

operable JJ Condition
gastric JJ Condition
cancer NN Condition
: : Condition
Dutch JJ Condition
patients NNS None
with IN None
operable JJ None
gastric JJ None
cancer NN None
. . None
Patients NNS None
younger JJR None
than IN None
75 CD None
years NNS None
of IN None
age NN None
with IN None
a DT None
good JJ None
physical NN None
and CC None
mental JJ None
condition NN None
and CC None
a DT None
histologically RB None
proven JJ None
adenocarcinoma NN None
of IN None
the DT None
stomach NN None
without IN None
clinical JJ None
or CC None
radiographic JJ None
( ( None
computed JJ None
tomography NN None
scan NN None
) ) None
evidence NN None
of IN None
distant JJ None
metastases NNS None
Early JJ None
gastric JJ None
cancer NN None
or CC None
cardia VB None
carcinoma NN None
were VBD None
excluded VBN None
. . None
56 CD None
eligible JJ None
and CC None
evaluable JJ None
patients NNS None
were VBD None
entered VBN None
: : None
-DOCSTART- -X- N

sepsis-related JJ None
acute JJ None
kidney NN None
injury NN None
patients NNS None
. . None
sepsis-related JJ None
acute JJ None
kidney NN None
injury NN None
( ( None
AKI NNP None
) ) None
. . None
Twenty-eight JJ None
sepsis-related JJ None
AKI NNP None
patients NNS None
were VBD None
included VBN None
and CC None
randomized VBN None
into IN None
online JJ None
HDF NNP None
and CC None
high-flux JJ None
HD NNP None
. . None
state NN None
in IN None
sepsis-related JJ None
AKI NNP None
. . None
-DOCSTART- -X- N

gynaecologic JJ None
oncologic JJ None
surgery NN None
: : None
gynaecological JJ None
oncologic NN None
surgery NN None
. . None
102 CD None
consecutive JJ None
women NNS None
undergoing VBG None
gynaecologic JJ None
cancer NN None
surgery NN None
with IN None
pelvic NN None
and CC None
paraaortic JJ None
lymphadenectomy NN None
. . None
The DT None
two CD None
groups NNS None
were VBD None
well RB None
matched VBN None
for IN None
age NN None
, , None
weight NN None
, , None
and CC None
other JJ None
factors NNS None
-DOCSTART- -X- N

labour NN None
113 CD Size
women NNS Sex
attending VBG None
a DT None
university NN None
hospital NN None
obstetric JJ None
department NN None
. . None
The DT None
characteristics NNS None
of IN None
labour NN None
were VBD None
similar JJ None
in IN None
both DT None
groups NNS None
. . None
during IN Condition
labour JJR Condition
-DOCSTART- -X- N

children NNS None
with IN None
fetal JJ None
alcohol NN None
spectrum NN None
disorder NN None
. . None
children NNS None
with IN None
fetal JJ None
alcohol NN None
spectrum NN None
disorder NN None
( ( None
FASD NNP None
) ) None
A NNP None
group NN None
of IN None
children NNS None
with IN None
FASD NNP None
( ( None
n JJ None
= NNP None
27 CD None
) ) None
between IN None
the DT None
ages NNS None
of IN None
8 CD None
and CC None
16 CD None
and CC None
typically RB None
developing VBG None
control NN None
children NNS None
( ( None
n JJ None
= NNP None
27 CD None
) ) None
matched VBN None
for IN None
age NN None
and CC None
sex NN None
-DOCSTART- -X- N

patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
and CC None
normal JJ None
glucose JJ None
tolerance NN None
. . None
patients NNS None
with IN None
documented JJ None
stable JJ None
coronary JJ None
artery NN None
disease NN None
and CC None
normal JJ None
glucose JJ None
tolerance NN None
. . None
54 CD None
patients NNS None
with IN None
normal JJ None
fasting VBG None
glucose JJ None
levels NNS None
, , None
18 CD None
showed VBD None
impaired JJ None
glucose JJ None
tolerance NN None
and CC None
36 CD None
patients NNS None
with IN None
normal JJ None
glucose JJ None
tolerance NN None
were VBD None
randomized VBN None
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
. . None
normoglycemic JJ None
individuals NNS None
with IN None
stable JJ None
coronary JJ None
artery NN None
disease NN None
. . None
-DOCSTART- -X- N

optic JJ Condition
neuritis NN Condition
: : None
optic JJ Condition
neuritis NN Condition
Subjects NNPS None
in IN None
the DT None
Optic NNP None
Neuritis NNP None
Treatment NNP None
Trial NNP None
, , None
who WP None
were VBD None
enrolled VBN None
between IN None
July NNP None
1 CD None
, , None
1988 CD None
, , None
and CC None
June NNP None
30 CD None
, , None
1991 CD None
, , None
were VBD None
followed VBN None
up RP None
prospectively RB None
for IN None
15 CD None
years NNS None
, , None
with IN None
the DT None
final JJ None
examination NN None
in IN None
2006 CD None
. . None
Neurologic NNP None
and CC None
ophthalmologic JJ None
examinations NNS None
at IN None
13 CD None
clinical JJ None
sites NNS None
. . None
Three CD Size
hundred VBD Size
eighty-nine JJ Size
subjects NNS None
with IN None
acute JJ Condition
optic JJ Condition
neuritis NN Condition
. . None
-DOCSTART- -X- N

'high JJ None
risk NN None
' POS None
pre- NN None
and CC None
postmenopausal NN None
breast NN None
cancer NN None
patients NNS None
. . None
node JJ None
positive JJ None
breast NN None
cancer NN None
patients NNS None
in IN None
Sweden NNP None
. . None
the DT None
Stockholm NNP None
Breast NNP None
Cancer NNP None
Study NNP None
Group NNP None
pre- NN None
( ( None
n JJ None
= NNP None
547 CD None
) ) None
and CC None
postmenopausal NN None
( ( None
n JJ None
= NNP None
679 CD None
) ) None
patients NNS None
, , None
respectively RB None
, , None
with IN None
node JJ None
positive JJ None
disease NN None
or CC None
a DT None
tumour JJ None
diameter NN None
> VBD None
30 CD None
mm NN None
. . None
-DOCSTART- -X- N

Seventy-seven JJ None
consecutive JJ None
biopsies NNS None
a DT None
single JJ None
operator NN None
. . None
-DOCSTART- -X- N

rectal JJ Condition
cancer NN Condition
patients NNS Condition
with IN Condition
high JJ Condition
preoperative JJ Condition
CEA NNP Condition
levels NNS Condition
. . None
rectal JJ None
cancer NN None
. . None
Between NNP None
1994 CD None
and CC None
2004 CD None
, , None
we PRP None
retrospectively RB None
reviewed VBD None
122 CD Size
patients NNS None
with IN None
rectal JJ None
cancer NN None
whose WP$ None
serum JJ None
CEA NNP None
levels NNS None
were VBD None
measured VBN None
on IN None
the DT None
preoperative JJ None
day NN None
and CC None
postoperative JJ None
days NNS None
7 CD None
and CC None
30 CD None
. . None
Patients NNS None
with IN None
preoperative JJ None
CEA NNP None
levels NNS None
< VBP None
5.0 CD None
ng/ml NNS None
were VBD None
excluded VBN None
. . None
Patients NNS None
were VBD None
categorized VBN None
into IN None
three CD None
groups NNS None
based VBN None
on IN None
R NNP None
( ( None
2 CD None
) ) None
values NNS None
exponential JJ None
decrease NN None
group NN None
nearly RB None
exponential JJ None
decrease NN None
group NN None
randomized JJ None
clearance NN None
group NN None
patients NNS None
with IN None
stage NN Condition
III NNP Condition
rectal JJ Condition
cancer NN Condition
. . None
patients NNS None
with IN None
rectal JJ None
cancer NN None
. . None
Patients NNS None
with IN None
a DT None
randomized JJ None
pattern NN None
of IN None
CEA NNP None
clearance NN None
-DOCSTART- -X- N

inclusion NN None
body NN None
myositis NN None
44 CD Size
patients NNS None
with IN None
inclusion NN None
body NN None
myositis NN None
-DOCSTART- -X- N

localized VBN Condition
juvenile NN Condition
periodontitis NN Condition
16 CD Size
patients NNS Size
with IN None
localized JJ Condition
juvenile NN Condition
periodontitis NN Condition
patients NNS None
with IN None
localized JJ Condition
juvenile NN Condition
periodontitis NN Condition
-DOCSTART- -X- N

beta-adrenoceptor NN None
blockade NN None
in IN None
man NN None
by IN None
prizidilol JJ None
hydrochloride NN None
. . None
healthy JJ Condition
volunteers NNS Condition
. . None
-DOCSTART- -X- N

type NN None
2 CD None
diabetic JJ None
subjects NNS None
. . None
type NN None
2 CD None
diabetic JJ None
subjects NNS None
. . None
Twenty NNP Size
type NN Condition
2 CD Condition
diabetic JJ Condition
subjects NNS None
participated VBN None
in IN None
a DT None
crossover NN None
trial NN None
. . None
type NN None
2 CD None
diabetic JJ None
subjects NNS None
. . None
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
and CC None
patients NNS None
who WP None
are VBP None
post-thrombotic JJ None
. . None
Deep NNP None
vein NN None
thrombosis NN None
( ( None
DVT NNP None
) ) None
morbidity NN None
and CC None
mortality NN None
in IN None
patients NNS None
who WP None
are VBP None
hospitalized VBN None
. . None
healthy JJ None
volunteers NNS None
and CC None
patients NNS None
with IN None
severe JJ None
post-thrombotic JJ None
venous JJ None
disease NN None
. . None
Twenty-two NNP None
lower JJR None
extremities NNS None
from IN None
healthy JJ None
volunteers NNS None
and CC None
11 CD None
lower JJR None
extremities NNS None
from IN None
patients NNS None
with IN None
class NN None
4 CD None
to TO None
class NN None
6 CD None
post-thrombotic JJ None
chronic JJ None
venous JJ None
insufficiency NN None
were VBD None
studied VBN None
. . None
Patients NNS None
with IN None
post-thrombotic JJ None
venous JJ None
disease NN None
healthy JJ None
volunteers NNS None
and CC None
in IN None
patients NNS None
who WP None
were VBD None
post-thrombotic JJ None
. . None
-DOCSTART- -X- N

type NN Condition
IV NNP Condition
hyperlipoproteinemia NN Condition
. . Condition
group NN None
of IN None
30 CD None
patients NNS None
with IN None
a DT None
type NN None
IV NNP None
hyperlipoproteinemia NN None
. . None
type NN None
IV NNP None
hyperlipoproteinemia NN None
-DOCSTART- -X- N

melanoma NN Condition
families NNS None
families NNS None
families NNS None
affected VBN None
by IN None
melanoma NN Condition
three CD Size
family NN Size
members NNS Size
per IN Size
family NN Size
for IN None
assessment NN None
- : None
the DT None
melanoma NN None
case NN None
, , None
a DT None
first-degree JJ None
relative NN None
( ( None
FDR NNP None
) ) None
, , None
and CC None
a DT None
relative NN None
who WP None
is VBZ None
a DT None
parent NN None
of IN None
a DT None
child JJ None
age NN None
18 CD Age
or CC Age
younger JJR Age
. . None
1380 CD Size
families NNS None
approached VBD None
, , None
313 CD Size
were VBD None
enrolled VBN None
, , None
263 CD None
were VBD None
excluded VBN None
because IN None
we PRP None
could MD None
not RB None
find VB None
or CC None
contact VB None
a DT None
family NN None
member NN None
( ( None
FDR CD None
or CC None
parent NN None
) ) None
, , None
331 CD None
did VBD None
not RB None
have VB None
eligible JJ None
family NN None
members NNS None
, , None
and CC None
473 CD None
refused VBD None
. . None
-DOCSTART- -X- N

pasture-fed JJ Condition
dairy NN None
cows NNS None
. . None
dairy NN None
cows NNS None
under IN None
farming VBG None
conditions NNS None
in IN None
New NNP None
Zealand NNP None
. . None
Spring-calved JJ None
dairy NN None
cows NNS None
were VBD None
grazed VBN None
for IN None
101 CD None
days NNS None
in IN None
paddocks NNS None
that WDT None
were VBD None
either RB None
not RB None
fertilised VBN None
( ( None
Control NNP None
; : None
n=20 CC Size
) ) None
during IN None
the DT None
course NN None
of IN None
the DT None
study NN None
, , None
or CC None
were VBD None
fertilised VBN None
with IN None
40-50 JJ None
kg NNS None
nitrogen NN None
( ( None
N NNP None
) ) None
/ha VBP None
every DT None
4-6 JJ None
weeks NNS None
( ( None
High-N NNP None
; : None
n=20 NN Size
) ) None
. . None
pasture-fed JJ None
dairy NN None
cows NNS None
-DOCSTART- -X- N

post-menopausal JJ None
women NNS None
treated VBN None
with IN None
oral JJ None
estrogens NNS None
administered VBN None
at IN None
different JJ None
times NNS None
. . None
twenty-four JJ None
post-menopausal JJ None
women NNS None
. . None
-DOCSTART- -X- N

influenza VB Condition
vaccine NN Condition
in IN None
the DT None
elderly JJ Age
. . None
in IN None
elderly JJ None
subjects NNS None
. . None
Seventy-one CD Size
elderly JJ Age
volunteers NNS None
, , None
aged VBN None
61-89 CD Age
years NNS Age
-DOCSTART- -X- N

surgery NN None
of IN None
the DT None
abdominal JJ None
aorta NN None
] NNP None
lower JJR None
abdominal JJ None
surgery NN None
major JJ None
transabdominal JJ None
surgery NN None
. . None
31 CD None
patients NNS None
undergoing JJ None
elective JJ None
surgery NN None
of IN None
the DT None
abdominal JJ None
aorta NN None
-DOCSTART- -X- N

moderate JJ None
hypertension NN None
. . None
10 CD None
previously RB None
untreated JJ None
hypertensive JJ None
patients NNS None
. . None
-DOCSTART- -X- N

primary JJ None
stenting NN None
of IN None
totally RB None
occluded JJ None
native JJ None
coronary JJ None
arteries NNS None
: : None
total JJ Condition
coronary JJ Condition
occlusions NNS Condition
patients NNS None
enrolled VBN None
in IN None
the DT None
Primary NNP None
Stenting NNP None
of IN None
Totally NNP None
Occluded NNP None
Native NNP None
Coronary NNP None
Arteries NNP None
II NNP None
study NN None
. . None
Patients NNPS None
with IN None
totally RB Condition
occluded JJ Condition
coronary JJ Condition
arteries NNS Condition
( ( None
100 CD Size
patients NNS None
) ) None
bare-metal JJ None
BxVelocity NNP None
stents NNS None
( ( None
BMSs NNP None
) ) None
( ( None
Cordis NNP None
) ) None
( ( None
100 CD Size
patients NNS None
) ) None
-DOCSTART- -X- N

advanced JJ Condition
cancer NN Condition
of IN Condition
the DT Condition
uterine JJ Condition
cervix NN Condition
. . None
two CD None
different JJ None
radiotherapy NN None
techniques NNS None
83 CD Size
patients NNS None
with IN None
advanced JJ None
cancer NN None
of IN None
the DT None
uterine JJ None
cervix NN None
( ( None
stage JJ None
IIIB NNP None
) ) None
employing VBG None
external JJ None
irradiation NN None
alone RB None
-DOCSTART- -X- N

middle JJ Age
aged VBN Age
men NNS Sex
31 CD Size
healthy JJ Condition
middle NNS None
aged VBN None
men NNS None
healthy JJ None
middle NN None
aged VBN None
men NNS None
-DOCSTART- -X- N

( ( None
COPD NNP None
) ) None
. . None
One CD None
hundred CD None
and CC None
forty VB None
four CD None
patients NNS None
with IN None
moderate JJ None
or CC None
severe JJ None
COPD NNP None
patients NNS None
receiving VBG None
combination NN None
treatment NN None
-DOCSTART- -X- N

acute JJ Condition
bacterial JJ Condition
maxillary JJ Condition
sinusitis NN Condition
in IN None
adults NNS Age
. . Age
outpatients NNS None
with IN None
both DT None
clinical JJ None
signs NNS None
and CC None
symptoms NNS None
and CC None
radiographic JJ None
evidence NN None
of IN None
acute JJ Condition
sinusitis NN Condition
452 CD Size
patients NNS None
considered VBN None
valid JJ None
for IN None
clinical JJ None
efficacy NN None
-DOCSTART- -X- N

patients NNS None
with IN None
WAD NNP Condition
. . None
26 CD Size
patients NNS None
with IN None
chronic JJ Condition
neck NN Condition
pain NN Condition
( ( None
WAD-II NNP None
chronic NN None
) ) None
subsequent NN None
to TO None
a DT None
motor NN None
vehicle NN None
accident NN None
. . None
Fourteen NNP Size
subjects VBZ None
receiving VBG None
BTX-A NNP None
and CC None
12 CD None
receiving NN None
saline NN None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

obsessive JJ None
compulsive JJ None
disorder NN None
. . None
obsessive JJ None
compulsive JJ None
disorder NN None
( ( None
OCD NNP None
) ) None
. . None
One CD None
hundred CD None
and CC None
ten VB None
out-patients NNS None
with IN None
OCD NNP None
-DOCSTART- -X- N

adults NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . None
individuals NNS None
with IN None
an DT None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( Condition
ASD NNP Condition
) ) Condition
14 CD Size
high-functioning JJ None
adults NNS Age
with IN None
ASD NNP Condition
and CC None
a DT None
demographically-matched JJ None
comparison NN None
group NN None
of IN None
13 CD Size
typically RB None
developing VBG None
individuals NNS None
participated VBN None
. . None
Individuals NNS None
with IN None
ASD NNP Condition
-DOCSTART- -X- N

Operators NNS None
in IN None
complex JJ None
event-driven JJ None
domains NNS None
48 CD Size
participants NNS None
performed VBD None
a DT None
visually RB Condition
demanding VBG Condition
air NN Condition
traffic NN Condition
control NN Condition
( ( Condition
ATC NNP Condition
) ) Condition
task NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
97 CD None
patients NNS None
( ( None
aged VBN None
31-83 CD None
years NNS None
) ) None
belonging VBG None
to TO None
NYHA NNP None
class NN None
II NNP None
and CC None
III NNP None
with IN None
congestive JJ None
heart NN None
failure NN None
of IN None
different JJ None
aetiology NN None
, , None
but CC None
without IN None
any DT None
complex JJ None
ventricular NN None
arrhythmias NN None
in IN None
basal NN None
conditions NNS None
( ( None
couplets NNS None
with IN None
R'-R NNP None
less JJR None
than IN None
or CC None
equal JJ None
to TO None
400 CD None
msec NNS None
, , None
ventricular JJ None
tachycardia NN None
, , None
R NNP None
on IN None
T NNP None
phenomena NN None
) ) None
. . None
-DOCSTART- -X- N

Eighteen NNP Size
depressed VBD Condition
patients NNS None
( ( None
6 CD Size
men NNS Condition
, , None
12 CD Size
women NNS Condition
; : None
69 CD Age
+/- JJ Age
12.8 CD Age
years NNS None
old JJ None
) ) None
received VBD None
-DOCSTART- -X- N

vaccines NNS None
after IN None
a DT None
primary JJ None
vaccination NN None
series NN None
in IN None
Philippine NNP None
infants NNS Age
. . None
in IN None
174 CD Size
Philippine JJ None
infants NNS None
after IN None
a DT None
primary JJ Condition
vaccination NN Condition
series NN None
. . None
Philippine JJ None
infants NNS None
. . None
-DOCSTART- -X- N

naturally RB None
occurring VBG None
common JJ Condition
colds NNS Condition
. . None
patients NNS None
with IN None
naturally RB Condition
occurring VBG Condition
common JJ Condition
colds NNS Condition
of IN None
less JJR None
than IN None
or CC None
equal JJ None
to TO None
48 CD None
h NNS None
duration NN None
10-MU JJ None
( ( None
n JJ None
= NNP None
74 CD Size
) ) None
, , None
20-MU JJ None
( ( None
n JJ None
= NNP None
74 CD Size
) ) None
, , None
and CC None
placebo NN None
( ( None
n JJ None
= NNP None
72 CD Size
) ) None
groups NNS None
-DOCSTART- -X- N

coronary JJ Condition
artery NN Condition
bypass NN Condition
grafting VBG Condition
patients NNS None
randomized VBN None
into IN None
allopurinol NN None
( ( None
n JJ None
= NNP None
14 CD Size
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= NNP None
13 CD Size
) ) None
groups NNS None
. . None
All DT None
patients NNS None
in IN None
both DT None
groups NNS None
-DOCSTART- -X- N

autism NN None
and CC None
pervasive JJ None
developmental JJ None
disorder NN None
. . None
children NNS None
with IN None
autism NN None
and CC None
pervasive JJ None
developmental JJ None
disorder NN None
. . None
children NNS None
with IN None
autism NN None
and CC None
pervasive JJ None
developmental NN None
disorder NN None
Thirty-seven JJ Age
children NNS Age
between IN Age
3 CD Age
and CC Age
11 CD Age
years NNS Age
of IN Age
age NN Age
with IN Age
a DT Age
diagnosis NN Age
of IN Age
autism NN Age
and/or JJ Age
pervasive JJ Age
developmental NN Age
disorder NN Age
children NNS None
who WP None
participated VBD None
in IN None
this DT None
study NN None
were VBD None
a DT None
heterogeneous JJ None
group NN None
-DOCSTART- -X- N

children NNS Age
with IN None
cystic JJ Condition
fibrosis NN Condition
children NNS Age
with IN None
advanced JJ Condition
cystic JJ Condition
fibrosis NN Condition
hospitalized VBN Condition
with IN None
respiratory JJ Condition
exacerbations NNS Condition
. . None
Twenty-two JJ Size
children NNS Age
with IN None
severe JJ Condition
CF NNP Condition
and CC None
signs NNS None
of IN None
acute NN Condition
lower JJR Condition
respiratory NN Condition
infection NN Condition
Pseudomonas NNP None
aeruginosa NN None
was VBD None
the DT None
predominant JJ None
sputum NN None
pathogen NN None
in IN None
most JJS None
patients NNS None
. . None
-DOCSTART- -X- N

B-cell NNP Condition
non-Hodgkin NN Condition
's POS Condition
lymphoma NN Condition
. . None
patients NNS None
with IN None
non-Hodgkin JJ Condition
's POS Condition
lymphoma NN Condition
. . None
Twenty NNP Condition
seven CD Condition
patients NNS None
were VBD None
mobilized VBN None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
myasthenia JJ Condition
gravis NN Condition
. . Condition
Patients NNPS None
with IN None
myasthenia NNP None
gravis FW None
receive JJ None
pyridostigmine NN None
, , None
an DT None
anticholinesterase NN None
agent NN None
patients NNS None
with IN None
myasthenia JJ None
gravis NN None
on IN None
pyridostigmine NN None
therapy NN None
. . None
Medically NNP None
( ( None
oral JJ None
pyridostigmine NN None
) ) None
well-controlled JJ None
adult NN None
patients NNS None
with IN None
myasthenia JJ None
gravis NNS None
who WP None
were VBD None
posted VBN None
for IN None
thymectomy NN None
Fourteen JJ None
patients NNS None
myasthenia JJ None
gravis NN None
-DOCSTART- -X- N

pregnant JJ None
women NNS None
infected VBN None
with IN None
HIV NNP None
. . None
Pregnant NNP None
women NNS None
with IN None
WHO NNP None
stage VBP None
1 CD None
, , None
2 CD None
, , None
or CC None
3 CD None
HIV-1 JJ None
infection NN None
who WP None
had VBD None
CD4 NNP None
cell NN None
counts NNS None
of IN None
200-500 JJ None
cells NNS None
per IN None
?L NN None
in IN None
Burkina NNP None
Faso NNP None
, , None
Kenya NNP None
, , None
and CC None
South NNP None
Africa NNP None
to TO None
start VB None
study VB None
treatment NN None
at IN None
28-36 JJ None
weeks NNS None
' POS None
gestation NN None
. . None
All DT None
infants NNS None
received VBD None
FINDINGS NNP None
From IN None
June NNP None
, , None
2005 CD None
, , None
to TO None
August NNP None
, , None
2008 CD None
, , None
882 CD None
women NNS None
were VBD None
enrolled VBN None
, , None
824 CD None
805 CD None
singleton NN None
or CC None
first JJ None
, , None
liveborn JJ None
infants NNS None
. . None
The DT None
-DOCSTART- -X- N

Risperidone CD None
dosing NN None
in IN None
children NNS None
and CC None
adolescents NNS None
with IN None
autistic JJ None
disorder NN None
: : None
children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
. . None
Patients NNS None
( ( None
N NNP None
= NNP None
96 CD None
; : None
5-17 CD None
years NNS None
) ) None
, , None
received VBD None
only RB None
in IN None
the DT None
high-dose JJ None
group NN None
, , None
consistent JJ None
in IN None
high-versus JJ None
low-dose JJ None
groups NNS None
. . None
Overall JJ None
-DOCSTART- -X- N

Forty NNP None
premenopausal JJ None
women NNS None
with IN None
large JJ None
, , None
symptomatic JJ None
leiomyomata NNS None
Nineteen NNP None
of IN None
20 CD None
subjects NNS None
-DOCSTART- -X- N

transitionally RB None
frail JJ None
older JJR None
adults NNS None
: : None
falling VBG None
risk NN None
among IN None
older JJR None
adults NNS None
. . None
older JJR None
fall-prone NN None
individuals NNS None
. . None
transitionally RB None
frail JJ None
older JJR None
adults NNS None
. . None
30 CD None
transitionally RB None
frail JJ None
older JJR None
adults NNS None
( ( None
mean JJ None
age NN None
82.6 CD None
+/- JJ None
7.1 CD None
years NNS None
, , None
90 CD None
% NN None
female NN None
) ) None
walking VBG None
alone RB None
, , None
performing VBG None
a DT None
simple JJ None
arithmetic JJ None
task NN None
, , None
or CC None
performing VBG None
a DT None
task NN None
of IN None
verbal JJ None
fluency NN None
. . None
transitional JJ None
older NN None
adults NNS None
older JJR None
adults NNS None
-DOCSTART- -X- N

rheumatoid JJ Condition
arthritis NN Condition
. . None
( ( None
n JJ None
= NNP None
20 CD Size
) ) None
( ( None
m JJ None
= NNP None
19 CD Size
) ) None
patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
of IN None
mild-moderate JJ None
activity NN None
. . None
-DOCSTART- -X- N

a DT None
group NN None
of IN None
30 CD None
senior JJ None
medical JJ None
students NNS None
were VBD None
randomly RB None
assigned VBN None
30 CD None
senior JJ None
medical JJ None
students NNS None
used VBN None
in IN None
the DT None
first JJ None
study NN None
was VBD None
used VBN None
as IN None
novice JJ None
raters NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
cough NN Condition
associated VBN None
with IN None
captopril NN None
and CC None
enalapril NN None
. . None
10 CD Size
hypertensive JJ Condition
patients NNS None
receiving VBG None
ACE NNP None
inhibitors NNS None
. . None
Of IN None
these DT None
patients NNS None
, , None
five CD Size
had VBD None
reported VBN None
cough NN Condition
with IN None
ACE NNP None
inhibitors NNS None
. . None
BK NNP None
caused VBD None
cough NN None
at IN None
13.4 CD None
+/- JJ None
1.2 CD None
( ( None
-log NNP None
M NNP None
) ) None
in IN None
5 CD Size
patients NNS None
with IN None
cough NN None
associated VBN None
with IN None
ACE NNP None
inhibitors NNS None
, , None
but CC None
it PRP None
did VBD None
not RB None
cause VB None
cough NN None
at IN None
concentrations NNS None
up RB None
to TO None
10 CD None
( ( None
-5 NN None
) ) None
M NNP None
in IN None
other JJ None
5 CD Size
patients NNS None
. . None
5 CD Size
patients NNS None
were VBD None
free JJ None
from IN None
cough NN None
symptoms NNS None
, , None
and CC None
BK NNP None
did VBD None
not RB None
cause VB None
cough NN None
up RB None
to TO None
10 CD None
( ( None
-5 NN None
) ) None
M NNP None
in IN None
these DT None
patients NNS None
, , None
except IN None
for IN None
one CD None
who WP None
coughed VBD None
at IN None
10 CD None
( ( None
-9 NN None
) ) None
M NNP None
hypertensive JJ None
patients NNS None
receiving VBG None
ACE NNP None
inhibitors NNS None
. . None
-DOCSTART- -X- N

ten JJ Size
healthy JJ Condition
male NN Sex
volunteers NNS None
-DOCSTART- -X- N

patients NNS None
treated VBN None
in IN None
the DT None
CHART NNP None
trial NN None
of IN None
accelerated JJ None
radiotherapy NN None
in IN None
head NN None
and CC None
neck NN None
cancer NN None
. . None
402 CD None
patients NNS None
-DOCSTART- -X- N

in IN None
vitro JJ None
fertilization NN None
: : None
human JJ None
clinical JJ None
IVF NNP None
. . None
PATIENT NNP None
( ( None
S NNP None
) ) None
Infertile NNP None
couples NNS None
( ( None
n=52 NN None
) ) None
with IN None
a DT None
female JJ None
partner NN None
less JJR None
than IN None
42 CD None
years NNS None
old JJ None
with IN None
eight CD None
or CC None
more JJR None
mature JJ None
oocytes VBZ None
retrieved VBN None
. . None
total NN None
of IN None
805 CD None
mature NN None
oocytes NNS None
were VBD None
-DOCSTART- -X- N

the DT None
gambia NN None
and CC None
Tanzania NNP None
: : None
randomly RB None
selected VBN None
children NNS Age
aged VBN None
0-5 CD Age
years NNS Age
from IN None
48 CD None
Gambian JJ None
and CC None
36 CD None
Tanzanian JJ None
communities NNS None
. . None
The DT None
Gambia NNP None
Tanzania NNP None
. . None
Tanzania NNP None
were VBD None
Tanzania NNP None
were VBD None
The DT None
Gambia NNP None
, , None
The DT None
Gambia NNP None
highlights VBZ None
The DT None
Gambia NNP None
, , None
-DOCSTART- -X- N

1981-1983 JJ None
in IN None
North NNP None
Karelia NNP None
, , None
Finland NNP None
middle-aged JJ None
men NNS None
and CC None
women NNS None
in IN None
rural JJ None
or CC None
semirural JJ None
areas NNS None
and CC None
comprised VBD None
a DT None
baseline NN None
period NN None
, , None
a DT None
six CD None
week NN None
( ( None
or CC None
12 CD None
weeks NNS None
in IN None
the DT None
third JJ None
study NN None
) ) None
intervention NN None
period NN None
and CC None
a DT None
four CD None
to TO None
six CD None
week NN None
return NN None
to TO None
baseline VB None
. . None
-DOCSTART- -X- N

patients NNS None
treated VBN None
for IN None
Helicobacter NNP Condition
pylori JJ Condition
infection NN Condition
. . None
795 CD Size
adults NNS Age
with IN None
preneoplastic JJ Condition
gastric JJ Condition
lesions NNS Condition
was VBD None
randomised VBN None
to TO None
receive VB None
anti-H JJ None
pylori NN None
treatment NN None
Ninety NNP None
seven CD None
per IN None
cent NN None
of IN None
subjects NNS None
were VBD None
H NNP None
pylori JJ None
positive JJ None
at IN None
baseline NN None
, , None
and CC None
53 CD None
% NN None
were VBD None
positive JJ None
at IN None
12 CD None
years NNS None
. . None
patients NNS None
with IN None
preneoplastic JJ Condition
gastric JJ Condition
lesions NNS Condition
-DOCSTART- -X- N

human JJ Condition
circulation NN Condition
. . None
Twenty NNP Size
healthy JJ None
subjects NNS None
participated VBN None
-DOCSTART- -X- N

X-linked JJ None
retinitis NN None
pigmentosa NN None
: : None
patients NNS None
with IN None
X-linked JJ None
retinitis NN None
pigmentosa NN None
( ( None
XLRP NNP None
) ) None
Males NNP None
( ( None
n JJ None
= VBZ None
78 CD None
; : None
7-31 CD None
years NNS None
) ) None
meeting NN None
entry NN None
criteria NNS None
were VBD None
enrolled VBN None
. . None
patients NNS None
with IN None
XLRP NNP None
was VBD None
-DOCSTART- -X- N

Forty NNP None
human JJ None
third JJ None
molars NNS None
-DOCSTART- -X- N

Fifty-nine NNP None
episodes NNS None
of IN None
atrial JJ Condition
flutter NN Condition
in IN None
54 CD Size
patients NNS None
who WP None
failed VBD None
to TO None
terminate VB None
with IN None
an DT None
intravenous JJ None
infusion NN None
of IN None
ibutilide NN None
, , None
procainamide NN None
, , None
or CC None
placebo VB None
alone JJ None
underwent JJ None
attempts NNS None
at IN None
pacing VBG None
termination NN None
using VBG None
a DT None
standard JJ None
protocol NN None
of IN None
burst JJ None
atrial JJ None
overdrive JJ None
pacing NN None
. . None
-DOCSTART- -X- N

A DT None
limited JJ None
sampling NN None
method NN None
for IN None
the DT None
estimation NN None
epileptic JJ Condition
patients NNS Condition
who WP None
were VBD None
receiving VBG Condition
phenytoin NN Condition
or CC Condition
carbamazepine NN Condition
or CC Condition
both DT Condition
30 CD None
, , None
20 CD None
, , None
15 CD None
, , None
or CC None
10 CD None
patients NNS None
at IN None
one CD None
or CC None
two CD None
time NN None
points NNS None
. . None
64 CD Size
patients NNS None
-DOCSTART- -X- N

six CD Size
healthy JJ None
female NN Sex
volunteers NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
stable JJ None
angina NNS None
and CC None
angiographically RB None
proven JJ None
relevant JJ None
coronary JJ None
stenosis NN None
i.v NN None
. . None
application NN None
of IN None
0.75 CD None
mg/kg NN None
-DOCSTART- -X- N

participants NNS None
undertook VBP None
an DT None
active JJ None
object NN Condition
location NN Condition
memory NN Condition
task NN Condition
within IN None
a DT None
virtual JJ None
house NN None
in IN None
which WDT None
each DT None
room NN None
was VBD None
associated VBN None
with IN None
a DT None
different JJ None
schedule NN None
of IN None
task-irrelevant JJ None
emotional JJ None
events NNS None
. . None
participants NNS None
participants NNS None
-DOCSTART- -X- N

caesarean JJ None
section NN None
in IN None
severe JJ None
pre-eclampsia NN None
. . None
patients NNS None
undergoing VBG None
Caesarean JJ None
section NN None
, , None
either CC None
enflurane NN None
( ( None
mean JJ None
0.24 CD None
MAC-h NN None
) ) None
or CC None
halothane NN None
( ( None
mean JJ None
0.23 CD None
MAC-h NN None
) ) None
and CC None
50 CD None
% NN None
nitrous JJ None
oxide NN None
in IN None
oxygen NN None
women NNS None
( ( None
n JJ None
= NNP None
12 CD None
) ) None
with IN None
severe JJ None
pre-eclampsia-eclampsia NN None
and CC None
to TO None
16 CD None
healthy JJ None
pregnant JJ None
patients NNS None
with IN None
normal JJ None
renal JJ None
and CC None
hepatic JJ None
function NN None
. . None
In IN None
patients NNS None
with IN None
severe JJ None
pre-eclampsia NN None
-DOCSTART- -X- N

anemic JJ Condition
cancer NN Condition
patients NNS Condition
on IN Condition
combination NN Condition
chemotherapy NN Condition
. . None
Patients NNPS None
with IN None
advanced JJ None
cancer NN None
frequently RB None
experience VBZ None
clinically RB None
significant JJ None
anemia NN None
cancer NN None
patients NNS None
. . None
patients NNS None
with IN None
advanced JJ None
cancer NN None
who WP None
were VBD None
receiving VBG None
myelosuppressive JJ None
chemotherapy NN None
( ( None
excluding VBG None
cisplatin NN None
) ) None
. . None
153 CD Size
anemic JJ None
cancer NN None
patients NNS None
receiving VBG Condition
cyclic JJ Condition
combination NN Condition
chemotherapy NN Condition
patients NNS None
rHuEPO-treated JJ Condition
group NN None
placebo-treated JJ Condition
group NN None
rHuEPO-treated JJ None
patients NNS None
placebo-treated JJ None
patients NNS None
rHuEPO-treated JJ None
patients NNS None
rHuEPO-treated JJ None
group NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
subclinical JJ Condition
hypothyroidism NN Condition
. . None
subclinical JJ Condition
hypothyroidism NN Condition
( ( None
SH NNP None
) ) None
SH NNP Condition
patients NNS None
. . None
42 CD Condition
patients NNS Condition
( ( None
29 CD Condition
women NNS Condition
and CC None
13 CD Condition
men NNS Condition
; : None
mean JJ None
age NN None
53.2+/-14.2 JJ Age
years NNS None
; : None
body NN None
surface JJ None
area NN None
1.76+/-0.14 JJ None
m2 NN None
) ) None
with IN None
SH NNP Condition
, , None
as IN None
judged VBN None
by IN None
elevated JJ None
serum NN None
TSH NNP None
levels NNS None
( ( None
> $ None
3.6 CD None
mIU/l NN None
; : None
range NN None
, , None
3.8-12.0 JJ None
) ) None
and CC None
normal JJ None
free JJ None
thyroid NN None
hormones NNS None
( ( None
FT4 NNP None
and CC None
FT3 NNP None
) ) None
and CC None
30 CD None
euthyroid JJ None
volunteer NN None
. . None
Subjects NNS None
with IN None
cardiac NN Condition
, , Condition
metabolic NN Condition
, , Condition
neurological JJ Condition
disease NN Condition
or CC None
any DT None
other JJ None
systemic JJ Condition
disease NN Condition
that WDT None
could MD None
affect VB None
autonomic JJ None
activity NN None
were VBD None
excluded VBN None
from IN None
the DT None
study NN None
. . None
Patients NNS None
with IN None
SH NNP Condition
Patients NNPS None
with IN None
SH NNP Condition
SH NNP Condition
patients NNS None
-DOCSTART- -X- N

upper JJ None
lobectomy NN None
-- : None
randomized VBD None
Sixty NNP None
patients NNS None
who WP None
underwent VBP None
upper JJ None
lobectomy NN None
30 CD None
patients NNS None
-DOCSTART- -X- N

granulocyte JJ None
colony-stimulating JJ None
factor NN None
therapy NN None
after IN None
autologous JJ None
blood NN None
stem NN None
cell NN None
transplantation NN None
in IN None
children NNS Age
: : None
Japanese JJ None
Cooperative NNP None
Study NNP None
Group NNP None
of IN None
PBSCT NNP None
. . None
74 CD Size
children NNS Age
who WP None
were VBD None
scheduled VBN None
to TO None
undergo VB None
high-dose JJ Condition
chemotherapy NN Condition
followed VBN None
by IN None
autologous JJ Condition
peripheral JJ Condition
blood NN Condition
stem NN Condition
cell NN Condition
transplantation NN Condition
( ( None
PBSCT NNP Condition
) ) None
The DT None
diagnosis NN None
included VBD None
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
( ( None
ALL DT None
) ) None
( ( None
n JJ None
= NNP None
27 CD Size
) ) None
, , None
neuroblastoma FW Condition
( ( None
n JJ None
= NNP None
29 CD Size
) ) None
, , None
and CC None
miscellaneous JJ None
solid JJ None
tumors NNS None
( ( None
n JJ None
= NNP None
18 CD Size
) ) None
. . None
Eligibility NNP None
criteria NNS None
included VBD None
( ( None
1 CD None
) ) None
primary NN None
PBSCT NNP None
, , None
( ( None
2 CD None
) ) None
chemotherapy-responsive JJ None
disease NN None
, , None
and CC None
( ( None
3 CD None
) ) None
collected VBN None
cell NN None
number NN None
> $ None
1 CD None
x $ None
10 CD None
( ( None
5 CD None
) ) None
colony-forming NN None
unit-granulocyte-macrophage JJ None
( ( None
CFU-GM NNP None
) ) None
/kg NN None
and CC None
> $ None
1 CD None
x $ None
10 CD None
( ( None
6 CD None
) ) None
CD34 NNP None
( ( None
+ NNP None
) ) None
cells/kg VBP None
patient NN None
's POS None
body NN None
weight NN None
. . None
11 CD Size
patients NNS None
were VBD None
excluded VBN None
due JJ None
to TO None
disease VB None
progression NN None
before IN None
PBSCT NNP None
( ( None
n JJ None
= NNP None
6 CD Size
) ) None
or CC None
a DT None
low JJ None
number NN None
of IN None
harvested JJ None
cells NNS None
( ( None
n JJ None
= NNP None
5 CD None
) ) Size
, , None
leaving VBG None
63 CD Size
patients NNS None
for IN None
analysis NN None
; : None
32 CD Size
patients NNS None
Five CD Size
patients NNS None
( ( None
two CD Size
in IN None
the DT None
treatment NN None
group NN None
and CC None
three CD Size
in IN None
the DT None
control NN None
group NN None
) ) None
were VBD None
subsequently RB None
removed VBN None
due JJ None
to TO None
protocol VB None
violations NNS None
. . None
PBSCT NNP None
. . None
G-CSF NNP None
therapy NN None
in IN None
children NNS Age
undergoing VBG None
PBSCT NNP Condition
-DOCSTART- -X- N

self-injurious JJ None
and CC None
autistic JJ None
behavior NN None
in IN None
mentally RB None
retarded JJ None
adults NNS None
. . None
SIB NNP Condition
and CC Condition
autism NN Condition
in IN None
mentally RB None
retarded JJ None
adults NNS None
. . None
Thirty-three NNP Size
mentally RB None
retarded VBD None
adults NNS Age
with IN None
autism NN None
and/or NN None
SIB NNP None
participated VBD None
in IN None
double-blind NN None
, , None
placebo-controlled JJ None
crossover NN None
studies NNS None
. . None
-DOCSTART- -X- N

foreign-born JJ Condition
adolescents NNS Age
treated VBN None
for IN None
latent JJ Condition
tuberculosis NN Condition
infection NN Condition
in IN None
Los NNP None
Angeles NNP None
. . None
Two CD None
health NN None
clinics NNS None
in IN None
Los NNP None
Angeles NNP None
County NNP None
, , None
California NNP None
. . None
foreign-born JJ Condition
adolescents NNS Age
treated VBN None
for IN None
latent JJ Condition
tuberculosis NN Condition
infection NN Condition
( ( Condition
LTBI NNP Condition
) ) Condition
. . None
A DT None
total NN None
of IN None
766 CD Size
low-income JJ Condition
adolescents NNS Age
( ( None
79 CD None
% NN None
participation NN None
rate NN None
) ) None
, , None
including VBG None
610 CD Size
foreign-born JJ Condition
, , None
were VBD None
recruited VBN None
. . None
Foreign-born JJ Condition
adolescents NNS Age
foreign-born JJ Condition
adolescents NNS Age
. . None
-DOCSTART- -X- N

young JJ None
children NNS None
with IN None
high JJ None
functioning VBG None
autism NN None
spectrum NN None
disorders NNS None
: : None
young JJ None
children NNS None
with IN None
Autism NNP None
Spectrum NNP None
Disorders NNP None
( ( None
ASD NNP None
) ) None
Eleven NNP None
5-7 JJ None
year-old JJ None
children NNS None
participated VBN None
parent NN None
reported VBD None
negativity/lability NN None
young JJ None
children NNS None
with IN None
high JJ None
functioning VBG None
ASD NNP None
-DOCSTART- -X- N

5-fluorouracil JJ None
and CC None
filtration NN None
surgery NN None
. . None
postoperative JJ None
blebs NN None
5-FU JJ None
group NN None
. . None
-DOCSTART- -X- N

Japanese JJ None
breast NN Condition
cancer NN Condition
patients NNS Condition
subgroup NN None
of IN None
postmenopausal NN None
, , None
estrogen VBP None
receptor-positive JJ None
Japanese JJ None
breast NN Condition
cancer NN Condition
patients NNS Condition
from IN None
the DT None
Pre-Operative JJ None
Arimidex NNP None
Compared NNP None
with IN None
Tamoxifen NNP None
trial NN None
Patients NNS None
with IN None
large JJ None
, , None
potentially RB None
operable JJ None
, , None
locally-advanced JJ Condition
breast NN Condition
cancer NN Condition
-DOCSTART- -X- N

irritable JJ None
bowel NN None
syndrome NN None
. . None
patients NNS None
with IN None
irritable JJ None
bowel NN None
syndrome NN None
( ( None
IBS NNP None
) ) None
IBS NNP None
patients NNS None
. . None
Patients NNPS None
with IN None
IBS NNP None
according VBG None
to TO None
the DT None
Rome NNP None
II NNP None
criteria NNS None
-DOCSTART- -X- N

spondylitis NN None
: : None
patients NNS None
with IN None
AS NNP None
. . None
Patients NNPS None
with IN None
AS NNP None
patients NNS None
who WP None
had VBD None
predominantly RB None
axial JJ None
symptoms NNS None
Twenty-six JJ None
patients NNS None
were VBD None
included VBN None
patients NNS None
with IN None
AS NNP None
. . None
-DOCSTART- -X- N

patients NNS None
suffering VBG None
from IN None
intractable JJ Condition
periorbital NN Condition
pain NN Condition
after IN None
acute JJ Condition
angle JJ Condition
closure NN Condition
glaucoma NN Condition
( ( None
AACG NNP None
) ) None
. . None
19 CD Size
patients NNS None
suffering VBG None
from IN None
periorbital JJ None
pain NN None
after IN None
an DT None
AACG NNP Condition
attack NN None
-DOCSTART- -X- N

in IN None
children NNS Age
. . None
a DT None
pediatric JJ None
intensive JJ None
care NN None
unit NN None
( ( None
PICU NNP None
) ) None
. . None
enrolled VBD None
children NNS Age
aged VBN None
28 CD Age
days NNS Age
to TO Age
4 CD Age
years NNS Age
who WP None
were VBD None
admitted VBN None
to TO None
a DT None
PICU NNP None
between IN None
October NNP None
of IN None
2005 CD None
and CC None
June NNP None
of IN None
2007 CD None
and CC None
put VB None
on IN None
mechanical JJ None
ventilation NN None
( ( None
MV NNP None
) ) None
for IN None
more JJR None
than IN None
48 CD None
hours NNS None
. . None
Children NNP Age
were VBD None
excluded VBN None
if IN None
they PRP None
had VBD None
undergone JJ None
tracheotomy NN None
or CC None
had VBD None
chronic JJ Condition
respiratory NN Condition
diseases NNS Condition
. . Condition
children NNS Age
studied VBN None
here RB None
-DOCSTART- -X- N

children NNS Age
with IN None
developmental JJ Condition
disabilities NNS Condition
. . None
children NNS Age
with IN None
developmental JJ Condition
disabilities NNS Condition
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
ambulatory JJ Condition
cosmetic JJ Condition
surgery NN Condition
. . Condition
postoperative JJ Condition
nausea NN Condition
and CC Condition
vomiting NN Condition
( ( None
PONV NNP Condition
) ) None
. . None
Academic NNP None
hospital NN None
. . None
126 CD Size
ASA NNP Condition
physical JJ Condition
status NN Condition
I PRP Condition
and CC Condition
II NNP Condition
patients NNS Condition
undergoing VBG None
outpatient JJ Condition
plastic NN Condition
surgery NN Condition
with IN None
three CD None
or CC None
more JJR None
risk NN None
factors NNS None
for IN None
PONV NNP Condition
. . None
patients NNS None
at IN None
high JJ None
risk NN None
for IN None
PONV NNP None
undergoing JJ None
outpatient NN None
plastic NN None
surgery NN None
-DOCSTART- -X- N

nursing NN Condition
home NN Condition
patients NNS Condition
: : None
nursing JJ None
home NN None
patients NNS None
. . None
624 CD Size
nursing NN None
home NN None
patients NNS None
with IN None
dementia NN Condition
, , None
446 CD Size
completed VBD None
follow-up JJ None
assessments NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
atrial JJ None
fibrillation NN None
undergoing VBG None
cardiac JJ None
surgery NN None
. . None
atrial JJ None
fibrillation NN None
( ( None
AF NNP None
) ) None
patients NNS None
One CD None
hundred CD None
and CC None
fifty JJ None
patients NNS None
with IN None
documented JJ None
AF NNP None
One CD None
hundred CD None
and CC None
thirty-two JJ None
patients NNS None
were VBD None
included VBN None
in IN None
the DT None
cost-effectiveness NN None
study NN None
. . None
-DOCSTART- -X- N

men NNS Sex
receiving VBG None
therapy NN None
for IN None
prostate NN Condition
cancer NN Condition
. . None
men NNS None
receiving VBG None
androgen NN Condition
deprivation NN Condition
for IN None
their PRP$ None
prostate NN None
cancer NN None
. . None
195 CD Size
men NNS Sex
( ( None
65 CD None
subjects NNS None
per IN None
arm NN None
) ) None
undergoing NN None
treatment NN None
for IN None
prostate NN Condition
cancer NN Condition
involving VBG Condition
ADT NNP Condition
in IN None
the DT None
cities NNS None
of IN None
Perth NNP None
and CC None
Brisbane NNP None
in IN None
Australia NNP None
. . None
-DOCSTART- -X- N

diabetic JJ None
gastroparesis NN Condition
. . None
seven CD Size
diabetic JJ Condition
patients NNS None
with IN None
medically RB Condition
refractory JJ Condition
gastroparesis NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
multiple JJ Condition
sclerosis NN Condition
. . None
24 CD Size
patients NNS None
with IN None
clinically RB None
definite JJ None
multiple JJ Condition
sclerosis NN Condition
and CC None
in IN None
36 CD Size
healthy JJ Condition
control NN Condition
subjects NNS None
. . None
-DOCSTART- -X- N

eroded JJ Condition
root NN Condition
dentine NN Condition
acid-eroded JJ Condition
dentine NN Condition
One-hundred JJ Size
and CC Size
twenty JJ Size
bovine NN Size
root NN Size
dentine NN Size
slabs NN Size
10 CD Size
volunteers NNS None
-DOCSTART- -X- N

pediatric JJ None
obesity NN Condition
. . None
Obese JJ Condition
children NNS None
-DOCSTART- -X- N

paediatric JJ Condition
tonsillectomy NN Condition
. . None
forty-two JJ Size
children NNS Age
scheduled VBN None
for IN None
elective JJ None
adenotonsillectomy NN None
children NNS Age
children NNS Age
having VBG None
tonsillectomy NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
heart NN Condition
failure NN Condition
] NNP None
patients NNS None
with IN None
chronic JJ Condition
heart NN Condition
failure NN Condition
( ( Condition
CHF NNP Condition
) ) Condition
. . None
52 CD Size
male JJ Sex
patients NNS None
with IN None
postinfarction NN None
cardiosclerosis NN None
( ( None
PICS NNP None
) ) None
who WP None
have VBP None
developed VBN None
CHF NNP Condition
have VBP None
been VBN None
observed VBN None
. . None
The DT None
age NN None
of IN None
the DT None
patients NNS None
varied VBD None
from IN None
38 CD Age
till NN Age
60 CD Age
. . None
CHF NNP Condition
patients NNS None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS Condition
. . Condition
Twenty CD Size
volunteers NNS None
were VBD None
given VBN None
single JJ None
doses NNS None
of IN None
fluoxetine JJ None
20 CD None
mg NN None
or CC None
an DT None
identical JJ None
placebo NN None
daily RB None
for IN None
28 CD None
days NNS None
prior RB None
to TO None
receiving VBG None
a DT None
single JJ None
10 CD None
mg JJ None
oral JJ None
dose NN None
of IN None
zolmitriptan NN None
. . None
Sixteen JJ Size
volunteers NNS None
completed VBD None
the DT None
two CD None
treatment NN None
phases NNS None
. . None
patients NNS None
treated VBN None
concurrently RB None
with IN None
selective JJ None
serotonin NNS Condition
reuptake VBP Condition
inhibitors NNS Condition
-DOCSTART- -X- N

traumatic JJ None
brain NN None
injury NN None
: : None
patients NNS None
with IN None
traumatic JJ None
brain NN None
injury NN None
and CC None
raised VBD None
intracranial JJ None
pressure NN None
that WDT None
does VBZ None
not RB None
respond VB None
to TO None
initial JJ None
treatment NN None
measures NNS None
. . None
-DOCSTART- -X- N

childhood NN Age
hemolytic-uremic JJ None
syndrome NN None
: : None
1976 CD None
to TO None
1985 CD None
, , None
a DT None
total NN None
of IN None
58 CD Size
infants NNS Age
and CC Age
children NNS Age
with IN None
the DT None
hemolytic-uremic JJ Condition
syndrome NN Condition
childhood NN Condition
hemolytic-uremic JJ Condition
syndrome NN Condition
. . None
-DOCSTART- -X- N

[ NNP None
Medical NNP Condition
safety NN Condition
and CC None
staff NN None
mental JJ None
health NN None
] NNP None
nurses NNS Condition
with IN Condition
rapidly RB Condition
rotating VBG Condition
shifts NNS Condition
. . None
night-shift JJ None
workers NNS None
. . None
-DOCSTART- -X- N

aspirin-treated JJ Condition
patients NNS Condition
during IN None
and CC None
after IN None
cardiopulmonary JJ Condition
bypass NN Condition
. . None
aspirin-treated JJ Condition
patients NNS Condition
40 CD None
patients NNS None
undergoing JJ Condition
coronary JJ Condition
artery NN Condition
bypass NN Condition
grafting NN Condition
. . None
aspirin-treated JJ None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
illness NN Condition
. . None
heterogeneous JJ None
cohort NN None
of IN None
patients NNS None
with IN None
chronic JJ Condition
illness NN Condition
initially RB None
exposed VBD None
to TO None
a DT None
multidisciplinary JJ None
, , None
home-based JJ None
intervention NN None
( ( None
HBI NNP None
) ) None
( ( None
n JJ None
= NNP None
260 CD None
) ) None
or CC None
to TO None
usual JJ None
postdischarge NN None
care NN None
( ( None
n JJ None
= NNP None
268 CD None
) ) None
. . None
patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
-DOCSTART- -X- N

subjects NNS None
with IN None
inflammatory JJ None
arthritis NN None
. . None
15 CD Condition
subjects NNS Condition
with IN Condition
inflammatory JJ Condition
arthritis NN Condition
( ( Condition
14 CD Condition
with IN Condition
rheumatoid JJ Condition
arthritis NN Condition
and CC Condition
1 CD Condition
with IN Condition
ankylosing VBG Condition
spondylitis NN Condition
) ) Condition
not RB Condition
receiving VBG Condition
tumour JJ Condition
necrosis NN Condition
factor NN Condition
alpha NN Condition
( ( Condition
TNFalpha NNP Condition
) ) Condition
inhibitors NNS Condition
with IN Condition
persistent JJ Condition
moderate NN Condition
( ( Condition
grade JJ Condition
2 CD Condition
) ) Condition
or CC Condition
severe JJ Condition
( ( Condition
grade JJ Condition
3 CD Condition
) ) Condition
swelling NN Condition
in IN Condition
a DT Condition
target NN Condition
joint NN Condition
due JJ Condition
to TO Condition
inflammatory JJ Condition
arthritis NN Condition
patients NNS None
with IN None
inflammatory JJ None
arthritis NN None
. . None
-DOCSTART- -X- N

Adults NNP Age
with IN None
uncomplicated JJ None
acute NN Condition
appendicitis NN Condition
The DT None
trial NN None
was VBD None
planned VBN None
for IN None
150 CD None
patients NNS None
, , None
but CC None
was VBD None
halted VBN None
after IN None
75 CD Condition
patients NNS None
when WRB None
planned VBN None
interim NN None
analysis NN None
showed VBD None
that IN None
SILS NNP None
patients NNS None
had VBD None
more RBR None
postoperative JJ Condition
pain NN Condition
-DOCSTART- -X- N

brucellosis NN None
. . None
Forty JJ None
patients NNS None
were VBD None
diagnosed VBN None
with IN None
brucellosis NN None
based VBN None
on IN None
clinical JJ None
and CC None
microbiological JJ None
findings NNS None
. . None
-DOCSTART- -X- N

burned JJ Condition
patients NNS Condition
with IN None
sepsis NN Condition
. . None
severely RB Condition
burned VBN Condition
patients NNS Condition
with IN None
sepsis NN Condition
. . None
Twenty NNP Size
adult NN None
severely RB Condition
burned VBD Condition
patients NNS Condition
with IN Condition
sepsis NN Condition
were VBD None
studied VBN None
. . None
-DOCSTART- -X- N

human JJ None
atherosclerosis NN Condition
: : None
atherosclerotic JJ Condition
disease NN Condition
. . None
human JJ None
atherosclerosis NN Condition
. . None
biobank NN None
of IN None
aortic JJ Condition
wall NN Condition
samples NNS None
from IN None
organ JJ None
donors NNS None
. . None
in IN None
patients NNS None
with IN None
symptomatic JJ None
peripheral JJ None
artery NN None
disease NN None
. . None
for IN None
progressive JJ None
human JJ None
atherosclerotic JJ None
disease NN None
. . None
-DOCSTART- -X- N

spinal JJ Condition
anesthesia NN Condition
. . None
Sixty CD None
patients NNS None
undergoing JJ None
ambulatory JJ None
anterior JJ None
cruciate NN None
ligament NN None
repair NN None
of IN None
the DT None
knee NN None
under IN None
spinal JJ Condition
anesthesia NN Condition
were VBD None
randomized VBN None
into IN None
two CD None
groups NNS None
; : None
Group NNP None
1 CD None
Group NNP None
2 CD None
-DOCSTART- -X- N

oxidation NN None
in IN None
subjects NNS None
with IN None
impaired JJ Condition
glucose JJ Condition
tolerance NN Condition
. . None
29 CD Size
subjects NNS None
with IN None
impaired JJ None
glucose JJ None
tolerance NN None
. . None
subjects NNS None
with IN None
impaired JJ None
glucose JJ None
tolerance NN None
-DOCSTART- -X- N

epistaxis VBP Condition
. . None
Subjects NNPS None
comprised VBD None
131 CD Size
adult NN Age
patients NNS None
who WP Condition
under-went JJ Condition
NTI NNP Condition
. . None
Subjects NNS None
were VBD None
randomly RB None
divided VBN None
into IN None
two CD None
groups NNS None
: : None
a DT None
) ) None
NTI NNP None
under IN None
CTSC NNP None
guidance NN None
( ( None
G NNP None
[ NNP None
+ NNP None
] NNP None
group NN None
) ) None
epistaxis NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ None
heart NN None
failure NN None
patients NNS None
with IN None
chronic JJ None
heart NN None
failure NN None
( ( None
CHF NNP None
) ) None
patients NNS None
with IN None
CHF NNP None
. . None
Patients NNPS None
with IN None
stable JJ None
CHF NNP None
( ( None
NYHA NNP None
II/III NNP None
; : None
59 CD None
( ( None
11 CD None
) ) None
years NNS None
) ) None
-DOCSTART- -X- N

white JJ None
spot NN None
lesions NNS None
( ( None
WSL NNP None
) ) None
. . None
26 CD None
healthy JJ None
adolescents NNS None
( ( None
mean JJ None
age NN None
14.6 CD None
years NNS None
) ) None
exhibiting VBG None
60 CD None
teeth NNS None
with IN None
152 CD None
visible JJ None
WSL NNP None
sites NNS None
on IN None
incisors NNS None
and CC None
canines NNS None
immediately RB None
after IN None
debonding VBG None
of IN None
fixed VBN None
orthodontic JJ None
appliances NNS None
. . None
-DOCSTART- -X- N

hypertension NN Condition
hypertensive JJ Condition
patients NNS None
-DOCSTART- -X- N

Half PDT None
the DT None
subjects NNS None
were VBD None
instructed VBN None
not RB Condition
to TO Condition
blink VB Condition
-DOCSTART- -X- N

race-discordant JJ None
patient-provider JJ None
African JJ None
American JJ None
patients NNS None
and CC None
white JJ None
health NN None
care NN None
providers NNS None
99 CD Size
African JJ None
American JJ None
patients NNS None
with IN None
hypertension NN Condition
-DOCSTART- -X- N

asthma NN None
. . None
12 CD None
nonsmoking VBG None
atopic NN None
asthmatic JJ None
subjects NNS None
( ( None
three CD None
women NNS None
, , None
nine CD None
men NNS None
; : None
21 CD None
to TO None
29 CD None
yr NN None
of IN None
age NN None
; : None
FEV1 NNP None
, , None
74 CD None
to TO None
120 CD None
% NN None
pred VBD None
; : None
PC20FEV1 NNP None
methacholine VBP None
< $ None
9.6 CD None
mg/ml NN None
) ) None
-DOCSTART- -X- N

for IN None
patients NNS None
with IN None
noncuratively RB Condition
resected VBN Condition
colorectal JJ Condition
carcinoma NN Condition
54 CD Size
institutions NNS None
in IN None
the DT None
Kyushu NNP None
and CC None
Chugoku NNP None
areas NNS None
of IN None
Japan NNP None
. . None
The DT None
criteria NNS None
for IN None
patient JJ None
selection NN None
were VBD None
as IN None
follows VBZ None
: : None
1 CD None
) ) None
Age NNP Age
of IN Age
75 CD Age
years NNS None
or CC None
less JJR None
and CC None
not RB None
accompanied VBN None
by IN None
any DT None
serious JJ None
disease NN None
. . None
2 CD None
) ) None
Macroscopic NNP None
diagnosis NN None
as IN None
being VBG None
noncuratively RB None
resected VBN None
on IN None
completion NN None
of IN None
the DT None
surgical JJ None
procedure NN None
. . None
3 CD None
) ) None
Definitive JJ None
diagnosis NN None
of IN None
colorectal JJ None
carcinomas NN None
, , None
histologically RB None
. . None
4 CD None
) ) None
No DT None
synchronous JJ None
or CC None
metachronous JJ None
double JJ None
cancer NN None
. . None
MMC NNP None
group NN None
-DOCSTART- -X- N

persistent JJ None
insomnia NN Condition
in IN None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
sleep JJ None
disorders NNS None
in IN None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
One CD Size
hundred CD Size
and CC Size
sixty JJ Size
children NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
, , None
aged VBN Age
4-10 CD Age
years NNS Age
, , None
suffering VBG None
from IN None
sleep JJ Condition
onset NN Condition
insomnia NN Condition
and CC Condition
impaired JJ Condition
sleep JJ Condition
maintenance NN Condition
-DOCSTART- -X- N

young JJ Age
children NNS Age
with IN None
autism NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . None
Forty-eight JJ None
18- JJ None
to TO None
30-month-old JJ None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
Age-matched JJ None
typical JJ None
children NNS None
young JJ None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
. . None
-DOCSTART- -X- N

infants NNS Age
with IN None
Down NNP Condition
syndrome NN Condition
. . None
infants NNS Age
with IN None
Down NNP Condition
syndrome NN Condition
( ( None
DS NNP Condition
) ) None
. . None
The DT None
first JJ None
cohort NN None
included VBD None
30 CD Size
infants NNS Age
with IN None
DS NNP Condition
( ( None
17 CD Size
males NNS Sex
, , None
13 CD Size
females NNS Sex
; : None
mean JJ None
age NN None
10 CD Age
mo NN Age
[ NNP None
SD NNP None
1.9 CD None
mo NN None
] NN None
) ) None
A DT None
control NN Condition
( ( Condition
C NNP Condition
) ) Condition
group NN Condition
from IN None
another DT None
study NN None
, , None
who WP None
did VBD None
not RB None
receive VB None
treadmill NN None
training NN None
, , None
served VBD None
as IN None
the DT None
control NN None
( ( None
eight CD Size
males NNS Sex
, , None
seven CD Size
females NNS Sex
; : None
mean JJ None
age NN None
10.4 CD Age
mo NN Age
[ NNP None
SD NNP None
2.2 CD None
mo NN None
] NN None
) ) None
. . None
infants NNS Age
with IN None
DS NNP Condition
. . None
-DOCSTART- -X- N

Graves NNP Condition
' POS Condition
disease NN Condition
This DT None
study NN None
was VBD None
carried VBN None
out RP None
on IN None
55 CD Size
patients NNS None
, , None
who WP None
were VBD None
either RB None
treated VBN None
for IN None
six CD None
( ( None
n JJ None
= NNP None
16 CD None
) ) None
or CC None
18 CD None
months NNS None
( ( None
n JJ None
= NNP None
39 CD None
) ) None
and CC None
followed VBD None
up RP None
for IN None
an DT None
additional JJ None
two-year JJ None
period NN None
. . None
TSAb NNP None
was VBD None
determined VBN None
on IN None
whole JJ None
serum NN None
in IN None
29 CD Size
patients NNS None
before IN None
and CC None
at IN None
the DT None
end NN None
of IN None
treatment NN None
, , None
and CC None
in IN None
26 CD Size
patients NNS None
at IN None
the DT None
end NN None
of IN None
treatment NN None
only RB None
. . None
TSAb NNP None
determined VBD None
again RB None
during IN None
follow-up NN None
was VBD None
negative JJ None
in IN None
each DT None
of IN None
the DT None
18 CD Size
patients NNS None
in IN Condition
remission NN Condition
, , None
and CC None
positive JJ None
in IN None
8/10 CD Size
patients NNS None
at IN None
the DT None
time NN None
of IN None
relapse NN Condition
, , None
whatever WDT None
its PRP$ None
level NN None
at IN None
the DT None
end NN None
of IN None
the DT None
drug NN None
course NN None
. . None
-DOCSTART- -X- N

knee NN Condition
osteoarthritis NN Condition
( ( Condition
KOA NNP Condition
, , Condition
Bi NNP Condition
syndrome NN Condition
of IN Condition
knee NN Condition
) ) Condition
Totally RB None
61 CD Size
patients NNS None
with IN None
grade NN Condition
I PRP Condition
to TO Condition
III NNP Condition
KOA NNP Condition
-DOCSTART- -X- N

patients NNS None
with IN None
breast JJ Condition
cancer NN Condition
metastatic NN None
to TO None
bone NN None
: : None
breast NN Condition
cancer NN Condition
patients NNS None
with IN None
newly RB None
diagnosed VBN None
bone NN Condition
metastases NNS Condition
. . None
Patients NNS None
diagnosed VBD None
with IN None
bone NN Condition
metastases NNS Condition
< VBP None
or CC None
= VBP None
6 CD None
weeks NNS None
prior RB None
to TO None
first JJ None
visit NN None
312 CD Size
patients NNS None
enrolled VBD None
Breast NNP Condition
cancer NN Condition
patients NNS None
with IN None
newly RB None
diagnosed VBN None
bone NN Condition
metastases NNS Condition
-DOCSTART- -X- N

outpatient JJ None
burn NN None
dressing VBG None
. . None
outpatient NN None
burns NNS None
. . None
two CD None
treatment NN None
groups NNS None
were VBD None
closely RB None
matched VBN None
in IN None
age NN None
, , None
sex NN None
, , None
per IN None
cent NN None
of IN None
BSA NNP None
burned VBD None
, , None
and CC None
in IN None
burn JJ None
severity NN None
and CC None
locations NNS None
. . None
outpatient NN None
burns NNS None
-DOCSTART- -X- N

Seventy-six JJ None
patients NNS None
with IN None
esophageal JJ None
gastric JJ None
carcinoma NN None
FZYLG NNP None
group NN None
control NN None
group NN None
. . None
-DOCSTART- -X- N

somatic JJ None
pain NN None
and CC None
temporal JJ None
summation NN None
. . None
20 CD Size
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

neonatal JJ Condition
resuscitation NN Condition
protocol-helping JJ Condition
babies NNS Condition
breathe VBP Condition
at IN Condition
birth NN Condition
Nepal NNP None
low JJ None
and CC None
middle JJ None
income NN None
countries NNS None
tertiary JJ None
hospital NN None
in IN None
Nepal NNP None
. . None
skilled JJ None
birth NN None
attendants NNS None
tertiary JJ None
level NN None
maternity NN None
hospital NN None
in IN None
Nepal NNP None
. . None
-DOCSTART- -X- N

University NNP None
Hospital NNP None
. . None
35 CD None
patients NNS None
with IN None
chronic JJ None
stable JJ None
coronary JJ None
artery NN None
disease NN None
. . None
patients NNS None
with IN None
chronic JJ None
coronary JJ None
artery NN None
disease NN None
. . None
-DOCSTART- -X- N

duodenal JJ Condition
ulcer JJ Condition
Ninety-seven JJ Size
patients NNS None
received VBD None
rioprostil JJ None
, , None
600 CD None
micrograms NNS None
once-daily RB None
orally RB None
, , None
and CC None
110 CD Size
patients NNS None
received JJ None
ranitidine NN None
-DOCSTART- -X- N

patients NNS None
on IN None
thyroid JJ Condition
hormone NN Condition
replacement NN Condition
. . None
697 CD Size
patients NNS None
on IN None
thyroid JJ None
hormone NN None
replacement NN None
therapy NN None
at IN None
entry NN None
to TO None
a DT None
randomized VBN None
, , None
controlled VBD None
trial NN None
of IN None
combined JJ None
T NNP None
( ( None
4 CD None
) ) None
and CC None
T NNP None
( ( None
3 CD None
) ) None
replacement NN None
therapy NN None
. . None
All DT None
patients NNS None
were VBD None
on IN None
100 CD None
mug NN None
or CC None
more JJR None
T NNP None
( ( None
4 CD None
) ) None
. . None
treated JJ None
hypothyroid NN Condition
patients NNS None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
nosocomial JJ Condition
pneumonia NN Condition
: : None
intubated JJ Condition
and CC Condition
mechanically RB Condition
ventilated JJ Condition
patients NNS Condition
with IN None
nosocomial JJ Condition
pneumonia NN Condition
. . None
Thirty-eight NNP Size
mechanically RB Condition
ventilated VBD Condition
patients NNS Condition
with IN Condition
documented JJ Condition
nosocomial JJ Condition
pneumonia NN Condition
were VBD None
included VBN None
. . None
Respiratory NNP None
tolerance NN None
was VBD None
good JJ None
in IN None
all DT None
but CC None
two CD None
patients NNS None
. . None
ventilated JJ Condition
patients NNS Condition
with IN Condition
documented JJ Condition
nosocomial JJ Condition
pneumonia NN Condition
. . None
-DOCSTART- -X- N

Neurosurgical JJ None
unit NN None
and CC None
haematology NN None
ward NN None
of IN None
university NN None
hospital NN None
. . None
100 CD Size
neurosurgical JJ None
patients NNS None
and CC None
40 CD Size
patients NNS None
with IN None
leukaemia NNS Condition
who WP None
required VBD None
chemotherapy NN None
. . None
-DOCSTART- -X- N

prostate NN None
cancer NN None
. . None
patients NNS None
with IN None
high-risk JJ None
prostate NN None
cancer NN None
. . None
Between NNP None
January NNP None
2003 CD None
and CC None
December NNP None
2007 CD None
, , None
168 CD None
patients NNS None
All DT None
patients NNS None
had VBD None
undergone RP None
a DT None
9-month JJ None
course NN None
of IN None
total JJ None
androgen NN None
deprivation NN None
, , None
with IN None
radiotherapy NN None
starting VBG None
2 CD None
months NNS None
after IN None
initiation NN None
of IN None
the DT None
total JJ None
androgen NN None
deprivation NN None
. . None
-DOCSTART- -X- N

metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
. . Condition
patients NNS None
with IN None
metastatic JJ Condition
colorectal NN Condition
cancer NN Condition
( ( Condition
mCRC NN Condition
) ) Condition
17 CD None
polymorphisms NNS None
in IN None
genes NNS None
encoding VBG None
drug NN None
targets NNS None
, , None
pathway NN None
molecules NNS None
and CC None
detoxification NN None
enzymes NNS None
was VBD None
analyzed VBN None
in IN None
279 CD Size
previously RB Condition
untreated JJ Condition
mCRC NN Condition
patients NNS None
treated VBN None
with IN None
capecitabine NN None
, , None
oxaliplatin NN None
and CC None
bevacizumab NN None
( ( None
CAPOX-B NNP None
) ) None
. . None
mCRC NN Condition
patients NNS None
. . None
-DOCSTART- -X- N

advanced JJ None
laryngeal NN None
and CC None
hypopharyngeal NN None
squamous JJ None
carcinoma NN None
. . None
Two CD None
hundred VBD None
and CC None
twelve JJ None
patients NNS None
with IN None
previously RB Condition
untreated VBN Condition
advanced JJ Condition
squamous JJ Condition
carcinoma NN Condition
of IN Condition
the DT Condition
larynx NN Condition
or CC Condition
hypopharynx NN Condition
Two CD None
hundred VBD None
and CC None
nine CD None
of IN None
the DT None
212 CD None
patients NNS None
randomized VBN None
were VBD None
included VBN None
in IN None
the DT None
analyses NNS None
. . None
-DOCSTART- -X- N

infantile JJ Condition
autism NN Condition
: : None
infantile JJ Condition
autism NN Condition
. . None
9 CD Size
children NNS Age
with IN None
autism NN Condition
, , None
likely RB None
severely RB None
mentally RB Condition
retarded JJ Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
diabetic JJ Condition
polyneuropathy NN Condition
: : None
patients NNS None
with IN None
diabetic JJ Condition
polyneuropathy NN Condition
. . None
Eighty-four JJ None
outpatient NN None
centers NNS None
throughout IN None
the DT None
United NNP None
States NNPS None
. . None
A DT None
total NN None
of IN None
1019 CD Size
men NNS Sex
and CC None
women NNS Sex
aged VBD None
18 CD Age
to TO Age
74 CD Age
years NNS None
with IN None
either DT None
type NN Condition
1 CD Condition
or CC Condition
type VB Condition
2 CD Condition
diabetes NNS Condition
and CC None
a DT None
sensory JJ Condition
polyneuropathy NN Condition
attributable JJ None
to TO None
diabetes NNS Condition
. . None
-DOCSTART- -X- N

African JJ None
Americans NNPS None
: : None
African JJ None
Americans NNPS None
have VBP None
a DT None
disproportionate JJ None
burden NN None
of IN None
inflammation-associated JJ None
chronic JJ None
diseases NNS None
328 CD None
African JJ None
Americans NNPS None
( ( None
median JJ None
age NN None
, , None
51 CD None
years NNS None
) ) None
of IN None
public JJ None
housing NN None
communities NNS None
in IN None
Boston NNP None
, , None
MA NNP None
, , None
who WP None
were VBD None
enrolled VBN None
over RP None
three CD None
consecutive JJ None
winter NN None
periods NNS None
( ( None
2007-2010 JJ None
) ) None
. . None
of IN None
cancer NN None
health NN None
disparities NNS None
in IN None
African JJ None
Americans NNPS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
mild-to-moderately-active JJ None
ulcerative JJ Condition
colitis NN Condition
: : None
multicenter NN None
study NN None
patients NNS None
with IN None
symptoms NNS None
of IN None
acute JJ Condition
UC NNP Condition
and CC None
a DT None
baseline NN None
Modified NNP None
Mayo NNP None
Disease NNP None
Activity NNP None
Index NNP None
( ( None
MMDAI NNP None
) ) None
score NN None
between IN None
6 CD None
and CC None
10 CD None
, , None
inclusive JJ None
, , None
with IN None
a DT None
subscale JJ None
rating NN None
of IN None
> NNP None
or CC None
=2 NN None
for IN None
both DT None
rectal JJ None
bleeding NN None
and CC None
mucosal JJ None
appearance NN None
A DT None
total NN None
of IN None
249 CD Size
patients NNS None
( ( None
166 CD Size
balsalazide NN None
, , None
83 CD Size
placebo NN None
) ) None
patients NNS None
with IN None
active JJ Condition
UC NNP Condition
. . None
-DOCSTART- -X- N

post-operative JJ None
pain NN None
management NN None
. . None
Thirty-eight NNP None
patients NNS None
with IN None
post-operative JJ None
pain NN None
following VBG None
hip NN None
replacement NN None
surgery NN None
-DOCSTART- -X- N

anastomotic JJ Condition
bleeding NN Condition
during IN None
aortic JJ None
reconstruction NN None
: : None
managing VBG None
anastomotic JJ Condition
bleeding NN Condition
after IN None
implantation NN None
of IN None
Dacron NNP None
grafts NNS None
during IN None
aortic JJ None
reconstruction NN None
for IN None
nonruptured JJ Condition
aneurysms NNS Condition
. . None
37 CD Size
experimental JJ None
( ( None
59 CD None
sites NNS None
) ) None
and CC None
17 CD Size
control NN None
subjects NNS None
( ( None
27 CD None
sites NNS None
) ) None
. . None
intraoperative JJ None
management NN None
of IN None
anastomotic JJ Condition
bleeding NN Condition
during IN None
aortic JJ None
reconstruction NN None
procedures NNS None
. . None
-DOCSTART- -X- N

influenza NN None
A NNP None
, , None
Parkinson NNP None
's POS None
disease NN None
( ( None
PD NNP None
) ) None
, , None
and CC None
acute NN None
or CC None
chronic JJ None
drug-induced JJ None
dyskinesia NN None
. . None
normal JJ Condition
subjects NNS None
. . None
14 CD Condition
healthy JJ Condition
subjects NNS None
-DOCSTART- -X- N

primary JJ Condition
open-angle JJ Condition
glaucoma NN Condition
. . None
eyes NNS Condition
with IN Condition
open-angle JJ Condition
glaucoma NN Condition
. . None
A NNP None
total NN None
of IN None
90 CD Size
eyes NNS Size
of IN Size
90 CD Size
patients NNS Size
with IN None
primary JJ Condition
open-angle JJ Condition
glaucoma NN Condition
or CC Condition
pseudoexfoliative JJ Condition
glaucoma NN Condition
underwent JJ None
deep JJ None
sclerectomy NN None
. . None
-DOCSTART- -X- N

advanced JJ Condition
nasopharyngeal JJ Condition
carcinoma NN Condition
Nasopharyngeal NNP Condition
carcinoma NN Condition
( ( Condition
NPC NNP Condition
) ) Condition
patients NNS None
with IN None
advanced JJ Condition
NPC NNP Condition
From NNP None
December NNP None
1993 CD None
to TO None
April NNP None
1999 CD None
, , None
284 CD Size
patients NNS None
with IN None
1992 CD None
American NNP None
Joint NNP None
Committee NNP None
on IN None
Cancer NNP Condition
stage NN Condition
III NNP Condition
to TO Condition
IV NNP Condition
( ( Condition
M0 NNP Condition
) ) Condition
NPC NNP Condition
patients NNS None
with IN None
advanced JJ Condition
NPC NNP Condition
-DOCSTART- -X- N

elderly JJ None
patients NNS None
with IN None
heart NN None
failure NN None
. . None
elderly JJ None
patients NNS None
with IN None
heart NN None
failure NN None
. . None
at IN None
a DT None
single JJ None
centre NN None
patients NNS None
being VBG None
selected VBN None
for IN None
inclusion NN None
from IN None
the DT None
outpatient JJ None
population NN None
. . None
Sixty-one CD None
patients NNS None
-DOCSTART- -X- N

Nineteen JJ Size
ragweed-sensitive JJ Condition
patients NNS None
were VBD Condition
randomized VBN Condition
into IN Condition
2 CD Condition
groups NNS Condition
; : Condition
10 CD Size
received VBD None
the DT None
polymerized JJ None
form NN None
and CC Condition
9 CD Size
received VBD None
the DT None
monomeric JJ None
form NN None
. . Condition
-DOCSTART- -X- N

disability NN None
: : None
vocational JJ None
rehabilitation NN None
( ( None
VR NNP None
) ) None
clients NNS None
. . None
people NNS None
with IN None
disabilities NNS None
. . None
A NNP None
total NN None
of IN None
297 CD None
VR NNP None
clients NNS None
participated VBD None
in IN None
a DT None
randomized JJ None
trial NN None
VR NNP None
clients NNS None
with IN None
higher JJR None
rates NNS None
of IN None
secondary JJ None
health NN None
conditions NNS None
-DOCSTART- -X- N

Pruritus NNP Condition
in IN None
HIV-1+ NNP Condition
patients NNS None
patients NNS None
on IN None
four CD None
different JJ None
forms NNS None
of IN None
therapy NN None
for IN None
their PRP$ None
pruritus NN Condition
. . None
Patients NNS None
on IN None
pentoxifylline NN None
-DOCSTART- -X- N

competitive JJ None
athletes NNS None
Twenty NNP None
young JJ None
, , None
active JJ None
men NNS None
( ( None
mean JJ None
age NN None
26.2 CD None
? . None
2.1 CD None
years NNS None
) ) None
-DOCSTART- -X- N

early JJ None
peripheral JJ None
facial JJ None
paralysis NN None
] NN None
peripheral JJ None
facial JJ None
paralysis NN None
. . None
Fifty-two JJ None
cases NNS None
facial JJ None
paralysis NN None
. . None
-DOCSTART- -X- N

Investigation NN None
of IN None
maxillary JJ None
tooth NN None
sizes NNS None
in IN None
patients NNS None
with IN None
palatal JJ None
canine NN None
displacement NN None
. . None
patients NNS None
with IN None
and CC None
without IN None
palatal JJ None
canine NN None
displacement NN None
. . None
115 CD None
patients NNS None
( ( None
mean JJ None
age NN None
: : None
14 CD None
years NNS None
10 CD None
months NNS None
; : None
females NNS None
: : None
77 CD None
males NNS None
: : None
38 CD None
) ) None
treated VBN None
in IN None
the DT None
Department NNP None
of IN None
Orthodontics NNP None
, , None
University NNP None
of IN None
Munich NNP None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
65 CD None
of IN None
the DT None
patients NNS None
showed VBD None
at IN None
least JJS None
one CD None
palatally-displaced JJ None
canine NN None
. . None
Diagnosis NN None
and CC None
the DT None
location NN None
of IN None
the DT None
displacement NN None
were VBD None
determined VBN None
on IN None
the DT None
basis NN None
of IN None
standardized JJ None
radiographs NN None
and CC None
confirmed VBN None
by IN None
surgical JJ None
documentation NN None
. . None
Each DT None
maxillary JJ None
tooth NN None
's POS None
mesiodistal JJ None
and CC None
vestibulo-oral JJ None
width NN None
was VBD None
measured VBN None
using VBG None
a DT None
dial JJ None
caliper NN None
on IN None
each DT None
dental JJ None
cast NN None
. . None
Excluded VBN None
were VBD None
partially-erupted JJ None
teeth NNS None
and CC None
surfaces NNS None
with IN None
caries NNS None
or CC None
restorations NNS None
that WDT None
had VBD None
to TO None
be VB None
measured VBN None
. . None
-DOCSTART- -X- N

persons NNS Condition
with IN Condition
heart NN Condition
failure NN Condition
persons NNS Condition
with IN Condition
chronic JJ Condition
heart NN Condition
failure NN Condition
9 CD None
persons NNS None
with IN None
heart NN None
failure NN None
to TO None
mentor VB None
other JJ None
heart NN None
failure NN None
patients NNS None
( ( None
37 CD None
% NN None
) ) None
of IN None
the DT None
eligible JJ None
population NN None
of IN None
hospitalized JJ None
patients NNS None
agreed VBD None
to TO None
participate VB None
. . None
-DOCSTART- -X- N

minimally RB None
invasive JJ None
surgery NN None
. . None
minimally RB None
invasive JJ None
surgery NN None
( ( None
MIS NNP None
) ) None
experienced JJ None
surgeons NNS None
Twenty CD Size
surgeons NNS None
were VBD None
presented VBN None
objects NNS None
in IN None
a DT None
random NN None
order NN None
, , None
with IN None
participants NNS None
blinded VBN None
as IN None
to TO None
their PRP$ None
identity NN None
. . None
surgeons NNS None
-DOCSTART- -X- N

subjects NNS None
with IN None
mild-to-moderate JJ Condition
Alzheimer NNP Condition
disease NN Condition
: : None
in IN None
subjects NNS None
with IN None
mild-to-moderate JJ None
AD NNP None
. . None
-DOCSTART- -X- N

malaria NNS Condition
chemoprophylaxis NNS None
: : None
users NNS None
of IN None
malaria NNS Condition
chemoprophylaxis JJ None
regimens NNS None
( ( None
atovaquone-proguanil JJ None
, , None
chloroquine-proguanil JJ None
, , None
doxycycline JJ None
, , None
or CC None
mefloquine NN None
) ) None
in IN None
a DT None
group NN None
of IN None
nonimmune JJ None
tourists NNS None
to TO None
sub-Saharan JJ None
Africa NNP None
. . None
travel NN None
clinics NNS None
in IN None
Switzerland NNP None
, , None
Germany NNP None
, , None
and CC None
Israel NNP None
( ( None
n= JJ None
547 CD Size
) ) None
age NN None
group NN None
( ( None
below IN None
median JJ None
age NN None
34 CD Age
y NN None
vs NN None
median JJ None
age NN None
and CC None
above IN None
) ) None
aged VBN None
34 CD Age
years NNS None
and CC None
older JJR None
Younger JJR Age
participants NNS None
, , None
aged VBD None
< JJ None
34 CD Age
years NNS None
standard JJ None
malaria NN Condition
chemoprophylaxis NN None
regimens NNS None
younger JJR Age
persons NNS None
aged VBD None
less JJR None
than IN None
34 CD Age
years NNS None
older JJR Age
counterparts NNS None
. . None
-DOCSTART- -X- N

allergic JJ Condition
reaction NN Condition
-- : None
a DT None
case NN None
series NN None
. . None
first JJ None
six CD Size
subjects NNS None
Peanut-allergic JJ Condition
subjects NNS None
food-allergic JJ Condition
consumers NNS None
-DOCSTART- -X- N

hypertensive JJ None
patients NNS None
. . None
12 CD None
patients NNS None
with IN None
essential JJ None
hypertension NN None
. . None
-DOCSTART- -X- N

advanced JJ None
infectious JJ None
keratitis NN None
with IN None
corneal JJ None
melting NN None
. . None
Forty NNP None
eyes NNS None
from IN None
40 CD Size
patients NNS None
with IN None
advanced JJ Condition
infectious JJ Condition
keratitis NN Condition
and CC Condition
coexisting VBG Condition
corneal NN Condition
melting NN Condition
. . None
Twenty-one CD Size
patients NNS Size
( ( None
21 CD None
eyes NNS None
) ) None
underwent JJ None
PACK-CXL JJ Condition
treatment NN Condition
in IN Condition
addition NN Condition
to TO Condition
antimicrobial JJ Condition
therapy NN Condition
. . None
The DT Size
control NN Size
group NN Size
consisted VBD Size
of IN Size
19 CD Size
patients NNS Size
( ( None
19 CD None
eyes NNS None
) ) None
-DOCSTART- -X- N

Fifty-eight JJ None
patients NNS None
with IN None
posterior JJ None
benign NN None
paroxysmal JJ None
positional JJ None
vertigo NN None
-DOCSTART- -X- N

South JJ None
African JJ None
patients NNS None
with IN None
DLBCL NNP Condition
. . None
93 CD Size
de NNS None
novo FW None
diffuse RB None
large JJ None
B-cell NNP None
lymphoma NN None
patients NNS None
seen VBN None
between IN None
1995 CD None
and CC None
2009 CD None
randomly NN None
receiving VBG None
either CC None
standard JJ None
combination NN None
chemotherapy NN None
( ( None
CHOP NNP None
, , None
n=48 NN Size
) ) None
or CC None
the DT None
identical JJ None
program NN None
with IN None
rituximab NN None
( ( None
n=45 JJ Size
) ) None
South JJ None
African JJ None
public JJ None
hospitals NNS None
-DOCSTART- -X- N

Forty-nine NNP Size
healthy JJ None
women NNS Sex
aged VBN None
20-35 JJ Age
years NNS None
who WP None
had VBD None
not RB None
been VBN None
pregnant JJ None
or CC None
using VBG None
an DT None
oral JJ None
contraceptive NN None
( ( None
OC NNP None
) ) None
for IN None
the DT None
previous JJ None
3 CD None
months NNS None
-DOCSTART- -X- N

infants NNS None
with IN None
chronic JJ None
bronchopulmonary JJ None
dysplasia NN None
: : None
double-blind JJ None
crossover NN None
sequential JJ None
trial NN None
. . None
ten JJ None
infants NNS None
with IN None
bronchopulmonary JJ None
dysplasia NN None
( ( None
BPD NNP None
) ) None
. . None
infants NNS None
' POS None
rate NN None
of IN None
weight NN None
infants NNS None
infants NNS None
infants NNS None
-DOCSTART- -X- N

prolonged JJ Condition
anaesthesia NN Condition
for IN None
acoustic JJ Condition
neuroma NN Condition
surgery NN Condition
: : None
33 CD Size
patients NNS None
acoustic JJ Condition
neuroma NN Condition
surgery NN None
. . None
acoustic JJ Condition
neuroma NN Condition
surgery NN None
. . None
-DOCSTART- -X- N

individuals NNS None
with IN None
ASD NNP Condition
. . None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( None
ASD NNP None
) ) None
people NNS None
with IN None
ASD NNP None
37 CD Size
participants NNS None
( ( None
22 CD Size
male NN Sex
, , None
15 CD Size
female NN Sex
) ) None
, , None
ages VBZ None
17-39 JJ Age
( ( None
M NNP None
= NNP None
31.49 CD Age
) ) None
years NNS None
at IN None
the DT None
beginning NN None
of IN None
the DT None
programme NN None
) ) None
diagnosed VBD None
with IN None
an DT None
ASD NNP None
and CC None
a DT None
group NN None
of IN None
34 CD Size
adults NNS None
with IN None
ASD NNP None
as IN None
control NN None
group NN None
( ( None
waiting VBG None
list NN None
) ) None
( ( None
19 CD Size
male NN Sex
, , None
15 CD Size
female NN Sex
) ) None
, , None
ages VBZ None
24-38 JJ Age
( ( None
M NNP None
= VBZ None
30 CD Age
at IN None
programme JJ None
initiation NN None
) ) None
years NNS None
. . None
individuals NNS None
with IN None
ASD NNP None
adults NNS Age
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
atrial JJ None
fibrillation NN None
or CC None
atrial JJ None
flutter NN None
. . None
patients NNS None
in IN None
atrial JJ None
fibrillation NN None
and/or IN None
atrial JJ None
flutter NN None
. . None
32 CD None
patients NNS None
with IN None
atrial JJ None
fibrillation NN None
or CC None
atrial JJ None
flutter NN None
( ( None
mean JJ None
+/- NN None
SD NNP None
age NN None
, , None
66 CD None
+/- JJ None
7 CD None
years NNS None
; : None
mean VB None
baseline JJ None
heart NN None
rate NN None
, , None
131 CD None
+/- JJ None
10 CD None
beats NNS None
per IN None
minute NN None
) ) None
after IN None
20 CD None
mg NN None
or CC None
20 CD None
mg NN None
followed VBN None
by IN None
25-mg JJ None
bolus NN None
doses NNS None
and CC None
a DT None
10 CD None
and CC None
15 CD None
mg/hr NN None
infusion NN None
for IN None
24 CD None
hours NNS None
Thirty NNP None
of IN None
32 CD None
patients NNS None
patients NNS None
with IN None
atrial JJ None
fibrillation NN None
or CC None
atrial JJ None
flutter NN None
-DOCSTART- -X- N

coronary JJ Condition
artery NN Condition
dissections NNS Condition
523 CD Size
patients NNS None
undergoing JJ None
balloon NN Condition
angioplasty NN Condition
and CC Condition
sequential JJ Condition
intracoronary JJ Condition
Doppler NN Condition
measurements NNS Condition
After IN None
successful JJ None
balloon NN None
angioplasty NN None
Patients NNS None
with IN None
severe JJ None
dissections NNS None
( ( None
n JJ None
= NNP None
128 CD None
) ) None
or CC None
without IN None
available JJ None
reference NN None
vessel NN None
CFVR NNP None
( ( None
n JJ None
= NNP None
139 CD None
) ) None
were VBD None
excluded VBN None
. . None
remaining VBG None
256 CD Size
patients NNS Size
-DOCSTART- -X- N

caudal NN Condition
blockade NN Condition
in IN None
children NNS Age
. . None
caudal JJ None
administration NN None
in IN None
children NNS None
. . None
40 CD Size
ASA NNP None
1 CD None
paediatric JJ Age
patients NNS Age
undergoing VBG None
subumbilical JJ Condition
surgery NN Condition
-DOCSTART- -X- N

hospitalized JJ None
patients NNS None
with IN None
ocular JJ None
hypertension NN None
or CC None
glaucoma NN None
. . None
Patients NNS None
in IN None
group NN None
1 CD None
( ( None
n=9 NN None
) ) None
Patients NNS None
in IN None
group NN None
2 CD None
( ( None
n=10 NN None
) ) None
-DOCSTART- -X- N

ADDITION-Cambridge NNP None
trial NN None
protocol NN None
: : None
type NN None
2 CD None
diabetes NNS None
and CC None
intensive JJ None
treatment NN None
for IN None
screen-detected JJ None
patients NNS None
. . None
people NNS None
with IN None
screen-detected JJ None
diabetes NNS None
in IN None
primary JJ None
care NN None
. . None
63 CD None
practices NNS None
in IN None
the DT None
East NNP None
Anglia NNP None
region NN None
participated VBD None
. . None
people NNS None
aged VBN None
40-69 JJ None
years NNS None
at IN None
high-risk NN None
of IN None
undiagnosed JJ None
diabetes NNS None
. . None
individuals NNS None
with IN None
clinically RB None
diagnosed VBN None
diabetes NNS None
-DOCSTART- -X- N

320 CD None
multiple JJ None
myeloma NN None
( ( None
MM NNP None
) ) None
patients NNS None
entering VBG None
the DT None
German JJ None
Myeloma NNP None
Treatment NNP None
Group NNP None
( ( None
GMTG NNP None
) ) None
trial NN None
MM01 NNP None
poor JJ None
prognosis NN None
patients NNS None
( ( None
50 CD None
% NN None
TRS NNP None
: : None
16 CD None
months NNS None
) ) None
characterised VBN None
by IN None
pretreatment JJ None
platelets NNS None
of IN None
< NN None
or CC None
= $ None
150,000 CD None
Patients NNS None
lacking VBG None
both DT None
risk NN None
factors NNS None
-DOCSTART- -X- N

Mexican JJ Condition
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
mellitus NN Condition
: : None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
mellitus VBN None
Mexican JJ None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
who WP None
received VBD None
pioglitazone NN None
or CC None
glimepiride NN None
for IN None
1 CD None
year NN None
. . None
Two CD None
hundred VBD None
forty-four JJ None
patients NNS None
( ( None
125 CD None
women NNS None
, , None
119 CD None
men NNS None
; : None
all DT Condition
but CC Condition
1 CD Condition
Hispanic NNP Condition
) ) None
were VBD None
randomized VBN None
Mexican JJ None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
-DOCSTART- -X- N

Hypertension NN Condition
and CC None
non-insulin-dependent JJ Condition
diabetes NNS Condition
. . None
162 CD Size
non-insulin-dependent JJ Condition
diabetic JJ Condition
hypertensive NN Condition
patients NNS None
non-insulin-dependent JJ Condition
diabetic JJ Condition
patients NNS None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Sex
: : None
postmenopausal JJ Condition
women NNS Sex
. . None
One CD Size
hundred CD Size
and CC Size
thirty-four JJ Size
subjects NNS None
were VBD None
randomized VBN None
into IN None
exercise NN None
groups NNS None
or CC None
a DT None
control NN None
group NN None
and CC None
130 CD Size
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

young JJ None
adults NNS None
with IN None
childhood-onset JJ None
growth NN None
hormone NN None
deficiency NN None
. . None
young JJ None
adults NNS None
with IN None
childhood-onset JJ None
GH NNP None
deficiency NN None
In IN None
young JJ None
adults NNS None
with IN None
childhood-onset JJ None
growth NN None
hormone NN None
deficiency NN None
( ( None
CO NNP None
GHD NNP None
) ) None
Patients NNPS None
( ( None
n JJ None
= VBZ None
160 CD None
; : None
mean JJ None
age NN None
, , None
21.2 CD None
years NNS None
; : None
63 CD None
% NN None
males NNS None
) ) None
with IN None
CO NNP None
GHD NNP None
-DOCSTART- -X- N

non-variceal JJ Condition
upper JJ Condition
gastrointestinal JJ Condition
bleeding NN Condition
: : None
acute JJ Condition
non-variceal JJ Condition
gastrointestinal JJ Condition
bleeding NN Condition
. . None
A NNP None
total NN None
of IN None
48 CD Size
patients NNS None
with IN None
acute JJ Condition
upper JJ Condition
gastrointestinal NN Condition
bleeding NN Condition
due JJ None
to TO None
duodenal JJ Condition
or CC Condition
gastric JJ Condition
ulcer NN Condition
15 CD Size
patients NNS None
with IN None
Forrest NNP None
IB NNP None
30 CD Size
patients NNS None
with IN None
Forrest NNP None
II NNP None
. . None
-DOCSTART- -X- N

active JJ None
compression-decompression NN None
cardiopulmonary JJ None
resuscitation NN None
. . None
patients NNS None
ventilated VBN None
with IN None
an DT None
endotracheal JJ None
tube NN None
( ( None
ETT NNP None
) ) None
during IN None
active JJ None
compression-decompression NN None
cardiopulmonary JJ None
resuscitation NN None
. . None
active JJ None
compression-decompression NN None
cardiopulmonary JJ None
resuscitation NN None
in IN None
13 CD None
out-of-hospital JJ None
cardiac JJ None
arrest NN None
patients NNS None
-DOCSTART- -X- N

age-related JJ None
macular JJ None
degeneration NN None
( ( None
AMD NNP None
) ) None
. . None
patients NNS None
comprised VBD None
some DT None
randomized VBN None
to TO None
0 CD None
vs NNS None
10 CD None
vs NNS None
36 CD None
Gy NNP None
of IN None
radiation NN None
and CC None
( ( None
after IN None
a DT None
change NN None
of IN None
the DT None
study NN None
protocol NN None
became VBD None
necessary JJ None
) ) None
others NNS None
who WP None
participated VBD None
in IN None
a DT None
prospective JJ None
, , None
controlled VBD None
non-randomized JJ None
pilot NN None
study NN None
. . None
eyes NNS None
with IN None
visual JJ None
acuity NN None
of IN None
> NN None
or CC None
= VB None
0.1 CD None
and CC None
< NNP None
or CC None
= $ None
0.6 CD None
revealing VBG None
a DT None
juxta-subfoveal JJ None
CNV NNP None
either NN None
of IN None
the DT None
occult NN None
type NN None
( ( None
type JJ None
1 CD None
) ) None
or CC None
the DT None
classic JJ None
type NN None
( ( None
isolated JJ None
or CC None
as IN None
part NN None
of IN None
a DT None
predominantly RB None
occult JJ None
lesion NN None
) ) None
. . None
-DOCSTART- -X- N

Cows NNS Condition
were VBD None
enrolled VBN None
from IN None
24 CD None
dairy NN None
herds NNS None
from IN None
three CD None
geographical JJ None
regions NNS None
of IN None
Canada NNP None
. . None
Data NNP None
from IN None
248 CD Size
cows NNS None
and CC None
938 CD None
bacteriologically RB None
negative JJ None
quarters NNS None
at IN None
drying-off NN None
are VBP None
summarized VBN None
. . None
-DOCSTART- -X- N

hookworm NN None
in IN None
Vietnam NNP None
: : None
Vietnam NNP None
hookworm NN None
infection NN None
trial NN None
among IN None
271 CD None
Vietnamese JJ None
schoolchildren NNS None
. . None
209 CD None
adults NNS None
in IN None
the DT None
same JJ None
area NN None
. . None
-DOCSTART- -X- N

lowlanders NNS Condition
and CC Condition
native JJ Condition
highlanders NNS Condition
: : Condition
( ( None
1 CD None
) ) None
healthy JJ None
lowlanders NNS None
during IN None
acute JJ None
hypoxia NN None
and CC None
prolonged JJ None
( ( None
?2 JJ None
weeks NNS None
) ) None
exposure NN None
to TO None
high JJ None
altitude NN None
, , None
and CC None
( ( None
2 CD None
) ) None
high-altitude NN None
natives NNS None
at IN None
5050 CD None
m NN None
( ( None
highlanders NNS None
) ) None
. . None
12 CD None
healthy JJ None
lowlanders NNS None
( ( None
aged VBN None
32 CD None
? . None
7 CD None
years NNS None
) ) None
and CC None
12 CD None
highlanders NNS None
( ( None
Sherpa NNP None
; : None
33 CD None
? . None
14 CD None
years NNS None
) ) None
we PRP None
assessed VBD None
brachial JJ None
endothelium-dependent JJ None
flow-mediated JJ None
dilatation NN None
( ( None
FMD NNP None
) ) None
, , None
endothelium-independent JJ None
dilatation NN None
( ( None
via IN None
glyceryl NN None
trinitrate NN None
; : None
GTN NNP None
) ) None
, , None
common JJ None
carotid NN None
intima-media JJ None
thickness NN None
( ( None
CIMT NNP None
) ) None
and CC None
diameter NN None
( ( None
ultrasound JJ None
) ) None
, , None
and CC None
arterial JJ None
stiffness NN None
via IN None
pulse JJ None
wave VBP None
velocity NN None
( ( None
PWV NNP None
; : None
applanation NN None
tonometry NN None
) ) None
. . None
Cephalic NNP None
-DOCSTART- -X- N

urban JJ None
youth NN None
: : None
predominately RB None
low-income JJ None
and CC None
ethnic JJ None
minority NN None
urban JJ None
youth NN None
. . None
14 CD None
Chicago NNP None
public JJ None
schools NNS None
. . None
6-year JJ None
period NN None
of IN None
program NN None
implementation NN None
for IN None
a DT None
cohort NN None
of IN None
youth NN None
in IN None
each DT None
school NN None
, , None
followed VBD None
from IN None
grades NNS None
3 CD None
to TO None
8 CD None
. . None
of IN None
youth NN None
in IN None
low-income JJ None
, , None
urban JJ None
settings NNS None
. . None
The DT None
-DOCSTART- -X- N

adults NNS Age
with IN None
asthma NN Condition
. . None
inactive JJ Condition
asthmatic JJ Condition
patients NNS None
Thirty-two JJ Size
adults NNS None
with IN None
asthma NN Condition
Ten CD Size
patients NNS None
, , None
5 CD Size
in IN None
each DT None
group NN None
-DOCSTART- -X- N

patients NNS None
< JJ Age
65 CD Age
years NNS Age
with IN None
poor JJ None
prognosis NN None
histologically RB None
aggressive JJ None
NHL NNP Condition
. . None
457 CD Size
patients NNS None
patients NNS None
with IN None
poor JJ None
prognosis NN None
histologically RB None
aggressive JJ None
non-Hodgkin JJ Condition
lymphoma NN Condition
( ( None
NHL NNP None
) ) None
showing VBG None
a DT None
response NN None
to TO None
initial JJ None
CHOP NNP None
( ( None
cyclophosphamide NN None
-DOCSTART- -X- N

subjects NNS Condition
who WP Condition
had VBD Condition
received VBN Condition
their PRP$ Condition
last JJ Condition
diphtheria NN Condition
vaccination NN Condition
more JJR Condition
than IN Condition
10 CD Condition
years NNS Condition
ago RB Condition
. . Condition
102 CD None
subjects NNS None
received VBD None
the DT None
first JJ None
booster NN None
vaccination NN None
, , None
and CC None
83 CD None
were VBD None
vaccinated VBN None
twice RB None
. . None
27 CD None
% NN None
of IN None
the DT None
subjects NNS None
7 CD None
% NN None
and CC None
8 CD None
% NN None
of IN None
the DT None
subjects NNS None
-DOCSTART- -X- N

women NNS Sex
with IN None
established VBN None
postmenopausal NN Condition
osteoporosis NN Condition
. . None
postmenopausal JJ None
women NNS None
with IN None
established VBN Condition
osteoporosis NN Condition
. . None
80 CD None
study NN None
centers NNS None
in IN None
Europe NNP None
and CC None
Australia NNP None
. . None
Postmenopausal NNP None
women NNS None
( ( None
n JJ None
= NN None
1226 CD None
) ) None
with IN None
two CD Condition
or CC Condition
more JJR Condition
prevalent JJ Condition
vertebral JJ Condition
fractures NNS Condition
severe JJ Condition
postmenopausal NN Condition
osteoporosis NN Condition
women NNS None
with IN None
established VBN Condition
disease NN Condition
. . None
-DOCSTART- -X- N

type NN None
2 CD None
( ( None
non-insulin-dependent JJ None
) ) None
diabetes VBZ None
mellitus VBN None
of IN None
6,956 CD None
47-49-year-old JJ None
Malm? NNP None
males NNS None
, , None
a DT None
series NN None
of IN None
41 CD None
subjects NNS None
with IN None
early-stage JJ None
Type NNP None
2 CD None
( ( None
non-insulin-dependent JJ None
) ) None
diabetes VBZ None
mellitus JJ None
and CC None
181 CD None
subjects NNS None
with IN None
impaired JJ None
glucose JJ None
tolerance NN None
were VBD None
-DOCSTART- -X- N

distressed JJ Condition
neonates NNS None
neonates NNS Age
with IN None
respiratory JJ Condition
distress NN Condition
. . Condition
84 CD Size
mechanically RB Condition
ventilated VBN Condition
distressed JJ Condition
neonates NNS None
Newborns NNP Age
with IN None
respiratory JJ Condition
difficulties NNS Condition
-DOCSTART- -X- N

smokers NNS Condition
general JJ None
population NN None
. . None
Smokers NNS None
initial JJ None
subject JJ None
pool NN None
was VBD None
the DT None
24,178 JJ Size
members NNS None
of IN None
a DT None
managed VBN None
care NN None
company NN None
. . None
19,236 CD Size
members NNS None
( ( None
79.6 CD None
% NN None
) ) None
, , None
of IN None
whom WP None
4,653 CD Size
were VBD None
smokers NNS None
; : None
85.3 CD None
% NN None
of IN None
the DT None
smokers NNS None
were VBD None
enrolled VBN None
. . None
Thirty-eight JJ None
percent NN None
were VBD None
in IN None
the DT None
precontemplation NN None
stage NN None
, , None
45 CD None
% NN None
in IN None
the DT None
contemplation NN None
stage NN None
, , None
and CC None
only RB None
17 CD None
% NN None
in IN None
the DT None
preparation NN None
stage NN None
. . None
population NN None
of IN None
smokers NNS None
-DOCSTART- -X- N

melatonin NN None
on IN None
sleep NN Condition
problems NNS Condition
in IN None
children NNS None
participants NNS None
for IN None
2 CD None
weeks NNS None
All DT None
participants NNS None
12 CD Condition
of IN None
18 CD Condition
subjects NNS None
who WP None
completed VBD None
the DT None
study NN None
( ( None
11 CD Condition
males NNS None
, , None
age NN None
range NN None
2 CD None
to TO None
15.25 CD None
years NNS None
, , None
mean JJ None
5.47 CD None
, , None
SD NNP None
3.6 CD None
) ) None
. . None
Five CD Condition
participants NNS None
Eight CD Condition
out IN None
of IN None
12 CD Condition
had VBD None
melatonin VBN None
first RB None
-DOCSTART- -X- N

loco NN Condition
classico NN Condition
radius NN Condition
fracture NN Condition
. . Condition
50 CD None
patients NNS None
with IN None
type NN None
A DT None
2.2 CD None
, , None
A DT None
3.3 CD None
, , None
C NNP None
1.2 CD None
or CC None
C $ None
2.2 CD None
( ( None
AO NNP None
classification NN None
) ) None
fractures NNS None
of IN None
the DT None
radius NN None
5 CD None
patients NNS None
with IN None
significant JJ None
disability NN None
-DOCSTART- -X- N

metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
. . None
patients NNS None
with IN None
epidermal JJ Condition
growth NN Condition
factor NN Condition
receptor-expressing NN Condition
, , None
metastatic JJ Condition
colorectal NN Condition
carcinoma NN Condition
with IN None
disease JJ None
progression NN None
on IN None
or CC None
following VBG None
fluoropyrimidine- JJ None
, , None
oxaliplatin- JJ None
, , None
and CC None
irinotecan-containing JJ None
chemotherapy NN None
regimens NNS None
. . None
patients NNS None
with IN None
metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
. . None
Patients NNS None
receiving VBG None
panitumumab NN None
patients NNS None
receiving VBG None
bevacizumab NN None
and CC None
chemotherapy NN None
alone RB None
. . None
metastatic JJ None
colorectal NN Condition
cancer NN Condition
-DOCSTART- -X- N

breast NN None
cancer NN None
surgery NN None
Japanese JJ None
patients NNS None
patient NN None
under IN None
general JJ None
anesthesia NN None
breast NN Condition
cancer NN Condition
surgery NN Condition
in IN None
Japanese JJ Condition
patients NNS None
Japanese JJ None
women NNS Sex
A DT None
total NN None
of IN None
100 CD Size
women NNS None
( ( None
mean JJ Age
[ NNP Age
SD NNP Age
] NNP Age
age NN Age
, , Age
52 CD Age
[ NN Age
7 CD Age
] CD Age
years NNS Age
; : None
height VBD None
, , None
154 CD None
[ NN None
6 CD None
] NNP None
cm NN None
; : None
weight NN None
, , None
54 CD None
[ NN None
7 CD None
] NNP None
kg NN None
) ) None
-DOCSTART- -X- N

apical JJ None
defibrillation NN None
paddle NN None
of IN None
importance NN None
Twenty NNP None
sequential NN None
anaesthetised VBD None
patients NNS None
-DOCSTART- -X- N

dependent NN None
and CC None
nondependent JJ None
harmful JJ None
drinkers NNS None
. . None
patients NNS None
with IN None
dependent JJ None
or CC None
harmful JJ None
drinking NN None
behaviors NNS None
. . None
83 CD None
first- JJ None
, , None
second- JJ None
, , None
and CC None
third-year JJ None
medical JJ None
residents NNS None
to TO None
receive VB None
or CC None
not RB None
to TO None
receive VB None
diagnostic JJ None
information NN None
and CC None
counseling VBG None
directives NNS None
on IN None
214 CD None
patients NNS None
who WP None
reported VBD None
at IN None
least JJS None
one CD None
symptom NN None
of IN None
alcohol NN None
impairment NN None
as IN None
defined VBN None
in IN None
the DT None
Diagnostic NNP None
and CC None
Statistical NNP None
Manual NNP None
of IN None
Mental NNP None
Disorders NNP None
, , None
Third NNP None
Edition NNP None
. . None
female JJ None
patients NNS None
, , None
patients NNS None
with IN None
inactive JJ None
disorders NNS None
, , None
and CC None
nondependent NN None
but CC None
harmful JJ None
drinkers NNS None
. . None
-DOCSTART- -X- N

hypercholesterolemia NN None
. . None
patients NNS None
with IN None
coronary JJ Condition
heart NN Condition
disease NN Condition
and CC None
hypercholesterolemia NN None
treated VBN None
with IN None
simvastatin NN None
( ( None
Zocor NNP None
, , None
inhibitor NN None
of IN None
the DT None
key JJ None
enzyme NN None
of IN None
cholesterol NN None
synthesis NN None
) ) None
and CC None
preparation NN None
of IN None
polyunsaturated JJ None
phospholipids NNS None
( ( None
lipostabil JJ None
forte NN None
) ) None
. . None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS None
. . None
Twenty-four JJ Size
Helicobacter NNP Condition
pylori-negative JJ Condition
subjects NNS None
-DOCSTART- -X- N

patients NNS None
who WP None
undergo VBP None
laparoscopic JJ Condition
surgical JJ Condition
operations NNS Condition
. . None
42 CD Size
patients NNS None
subdivided VBD None
into IN None
four CD None
groups NNS None
namely RB None
, , None
higher JJR None
or CC None
lower JJR None
insufflation NN None
pressures NNS None
, , None
chemically RB None
inert JJ None
insufflation NN None
gas NN None
and CC None
control NN None
groups NNS None
; : None
-DOCSTART- -X- N

25 CD None
randomly RB None
selected VBN None
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
herpes NNS Condition
zoster NN Condition
. . None
-DOCSTART- -X- N

southern JJ None
Ghana NNP None
. . None
acellular JJ None
diphtheria/pertussis/tetanus NN Condition
( ( None
ADPT NNP None
) ) None
in IN None
infants NNS Age
was VBD None
conducted VBN None
in IN None
a DT None
peri-urban JJ None
community NN None
( ( None
Ashaiman NNP None
) ) None
in IN None
southern JJ None
Ghana NNP None
. . None
pertussis NN Condition
in IN None
children NNS Age
under IN None
5 CD Age
years NNS None
of IN None
age NN None
in IN None
the DT None
study NN None
area NN None
were VBD None
also RB None
determined VBN None
. . None
2 CD Size
% NN Size
( ( None
8/399 CD None
) ) None
to TO None
2.3 CD Size
% NN Size
( ( None
9/385 CD None
) ) None
of IN None
the DT None
acellular JJ None
vaccine NN None
recipients NNS None
as IN None
against IN None
31 CD Size
% NN Size
( ( None
122/394 CD None
) ) None
in IN None
the DT None
whole-cell JJ None
vaccine NN None
group NN None
. . None
-DOCSTART- -X- N

ulcerative JJ Condition
colitis NN Condition
patients NNS None
and CC None
their PRP$ None
doctors NNS None
6 CD None
specialists NNS None
and CC None
16 CD None
GPs NNP None
. . None
Patients NNS None
' POS None
views NNS None
were VBD None
obtained VBN None
from IN None
written VBN None
responses NNS None
to TO None
a DT None
postal JJ None
questionnaire NN None
( ( None
136 CD None
replies NNS None
) ) None
. . None
-DOCSTART- -X- N

United NNP None
States NNPS None
children NNS Age
two CD Age
months NNS Age
of IN None
age NN None
439 CD Size
children NNS Age
at IN Age
two CD Age
, , Age
four CD Age
, , Age
and CC Age
six CD Age
months NNS Age
of IN Age
age NN Age
and CC None
from IN None
85 CD Size
children NNS Age
at IN Age
18 CD Age
and CC Age
20 CD Age
months NNS Age
of IN Age
age NN Age
-DOCSTART- -X- N

low JJ None
birth NN None
weight NN None
infants NNS None
. . None
low JJ None
birth NN None
weight NN None
infants NNS None
. . None
low JJ None
birth NN None
weight NN None
infants NNS None
( ( None
average JJ None
birth NN None
weight NN None
1489 CD None
g NN None
) ) None
. . None
low JJ None
birth NN None
weight NN None
infants NNS None
-DOCSTART- -X- N

hip NN None
and CC None
knee NN None
arthroplasty NN Condition
. . None
Inpatient NNP None
anesthesia NN None
at IN None
a DT None
university NN None
department NN None
of IN None
orthopedic JJ None
surgery NN None
. . None
PATIENTS CC None
30 CD Size
ASA NNP None
physical JJ None
status NN None
I PRP Size
and CC None
II NNP Size
patients NNS None
, , None
who WP None
were VBD None
scheduled VBN None
for IN None
elective JJ None
hip NN None
or CC None
knee VB None
arthroplasty JJ None
and CC None
were VBD None
free JJ None
from IN None
systemic JJ Condition
disease NN Condition
. . Condition
elective JJ None
hip NN None
and CC None
knee NN None
arthroplasty NN None
-DOCSTART- -X- N

low-income JJ None
African JJ None
American JJ None
families NNS None
of IN None
young JJ None
children NNS Age
with IN None
asthma NN Condition
. . None
Of IN None
55 CD Size
families NNS None
, , None
71 CD Size
% NN Size
completed VBD None
the DT None
program NN None
low-income JJ None
families NNS None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
retinal JJ Condition
angiography NN Condition
. . None
diabetic JJ Condition
and CC None
nondiabetic JJ Condition
patients NNS None
undergoing VBG None
retinal JJ None
angiography NN None
by IN None
comparing VBG None
it PRP None
with IN None
usually RB None
administered VBN None
eyedrops NNS None
( ( None
tropicamide VB None
1 CD None
% NN None
and CC None
phenylephrine VB None
10 CD None
% NN None
) ) None
total NN None
of IN None
154 CD None
eyes NNS None
of IN None
77 CD Size
patients NNS None
were VBD None
randomly RB None
divided VBN None
into IN None
2 CD None
groups NNS None
: : None
diabetic JJ Condition
patients NNS Condition
diabetic JJ None
and CC None
nondiabetic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

adults NNS None
in IN None
adults NNS None
46 CD None
adults NNS None
ASA NNP None
I-II NNP None
, , None
undergoing VBG None
elective JJ None
gynecological NN None
or CC None
general JJ None
surgery NN None
with IN None
balanced JJ None
general JJ None
anesthesia NN None
-DOCSTART- -X- N

community-based JJ None
pediatric JJ Age
ADHD NNP Condition
care NN None
: : None
pediatricians NNS None
' POS None
Forty-nine JJ Size
community-based JJ None
pediatricians NNS None
at IN None
8 CD None
practices NNS None
participated VBN None
in IN None
a DT None
cluster-randomized JJ None
trial NN None
. . None
numbers NNS None
of IN None
pediatricians NNS None
and CC None
the DT None
proportions NNS None
of IN None
patients NNS None
receiving VBG None
Medicaid NNP None
. . None
community-based JJ None
pediatric JJ None
settings NNS None
. . None
-DOCSTART- -X- N

healthy JJ Condition
postmenopausal NN Condition
women NNS Sex
. . None
25 CD Size
healthy JJ Condition
postmenopausal NN Condition
women NNS Sex
( ( None
52.5 CD Age
+/- JJ Age
2.8 CD Age
years NNS None
) ) None
postmenopausal JJ Condition
women NNS Sex
-DOCSTART- -X- N

oral JJ Condition
health NN Condition
improvement NN Condition
previous JJ None
users NNS None
of IN None
traditional JJ None
materials NNS None
in IN None
a DT None
rural JJ None
population NN None
in IN None
Andhra NNP None
Pradesh NNP None
, , None
India NNP None
. . None
oral JJ Condition
health NN Condition
of IN None
an DT None
economically RB None
disadvantaged JJ None
rural JJ None
population NN None
in IN None
Andhra NNP None
Pradesh NNP None
, , None
India NNP None
who WP None
were VBD None
primarily RB None
users NNS None
of IN None
traditional JJ None
materials NNS None
. . None
150 CD Size
of IN None
the DT None
original JJ None
study NN None
population NN None
. . None
-DOCSTART- -X- N

superficial JJ None
bladder NN None
cancer NN None
superficial JJ None
bladder NN None
cancer NN None
. . None
total NN None
of IN None
99 CD None
subjects NNS None
with IN None
resected JJ None
superficial JJ None
bladder NN None
cancer NN None
( ( None
pTa NN None
, , None
pT1 NN None
) ) None
bladder NN None
cancer NN None
. . None
-DOCSTART- -X- N

working VBG Condition
population NN Condition
volunteers NNS None
from IN None
1100 CD Size
eligible JJ None
employees NNS None
of IN None
a DT None
Finnish JJ None
insurance NN None
company NN None
. . None
-DOCSTART- -X- N

in IN None
overweight JJ None
adults NNS None
: : None
stiffness NN None
in IN None
sedentary JJ None
, , None
overweight JJ None
individuals NNS None
. . None
Seventy-seven JJ None
individuals NNS None
( ( None
19 CD None
men NNS None
, , None
58 CD None
women NNS None
; : None
age NN None
, , None
30-55 CD None
years NNS None
) ) None
groups NNS None
; : None
two CD None
groups NNS None
completed VBD None
30 CD None
minutes NNS None
of IN None
accumulated JJ None
walking VBG None
with IN None
either DT None
monthly JJ None
or CC None
weekly JJ None
telephone NN None
support NN None
; : None
the DT None
third JJ None
group NN None
( ( None
control NN None
) ) None
performed VBD None
stretching VBG None
exercises NNS None
. . None
The DT None
walking VBG None
groups NNS None
in IN None
overweight JJ None
individuals NNS None
. . None
-DOCSTART- -X- N

seven CD Size
subjects NNS None
with IN None
autistic JJ Condition
disorder NN Condition
Seven NNP Size
subjects NNS None
, , None
ages VBZ Age
6-18 CD Age
years NNS Age
, , None
with IN None
autistic JJ Condition
disorder NN Condition
seven CD Size
subjects NNS None
-DOCSTART- -X- N

Four CD Size
healthy JJ Condition
volunteers NNS None
with IN None
significant JJ None
erythema NN Condition
and CC None
telangiectasia NN Condition
on IN Condition
the DT Condition
face NN Condition
telangiectasias NN None
. . None
-DOCSTART- -X- N

One CD Size
hundred VBD Size
twenty-five JJ Size
volunteers NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
the DT None
treatment NN Size
( ( Size
n JJ Size
= NNP Size
100 CD Size
) ) Size
or CC None
control VB Size
group NN Size
( ( Size
n JJ Size
= NNP Size
25 CD Size
) ) Size
after IN None
examination NN None
by IN None
the DT None
team NN None
neurologist NN None
to TO None
ensure VB None
a DT None
diagnosis NN None
of IN None
migraine NN Condition
headache NN Condition
. . None
100 CD Size
patients NNS None
in IN None
the DT None
treatment NN None
group NN None
-DOCSTART- -X- N

malignant JJ None
dysphagia NN None
. . None
Patients NNS None
with IN None
inoperable JJ None
carcinoma NN None
of IN None
the DT None
oesophagus NN None
Fourteen JJ None
patients NNS None
were VBD None
randomised VBN None
to TO None
receive VB None
laser NN None
only RB None
, , None
and CC None
12 CD None
to TO None
receive VB None
laser NN None
followed VBN None
by IN None
brachytherapy NN None
. . None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS None
. . None
hypertensive JJ Condition
patients NNS None
. . None
healthy JJ Condition
males NNS Sex
. . None
young JJ Age
healthy JJ Condition
men NNS Sex
. . None
-DOCSTART- -X- N

people NNS None
at IN None
high JJ None
cardiovascular JJ None
risk NN None
people NNS None
with IN None
diabetes NNS None
7674 CD None
participants NNS None
with IN None
albuminuria NNS None
data NNS None
at IN None
baseline NN None
and CC None
at IN None
follow-up JJ None
nondiabetic JJ None
and CC None
in IN None
diabetic JJ None
people NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
head-and-neck JJ None
cancer NN None
. . None
Fifty NNP None
patients NNS None
were VBD None
randomized VBN None
to TO None
receive VB None
conventional JJ None
radiotherapy NN None
( ( None
RT NNP None
) ) None
( ( None
2-Gy JJ None
fractions NNS None
, , None
5 CD None
days NNS None
weekly RB None
, , None
to TO None
a DT None
total NN None
of IN None
60-74 JJ None
Gy NNP None
, , None
depending VBG None
on IN None
the DT None
tumor NN None
localization NN None
and CC None
TNM NNP None
classification NN None
) ) None
and CC None
carboplatin NN None
( ( None
90 CD None
mg/m NN None
( ( None
2 CD None
) ) None
infusion NN None
once RB None
per IN None
week NN None
before IN None
RT NNP None
) ) None
amifostine-treated JJ None
group NN None
patients NNS None
with IN None
head-and-neck JJ None
cancer NN None
. . None
-DOCSTART- -X- N

temporomandibular JJ Condition
disorder NN Condition
patients NNS None
with IN None
myofascial JJ None
pain NN None
after IN None
6 CD None
and CC None
12 CD None
months NNS None
. . None
temporomandibular JJ Condition
disorder NN Condition
( ( None
TMD NNP Condition
) ) None
patients NNS None
with IN None
myofascial JJ None
pain NN None
. . None
60 CD Size
patients NNS None
( ( None
mean JJ None
age NN None
29 CD Age
years NNS Age
) ) None
with IN None
myofascial JJ Condition
pain NN Condition
were VBD None
evaluated VBN None
after IN None
10 CD None
weeks NNS None
of IN None
treatment NN None
with IN None
either CC None
a DT None
stabilization NN None
appliance NN None
or CC None
a DT None
control JJ None
appliance NN None
. . None
60 CD Size
patients NNS None
patients NNS None
with IN None
myofascial JJ Condition
pain NN Condition
TMD NNP Condition
patients NNS None
with IN None
myofascial JJ Condition
pain NN Condition
. . None
-DOCSTART- -X- N

humans NNS None
. . None
Patients NNP None
undergoing JJ Condition
carotid NNS Condition
endarterectomy VBP Condition
( ( None
n=14 NN None
) ) None
( ( None
n=14 NN None
) ) None
( ( None
n=14 JJ None
) ) None
All DT None
patients NNS None
were VBD None
pretreated VBN None
with IN None
aspirin NN None
and CC None
given VBN None
heparin NNS None
during IN None
surgery NN None
. . None
thromboembolic JJ Condition
disease NN Condition
. . None
relatively RB None
small JJ None
numbers NNS None
of IN None
patients NNS None
. . None
-DOCSTART- -X- N

piglet NN None
small JJ None
intestine NN None
from IN None
28-d-old JJ Age
pigs NNS None
weaned VBD None
at IN None
21 CD Age
d NN Age
of IN None
age NN None
and CC None
from IN None
age-matched JJ None
suckling VBG None
piglets NNS None
. . None
young JJ None
mammals NNS None
. . None
-DOCSTART- -X- N

elite JJ None
junior JJ None
soccer NN None
players NNS None
. . None
male JJ Sex
elite JJ None
junior JJ None
soccer NN None
players NNS None
. . None
Twenty NNP None
highly RB None
trained VBD None
soccer NN None
players NNS None
( ( None
age NN None
18.3 CD Age
+/- JJ Age
0.6 CD Age
years NNS Age
, , None
height VBD None
177 CD None
+/- JJ None
4 CD None
cm NN None
, , None
body NN None
mass VBD None
71.4 CD None
+/- JJ None
6.9 CD None
kg NN None
, , None
sum NN None
skinfolds NNS None
48.1 CD None
+/- JJ None
11.4 CD None
mm NN None
) ) None
, , None
members NNS None
of IN None
a DT None
professional JJ None
soccer NN None
academy NN None
young JJ None
elite JJ None
soccer NN None
players NNS None
-DOCSTART- -X- N

5-year JJ None
failure-free JJ None
survival NN None
in IN None
group NN None
III NNP None
rhabdomyosarcoma NN None
: : None
osteosarcoma NN None
and CC None
Ewing NNP None
's POS None
sarcoma NN None
. . None
patients NNS None
with IN None
group NN None
III NNP None
rhabdomyosarcoma NN None
444 CD None
group NN None
III NNP None
patients NNS None
who WP None
received VBD None
induction NN None
therapy NN None
, , None
had VBD None
response NN None
assessed VBN None
at IN None
week NN None
8 CD None
by IN None
anatomic JJ None
imaging NN None
, , None
and CC None
continued VBD None
with IN None
protocol NN None
therapy NN None
. . None
group NN None
III NNP None
patients NNS None
-DOCSTART- -X- N

pulpless NN None
teeth NNS None
restored VBD None
with IN None
fiber NN None
reinforced VBN None
composite JJ None
posts NNS None
A NNP None
total NN None
of IN None
42 CD Size
recently RB None
extracted VBN None
upper JJ None
incisors NNS None
were VBD None
randomly RB None
divided VBN None
into IN None
3 CD None
groups NNS None
. . None
All DT None
teeth NNS None
were VBD None
fully RB None
covered VBN None
with IN None
polycarbonate JJ None
resin NN None
crowns NNS None
. . None
-DOCSTART- -X- N

children NNS Condition
with IN Condition
autistic JJ Condition
spectrum NN Condition
disorder NN Condition
. . Condition
children NNS None
with IN None
autistic JJ None
spectrum NN None
disorder NN None
. . None
Twenty NNP None
( ( None
20 CD None
) ) None
children NNS None
with IN None
autistic JJ None
spectrum NN None
disorder NN None
, , None
ages VBZ None
3-8 CD None
years NNS None
. . None
autistic JJ None
children NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
: : None
Children NNP Age
who WP None
have VBP None
a DT None
combination NN None
of IN None
language NN Condition
and CC Condition
developmental JJ Condition
disabilities NNS Condition
with IN None
autism NN Condition
Participants NNS None
were VBD None
two CD None
groups NNS None
of IN None
children NNS Age
with IN None
autism NN Condition
, , None
aged VBD None
between IN None
3 CD Age
and CC None
7 CD Age
years NNS None
. . None
-DOCSTART- -X- N

paediatric JJ Age
liver JJ None
transplantation NN None
. . None
group NN None
of IN None
children NNS Age
post VBN None
liver JJ None
transplantation NN None
gingival JJ Condition
overgrowth NN Condition
in IN None
children NNS None
receiving VBG None
FK506 NNP None
Seventy-nine JJ Size
children NNS None
( ( None
aged VBN None
15-196 CD None
months NNS None
) ) None
undergoing VBG None
liver JJ None
transplantation NN None
at IN None
Birmingham NNP None
Children NNP None
's POS None
Hospital NNP None
between IN None
October NNP None
1998 CD None
and CC None
October NNP None
2000 CD None
Fifty-two JJ Condition
patients NNS Condition
Eighteen JJ None
children NNS Age
41 CD Size
children NNS Age
receiving VBG None
cyclosporin NN None
alone RB None
, , None
26 CD Size
exhibited VBD None
gingival NN Condition
overgrowth NN Condition
compared VBN None
to TO None
zero CD Size
of IN Size
20 CD Size
patients NNS Size
receiving VBG None
tacrolimus JJ None
alone RB None
. . None
children NNS None
treated VBN None
with IN None
immunosuppression NN None
liver JJ None
transplantation NN None
in IN None
children NNS None
-DOCSTART- -X- N

children NNS Age
in IN None
need NN None
of IN None
treatment NN None
in IN None
Northern NNP None
Ireland NNP None
. . None
children NNS None
with IN None
a DT None
dental JJ Condition
health NN Condition
need NN None
children NNS Age
with IN None
a DT None
treatment NN None
need NN None
Sixty-four JJ Size
participating NN None
schools NNS None
A DT None
total NN None
of IN None
2,321 CD Size
children NNS Size
were VBD None
screened VBN None
, , None
with IN None
980 CD Size
having VBG None
a DT None
positive JJ None
result NN None
. . None
664 CD Size
completed VBN None
questionnaires NNS None
-DOCSTART- -X- N

24 CD Size
healthy JJ None
students NNS None
( ( None
17 CD Size
men NNS Sex
and CC None
7 CD Size
women NNS Sex
) ) None
who WP None
stretched VBD Condition
their PRP$ Condition
right JJ Condition
hamstrings NNS Condition
for IN None
durations NNS None
of IN None
20 CD None
, , None
60 CD None
-DOCSTART- -X- N

streptococcal JJ Condition
tonsillopharyngitis NN Condition
. . None
group NN None
A NNP None
streptococcal JJ None
tonsillopharyngitis NN None
in IN None
children NNS None
. . None
Of IN None
the DT None
409 CD Size
patients NNS None
enrolled VBD None
, , None
323 CD Size
were VBD None
evaluable JJ None
for IN None
their PRP$ None
clinical JJ None
and CC None
bacteriological JJ None
responses NNS None
; : None
323 CD Size
children NNS None
streptococcal JJ Condition
pharyngitis NN Condition
in IN None
children NNS None
. . None
-DOCSTART- -X- N

liver NN None
function NN None
with IN None
fewer JJR None
side NN None
effects NNS None
. . None
subjects NNS None
with IN None
normal JJ None
( ( None
n JJ None
= NNP None
5 CD None
) ) None
and CC None
severely RB None
impaired JJ None
liver NN None
function NN None
( ( None
n JJ None
= NNP None
7 CD None
) ) None
( ( None
study NN None
I PRP None
) ) None
. . None
15 CD None
individuals NNS None
with IN None
normal JJ None
liver NN None
function NN None
and CC None
45 CD None
patients NNS None
with IN None
cirrhosis NN None
( ( None
15 CD None
Child NNP None
A NNP None
, , None
15 CD None
Child NNP None
B NNP None
, , None
and CC None
15 CD None
Child NNP None
C NNP None
) ) None
. . None
-DOCSTART- -X- N

gastrointestinal JJ None
surgery NN None
. . None
patients NNS None
undergoing VBG None
elective JJ None
gastrointestial JJ None
surgery NN None
during IN None
the DT None
early JJ None
postoperative JJ None
period NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
acute NN None
severe JJ None
pulmonary JJ None
embolism NN None
( ( None
PE NNP None
) ) None
. . None
PE NNP None
was VBD None
less JJR None
than IN None
5 CD None
days NNS None
old JJ None
133 CD None
patients NNS None
two CD None
patients NNS None
died VBD None
before IN None
treatment NN None
and CC None
two CD None
were VBD None
excluded VBN None
retrospectively RB None
, , None
leaving VBG None
129 CD None
patients NNS None
for IN None
final JJ None
analysis NN None
two CD None
groups NNS None
-DOCSTART- -X- N

anxiety NN Condition
in IN None
children NNS None
with IN None
Asperger NNP Condition
syndrome NN Condition
. . None
children NNS Age
diagnosed VBN None
with IN None
Asperger NNP Condition
syndrome NN Condition
( ( Condition
AS IN Condition
) ) Condition
. . None
Seventy-one JJ Condition
children NNS None
aged VBN None
ten NNS None
to TO None
twelve VB None
years NNS None
were VBD None
recruited VBN None
All DT None
children NNS None
were VBD None
diagnosed VBN None
with IN None
AS NNP Condition
and CC None
the DT None
presence NN None
of IN None
anxiety NN Condition
symptoms NNS Condition
children NNS None
diagnosed VBN None
with IN None
Asperger NNP Condition
syndrome NN Condition
and CC None
exhibiting VBG None
anxiety NN Condition
symptoms NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
stable JJ Condition
angina NN Condition
. . None
Eight-seven JJ Size
angina NNS None
pectoris JJ None
patients NNS None
, , None
mean JJ Age
age NN Age
of IN Age
57 CD Age
+/- JJ Age
9 CD Age
, , None
82 CD None
white JJ None
and CC None
79 CD Sex
male NN Sex
patients NNS None
with IN None
stable JJ None
angina NN None
. . None
-DOCSTART- -X- N

beef NN None
heifers NNS None
fed VBP None
high- JJ None
or CC None
low-starch JJ None
diets NNS None
for IN None
different JJ None
periods NNS None
before IN None
breeding VBG None
. . None
Spring-born JJ None
Hereford NNP None
x NNP None
Angus NNP None
heifers NNS None
( ( None
n JJ None
= NNP None
206 CD None
) ) None
heifers NNS None
( ( None
205 CD None
+/- JJ None
5 CD None
kg NN None
; : None
n CC None
= VB None
68 CD None
) ) None
grazing NN None
dormant JJ None
native JJ None
pasture NN None
Heifers NNS None
HS NNP None
and CC None
LS NNP None
heifers NNS None
HS NNP None
and CC None
LS NNP None
heifers NNS None
HS NNP None
and CC None
LS NNP None
heifers NNS None
heifers NNS None
-DOCSTART- -X- N

multicenter NN None
, , None
open-label JJ None
, , None
pilot NN None
study NN None
enrolling VBG None
consecutive JJ None
non-ulcer JJ Condition
dyspepsia NN Condition
patients NNS None
with IN None
H. NNP None
pylori FW None
infection NN None
never RB None
previously RB None
treated VBN None
for IN None
the DT None
infection NN None
. . None
270 CD Size
patients NNS None
were VBD None
enrolled VBN None
, , None
but CC None
13 CD Size
patients NNS None
early RB None
interrupted VBN None
treatment NN None
-DOCSTART- -X- N

Sixty-one JJ Size
patients NNS None
with IN None
ovarian JJ Condition
cancer NN Condition
or CC None
endometrial JJ Condition
cancer NN Condition
who WP None
underwent JJ None
retroperitoneal NN Condition
lymph NN Condition
node JJ Condition
resection NN Condition
-DOCSTART- -X- N

Forty-three JJ None
chronic JJ None
stroke NN None
patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
upper JJ None
extremity NN None
impairment NN None
-DOCSTART- -X- N

Management NN None
of IN None
the DT None
thyroid JJ None
isthmus NN None
in IN None
tracheostomy NN None
: : None
a DT None
prospective JJ None
and CC None
retrospective JJ None
study NN None
. . None
-DOCSTART- -X- N

mild JJ Condition
cognitive JJ Condition
impairment NN Condition
: : Condition
Individuals NNS None
with IN None
amnestic JJ Condition
mild NNS Condition
cognitive JJ Condition
impairment NN Condition
( ( Condition
MCI NNP Condition
) ) Condition
individuals NNS None
with IN None
amnestic JJ None
MCI NNP Condition
. . Condition
Forty NNP Size
individuals NNS None
with IN None
single JJ None
domain NN None
amnestic JJ None
MCI NNP None
and CC None
their PRP$ None
program NN None
partners NNS None
were VBD None
randomized VBN None
-DOCSTART- -X- N

All NNP None
152 CD Size
male NN Age
employees NNS Condition
in IN Condition
a DT Condition
computer NN Condition
company NN Condition
, , None
25-45 JJ Age
years NNS Age
of IN Age
age NN Age
, , None
were VBD None
invited VBN None
to TO None
participate VB None
Eighty-five JJ Size
( ( None
56 CD None
% NN None
) ) None
men NNS None
participated VBD None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
duodenal JJ Condition
ulcer NN Condition
. . None
two CD None
parallel JJ None
groups NNS None
patients NNS None
with IN None
duodenal JJ None
ulcer NN None
. . None
Thirty JJ None
patients NNS None
were VBD None
included VBN None
, , None
divided VBN None
into IN None
two CD Size
groups NNS Size
of IN Size
15 CD Size
, , None
to TO None
whom WP None
one CD None
of IN None
the DT None
study NN None
therapies NNS None
was VBD None
administered VBN None
based VBN None
on IN None
a DT None
randomization NN None
code NN None
. . None
-DOCSTART- -X- N

allogeneic JJ None
sibling VBG None
stem-cell JJ None
transplantation NN None
: : None
French JJ None
study NN None
. . None
prospective JJ None
French JJ None
study NN None
comparing VBG None
four CD None
doses NNS None
of IN None
immunoglobulins NNS None
. . None
hematopoietic JJ None
stem-cell NN None
transplant NN None
recipients NNS None
85 CD Size
patients NNS None
from IN None
five CD None
centers NNS None
were VBD None
collected VBN None
prospectively RB None
and CC None
costed VBN None
patient NN None
's POS None
pretransplant JJ Condition
status NN Condition
and CC Condition
transplant-related JJ Condition
complications NNS Condition
. . Condition
homogeneous JJ None
group NN None
of IN None
patients NNS None
. . None
-DOCSTART- -X- N

in IN None
patients NNS None
with IN None
intermittent JJ None
claudication NN None
and CC None
arterial JJ None
hypertension NN None
: : None
patients NNS None
. . None
A DT None
total NN None
of IN None
128 CD None
patients NNS None
with IN None
intermittent JJ None
claudication NN None
and CC None
essential JJ None
hypertension NN None
were VBD None
tolerated VBN None
in IN None
patients NNS None
with IN None
intermittent JJ None
claudication NN None
and CC None
arterial JJ None
hypertension NN None
during IN None
-DOCSTART- -X- N

symptomatic JJ None
myocardial JJ None
ischemia NN None
. . None
an DT None
open JJ None
study NN None
in IN None
patients NNS None
with IN None
symptomatic JJ None
myocardial JJ None
ischemia NN None
. . None
data NNS None
from IN None
78 CD None
patients NNS None
. . None
-DOCSTART- -X- N

users NNS None
of IN None
ecstasy NN Condition
. . None
humans NNS None
Two CD None
groups NNS None
of IN None
21 CD None
males NNS Sex
with IN None
moderate JJ Condition
and CC Condition
heavy JJ Condition
recreational JJ Condition
use NN Condition
of IN Condition
MDMA NNP Condition
, , Condition
respectively RB Condition
, , None
and CC None
a DT None
control NN None
group NN None
of IN None
20 CD None
males NNS None
without IN None
use NN None
of IN None
MDMA NNP None
were VBD None
compared VBN None
. . None
same JJ None
subculture NN None
. . None
-DOCSTART- -X- N

in IN None
Canadian JJ None
Cree NNP None
infants NNS None
. . None
studied VBD None
184 CD None
Cree NNP None
Indian JJ None
infants NNS None
from IN None
26 CD None
infants NNS None
without IN None
BCG NNP None
vaccination NN None
rose VBD None
for IN None
66 CD None
infants NNS None
who WP None
received VBD None
BCG NNP None
in IN None
the DT None
first JJ None
7 CD None
days NNS None
of IN None
life NN None
, , None
-DOCSTART- -X- N

patients NNS None
requiring VBG None
mechanical JJ None
ventilation NN None
postacute NN None
care NN None
a DT None
mean JJ None
length NN None
of IN None
stay NN None
of IN None
25 CD None
days NNS None
or CC None
more JJR None
. . None
patients NNS None
requiring VBG None
mechanical JJ None
ventilation NN None
patient NN None
receiving VBG None
mechanical JJ None
ventilation NN None
hospital JJ None
discharge NN None
and CC None
billing NN None
data NNS None
from IN None
the DT None
2005 CD None
Nationwide NNP None
Inpatient NNP None
Sample NNP None
for IN None
54 CD None
686 CD None
Medicare NNP None
beneficiaries NNS None
admitted VBD None
to TO None
US NNP None
community NN None
hospitals NNS None
who WP None
met VBD None
the DT None
study NN None
's POS None
eligibility NN None
criteria NNS None
. . None
-DOCSTART- -X- N

conservative JJ None
surgery NN None
for IN None
early-stage JJ None
breast NN Condition
cancer NN Condition
. . None
Patients NNPS None
with IN None
early-stage JJ None
breast NN Condition
cancer NN Condition
who WP None
are VBP None
at IN None
substantial JJ None
risk NN None
for IN None
systemic JJ None
metastases NNS Condition
Two CD Size
hundred VBD Size
forty-four JJ Size
patients NNS None
with IN None
stage NN None
I PRP None
or CC None
II NNP None
breast NN Condition
cancer NN Condition
who WP None
were VBD None
at IN None
substantial JJ None
risk NN None
for IN None
distant JJ None
metastases NNS Condition
All DT None
had VBD None
had VBN None
breast-conserving JJ None
surgery NN None
. . None
patients NNS None
ar VBP None
substantial JJ None
risk NN None
for IN None
systemic JJ None
metastases NNS Condition
-DOCSTART- -X- N

people NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
. . None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
people NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
. . None
Ten CD None
male JJ None
subjects NNS None
with IN None
untreated JJ None
type NN None
2 CD None
diabetes NNS None
-DOCSTART- -X- N

platelet NN None
function NN None
in IN None
patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
hypertension NN Condition
. . None
patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
arterial JJ Condition
hypertension NN Condition
. . None
24 CD Size
patients NNS None
( ( None
2 CD None
groups NNS None
of IN None
12 CD Size
patients NNS None
each DT None
) ) None
. . None
hypertensive JJ Condition
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
hypertriglyceridemia NN Condition
. . None
patients NNS None
with IN None
hypertriglyceridemia NN Condition
. . None
Fifty JJ Size
patients NNS None
in IN None
each DT None
group NN None
patients NNS None
with IN None
hypertriglyceridemia NN None
. . None
-DOCSTART- -X- N

progressive JJ Condition
IgA NNP Condition
nephropathy NN Condition
. . None
38 CD Size
patients NNS None
with IN None
progressive JJ Condition
IgA NNP Condition
nephropathy NN Condition
and CC None
controlled VBN None
hypertension NN Condition
Proteinuria NNP Condition
, , None
present NN None
in IN None
all DT None
patients NNS None
at IN None
the DT None
time NN None
of IN None
entry NN None
into IN None
the DT None
trial NN None
Patients NNS None
selected VBN None
for IN None
moderately RB Condition
progressive JJ Condition
IgA NNP Condition
nephropathy JJ Condition
-DOCSTART- -X- N

patients NNS None
treated VBN None
for IN None
localized JJ None
prostatic JJ None
carcinoma NN None
in IN None
a DT None
Phase NNP None
III NNP None
radiotherapy NN None
( ( None
RT NNP None
) ) None
protocol NN None
, , None
Radiation NNP None
Therapy NNP None
Oncology NNP None
Group NNP None
( ( None
RTOG NNP None
) ) None
77-06 NN None
. . None
Patients NNS None
with IN None
T18N0M0 NNP None
( ( None
A2 NNP None
) ) None
or CC None
T2N0M0 NNP None
( ( None
B NNP None
) ) None
disease NN None
after IN None
lymphangiogram NN None
( ( None
LAG NNP None
) ) None
or CC None
staging VBG None
laparotomy NN None
( ( None
SL NNP None
) ) None
were VBD None
randomized VBN None
between IN None
prophylactic JJ None
radiation NN None
to TO None
the DT None
pelvic JJ None
lymph NN None
nodes NNS None
and CC None
prostatic JJ None
bed NN None
vs. FW None
prostatic JJ None
bed NN None
alone RB None
. . None
A NNP None
total NN None
of IN None
449 CD None
eligible JJ None
males NNS None
were VBD None
entered VBN None
into IN None
RTOG NNP None
protocol NN None
7706 CD None
between IN None
1978 CD None
and CC None
1983 CD None
. . None
117 CD None
( ( None
26 CD None
% NN None
) ) None
patients NNS None
had VBD None
SL NNP None
, , None
while IN None
332 CD None
( ( None
74 CD None
% NN None
) ) None
had VBD None
LAG NNP None
. . None
-DOCSTART- -X- N

Hispanic JJ None
cancer NN Condition
patients NNS None
and CC None
their PRP$ None
family NN None
members NNS None
previously RB None
registered VBN None
in IN None
local JJ None
cancer NN Condition
registries NNS None
in IN None
Texas NNP None
. . None
Hispanics NNPS None
to TO None
the DT None
Cancer NNP Condition
Genetics NNP None
Network NNP None
national JJ None
cancer NN Condition
genetics NNS None
registry NN None
. . None
South NNP None
Texas NNP None
cancer NN Condition
registries NNS None
, , None
444 CD Size
Hispanic JJ None
men NNS Condition
and CC None
women NNS Condition
were VBD None
randomly RB None
assigned VBN None
154 CD Size
individuals NNS None
joined VBD None
the DT None
Cancer NNP Condition
Genetics NNP None
Network NNP None
. . None
-DOCSTART- -X- N

pelvic JJ Condition
radiotherapy NN Condition
: : None
90 CD Size
patients NNS None
UK NNP None
. . None
90 CD Size
patients NNS None
receiving VBG None
CT NNP None
planned VBD None
pelvic JJ Condition
radiotherapy NN Condition
using VBG None
weekly JJ None
anterior-posterior JJ None
and CC None
lateral JJ None
portal JJ None
films NNS None
. . None
-DOCSTART- -X- N

PoCT NNP None
device NN None
operators NNS None
-DOCSTART- -X- N

healthy JJ None
subjects NNS None
receiving VBG None
sertraline NN None
and CC None
lorazepam NN None
. . None
Patients NNS None
suffering VBG None
from IN None
some DT None
psychiatric JJ None
and CC None
neurological JJ None
disorders NNS None
patients NNS None
with IN None
schizophrenia NN None
. . None
Twenty NNP None
healthy JJ None
subjects NNS None
-DOCSTART- -X- N

patients NNS None
resuscitated VBN None
from IN None
near-fatal JJ None
ventricular JJ None
arrhythmias NN None
. . None
patients NNS None
who WP None
had VBD None
been VBN None
resuscitated VBN None
from IN None
near-fatal JJ None
ventricular JJ None
fibrillation NN None
or CC None
who WP None
had VBD None
undergone JJ None
cardioversion NN None
from IN None
sustained VBN None
ventricular JJ None
tachycardia NN None
. . None
Patients NNS None
with IN None
ventricular JJ None
tachycardia NN None
also RB None
had VBD None
either CC None
syncope NN None
or CC None
other JJ None
serious JJ None
cardiac NN None
symptoms NNS None
, , None
along IN None
with IN None
a DT None
left JJ None
ventricular JJ None
ejection NN None
fraction NN None
of IN None
0.40 CD None
or CC None
less JJR None
. . None
Of IN None
1016 CD None
patients NNS None
( ( None
45 CD None
percent NN None
of IN None
whom WP None
had VBD None
ventricular JJ None
fibrillation NN None
, , None
and CC None
55 CD None
percent NN None
ventricular JJ None
tachycardia NN None
) ) None
, , None
507 CD None
were VBD None
randomly RB None
assigned VBN None
to TO None
treatment NN None
with IN None
implantable JJ None
cardioverter-defibrillators NNS None
and CC None
509 CD None
to TO None
antiarrhythmic-drug JJ None
therapy NN None
. . None
survivors NNS None
of IN None
ventricular JJ None
fibrillation NN None
or CC None
sustained VBN None
ventricular JJ None
tachycardia NN None
causing VBG None
severe JJ None
symptoms NNS None
-DOCSTART- -X- N

exercise NN Condition
in IN None
humans NNS None
. . None
eight CD Size
volunteers NNS None
undergoing VBG None
physical JJ Condition
stress NN Condition
on IN None
an DT None
ergometric JJ None
bicycle NN None
. . None
-DOCSTART- -X- N

patients NNS None
( ( None
n=209 JJ None
MG NNP None
, , None
n=96 RB None
placebo NN None
) ) None
with IN None
UC NNP None
in IN None
remission NN None
[ NNS None
revised VBN None
Sutherland NNP None
Disease NNP None
Activity NNP None
Index NNP None
( ( None
SDAI NNP None
) ) None
rectal NN None
bleeding=0 NN None
, , None
mucosal JJ None
appearance NN None
< VBD None
2 CD None
] NN None
who WP None
took VBD None
MG NNP None
1.5 CD None
g NN None
or CC None
placebo VB None
once-daily RB None
for IN None
up IN None
to TO None
6 CD None
months NNS None
percentage NN None
of IN None
relapse-free JJ None
patients NNS None
at IN None
month NN None
6/end CD None
of IN None
treatment NN None
was VBD None
-DOCSTART- -X- N

schizophrenic JJ Condition
patient NN None
-DOCSTART- -X- N

clearly RB None
defined VBN None
PMS NNP Condition
sample JJ None
versus NNS None
women NNS Condition
with IN None
premenstrual JJ Condition
symptoms NNS None
in IN None
combination NN None
with IN None
dysphoric NN Condition
symptoms NNS None
throughout IN None
the DT None
cycle NN None
, , None
termed VBD None
the DT None
premenstrual JJ None
exacerbation NN None
( ( None
PME NNP None
) ) None
group NN None
. . None
Thirty-three NNP Size
eligible JJ None
women NNS Sex
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS None
. . None
healthy JJ None
, , None
lean JJ None
males NNS None
. . None
healthy JJ None
males NNS None
. . None
-DOCSTART- -X- N

risk NN None
of IN None
lung NN None
cancer NN None
. . None
susceptibility NN None
to TO None
lung NN None
cancer NN None
. . None
hospital-based JJ None
case-control NN None
study NN None
CA NNP None
repeat NN None
polymorphism NN None
in IN None
the DT None
EGFR NNP None
gene NN None
with IN None
risk NN None
of IN None
lung NN None
cancer NN None
in IN None
a DT None
Korean JJ None
population NN None
. . None
-DOCSTART- -X- N

premenarcheal JJ None
females NNS None
: : None
co-twin JJ None
premenarcheal JJ None
females NNS None
. . None
Fifty-one CD None
pairs NNS None
of IN None
premenarcheal JJ None
female NN None
twins NNS None
( ( None
27 CD None
monozygotic NN None
and CC None
24 CD None
dizygotic JJ None
; : None
mean JJ None
+/- JJ None
sd NN None
age NN None
, , None
10.3 CD None
+/- JJ None
1.5 CD None
yr NN None
) ) None
within-pair JJ None
differences NNS None
in IN None
height NN None
, , None
weight NN None
, , None
or CC None
calcium NN None
intake NN None
at IN None
baseline NN None
. . None
-DOCSTART- -X- N

development NN None
of IN None
parathyroid JJ Condition
gland NN Condition
insufficiency NN Condition
in IN None
our PRP$ None
group NN None
of IN None
patients NNS None
. . None
two CD None
groups NNS None
. . None
first JJ None
group NN None
of IN None
19 CD Size
patients NNS Size
, , None
main JJ None
trunk NN None
of IN None
the DT None
inferior JJ None
thyroid JJ None
artery NN None
was VBD None
ligated VBN None
and CC None
in IN None
the DT None
second JJ None
one CD None
consisting NN None
of IN None
18 CD Size
patients NNS Size
, , None
only RB None
the DT None
branches NNS None
of IN None
this DT None
artery NN None
were VBD None
ligated VBN None
. . None
-DOCSTART- -X- N

10 CD None
patients NNS None
with IN None
asthma NNS None
due JJ None
to TO None
HDM NNP None
-DOCSTART- -X- N

intermittent JJ Condition
claudication NN Condition
: : None
intermittent JJ None
claudication NN None
. . None
multicenter JJ None
trial NN None
, , None
performed VBN None
in IN None
24 CD None
Italian JJ None
centers NNS None
. . None
Two CD None
hundred VBD None
seventeen JJ None
patients NNS None
with IN None
intermittent JJ Condition
claudication NN Condition
( ( Condition
stages NNS Condition
IIa NNP Condition
and CC Condition
IIb NNP Condition
of IN Condition
Fontaine NNP Condition
's POS Condition
PAD NNP Condition
classification NN Condition
) ) Condition
patients NNS None
with IN None
intermittent JJ None
claudication NN None
-DOCSTART- -X- N

autism NN None
autism NN None
Compared VBN None
to TO None
ten VB None
IQ- NNP None
and CC None
age-matched JJ None
healthy JJ None
controls NNS None
, , None
eight CD None
participants NNS None
with IN None
autism NN None
-DOCSTART- -X- N

patients NNS None
with IN None
resectable JJ None
gastric JJ None
cancer NN None
: : None
386 CD None
Japanese JJ None
patients NNS None
with IN None
resectable JJ None
gastric JJ None
cancer NN None
. . None
264 CD None
patients NNS None
with IN None
curatively RB None
resected VBN None
cancer NN None
264 CD None
patients NNS None
patients NNS None
with IN None
a DT None
curatively RB None
resected VBN None
gastric JJ None
cancer NN None
-DOCSTART- -X- N

patients NNS None
hospitalized VBN None
for IN None
major JJ Condition
depression NN Condition
. . None
markedly RB None
or CC None
severely RB Condition
depressed JJ Condition
hospitalized JJ None
patients NNS None
. . None
patients NNS None
hospitalized VBN None
for IN None
major JJ Condition
depression NN Condition
. . None
120 CD Size
patients NNS None
hospitalized VBN None
for IN None
DSM-III-R NNP None
diagnosed VBD None
major JJ None
depression NN None
( ( None
without IN None
psychosis NN Condition
) ) None
Patients NNS None
with IN None
dysthymia NN Condition
in IN None
addition NN None
to TO None
major JJ Condition
depression NN Condition
marked VBN None
to TO None
severe VB None
major JJ Condition
depression NN Condition
in IN None
patients NNS None
requiring VBG None
hospitalization NN None
. . None
-DOCSTART- -X- N

after IN None
caesarean JJ None
section NN None
intramuscular JJ None
ketorolac NN None
30 CD None
mg NN None
( ( None
n JJ None
= NNP None
49 CD None
) ) None
and CC None
intramuscular JJ None
pethidine NN None
75 CD None
mg NN None
( ( None
n JJ None
= NNP None
51 CD None
) ) None
after IN None
elective JJ None
caesarean JJ None
section NN None
under IN None
general JJ None
anaesthesia NN None
. . None
In IN None
the DT None
recovery NN None
ward NN None
, , None
patients NNS None
who WP None
requested VBD None
analgesia NN None
were VBD None
allocated VBN None
randomly RB None
to TO None
receive VB None
ketorolac NN None
30 CD None
mg NN None
or CC None
pethidine VB None
75 CD None
mg NNS None
intramuscularly RB None
. . None
Twenty-six JJ None
patients NNS None
in IN None
the DT None
ketorolac NN None
group NN None
and CC None
17 CD None
patients NNS None
in IN None
the DT None
pethidine NN None
group NN None
-DOCSTART- -X- N

HIV-infected NNP Condition
Thai NNP None
patients NNS None
. . None
HIV NNP Condition
infection NN None
in IN None
Thai NNP Age
adults NNS Age
was VBD None
conducted VBN None
in IN None
3 CD None
hospitals NNS None
in IN None
northern JJ None
Thailand NNP None
during IN None
2002 CD None
to TO None
2003 CD None
. . None
HIV-infected JJ Condition
Thai NNP None
adults NNS Age
who WP None
had VBD None
never RB None
received VBN None
anti-retrovirals NNS None
, , None
had VBD None
a DT None
Karnofski NNP None
Performance NNP None
Score NNP None
( ( None
KPS NNP None
) ) None
of IN None
> NN None
or CC None
= $ None
70 CD None
, , None
and CC None
had VBD None
no DT None
opportunistic JJ None
infections NNS None
. . None
60 CD Size
evaluable JJ Size
subjects NNS Size
, , None
40 CD Size
in IN None
the DT None
SH NNP None
group NN None
and CC None
20 CD Size
in IN None
the DT None
placebo NN None
group NN None
-DOCSTART- -X- N

operable JJ None
breast NN Condition
cancer NN Condition
with IN None
0 CD None
to TO None
3 CD None
positive JJ None
axillary JJ None
nodes NNS None
: : None
metastatic JJ None
breast NN Condition
cancer NN Condition
. . None
operable JJ Condition
breast NN Condition
cancer NN Condition
. . None
Women NNP Sex
with IN None
invasive JJ Condition
breast NN Condition
cancer NN Condition
were VBD None
eligible JJ None
if IN None
there EX None
were VBD None
one CD None
to TO None
three CD None
positive JJ None
lymph NN None
nodes NNS None
or CC None
if IN None
the DT None
node-negative JJ None
tumor NN None
was VBD None
greater JJR None
than IN None
1 CD None
cm NN None
. . None
Patients NNS None
were VBD None
randomly RB None
assigned VBN None
after IN None
surgery NN None
patients NNS None
with IN None
estrogen JJ None
receptor NN None
( ( None
ER NNP None
) ) None
and/or VBP None
progesterone NN None
receptor NN None
( ( None
PR NNP None
) ) None
-positive JJ None
tumors NNS None
. . None
2,882 CD Size
eligible JJ None
patients NNS None
enrolled VBN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
: : None
Forty NNP Size
outpatients NNS None
aged VBD None
4 CD Age
to12 NN Age
years NNS None
, , None
who WP None
were VBD None
diagnosed VBN None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
based VBN None
on IN None
the DT None
Diagnostic NNP None
and CC None
Statistical NNP None
Manual NNP None
of IN None
Mental NNP None
Disorders NNP None
, , None
Fourth NNP None
Edition NNP None
, , None
Text NNP None
Revision NNP None
criteria NNS None
-DOCSTART- -X- N

female JJ Sex
stress NN Condition
urinary JJ Condition
incontinence NN Condition
: : None
female JJ Sex
stress NN Condition
urinary JJ Condition
incontinence NN Condition
( ( Condition
SUI NNP Condition
) ) Condition
. . None
Women NNP Sex
with IN None
urodynamic JJ Condition
SUI NNP Condition
were VBD None
enrolled VBN None
Subjects NNPS None
Of IN None
285 CD Size
women NNS Sex
, , None
144 CD Size
had VBD None
the DT None
U-type JJ None
method NN None
and CC None
141 CD Size
had VBD None
the DT None
H-type JJ None
method NN None
. . None
female JJ None
SUI NNP Condition
. . None
-DOCSTART- -X- N

cesarean JJ Condition
delivery NN Condition
: : None
primary JJ Condition
and CC None
repeat JJ Condition
cesarean JJ Condition
deliveries NNS Condition
258 CD Size
women NNS Sex
undergoing VBG None
primary JJ None
and CC None
repeat JJ None
cesarean JJ None
deliveries NNS None
at IN None
32 CD None
weeks NNS None
of IN None
gestation NN None
or CC None
more JJR None
to TO None
creation NN None
( ( None
n=131 JJ Size
) ) None
or CC None
omission NN None
( ( None
n=127 JJ Size
) ) None
of IN None
the DT None
bladder NN None
flap NN None
. . None
-DOCSTART- -X- N

advanced JJ Condition
, , Condition
suboptimally RB Condition
debulked JJ Condition
ovarian JJ Condition
cancer NN Condition
. . Condition
176 CD None
eligible JJ None
patients NNS None
with IN None
advanced JJ None
suboptimally RB None
operated JJ None
ovarian JJ None
carcinoma NN None
Thirty-seven JJ None
platinum-resistant JJ None
and CC None
27 CD None
platinum-sensitive JJ None
tumours NNS None
Patients NNS None
with IN None
platinum-sensitive JJ None
tumours NNS None
suboptimally RB None
operated JJ None
ovarian JJ None
carcinoma NN None
patients NNS None
Patients NNS None
with IN None
recurrences NNS None
considered VBN None
as IN None
platinum-sensitive JJ None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN None
disorders NNS None
and CC None
developmental JJ None
disabilities NNS None
in IN None
a DT None
population-based JJ None
study NN None
. . None
preschoolers NNS Age
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
and CC None
other JJ None
developmental JJ None
disabilities NNS None
( ( None
DD NNP None
) ) None
. . None
Participants NNS None
were VBD None
578 CD Size
children NNS Age
who WP None
were VBD None
part NN None
of IN None
an DT None
ongoing JJ None
population-based JJ None
, , None
case-control JJ None
study NN None
of IN None
2- JJ Age
to TO Age
5-year JJ Age
olds NNS Age
with IN None
ASD NNP None
, , None
DD NNP None
, , None
and CC None
the DT None
general JJ None
population NN None
. . None
Four CD Size
hundred VBD Size
fifty-three JJ Size
children NNS None
with IN None
ASD NNP None
and CC None
125 CD Size
DD NNP None
children NNS Age
were VBD None
included VBN None
. . None
Hispanic JJ None
families NNS None
non-Hispanic JJ None
families NNS None
. . None
Families NNS None
Underimmunized VBN None
children NNS Age
families NNS None
of IN None
young JJ Age
children NNS Age
with IN None
neurodevelopmental JJ None
disorders NNS None
-DOCSTART- -X- N

Holstein NNP None
calves NNS None
during IN None
the DT None
preweaning NN None
and CC None
postweaning NN None
phases NNS None
. . None
Sixty NNP None
Holstein NNP None
calves VBZ None
( ( Condition
30 CD Condition
bulls NNS Condition
, , Condition
30 CD Condition
heifers NNS Condition
) ) Condition
Calves NNS None
Calves NNS None
raised VBD None
in IN None
the DT None
barn NN None
-DOCSTART- -X- N

40-year-old JJ Age
women NNS Sex
. . None
321 CD Size
women NNS Sex
aged VBN None
38-45 CD Age
years NNS None
was VBD None
conducted VBN None
. . None
Women NNP Sex
in IN None
the DT None
intervention NN None
group NN None
-DOCSTART- -X- N

duodenal JJ None
ulceration NN None
. . None
multi-clinic JJ None
study NN None
comparing VBG None
the DT None
therapeutic JJ None
efficacy NN None
and CC None
degree NN None
of IN None
oral JJ None
staining NN None
of IN None
new JJ None
colloidal JJ None
bismuth NN None
subcitrate NN None
( ( None
CBS NNP None
) ) None
coated VBD None
tablets NNS None
over IN None
4 CD None
weeks NNS None
of IN None
treatment NN None
in IN None
patients NNS None
suffering VBG None
from IN None
duodenal JJ None
ulceration NN None
9 CD None
clinics NNS None
in IN None
the DT None
Netherlands NNP None
, , None
Belgium NNP None
, , None
Ireland NNP None
, , None
the DT None
United NNP None
Kingdom NNP None
, , None
and CC None
Italy NNP None
. . None
94 CD None
patients NNS None
treated VBN None
with IN None
CBS NNP None
coated VBD None
tablets NNS None
and CC None
95 CD None
patients NNS None
treated VBN None
with IN None
CBS NNP None
chewing VBG None
tablets NNS None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
children NNS None
with IN None
autism NN None
47 CD None
teachers NNS None
and CC None
children NNS None
-DOCSTART- -X- N

non-dependent JJ None
humans NNS None
. . None
seven CD Size
non-physically-dependent JJ None
opioid JJ Condition
abuser NN Condition
volunteers NNS None
-DOCSTART- -X- N

high-risk JJ None
individuals NNS None
. . None
Three CD None
hundred VBD None
sixty-six JJ None
patients NNS None
undergoing VBG None
elective JJ None
cardiac JJ None
surgery NN None
with IN None
full JJ None
median JJ None
sternotomy NN None
and CC None
having VBG None
body NN None
surface JJ None
area NN None
( ( None
BSA NNP None
) ) None
less JJR None
than IN None
1.5 CD None
m NN None
( ( None
2 CD None
) ) None
following VBG None
median JJ None
sternotomy NN None
in IN None
high-risk JJ None
patients NNS None
with IN None
little JJ None
body NN None
mass NN None
. . None
-DOCSTART- -X- N

autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
individuals NNS None
with IN None
ASD NNP None
individuals NNS None
with IN None
ASD NNP Condition
High-functioning JJ Condition
children NNS Age
with IN None
ASD NNP Condition
a DT None
group NN None
of IN None
typically RB None
developing VBG None
children NNS None
. . None
individuals NNS None
with IN None
ASD NNP None
individuals NNS None
with IN None
ASD NNP None
-DOCSTART- -X- N

men NNS None
treated VBN None
with IN None
radiotherapy NN None
and CC None
androgen NN None
deprivation NN None
for IN None
prostate JJ None
cancer NN None
: : None
478 CD None
patient JJ None
cases NNS None
. . None
patients NNS None
with IN None
prostate JJ None
cancer NN None
-DOCSTART- -X- N

Half NN None
of IN None
the DT None
participants NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
the DT None
conscious-processing-condition NN None
( ( None
i.e. FW None
consciously RB None
thinking VBG None
about IN None
the DT None
information NN None
they PRP None
read VBP None
in IN None
the DT None
case NN None
description NN None
) ) None
, , None
the DT None
other JJ None
half NN None
to TO None
the DT None
unconscious-processing JJ None
condition NN None
( ( None
i.e. FW None
performing VBG None
an DT None
unrelated JJ None
distracter NN None
task NN None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
major JJ None
depressive JJ None
disorder NN None
( ( None
MDD NNP None
) ) None
. . None
15 CD None
MDD NNP None
patients NNS None
and CC None
14 CD None
age-matched JJ None
controls NNS None
. . None
MDD NNP None
patients NNS None
and CC None
age-matched JJ None
controls NNS None
MDD NNP None
patients NNS None
-DOCSTART- -X- N

of IN None
type NN Condition
1 CD Condition
diabetic JJ Condition
subjects NNS None
. . None
Referral JJ None
clinics NNS None
in IN None
27 CD None
academic JJ None
centers NNS None
. . None
PATIENTS NNP None
Type NNP None
1 CD None
diabetics NNS Condition
. . None
males NNS Sex
and CC None
females NNS Sex
, , None
tobacco NN None
users NNS None
Female JJ None
smokers NNS None
male JJ None
tobacco NN None
users NNS None
female JJ None
and CC None
male JJ None
tobacco NN None
users NNS None
. . None
former JJ None
tobacco NN None
users NNS None
-DOCSTART- -X- N

chronic JJ Condition
fatigue NN Condition
syndrome NN Condition
patients NNS None
meeting NN None
Oxford NNP None
criteria NN None
for IN None
chronic JJ Condition
fatigue NN Condition
syndrome NN Condition
were VBD None
recruited VBN None
from IN None
six CD None
secondary-care JJ None
clinics NNS None
in IN None
the DT None
UK NNP None
641 CD Condition
eligible JJ None
patients NNS None
criteria NNS None
for IN None
chronic JJ None
fatigue NN None
syndrome NN None
and CC None
-DOCSTART- -X- N

adolescents NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
adolescents NNS Age
with IN Age
higher-functioning JJ Age
ASD NNP Age
. . Age
58 CD None
participants NNS None
aged VBN None
11-16 JJ None
years-old JJ None
adolescents NNS Age
with IN Age
ASD NNP Age
. . Age
-DOCSTART- -X- N

patients NNS None
with IN None
rheumatic JJ None
valve NNS None
disease NN None
undergoing VBG None
valve JJ None
replacement NN None
surgery NN None
. . None
patients NNS None
undergoing VBG None
valve JJ None
replacement NN None
surgery NN None
. . None
Fifty-six JJ None
patients NNS None
with IN None
valvular JJ None
heart NN None
disease NN None
with IN None
or CC None
without IN None
AF NNP None
were VBD None
randomly RB None
divided VBN None
-DOCSTART- -X- N

childhood NN Age
. . None
500 CD None
mother-child JJ None
pairs NNS None
from IN None
a DT None
low-income JJ None
area NN None
of IN None
S?o NNP None
Leopoldo NNP None
, , None
State NNP None
of IN None
Rio NNP None
Grande NNP None
do VBP None
Sul NNP None
, , None
Brazil NNP None
, , None
to TO None
evaluate VB None
the DT None
impact NN None
of IN None
a DT None
nutritional JJ None
intervention NN None
in IN None
the DT None
first JJ None
year NN None
of IN None
life NN None
on IN None
the DT None
dietary JJ None
quality NN None
of IN None
3- JJ None
to TO None
4-y-old JJ None
children NNS None
. . None
for IN None
345 CD None
children NNS None
of IN None
children NNS None
in IN None
a DT None
low-income JJ None
population NN None
. . None
-DOCSTART- -X- N

incontinent JJ Condition
elderly RB None
in IN None
nursing VBG None
homes NNS None
: : None
133 CD None
incontinent JJ Condition
elderly RB None
in IN None
seven CD None
nursing NN None
homes NNS None
Trainees NNS None
with IN None
a DT None
high JJ None
frequency NN None
of IN None
incontinence NN None
during IN None
baseline NN None
, , None
relatively RB None
more RBR None
cognitive JJ None
residents NNS None
, , None
and CC None
residents NNS None
with IN None
a DT None
normal JJ None
bladder NN None
capacity NN None
nursing JJ None
home NN None
residents NNS None
. . None
-DOCSTART- -X- N

high-functioning JJ None
autism NN None
spectrum NN None
disorders NNS None
. . None
children NNS None
with IN None
HFASDs NNP None
. . None
-DOCSTART- -X- N

proactive JJ None
learning NN None
in IN None
hypnosis NN Condition
, , None
post-hypnotic JJ None
suggestion NN None
, , None
and CC None
academic JJ None
performance NN None
. . None
Participants NNS None
( ( None
N NNP None
= NNP None
56 CD Size
) ) None
control NN None
group NN None
treatment NN None
group NN None
. . None
-DOCSTART- -X- N

six CD Size
healthy JJ None
adult NN Age
volunteers NNS None
. . None
six CD None
subjects NNS None
-DOCSTART- -X- N

low-resourced JJ None
preschoolers NNS Age
with IN None
autism NN Condition
: : None
preschool-aged JJ Age
children NNS Age
with IN None
Autism NNP Condition
Spectrum NNP Condition
Disorder NNP Condition
who WP None
had VBD None
low JJ None
resources NNS None
. . None
Participants NNP None
included VBD None
112 CD Size
families NNS None
of IN None
a DT None
child NN Age
who WP None
had VBD None
Autism NNP Condition
Spectrum NNP Condition
Disorder NNP Condition
who WP None
met VBD None
criteria NNS None
for IN None
being VBG None
low-resourced JJ None
and CC None
who WP None
were VBD None
randomly RB None
assigned VBN None
to TO None
1 CD None
of IN None
2 CD None
3-month JJ None
interventions NNS None
, , None
group NN None
caregiver NN None
education NN None
or CC None
individualized VBN None
caregiver-mediated JJ None
intervention NN None
( ( None
CMM NNP None
) ) None
. . None
low-resourced JJ None
families NNS None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
autistic JJ Condition
disorder NN Condition
. . None
children NNS None
with IN None
autism NN Condition
. . None
Thirty-nine JJ Size
subjects NNS Size
( ( None
intent NN None
to TO None
treat VB None
; : None
5-19 CD None
years NNS None
old JJ None
; : None
IQ NNP None
> NNP None
35 CD None
) ) None
had VBD None
autism NN Condition
diagnosed VBN Condition
according VBG Condition
to TO Condition
DSM-IV NNP Condition
and CC Condition
ICD-10 NNP Condition
criteria NNS Condition
using VBG Condition
the DT Condition
Autism NNP Condition
Diagnostic NNP Condition
Interview-Revised JJ Condition
and CC Condition
the DT Condition
Autism NNP Condition
Diagnostic NNP Condition
Observation NNP Condition
Schedule-Generic NNP Condition
. . None
children NNS None
with IN None
autistic JJ Condition
disorder NN Condition
-DOCSTART- -X- N

PCI NNP None
. . None
percutaneous JJ None
coronary JJ None
intervention NN None
( ( None
PCI NNP None
) ) None
. . None
5362 CD Size
patients NNS None
who WP None
had VBD None
not RB None
been VBN None
treated VBN None
with IN None
clopidogrel NN None
to TO None
receive VB None
either DT None
cangrelor NN None
or CC None
placebo NN None
at IN None
the DT None
time NN None
of IN None
PCI NNP None
, , None
followed VBN None
by IN None
600 CD None
mg NNS None
of IN None
clopidogrel NN None
. . None
primary JJ None
end NN None
point NN None
occurred VBD None
in IN None
185 CD None
of IN None
2654 CD Size
patients NNS None
receiving VBG None
cangrelor NN None
( ( None
7.0 CD None
% NN None
) ) None
and CC None
in IN None
210 CD None
of IN None
2641 CD Size
patients NNS None
receiving VBG None
placebo NN None
( ( None
8.0 CD None
% NN None
) ) None
-DOCSTART- -X- N

bipolar JJ None
bipolar JJ None
depression NN None
: : None
paroxetine NN None
study NN None
352 CD None
. . None
117 CD Size
patients NNS None
with IN None
bipolar JJ Condition
type NN Condition
I PRP Condition
major JJ Condition
depressive JJ Condition
episode NN Condition
which WDT None
was VBD None
unresponsive JJ None
to TO None
prior VB None
lithium NN None
carbonate NN None
therapy NN None
. . None
-DOCSTART- -X- N

obese JJ Condition
patients NNS None
with IN None
heart NN Condition
failure NN Condition
: : None
obese JJ Condition
patients NNS None
with IN None
heart NN Condition
failure NN Condition
obese JJ Condition
patients NNS None
with IN None
ejection NN None
fractions NNS None
< VBP None
or CC None
=40 CD None
% NN None
. . None
Twenty-one JJ Size
consecutive JJ None
obese JJ None
patients NNS None
with IN None
heart NN Condition
failure NN Condition
were VBD None
recruited VBN None
. . None
-DOCSTART- -X- N

subgroups NNS None
with IN None
glucocorticoid-induced JJ None
osteoporosis NN None
. . None
different JJ None
subgroups NNS None
with IN None
glucocorticoid-induced JJ None
osteoporosis NN None
. . None
patients NNS None
on IN None
glucocorticoids NNS None
different JJ None
patient NN None
subgroups NNS None
Patients NNPS None
subpopulations NNS None
] VBP None
were VBD None
subgrouped VBN None
by IN None
age NN None
; : None
gender NN None
; : None
menopausal NN None
status NN None
in IN None
women NNS None
; : None
dose VB None
and CC None
duration NN None
of IN None
prednisone NN None
during IN None
the DT None
trial NN None
; : None
and CC None
baseline VB None
serum JJ None
25-OH JJ None
vitamin NN None
D NNP None
, , None
LS NNP None
BMD NNP None
T-score NNP None
, , None
creatinine JJ None
clearance NN None
, , None
and CC None
concomitant JJ None
medication NN None
use NN None
. . None
Osteoporotic JJ None
patients NNS None
in IN None
-DOCSTART- -X- N

total JJ Condition
hip NN Condition
replacement NN Condition
. . None
10 CD Size
patients NNS None
undergoing JJ None
total JJ None
hip NN None
replacement NN None
( ( None
THR NNP Condition
) ) None
patients NNS None
undergoing JJ Condition
THR NNP Condition
. . None
100 CD Size
patients NNS None
were VBD None
randomized VBN None
. . None
patients NNS None
undergoing JJ None
total JJ None
hip NN None
replacement NN None
-DOCSTART- -X- N

Maternal NNP None
erythropoietin NN None
in IN None
singleton NN Condition
pregnancies NNS Condition
: : None
97 CD Size
patients NNS None
with IN None
a DT None
first-trimester JJ None
hemoglobin NN None
level NN None
> NN None
or CC None
= $ None
14.0 CD None
gm/dl NN None
( ( None
hematinic JJ None
group NN None
, , None
n RB None
= VBZ None
53 CD Size
) ) None
or CC None
a DT None
placebo NN None
( ( None
n JJ None
= NNP None
44 CD Size
) ) None
. . None
-DOCSTART- -X- N

anxiety NN Condition
in IN None
children NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
children NNS None
with IN None
high-functioning JJ Condition
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( Condition
ASD NNP Condition
) ) Condition
and CC None
clinically RB Condition
significant JJ Condition
anxiety NN Condition
A NNP None
total NN None
of IN None
45 CD Size
children NNS None
( ( None
7-11 CD None
years NNS None
of IN None
age NN None
) ) None
with IN None
high-functioning JJ Condition
ASD NNP Condition
and CC None
clinically RB Condition
significant JJ Condition
anxiety NN Condition
-DOCSTART- -X- N

autism NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
. . None
Forty-two JJ Size
children NNS Age
with IN None
the DT None
diagnosis NN None
of IN None
autism NN Condition
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
. . None
autistic JJ None
spectrum NN None
disorders NNS None
Parent NN None
and CC None
teacher NN None
data NNS None
from IN None
the DT None
Aberrant NNP None
Behavior NNP None
Checklist NNP None
eight CD None
male JJ None
children NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
early JJ None
breast NN Condition
cancer NN Condition
: : None
285 CD Size
premenopausal NN Condition
breast NN Condition
cancer NN Condition
patients NNS None
, , None
in IN None
a DT None
randomized JJ None
adjuvant JJ None
trial NN None
( ( None
Zoladex NNP None
in IN None
premenopausal NN None
patients NNS None
( ( None
ZIPP NNP None
) ) None
) ) None
Node NNP None
positive JJ None
patients NNS None
-DOCSTART- -X- N

The DT None
three CD None
data NNS None
sources NNS None
for IN None
the DT None
study NN None
were VBD None
( ( None
1 CD None
) ) None
the DT None
generic JJ None
screen NN None
results NNS None
of IN None
a DT None
3 CD None
percent NN None
random JJ None
sample NN None
of IN None
Medicare NNP None
beneficiaries NNS None
age NN None
65 CD None
years NNS None
or CC None
older JJR None
who WP None
were VBD None
admitted VBN None
to TO None
California NNP None
hospitals NNS None
between IN None
1 CD None
July NNP None
1987 CD None
and CC None
30 CD None
June NNP None
1988 CD None
( ( None
n JJ None
= $ None
20,136 CD None
patients NNS None
) ) None
; : None
( ( None
2 CD None
) ) None
the DT None
1987 CD None
and CC None
1988 CD None
California NNP None
Medicare NNP None
Provided VBD None
Analysis NNP None
and CC None
Review NNP None
( ( None
MEDPAR NNP None
) ) None
data NN None
files NNS None
; : None
and CC None
( ( None
3 CD None
) ) None
the DT None
American NNP None
Hospital NNP None
Association NNP None
( ( None
AHA NNP None
) ) None
1988 CD None
Annual NNP None
Survey NNP None
of IN None
Hospitals NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
locally RB None
advanced JJ None
gastric JJ Condition
cancer NN Condition
. . Condition
gastric JJ Condition
cancer NN Condition
patients NNS None
advanced JJ None
gastric JJ Condition
cancer NN Condition
. . Condition
patients NNS None
with IN None
locally RB None
advanced VBN None
resectable JJ Condition
gastric JJ Condition
cancer NN Condition
. . Condition
156 CD Size
patients NNS None
with IN None
stage NN Condition
III NNP Condition
or CC Condition
IV NNP Condition
gastric JJ Condition
cancer NN Condition
who WP None
had VBD None
undergone JJ None
curative JJ Condition
resection NN Condition
patients NNS None
with IN None
pT2/T3 JJ Condition
primary JJ Condition
tumors NNS Condition
patients NNS None
with IN None
intestinal-type JJ Condition
but CC Condition
not RB Condition
diffuse-type JJ Condition
cancer NN Condition
. . Condition
limited JJ None
number NN None
of IN None
patients NNS None
gastric JJ Condition
cancer NN Condition
patients NNS None
after IN None
curative JJ Condition
gastrectomy NN Condition
; : None
in IN None
particular JJ None
, , None
in IN None
patients NNS None
with IN None
pT2/T3 JJ Condition
tumors NNS Condition
and CC Condition
intestinal-type JJ Condition
primary JJ Condition
tumors NNS Condition
. . Condition
-DOCSTART- -X- N

ischaemic JJ Condition
ulcers NNS Condition
of IN None
the DT None
lower JJR None
limb NN None
. . None
Scandinavian-Polish JJ None
placebo NN None
controlled VBN None
, , None
randomised VBN None
multicenter NN None
study NN None
. . None
103 CD Size
patients NNS None
with IN None
ischaemic JJ None
ulcers NNS None
who WP None
were VBD None
randomised VBN None
to TO None
receive VB None
active JJ None
treatment NN None
or CC None
placebo NN None
. . None
-DOCSTART- -X- N

myopia NN Condition
95 CD Size
subjects NNS None
enrolled VBN None
in IN None
the DT None
United NNP None
States NNPS None
Food NNP None
and CC None
Drug NNP None
Administration NNP None
Phase NNP None
III NNP None
clinical JJ None
trials NNS None
. . None
99 CD None
% NN None
of IN None
patients NNS None
( ( None
89 CD Size
of IN None
90 CD Size
) ) None
had VBD None
20/40 CD Condition
uncorrected JJ Condition
vision NN Condition
or CC Condition
better JJR Condition
. . None
-DOCSTART- -X- N

caries NNS None
removal VBP None
techniques NNS None
on IN None
human JJ None
dentin NN None
. . None
different JJ None
caries NNS None
removal VBP None
techniques NNS None
on IN None
human JJ None
dentin NN None
topography NN None
. . None
Thirty-six NNP None
extracted VBD None
human JJ None
carious JJ None
mandibular NN None
molars NNS None
six CD None
groups NNS None
according VBG None
to TO None
caries NNS None
removal NN None
technique NN None
. . None
-DOCSTART- -X- N

A NNP None
total NN None
of IN None
78 CD None
boys NNS None
age NN None
13-15 CD None
years NNS None
with IN None
a DT None
mean JJ None
body NN None
fat JJ None
percentage NN None
of IN None
30 CD None
% NN None
+/-9 JJ None
% NN None
normotensive JJ None
and CC None
normolipidemic JJ None
slightly RB None
overweight JJ None
adolescent NN None
boys NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
( ( None
RA NNP None
) ) None
38 CD None
patients NNS None
with IN None
RA NNP None
and CC None
20 CD None
controls NNS None
-DOCSTART- -X- N

data NNS None
from IN None
the DT None
Physicians NNPS None
' POS None
Health NNP None
Study NNP None
aspirin JJ Condition
users NNS Condition
22071 CD Size
U.S. NNP None
male JJ Sex
physicians NNS None
. . None
aspirin JJ None
arm NN None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Sex
with IN None
chronic JJ Condition
venous JJ Condition
insufficiency NN Condition
: : None
postmenopausal JJ Condition
women NNS None
with IN None
chronic JJ Condition
venous JJ Condition
insufficiency NN Condition
( ( Condition
CVI NNP Condition
) ) Condition
. . None
Consecutive JJ None
postmenopausal NN None
women NNS None
( ( None
N=130 NNP None
; : None
mean JJ None
age NN None
? . None
SD NNP None
, , None
65.44?14.7y CD None
) ) None
with IN None
mild JJ None
CVI NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
gastrointestinal JJ Condition
cancer NN Condition
. . None
patients NNS None
with IN None
gastrointestinal JJ Condition
cancer NN Condition
. . None
among IN None
512 CD Size
patients NNS None
with IN None
gastrointestinal JJ Condition
cancer NN Condition
included VBD None
in IN None
the DT None
TACTIC NNP None
study NN None
. . None
89.2 CD None
per IN None
cent NN None
of IN None
patients NNS None
had VBD None
a DT None
primary JJ Condition
tumour NN Condition
and CC None
79.7 CD None
per IN None
cent NN None
underwent NN None
surgery NN None
with IN None
curative JJ None
intent NN None
; : None
243 CD Size
patients NNS None
received VBD None
perioperative JJ None
RBC NNP None
transfusion NN None
( ( None
median JJ None
3 CD None
units NNS None
) ) None
. . None
LD NNP None
group NN None
non-LD JJ None
group NN None
patients NNS None
with IN None
gastrointestinal JJ Condition
cancer NN Condition
. . None
-DOCSTART- -X- N

Supervisor NNP None
tolerance-responsiveness NN None
Supervisor NNP None
tolerance-responsiveness JJ None
troubled JJ None
employees NNS None
supervisor NN None
responsiveness NN None
to TO None
employee NN None
substance NN None
abuse NN None
. . None
supervisor NN None
response NN None
to TO None
and CC None
tolerance NN None
of IN None
coworker NN None
substance NN None
use NN None
Employee NNP None
Assistance NNP None
Program NNP None
( ( None
EAP NNP None
) ) None
in IN None
two CD None
workplaces NNS None
( ( None
n JJ None
= NN None
244 CD None
and CC None
107 CD None
) ) None
. . None
Supervisors NNS None
receiving VBG None
this DT None
training NN None
( ( None
n JJ None
= NNP None
29 CD None
) ) None
supervisors NNS None
who WP None
received VBD None
a DT None
more RBR None
didactic JJ None
, , None
informational JJ None
training NN None
( ( None
n JJ None
= NNP None
23 CD None
) ) None
or CC None
a DT None
no-training JJ None
control NN None
group NN None
( ( None
n JJ None
= NNP None
17 CD None
) ) None
. . None
Trained VBN None
supervisors NNS None
-DOCSTART- -X- N

25 CD None
couples NNS Condition
-DOCSTART- -X- N

alcoholic JJ None
cirrhosis NN None
. . None
30 CD None
patients NNS None
with IN None
biopsy-proven JJ None
alcoholic JJ None
liver NN None
cirrhosis NN None
. . None
cirrhotics NNS None
-DOCSTART- -X- N

treatment NN None
of IN None
Helicobacter NNP Condition
pylori NN Condition
. . None
Helicobacter NNP None
pylori JJ None
infection NN None
. . None
patients NNS None
with IN None
H. NNP None
pylori JJ None
infection NN None
. . None
Sixty JJ Size
patients NNS None
with IN None
peptic JJ Condition
ulcer NN Condition
( ( None
gastric JJ Condition
, , None
32 CD Size
patients NNS None
; : None
duodenal JJ Condition
, , None
28 CD Size
patients NNS None
) ) None
who WP None
had VBD None
a DT None
history NN Condition
of IN Condition
ulcer JJ Condition
recurrence NN Condition
Forty-eight JJ Size
patients NNS None
completed VBD None
the DT None
protocol NN None
; : None
-DOCSTART- -X- N

young JJ Sex
women NNS Sex
young JJ Age
, , None
healthy JJ None
women NNS Age
. . None
Subjects NNS None
were VBD None
155 CD Size
young JJ None
( ( None
aged VBN None
18-30 CD Age
y NN None
) ) None
, , None
healthy JJ None
, , None
normal-weight JJ None
women NNS None
with IN None
intake NN None
of IN None
dietary JJ None
calcium NN None
< VBZ None
800 CD None
mg/d NN None
and CC None
energy NN None
intake VBP None
< CD None
/= JJ None
2200 CD None
kcal/d NN None
. . None
One CD Size
hundred VBD Size
thirty-five JJ Size
women NNS None
completed VBD None
the DT None
trial NN None
. . None
young JJ Age
, , None
healthy JJ None
women NNS Age
-DOCSTART- -X- N

patients NNS None
with IN None
metastatic JJ Condition
breast NN Condition
cancer NN Condition
( ( None
MBC NNP Condition
) ) None
who WP None
had VBD None
previously RB Condition
received VBN Condition
anthracyclines NNS Condition
. . None
total NN None
of IN None
210 CD Size
patients NNS None
204 CD Size
patients NNS None
evaluable JJ None
for IN None
response NN None
assessment NN None
, , None
the DT None
response NN None
rates NNS None
were VBD None
48.6 CD None
% NN None
for IN None
GP1 NNP None
, , None
52.2 CD None
% NN None
for IN None
GP2 NNP None
, , None
and CC None
52.3 CD None
% NN None
for IN None
GD NNP None
. . None
208 CD Size
patients NNS None
evaluable JJ None
for IN None
safety NN None
-DOCSTART- -X- N

lactational JJ None
amenorrhea NN None
in IN None
Honduran NNP None
women NNS None
. . None
postpartum NN None
low-income JJ None
Honduran NNP None
women NNS None
who WP None
had VBD None
breast-fed VBN None
fully RB None
for IN None
4 CD None
mo NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
one CD None
of IN None
three CD None
groups NNS None
: : None
-DOCSTART- -X- N

restless JJ Condition
legs JJ Condition
syndrome NN Condition
in IN Condition
patients NNS Condition
on IN Condition
chronic JJ Condition
hemodialysis NN Condition
: : Condition
patients NNS None
with IN None
renal JJ Condition
failure NN Condition
. . None
11 CD Size
patients NNS None
with IN None
RLS NNP None
on IN None
chronic JJ None
hemodialysis NN None
. . None
Eleven NNP None
patients NNS None
( ( None
7 CD Size
men NNS Sex
, , None
4 CD Size
women NNS Sex
) ) None
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
The DT None
10 CD Size
patients NNS None
who WP None
completed VBD None
the DT None
study NN None
patients NNS None
on IN None
chronic JJ None
hemodialysis NN None
. . None
-DOCSTART- -X- N

patient JJ None
Patients NNS None
who WP None
were VBD None
taught VBN None
about IN None
their PRP$ None
health NN Condition
problems NNS Condition
while IN None
waiting VBG None
in IN None
the DT None
clinic NN None
( ( None
n JJ None
= NNP None
104 CD Size
) ) None
control NN None
group NN None
( ( None
n JJ None
= NNP None
101 CD Size
) ) None
. . None
-DOCSTART- -X- N

Four CD Size
hundred VBD Size
two CD Size
patients NNS None
with IN None
suspected JJ Condition
myocardial JJ Condition
infarction NN Condition
seen VBN None
within IN None
6 CD None
hours NNS None
of IN None
the DT None
onset NN None
of IN None
symptoms NNS None
204 CD Size
patients NNS None
with IN None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
four CD None
patients NNS None
-DOCSTART- -X- N

chronic JJ Condition
, , None
non-healing JJ Condition
ulcers NNS Condition
of IN None
the DT None
lower JJR Condition
limb NN Condition
in IN None
patients NNS None
with IN None
diabetes NNS Condition
mellitus NNS Condition
: : None
diabetic JJ Condition
ulcers NNS Condition
. . None
patients NNS None
with IN None
diabetes NNS None
mellitus NNS None
and CC None
chronic JJ Condition
ulcers NNS Condition
of IN None
the DT None
lower JJR Condition
limb NN Condition
. . None
One CD Size
hundred CD Size
and CC Size
eighteen JJ Size
( ( None
59 CD Size
patients NNS None
per IN None
arm NN None
) ) None
patients NNS None
with IN None
non-healing JJ Condition
diabetic JJ Condition
ulcers NNS Condition
of IN None
the DT None
lower JJR Condition
limb NN Condition
, , None
referred VBD None
to TO None
the DT None
Judy NNP None
Dan NNP None
Research NNP None
and CC None
Treatment NNP None
Centre NNP None
are VBP None
being VBG None
recruited VBN None
if IN None
they PRP None
are VBP None
at IN None
least JJS None
18 CD Age
years NNS None
of IN None
age NN None
, , None
have VBP None
either DT None
Type NNP Condition
1 CD Condition
or CC Condition
2 CD Condition
diabetes NNS Condition
with IN None
a DT None
Wagner NNP None
grading NN None
of IN None
foot NN None
lesions NNS None
2 CD None
, , None
3 CD None
or CC None
4 CD None
on IN None
lower JJR None
limb NN None
not RB None
healing VBG None
for IN None
at IN None
least JJS None
4 CD None
weeks NNS None
. . None
non-healing JJ None
ulcers NNS None
of IN None
the DT None
lower JJR None
limb NN None
. . None
diabetic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

greyhound VB None
dogs NNS None
wearing VBG None
leg NN None
casts NNS None
The DT None
animal NN None
used VBN None
for IN None
these DT None
studies NNS None
was VBD None
the DT None
greyhound NN None
, , None
which WDT None
has VBZ None
thin JJ None
skin NN None
, , None
angular JJ None
conformation NN None
, , None
limited JJ None
body NN None
fat JJ None
and CC None
is VBZ None
predisposed VBN None
to TO None
pressure VB None
ulcers NNS None
similar JJ None
to TO None
those DT None
occurring VBG None
in IN None
humans NNS None
. . None
-DOCSTART- -X- N

dysmenorrhoea NN None
. . None
Kerman NNP None
, , None
Islamic NNP None
Republic NNP None
of IN None
Iran NNP None
in IN None
2002 CD None
primary JJ None
dysmenorrhoea NN None
. . None
Two CD None
groups NNS None
of IN None
high-school JJ None
girls NNS None
( ( None
mean JJ None
age NN None
13 CD None
years NNS None
) ) None
suffering VBG None
dysmenorrhoea NN None
were VBD None
randomized VBN None
-DOCSTART- -X- N

human JJ None
platelet NN None
aggregation NN None
. . None
40 CD None
aspirin-na?ve JJ None
volunteers NNS None
with IN None
at IN None
least JJS None
one CD None
cardiovascular NN None
risk NN None
factor NN None
20 CD None
patients NNS None
with IN None
a DT None
prior JJ None
diagnosis NN None
of IN None
coronary JJ None
heart NN None
disease NN None
who WP None
were VBD None
chronically RB None
assuming VBG None
aspirin NN None
was VBD None
-DOCSTART- -X- N

autism NN None
spectrum NN None
disorders NNS None
: : None
46 CD None
children NNS None
, , None
3-7 CD None
years NNS None
of IN None
age NN None
diagnosed VBN None
with IN None
an DT None
ASD NNP None
-DOCSTART- -X- N

obese JJ Condition
, , None
insulin JJ Condition
resistant NN Condition
, , None
normoglycemic JJ Condition
, , None
hypertensive JJ Condition
men NNS None
. . None
6 CD Size
obese JJ Condition
insulin NN Condition
resistant NN Condition
, , None
normoglycemic JJ Condition
hypertensive JJ Condition
men NNS None
were VBD None
investigated VBN None
( ( None
age NN None
49 CD Age
+/- JJ Age
2 CD Age
years NNS None
, , None
BMI NNP None
27.6 CD None
+/- JJ None
1.2 CD None
, , None
mean JJ None
+/- JJ None
SEM NNP None
) ) None
. . None
-DOCSTART- -X- N

venous JJ None
thromboembolism NN None
after IN None
abdominal JJ None
surgery NN None
: : None
venous JJ None
thromboembolism NN None
after IN None
abdominal JJ None
surgery NN None
Patients NNS None
aged VBN None
at IN None
least JJS None
40 CD None
years NNS None
undergoing JJ None
abdominal JJ None
surgery NN None
1309 CD None
patients NNS None
fondaparinux-treated JJ None
patients NNS None
placebo-treated JJ None
patients NNS None
patients NNS None
undergoing JJ None
abdominal JJ None
surgery NN None
and CC None
receiving VBG None
intermittent JJ None
pneumatic JJ None
compression NN None
-DOCSTART- -X- N

preeclampsia NN Condition
. . None
pregnant JJ None
women NNS Sex
with IN None
a DT None
high JJ None
risk NN None
of IN None
preeclampsia NN Condition
Forty NNP Size
pregnant JJ None
women NNS Sex
preeclampsia NN Condition
in IN None
high-risk JJ None
pregnant JJ None
women NNS None
. . None
-DOCSTART- -X- N

adolescent JJ None
girls NNS None
: : None
adolescent JJ None
girls NNS None
33 CD None
sexually-active JJ None
, , None
single JJ None
girls NNS None
. . None
62 CD None
sexually-active JJ None
, , None
single JJ None
girls NNS None
. . None
girls NNS None
-DOCSTART- -X- N

humans NNS None
: : None
living NN None
humans NNS None
A DT None
total NN None
of IN None
35 CD None
healthy JJ None
men NNS None
were VBD None
studied VBN None
humans NNS None
-DOCSTART- -X- N

memory-based JJ None
automaticity NN None
: : None
Participants NNS None
-DOCSTART- -X- N

women NNS Sex
who WP None
seek VBP None
reduction NN Condition
mammaplasty NN Condition
have VBP None
pathological JJ None
degrees NNS None
of IN None
anxiety NN None
or CC None
depression NN None
, , None
or CC None
both DT None
. . None
Eighty-two JJ Size
patients NNS None
were VBD None
randomised VBN None
, , None
40 CD None
to TO None
have VB None
the DT None
operation NN None
, , None
and CC None
42 CD None
patients NNS None
to TO None
conservative JJ None
treatment NN None
. . None
Twenty-nine JJ None
patients NNS None
in IN None
the DT None
operated JJ None
group NN None
and CC None
35 CD None
patients NNS None
in IN None
the DT None
conservative JJ None
group NN None
-DOCSTART- -X- N

women NNS None
with IN None
breast NN Condition
cancer NN Condition
and CC None
their PRP$ None
partners NNS None
. . None
both DT None
women NNS None
with IN None
breast NN Condition
cancer NN Condition
and CC None
their PRP$ None
partners NNS None
women NNS Sex
and CC None
their PRP$ None
partners NNS Sex
. . None
women NNS None
with IN None
breast NN Condition
cancer NN Condition
and CC None
their PRP$ None
partners NNS None
. . None
Ninety-six JJ Size
women NNS Size
and CC None
their PRP$ None
96 CD Size
partners NNS Size
women NNS None
with IN None
breast NN Condition
cancer NN Condition
women NNS None
's POS None
partners NNS None
' POS None
partners NNS None
women NNS None
, , None
partners NNS None
' POS None
-DOCSTART- -X- N

Irrigation NN None
with IN None
bupivacaine NN None
at IN None
the DT None
surgical JJ None
bed NN None
for IN None
postoperative JJ Condition
pain NN Condition
relief NN None
after IN None
laparoscopic JJ None
cholecystectomy NN None
. . None
laparoscopic JJ None
cholecystectomy NN None
patients NNS None
. . None
60 CD Size
patients NNS None
undergoing JJ None
elective JJ None
laparoscopic NN Condition
cholecystectomy NN Condition
who WP None
were VBD None
prospectively RB None
randomized VBN None
into IN None
2 CD None
groups NNS None
. . None
-DOCSTART- -X- N

secondarily RB None
infected VBN None
dermatitis NN None
: : None
patients NNS None
with IN None
secondarily RB None
infected VBN None
dermatitis NN None
( ( None
SID NNP None
) ) None
. . None
Patients NNPS None
with IN None
SID NNP None
patients NNS None
with IN None
SID NNP None
-DOCSTART- -X- N

a DT None
Danish JJ None
population NN None
. . None
healthy JJ Condition
people NNS None
population-based JJ None
study NN None
in IN None
general JJ None
practices NNS None
in IN None
Ebeltoft NNP None
, , None
Denmark NNP None
. . None
All NNP None
general JJ None
practitioners NNS None
from IN None
the DT None
four CD None
practices NNS None
in IN None
Ebeltoft NNP None
and CC None
a DT None
random JJ None
sample NN None
of IN None
2000 CD Size
people NNS None
aged VBN None
between IN None
30 CD Age
and CC Age
50 CD Age
years NNS None
were VBD None
invited VBN None
to TO None
participate VB None
. . None
total NN None
of IN None
1370 CD Size
people NNS None
participated VBN None
in IN None
the DT None
study NN None
456 CD Size
participants NNS None
( ( None
96 CD None
% NN None
) ) None
64 CD None
% NN None
of IN None
the DT None
456 CD Size
participants NNS None
Eleven NNP Size
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
. . None
healthy JJ None
volunteers NNS None
. . None
Twenty-four JJ None
volunteers NNS None
were VBD None
recruited VBN None
into IN None
an DT None
open-label JJ None
, , None
randomised JJ None
, , None
two-period JJ None
, , None
single-centre JJ None
study NN None
-DOCSTART- -X- N

practice NN None
nurses NNS None
: : None
Practice NNP None
nurses NNS None
nurses NNS None
This DT None
study NN None
was VBD None
nested VBN None
in IN None
the DT None
IMPALA NNP None
study NN None
, , None
a DT None
clustered VBN None
randomised VBN None
controlled VBN None
trial NN None
involving VBG None
24 CD None
general JJ None
practices NNS None
in IN None
The DT None
Netherlands NNP None
. . None
24 CD None
practice NN None
nurses NNS None
, , None
trained VBN None
in IN None
10-year JJ None
cardiovascular JJ None
risk NN None
assessment NN None
421 CD None
patients NNS None
without IN None
established VBN None
cardiovascular JJ None
diseases NNS None
but CC None
eligible JJ None
for IN None
cardiovascular JJ None
risk NN None
assessment NN None
. . None
Elderly JJ None
patients NNS None
male JJ None
patients NNS None
( ( None
vs. FW None
female NN None
smoking NN None
patients NNS None
( ( None
vs. IN None
non-smoking NN None
Ten NNP None
( ( None
28 CD None
% NN None
) ) None
of IN None
the DT None
36 CD None
patients NNS None
who WP None
should MD None
be VB None
assigned VBN None
to TO None
the DT None
high-risk JJ None
treatment NN None
category NN None
trained JJ None
practice NN None
nurses NNS None
in IN None
actual JJ None
practice NN None
nurses NNS None
in IN None
general JJ None
practice NN None
-DOCSTART- -X- N

men NNS Sex
receiving VBG Condition
finasteride NN Condition
for IN Condition
2 CD Condition
years NNS Condition
. . None
men NNS None
with IN None
urodynamically RB None
documented VBN None
bladder NN None
outflow JJ None
obstruction NN None
( ( None
BOO NNP None
) ) None
. . None
One CD Size
hundred VBD Size
twenty-one NN Size
men NNS Sex
with IN None
benign JJ Condition
prostatic JJ Condition
enlargement NN Condition
( ( None
BPE NNP None
) ) None
and CC None
lower JJR Condition
urinary JJ Condition
tract NN Condition
symptoms NNS Condition
( ( None
LUTS NNP None
) ) None
Patients NNS None
who WP None
were VBD None
obstructed VBN None
according VBG None
to TO None
a DT None
modified VBN None
Abrams-Griffiths JJ None
nomogram NNS None
men NNS None
with IN None
BPE NNP None
and CC None
LUTS NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
severe JJ Condition
acute JJ Condition
respiratory NN Condition
distress JJ Condition
syndrome NN Condition
: : None
adult NN Age
patients NNS None
with IN None
acute JJ Condition
respiratory NN Condition
distress NN Condition
syndrome NN Condition
( ( Condition
ARDS NNP Condition
) ) Condition
. . None
40 CD Size
ARDS NNP Condition
patients NNS None
Patients NNS None
were VBD None
randomized VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
chemotherapy-induced JJ Condition
painful JJ Condition
peripheral JJ Condition
neuropathy NN Condition
231 CD Condition
patients NNS None
who WP None
were VBD None
25 CD None
years NNS None
or CC None
older JJR None
being VBG None
treated VBN None
at IN None
community NN None
and CC None
academic JJ None
settings NNS None
between IN None
April NNP None
2008 CD None
and CC None
March NNP None
2011 CD None
Eligibility NN None
required VBD None
that IN None
patients NNS None
have VBP None
grade VBN Condition
1 CD Condition
or CC Condition
higher JJR Condition
sensory NN Condition
neuropathy JJ Condition
according VBG None
to TO None
the DT None
NCI NNP None
Common NNP None
Terminology NNP None
Criteria NNP None
for IN None
Adverse NNP None
Events NNS None
and CC None
at IN None
least JJS None
4 CD Condition
on IN Condition
a DT Condition
scale NN Condition
of IN Condition
0 CD Condition
to TO Condition
10 CD Condition
, , Condition
representing VBG Condition
average JJ Condition
chemotherapy-induced JJ Condition
pain NN Condition
, , None
after IN None
paclitaxel NN None
, , None
other JJ None
taxane NN None
, , None
or CC None
oxaliplatin JJ None
treatment NN None
patients NNS None
with IN None
painful JJ Condition
chemotherapy-induced JJ Condition
peripheral JJ Condition
neuropathy NN Condition
-DOCSTART- -X- N

US NNP None
population NN None
of IN None
mildly RB Condition
hypercholesterolemic JJ Condition
men NNS Sex
and CC None
women NNS Sex
: : None
US NNP None
population NN None
. . None
318 CD Size
subjects NNS None
mildly RB Condition
hypercholesterolemic JJ Condition
US NNP None
population NN None
-DOCSTART- -X- N

during IN None
labor NN None
. . None
Eighty NNP None
healthy JJ None
women NNS None
beginning VBG None
active JJ None
labor NN None
( ( None
cervical JJ None
dilation NN None
4 CD None
cm NN None
) ) None
at IN None
term NN None
were VBD None
assigned VBN None
to TO None
receive VB None
fentanyl NN None
intravenously RB None
by IN None
either CC None
patient-controlled JJ None
administration NN None
( ( None
n=37 JJ None
) ) None
or CC None
nurse JJ None
administration NN None
on IN None
demand NN None
( ( None
n=43 JJ None
) ) None
-DOCSTART- -X- N

spontaneous JJ None
pneumothorax NN None
] NNP None
Spontaneous JJ None
pneumothorax NN None
( ( None
SP NNP None
) ) None
young JJ None
, , None
thin JJ None
and CC None
otherwise RB None
healthy JJ None
males NNS None
. . None
40 CD None
patients NNS None
admitted VBN None
in IN None
a DT None
five-year JJ None
period NN None
, , None
with IN None
a DT None
SP NNP None
-DOCSTART- -X- N

heifers NNS Sex
. . None
30 CD None
heifers NNS Sex
30 CD None
heifers NNS Sex
-DOCSTART- -X- N

older JJR Age
women NNS Sex
with IN None
breast NN Condition
cancer NN Condition
. . None
chemotherapy-related JJ None
symptom NN None
distress NN None
levels NNS None
in IN None
16 CD Size
women NNS Condition
aged VBD None
50 CD Age
and CC Age
older JJR Age
. . None
older JJR None
women NNS Condition
with IN None
breast NN Condition
cancer NN Condition
women NNS None
-DOCSTART- -X- N

children NNS None
. . None
LMA-Unique NNP None
in IN None
60 CD None
children NNS None
undergoing JJ None
surgery NN None
. . None
Outcomes CC None
-DOCSTART- -X- N

adenoidectomy NN Condition
: : None
adenoidectomy NN None
among IN None
children NNS Age
< VBP Age
6 CD Age
years NNS Age
of IN None
age NN None
. . None
Kanta-Hame JJ None
Central NNP None
Hospital NNP None
, , None
a DT None
district NN None
referral NN None
center NN None
in IN None
Finland NNP None
. . None
93 CD Size
children NNS Age
undergoing JJ None
outpatient JJ None
adenoidectomy NN None
. . None
patients NNS None
with IN None
extensive JJ Condition
adenoids NNS Condition
and/or VBP None
profuse RB Condition
intraoperative JJ Condition
bleeding NN Condition
. . None
adenoidectomy NN None
among IN None
children NNS Age
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
definite JJ Condition
diabetic JJ Condition
autonomic JJ Condition
neuropathy NN Condition
over IN Condition
a DT Condition
period NN Condition
of IN Condition
2 CD Condition
years NNS Condition
. . None
35 CD Size
patients NNS None
35 CD Size
controls NNS Condition
with IN Condition
diabetes NNS Condition
mellitus NNS Condition
, , Condition
of IN Condition
similar JJ Condition
age NN Condition
, , Condition
gender NN Condition
, , Condition
and CC Condition
glycemic JJ Condition
control NN Condition
. . Condition
patients NNS None
with IN None
definite JJ None
DAN NNP None
-DOCSTART- -X- N

hypertensive JJ Condition
disease NN Condition
in IN None
pregnancy NN None
: : None
Sixty-three JJ Size
women NNS Sex
with IN None
evidence NN None
of IN None
underlying VBG None
hypertensive JJ Condition
disease NN Condition
were VBD None
followed VBN None
Forty CD Size
patients NNS None
were VBD None
followed VBN None
in IN None
the DT None
high-risk JJ None
pregnancy NN None
clinics NNS None
at IN None
Duke NNP None
University NNP None
. . None
63 CD Size
hypertensive JJ Condition
women NNS None
-DOCSTART- -X- N

Automatic JJ None
detection NN None
of IN None
red JJ None
lesions NNS None
in IN None
digital JJ None
color NN None
fundus NN None
photographs NN None
. . None
digital JJ None
color NN None
fundus NN None
photographs NN None
diabetic JJ Condition
retinopathy NN None
. . None
-DOCSTART- -X- N

Children NNP None
with IN None
autistic JJ None
spectrum NN None
disorders NNS None
. . None
parents NNS None
children NNS None
with IN None
autism NN None
parents NNS None
of IN None
children NNS None
with IN None
autism NN None
Sixty CD None
two CD None
children NNS None
with IN None
autism NN None
( ( None
aged VBN None
43-103 CD None
months NNS None
) ) None
parents NNS None
Twenty NNP None
seven CD None
families NNS None
27 CD None
guessed VBN None
incorrectly RB None
. . None
Six NNP None
families NNS None
parents NNS None
of IN None
young JJ None
children NNS None
with IN None
autism NN None
-DOCSTART- -X- N

Thirteen NNP Size
emmetropic JJ Condition
subjects NNS None
-DOCSTART- -X- N

Thai NNP Condition
hypertensive JJ Condition
population NN None
: : None
people NNS None
living VBG None
with IN None
hypertension NN Condition
. . None
Forty-four NNP Size
subjects NNS None
, , None
aged VBD None
35 CD Age
to TO Age
59-year-old JJ Age
, , None
with IN None
hypertension NN Condition
in IN None
Nakhon NNP None
Pathom NNP None
Province NNP None
, , None
Thailand NNP Condition
-DOCSTART- -X- N

typically-developing NN None
, , None
anxiety-disordered JJ None
children NNS None
( ( None
N NNP None
= NNP None
50 CD None
) ) None
treated VBN None
children NNS None
with IN None
moderate JJ None
autistic JJ None
symptomology NN None
( ( None
-DOCSTART- -X- N

artery NN Condition
bypass NN Condition
grafting NN Condition
. . Condition
patients NNS Condition
who WP Condition
undergo VBP Condition
off-pump JJ Condition
coronary JJ Condition
artery NN Condition
bypass NN Condition
grafting NN Condition
( ( Condition
CABG NNP Condition
) ) Condition
. . Condition
Thirty-two JJ Condition
patients NNS Condition
with IN Condition
left JJ Condition
anterior JJ Condition
descending VBG Condition
coronary JJ Condition
artery NN Condition
( ( Condition
LAD NNP Condition
) ) Condition
or CC Condition
two-vessel JJ Condition
heart NN Condition
disease NN Condition
( ( Condition
including VBG Condition
LAD NNP Condition
) ) Condition
who WP Condition
were VBD Condition
to TO Condition
undergo VB Condition
off-pump JJ Condition
CABG NNP Condition
patients NNS None
undergoing VBG None
off-pump JJ None
myocardial JJ None
revascularization NN None
-DOCSTART- -X- N

bleeding NN Condition
or CC None
blood NN Condition
product NN Condition
requirements NNS Condition
associated VBN None
with IN None
cardiopulmonary JJ Condition
bypass NN Condition
. . None
92 CD Size
patients NNS None
with IN None
overt JJ Condition
bleeding NN Condition
and CC None
a DT None
prolonged JJ Condition
bleeding NN Condition
time NN Condition
. . None
patients NNS None
with IN None
excessive JJ None
immediate JJ None
postoperative JJ Condition
bleeding NN Condition
. . None
-DOCSTART- -X- N

acute JJ Condition
myelogenous JJ Condition
leukemia NN Condition
in IN None
relapse NN None
: : None
a DT None
Leukemia NNP None
Intergroup NNP None
Study NNP None
. . None
Patients NNS None
with IN None
acute JJ Condition
myelogenous JJ Condition
leukemia NN Condition
in IN None
relapse NN None
who WP None
were VBD None
ineligible JJ None
for IN None
further JJ None
anthracycline NN Condition
therapy NN Condition
either CC None
because IN None
they PRP None
were VBD None
judged VBN None
to TO None
be VB None
anthracycline JJ Condition
resistant NN Condition
or CC None
had VBD None
received VBN None
the DT None
maximum JJ None
doses NNS None
three CD None
of IN None
25 CD Size
patients NNS None
given VBN None
high-dose JJ None
cytarabine NN None
and CC None
three CD None
of IN None
23 CD Size
given VBN None
amsacrine NN None
-DOCSTART- -X- N

Forty NNP Age
women NNS Age
, , Age
aged VBN Age
26-40 CD Age
years NNS Age
gastric JJ None
contents NNS None
and CC None
pH NN None
before IN None
general JJ None
anaesthesia NN None
. . None
-DOCSTART- -X- N

adult NN Age
autistic JJ Condition
disorders NNS Condition
. . None
adult NN None
autistic JJ None
patients NNS None
and CC None
matched VBD None
normal JJ None
controls NNS None
. . None
11 CD None
adult NN None
patients NNS None
with IN None
autism NN None
or CC None
Asperger NNP None
's POS None
disorder NN None
were VBD None
compared VBN None
with IN None
nine CD None
matched JJ None
controls NNS None
. . None
autistic JJ None
patients NNS None
-DOCSTART- -X- N

randomized VBN None
crossover NN None
study NN None
spinal JJ None
2-CP JJ None
( ( None
30 CD None
mg NN None
) ) None
with IN None
and CC None
without IN None
clonidine NN None
( ( None
15 CD None
microg NN None
) ) None
in IN None
eight CD Size
volunteers NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
diffuse NN None
peritonitis NN None
at IN None
the DT None
postoperative JJ None
period NN None
] NNP None
64 CD None
patients NNS None
that IN None
inclusion NN None
of IN None
complex JJ None
antioxidant NN None
cytoflavin NN None
in IN None
intensive JJ None
therapy NN None
at IN None
the DT None
postoperative JJ None
period NN None
of IN None
diffuse NN None
peritonitis NN None
-DOCSTART- -X- N

hydrochloride NN None
in IN None
children NNS None
Seventy-two JJ None
drug-free JJ None
children NNS None
, , None
aged VBD None
5 CD None
to TO None
14 CD None
years NNS None
, , None
with IN None
pervasive JJ None
developmental NN None
disorders NNS None
accompanied VBN None
by IN None
moderate JJ None
to TO None
severe JJ None
hyperactivity NN None
. . None
subjects NNS None
Subjects NNS None
who WP None
tolerated VBD None
the DT None
test NN None
dose NN None
Children NNP None
responding VBG None
to TO None
methylphenidate VB None
Thirty-five JJ None
( ( None
49 CD None
% NN None
) ) None
of IN None
72 CD None
enrolled JJ None
subjects NNS None
13 CD None
( ( None
18 CD None
% NN None
) ) None
of IN None
72 CD None
subjects NNS None
. . None
-DOCSTART- -X- N

adults NNS None
with IN None
high JJ None
functioning VBG None
autism NN None
spectrum NN None
disorders NNS None
. . None
adults NNS None
with IN None
ASD NNP None
who WP None
showed VBD None
initial JJ None
impairment NN None
in IN None
face NN None
recognition NN None
. . None
individuals NNS None
with IN None
ASD NNP None
-DOCSTART- -X- N

pregnant JJ Condition
smokers NNS Condition
. . None
One CD Size
hundred VBD Size
forty-two NN Size
pregnant NN None
, , None
predominantly RB None
Hispanic JJ None
women NNS Sex
-DOCSTART- -X- N

postoperative JJ None
patient-controlled JJ None
epidural JJ None
analgesia NN None
. . None
Thirty NNP None
patients NNS None
undergoing VBG None
lower JJR None
abdominal JJ None
surgery NN None
were VBD None
randomized VBN None
-DOCSTART- -X- N

rheumatic JJ None
arthropathies NNS None
( ( None
inflammatory NN None
and CC None
degenerative NN None
) ) None
] NN None
patients NNS None
suffering VBG None
from IN None
inflammatory NN None
and CC None
degenerative JJ None
rheumatic JJ None
arthropathies NNS None
. . None
30 CD None
subjects NNS None
using VBG None
the DT None
controlled JJ None
experiment NN None
technique NN None
according VBG None
to TO None
the DT None
between IN None
patient NN None
pattern NN None
, , None
attributing VBG None
parsalmide NN None
and CC None
indomethacin NN None
at IN None
random NN None
to TO None
two CD None
groups NNS None
. . None
-DOCSTART- -X- N

alcohol NN None
dependent JJ None
treatment NN None
sample NN None
. . None
alcohol NN None
problems NNS None
. . None
posttreatment NN None
levels NNS None
of IN None
alcohol NN None
use NN None
men NNS None
and CC None
women NNS None
( ( None
N=77 NNP None
) ) None
enrolled VBD None
in IN None
a DT None
12-week JJ None
cognitive-behavioral JJ None
intervention NN None
for IN None
alcohol NN None
dependence NN None
. . None
those DT None
seeking VBG None
treatment NN None
for IN None
alcohol NN None
dependence NN None
. . None
-DOCSTART- -X- N

premature JJ Condition
ejaculation NN Condition
. . None
premature JJ None
ejaculation NN None
. . None
Forty-three JJ Size
patients NNS None
suffering VBG None
from IN None
premature JJ None
ejaculation NN None
The DT None
exclusion NN None
criteria NNS None
were VBD None
erectile JJ None
dysfunction NN None
, , None
loss NN None
of IN None
libido NN None
, , None
alcohol NN None
and CC None
substance NN None
abuse NN None
, , None
mental JJ None
retardation NN None
, , None
diabetes VBZ None
mellitus NN None
, , None
thyroid JJ None
disease NN None
, , None
hypotension NN None
, , None
previous JJ None
use NN None
of IN None
these DT None
drugs NNS None
and CC None
urogenital JJ None
infections NNS None
. . None
The DT None
patients NNS None
' POS None
ages NNS None
ranged VBD None
from IN None
19 CD Age
to TO Age
48 CD Age
years NNS Age
( ( None
mean JJ None
age NN None
28 CD Age
+/- JJ Age
1.6 CD Age
) ) None
. . None
They PRP None
had VBD None
regular JJ None
sexual JJ None
lives NNS None
. . None
They PRP None
had VBD None
normal JJ None
psychiatric JJ None
consultation NN None
and CC None
the DT None
Glombock NNP None
Rast NNP None
Sexual NNP None
Satisfactory NNP None
Test NNP None
( ( None
GRISS NNP None
) ) None
psychiatric JJ None
test NN None
were VBD None
in IN None
accordance NN None
with IN None
premature JJ None
ejaculation NN None
. . None
No UH None
patients NNS None
were VBD None
excluded VBN None
from IN None
the DT None
study NN None
due JJ None
to TO None
side VB None
effects NNS None
. . None
premature JJ None
ejaculation NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
oesophageal JJ Condition
cancer NN Condition
patients NNS None
with IN None
incurable JJ None
oesophageal JJ Condition
cancer NN Condition
. . None
41 CD Size
Patients NNPS None
-DOCSTART- -X- N

couples NNS None
with IN None
unexplained JJ Condition
subfertility NN Condition
and CC None
an DT None
intermediate JJ None
prognosis NN None
: : None
couples NNS None
with IN None
unexplained JJ Condition
subfertility NN Condition
. . None
couples NNS None
with IN None
unexplained JJ Condition
subfertility NN Condition
253 CD Size
couples NNS None
with IN None
unexplained JJ Condition
subfertility NN Condition
and CC None
a DT None
probability NN None
of IN None
a DT None
spontaneous JJ None
ongoing JJ None
pregnancy NN None
of IN None
30 CD None
% NN None
to TO None
40 CD None
% NN None
within IN None
12 CD None
months NNS None
-DOCSTART- -X- N

cytomegalovirus NN Condition
retinitis NN Condition
in IN None
patients NNS None
with IN None
acquired JJ None
immunodeficiency NN None
syndrome NN None
: : None
The DT None
Studies NNPS None
of IN None
Ocular JJ Condition
Complications NNS Condition
of IN None
AIDS NNP None
Research NNP None
Group NNP None
. . None
AIDS NNP None
Clinical JJ None
Trials NNP None
Group NNP None
. . None
Two CD Size
hundred VBD Size
nine CD Size
patients NNS None
with IN None
acquired JJ Condition
immunodeficiency NN Condition
syndrome NN Condition
and CC None
active JJ None
CMV NNP Condition
retinitis NN Condition
were VBD None
enrolled VBN None
in IN None
a DT None
multicenter NN None
, , None
phase NN None
2/3 CD None
, , None
randomized VBN None
, , None
placebo-controlled JJ None
clinical JJ None
trial NN None
. . None
Among IN None
patients NNS None
with IN None
newly RB None
diagnosed VBN Condition
retinitis NN Condition
-DOCSTART- -X- N

postoperative JJ Condition
pain NN Condition
in IN None
children NNS Age
after IN None
tonsillectomy NN Condition
. . None
children NNS Age
undergoing VBG None
outpatient JJ None
tonsillectomy NN None
. . None
Children NNP None
6 CD Age
to TO Age
15 CD Age
years NNS Age
of IN Age
age NN Age
Parents NNS None
-DOCSTART- -X- N

Primary JJ None
capsulectomy NN None
, , None
anterior JJ None
vitrectomy NN None
, , None
lensectomy NN None
, , None
and CC None
posterior JJ None
chamber NN None
lens NNS None
implantation NN None
in IN None
children NNS Age
: : None
childhood NN Age
cataract NN Condition
. . None
45 CD None
eyes NNS None
38 CD None
eyes NNS None
were VBD None
included VBN None
All DT None
eyes NNS None
had VBD None
lensectomy NN None
and CC None
posterior JJ None
chamber NN None
intraocular JJ None
lens NNS None
( ( None
PC NNP None
IOL NNP None
) ) None
implantation NN None
. . None
children NNS Age
. . None
-DOCSTART- -X- N

writer NN None
's POS None
cramp NN None
dystonia NN None
: : None
Ten CD None
patients NNS None
with IN None
writer NN None
's POS None
cramp NN None
-DOCSTART- -X- N

patients NNS None
with IN None
previously RB None
untreated VBN None
metastatic JJ Condition
colorectal NN Condition
cancer NN Condition
. . None
previously RB None
untreated VBN None
metastatic JJ Condition
colorectal NN Condition
carcinoma NN Condition
( ( Condition
CRC NNP Condition
) ) Condition
patients NNS None
. . None
Between NNP None
May NNP None
1996 CD None
and CC None
July NNP None
1997 CD None
, , None
380 CD Size
patients NNS Size
320 CD None
events NNS None
-DOCSTART- -X- N

small JJ None
cell NN None
lung NN None
cancer NN None
: : None
610 CD None
patients NNS None
with IN None
small JJ None
cell NN None
lung NN None
cancer NN None
196 CD None
( ( None
32.1 CD None
% NN None
) ) None
had VBD None
limited VBN None
disease NN None
and CC None
414 CD None
( ( None
67.9 CD None
% NN None
) ) None
extensive JJ None
disease NN None
. . None
-DOCSTART- -X- N

scleral JJ Condition
buckling NN Condition
surgery NN Condition
. . None
scleral JJ Condition
buckling NN Condition
procedures NNS Condition
. . None
60 CD Size
patients NNS None
. . None
Thirty JJ Size
patients NNS None
scleral JJ None
buckling NN None
procedures NNS None
. . None
-DOCSTART- -X- N

total JJ Condition
hip NN Condition
arthroplasty NN Condition
: : None
Minimally NNP None
invasive JJ None
total NN None
hip NN None
arthroplasty NN None
Twenty NNP Size
randomized VBD None
patients NNS None
who WP None
underwent VBP None
a DT None
primary JJ Condition
total JJ Condition
hip NN Condition
replacement NN Condition
with IN None
use NN None
of IN None
a DT None
minimally RB None
invasive JJ None
modified VBN None
Watson-Jones JJ None
approach NN None
( ( None
minimally RB None
invasive JJ None
group NN None
) ) None
were VBD None
compared VBN None
with IN None
a DT None
group NN None
of IN None
twenty NN Size
patients NNS None
who WP None
underwent VBD None
a DT None
total JJ None
hip NN None
arthroplasty NN None
with IN None
use NN None
of IN None
a DT None
standard JJ None
transgluteal NN None
Hardinge NNP None
approach NN None
( ( None
standard JJ None
group NN None
) ) None
. . None
patients NNS None
who WP None
underwent VBD None
a DT None
total JJ Condition
hip NN Condition
arthroplasty NN Condition
through IN None
a DT None
minimally RB None
invasive JJ None
Watson-Jones NNS None
approach NN None
standard JJ Condition
transgluteal NN Condition
approach NN Condition
. . None
-DOCSTART- -X- N

bony NN Condition
defects NNS Condition
bony NN None
defects NNS None
Thirty-two NNP None
implants NNS None
were VBD None
randomly RB None
allocated VBN None
four CD None
types NNS None
of IN None
bone NN None
defects NNS None
: : None
marginal JJ None
bone NN None
loss NN None
, , None
peri-apical JJ Condition
bone NN Condition
defect NN Condition
, , None
constant JJ None
width NN None
dehiscence NN None
and CC None
constant JJ None
length NN None
dehiscences NNS None
. . None
-DOCSTART- -X- N

amnesics VB Condition
memory-impaired JJ Condition
acquired VBD Condition
brain-injured JJ Condition
persons NNS None
Forty NNP Size
individuals NNS None
comprised VBD None
the DT None
simulating NN None
and CC None
control NN None
group NN None
Twenty CD Size
memory-impaired JJ Condition
patients NNS None
, , None
all DT None
of IN None
whom WP None
had VBD None
been VBN None
diagnosed VBN None
as IN None
suffering VBG None
from IN None
a DT None
memory NN Condition
impairment NN Condition
following VBG None
acquired VBD Condition
brain NN Condition
damage NN Condition
, , Condition
participated VBD None
as IN None
the DT None
memory-impaired JJ None
control NN None
group NN None
. . None
-DOCSTART- -X- N

coronary-prone NN None
( ( None
Type NNP None
A NNP None
) ) None
managers NNS None
. . None
type NN None
A DT None
intervention NN None
project NN None
for IN None
healthy JJ None
managers NNS None
manifestations NNS None
of IN None
clinical JJ None
CHD NNP None
) ) None
all DT None
three CD None
groups NNS None
-DOCSTART- -X- N

partial JJ None
ceramic JJ None
crowns NNS None
partial JJ None
ceramic JJ None
crowns NNS None
( ( None
PCCs NNP None
) ) None
inserted VBD None
with IN None
RelyX NNP None
Unicem NNP None
( ( None
RXU NNP None
) ) None
34 CD None
patients NNS None
( ( None
15 CD None
male NN None
, , None
19 CD None
female NN None
) ) None
participated VBD None
in IN None
the DT None
investigation NN None
, , None
with IN None
a DT None
total NN None
of IN None
68 CD None
PCC NNP None
restorations NNS None
. . None
median JJ None
patient NN None
age NN None
was VBD None
41 CD None
years NNS None
( ( None
24-59 CD None
years NNS None
) ) None
. . None
All DT None
patients NNS None
were VBD None
available JJ None
for IN None
the DT None
three CD None
recall NN None
appointments NNS None
. . None
-DOCSTART- -X- N

Midlife NNP None
women NNS None
Midlife NNP None
women NNS None
unintended JJ None
pregnancy NN None
and CC None
STI NNP None
midlife JJ None
women NNS None
was VBD None
conducted VBN None
with IN None
164 CD None
women NNS None
ages VBZ None
40-55 CD None
years NNS None
of IN None
age NN None
. . None
midlife VB None
women NNS None
-DOCSTART- -X- N

newly RB Condition
diagnosed VBN Condition
stage NN Condition
1 CD Condition
hypertensive JJ Condition
patients NNS Condition
] VBP Condition
hypertensive JJ Condition
patients NNS Condition
. . Condition
newly RB Condition
diagnosed VBN Condition
stage NN Condition
1 CD Condition
hypertensive JJ Condition
patients NNS Condition
. . Condition
60 CD Condition
newly RB Condition
diagnosed VBN Condition
stage NN Condition
1 CD Condition
hypertensive JJ Condition
patients NNS Condition
with IN Condition
no DT Condition
other JJ Condition
systemic JJ Condition
disease NN Condition
. . Condition
nebivolol JJ None
5 CD None
mg NN None
and CC None
valsartan $ None
160 CD None
mg NN None
-DOCSTART- -X- N

patients NNS None
with IN None
non-small JJ None
cell NN None
lung NN None
cancer NN None
after IN None
antiangiogenesis NN None
therapy NN None
. . None
Patients NNPS None
of IN None
non-small JJ None
cell NN None
lung NN None
cancer NN None
( ( None
NSCLC NNP None
) ) None
treated VBD None
with IN None
chemotherapy NN None
with IN None
or CC None
without IN None
Endostar NNP None
-DOCSTART- -X- N

advanced VBD Condition
melanoma NN Condition
. . None
patients NNS None
with IN None
BRAF NNP Condition
( ( Condition
V600E/K NNP Condition
) ) Condition
advanced VBD Condition
melanoma NN Condition
treated VBN None
with IN None
vemurafenib NN None
. . None
patients NNS None
enrolled VBN None
in IN None
the DT None
BRIM2 NNP Condition
( ( None
n JJ None
= NNP None
59 CD Size
) ) None
and CC None
BRIM3 NNP Condition
( ( None
n JJ None
= NNP None
150 CD Size
) ) None
-DOCSTART- -X- N

experimental JJ None
human JJ None
influenza NN Condition
: : None
treatment NN None
of IN None
influenza NN None
in IN None
experimentally RB None
infected JJ None
humans NNS None
. . None
2 CD None
large JJ None
US NNP None
university NN None
medical JJ None
schools NNS None
. . None
A DT None
total NN None
of IN None
117 CD Size
healthy JJ Condition
adult NN Age
volunteers NNS Age
( ( None
aged VBN Age
18-40 CD Age
years NNS Age
; : Age
median JJ Age
age NN Age
, , Age
21 CD Age
years NNS Age
) ) None
who WP None
were VBD None
susceptible JJ Condition
( ( Condition
hemagglutination-inhibition NN Condition
antibody NN Condition
titer NN Condition
< NN None
or CC None
=1:8 NN None
) ) None
. . None
experimental JJ None
human JJ None
influenza NN Condition
-DOCSTART- -X- N

men NNS Sex
with IN None
signs NNS None
and CC None
symptoms NNS None
of IN None
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
: : None
Men NNP Sex
50 CD Age
years NNS Age
or CC Age
older JJR Age
with IN None
an DT None
International NNP None
Prostate NNP Condition
Symptom NNP None
Score NNP None
of IN None
13 CD None
or CC None
greater JJR None
and CC None
peak JJ None
urinary JJ None
flow NN None
rate NN None
of IN None
4 CD None
to TO None
15 CD None
ml NNS None
per IN None
second JJ None
received VBN None
placebo NN None
or CC None
8 CD None
mg NNS None
silodosin JJ None
daily JJ None
with IN None
breakfast NN None
for IN None
12 CD None
weeks NNS None
. . None
923 CD Size
patients NNS None
( ( None
mean JJ None
age NN None
65 CD Age
years NNS None
) ) None
466 CD Size
received VBN None
silodosin NN None
and CC None
457 CD Size
placebo NN None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
transurethral JJ Condition
resection NN Condition
of IN Condition
the DT Condition
prostate NN Condition
( ( None
TURP NNP None
) ) None
. . None
Fifty-six NNP Size
male NN Sex
patients NNS None
( ( None
mean JJ None
age NN None
71.2 CD Age
+/- JJ None
8.2 CD None
years NNS None
) ) None
scheduled VBD None
for IN None
TURP NNP Condition
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
27 CD Size
patients NNS None
29 CD Size
patients NNS None
-DOCSTART- -X- N

aging VBG None
humans NNS None
. . None
aging VBG None
adults NNS None
. . None
Twenty-six JJ None
sedentary JJ None
but CC None
healthy JJ None
middle-aged JJ None
and CC None
older JJR None
subjects NNS None
intervention NN None
group NN None
( ( None
52 CD None
+/- JJ None
2 CD None
yr NN None
, , None
3 CD None
men NNS None
, , None
10 CD None
women NNS None
) ) None
a DT None
control NN None
group NN None
( ( None
53 CD None
+/- JJ None
2 CD None
yr NN None
, , None
4 CD None
men NNS None
, , None
9 CD None
women NNS None
) ) None
At IN None
baseline NN None
, , None
there EX None
were VBD None
no DT None
significant JJ None
differences NNS None
in IN None
blood NN None
pressure NN None
, , None
cardiac JJ None
output NN None
, , None
basal JJ None
femoral JJ None
blood NN None
flow NN None
( ( None
via IN None
Doppler NNP None
ultrasound NN None
) ) None
, , None
vascular JJ None
conductance NN None
, , None
and CC None
vascular JJ None
resistance NN None
between IN None
the DT None
two CD None
groups NNS None
. . None
healthy JJ None
middle-aged JJ None
and CC None
older JJR None
adults NNS None
. . None
-DOCSTART- -X- N

renal JJ Condition
transplantation NN Condition
. . Condition
( ( None
CMV NNP None
) ) None
disease NN None
after IN None
renal JJ None
transplantation NN None
( ( None
RTx NNP None
) ) None
. . None
total NN None
of IN None
38 CD None
patients NNS None
was VBD None
randomized VBN None
to TO None
3-month JJ None
treatment NN None
with IN None
either DT None
oral JJ None
ganciclovir NN None
( ( None
1 CD None
g NN None
t.i.d. NN None
n=14 RB None
, , None
GAN NNP None
group NN None
) ) None
or CC None
oral JJ None
valacyclovir NN None
( ( None
2 CD None
g NN None
q.i.d. NN None
n=12 RB None
, , None
VAL NNP None
group NN None
) ) None
-DOCSTART- -X- N

Assessment NN None
of IN None
the DT None
pain NN None
of IN None
blood-sugar JJ None
testing NN None
: : None
a DT None
randomised JJ None
controlled VBN None
trial NN None
. . None
-DOCSTART- -X- N

adult NN None
respiratory NN Condition
distress JJ Condition
syndrome NN Condition
. . None
G-CSF NNP None
group NN None
which WDT None
received VBD None
chemotherapy NN None
with IN None
G-CSF NNP None
and CC None
historical JJ None
controls NNS None
without IN None
G-CSF NNP None
. . None
132 CD Size
patients NNS None
with IN None
hematological JJ Condition
malignancy NN Condition
in IN None
complete JJ None
remission NN None
without IN None
any DT None
main JJ None
organ JJ None
dysfunction NN None
who WP None
had VBD None
been VBN None
treated VBN None
between IN None
April NNP None
1983 CD None
and CC None
December NNP None
1997 CD None
. . None
who WP None
received VBD None
G-CSF NNP None
There EX None
was VBD None
no DT None
remarkable JJ None
difference NN None
in IN None
the DT None
number NN None
of IN None
patients NNS None
, , None
gender NN None
, , None
age NN None
, , None
or CC None
distribution NN None
of IN None
primary JJ None
diseases NNS None
between IN None
the DT None
two CD None
groups NNS None
. . None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Condition
autistic JJ None
children NNS None
A NNP Condition
total NN Condition
of IN Condition
81 CD Condition
cases NNS Condition
of IN Condition
autistic JJ Condition
children NNS Condition
autistic JJ None
children NNS None
-DOCSTART- -X- N

schizophrenics NNS Condition
schizophrenics NNS Condition
81 CD Condition
schizophrenics NNS Condition
schizophrenics NNS None
-DOCSTART- -X- N

early JJ Condition
recurrent NN Condition
ischemia NN Condition
after IN None
non-Q-wave JJ None
myocardial JJ None
infarction NN None
: : None
576 CD None
patients NNS None
with IN None
non-Q-wave JJ Condition
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
enrolled VBN None
in IN None
the DT None
Diltiazem NNP None
Reinfarction NNP None
Study NNP None
, , None
246 CD None
( ( None
43 CD None
% NN None
) ) None
had VBD None
1 CD None
or CC None
more JJR None
episodes NNS None
of IN None
angina NN None
at IN None
rest NN None
or CC None
with IN None
minimal JJ None
effort NN None
during IN None
10.5 CD None
days NNS None
of IN None
treatment NN None
with IN None
either DT None
diltiazem NN None
( ( None
90 CD None
mg NN None
every DT None
6 CD None
hours NNS None
) ) None
or CC None
placebo NN None
. . None
patients NNS None
with IN None
early JJ Condition
postinfarction NN Condition
angina NN Condition
-DOCSTART- -X- N

transrectal JJ Condition
prostate NN Condition
biopsy NN Condition
: : None
transrectal JJ Condition
prostate NN Condition
biopsy NN Condition
( ( None
TPB NNP Condition
) ) None
patients NNS None
receiving VBG None
perianal-intrarectal JJ None
lidocaine-prilocaine NN None
( ( None
PILP NNP None
) ) None
cream NN None
before IN None
PPNB NNP None
. . None
Three NNP Size
hundred VBD Size
consecutive JJ None
patients NNS None
scheduled VBN None
for IN None
US-guided JJ None
TPB NNP Condition
-DOCSTART- -X- N

patients NNS None
with IN None
metastatic JJ Condition
breast NN Condition
cancer NN Condition
: : None
Three NNP Size
hundred VBD Size
two CD Size
patients NNS None
with IN Condition
no DT Condition
previous JJ Condition
chemotherapy NN Condition
for IN None
MBC NNP Condition
patients NNS None
with IN None
no DT None
previous JJ None
chemotherapy NN None
for IN None
MBC NNP None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
severe JJ Condition
aplastic JJ Condition
anemia NN Condition
( ( Condition
SAA NNP Condition
) ) Condition
treated VBD Condition
with IN Condition
anti-lymphocyte JJ Condition
globulin NN Condition
( ( Condition
ALG NNP Condition
) ) Condition
, , Condition
cyclosporin NN Condition
( ( Condition
CyA NNP Condition
) ) Condition
and CC Condition
granulocyte JJ Condition
colony-stimulating JJ Condition
factor NN Condition
( ( Condition
G-CSF NNP Condition
) ) Condition
multicenter NN None
prospective JJ None
trial NN None
in IN None
77 CD None
SAA NNP None
patients NNS None
treated VBD None
with IN None
horse NN None
ALG NNP None
( ( None
15 CD None
mg/kg/day RB None
day1-5 NN None
) ) None
and CC None
CyA NNP None
( ( None
5 CD None
mg/kg/day RB None
day NN None
1-180 JJ None
) ) None
. . None
Patients NNS None
were VBD None
randomized VBN None
Thirteen JJ None
patients NNS None
( ( None
5 CD None
in IN None
group NN None
A NNP None
and CC None
8 CD None
in IN None
group NN None
B NNP None
) ) None
patients NNS None
with IN None
SAA NNP None
receiving VBG None
ALG NNP None
and CC None
CyA NNP None
. . None
-DOCSTART- -X- N

40 CD Size
healthy JJ Condition
subjects NNS None
. . None
-DOCSTART- -X- N

for IN None
advanced JJ None
myeloid NN None
leukemia NN None
and CC None
MDS NNP None
. . None
in IN None
patients NNS None
with IN None
myeloid JJ None
leukemia NN None
undergoing VBG None
allogeneic JJ None
stem NN None
cell NN None
transplantation NN None
( ( None
allo-SCT JJ None
) ) None
. . None
. . None
Fifty-one CD None
patients NNS None
have VBP None
been VBN None
enrolled VBN None
with IN None
days NNS None
. . None
There EX None
were VBD None
32 CD None
males NNS None
and CC None
19 CD None
females NNS None
, , None
with IN None
a DT None
median JJ None
age NN None
of IN None
45 CD None
years NNS None
( ( None
range NN None
: : None
6-59 JJ None
) ) None
. . None
Nine JJ None
patients NNS None
had VBD None
chronic JJ None
myeloid NN None
leukemia NN None
( ( None
CML NNP None
) ) None
( ( None
BC NNP None
: : None
2 CD None
, , None
second JJ None
AP NNP None
: : None
3 CD None
, , None
and CC None
tyrosine-kinase JJ None
inhibitor NN None
refractory NN None
first RB None
chronic JJ None
phase NN None
[ NNP None
CP NNP None
] NN None
: : None
4 CD None
) ) None
. . None
Forty-two JJ None
patients NNS None
had VBD None
AML NNP None
: : None
14 CD None
were VBD None
induction NN None
failures NNS None
, , None
8 CD None
in IN None
first JJ None
chemotherapy-refractory JJ None
relapse NN None
, , None
7 CD None
in IN None
untreated JJ None
relapse NN None
, , None
3 CD None
in IN None
second JJ None
or CC None
subsequent JJ None
relapse NN None
, , None
4 CD None
were VBD None
in IN None
second JJ None
complete JJ None
remission NN None
( ( None
CR NNP None
) ) None
, , None
and CC None
3 CD None
in IN None
second JJ None
CR NNP None
without IN None
platelet NN None
recovery NN None
( ( None
CRp NNP None
) ) None
, , None
2 CD None
were VBD None
in IN None
high-risk JJ None
CR1 NNP None
. . None
Finally NNP None
, , None
1 CD None
patient NN None
was VBD None
in IN None
first JJ None
CRp NNP None
. . None
Graft-versus-host NNP None
engrafted VBN None
. . None
Forty-one CD None
patients NNS None
had VBD None
active JJ None
leukemia NN None
at IN None
the DT None
time NN None
of IN None
transplant NN None
, , None
and CC None
35 CD None
achieved VBN None
CR NNP None
( ( None
. . None
Twenty CD None
in IN None
high-risk JJ None
myeloid JJ None
leukemia NN None
patients NNS None
; : None
( ( None
2 CD None
) ) None
clofarabine NN None
-DOCSTART- -X- N

donor JJ None
hepatic JJ None
transection NN None
: : None
Twenty-four CD None
living NN None
liver NN None
donors NNS None
( ( None
n JJ None
= VBP None
12 CD None
for IN None
each DT None
group NN None
) ) None
-DOCSTART- -X- N

distal JJ Condition
radial JJ Condition
fractures NNS Condition
. . Condition
nonoperated JJ None
distal JJ None
radial NN None
fractures NNS None
One CD None
third NN None
of IN None
the DT None
patients NNS None
of IN None
the DT None
international JJ None
trial NN None
were VBD None
treated VBN None
at IN None
Link?ping NNP None
University NNP None
Hospital NNP None
. . None
our PRP$ None
27 CD None
patients NNS None
. . None
in IN None
distal JJ None
radial JJ None
fractures NNS None
. . None
-DOCSTART- -X- N

provisional JJ Condition
restorations NNS Condition
: : Condition
polymethyl NN None
methacrylate NN None
( ( None
PMMA NNP None
) ) None
self-cured VBD None
acrylic JJ None
resin NN None
provisional JJ None
crowns NNS None
. . None
Three NNP None
types NNS None
of IN None
PMMA NNP None
surfaces NNS None
were VBD None
tested VBN None
: : None
( ( None
1 CD None
) ) None
polished VBN None
, , None
( ( None
2 CD None
) ) None
polished VBN None
and CC None
coated VBN None
with IN None
bonding NN None
agent NN None
, , None
and CC None
( ( None
3 CD None
) ) None
polished VBN None
and CC None
coated VBN None
with IN None
light-cured JJ None
liquid JJ None
polish NN None
. . None
-DOCSTART- -X- N

uncomplicated JJ None
gonorrhea NN Condition
. . None
unblinded JJ None
multicenter NN None
study NN None
of IN None
209 CD Size
men NNS None
and CC None
124 CD Size
women NNS None
with IN None
uncomplicated JJ None
gonorrhea NN Condition
-DOCSTART- -X- N

endogenous JJ None
fibrinolysis NN None
. . None
hypertensive JJ None
patients NNS None
. . None
Fifty-five JJ None
hypertensive JJ None
participants NNS None
( ( None
35 CD None
African-American JJ None
, , None
20 CD None
white JJ None
) ) None
whites NNS None
African-Americans NNP None
white JJ None
, , None
but CC None
not RB None
African-American JJ None
hypertensive JJ None
individuals NNS None
. . None
whites NNS None
or CC None
African-Americans NNS None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG Condition
surgical JJ Condition
procedures NNS Condition
under IN Condition
regional JJ Condition
anaesthesia NN Condition
. . None
Forty NNP Size
adult JJ None
American JJ None
Society NNP None
of IN None
Anaesthesiologists NNP None
( ( None
ASA NNP None
) ) None
grade VBD None
1-111 JJ None
patients NNS None
, , None
aged VBN None
between IN None
40-65 JJ Age
years NNS Age
undergoing VBG Condition
surgery NN Condition
under IN Condition
regional JJ Condition
anaesthesia NN Condition
( ( Condition
sub-arachnoid JJ Condition
block NN Condition
) ) None
were VBD None
included VBN None
. . None
-DOCSTART- -X- N

in IN None
12 CD Size
patients NNS None
with IN None
atherosclerotic JJ Condition
disease NN Condition
-DOCSTART- -X- N

the DT None
spectrum NN None
of IN None
acute JJ None
coronary JJ None
syndromes NNS None
. . None
acute JJ None
coronary JJ None
syndromes NNS None
( ( None
ACS NNP None
) ) None
. . None
3225 CD None
patients NNS None
with IN None
ACS NNP None
. . None
-DOCSTART- -X- N

individuals NNS None
with IN None
a DT None
brain NN Condition
injury NN Condition
. . None
people NNS None
with IN None
a DT None
brain NN Condition
injury NN Condition
. . None
Sixteen JJ Size
outpatients NNS None
with IN None
a DT None
brain NN Condition
injury NN Condition
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

cervical JJ None
intraepithelial JJ None
neoplasia NN None
: : None
cervical JJ None
intraepithelial JJ None
neoplasia NN None
( ( None
CIN NNP None
) ) None
gynaecological JJ None
oncology NN None
centre NN None
and CC None
a DT None
teaching JJ None
hospital NN None
in IN None
West NNP None
London NNP None
. . None
Four CD None
hundred VBD None
and CC None
four CD None
women NNS None
due JJ None
to TO None
receive VB None
treatment NN None
for IN None
suspected JJ None
CIN NNP None
. . None
Four NNP None
randomised VBD None
women NNS None
-DOCSTART- -X- N

subacute JJ Condition
poststroke NN Condition
patients NNS None
: : None
poststroke NN Condition
patients NNS None
; : None
poststroke NN None
patients NNS None
Loewenstein NNP None
Rehabilitation NNP None
Hospital NNP None
, , None
Israel NNP None
. . None
Twenty-eight NNP Size
subacute JJ Condition
stroke VBD Condition
patients NNS None
with IN None
arm JJ None
paresis NN None
after IN None
a DT None
first JJ None
ischemic JJ Condition
stroke NN Condition
in IN None
the DT None
middle JJ None
cerebral JJ None
artery NN None
area NN None
CIMT NNP None
group NN None
-DOCSTART- -X- N

radial JJ Condition
artery NN Condition
occlusion NN Condition
after IN Condition
transradial JJ Condition
catheterization NN Condition
. . Condition
500 CD None
consecutive JJ None
patients NNS None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
hypercholesterolemia NN Condition
multicenter NN Condition
534 CD None
hypercholesterolemic JJ None
patients NNS None
( ( None
low-density JJ None
lipoprotein NN None
[ NNP None
LDL NNP None
] NNP None
cholesterol NN None
> NN None
or CC None
= $ None
160 CD None
mg/dl NN None
[ VBD None
4.2 CD None
mmol/L NN None
] NN None
and CC None
triglycerides NNS None
< VBP None
or CC None
= VBP None
400 CD None
mg/dl NN None
[ VBD None
4.5 CD None
mmol/L NNS None
] RB None
) ) None
. . None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Sex
with IN None
advanced JJ Condition
breast NN Condition
carcinoma NN Condition
who WP None
had VBD None
disease NN None
progression NN None
after IN None
receipt NN None
of IN None
previous JJ None
endocrine NN None
treatment NN None
. . None
319 CD Size
( ( None
74.5 CD None
% NN None
) ) None
patients NNS None
in IN None
the DT None
fulvestrant JJ None
group NN None
and CC None
322 CD Size
( ( None
76.1 CD None
% NN None
) ) None
patients NNS None
in IN None
the DT None
anastrozole JJ None
group NN None
postmenopausal JJ Condition
women NNS Sex
with IN None
advanced JJ Condition
breast NN Condition
carcinoma NN Condition
. . None
-DOCSTART- -X- N

elderly JJ Age
hypertensives NNS Condition
. . None
Forty-two JJ Size
hypertensives NNS Condition
60 CD Age
years NNS Age
of IN Age
age NN Age
or CC Age
above NN Age
, , None
without IN None
evidence NN None
of IN None
ischemic JJ Condition
disease NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
prolapsing JJ None
hemorrhoids NNS None
. . None
Between NNP None
January NNP None
2002 CD None
and CC None
November NNP None
2004 CD None
, , None
200 CD Size
patients NNS Size
undergoing VBG None
stapled JJ Condition
hemorrhoidopexy NN Condition
were VBD None
enrolled VBN None
One CD Size
hundred VBD Size
patients NNS Size
were VBD None
randomly RB None
assigned VBN None
to TO None
the DT None
control NN None
group NN None
; : None
the DT None
study NN None
group NN None
consisted VBD None
of IN None
100 CD None
patients NNS None
-DOCSTART- -X- N

after IN None
GnRH NNP None
agonist NN None
treatment NN None
. . None
hormone NN None
replacement NN None
therapy NN None
28 CD None
patients NNS None
treated VBD None
for IN None
6 CD None
months NNS None
with IN None
a DT None
GnRH NNP None
agonist NN None
. . None
postmenopausal JJ None
women NNS None
with IN None
high JJ None
bone NN None
turnover NN None
treated VBN None
with IN None
HRT NNP None
. . None
women NNS None
with IN None
ovarian JJ None
deficiency NN None
. . None
-DOCSTART- -X- N

type NN Condition
II NNP Condition
diabetes VBZ Condition
mellitus NN Condition
. . None
To TO None
identify VB None
patients NNS None
with IN None
type JJ Condition
II NNP Condition
diabetes VBZ Condition
mellitus NN Condition
for IN None
whom WP None
insulin NN None
therapy NN None
is VBZ None
most RBS None
beneficial JJ None
, , None
we PRP None
conducted VBD None
a DT None
randomized VBN None
controlled VBN None
trial NN None
in IN None
the DT None
general JJ None
medicine NN None
clinic NN None
of IN None
a DT None
university NN None
hospital NN None
. . None
Asymptomatic NNP None
, , None
obese JJ Condition
, , None
insulin-treated JJ None
patients NNS None
25 CD Size
insulin-withdrawal JJ Size
patients NNS None
24 CD Size
control NN None
subjects NNS None
. . None
-DOCSTART- -X- N

familial JJ None
adenomatous JJ None
polyposis NN None
. . None
patients NNS None
with IN None
familial JJ None
adenomatous JJ None
polyposis NN None
( ( None
FAP NNP None
) ) None
. . None
FAP NNP None
patients NNS None
. . None
relevance-M66I NN None
, , None
P153L NNP None
, , None
E158K NNP None
, , None
V257M NNP None
, , None
E305X NNP None
, , None
E308G NNP None
, , None
and CC None
R492W-in NNP None
21 CD None
and CC None
20 CD None
FAP NNP None
patients NNS None
, , None
who WP None
received VBD None
sulindac NN None
and CC None
placebo NN None
, , None
respectively RB None
. . None
41 CD None
patients NNS None
sulindac-treated JJ None
patients NNS None
patients NNS None
on IN None
sulindac NN None
-DOCSTART- -X- N

persistent JJ Condition
corneal JJ Condition
epithelial JJ Condition
defects NNS Condition
. . Condition
persistent JJ Condition
corneal JJ Condition
epithelial JJ Condition
defects NNS Condition
. . Condition
60 CD None
eyes NNS None
of IN None
59 CD None
patients NNS None
-DOCSTART- -X- N

acute JJ Condition
blood NN Condition
loss NN Condition
in IN None
mallard NN None
ducks NNS None
( ( None
Anas NNP None
platyrhynchos NN None
) ) None
. . None
acute JJ Condition
blood NN Condition
loss NN Condition
in IN None
mallard NN None
ducks NNS None
( ( None
Anas NNP None
platyrhynchos NN None
) ) None
Medical NNP None
College NNP None
of IN None
Wisconsin NNP None
Research NNP None
facility NN None
. . None
Eighteen NNP Size
mallard NN None
ducks NNS None
28 CD Size
mallard NN None
ducks NNS None
-DOCSTART- -X- N

tracheal JJ Condition
intubation NN Condition
. . None
Laryngoscopy NNP None
and CC None
tracheal JJ None
intubation NN None
laryngoscopy NN None
and CC None
tracheal JJ None
intubation NN None
. . None
Forty-three JJ Size
female JJ Sex
patients NNS None
tracheal JJ None
intubation NN None
-DOCSTART- -X- N

heart NN Condition
transplant NN Condition
recipients NNS Condition
. . None
heart-transplant JJ None
recipients NNS None
. . None
Twenty NNP Size
heart-transplant JJ None
recipients NNS None
were VBD None
randomised VBN None
into IN None
either CC None
a DT None
treated JJ None
or CC None
a DT None
placebo NN None
group NN None
. . None
one CD None
patient NN None
in IN None
the DT None
ticlopidine NN None
group NN None
was VBD None
withdrawn VBN None
because IN None
of IN None
a DT None
major JJ None
fall NN None
in IN None
cyclosporin JJ None
blood NN None
level NN None
within IN None
3 CD None
days NNS None
of IN None
treatment NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ Condition
leukemia NN Condition
. . None
rectal JJ Condition
infections NNS Condition
patients NNS None
with IN None
acute JJ Condition
leukemia NN Condition
. . None
sample NN None
consisted VBD None
of IN None
40 CD Size
patients NNS None
-DOCSTART- -X- N

patients NNS None
. . None
Emergency NNP None
Department NNP None
, , None
University NNP None
Hospital NNP None
of IN None
Wales NNP None
. . None
A DT None
total NN None
of IN None
302 CD None
patients NNS None
aged VBN None
over IN None
15 CD None
years NNS None
. . None
-DOCSTART- -X- N

endocrine NN Condition
physiology NN Condition
and CC Condition
metabolism NN Condition
in IN None
rats NNS Condition
. . None
experimental JJ Condition
animals NNS Condition
Male JJ Sex
Sprague-Dawley JJ Condition
rats NNS Condition
( ( None
n JJ Size
= $ Size
6 CD Size
per IN Size
group NN Size
) ) None
-DOCSTART- -X- N

endoscopic NN None
procedures NNS None
. . None
Subjects NNS None
scheduled VBN Condition
for IN Condition
colonoscopies NNS Condition
convenience NN None
sample NN None
of IN None
96 CD Size
subjects NNS None
-DOCSTART- -X- N

middle-aged JJ Age
adults NNS Age
with IN None
cardiovascular JJ Condition
risk NN Condition
factors NNS Condition
. . None
The DT None
Stages NNPS None
to TO None
Healthy NNP None
Eating NNP None
Patterns NNP None
Study NNP None
( ( None
STEPs NNP None
) ) None
middle-aged JJ Age
adults NNS Age
with IN None
cardiovascular JJ Condition
risk NN Condition
factors NNS Condition
middle-aged JJ Age
adults NNS Age
with IN None
cardiovascular JJ Condition
risk NN Condition
factors NNS Condition
. . None
-DOCSTART- -X- N

100 CD Size
patients NNS None
experiencing VBG None
primary JJ Condition
TKA NNP Condition
-DOCSTART- -X- N

men NNS None
aged VBN None
?40 CD None
years NNS None
with IN None
erectile JJ None
dysfunction NN None
? . None
men NNS None
aged VBN None
?40 CD None
years NNS None
with IN None
erectile JJ None
dysfunction NN None
( ( None
ED NNP None
) ) None
. . None
PATIENTS NNP None
partners NNS None
. . None
Men NNP Sex
aged VBD None
?40 CD None
years NNS None
who WP None
were VBD None
not RB None
receiving VBG None
lipid JJ None
lowering NN None
or CC None
anti-hypertensive JJ Condition
medication NN None
and CC None
not RB None
at IN None
high JJ None
cardiovascular JJ None
risk NN None
were VBD None
recruited VBN None
from IN None
10 CD None
general JJ None
practices NNS None
in IN None
the DT None
East NNP None
of IN None
England NNP None
, , None
173 CD Size
eligible JJ None
men NNS Sex
with IN None
untreated JJ Condition
ED NNP Condition
were VBD None
randomized VBN None
to TO None
double-blind VB None
treatment NN None
with IN None
40 CD None
Identifying VBG None
men NNS None
with IN None
ED NNP None
provides VBZ None
-DOCSTART- -X- N

patients NNS None
with IN None
ocular JJ Condition
burns NNS Condition
] FW None
patients NNS None
with IN None
ocular JJ Condition
burns NNS Condition
. . None
Fifty-five JJ Size
cases NNS None
of IN None
patients NNS None
with IN None
ocular JJ Condition
burns NNS Condition
( ( None
in IN None
88 CD Size
eyes NNS None
) ) None
49 CD None
eyes NNS None
were VBD None
transplanted VBN None
patients NNS None
with IN None
ocular JJ Condition
burns NNS Condition
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
: : None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
. . None
inhospital JJ None
ventricular JJ None
fibrillation NN None
( ( None
VF NNP None
) ) None
and CC None
ventricular JJ None
tachycardia NN None
( ( None
VT NNP None
) ) None
and CC None
compared VBN None
30-day JJ None
and CC None
1-year JJ None
mortality NN None
rates NNS None
of IN None
patients NNS None
who WP None
did VBD None
( ( None
n VB None
= NNP None
1121 CD None
) ) None
and CC None
did VBD None
not RB None
( ( None
n JJ None
= NNP None
13,921 CD None
) ) None
have VBP None
these DT None
arrhythmias NNS None
during IN None
the DT None
index NN None
hospitalization NN None
. . None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
-DOCSTART- -X- N

severely JJ Age
obese JJ Age
adolescents NNS Age
. . Age
severely RB Age
obese JJ Age
adolescents NNS Age
. . Age
Forty-six JJ Size
subjects NNS None
( ( None
24 CD Size
HPLC NNP None
, , None
22 CD Size
in IN None
low JJ None
fat NN None
) ) None
initiated VBD None
and CC None
33 CD Size
subjects NNS None
completed VBD None
the DT None
intervention NN None
; : None
severely JJ Age
obese JJ Age
adolescents NNS Age
. . Age
-DOCSTART- -X- N

patients NNS None
with IN None
coronary JJ None
heart NN None
disease NN None
( ( None
CHD NNP None
) ) None
or CC None
CHD NNP None
risk NN None
equivalents NNS None
( ( None
clinical JJ None
trials.gov NN None
NCT00685776 NNP None
) ) None
. . None
Eligible JJ None
patients NNS None
at IN None
National NNP None
Cholesterol NNP None
Education NNP None
Program-Adult NNP None
Treatment NNP None
Panel NNP None
III NNP None
LDL-C NNP None
treatment NN None
goal NN None
on IN None
a DT None
statin NN None
, , None
with IN None
or CC None
without IN None
other JJ None
lipid-modifying JJ None
medications NNS None
total NN None
of IN None
2,757 CD None
patients NNS None
were VBD None
screened VBN None
at IN None
153 CD None
centers NNS None
in IN None
20 CD None
countries NNS None
, , None
and CC None
1,623 CD None
patients NNS None
were VBD None
randomized VBN None
-DOCSTART- -X- N

infants NNS Age
with IN None
single-ventricle JJ Condition
lesions NNS Condition
infants NNS Age
undergoing VBG Condition
the DT Condition
Norwood NNP Condition
procedure NN Condition
549 CD None
subjects NNS None
( ( None
follow-up JJ None
, , None
2.7 CD None
? . None
0.9 CD None
years NNS None
infants NNS None
infants NNS None
-DOCSTART- -X- N

A DT None
double-blind JJ None
crossover NN None
comparison NN None
of IN None
pindolol NN None
, , None
metoprolol NN None
, , None
atenolol NN None
and CC None
labetalol NN None
in IN None
mild NN None
to TO None
moderate VB None
hypertension NN None
. . None
-DOCSTART- -X- N

muscle NN None
relaxants NNS None
Six CD Size
patients NNS None
in IN None
each DT None
group NN None
-DOCSTART- -X- N

colonoscopy NN None
or CC None
sigmoidoscopy JJ None
preparation NN None
. . None
One CD None
hundred VBD None
thirteen JJ None
patients NNS None
-DOCSTART- -X- N

nematode JJ Condition
parasites NNS Condition
of IN None
small JJ None
ruminants NNS None
on IN None
government NN None
breeding NN None
farms NNS None
in IN None
Sabah NNP None
, , None
East NNP None
Malaysia NNP None
. . None
Government-owned JJ None
small-ruminant JJ None
breeding NN None
farms NNS None
eastern JJ None
Malaysian JJ None
state NN None
of IN None
Sabah NNP None
nematode JJ Condition
parasite NN Condition
Haemonchus NNP Condition
contortus NN Condition
. . None
sheep NN None
and CC None
goats NNS None
on IN None
all DT None
farms NNS None
. . None
-DOCSTART- -X- N

postmenopausal NN Condition
hormone CD None
replacement NN None
therapy NN None
( ( None
HRT NNP None
) ) None
in IN None
women NNS Sex
with IN None
and CC None
without IN None
a DT None
history NN None
of IN None
premenstrual JJ Condition
syndrome NN Condition
( ( Condition
PMS NNP Condition
) ) Condition
. . Condition
36 CD Size
postmenopausal JJ Condition
women NNS Sex
at IN None
three CD None
health NN None
care NN None
areas NNS None
in IN None
northern JJ None
Sweden NNP None
. . None
-DOCSTART- -X- N

adult NN Age
autistic JJ Condition
disorder NN Condition
. . None
repetitive JJ None
behaviors NNS None
in IN None
adult NN Age
autistic JJ Condition
patients NNS None
. . None
Eleven NNP Size
adult NN Age
patients NNS None
with IN None
autism NN Condition
or CC None
Asperger NNP Condition
's POS Condition
disorder NN Condition
were VBD None
randomized VBN None
-DOCSTART- -X- N

dairy NN None
cows NNS None
36 CD Size
primiparous JJ None
and CC None
40 CD Size
multiparous JJ None
Holstein NNP None
cows NNS None
cows VBZ None
consuming VBG None
WCGF NNP None
consuming VBG None
WCGF NNP None
-DOCSTART- -X- N

acute JJ None
invasive JJ None
diarrhea NN None
in IN None
children NNS None
children NNS None
acute JJ Condition
invasive JJ Condition
diarrhea NN Condition
in IN None
infants NNS None
and CC None
children NNS None
201 CD None
evaluable JJ None
children NNS None
ages VBZ Age
6 CD Age
months NNS Age
to TO Age
10 CD Age
years NNS Age
( ( Age
35 CD Age
% NN Age
< CC Age
1 CD Age
year NN Age
; : Age
70 CD Age
% NN Age
< JJ Age
3 CD Age
years NNS Age
) ) Age
presenting VBG None
with IN None
acute JJ None
invasive JJ None
diarrhea NN None
at IN None
the DT None
Pediatric NNP None
Emergency NNP None
Room NNP None
ambulatory JJ Condition
pediatric JJ Condition
patients NNS Condition
requiring VBG Condition
an DT Condition
emergency NN Condition
room NN Condition
visit NN Condition
. . None
-DOCSTART- -X- N

in IN None
patients NNS None
> JJ Age
or=12 CD Age
years NNS Age
old JJ Age
with IN None
mild-to-moderate JJ Condition
persistent JJ Condition
asthma NN Condition
. . None
1233 CD Size
patients NNS None
were VBD None
randomized VBN None
. . None
-DOCSTART- -X- N

maternal JJ Condition
and CC Condition
newborn JJ Condition
care NN Condition
, , Condition
with IN Condition
prevention NN Condition
of IN Condition
mother-to-child JJ Condition
transmission NN Condition
of IN Condition
HIV NNP Condition
in IN Condition
a DT Condition
South JJ Condition
African JJ Condition
township NN Condition
. . None
peri-urban JJ None
poor JJ None
. . None
30 CD None
clusters NNS None
( ( None
15 CD None
in IN None
each DT None
arm NN None
) ) None
to TO None
evaluate VB None
an DT None
integrated VBN None
, , None
scalable JJ None
package NN None
providing VBG None
two CD None
pregnancy NN None
visits NNS None
and CC None
five CD None
post-natal JJ None
home NN None
visits NNS None
delivered VBN None
by IN None
community NN None
health NN None
workers NNS None
in IN None
Umlazi NNP None
, , None
Durban NNP None
, , None
South NNP None
Africa NNP None
. . None
12 CD Condition
weeks NNS Condition
post-natally RB Condition
and CC Condition
HIV-free JJ Condition
infant NN Condition
survival NN Condition
. . None
12 CD Age
weeks NNS Age
of IN Age
infant JJ Age
age NN Age
-DOCSTART- -X- N

acute JJ Condition
depressive JJ Condition
mixed JJ Condition
state NN Condition
. . None
patients NNS None
with IN None
mixed JJ Condition
depressive JJ Condition
state NN Condition
. . None
72 CD Size
patients NNS None
were VBD None
randomized VBN None
-DOCSTART- -X- N

men NNS None
with IN None
flat JJ Condition
( ( Condition
FC NNP Condition
) ) Condition
or CC Condition
acuminata NN Condition
( ( Condition
CA NNP Condition
) ) Condition
condylomata NN Condition
with IN None
interferon JJ None
alpha-2a NN None
. . None
C.A NNP Condition
. . Condition
or CC None
F.C NNP Condition
. . None
of IN None
the DT None
male JJ None
genital JJ None
tract NN None
. . None
From IN None
March NNP None
1986 CD None
to TO None
September NNP None
1991 CD None
, , None
1372 CD Size
men NNS None
, , None
sexual JJ None
partners NNS None
of IN None
women NNS None
with IN None
F.C NNP Condition
. . Condition
or CC None
C.A NNP Condition
. . Condition
or CC None
cervical JJ Condition
intraepithelial JJ Condition
neoplasia NN Condition
, , None
were VBD None
submitted VBN None
to TO None
peoscopy VB Condition
. . None
One CD Size
thousand NN Size
and CC Size
nineteen JJ Size
( ( None
74.27 CD None
% NN None
) ) None
men NNS None
presented VBN None
with IN None
various JJ None
penile JJ Condition
lesions NNS Condition
caused VBN None
by IN None
HPV NNP None
( ( None
histologically RB None
confirmed VBN None
) ) None
; : None
505 CD Size
were VBD None
treated VBN None
for IN None
C.A NNP Condition
. . Condition
or CC None
F.C NNP Condition
. . None
or CC None
a DT None
combination NN None
of IN None
F.C NNP None
. . None
and CC None
C.A NNP None
. . None
C.A NNP Condition
. . Condition
or CC None
F.C NNP Condition
. . Condition
or CC None
combined VBN Condition
condylomata NNS Condition
-DOCSTART- -X- N

supraventricular JJ Condition
tachyarrhythmias NN Condition
. . None
patients NNS None
with IN None
supraventricular JJ Condition
tachyarrhythmias NN Condition
( ( None
heart NN None
rate NN None
greater JJR None
than IN None
120 CD None
bpm NN None
) ) None
Seventy-one CD Size
patients NNS None
-DOCSTART- -X- N

on IN None
clinical JJ None
outcome NN None
after IN None
balloon NN None
coronary JJ None
angioplasty NN None
. . None
Between NNP None
September NNP None
1985 CD None
and CC None
April NNP None
1987 CD None
, , None
110 CD None
consecutive JJ None
patients NNS None
who WP None
had VBD None
successful JJ None
coronary JJ None
angioplasty NN None
One CD None
hundred CD None
and CC None
eight CD None
( ( None
98 CD None
% NN None
) ) None
of IN None
patients NNS None
were VBD None
followed VBN None
up RP None
clinically RB None
after IN None
a DT None
median NN None
of IN None
five CD None
months NNS None
( ( None
range VB None
1-20 CD None
) ) None
. . None
Eighty NNP None
five CD None
( ( None
77 CD None
% NN None
) ) None
had VBD None
follow VBN None
up RP None
angiography NN None
at IN None
five CD None
months NNS None
. . None
-DOCSTART- -X- N

SDAT NNP Condition
and CC None
MID NNP Condition
. . None
96 CD Size
mildly RB None
to TO None
moderately RB None
demented JJ None
patients NNS None
( ( None
72 CD Size
women NNS Sex
, , None
24 CD Size
men NNS Sex
) ) None
, , None
aged VBN None
61-96 CD Age
years NNS Age
( ( None
mean VB None
82 CD Age
) ) None
, , None
diagnosed VBD None
according VBG None
to TO None
DSM-III NNP None
criteria NNS None
. . None
Patients NNS None
were VBD None
off RP None
drugs NNS None
for IN None
at IN None
least JJS None
2 CD None
weeks NNS None
and CC None
subdiagnosed VBD None
according VBG None
to TO None
the DT None
modified VBN None
Marshall-Hachinski NNP None
ischemic JJ None
score NN None
and CC None
CT NNP None
in IN None
45 CD Size
senile JJ Condition
dementia NN Condition
of IN None
the DT None
Alzheimer NNP Condition
type NN Condition
( ( Condition
SDAT NNP Condition
) ) Condition
and CC None
51 CD Size
multiinfarct NN Condition
dementia NN Condition
( ( Condition
MID NNP Condition
) ) Condition
patients NNS None
. . None
-DOCSTART- -X- N

hypercholesterolemia NN Condition
] NN None
24 CD Size
patients NNS None
with IN None
familial JJ Condition
hypercholesterolemia NN Condition
. . None
heterozygous JJ Condition
familial JJ Condition
hypercholesterolemia NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
non-erosive JJ Condition
reflux NN Condition
disease NN Condition
. . None
patients NNS None
with IN None
reflux NN Condition
symptoms NNS None
patients NNS None
with IN None
non-erosive JJ Condition
reflux NN Condition
disease NN Condition
. . None
multicentre NN None
Adults NNS Age
with IN None
a DT None
history NN None
of IN None
reflux NN Condition
symptoms NNS None
, , None
a DT None
negative JJ None
endoscopy NN None
, , None
and CC None
> NNP None
or CC None
= VB None
3 CD None
days NNS None
of IN None
moderate JJ None
to TO None
very RB None
severe JJ None
heartburn NN Condition
in IN None
the DT None
7 CD None
days NNS None
before IN None
enrollment NN None
( ( None
N NNP None
= NNP None
535 CD None
) ) None
Patients NNS None
with IN None
complete JJ None
symptom NN None
relief NN None
then RB None
entered VBD None
the DT None
on-demand JJ None
phase NN None
. . None
non-erosive JJ Condition
reflux NN Condition
disease NN Condition
patients NNS None
. . None
-DOCSTART- -X- N

allergic JJ Condition
rhinitis NN Condition
and CC None
urticaria NN Condition
. . None
Eight CD Size
volunteers NNS None
were VBD None
enrolled VBN None
-DOCSTART- -X- N

diabetic JJ Condition
rats NNS None
. . None
diabetic JJ None
rats NNS None
. . None
Thirty NNP Size
male NN Sex
rats NNS None
-DOCSTART- -X- N

age NN Condition
related VBN Condition
macular JJ Condition
degeneration NN Condition
( ( Condition
AMD NNP Condition
) ) Condition
Patients NNPS None
that WDT None
had VBD None
nonexudative JJ None
age-related JJ None
macular JJ None
degeneration NN None
( ( None
AMD NNP None
) ) None
and CC None
certain JJ None
hemorheologic JJ None
abnormalities NNS None
A DT None
total NN None
of IN None
216 CD None
patients NNS None
198 CD None
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
type JJ Condition
1 CD Condition
diabetes NNS Condition
and CC None
unawareness NN Condition
of IN Condition
hypoglycemia NN Condition
. . None
type NN Condition
1 CD Condition
diabetic JJ Condition
patients NNS Condition
. . None
patients NNS None
with IN None
type JJ Condition
1 CD Condition
diabetes NNS Condition
and CC None
hypoglycemia NN Condition
unawareness NN Condition
. . None
12 CD Size
subjects NNS Size
with IN None
type JJ Condition
1 CD Condition
diabetes NNS Condition
and CC None
hypoglycemia NN Condition
unawareness NN Condition
. . None
subjects NNS Size
patients NNS None
with IN None
type JJ Condition
1 CD Condition
diabetes NNS Condition
and CC None
hypoglycemia NN Condition
unawareness NN Condition
. . None
-DOCSTART- -X- N

Eighty NNP Size
pregnant JJ Condition
women NNS None
at IN None
high JJ Condition
risk NN Condition
of IN Condition
giving VBG Condition
birth NN Condition
prematurely RB Condition
-DOCSTART- -X- N

Between NNP None
1999 CD None
and CC None
2002 CD None
, , None
1397 CD Size
antiretroviral-treatment-naive JJ Condition
patients NNS None
, , None
presenting VBG None
at IN None
18 CD None
clinical JJ None
trial NN None
units NNS None
with IN None
80 CD None
research NN None
sites NNS None
in IN None
the DT None
USA NNP None
1397 CD Size
patients NNS None
were VBD None
assessed VBN None
for IN None
the DT None
composite JJ None
endpoint NN None
. . None
388 CD Size
participants NNS None
developed VBD None
the DT None
composite JJ None
endpoint NN None
, , None
302 CD Size
developed VBD None
AIDS NNP Condition
or CC None
died VBN None
, , None
and CC None
188 CD Size
died VBD None
. . None
treatment-naive JJ None
patients NNS None
with IN None
HIV NNP Condition
. . None
-DOCSTART- -X- N

asthma NN Condition
. . None
231 CD Size
patients NNS None
with IN None
chronic JJ Condition
reversible JJ Condition
obstructive JJ Condition
airway NN Condition
disease NN Condition
half NN Size
preferred VBD None
using VBG None
the DT None
powder NN None
. . None
-DOCSTART- -X- N

12 CD None
normal JJ None
subjects NNS None
( ( None
6 CD None
men NNS None
, , None
6 CD None
women NNS None
; : None
ages VBZ None
21 CD None
to TO None
26 CD None
years NNS None
) ) None
before IN None
and CC None
after IN None
ingestion NN None
of IN None
caffeine NN None
normal JJ None
subjects NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
progressive JJ None
castrate NN None
metastatic JJ None
prostate NN None
cancer NN None
. . None
chemotherapy-naive JJ None
patients NNS None
with IN None
progressive JJ None
castrate NN None
metastatic JJ None
prostate NN None
cancer NN None
. . None
Between NNP None
December NNP None
2001 CD None
and CC None
October NNP None
2003 CD None
, , None
92 CD None
patients NNS None
were VBD None
enrolled VBN None
and CC None
randomly RB None
assigned VBN None
treatment NN None
with IN None
ixabepilone NN None
alone RB None
( ( None
45 CD None
patients NNS None
) ) None
or CC None
in IN None
combination NN None
with IN None
EMP NNP None
( ( None
47 CD None
patients NNS None
) ) None
. . None
patients NNS None
with IN None
castrate JJ None
metastatic JJ None
prostate NN None
cancer NN None
. . None
-DOCSTART- -X- N

Elite NNP None
sprint NN None
and CC None
middle-distance NN None
swimmers NNS None
( ( None
three CD Size
females NNS Sex
and CC None
six CD Size
males NNS Sex
; : None
aged VBN Age
21-26 JJ Age
yr NN None
) ) None
performed VBD None
6-13 JJ None
time NN None
trials NNS None
in IN None
training NN None
and CC None
competition NN None
in IN None
the DT None
9 CD None
wk NN None
before IN None
and CC None
including VBG None
Olympic-qualifying JJ None
trials NNS None
, , None
all DT None
in IN None
their PRP$ None
specialty NN None
event NN None
. . None
elite JJ None
athletes NNS None
. . None
-DOCSTART- -X- N

European NNP None
multicentre NN None
trial NN None
. . None
230 CD Size
patients NNS None
with IN None
endoscopically RB None
documented VBN None
gastric NN Condition
( ( None
71 CD Size
) ) None
or CC None
duodenal JJ Condition
( ( None
159 CD Size
) ) None
ulcers NNS Condition
. . None
Gastric NNP Condition
ulcer JJ Condition
patients NNS None
who WP None
satisfied VBD None
all DT None
criteria NNS None
for IN None
inclusion NN None
and CC None
exclusion NN None
treatment NN None
of IN None
duodenal JJ Condition
and CC Condition
gastric JJ Condition
ulceration NN Condition
. . Condition
-DOCSTART- -X- N

metastatic JJ Condition
breast NN Condition
cancer NN Condition
patients NNS None
: : None
patients NNS None
with IN None
metastatic JJ Condition
breast NN Condition
cancer NN Condition
( ( Condition
MBC NNP Condition
) ) Condition
. . None
Four NNP Size
hundred VBD Size
seventeen JJ Size
anthracycline-naive JJ Condition
MBC NNP Condition
patients NNS None
-DOCSTART- -X- N

children NNS None
with IN None
learning VBG None
disabilities NNS None
] NNP None
children NNS None
with IN None
learning VBG None
disabilities NNS None
( ( None
LD NNP None
) ) None
. . None
children NNS None
with IN None
LD NNP None
. . None
85 CD None
children NNS None
with IN None
LD NNP None
, , None
with IN None
age NN None
range NN None
between IN None
8 CD None
years NNS None
and CC None
10 CD None
years NNS None
( ( None
age NN None
, , None
M=111.02 NNP None
, , None
SD=9.6 NNP None
) ) None
, , None
whose WP$ None
spelling VBG None
performance NN None
was VBD None
two CD None
years NNS None
below IN None
grade JJ None
level NN None
. . None
-DOCSTART- -X- N

87 CD Size
volunteers NNS None
who WP None
wanted VBD None
to TO None
quit VB None
cigarette NN Condition
smoking NN Condition
individuals NNS None
-DOCSTART- -X- N

16 CD None
healthy JJ None
elderly JJ None
subjects NNS None
, , None
ages VBZ None
60 CD None
years NNS None
and CC None
older JJR None
. . None
-DOCSTART- -X- N

40 CD None
patients NNS None
to TO None
evaluate VB None
the DT None
need NN None
for IN None
antibiotics NNS None
in IN None
acute JJ None
exacerbations NNS None
of IN None
chronic JJ None
bronchitis NN None
. . None
All DT None
patients NNS None
were VBD None
sufficiently RB None
ill VBN None
to TO None
require VB None
hospitalization NN None
although IN None
none NN None
needed VBD None
ventilatory JJ None
support NN None
; : None
the DT None
presence NN None
of IN None
pneumonia NN None
was VBD None
excluded VBN None
. . None
moderately RB None
ill JJ None
patients NNS None
with IN None
exacerbations NNS None
of IN None
chronic JJ None
bronchitis NN None
. . None
-DOCSTART- -X- N

amblyopia NN None
. . None
51 CD None
participants NNS None
with IN None
amblyopia NN None
( ( None
strabismic JJ None
n=17 NN None
; : None
anisometropic CC None
n=10 VBP None
; : None
combined VBN None
n=24 NN None
) ) None
, , None
mean JJ None
age NN None
10 CD None
years NNS None
8 CD None
months NNS None
. . None
The DT None
amblyopia NN None
was VBD None
defined VBN None
as IN None
severe/moderate NN None
( ( None
< JJ None
0.250 CD None
logMAR NN None
) ) None
, , None
n=41 RB None
or CC None
mild VB None
( ( None
> CD None
or CC None
= VB None
0.250 CD None
logMAR NN None
) ) None
, , None
n=10 RB None
. . None
subgroup NN None
with IN None
severe/moderate NN None
amblyopia NN None
( ( None
0.074+/-0.036 JJ None
) ) None
-DOCSTART- -X- N

postsurgical JJ Condition
orthopedic JJ Condition
patients NNS Condition
: : None
postsurgical JJ Condition
orthopedic JJ Condition
patients NNS None
Patients NNPS None
( ( None
N=60 NNP Size
) ) None
admitted VBD None
to TO None
our PRP$ None
department NN None
postorthopedic NN None
surgery NN None
Exclusion NN None
criteria NNS None
were VBD None
age NN None
18 CD Age
years NNS Age
or CC Age
younger JJR Age
and CC Age
90 CD Age
years NNS Age
or CC Age
older JJR Age
, , None
Mini-Mental JJ None
State NNP None
Examination NNP None
score NN None
of IN None
21 CD None
of IN None
30 CD None
or CC None
lower JJR None
, , None
no DT None
ambulating VBG None
order NN None
, , None
advanced JJ None
vision NN None
impairment NN None
, , None
malignancy NN None
, , None
pneumonia NN None
, , None
or CC None
heart NN None
failure NN None
. . None
conventional JJ None
physiotherapy NN None
. . None
postsurgical JJ None
orthopedic JJ None
patients NNS None
. . None
nonneurologic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

advanced JJ Condition
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
patients NNS Condition
. . Condition
first-line JJ None
treatment NN None
of IN None
patients NNS None
with IN None
advanced JJ None
head NN None
and CC None
neck NN None
cancer NN None
. . None
successive JJ None
patients NNS None
with IN None
unresectable JJ None
grade NN None
I/II NNP None
head NN None
and CC None
neck NN None
cancer NN None
who WP None
were VBD None
not RB None
suitable JJ None
for IN None
irradiation NN None
treatment NN None
( ( None
T NNP None
any DT None
N3 NNP None
or CC None
T4 NNP None
N2C NNP None
) ) None
, , None
metastatic JJ None
or CC None
previously RB None
irradiated VBN None
. . None
A DT Condition
total NN Condition
of IN Condition
170 CD Condition
patients NNS Condition
were VBD Condition
included VBN Condition
in IN Condition
the DT Condition
study NN Condition
. . Condition
head NN None
and CC None
neck NN None
cancer NN None
patients NNS None
. . None
-DOCSTART- -X- N

subjects NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
consuming VBG None
a DT None
high-fiber JJ None
diet NN None
subjects NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
Subjects VBZ None
with IN None
type NN Condition
2 CD Condition
diabetes NNS Condition
( ( None
n JJ None
= NNP None
62 CD Size
) ) None
subjects NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
-DOCSTART- -X- N

patients NNS Condition
unfit JJ Condition
for IN Condition
open JJ Condition
repair NN Condition
of IN Condition
abdominal JJ Condition
aortic JJ Condition
aneurysm NN Condition
( ( None
EVAR NNP None
trial NN None
2 CD None
) ) None
: : None
patients NNS None
of IN None
poor JJ None
health NN None
status NN None
considered VBN None
unfit NN None
for IN None
major JJ None
surgery NN None
. . None
patients NNS None
unfit JJ None
for IN None
open JJ None
repair NN None
of IN None
aortic JJ None
aneurysm NN None
. . None
338 CD Size
patients NNS Size
aged VBN Age
60 CD Age
years NNS Age
or CC Age
older JJR Age
who WP None
had VBD None
aneurysms NNS Condition
of IN None
at IN None
least JJS None
5.5 CD None
cm NN None
in IN None
diameter NN None
and CC None
who WP None
had VBD None
been VBN None
referred VBN None
to TO None
one CD None
of IN None
31 CD None
hospitals NNS None
in IN None
the DT None
UK NNP None
. . None
197 CD None
patients NNS None
-DOCSTART- -X- N

general JJ None
population NN None
in IN None
Japan NNP None
: : None
general JJ None
sexual JJ None
behavioral JJ None
survey NN None
in IN None
Japan NNP None
. . None
The DT None
sample NN None
( ( None
360 CD Size
potential JJ Size
respondents NNS Size
) ) None
was VBD None
selected VBN None
randomly RB None
from IN None
basic JJ None
resident NN None
registers NNS None
two CD None
geographically RB None
different JJ None
areas NNS None
. . None
90 CD Size
residents NNS Size
, , None
aged VBD None
20 CD None
to TO None
49 CD None
years NNS None
old JJ None
October NNP None
1995 CD None
to TO None
February NNP None
1996 CD None
. . None
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS Condition
. . None
healthy JJ None
subjects NNS None
. . None
Twelve NNP None
healthy JJ None
volunteers NNS None
, , None
six CD None
men NNS Sex
and CC None
six CD None
women NNS Sex
, , None
mean JJ Age
age NN Age
34.4 CD Age
( ( Age
range VB Age
23-48 CD Age
) ) Age
healthy JJ None
persons NNS None
-DOCSTART- -X- N

adults NNS Age
with IN None
an DT None
autism NN Condition
spectrum NN Condition
disorder NN Condition
: : None
high-functioning NN Condition
adults NNS Age
with IN None
ASD NNP Condition
. . None
42 CD Size
participants NNS None
adults NNS Age
with IN None
ASD NNP Condition
-DOCSTART- -X- N

humans NNS Condition
. . None
Twenty-four NNP Size
subjects NNS None
, , None
each DT None
requiring VBG None
a DT None
nonmolar JJ Condition
extraction NN Condition
and CC None
delayed JJ Condition
implant NN Condition
placement NN Condition
-DOCSTART- -X- N

in IN None
children NNS None
with IN None
malignant JJ Condition
disease NN Condition
: : Condition
children NNS None
with IN None
malignant JJ Condition
disease NN Condition
. . Condition
82 CD Size
children NNS None
who WP None
received VBD None
a DT None
full JJ None
course NN None
of IN None
6 CD None
days NNS None
or CC None
more JJR None
of IN None
AmB NNP Condition
( ( None
117 CD None
courses NNS None
) ) None
children NNS Age
with IN None
malignant JJ Condition
disease NN Condition
. . None
-DOCSTART- -X- N

auditory JJ None
processing NN None
disorders NNS None
( ( None
APD NNP None
) ) None
listeners NNS None
with IN None
APD NNP None
. . None
normal-hearing JJ None
participants NNS None
of IN None
varying VBG None
ages NNS None
33 CD None
adults NNS None
and CC None
30 CD None
children NNS None
( ( None
aged VBN None
8-11 CD None
years NNS None
) ) None
with IN None
no DT None
known JJ None
history NN None
of IN None
listening VBG None
difficulties NNS None
Adult NN None
participants NNS None
child NN None
participants NNS None
. . None
-DOCSTART- -X- N

We PRP None
analysed VBD None
data NNS None
from IN None
5161 CD None
patients NNS None
undergoing VBG None
general JJ None
anaesthesia NN None
postoperative JJ None
nausea NN None
and CC None
postoperative JJ None
vomiting NN None
-DOCSTART- -X- N

International NNP None
Czech NNP None
and CC None
Slovak NNP None
patients NNS None
with IN None
differentiated JJ Condition
thyroid NN Condition
cancer NN Condition
. . None
Slovak NNP None
patients NNS None
with IN None
differentiated JJ None
thyroid NN None
cancer NN None
in IN None
Slovak NNP None
and CC None
Czech NNP None
hospitals NNS None
. . None
From NNP None
September NNP None
1991 CD None
to TO None
October NNP None
2005 CD None
in IN None
the DT None
Department NNP None
of IN None
Nuclear NNP None
Medicine NNP None
in IN None
Ostrava NNP None
357 CD Size
patients NNS None
from IN None
the DT None
Slovak NNP None
Republic NNP None
with IN None
differentiated VBN Condition
thyroid NN Condition
cancers NNS Condition
( ( None
follicular JJ Condition
and CC Condition
papillary JJ Condition
) ) None
underwent NN None
complex JJ None
therapy NN None
. . None
They PRP None
were VBD None
diagnosed VBN None
and CC None
operated VBN None
due JJ None
to TO None
the DT None
cancer NN None
( ( None
near-total JJ Condition
thyroidectomy NN Condition
and CC None
removal NN Condition
of IN Condition
lymph JJ Condition
node JJ Condition
metastases NNS Condition
) ) None
in IN None
Slovak NNP None
hospitals NNS None
. . None
Then RB None
they PRP None
were VBD None
sent VBN None
to TO None
the DT None
Department NNP None
of IN None
Nuclear NNP None
Medicine NNP None
in IN None
Ostrava NNP None
in IN None
the DT None
Czech NNP None
Republic NNP None
. . None
Slovak NNP None
Republic NNP None
, , None
in IN None
the DT None
University NNP None
Hospital NNP None
in IN None
Martin NNP None
. . None
-DOCSTART- -X- N

metronidazole NN Condition
as IN Condition
a DT Condition
disease NN Condition
modifying VBG Condition
agent NN Condition
in IN Condition
the DT Condition
treatment NN Condition
of IN Condition
rheumatoid JJ Condition
arthritis NN Condition
. . Condition
treatment NN None
of IN None
rheumatoid JJ None
arthritis NN None
. . None
Fifty JJ None
patients NNS None
with IN None
active JJ None
rheumatoid NN None
arthritis NN None
were VBD None
randomly RB None
allocated VBN None
to TO None
receive VB None
active JJ None
drug NN None
( ( None
n JJ None
= NNP None
24 CD None
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= NNP None
26 CD None
) ) None
and CC None
reviewed VBN None
at IN None
weeks NNS None
0 CD None
, , None
1 CD None
, , None
4 CD None
, , None
8 CD None
, , None
12 CD None
, , None
16 CD None
, , None
and CC None
24 CD None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
normal-tension JJ Condition
glaucoma NN Condition
with IN None
low-normal JJ Condition
intraocular JJ Condition
pressure NN Condition
. . None
patients NNS None
with IN None
normal-tension JJ Condition
glaucoma NN Condition
( ( None
NTG NNP None
) ) None
with IN None
low-normal JJ None
intraocular JJ None
pressure NN None
( ( None
IOP NNP None
) ) None
. . None
Fifty-two JJ Size
patients NNS None
with IN None
NTG NNP Condition
( ( None
average JJ None
age NN None
57.7 CD Age
years NNS None
) ) None
with IN None
an DT None
IOP NNP None
that WDT None
was VBD None
consistently RB None
less JJR None
than IN None
15 CD None
mmHg NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
patients NNS None
with IN None
NTG NNP Condition
who WP None
have VBP None
low-normal JJ None
IOP NNP None
. . None
-DOCSTART- -X- N

Two CD None
hundred VBD None
children NNS None
undergoing VBG None
bilateral JJ None
TT NNP None
placement NN None
were VBD None
categorized VBN None
as IN None
having VBG None
unilateral JJ None
( ( None
wet/dry JJ None
) ) None
, , None
bilateral JJ None
( ( None
wet/wet NN None
) ) None
, , None
or CC None
no DT None
( ( None
dry/dry NN None
) ) None
effusion NN None
at IN None
the DT None
time NN None
of IN None
surgery NN None
. . None
patients NNS None
with IN None
bilateral JJ None
effusion NN None
at IN None
the DT None
time NN None
of IN None
surgery NN None
. . None
-DOCSTART- -X- N

hyperglycemia NN None
in IN None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
inadequately RB None
controlled VBN None
by IN None
metformin NN None
monotherapy NN None
. . None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
exhibiting VBG None
inadequate JJ None
glycemic NNS None
control NN None
( ( None
A1C NNP None
7-11 CD None
% NN None
) ) None
. . None
302 CD None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
( ( None
mean JJ None
A1C NNP None
8.3 CD None
% NN None
) ) None
on IN None
metformin NN None
monotherapy NN None
( ( None
mean JJ None
1.5 CD None
g/day NN None
) ) None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
who WP None
had VBD None
inadequate JJ None
glycemic NNS None
control NN None
with IN None
metformin NN None
alone RB None
. . None
type NN None
2 CD None
diabetes NNS None
. . None
-DOCSTART- -X- N

advanced JJ None
upper JJ None
gastrointestinal JJ None
cancer NN None
: : None
advanced JJ None
carcinoma NN None
of IN None
the DT None
stomach NN None
and CC None
pancreas NNS None
. . None
-DOCSTART- -X- N

100 CD Size
patients NNS None
-DOCSTART- -X- N

rat NN None
. . None
nonsurgical JJ None
rats NNS None
rat NN None
surgical JJ None
model NN None
rats NNS None
( ( None
defect JJ None
rats NNS None
) ) None
defect NN None
rats NNS None
-DOCSTART- -X- N

Finland NNP Condition
: : None
prostate NN Condition
, , Condition
breast NN Condition
, , Condition
and CC Condition
colorectal JJ Condition
cancer NN Condition
risk NN Condition
. . None
Finns NNP None
more JJR None
than IN None
4,000 CD Size
prostate JJ None
cancer NN None
cases NNS None
and CC None
5,000 CD Size
controls NNS None
. . None
In IN None
addition NN None
, , None
986 CD Size
breast NN None
cancer NN None
and CC None
442 CD Size
colorectal JJ None
cancer NN None
( ( None
CRC NNP None
) ) None
cases NNS None
were VBD None
studied VBN None
. . None
Finnish JJ None
population NN None
, , None
particularly RB None
cases NNS None
with IN None
mutation NN None
in IN None
prostate NN None
cancer NN None
susceptibility NN None
-DOCSTART- -X- N

seven CD None
antiarrhythmic JJ None
drugs NNS None
in IN None
patients NNS None
with IN None
ventricular JJ Condition
tachyarrhythmias NNS Condition
. . None
patients NNS None
with IN None
ventricular JJ Condition
tachyarrhythmias NNS Condition
Patients NNPS None
486 CD Size
randomized VBN None
subjects NNS None
. . None
296 CD Size
patients NNS None
-DOCSTART- -X- N

12 CD Condition
patients NNS Condition
with IN Condition
essential JJ Condition
hypertension NN Condition
. . Condition
cardiovascular JJ Condition
disorders NNS Condition
angina JJ None
pectoris NN None
in IN None
patients NNS None
without IN None
hypertension NN Condition
or CC None
cardiac JJ Condition
arrhythmia NN Condition
. . None
-DOCSTART- -X- N

child NN Condition
's POS Condition
autism NN Condition
] NN Condition
children NNS None
's POS None
autism NN None
. . None
Forty NNP None
autistic JJ None
children NNS None
receiving VBG None
rehabilitation NN None
training NN None
child NN Condition
's POS Condition
autism NN Condition
. . Condition
-DOCSTART- -X- N

Chinese JJ None
ring-necked JJ None
pheasants NNS None
( ( None
Phasianus NNP None
colchicus NN None
) ) None
. . None
game NN None
farm-reared JJ None
pheasants NNS None
in IN None
the DT None
United NNP None
States NNPS None
. . None
Chinese JJ None
ring-necked JJ None
pheasants NNS None
Pheasant JJ None
chicks NNS None
( ( Age
approximately RB Age
1 CD Age
day-old JJ Age
; : Age
n CC Condition
= VB Condition
160 CD Condition
) ) None
Chinese JJ None
ring-necked JJ None
pheasants NNS None
. . None
-DOCSTART- -X- N

adjuvant JJ None
chemotherapy NN None
for IN None
breast NN None
cancer NN None
breast NN None
cancer NN None
chemotherapy-na?ve JJ None
patients NNS None
with IN None
breast JJ None
cancer NN None
age NN None
of IN None
the DT None
94 CD None
women NNS None
was VBD None
51 CD None
years NNS None
( ( None
range VB None
27-76 JJ None
) ) None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
coronary JJ Condition
heart NN Condition
disease NN Condition
. . None
patients NNS None
with IN None
coronary JJ None
heart NN None
disease NN None
( ( None
CHD NNP None
) ) None
Fifty-eight JJ Size
patients NNS Size
-DOCSTART- -X- N

papular JJ Condition
urticaria NN Condition
in IN None
children NNS Age
. . None
Papular JJ Condition
urticaria NN Condition
( ( None
PU NNP None
) ) None
-DOCSTART- -X- N

ulcerative JJ None
colitis NN None
( ( None
UC NNP None
) ) None
Ten NNP None
healthy JJ None
volunteers NNS None
, , None
and CC None
seven CD None
with IN None
UC NNP None
in IN None
symptomatic JJ None
remission NN None
took VBD None
part NN None
; : None
all DT None
were VBD None
non-smokers NNS None
. . None
17 CD None
subjects NNS None
17 CD None
subjects NNS None
normal JJ None
subjects NNS None
and CC None
patients NNS None
with IN None
UC NNP None
. . None
-DOCSTART- -X- N

One CD None
hundred VBD None
patients NNS None
were VBD None
randomized VBN None
into IN None
2 CD None
groups NNS None
to TO None
undergo VB None
percutaneous JJ None
transmitral JJ None
commissurotomy NN None
( ( None
PTMC NNP None
) ) None
by IN None
means NNS None
of IN None
the DT None
Inoue NNP None
balloon NN None
technique NN None
( ( None
IBMC NNP None
, , None
n JJ None
= NNP None
49 CD None
) ) None
or CC None
metallic JJ None
commissurotomy NN None
( ( None
PMMC NNP None
, , None
n JJ None
= NNP None
51 CD None
) ) None
. . None
severe JJ Condition
mitral JJ Condition
stenosis NN Condition
-DOCSTART- -X- N

acute NN None
low JJ None
back RB None
pain NN None
: : None
subjects NNS None
with IN None
acute NN None
low JJ None
back RB None
pain NN None
( ( None
LBP NNP None
) ) None
. . None
Outpatient NNP None
physiotherapy NN None
departments NNS None
in IN None
hospital NN None
and CC None
university NN None
settings NNS None
. . None
60 CD None
eligible JJ None
patients NNS None
with IN None
back JJ None
pain NN None
( ( None
28 CD None
men NNS None
, , None
32 CD None
women NNS None
) ) None
were VBD None
recruited VBN None
by IN None
general JJ None
practitioners NNS None
and CC None
self-referral JJ None
-DOCSTART- -X- N

exposure NN None
prevention NN None
intervention NN None
on IN None
hazardous JJ None
substance NN None
exposures NNS None
in IN None
manufacturing VBG None
work NN None
sites NNS None
an DT None
industrial JJ None
hygienist NN None
walk-through JJ None
inspection NN None
( ( None
N NNP None
= NNP None
131 CD None
manufacturing NN None
processes/areas NNS None
in IN None
17 CD None
large JJ None
work NN None
sites NNS None
) ) None
. . None
A DT None
second JJ None
hygienist NN None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ None
kidney NN None
disease NN None
patients NNS None
with IN None
mild JJ None
renal JJ None
impairment NN None
patients NNS None
who WP None
underwent VBP None
percutaneous JJ None
coronary JJ None
intervention NN None
( ( None
PCI NNP None
) ) None
. . None
patients NNS None
enrolled VBN None
in IN None
the DT None
Enhanced NNP None
Suppression NNP None
of IN None
the DT None
Platelet NNP None
IIb/IIIa NNP None
Receptor NNP None
with IN None
Integrilin NNP None
Therapy NNP None
( ( None
ESPRIT NNP None
) ) None
trial NN None
. . None
Patients NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
placebo VB None
or CC None
eptifibatide VB None
Patients NNS None
with IN None
CrCl NNP None
< NNP None
60 CD None
ml/min NN None
were VBD None
more RBR None
likely JJ None
to TO None
be VB None
older JJR None
, , None
women NNS None
patients NNS None
with IN None
mild JJ None
renal JJ None
impairment NN None
. . None
-DOCSTART- -X- N

growth NN Condition
hormone NN Condition
deficient NN Condition
adults NNS Age
. . None
GH-deficient NNP Condition
adults NNS Condition
Thirteen JJ Size
GH-deficient JJ Condition
adults NNS Condition
( ( Size
4 CD Size
females NNS Sex
, , None
9 CD Size
males NNS Sex
; : None
mean FW None
( ( None
SEM NNP None
) ) None
age NN None
26.4 CD Age
( ( None
1.7 CD None
) ) None
years NNS None
) ) None
normal JJ Condition
subjects NNS None
-DOCSTART- -X- N

schizophrenia NN Condition
and CC Condition
schizoaffective JJ Condition
disorder NN Condition
: : None
acutely RB Condition
exacerbating VBG Condition
schizophrenic JJ Condition
or CC Condition
schizoaffective JJ Condition
patients NNS Condition
111 CD Size
patients NNS None
-DOCSTART- -X- N

hyperphosphatemia NN Condition
in IN None
hemodialysis NN Condition
patients NNS Condition
in IN None
Japan NNP None
. . None
86 CD Size
hemodialysis NN None
patients NNS None
in IN None
Japan NNP None
. . None
Of IN None
the DT None
86 CD None
patients NNS None
, , None
62 CD Size
finished VBD None
the DT None
study NN None
without IN None
a DT None
change NN None
of IN None
dosage NN None
and CC None
their PRP$ None
data NNS None
were VBD None
analyzed VBN None
( ( None
group NN None
A NNP None
, , None
N=16 NNP Size
; : None
group NN None
B NNP None
, , None
N=26 NNP Size
; : None
group NN None
C NNP None
, , None
N=20 NNP Size
) ) None
. . None
-DOCSTART- -X- N

benign JJ Condition
prostatic JJ Condition
hypertrophy NN Condition
. . None
270 CD Size
patients NNS None
with IN None
benign JJ Size
prostatic JJ Size
hypertrophy NN Size
patients NNS None
with IN None
benign JJ Size
prostatic JJ Size
hypertrophy NN Size
. . None
-DOCSTART- -X- N

tropical JJ None
hair NN None
sheep NN None
. . None
sheep NN None
Barbados NNP None
Black NNP None
Belly NNP None
ewes FW None
( ( None
n=34 NN None
) ) None
and CC None
ewe JJ None
lambs NN None
( ( None
n=35 JJ None
; : None
37.5?0.9 CD None
kg NN None
) ) None
ewe NN None
lambs NNS None
than IN None
ewes NN None
( ( None
treatment NN None
animals NNS None
. . None
In IN None
Experiment JJ None
2 CD None
, , None
lactating VBG None
ewes NN None
from IN None
experiment JJ None
1 CD None
( ( None
n=61 NN None
) ) None
60-85 JJ None
days NNS None
postpartum NN None
were VBD None
observed VBN None
in IN None
ewes NN None
in IN None
productivity NN None
in IN None
tropical JJ None
breeds NNS None
of IN None
sheep NN None
. . None
-DOCSTART- -X- N

angina JJ None
pectoris NN None
. . None
11 CD None
patients NNS None
with IN None
stable JJ None
angina NNS None
pectoris VBP None
-DOCSTART- -X- N

Occluded NNP None
Native NNP None
Coronary NNP None
Arteries NNP None
( ( None
PRISON NNP None
) ) None
total JJ None
coronary JJ None
occlusions NNS None
balloon NN None
angioplasty NN None
chronic JJ Condition
total JJ Condition
occlusions NNS Condition
. . None
200 CD None
patients NNS None
were VBD None
enrolled VBN None
. . None
chronic JJ None
total JJ None
occlusions NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
mellitus NN None
and CC None
coronary JJ None
artery NN None
disease NN None
on IN None
dual JJ None
antiplatelet NN None
therapy NN None
with IN None
aspirin NN None
and CC None
clopidogrel NN None
. . None
patients NNS None
receiving VBG None
dual JJ None
antiplatelet NN None
therapy NN None
( ( None
DAPT NNP None
) ) None
. . None
DM NNP None
patients NNS None
with IN None
stable JJ None
coronary JJ None
artery NN None
disease NN None
receiving VBG None
DAPT NNP None
. . None
40 CD None
patients NNS None
DM NNP None
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
receiving VBG None
DAPT NNP None
. . None
-DOCSTART- -X- N

Participants NNS None
were VBD None
236 CD None
heavy JJ Condition
drinking NN Condition
smokers NNS Condition
-DOCSTART- -X- N

patients NNS None
with IN None
interstitial JJ Condition
cystitis NN Condition
. . None
pain NN None
associated VBN None
with IN None
sex NN None
in IN None
patients NNS None
with IN None
IC NNP Condition
. . None
Each DT None
participant NN None
met VBD None
all DT None
of IN None
the DT None
clinical JJ None
National NNP None
Institute NNP None
of IN None
Diabetes NNP Condition
and CC None
Digestive NNP None
and CC None
Kidney NNP Condition
Diseases NNP Condition
criteria NNS None
( ( None
excluding VBG None
cystoscopy NN None
) ) None
for IN None
IC NNP None
. . None
Eighteen NNP None
( ( None
18 CD Size
) ) None
patients NNS None
completed VBD None
the DT None
trial NN None
. . None
patients NNS None
with IN None
IC NNP None
. . None
-DOCSTART- -X- N

kala-azar NN Condition
. . None
288 CD Size
parasitologically RB Condition
proved JJ Condition
patients NNS Condition
of IN Condition
kala-azar NNS Condition
Indian JJ Condition
kala-azar JJ Condition
patients NNS Condition
-DOCSTART- -X- N

caffeine JJ Condition
responses NNS Condition
and CC Condition
levels NNS Condition
of IN Condition
saliva JJ Condition
concentration NN Condition
of IN Condition
caffeine NN Condition
in IN None
52 CD None
subjects NNS None
who WP None
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
one CD None
of IN None
two CD None
drug NN None
administration NN None
instructions NNS None
: : None
-DOCSTART- -X- N

Thirty-seven JJ None
outpatients NNS None
( ( None
11 CD None
men NNS None
and CC None
26 CD None
women NNS None
) ) None
meeting VBG None
DSM-III-R JJ None
criteria NNS None
for IN None
major JJ None
depressive JJ None
disorder NN None
-DOCSTART- -X- N

major JJ Condition
abdominal JJ Condition
trauma NN Condition
-- : None
reduced VBD None
septic JJ Condition
morbidity NN Condition
. . None
the DT None
critically RB Condition
injured VBN Condition
. . None
Seventy-five JJ Size
patients NNS None
with IN None
an DT None
abdominal JJ Condition
trauma NN Condition
index NN None
( ( None
ATI NNP None
) ) None
greater JJR None
than IN None
15 CD None
and CC None
less JJR None
than IN None
40 CD None
were VBD None
randomized VBN None
at IN None
initial JJ None
laparotomy NN Condition
to TO None
receive VB None
either RB None
TEN NNP None
( ( None
Vivonex NNP None
TEN NNP None
) ) None
or CC None
TPN NNP None
( ( None
Freamine NNP None
HBC NNP None
6.9 CD None
% NN None
and CC None
Trophamine NNP None
6 CD None
% NN None
) ) None
; : None
both DT None
regimens NNS None
contained VBD None
2.5 CD None
% NN None
fat NN None
, , None
33 CD None
% NN None
branched VBD None
chain NN None
amino NN None
acids NNS None
, , None
and CC None
had VBD None
a DT None
calorie NN None
to TO None
nitrogen VB None
ratio NN None
of IN None
150:1 CD None
. . None
severely RB Condition
injured JJ Condition
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
open JJ None
heart NN None
surgery NN None
. . None
38 CD Size
patients NNS None
. . None
Seventeen JJ None
subjects NNS None
underwent JJ None
mitral JJ None
valve NN None
replacement NN None
and CC None
19 CD Size
patients NNS None
coronary JJ Condition
artery JJ Condition
bypass NN None
grafting NN None
. . None
patients NNS None
requiring VBG None
cardiac JJ None
surgery NN None
. . None
haemodynamically RB None
compromised JJ None
patients NNS None
-DOCSTART- -X- N

morbidly JJ None
obese JJ None
patient NN None
. . None
general JJ None
anesthesia NN None
for IN None
the DT None
morbidly JJ None
obese JJ None
patient NN None
26 CD None
morbidly RB None
obese JJ None
patients NNS None
( ( None
body JJ None
mass NN None
index-BMI JJ None
56 CD None
+/- JJ None
3 CD None
) ) None
-DOCSTART- -X- N

women NNS Sex
with IN None
a DT None
large JJ Condition
uterus NN Condition
( ( Condition
> JJ Condition
14 CD Condition
wks NNS Condition
) ) Condition
Sixty-two JJ Size
women NNS Sex
with IN None
symptomatic JJ Condition
uterine JJ Condition
myomas NN Condition
( ( None
size NN None
16-20 CD None
wks NN None
) ) None
. . None
women NNS Sex
with IN None
a DT None
large JJ Condition
uterus NN Condition
-DOCSTART- -X- N

advanced JJ Condition
Hodgkin NNP Condition
lymphoma NN Condition
: : None
large JJ None
North JJ None
American JJ None
cooperative NN None
group NN None
trial NN None
. . None
Specimens NNS None
from IN None
the DT None
Cancer NNP None
Cooperative NNP None
Intergroup NNP None
Trial NNP None
E2496 NNP None
plasma NN None
specimens NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
benign JJ None
prostate NN None
hyperplasia NN None
( ( None
BPH NNP None
) ) None
in IN None
our PRP$ None
clinic NN None
. . None
57 CD None
patients NNS None
for IN None
whom WP None
we PRP None
thought VBD None
an DT None
operative JJ None
intervention NN None
was VBD None
necessary JJ None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
severe JJ Condition
chronic JJ Condition
heart NN Condition
failure NN Condition
. . Condition
patients NNS None
with IN None
severe JJ None
chronic JJ None
heart NN None
failure NN None
. . None
Twenty-six JJ None
patients NNS None
( ( None
22 CD None
men NNS None
, , None
4 CD None
women NNS None
; : None
mean VB None
+/- JJ None
SD NNP None
age NN None
, , None
54 CD None
+/- JJ None
9yrs CD None
) ) None
with IN None
a DT None
history NN None
of IN None
severe JJ None
chronic JJ None
heart NN None
failure NN None
( ( None
left JJ None
ventricular JJ None
ejection NN None
fraction NN None
of IN None
18 CD None
% NN None
+/- JJ None
8 CD None
% NN None
) ) None
. . None
patients NNS None
with IN None
severe JJ None
chronic JJ None
heart NN None
failure NN None
. . None
-DOCSTART- -X- N

Sixty-four JJ Size
patients NNS None
with IN None
a DT None
first-time JJ None
sick NN None
leave VBP None
between IN None
3 CD None
and CC None
12 CD None
weeks NNS None
due JJ None
to TO None
low VB Condition
back RB Condition
pain NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
permanent JJ Condition
atrial JJ Condition
fibrillation NN Condition
. . None
patients NNS None
with IN None
permanent JJ Condition
atrial JJ Condition
fibrillation NN Condition
undergoing VBG None
mitral JJ None
surgery NN None
. . None
50 CD Size
patients NNS None
with IN None
permanent JJ Condition
atrial JJ Condition
fibrillation NN Condition
and CC None
dilated VBD Condition
left JJ Condition
atrium NN Condition
, , None
submitted VBN None
to TO None
surgical JJ None
mitral JJ None
repair NN None
25 CD Size
patients NNS None
with IN None
left JJ Condition
auricular JJ Condition
reduction NN Condition
and CC Condition
mitral JJ Condition
surgery NN Condition
25 CD None
patients NNS None
with IN None
isolated JJ Condition
valve NN Condition
surgery NN Condition
. . None
-DOCSTART- -X- N

228 CD Size
patients NNS None
( ( None
development NN None
set VBN None
) ) None
with IN None
symptoms NNS None
compatible JJ None
with IN None
AMI NNP Condition
and CC None
tested VBN None
in IN None
a DT None
similar JJ None
group NN None
of IN None
223 CD Size
patients NNS None
( ( None
test NN None
set VBN None
) ) None
from IN None
the DT None
Thrombolysis NNP None
and CC None
Angioplasty NNP None
in IN None
Myocardial NNP None
Infarction NNP None
( ( None
TAMI-5 NNP None
) ) None
Trial NNP None
. . None
-DOCSTART- -X- N

unstable JJ Condition
angina NN Condition
at IN None
rest NN None
12 CD Size
patients NNS Size
admitted VBN None
to TO None
our PRP$ None
coronary JJ None
care NN None
unit NN None
because IN None
of IN None
frequent JJ None
daily JJ None
attacks NNS None
of IN None
angina NN Condition
at IN None
rest NN None
attributed VBN None
to TO None
coronary JJ Condition
vasospasm NN Condition
. . None
patients NNS None
with IN None
frequent JJ None
attacks NNS None
of IN None
angina NN Condition
at IN None
rest NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
moderately RB None
severe JJ None
reflux NN Condition
oesophagitis NN Condition
. . None
133 CD Size
patients NNS None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN Condition
3-12 JJ Age
year-old JJ Age
children NNS Age
with IN None
autism NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
unresectable JJ None
and/or JJ None
recurrent NN None
advanced VBD None
gastric JJ Condition
cancer NN Condition
. . None
Patients NNPS None
with IN None
unresectable JJ Condition
and/or JJ Condition
recurrent NN Condition
advanced VBD Condition
gastric JJ Condition
cancer NN Condition
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
one CD None
of IN None
the DT None
two CD None
regimens NNS None
: : None
S-1 NNP None
( ( None
40 CD None
mg NN None
m NN None
( ( None
-2 NNP None
) ) None
twice RB None
daily RB None
) ) None
on IN None
days NNS None
1-14 JJ None
plus JJ None
paclitaxel NN None
( ( None
60 CD None
mg NN None
m NN None
( ( None
-2 NNP None
) ) None
) ) None
on IN None
days NNS None
1 CD None
, , None
8 CD None
, , None
and CC None
15 CD None
of IN None
a DT None
4-week JJ None
cycle NN None
( ( None
S-1+paclitaxel NNP None
) ) None
or CC None
S-1 NNP None
( ( None
40 CD None
mg NN None
m NN None
( ( None
-2 NNP None
) ) None
twice RB None
daily RB None
) ) None
on IN None
days NNS None
1-21 JJ None
plus JJ None
cisplatin NN None
( ( None
60 CD None
mg NN None
m NN None
( ( None
-2 NNP None
) ) None
) ) None
on IN None
day NN None
8 CD None
of IN None
a DT None
5-week JJ None
cycle NN None
( ( None
S-1+cisplatin NNP None
) ) None
. . None
83 CD None
patients NNS None
patients NNS None
with IN None
advanced JJ Condition
gastric JJ Condition
cancer NN Condition
. . None
-DOCSTART- -X- N

aortic JJ None
and CC None
hepatic JJ None
enhancement NN None
at IN None
multidetector NN None
CT NNP None
: : None
One CD None
hundred VBD None
twenty NN None
patients NNS None
( ( None
54 CD None
men NNS None
, , None
66 CD None
women NNS None
; : None
mean JJ None
age NN None
, , None
64.1 CD None
years NNS None
; : None
range NN None
, , None
19-88 CD None
years NNS None
) ) None
who WP None
underwent JJ None
multidetector NN None
CT NNP None
of IN None
the DT None
upper JJ None
abdomen NNS None
-DOCSTART- -X- N

gastroesophageal JJ None
reflux JJ None
disease NN None
in IN None
children NNS None
. . None
Seventy-eight JJ None
children NNS None
presenting VBG None
with IN None
typical JJ None
and CC None
extraesophageal JJ None
symptoms NNS None
of IN None
gastroesophageal JJ None
reflux JJ None
disease NN None
underwent VBD None
a DT None
multichannel JJ None
intraluminal JJ None
impedance NN None
and CC None
pH NN None
monitoring NN None
( ( None
MII/pH NNP None
) ) None
. . None
-DOCSTART- -X- N

acute NN Condition
low JJ Condition
back RB Condition
pain NN Condition
with IN None
severe JJ None
disability NN None
: : None
patients NNS None
with IN None
low JJ Condition
back RB Condition
pain NN Condition
In IN None
Korea NNP None
Participants NNS None
with IN None
acute NN None
low JJ Condition
back RB Condition
pain NN Condition
and CC None
severe JJ None
functional JJ None
disability NN None
, , None
defined VBD None
as IN None
an DT None
Oswestry NNP None
Disability NNP None
Index NNP None
( ( None
ODI NNP None
) ) None
value NN None
> $ None
60 CD None
% NN None
-DOCSTART- -X- N

developmental JJ None
age NN None
Thirty NN None
patients NNS None
( ( None
mean JJ None
age NN None
: : None
10.38 CD None
years NNS None
) ) None
affected VBN None
by IN None
primary JJ None
headache NN None
were VBD None
selected VBN None
-DOCSTART- -X- N

melanoma NN Condition
Nearly RB None
2000 CD Size
patients NNS None
with IN None
stage NN None
IIB NNP None
and CC None
III NNP None
melanoma NNS Condition
patients NNS None
with IN None
high-risk JJ Condition
resected JJ Condition
melanoma NN Condition
-DOCSTART- -X- N

community-dwelling JJ Condition
older JJR Age
Black NNP Condition
adults NNS Age
. . None
community-dwelling JJ Condition
older JJR Age
Black NNP Condition
adults NNS Age
. . None
Churches NNP None
and CC None
community-based JJ None
organizations NNS None
. . None
Men NNP None
and CC None
women NNS None
( ( None
n JJ None
= NNP None
110 CD Size
) ) None
50 CD Age
years NNS Age
old JJ Age
and CC Age
older JJR Age
from IN Condition
3 CD Condition
south JJ Condition
Florida NNP Condition
counties NNS Condition
. . None
-DOCSTART- -X- N

individuals NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
individuals NNS None
with IN None
high JJ None
functioning VBG None
Autism NNP None
Spectrum NNP None
Disorders NNP None
. . None
twenty-two JJ None
youth NN None
, , None
ages VBZ None
16-19 JJ None
, , None
were VBD None
evaluated VBN None
during IN None
two CD None
employment NN None
interviews NNS None
. . None
-DOCSTART- -X- N

those DT None
with IN None
recent JJ None
ischemic JJ None
stroke NN None
: : None
50 CD None
patients NNS None
with IN None
acute JJ None
ischemic JJ None
stroke NN None
( ( None
17 CD None
, , None
17 CD None
, , None
and CC None
16 CD None
in IN None
the DT None
high JJ None
, , None
low JJ None
, , None
and CC None
placebo NN None
groups NNS None
, , None
respectively RB None
) ) None
Mean NNP None
( ( None
+/-SD NNP None
) ) None
age NN None
was VBD None
70 CD None
( ( None
+/-13 JJ None
) ) None
years NNS None
. . None
-DOCSTART- -X- N

mitral JJ Condition
valve FW Condition
replacement NN Condition
. . None
Sixteen NNP Size
patients NNS None
who WP None
had VBD None
chronic JJ None
mitral JJ None
regurgitation NN None
due JJ None
to TO None
myxomatous JJ None
degeneration NN None
were VBD None
randomized VBN None
to TO None
preservation NN None
( ( None
Pres NNP None
group NN None
, , None
n RB None
= VBZ None
8 CD Size
) ) None
or CC None
no DT None
preservation NN None
( ( None
No NNP None
Pres NNP None
group NN None
, , None
n RB None
= VBZ None
8 CD Size
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
. . None
One CD Size
hundred VBD Size
twenty-two JJ Size
chemotherapy-naive JJ None
patients NNS None
with IN None
histologically RB None
confirmed VBN None
colorectal JJ Condition
adenocarcinoma NN Condition
In IN None
both DT None
groups NNS None
, , None
patients NNS None
received VBD None
continuous JJ None
infusion NN None
FU NNP None
1,000 CD None
mg/m2/d NN None
for IN None
5 CD None
consecutive JJ None
days NNS None
every DT None
4 CD None
weeks NNS None
. . None
patients NNS None
with IN None
advanced JJ Condition
colorectal JJ Condition
carcinoma NN Condition
. . None
-DOCSTART- -X- N

women NNS None
Forty JJ None
volunteers NNS None
were VBD None
randomized VBN None
( ( None
ten VB None
each DT None
) ) None
to TO None
three CD None
different JJ None
pill NN None
regimens VBZ None
or CC None
to TO None
nonsteroidal DT None
contraception NN None
. . None
-DOCSTART- -X- N

subjects NNS None
participating VBG None
in IN None
a DT None
trial NN None
of IN None
the DT None
treatment NN None
of IN None
heart NN Condition
failure NN Condition
. . None
Patients NNS None
were VBD None
assessed VBN None
on IN None
entry NN None
and CC None
after IN None
three CD None
months NNS None
treatment NN None
. . None
fatigue JJ None
, , None
breathlessness NN None
and CC None
chest NN Condition
pain NN Condition
. . None
-DOCSTART- -X- N

lipoprotein JJ None
subfractions NNS None
15 CD None
lipoprotein JJ None
subfractions NNS None
( ( None
L1-L15 NNP None
) ) None
in IN None
1791 CD None
samples NNS None
using VBG None
( ( None
1 CD None
) ) None
H-NMR NNP None
( ( None
nuclear JJ None
magnetic JJ None
resonance NN None
) ) None
spectroscopy NN None
. . None
-DOCSTART- -X- N

uveal JJ Condition
melanoma NN Condition
: : Condition
uveal JJ Condition
melanoma NN Condition
. . None
from IN None
August NNP None
2010 CD None
through IN None
December NNP None
2013 CD None
among IN None
120 CD Size
patients NNS Size
with IN None
metastatic JJ Condition
uveal JJ Condition
melanoma NN Condition
at IN None
15 CD None
academic JJ None
oncology NN None
centers NNS None
in IN None
the DT None
United NNP None
States NNPS None
and CC None
Canada NNP None
. . None
One CD Size
hundred VBD Size
one CD Size
patients NNS None
were VBD None
randomized VBN None
in IN None
a DT None
1:1 CD None
ratio NN None
, , None
19 CD None
patients NNS None
were VBD None
registered VBN None
and CC None
18 CD None
treated VBN None
with IN None
selumetinib NN None
without IN None
randomization NN None
to TO None
complete VB None
the DT None
planned VBN None
120-patient JJ None
enrollment NN None
. . None
Patients NNS None
hypothesis-generating JJ None
study NN None
of IN None
patients NNS None
with IN None
advanced JJ None
uveal JJ None
melanoma NN None
, , None
-DOCSTART- -X- N

Ten CD Size
active JJ None
female JJ Sex
subjects NNS None
participated VBD None
( ( None
32 CD Age
+/- JJ Age
7 CD Age
yrs NN Age
( ( Age
mean JJ Age
+/- NNP Age
SD NNP Age
) ) None
; : None
65.7 CD None
+/- JJ None
16.4 CD None
kg NN None
; : None
VO2peak NNP None
40.0 CD None
+/- JJ None
7.5 CD None
ml.kg-1.min-1 NN None
) ) None
. . None
-DOCSTART- -X- N

distal JJ Condition
ulcerative JJ Condition
colitis NN Condition
. . None
Twenty-nine JJ Size
patients NNS Size
with IN None
attacks NNS Condition
of IN Condition
distal JJ Condition
ulcerative JJ Condition
colitis NN Condition
distal JJ Condition
ulcerative JJ Condition
colitis NN Condition
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
severe JJ None
falciparum NN Condition
malaria NN Condition
. . None
11 CD Size
Karen NNP Condition
children NNS None
aged VBD None
between IN Age
1.7 CD Age
and CC Age
11 CD Age
y NN Age
with IN None
severe JJ None
falciparum NN Condition
malaria NN Condition
. . None
Eight CD Size
of IN None
the DT None
children NNS None
were VBD None
comatose JJ None
. . None
9 CD None
further JJ None
children NNS None
with IN None
severe JJ None
malaria NNS None
of IN None
similar JJ None
age NN None
range NN None
( ( None
four CD None
of IN None
whom WP None
were VBD None
unconscious JJ None
) ) None
children NNS None
with IN None
severe JJ None
malaria NNS None
; : None
-DOCSTART- -X- N

hypertensive JJ None
patients NNS None
with IN None
echolucent JJ None
plaques NNS None
in IN None
the DT None
carotid NN None
artery NN None
. . None
high-risk JJ None
hypertensive JJ None
men NNS None
patients NNS None
with IN None
carotid JJ None
artery NN None
plaques NNS None
. . None
usual JJ None
care NN None
group NN None
17 CD None
of IN None
32 CD None
( ( None
53 CD None
% NN None
) ) None
patients NNS None
with IN None
echolucent JJ None
plaques NNS None
at IN None
baseline NN None
-DOCSTART- -X- N

Fifty-six JJ Size
patients NNS None
( ( None
49 CD Size
boys NNS Condition
, , None
7 CD Size
girls NNS Condition
, , None
mean JJ Age
age NN Age
= VBD Age
6.4 CD Age
years NNS Age
, , Age
SD NNP Age
= NNP Age
2.7 CD Age
) ) None
enrolled VBN None
in IN None
an DT None
open-label JJ None
trial NN None
of IN None
secretin NN None
, , None
during IN None
which WDT None
they PRP None
received VBD None
one CD None
injection NN None
of IN None
the DT None
hormone NN None
( ( None
2 CD None
IU/kg NNP None
) ) None
. . None
Thirty-four JJ Size
patients NNS None
were VBD None
labeled VBN None
with IN None
Pervasive NNP Condition
Developmental NNP Condition
Disorder NNP Condition
Not RB None
Otherwise NNP None
Specified NNP None
, , None
and CC None
22 CD Size
met VBD None
diagnostic JJ None
criteria NNS None
for IN None
Autistic JJ Condition
Disorder NNP Condition
. . None
Forty-five JJ Size
patients NNS None
were VBD None
concurrently RB None
on IN None
other JJ None
drug NN Condition
treatments NNS Condition
. . None
Patients NNS None
from IN None
Study NNP None
1 CD None
entered VBD None
into IN None
Study NNP None
2 CD None
at IN None
an DT None
average NN None
of IN None
6.5 CD None
( ( None
SD NNP None
= NNP None
0.8 CD None
) ) None
weeks NNS None
after IN None
beginning VBG None
Study NNP None
1 CD None
. . None
-DOCSTART- -X- N

130 CD Condition
patients NNS Condition
with IN Condition
inferior JJ Condition
alveolar JJ Condition
nerve NN Condition
( ( Condition
IAN NNP Condition
) ) Condition
and CC Condition
lingual JJ Condition
nerve NN Condition
( ( Condition
LN NNP Condition
) ) Condition
injuries NNS Condition
. . Condition
IAN NNP None
patients NNS None
the DT None
IAN NNP None
and CC None
LN NNP None
patient JJ None
populations NNS None
. . None
patients NNS None
with IN None
IAN NNP None
injuries NNS None
. . None
-DOCSTART- -X- N

parenterally-fed JJ None
undernourished JJ Condition
patients NNS None
. . None
Ten CD Size
undernourished JJ Condition
patients NNS None
receiving VBG None
total JJ None
parenteral JJ None
nutrition NN None
and CC None
undergoing JJ None
major JJ None
intestinal JJ None
surgery NN None
major JJ None
surgery NN None
. . None
-DOCSTART- -X- N

man NN Sex
. . None
man NN Sex
. . None
Eight NNP Size
normal JJ Condition
male NN Sex
volunteers NNS None
Metoclopramide NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ None
cancer NN None
. . None
Eighteen JJ None
patients NNS None
of IN None
colorectal JJ None
cancer NN None
with IN None
metastases NNS None
to TO None
the DT None
liver NN None
or CC None
lung NN None
or CC None
of IN None
unresectable JJ None
hepatoma NN None
Of IN None
18 CD None
patients NNS None
12 CD None
were VBD None
evaluable JJ None
for IN None
their PRP$ None
response NN None
to TO None
therapy NN None
. . None
-DOCSTART- -X- N

non-insulin JJ Condition
dependent NN Condition
diabetes VBZ Condition
mellitus NN Condition
30 CD None
non-insulin JJ None
dependent NN None
( ( None
Type NNP None
II NNP None
) ) None
diabetic JJ None
subjects NNS None
Type NNP None
II NNP None
diabetic JJ None
-DOCSTART- -X- N

Gender NNP None
differences NNS None
tobacco NN None
withdrawal NN None
. . None
nicotine JJ None
reinforcement NN None
controls NNS None
smoking VBG None
to TO None
a DT None
greater JJR None
degree NN None
among IN None
men NNS None
than IN None
women NNS None
active JJ None
nicotine NN None
patch NN None
group NN None
and CC None
a DT None
placebo NN None
patch NN None
group NN None
( ( None
N NNP None
= NNP None
34 CD None
) ) None
. . None
gender NN None
differences NNS None
-DOCSTART- -X- N

pregnancy NN Condition
: : None
during IN None
pregnancy NN Condition
on IN None
maternal JJ None
and CC None
fetal JJ None
plasma NN None
levels NNS None
-DOCSTART- -X- N

cardiac JJ Condition
arrest NN Condition
. . Condition
Twelve CD Condition
patients NNS None
presenting VBG None
to TO None
an DT None
accident NN None
and CC None
emergency NN None
department NN None
in IN None
asystolic JJ None
cardiac JJ None
arrest NN None
were VBD None
randomly RB None
allocated VBN None
to TO None
treatment NN None
with IN None
endotracheal JJ None
adrenaline NN None
( ( None
five CD None
patients NNS None
) ) None
or CC None
peripheral JJ None
intravenous JJ None
adrenaline NN None
( ( None
seven CD None
patients NNS None
) ) None
. . None
-DOCSTART- -X- N

Laryngeal NNP Condition
Mask NNP Condition
Airway NNP Condition
insertion NN Condition
. . None
Laryngeal NNP None
Mask NNP None
Airway NNP None
( ( None
LMA NNP Condition
) ) None
insertion NN None
. . None
120 CD Size
ASA NNP None
physical JJ None
status NN None
1 CD None
and CC None
2 CD None
patients NNS None
undergoing JJ None
elective JJ None
orthopedic JJ Condition
surgeries NNS Condition
. . None
Group NNP None
A NNP None
patients NNS None
Group NNP None
B NNP None
patients NNS None
Group NNP None
C NNP None
, , None
patients NNS None
Group NNP None
D NNP None
, , None
patients NNS None
LMA NNP None
insertion NN None
-DOCSTART- -X- N

small-cell JJ Condition
lung NN Condition
cancer NN Condition
in IN Condition
complete JJ Condition
remission NN Condition
. . Condition
patients NNS Condition
with IN Condition
small-cell JJ Condition
lung NN Condition
cancer NN Condition
patients NNS Condition
in IN Condition
complete JJ Condition
remission NN Condition
. . None
patients NNS Condition
with IN Condition
small-cell JJ Condition
lung NN Condition
cancer NN Condition
in IN Condition
complete JJ Condition
remission NN Condition
. . None
300 CD Size
patients NNS Condition
who WP Condition
had VBD Condition
small-cell NN Condition
lung NN Condition
cancer NN Condition
that WDT Condition
was VBD Condition
in IN Condition
complete JJ Condition
remission NN Condition
. . None
Two CD Size
hundred VBD Size
ninety-four JJ Size
patients NNS Size
who WP None
did VBD None
not RB None
have VB None
brain NN None
metastases NNS None
patients NNS Condition
with IN Condition
small-cell JJ Condition
lung NN Condition
cancer NN Condition
in IN Condition
complete JJ Condition
remission NN Condition
patients NNS Condition
who WP Condition
are VBP Condition
in IN Condition
complete JJ Condition
remission NN Condition
. . None
patients NNS Condition
in IN Condition
complete JJ Condition
remission NN Condition
-DOCSTART- -X- N

Adult NNP None
patients NNS None
who WP None
underwent VBP None
laparotomy NN None
for IN None
bowel NN None
resection NN None
scheduled VBN None
for IN None
opioid-based JJ None
intravenous JJ None
patient-controlled JJ None
analgesia NN None
received VBD None
oral JJ None
alvimopan NN None
or CC None
placebo NN None
preoperatively RB None
and CC None
twice RB None
daily RB None
postoperatively RB None
until IN None
hospital JJ None
discharge NN None
or CC None
for IN None
7 CD None
postoperative JJ None
days NNS None
. . None
patients NNS None
undergoing VBG None
bowel JJ None
resection NN None
. . None
-DOCSTART- -X- N

preterm JJ Age
infants NNS Age
. . None
VLBW NNP None
premature NN Condition
infants NNS Condition
. . None
Sixteen JJ Size
infants NNS Age
( ( None
mean JJ None
+/- JJ None
standard NN None
error NN None
of IN None
the DT None
mean JJ None
birth NN None
weight VBD None
1,009 CD None
+/- JJ None
55 CD None
g NN None
and CC None
gestational JJ None
age NN None
27.3 CD Age
+/- JJ Age
0.3 CD Age
weeks NNS Age
) ) None
-DOCSTART- -X- N

hemodialysis NN Condition
patients NNS None
during IN None
growth NN Condition
hormone CD Condition
treatment NN Condition
. . None
Adult NNP Age
patients NNS None
with IN None
chronic JJ Condition
renal JJ Condition
failure NN Condition
( ( Condition
CRF NNP Condition
) ) Condition
20 CD Size
adult NN Age
enfeebled VBD Condition
hemodialysis NN Condition
patients NNS None
-DOCSTART- -X- N

in IN None
patients NNS None
with IN None
haematological JJ Condition
malignancies NNS Condition
. . None
Adults NNS Age
with IN None
haematological JJ None
malignancies NNS None
receiving VBG None
chemotherapy NN None
or CC None
bone NN None
marrow NN None
transplants NNS None
more RBR None
patients NNS None
receiving VBG None
flu NN None
required VBN None
amphotericin NN None
B NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
anemia NN Condition
and CC None
CKD NNP Condition
. . None
patients NNS None
with IN None
chronic JJ Condition
kidney NN Condition
disease NN Condition
( ( Condition
CKD NNP Condition
) ) Condition
. . None
outpatient JJ None
patients NNS None
with IN None
CKD NNP Condition
stages VBZ Condition
1 CD Condition
to TO Condition
5 CD Condition
and CC Condition
5D CD Condition
. . None
750 CD Size
patients NNS None
with IN None
CKD NNP Condition
stages VBZ Condition
1 CD Condition
to TO Condition
5 CD Condition
and CC Condition
5D CD Condition
. . None
750 CD Size
randomly NNS None
assigned VBD None
patients NNS None
with IN None
CKD NNP Condition
, , None
60 CD None
% NN None
were VBD None
not RB None
on IN None
dialysis NN None
therapy NN None
. . None
713 CD None
patients NNS None
received VBD None
ferumoxytol JJ None
, , None
and CC None
711 CD Size
received VBD None
placebo NN None
. . None
420 CD None
adverse JJ None
events NNS None
reported VBD None
; : None
242 CD None
in IN None
152 CD Size
patients NNS None
( ( None
21.3 CD None
% NN None
) ) None
with IN None
ferumoxytol NN None
and CC None
178 CD None
in IN None
119 CD Size
patients NNS None
( ( None
16.7 CD None
% NN None
) ) None
with IN None
placebo NN None
. . None
anemic JJ Condition
patients NNS None
with IN None
CKD NNP Condition
stages VBZ Condition
1 CD Condition
to TO Condition
5 CD Condition
and CC None
5D CD None
. . None
-DOCSTART- -X- N

preterm JJ Condition
premature JJ Condition
rupture NN Condition
of IN Condition
the DT Condition
membranes NNS Condition
: : Condition
preterm JJ None
premature JJ None
rupture NN None
of IN None
the DT None
membranes NNS None
. . None
27 CD None
randomized VBN None
controlled VBN None
trials NNS None
, , None
of IN None
which WDT None
13 CD None
met VBD None
inclusion NN None
criteria NNS None
. . None
Five CD Condition
randomized VBN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
hormone JJ None
receptor-positive JJ None
metastatic JJ Condition
breast NN Condition
cancer NN Condition
: : None
Patients NNPS None
with IN None
newly RB None
metastatic JJ Condition
disease NN Condition
or CC None
recurred VBN None
after IN None
adjuvant JJ None
tamoxifen NN None
( ( None
stratum JJ None
1 CD None
) ) None
, , None
or CC None
recurred VBD None
during/after NN None
adjuvant JJ None
aromatase NN None
inhibitor NN None
( ( None
AI NNP None
) ) None
or CC None
after IN None
failed VBN None
first-line NN None
AI NNP None
( ( None
stratum JJ None
2 CD None
) ) None
, , None
were VBD None
eligible JJ None
. . None
subset VB None
appropriate JJ None
patients NNS None
. . None
-DOCSTART- -X- N

chronic JJ Condition
alcoholic JJ Condition
patients NNS None
. . None
32 CD Size
randomly RB None
selected VBN None
hospitalized VBN None
male JJ Sex
alcoholic JJ Condition
patients NNS None
with IN None
clinical JJ None
, , None
biochemical JJ None
and CC None
histological JJ None
evidence NN None
of IN None
hepatic JJ Condition
damage NN Condition
. . None
ethanol-induced JJ Condition
liver NN Condition
damage NN Condition
patients NNS None
with IN None
alcoholic JJ Condition
liver NN Condition
disease NN Condition
( ( Condition
ALD NNP Condition
) ) Condition
. . None
-DOCSTART- -X- N

middle JJ Condition
ear NN Condition
surgery NN Condition
. . None
30 CD Size
patients NNS None
middle VB None
ear JJ None
surgery NN None
using VBG None
induced JJ None
hypotension NN Condition
to TO None
a DT None
mean JJ None
arterial JJ None
pressure NN None
of IN None
55 CD None
mm NN None
Hg NNP None
. . None
middle JJ None
ear NN None
surgery NN None
-DOCSTART- -X- N

type NN None
1 CD None
diabetes NNS None
: : None
multicenter NN None
436 CD None
children NNS None
and CC None
adults NNS None
with IN None
type JJ None
1 CD None
diabetes NNS None
-DOCSTART- -X- N

breast-cancer JJ None
prevention NN None
in IN None
postmenopausal JJ None
women NNS None
. . None
patients NNS None
with IN None
early-stage JJ None
breast NN None
cancer NN None
. . None
eligible JJ None
postmenopausal NN None
women NNS None
35 CD None
years NNS None
of IN None
age NN None
or CC None
older JJR None
had VBD None
at IN None
least JJS None
one CD None
of IN None
the DT None
following JJ None
risk NN None
factors NNS None
: : None
60 CD None
years NNS None
of IN None
age NN None
or CC None
older JJR None
; : None
Gail NNP None
5-year JJ None
risk NN None
score NN None
greater JJR None
than IN None
1.66 CD None
% NN None
( ( None
chances NNS None
in IN None
100 CD None
of IN None
invasive JJ None
breast NN None
cancer NN None
developing VBG None
within IN None
5 CD None
years NNS None
) ) None
; : None
prior JJ None
atypical JJ None
ductal NN None
or CC None
lobular JJ None
hyperplasia NN None
or CC None
lobular JJ None
carcinoma NN None
in IN None
situ NN None
; : None
or CC None
ductal JJ None
carcinoma NN None
in IN None
situ NN None
with IN None
mastectomy NN None
. . None
total NN None
of IN None
4560 CD None
women NNS None
for IN None
whom WP None
the DT None
median JJ None
age NN None
was VBD None
62.5 CD None
years NNS None
and CC None
the DT None
median JJ None
Gail NNP None
risk NN None
score NN None
was VBD None
2.3 CD None
% NN None
invasive JJ None
breast NN None
cancers NNS None
in IN None
postmenopausal JJ None
women NNS None
who WP None
were VBD None
at IN None
moderately RB None
increased VBN None
risk NN None
for IN None
breast NN None
cancer NN None
. . None
-DOCSTART- -X- N

adolescents NNS Condition
with IN Condition
higher JJR Condition
blood NN Condition
pressure NN Condition
] NNP Condition
adolescents NNS None
with IN None
higher JJR None
blood NN None
pressure NN None
. . None
220 CD None
adolescents NNS None
with IN None
higher JJR None
blood NN None
pressure NN None
, , None
aged VBD None
18 CD None
- : None
22 CD None
years NNS None
, , None
who WP None
were VBD None
randomly RB None
divided VBN None
into IN None
supplementary JJ None
group NN None
( ( None
n JJ None
= NNP None
110 CD None
) ) None
and CC None
control NN None
group NN None
( ( None
n JJ None
= NNP None
110 CD None
) ) None
. . None
Each DT None
of IN None
the DT None
subjects NNS None
in IN None
the DT None
supplementary JJ None
group NN None
and CC None
their PRP$ None
family NN None
members NNS None
adolescents NNS None
with IN None
higher JJR None
blood NN None
pressure NN None
. . None
-DOCSTART- -X- N

superficial JJ None
bladder NN Condition
cancer NN Condition
. . None
in IN None
patients NNS None
with IN None
primary JJ None
or CC None
recurrent JJ None
superficial JJ None
bladder NN None
tumors NNS None
, , None
including VBG None
carcinoma NN None
in IN None
situ NN None
( ( None
CIS NNP None
) ) None
. . None
Reported VBN None
are VBP None
the DT None
incidence NN None
of IN None
side NN None
effects NNS None
in IN None
165 CD None
patients NNS None
and CC None
the DT None
recurrence NN None
rate NN None
of IN None
tumors NNS None
in IN None
308 CD None
patients NNS None
after IN None
a DT None
follow-up JJ None
period NN None
of IN None
twelve JJ None
months NNS None
. . None
-DOCSTART- -X- N

physical JJ Condition
activity NN Condition
and CC Condition
diet NN Condition
. . Condition
adults NNS Age
with IN None
established VBN Condition
chronic JJ Condition
diseases NNS Condition
in IN None
a DT None
low JJ Condition
socio-economic JJ Condition
area NN Condition
of IN Condition
a DT Condition
major JJ Condition
Australian JJ Condition
city NN Condition
February NNP None
2005 CD None
and CC None
November NNP None
2007 CD None
-DOCSTART- -X- N

pulmonary JJ None
function NN None
following VBG None
coronary JJ None
artery JJ None
bypass NN None
graft NN None
surgery NN None
. . None
prospective JJ None
, , None
randomized VBN None
, , None
controlled VBD None
study NN None
of IN None
patients NNS None
following VBG None
coronary JJ None
artery JJ None
bypass NN None
graft NN None
( ( None
CABG NNP None
) ) None
surgery NN None
with IN None
the DT None
right NN None
or CC None
left VBD None
internal JJ None
thoracic NN None
artery NN None
( ( None
ITA NNP None
) ) None
. . None
Forty-five JJ None
male JJ None
patients NNS None
( ( None
mean JJ None
age NN None
, , None
57 CD None
+/- JJ None
6 CD None
years NNS None
) ) None
were VBD None
randomly RB None
assigned VBN None
TENS NNP None
group NN None
-DOCSTART- -X- N

One NNP Size
hundred VBD Size
and CC Size
eighty JJ Size
randomly RB None
selected VBN None
healthy JJ Condition
volunteers NNS None
( ( None
ASA NNP None
I PRP None
) ) None
-DOCSTART- -X- N

bipolar JJ Condition
type NN Condition
II NNP Condition
or CC Condition
bipolar JJ Condition
NOS NNP Condition
major JJ Condition
depression NN Condition
- : Condition
low JJ Condition
manic JJ Condition
switch NN Condition
rate NN Condition
. . None
bipolar JJ Condition
type NN Condition
II NNP Condition
( ( None
BP NNP Condition
II NNP Condition
) ) None
major JJ None
depressive JJ None
episode NN None
( ( None
MDE NNP None
) ) None
As IN None
part NN None
of IN None
a DT None
randomized JJ None
, , None
double-blind JJ None
, , None
placebo-controlled JJ None
relapse-prevention NN None
study NN None
of IN None
fluoxetine JJ None
monotherapy NN None
in IN None
BP NNP Condition
II NNP Condition
MDE NNP None
, , None
37 CD Size
patients NNS None
BP NNP Condition
II NNP Condition
MDE NNP Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
hematologic JJ Condition
malignancies NNS Condition
. . None
patients NNS None
with IN None
hematologic JJ Condition
malignancies NNS Condition
. . None
Seventy NNP Size
immunocompromised VBD None
febrile JJ None
patients NNS None
with IN None
hematologic JJ Condition
malignancies NNS Condition
vancomycin JJ None
therapeutic JJ None
drug NN None
monitoring NN None
group NN None
-DOCSTART- -X- N

primary JJ None
digestive JJ None
localizations NNS None
of IN None
non-Hodgkin NN Condition
's POS Condition
lymphoma NN Condition
] NN Condition
chemotherapy JJ None
treatment NN None
in IN None
82 CD Size
patients NNS None
presenting VBG None
with IN None
primary JJ Condition
digestive JJ Condition
lymphoma NN Condition
and CC None
included VBD None
in IN None
a DT None
study NN None
conducted VBN None
between IN None
October NNP None
1977 CD None
and CC None
October NNP None
1985 CD None
. . None
31 CD Size
gastric JJ Condition
lymphoma NN Condition
, , None
18 CD Size
small JJ Condition
intestinal JJ Condition
lymphomas NN Condition
, , None
and CC None
19 CD Size
with IN None
multiple JJ Condition
involvement NN Condition
: : None
63 CD None
patients NNS None
had VBD None
had VBN None
a DT None
surgical JJ None
staging NN None
with IN None
total JJ None
tumor NN None
resection NN None
in IN None
15 CD None
cases NNS None
. . None
Nineteen JJ Size
patients NNS None
with IN None
limited JJ Condition
disease NN Condition
( ( Condition
ID NNP Condition
and CC Condition
IID NNP Condition
) ) Condition
Twenty-seven JJ Size
stage NN Condition
IIID NNP Condition
and CC None
thirty-six JJ Size
stage NN Condition
IV NNP Condition
Low JJ None
grade NN None
lymphomas NN None
( ( None
16 CD None
patients NNS None
) ) None
Intermediate NNP None
( ( None
56 CD None
patients NNS None
) ) None
and CC None
high JJ None
grade NN None
( ( None
10 CD None
patients NNS None
) ) None
lymphomas VBP None
100 CD None
( ( None
51 CD None
patients NNS None
) ) None
with IN None
17 CD None
patients NNS None
in IN None
relapse NN None
within IN None
6 CD None
to TO None
40 CD None
months NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
hypertension NN Condition
: : None
cardiovascular JJ None
risk NN None
factors NNS None
in IN None
patients NNS None
with IN None
mild JJ Condition
to TO Condition
moderate VB Condition
hypertension NN Condition
The DT None
132 CD Size
subjects NNS None
in IN None
this DT None
randomized VBN None
, , None
controlled VBN None
trial NN None
were VBD None
in IN None
the DT None
age NN None
range NN None
of IN None
40-79 JJ Age
years NNS Age
. . None
The DT None
inclusion NN None
criteria NNS None
were VBD None
: : None
systolic JJ Condition
BP NNP Condition
( ( Condition
SBP NNP Condition
) ) Condition
ranging VBG Condition
from IN Condition
140-179 JJ Condition
mm NN Condition
Hg NNP Condition
and/or VBZ None
diastolic JJ Condition
BP NNP Condition
( ( Condition
DBP NNP Condition
) ) Condition
ranging VBG Condition
from IN Condition
90-99 CD Condition
mm NNS Condition
Hg NNP Condition
and CC None
treatment-naive JJ None
( ( None
untreated JJ None
for IN None
hypertension NN None
) ) None
; : None
or CC None
on IN None
a DT None
regimen NN None
of IN None
medication NN None
for IN None
hypertension NN Condition
. . None
Of IN None
these DT None
132 CD Size
subjects NNS None
, , None
124 CD Size
( ( None
94 CD None
% NN None
) ) None
were VBD None
already RB None
receiving VBG None
treatment NN None
with IN None
antihypertensive JJ Condition
medications NNS Condition
. . None
patients NNS None
with IN None
mild JJ Condition
to TO Condition
moderate VB Condition
hypertension NN Condition
-DOCSTART- -X- N

complex JJ Condition
regional JJ Condition
pain NN Condition
syndrome NN Condition
I PRP None
patients NNS None
pretreated VBN None
with IN None
spinal JJ None
cord NN None
stimulation NN None
: : None
Forty-three JJ Size
patients NNS None
with IN None
peripheral JJ Condition
neuropathic JJ Condition
pain NN Condition
, , None
exclusively RB None
pain NN None
reduced VBN None
by IN None
spinal JJ None
cord NN None
stimulation NN None
( ( None
SCS NNP None
) ) None
, , None
were VBD None
switched VBN None
into IN None
a DT None
painful JJ None
state NN None
after IN None
SCS NNP None
inactivation NN None
. . None
-DOCSTART- -X- N

Patients NNS None
with IN None
endoscopically RB Condition
documented VBN None
duodenal JJ Condition
ulcer NN Condition
69 CD Size
patients NNS None
in IN None
each DT None
group NN None
114 CD Size
patients NNS None
with IN None
healed JJ None
ulcer NN Condition
-DOCSTART- -X- N

preschoolers NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
36 CD Size
preschoolers NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . Condition
-DOCSTART- -X- N

Adult NNP None
inpatients NNS None
who WP None
had VBD None
received VBN None
warfarin JJ None
sodium NN None
10 CD None
mg JJ None
daily RB None
for IN None
less JJR None
than IN None
three CD None
days NNS None
were VBD None
eligible JJ None
for IN None
the DT None
study NN None
. . None
total NN None
of IN None
54 CD None
patients NNS None
met VBD None
the DT None
study NN None
criteria NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
hyperlipidaemia NN Condition
: : None
Fifty-two JJ Size
patients NNS None
with IN None
Fredrickson NNP Condition
Type NNP Condition
IIb NNP Condition
or CC Condition
Type NNP Condition
IV NNP Condition
hyperlipidaemia NN Condition
, , None
in IN None
whom WP None
diet NN None
had VBD None
not RB None
achieved VBN None
satisfactory JJ None
lipid JJ None
levels NNS None
patients NNS None
with IN None
hypertriglyceridaemia NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
elective JJ None
cardioversion NN None
. . None
patients NNS None
during IN None
induction NN None
of IN None
anesthesia NN None
with IN None
etomidate NN None
. . None
40 CD None
patients NNS None
( ( None
ASA NNP None
physical JJ None
status NN None
III-IV NNP None
) ) None
scheduled VBD None
for IN None
elective JJ None
cardioversion NN None
-DOCSTART- -X- N

hypertensive JJ Condition
patients NNS Condition
treated VBN None
with IN None
bendrofluazide NN None
. . None
hypertensive JJ Condition
patients NNS None
on IN None
treatment NN None
with IN None
a DT None
diuretic JJ None
. . None
13 CD Size
hypertensive JJ Condition
patients NNS None
on IN None
treatment NN None
with IN None
bendrofluazide JJ None
5 CD None
mg JJ None
daily RB None
hypertensive JJ Condition
patients NNS None
receiving VBG None
treatment NN None
with IN None
diuretics NNS None
-DOCSTART- -X- N

vaginal JJ Condition
adenosis NN Condition
in IN None
DES-exposed JJ Condition
offspring NN None
: : None
Seventy-nine JJ Size
patients NNS Size
with IN None
history NN None
and CC None
physical JJ None
findings NNS None
characteristic NN None
of IN None
antenatal JJ Condition
DES NNP Condition
exposure NN Condition
Fourty-four CD Size
DES-exposed JJ Condition
offspring VBG None
79 CD Size
DES-exposed JJ None
offspring VBG None
DES-exposed JJ None
offspring NN None
. . None
DES-exposed JJ Condition
offspring NN None
-DOCSTART- -X- N

pollinosis NN Condition
. . None
164 CD Size
patients NNS None
pollinosis NN None
. . None
-DOCSTART- -X- N

de FW None
novo FW None
liver NN Condition
transplant NN Condition
recipients VBZ None
de FW Condition
novo FW Condition
liver FW Condition
transplantation NN Condition
( ( Condition
LT NNP Condition
) ) Condition
patients NNS None
Seventy-eight JJ Size
patients NNS None
were VBD None
randomized VBN None
monotherapy NN None
in IN None
de FW None
novo FW None
LT NNP None
patients NNS None
is VBZ None
-DOCSTART- -X- N

intestinal JJ None
absorption NN None
of IN None
fructose NN None
25 CD Size
healthy JJ None
controls NNS None
-DOCSTART- -X- N

cancer NN None
patients NNS None
: : None
cancer NN None
patients NNS None
A DT None
total NN None
of IN None
117 CD None
patients NNS None
newly RB None
referred VBN None
to TO None
a DT None
medical JJ None
oncology NN None
clinic NN None
who WP None
were VBD None
to TO None
be VB None
given VBN None
'bad CD None
news NN None
' POS None
-DOCSTART- -X- N

septic JJ Condition
and CC Condition
SIRS JJ Condition
patients NNS None
] VBP None
59 CD Size
patients NNS None
with IN None
sepsis NN Condition
( ( None
n JJ None
= NNP None
43 CD None
) ) None
and CC None
SIRS NNP Condition
( ( None
n JJ None
= NNP None
16 CD None
) ) None
22 CD Size
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
metastatic JJ Condition
renal NN Condition
cell NN Condition
carcinoma VBZ Condition
previously RB None
treated VBN None
with IN None
a DT None
tyrosine JJ None
kinase NN None
inhibitor NN None
and CC None
everolimus VB None
36 CD Size
patients NNS None
treated VBN None
in IN None
France NNP None
in IN None
the DT None
RECORD-1 JJ None
Trial NNP None
. . None
patients NNS None
with IN None
metastatic JJ None
renal NN None
cell NN None
carcinoma NN None
( ( None
mRCC NN Condition
) ) None
patients NNS None
with IN None
disease JJ None
progression NN None
after IN None
a DT None
TKI-everolimus JJ None
sequence NN None
. . None
patients NNS None
enrolled VBN None
in IN None
RECORD-1 NNP None
( ( None
Renal NNP Condition
Cell NNP Condition
Cancer NNP Condition
Treatment NNP None
With IN None
Oral NNP None
RAD001 NNP None
Given NNP None
Daily NNP None
) ) None
at IN None
French JJ None
sites NNS None
. . None
patients NNS None
treated VBN None
with IN None
a DT None
TKI-everolimus-TKI JJ None
sequence NN None
. . None
Thirty-six JJ None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
hypertension NN Condition
: : None
30 CD Size
non-diabetic JJ Condition
patients NNS Condition
with IN Condition
hypertension NN Condition
-DOCSTART- -X- N

Naltrexone NN None
in IN None
autistic JJ Condition
children NNS Age
: : None
naltrexone NN None
in IN None
autistic JJ Condition
children NNS Age
Forty-one CD Size
children NNS Age
, , None
all DT None
inpatients NNS Condition
, , None
ages VBZ None
2.9 CD Age
to TO Age
7.8 CD Age
years NNS Age
, , None
completed VBD None
the DT None
study NN None
. . None
hyperactivity NN None
children NNS None
with IN None
moderate JJ Condition
to TO Condition
severe VB Condition
self-injurious JJ Condition
behavior NN Condition
. . None
-DOCSTART- -X- N

severe JJ None
head NN None
injury NN None
patients NNS None
] VBP None
severe JJ None
head NN None
injury NN None
patients NNS None
. . None
Ninety-six JJ Size
patients NNS None
48 CD Size
cases NNS None
in IN None
each DT None
group NN None
. . None
severe JJ None
head NN None
injury NN None
patients NNS None
. . None
-DOCSTART- -X- N

11 CD Size
patients NNS None
with IN None
at IN None
least JJS None
two CD None
screw JJ None
type NN None
implants NNS Condition
with IN Condition
bleeding VBG Condition
on IN None
probing VBG None
( ( None
BOP NNP None
) ) None
, , None
probing VBG None
pocket NN None
depth NN None
( ( None
PPD NNP None
) ) None
> VBD None
or CC None
=5 JJ None
mm NN None
, , None
and CC None
at IN None
least JJS None
1.5 CD Condition
mm JJ Condition
radiographic JJ Condition
bone NN Condition
loss NN Condition
and CC Condition
exposed VBN Condition
implant JJ Condition
threads NNS Condition
-DOCSTART- -X- N

awake JJ None
resting NN None
tobacco NN None
smokers NNS None
. . None
Eleven NNP None
healthy JJ None
tobacco NN None
smoking VBG None
adult NN None
male NN None
volunteers NNS None
of IN None
mixed JJ None
race NN None
-DOCSTART- -X- N

eyes NNS None
with IN None
functioning VBG None
filtering VBG None
blebs NN None
: : None
eyes NNS None
with IN None
filtering VBG None
blebs NN None
. . None
36 CD Size
eyes NNS Size
of IN Size
34 CD Size
patients NNS Size
with IN None
functioning VBG None
filtering VBG None
blebs NNS None
who WP None
were VBD None
to TO None
undergo VB None
cataract NN None
surgery NN None
. . None
-DOCSTART- -X- N

chronic JJ None
whiplash NN None
disorders NNS None
Whiplash-associated JJ None
disorder NN None
patients NNS None
with IN None
chronic JJ None
whiplash NN None
associated VBN None
disorders NNS None
people NNS None
with IN None
chronic JJ None
( ( None
symptoms NNS None
of IN None
> JJ None
3 CD None
months NNS None
duration NN None
) ) None
whiplash NN None
. . None
whiplash NN None
associated VBN None
disorders NNS None
. . None
whiplash NN None
and CC None
chronic JJ None
pain NN None
. . None
-DOCSTART- -X- N

Forty-one CD Size
consecutive JJ None
patients NNS None
with IN None
supratentorial JJ Condition
primary JJ Condition
brain NN Condition
tumors NNS Condition
( ( None
38 CD Size
Grade NNP Condition
III NNP Condition
and CC Condition
IV NNP Condition
astrocytomas RB Condition
, , None
one CD Size
giant-cell NN Condition
astrocytoma NN Condition
, , None
and CC None
two CD Size
cases NNS None
with IN None
insufficient JJ None
tissue NN None
for IN None
diagnosis NN None
) ) None
within IN None
2 CD None
weeks NNS None
of IN None
surgery NN None
-DOCSTART- -X- N

hyperactive JJ None
and CC None
impulsive JJ None
children NNS None
with IN None
autistic JJ None
disorder NN None
. . None
autistic JJ None
children NNS None
autistic JJ None
children NNS None
Eight NNP None
male NN None
children NNS None
( ( None
8.1 CD None
+/- JJ None
2.8 CD None
years NNS None
) ) None
with IN None
autistic JJ None
disorder NN None
, , None
diagnosed VBN None
by IN None
DSM-III-R NNP None
criteria NNS None
Subjects NNS None
were VBD None
included VBN None
in IN None
the DT None
study NN None
if IN None
they PRP None
had VBD None
inattention NN None
, , None
impulsivity NN None
, , None
and CC None
hyperactivity NN None
that WDT None
was VBD None
excessive JJ None
for IN None
their PRP$ None
developmental JJ None
level NN None
. . None
Subjects NNS None
had VBD None
not RB None
tolerated VBN None
or CC None
responded VBN None
to TO None
other JJ None
psychopharmacologic JJ None
treatments NNS None
( ( None
neuroleptics NNS None
, , None
methylphenidate NN None
, , None
or CC None
desipramine NN None
) ) None
. . None
children NNS None
with IN None
autistic JJ None
disorder NN None
. . None
-DOCSTART- -X- N

non-resectable JJ Condition
colorectal JJ Condition
liver NN Condition
metastases NNS Condition
] VBP None
unresectable JJ None
colorectal JJ None
liver NN None
metastases NNS None
-DOCSTART- -X- N

children NNS None
with IN None
Down NNP Condition
syndrome NN Condition
. . None
children NNS None
with IN None
diagnosis NN None
of IN None
Down NNP None
syndrome NN None
. . None
Eight NNP Size
children NNS Age
with IN None
Down NNP Condition
syndrome NN Condition
who WP None
displayed VBD None
autistic JJ Condition
features NNS None
were VBD None
compared VBN None
with IN None
eight CD Size
Down NNP Condition
syndrome NN Condition
children NNS None
without IN None
autistic JJ None
features NNS None
. . None
-DOCSTART- -X- N

participants NNS None
in IN None
the DT None
Appropriate NNP None
Blood NNP None
Pressure NNP None
Control NNP None
in IN None
Diabetes NNP None
trial NN None
. . None
two CD None
study NN None
populations NNS None
: : None
a DT None
hypertensive JJ None
one NN None
( ( None
diastolic JJ None
blood NN None
pressure NN None
of IN None
> NN None
or CC None
= $ None
90.0 CD None
mm NN None
Hg NNP None
at IN None
the DT None
time NN None
of IN None
randomization NN None
) ) None
and CC None
a DT None
normotensive JJ None
one NN None
( ( None
diastolic JJ None
blood NN None
pressure NN None
of IN None
80.0-89.0 JJ None
mm NN None
Hg NNP None
at IN None
the DT None
time NN None
of IN None
randomization NN None
) ) None
. . None
950 CD None
men NNS None
and CC None
women NNS None
aged VBN None
40-74 JJ None
years NNS None
There EX None
were VBD None
470 CD None
randomized JJ None
participants NNS None
in IN None
the DT None
hypertensive JJ None
population NN None
and CC None
480 CD None
randomized JJ None
participants NNS None
in IN None
the DT None
normotensive JJ None
population NN None
. . None
randomized JJ None
patients NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
: : None
children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
; : None
children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
parallel JJ None
groups NNS None
design NN None
, , None
12 CD Size
children NNS Age
with IN None
DSM-IV NNP Condition
autistic JJ Condition
disorder NN Condition
( ( None
mean JJ None
age NN None
7.8+/-2.1 CD Age
years NNS None
) ) None
were VBD None
randomized VBN None
children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
longstanding JJ Condition
post-irradiation NN Condition
GH NNP Condition
insufficiency NN Condition
. . None
patients NNS None
post VBP None
cranial JJ None
irradiation NN None
and CC None
in IN None
controls NNS None
. . None
Five CD Size
adult NN Age
male NN Sex
long-term JJ None
survivors NNS None
of IN None
childhood NN Size
brain NN Size
tumours NNS Size
( ( None
median JJ None
age NN None
21.8 CD None
years NNS None
( ( None
18.4-26.7 JJ None
) ) None
; : None
13.7 CD None
years NNS None
( ( None
11.4-15.7 JJ None
) ) None
post-radiotherapy NN None
, , None
> NNP None
30Gy CD None
) ) None
and CC None
five CD Size
matched VBN None
controls NNS None
were VBD None
studied VBN None
. . None
young JJ Age
males NNS None
adult JJ Age
long-term JJ None
survivors NNS None
of IN None
childhood NN Condition
brain NN Condition
tumours NN Condition
. . None
-DOCSTART- -X- N

postmenopausal JJ None
women NNS None
: : None
older JJR None
population NN None
. . None
postmenopausal JJ None
women NNS None
. . None
45 CD None
postmenopausal JJ None
women NNS None
recovery NN None
in IN None
postmenopausal JJ None
women NNS None
. . None
-DOCSTART- -X- N

carcinoma NN Condition
of IN Condition
the DT Condition
uterine JJ Condition
cervix NN Condition
. . None
carcinoma NN Condition
of IN Condition
the DT Condition
uterine JJ Condition
cervix NN Condition
. . None
Between NNP None
January NNP None
1983 CD None
and CC None
February NNP None
1989 CD None
, , None
a DT None
total NN None
of IN None
165 CD Size
patients NNS None
with IN None
carcinoma NN Condition
of IN Condition
the DT Condition
uterine JJ Condition
cervix NN Condition
was VBD None
entered VBN None
in IN None
a DT None
prospective JJ None
randomized NN None
study NN None
concerning VBG None
the DT None
point NN None
A NNP None
dose NN None
of IN None
HDR NNP None
therapy NN None
( ( None
6 CD None
Gy/fraction NNP None
vs FW None
7.5 CD None
Gy/fraction NNP None
) ) None
and CC None
external JJ None
irradiation NN None
dose NN None
at IN None
Department NNP None
of IN None
Radiation NNP None
Therapy NNP None
, , None
The DT None
Center NNP None
for IN None
Adult NNP None
Diseases NNP None
, , None
Osaka NNP None
. . None
UICC NNP None
[ VBD None
20 CD None
] JJ None
stage NN None
distribution NN None
of IN None
patients NNS None
was VBD None
as IN None
follows VBZ None
: : None
stage NN None
IA NNP None
= NNP None
4 CD Size
, , None
stage NN None
IB NNP None
= NNP None
33 CD Size
, , None
stage NN None
IIA NNP None
= NNP None
18 CD Size
, , None
stage NN None
IIB NNP None
= NNP None
38 CD Size
, , None
stage NN None
III NNP None
= NNP None
57 CD Size
, , None
stage NN None
IV NNP None
= VBZ None
15 CD Size
. . None
-DOCSTART- -X- N

lactating VBG None
women NNS Sex
. . None
Twenty-three JJ Size
women NNS None
who WP None
were VBD None
exclusively RB None
breast-feeding VBG None
their PRP$ None
infants NNS None
were VBD None
randomly RB None
assigned VBN None
breast-feeding JJ None
mothers NNS None
. . None
-DOCSTART- -X- N

methadone NN None
maintenance NN None
heroin VB Condition
addicts NNS Condition
waiting VBG None
for IN None
treatment NN None
in IN None
standard JJ None
comprehensive JJ None
methadone NN None
maintenance NN None
programs NNS None
. . None
New NNP None
York NNP None
City NNP None
. . None
A NNP None
sample NN None
of IN None
301 CD Size
volunteer NN None
subjects NNS None
recruited VBN None
from IN None
the DT None
waiting VBG None
list NN None
for IN None
treatment NN None
in IN None
the DT None
Beth NNP None
Israel NNP None
methadone NN None
program NN None
persons NNS None
awaiting VBG None
entry NN None
into IN None
comprehensive JJ None
treatment NN None
-DOCSTART- -X- N

chronic JJ Condition
cancer NN Condition
pain NN Condition
in IN None
adults NNS Age
: : None
Outpatients NNS None
with IN None
cancer NN None
were VBD None
eligible JJ None
for IN None
the DT None
study NN None
if IN None
they PRP None
were VBD None
aged VBN None
> JJ None
-18 CD None
years NNS None
and CC None
had VBD None
chronic VBN None
( ( None
duration NN None
, , None
> NNP None
/= VBZ None
3 CD None
months NNS None
) ) None
moderate VBP None
to TO None
severe VB None
cancer-related JJ None
pain NN None
( ( None
score NN None
on IN None
10-cm JJ None
visual JJ None
analog NN None
scale NN None
[ NNP None
VAS NNP None
] NNP None
, , None
> VBD None
3 CD None
cm NN None
[ NN None
moderate JJ None
] NN None
; : None
score NN None
on IN None
a DT None
4-point JJ None
verbal JJ None
pain-intensity NN None
scale NN None
, , None
> VBZ None
1 CD None
[ NN None
moderate JJ None
] NN None
) ) None
. . None
the DT None
121 CD None
patients NNS None
who WP None
participated VBD None
, , None
Of IN None
the DT None
total JJ None
number NN None
of IN None
cases NNS None
, , None
59 CD None
% NN None
were VBD None
aged VBN None
60 CD None
to TO None
89 CD None
years NNS None
, , None
and CC None
55 CD None
% NN None
were VBD None
men NNS None
. . None
these DT None
patients NNS None
with IN None
moderate JJ None
or CC None
severe JJ None
, , None
chronic JJ None
, , None
cancer-related JJ None
pain NN None
. . None
-DOCSTART- -X- N

occupational JJ Condition
irritant JJ Condition
contact NN Condition
dermatitis NN Condition
. . None
2 CD Size
panels NNS Size
of IN None
25 CD Size
hospital NN Size
nurses NNS None
with IN None
mild JJ None
signs NNS None
of IN None
skin JJ Condition
irritation NN Condition
-DOCSTART- -X- N

children NNS None
with IN None
pervasive JJ None
developmental NN None
disorders NNS None
and CC None
serious JJ None
behavior NN None
problems NNS None
: : None
children NNS None
with IN None
pervasive JJ None
developmental NN None
disorders NNS None
( ( None
PDDs NNP None
) ) None
have VBP None
serious JJ None
, , None
functionally RB None
impairing VBG None
behavioral JJ None
problems NNS None
. . None
children NNS None
with IN None
PDDs NNP None
. . None
124 CD None
children NNS None
, , None
aged VBD None
4 CD None
through IN None
13 CD None
years NNS None
, , None
with IN None
PDDs NNP None
, , None
accompanied VBN None
by IN None
frequent JJ None
tantrums NNS None
, , None
self-injury NN None
, , None
and CC None
aggression NN None
. . None
in IN None
children NNS None
with IN None
PDDs NNP None
, , None
with IN None
-DOCSTART- -X- N

survivors NNS None
of IN None
breast NN None
cancer NN None
: : None
breast NN None
cancer NN None
survivors NNS None
. . None
Participants NNP None
included VBD None
87 CD None
newly RB None
postmenopausal JJ None
women NNS None
with IN None
status NN None
post NN None
chemotherapy NN None
, , None
recruited VBN None
from IN None
a DT None
breast NN None
cancer NN None
clinic NN None
in IN None
an DT None
academic JJ None
medical JJ None
center NN None
. . None
women NNS None
with IN None
breast NN None
cancer NN None
treated VBN None
with IN None
chemotherapy NN None
. . None
breast NN None
cancer NN None
survivors NNS None
. . None
-DOCSTART- -X- N

severely RB None
immunocompromised JJ None
patients NNS None
. . None
varicella-zoster JJ None
virus NN None
infection NN None
in IN None
severely RB None
immunocompromised JJ None
patients NNS None
who WP None
presented VBD None
within IN None
72 CD None
hours NNS None
of IN None
onset NN None
of IN None
the DT None
infection NN None
. . None
Eleven JJ None
patients NNS None
were VBD None
treated VBN None
in IN None
each DT None
group NN None
. . None
immunocompromised JJ None
patients NNS None
. . None
-DOCSTART- -X- N

postmenopausal JJ None
women NNS None
with IN None
advanced JJ None
, , None
hormone-receptor-positive JJ None
breast NN None
cancer NN None
: : None
patients NNS None
with IN None
hormone-receptor-positive JJ None
breast NN None
cancer NN None
. . None
outpatient JJ None
clinics NNS None
and CC None
hospitals NNS None
. . None
We PRP None
enrolled VBD None
postmenopausal JJ None
women NNS None
with IN None
hormone-receptor-positive JJ None
, , None
locally RB None
advanced VBD None
or CC None
metastatic JJ None
breast NN None
cancer NN None
previously RB None
treated VBN None
with IN None
endocrine JJ None
treatment NN None
. . None
We PRP None
screened VBD None
189 CD None
patients NNS None
and CC None
enrolled VBD None
156 CD None
( ( None
106 CD None
in IN None
the DT None
ganitumab NN None
group NN None
and CC None
50 CD None
in IN None
the DT None
placebo NN None
group NN None
) ) None
. . None
treatment NN None
in IN None
women NNS None
with IN None
previously RB None
treated VBN None
hormone-receptor-positive JJ None
locally RB None
advanced VBD None
or CC None
metastatic JJ None
breast NN None
cancer NN None
-DOCSTART- -X- N

digital JJ None
nerve NN None
blocks NNS None
: : None
From IN None
March NNP None
of IN None
1999 CD None
to TO None
March NNP None
of IN None
2001 CD None
, , None
70 CD None
adult NN None
patients NNS None
who WP None
underwent VBP None
immediate JJ None
reconstruction NN None
for IN None
traumatic JJ None
injuries NNS None
of IN None
the DT None
digits NNS None
digital JJ None
nerve NN None
blocks NNS None
. . None
-DOCSTART- -X- N

partial JJ Condition
thickness NN Condition
burns NNS Condition
thermal JJ Condition
2nd CD Condition
degree NN Condition
burns NNS Condition
partial JJ Condition
thickness NN Condition
burns NNS Condition
. . None
40 CD Size
patients NNS None
received VBD None
either RB None
topical JJ None
treatment NN None
with IN None
Moist NNP None
Exposed VBD None
Burn NNP None
Ointment NNP None
( ( None
MEBO NNP None
) ) None
or CC None
standard JJ None
Flammazine NNP None
treatment NN None
. . None
All DT None
patients NNS None
suffered VBD None
from IN None
partial-thickness JJ None
burn NN None
injuries NNS None
( ( None
< VB None
20 CD None
% NN None
TBSA NNP None
) ) None
. . None
limited JJ Condition
partial JJ Condition
thickness NN Condition
thermal JJ Condition
burns NNS Condition
. . None
-DOCSTART- -X- N

sedation NN None
of IN None
autistic JJ Condition
patients NNS Condition
during IN None
dental JJ Condition
treatment NN Condition
. . None
sedating VBG None
autistic JJ None
patients NNS None
during IN None
dental JJ None
treatment NN None
. . None
13 CD None
subjects NNS None
aged VBD None
5.8 CD Age
to TO Age
14.7 CD Age
years NNS Age
. . None
autistic JJ None
patients NNS None
-DOCSTART- -X- N

inpatient JJ Condition
alcoholics NNS Condition
. . None
inpatient JJ None
alcoholics NNS None
with IN None
nursing NN None
home NN None
residents NNS None
( ( None
NHRs NNP None
) ) None
Fifty NNP None
alcoholic JJ None
inpatients NNS Condition
were VBD Condition
randomly RB Condition
assigned VBN Condition
to TO Condition
the DT Condition
PALS NNP Condition
program NN Condition
( ( Condition
n JJ Condition
= NNP Condition
25 CD Condition
) ) Condition
or CC Condition
to TO Condition
the DT Condition
library NN Condition
for IN Condition
free JJ Condition
reading NN Condition
time NN Condition
( ( Condition
n JJ Condition
= NNP Condition
25 CD Condition
) ) Condition
. . None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Condition
autistic JJ None
children NNS None
11 CD None
mothers NNS None
of IN None
children NNS None
diagnosed VBN None
, , None
according VBG None
to TO None
the DT None
criteria NNS None
established VBN None
by IN None
the DT None
DSM NNP None
IVtr NNP None
( ( None
APA NNP None
, , None
2002 CD None
) ) None
, , None
with IN None
autism NN None
( ( None
six CD None
) ) None
and CC None
with IN None
Asperger NNP None
Syndrome NNP None
( ( None
five CD None
) ) None
and CC None
who WP None
were VBD None
seen VBN None
at IN None
the DT None
Investigation NNP None
Laboratory NNP None
of IN None
Global NNP None
Developmental NNP None
Disorders NNP None
of IN None
the DT None
Federal NNP None
University NNP None
of IN None
S?o NNP None
Paulo NNP None
. . None
the DT None
Portuguese JJ None
language NN None
the DT None
mothers NNS None
of IN None
parents NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
essential JJ Condition
hypertension NN Condition
. . None
patients NNS None
with IN None
essential JJ None
hypertension NN None
-DOCSTART- -X- N

age NN None
of IN None
onset NN None
in IN None
panic JJ Condition
disorder NN Condition
Groups NNP None
the DT None
sample NN None
of IN None
the DT None
cross-national JJ None
collaborative NN None
panic NN None
study NN None
( ( None
CNCPS NNP None
) ) None
Patients NNS None
who WP None
developed VBD None
avoidance NN None
behavior NN None
before IN None
the DT None
full JJ Condition
syndrome NN Condition
of IN None
panic JJ Condition
disorder NN Condition
Patients NNS None
-DOCSTART- -X- N

premenopausal JJ Condition
women NNS Condition
. . Condition
premenopausal JJ None
women NNS None
22 CD None
premenopausal JJ None
women NNS None
, , None
age NN None
32.6 CD None
( ( None
range JJ None
20-45 CD None
years NNS None
) ) None
-DOCSTART- -X- N

atopic NN None
eczema NN None
. . None
allergic JJ None
inflammation NN None
at IN None
an DT None
early JJ None
age NN None
A NNP None
total NN None
of IN None
27 CD None
infants NNS None
, , None
mean JJ None
age NN None
4.6 CD None
months NNS None
, , None
who WP None
manifested VBD None
atopic JJ None
eczema NN None
during IN None
exclusive JJ None
breast-feeding NN None
and CC None
who WP None
have VBP None
had VBN None
no DT None
exposure NN None
to TO None
any DT None
infant NN None
or CC None
substitute NN None
formula NN None
infants NNS None
-DOCSTART- -X- N

youth NN None
with IN None
pervasive JJ None
developmental NN None
disorders NNS None
. . None
children NNS None
and CC None
adolescents NNS None
with IN None
pervasive JJ None
developmental NN None
disorders NNS None
( ( None
PDD NNP None
) ) None
. . None
30 CD None
subjects NNS None
( ( None
20 CD None
boys NNS None
, , None
10 CD None
girls NNS None
) ) None
6-20 CD None
years NNS None
of IN None
age NN None
with IN None
PDD NNP None
and CC None
significant JJ None
aggression NN None
were VBD None
randomized VBN None
outpatients NNS None
. . None
-DOCSTART- -X- N

A NNP None
series NN None
of IN None
25 CD None
patients NNS None
with IN None
advanced JJ None
esophageal NN None
cancer NN None
treated VBN None
from IN None
Mar NNP None
. . None
1981 CD None
to TO None
Sep. VB None
1982 CD None
by IN None
preoperative JJ None
chemotherapy NN None
plus CC None
surgery NN None
patients NNS None
came VBD None
from IN None
the DT None
hospitals NNS None
of IN None
the DT None
cooperative JJ None
research NN None
group NN None
By IN None
histology NN None
, , None
22 CD None
cases NNS None
were VBD None
squamous JJ None
cell NN None
carcinoma NN None
, , None
1 CD None
adenocarcinoma NN None
and CC None
2 CD None
squamous JJ None
adenocarcinoma NN None
. . None
-DOCSTART- -X- N

blepharitis NN Condition
of IN None
acute NN None
eyelid JJ None
diseases NNS None
like IN None
blepharitis NN None
. . None
patients NNS None
diagnosed VBN None
with IN None
blepharitis NN None
. . None
METHODS NNP None
this DT None
multi-center NN None
, , None
randomized VBN None
197 CD None
patients NNS None
( ( None
ITT NNP None
( ( None
intention-to-treat-group JJ None
) ) None
; : None
mean JJ None
age NN None
56 CD None
? . None
18 CD None
years NNS None
, , None
56 CD None
% NN None
female NN None
, , None
active JJ None
drug NN None
: : None
vehicle NN None
= IN None
97:100 CD None
) ) None
over IN None
2 CD None
weeks NNS None
-DOCSTART- -X- N

coformulated JJ None
elvitegravir/cobicistat/emtricitabine/tenofovir NN None
disoproxil NN None
fumarate NN None
versus NN None
efavirenz/emtricitabine/tenofovir NN None
disoproxil NN None
fumarate NN None
for IN None
initial JJ None
treatment NN None
of IN None
HIV-1 NNP Condition
infection NN Condition
: : Condition
( ( None
EVG/COBI/FTC/TDF NNP None
, , None
n JJ None
= NNP None
348 CD None
) ) None
( ( None
EFV/FTC/TDF NNP None
, , None
n JJ Size
= NNP Size
352 CD Size
) ) None
-DOCSTART- -X- N

neonates NNS None
undergoing VBG None
cardiac JJ None
surgery NN None
: : None
neonatal JJ None
cardiac NN None
surgery NN None
Neonates NNP None
scheduled VBD None
for IN None
cardiac JJ None
surgery NN None
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
n JJ None
= NNP None
39 CD None
) ) None
or CC None
operatively RB None
, , None
n JJ None
= NNP None
37 CD None
) ) None
methylprednisolone NN None
-DOCSTART- -X- N

Thirty-five JJ None
university NN None
students NNS None
-DOCSTART- -X- N

older JJR None
adults NNS None
: : None
older JJR None
adults NNS None
From IN None
a DT None
random JJ None
sample NN None
of IN None
health NN None
maintenance NN None
organization NN None
( ( None
HMO NNP None
) ) None
enrollees VBZ None
65 CD None
years NNS None
and CC None
older JJR None
, , None
1559 CD Size
ambulatory NN None
seniors NNS None
ambulatory NN Condition
HMO NNP Condition
enrollees NNS Condition
-DOCSTART- -X- N

children NNS Age
and CC None
adolescents NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
children NNS Age
and CC None
adolescents NNS Age
with IN None
ASD NNP Condition
. . None
total NN None
of IN None
55 CD Size
subjects NNS None
gavetheir JJ None
consent NN None
and CC None
27 CD Size
were VBD None
randomized VBN None
in IN None
a DT None
1 CD None
: : None
1 CD None
manner NN None
( ( None
mean JJ None
age NN None
9.46+/-2.46 CD Age
, , None
mean FW None
nonverbal JJ None
IQ NNP None
63.3+/-23.9 NN None
) ) None
. . None
-DOCSTART- -X- N

patients NNS Condition
treated VBN Condition
with IN Condition
oral JJ Condition
hypoglycaemic JJ Condition
agents NNS Condition
. . None
Twenty-two JJ Size
maturity-onset JJ None
type NN None
diabetics NNS Condition
treated VBD None
with IN None
oral JJ None
hypoglycaemic JJ None
agents NNS None
thirteen JJ Size
patients NNS None
, , None
under IN None
reasonably RB None
good JJ None
control NN None
maturity-onset JJ None
diabetics NNS None
not RB None
adequately RB None
controlled VBN None
by IN None
diet NN None
combined VBN None
with IN None
oral JJ None
hypoglycaemic JJ None
agents NNS None
. . None
-DOCSTART- -X- N

first JJ Condition
episode NN Condition
schizophrenia NN Condition
. . None
schizophrenia NN Condition
patients NNS None
with IN None
first JJ Condition
episode NN Condition
schizophrenia NN Condition
; : None
that WDT None
is VBZ None
, , None
before IN None
the DT None
effects NNS None
of IN None
chronic JJ Condition
illness NN Condition
, , None
institutionalization NN None
, , None
or CC None
treatment NN None
307 CD Size
schizophrenia NN Condition
subjects NNS None
in IN None
their PRP$ None
first JJ Condition
episode NN Condition
of IN Condition
illness NN Condition
Approximately RB None
two-thirds NNS Size
of IN None
the DT None
subjects NNS None
were VBD None
receiving VBG None
antipsychotic JJ None
treatment NN None
at IN None
the DT None
time NN None
of IN None
assessment NN None
; : None
however RB None
, , None
the DT None
duration NN None
of IN None
treatment NN None
was VBD None
limited VBN None
to TO None
12 CD None
weeks NNS None
or CC None
less JJR None
. . None
first JJ Condition
episode NN Condition
schizophrenia NN Condition
patients NNS None
schizophrenia NN Condition
-DOCSTART- -X- N

symptomatic JJ Condition
endometriosis NN Condition
: : Condition
endometriosis NN None
patients NNS None
of IN None
a DT None
12-month JJ None
course NN None
of IN None
GnRH NNP None
agonist VBP None
alone RB None
or CC None
with IN None
one CD None
of IN None
three CD None
add-back JJ None
regimens NNS None
. . None
All DT None
patients NNS None
had VBD None
received VBN None
monthly JJ None
leuprolide NN None
acetate NN None
201 CD Size
patients NNS None
enrolled VBN None
in IN None
the DT None
initial JJ None
trial NN None
, , None
123 CD Size
completed VBN None
at IN None
least JJS None
280 CD None
days NNS None
of IN None
therapy NN None
and CC None
entered VBD None
the DT None
follow-up JJ None
period NN None
. . None
symptomatic JJ None
endometriosis NN None
patients NNS None
-DOCSTART- -X- N

non-Hodgkin NN Condition
's POS Condition
lymphomas NN Condition
. . None
Between NNP None
July NNP None
1 CD None
, , None
1971 CD None
and CC None
December NNP None
31 CD None
, , None
1978 CD None
, , None
150 CD Size
patients NNS None
with IN None
favorable JJ None
subtypes NNS None
of IN None
non-Hodgkin NN Condition
's POS Condition
lymphoma NN Condition
[ NNP None
nodular JJ None
poorly RB None
differentiated VBN None
lymphocytic JJ None
( ( None
NLPD NNP None
) ) None
, , None
nodular JJ None
mixed JJ None
, , None
or CC None
diffuse RB None
well RB None
differentiated VBN None
lymphocytic JJ None
] NNS None
clinical JJ None
trials NNS None
at IN None
Stanford NNP None
University NNP None
. . None
-DOCSTART- -X- N

patients NNS None
( ( Age
aged VBN Age
18-75 CD Age
years NNS Age
) ) Age
with IN Condition
, , Condition
or CC Condition
with IN Condition
high JJ Condition
risk NN Condition
of IN Condition
, , Condition
coronary JJ Condition
heart NN Condition
disease NN Condition
189 CD Size
patients NNS None
were VBD None
screened VBN None
and CC None
130 CD Size
randomly RB None
assigned VBN Size
to TO None
placebo VB None
( ( None
66 CD Size
patients NNS None
) ) None
or CC None
dalcetrapib NN None
( ( None
64 CD Size
patients NNS None
) ) None
. . None
-DOCSTART- -X- N

long-term JJ None
exogenous JJ None
subclinical JJ None
hyperthyroid NN None
patients NNS None
Totally NNP None
25 CD None
patients NNS None
with IN None
a DT None
history NN None
of IN None
differentiated JJ None
thyroid JJ None
carcinoma NN None
on IN None
long-term JJ None
TSH-suppressive JJ None
levothyroxine NN None
( ( None
l-T JJ None
( ( None
4 CD None
) ) None
) ) None
substitution NN None
Additionally RB None
40 CD None
euthyroid JJ None
controls NNS None
were VBD None
studied VBN None
. . None
-DOCSTART- -X- N

acute JJ Condition
myeloid NN Condition
leukemia NN Condition
. . None
Fifty-four CD Size
patients NNS None
treated VBN None
with IN None
daunorubicin NN Condition
, , None
cytosine JJ Condition
arabinoside NN Condition
and CC None
thioquanine NN Condition
for IN None
acute JJ Condition
myeloid NN Condition
leukemia NN Condition
patients NNS None
undergoing JJ None
remission NN Condition
induction NN Condition
therapy NN Condition
for IN None
acute JJ Condition
myeloid NN Condition
leukemia NN Condition
. . None
-DOCSTART- -X- N

adults NNS None
with IN None
autistic JJ Condition
disorder NN Condition
and CC None
other JJ None
pervasive JJ None
developmental NN None
disorders NNS None
. . None
autism NN Condition
. . Condition
patients NNS None
with IN None
autism NN Condition
. . None
Thirty-one CD Size
adults NNS Age
( ( None
age NN None
[ VBZ None
mean+/-SD JJ None
] NNP None
, , None
28.1+/-7.3 JJ None
years NNS None
) ) None
with IN None
autistic JJ Condition
disorder NN Condition
( ( None
n=17 JJ None
) ) None
or CC None
pervasive JJ None
developmental JJ None
disorder NN None
not RB None
otherwise RB None
specified VBN None
( ( None
n=14 JJ Size
) ) None
participated VBD None
in IN None
a DT None
12-week JJ None
double-blind NN None
, , None
placebo-controlled JJ None
trial NN None
of IN None
risperidone NN None
. . None
autism NN Condition
in IN None
adults NNS Age
. . None
-DOCSTART- -X- N

women NNS Sex
with IN None
PCOS NNP Condition
patients NNS None
with IN None
polycystic JJ Condition
ovary JJ Condition
syndrome NN Condition
( ( Condition
PCOS NNP Condition
) ) Condition
. . Condition
From IN None
March NNP None
1998 CD None
to TO None
June NNP None
2000 CD None
, , None
a DT None
total NN None
of IN None
28 CD Size
women NNS Sex
underwent JJ None
36 CD None
completed VBN None
treatment NN None
cycles NNS None
patients NNS None
with IN None
PCOS NNP Condition
-DOCSTART- -X- N

migraine JJ Condition
Forty-two JJ Size
patients NNS None
with IN None
migraine NN None
without IN None
aura JJ None
underwent NN None
the DT None
test NN None
before IN None
and CC None
2 CD None
months NNS None
after IN None
antimigraine JJ None
therapy NN None
. . None
-DOCSTART- -X- N

nonclient JJ None
school NN None
population NN None
undergoing VBG None
mass NN None
inoculation NN None
against IN None
rubella NN None
. . None
Fifty-one CD None
girls NNS None
-DOCSTART- -X- N

cardiovascular JJ Condition
risks NNS Condition
in IN None
managers NNS None
: : None
managers NNS None
-- : None
was VBD None
145 CD Size
managers NNS None
from IN None
8 CD None
organizations NNS None
-DOCSTART- -X- N

in IN None
schools NNS None
children NNS Age
. . Age
in IN Age
children NNS Age
in IN None
school NN None
settings NNS None
. . None
23 CD None
sixth NNS None
grade JJ None
children NNS None
in IN None
Winnipeg NNP None
, , None
Manitoba NNP None
-DOCSTART- -X- N

renal JJ Condition
calculi NN Condition
. . None
Between NNP None
November NNP None
2005 CD None
and CC None
March NNP None
2006 CD None
, , None
48 CD Size
patients NNS None
were VBD None
randomized VBN None
to TO None
either DT None
an DT None
18F CD None
Re-entry JJ None
nephrostomy NN None
tube NN None
( ( None
group NN None
1 CD None
) ) None
or CC None
a DT None
6F CD None
Double-J JJ None
stent NN None
( ( None
group NN None
2 CD None
) ) None
. . None
-DOCSTART- -X- N

liver NN None
surgery NN None
II NNP None
-- : None
regional JJ None
chemotherapy NN None
] NN None
657 CD None
cases NNS None
of IN None
primary JJ None
and CC None
secondary JJ None
liver NN None
only RB None
malignancies VBZ None
. . None
colorectal JJ None
liver NN None
metastases NNS None
. . None
unresectable JJ None
colorectal JJ None
liver NN None
metastases NNS None
. . None
-DOCSTART- -X- N

in IN None
childhood NN Age
and CC Age
adolescent JJ Age
autism NN Condition
. . None
children NNS None
with IN None
autism NN None
. . None
repetitive JJ None
behaviors NNS None
in IN None
childhood NN None
and CC None
adolescent JJ None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASDs NNP Condition
) ) None
. . None
45 CD Size
child NN Age
or CC Age
adolescent JJ Age
patients NNS None
with IN None
ASD NNP Condition
were VBD None
randomized VBN None
into IN None
two CD None
acute JJ None
8-week JJ None
phases NNS None
in IN None
a DT None
double-blind JJ None
placebo-controlled JJ None
crossover NN None
study NN None
of IN None
liquid JJ None
fluoxetine NN None
. . None
repetitive JJ None
behaviors NNS None
-DOCSTART- -X- N

Abdominal NNP None
surgical JJ None
wound NN None
trauma NN None
patients NNS None
requiring VBG None
abdominal JJ None
exploration NN None
. . None
Five CD None
hundred VBD None
ninety-two JJ None
patients NNS None
were VBD None
evaluated VBN None
: : None
283 CD None
received VBD None
ampicillin/sulbactam NN None
and CC None
309 CD None
received VBD None
cefoxitin NN None
. . None
-DOCSTART- -X- N

rib NN Condition
fractures NNS Condition
. . None
pulmonary JJ Condition
morbidity NN Condition
after IN None
rib NN Condition
fractures NNS Condition
all DT None
patients NNS None
with IN None
rib JJ Condition
fractures NNS Condition
who WP None
received VBD None
ketorolac NN None
< $ None
4 CD None
days NNS None
after IN None
injury NN None
compared VBN None
with IN None
a DT None
random JJ None
sample NN None
of IN None
those DT None
who WP None
did VBD None
not RB None
. . None
202 CD Size
patients NNS None
who WP None
received VBD None
ketorolac NN None
and CC None
417 CD Size
who WP None
did VBD None
not RB None
patients NNS None
with IN None
rib JJ Condition
fractures NNS Condition
-DOCSTART- -X- N

children NNS None
in IN None
southern JJ None
India NNP None
receiving VBG None
a DT None
small JJ None
weekly JJ None
dose NN None
of IN None
vitamin NN None
A NNP None
. . None
in IN None
southern JJ None
India NNP None
involving VBG None
15,419 CD None
preschool-age JJ None
children NNS None
who WP None
received VBD None
either CC None
8.7 CD None
mumol NN None
( ( None
8333 CD None
IU NNP None
) ) None
of IN None
vitamin NN None
A NNP None
and CC None
46 CD None
mumol NN None
( ( None
20 CD None
mg NN None
) ) None
of IN None
vitamin NN None
E NNP None
( ( None
the DT None
treated VBN None
group NN None
) ) None
or CC None
vitamin JJ None
E NNP None
alone RB None
( ( None
the DT None
control NN None
group NN None
) ) None
-DOCSTART- -X- N

4 CD None
groups NNS None
of IN None
cancer NN None
patients NNS None
receiving VBG None
bone NN None
marrow NN None
transplants NNS None
( ( None
BMT NNP None
) ) None
: : None
( ( None
1 CD None
) ) None
treatment NN None
as IN None
usual JJ None
control NN None
, , None
( ( None
2 CD None
) ) None
therapist NN None
support NN None
, , None
( ( None
3 CD None
) ) None
relaxation NN None
and CC None
imagery NN None
training NN None
, , None
and CC None
( ( None
4 CD None
) ) None
training NN None
in IN None
a DT None
package NN None
of IN None
cognitive-behavioral JJ None
coping NN None
skills NNS None
which WDT None
included VBD None
relaxation NN None
and CC None
imagery NN None
. . None
94 CD None
patients NNS None
completed VBD None
the DT None
study NN None
which WDT None
involved VBD None
two CD None
training NN None
sessions NNS None
prior RB None
to TO None
treatment NN None
and CC None
twice RB None
a DT None
week NN None
'booster POS None
' POS None
sessions NNS None
during IN None
the DT None
first JJ None
5 CD None
weeks NNS None
of IN None
treatment NN None
. . None
-DOCSTART- -X- N

Older JJR Age
patients NNS None
with IN None
chronic JJ Condition
myeloid NN Condition
leukemia NN Condition
( ( None
?65 CD None
years NNS None
) ) None
profit NN None
than IN None
younger JJR None
patients NNS None
: : None
a DT None
older JJR None
patients NNS None
with IN None
chronic JJ None
myeloid NN None
leukemia NN None
in IN None
chronic JJ None
phase NN None
has VBZ None
randomized JJ None
five-arm JJ None
treatment NN None
optimization NN None
study NN None
in IN None
newly RB None
diagnosed VBN None
BCR-ABL-positive JJ None
chronic JJ None
myeloid NN None
leukemia NN None
in IN None
chronic JJ None
phase NN None
. . None
Patients NNS None
randomized VBD None
to TO None
imatinib VB None
400 CD None
mg/day NN None
( ( None
IM400 NNP None
) ) None
or CC None
imatinib $ None
800 CD None
mg/day NN None
( ( None
IM800 NNP None
) ) None
and CC None
stratified VBD None
according VBG None
to TO None
age NN None
( ( None
?65 CD None
years NNS None
vs. FW None
< RB None
65 CD None
years NNS None
) ) None
were VBD None
tolerability NN None
. . None
A DT None
total NN None
of IN None
828 CD None
patients NNS None
were VBD None
randomized VBN None
to TO None
IM800 NNP None
. . None
Seven NNP None
hundred VBD None
eighty-four JJ None
patients NNS None
were VBD None
evaluable JJ None
( ( None
IM400 NNP None
, , None
382 CD None
; : None
IM800 NNP None
, , None
402 CD None
) ) None
. . None
One CD None
hundred VBD None
ten JJ None
patients NNS None
( ( None
29 CD None
% NN None
) ) None
on IN None
IM400 NNP None
and CC None
83 CD None
( ( None
21 CD None
% NN None
) ) None
on IN None
IM800 NNP None
were VBD None
?65 JJ None
years NNS None
older JJR None
patients NNS None
younger JJR None
patients NNS None
. . None
-DOCSTART- -X- N

cardiac JJ None
surgery NN None
with IN None
cardiopulmonary JJ Condition
bypass NN Condition
patients NNS None
undergoing VBG None
cardiac JJ Condition
surgery NN Condition
with IN Condition
cardiopulmonary JJ Condition
bypass NN Condition
( ( Condition
CPB NNP Condition
) ) Condition
Pericardial NNP None
blood NN None
of IN None
13 CD Size
patients NNS None
patients NNS None
undergoing VBG None
cardiac JJ Condition
surgery NN Condition
with IN Condition
CPB NNP Condition
-DOCSTART- -X- N

earthquake-related JJ Condition
posttraumatic JJ Condition
stress NN Condition
disorder NN Condition
: : None
disaster NN Condition
survivors NNS Condition
Fifty-nine JJ Size
earthquake NN None
survivors NNS None
in IN None
Turkey NNP None
disaster NN None
survivors NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
excessive JJ Condition
sleepiness NN Condition
associated VBN None
with IN None
shift NN None
work NN None
disorder NN None
: : None
patients NNS None
with IN None
excessive JJ Condition
sleepiness NN Condition
associated VBN None
with IN None
shift NN Condition
work NN Condition
disorder NN Condition
( ( None
SWD NNP None
) ) None
. . None
randomized NNS None
463 CD Size
patients NNS None
with IN None
SWD NNP Condition
, , None
1 CD None
with IN None
armodafinil JJ None
150 CD None
mg/d NN None
and CC None
1 CD None
with IN None
modafinil NN None
200 CD None
mg/d NN None
( ( None
both DT None
administered VBN None
around IN None
2200 CD None
h NN None
before IN None
night NN None
shifts NNS None
) ) None
-DOCSTART- -X- N

cyclosporin-treated JJ Condition
renal JJ Condition
transplant NN Condition
recipients NNS Condition
: : None
Twenty NNP Size
nine CD Size
stable JJ Condition
renal JJ Condition
transplant NN Condition
recipients NNS Condition
, , None
10 CD Size
receiving VBG None
cyclosporin NN None
, , None
10 CD Size
cyclosporin-prednisolone NN None
and CC None
nine CD Size
azathioprine-prednisolone NN None
-DOCSTART- -X- N

following VBG None
total JJ Condition
hip JJ Condition
replacement NN Condition
: : None
Between NNP None
1995 CD None
and CC None
1996 CD None
, , None
100 CD Size
patients NNS Size
were VBD None
randomized VBN None
to TO None
receive VB None
a DT None
prophylactic JJ None
therapy NN None
for IN None
prevention NN None
of IN None
heterotopic NN Condition
ossification NN Condition
. . None
One CD Size
hundred VBD Size
patients NNS Size
receiving VBG None
no DT None
prophylactic JJ None
therapy NN None
after IN None
total JJ None
hip NN None
arthroplasty NN None
between IN None
1988 CD None
and CC None
1992 CD None
were VBD None
analyzed VBN None
and CC None
defined VBN None
as IN None
the DT None
historical JJ None
control NN None
group NN None
. . None
-DOCSTART- -X- N

symptomatic JJ Condition
reflux NN Condition
esophagitis NN Condition
. . None
32 CD Size
patients NNS None
with IN None
chronic JJ Condition
heartburn NN Condition
. . None
Entry NN None
criteria NNS None
included VBD None
the DT None
presence NN None
of IN None
symptomatic JJ None
gastroesophageal NN None
reflux NN None
confirmed VBN None
by IN None
both DT None
an DT None
acid JJ None
perfusion NN None
( ( None
Bernstein NNP None
) ) None
test NN None
and CC None
by IN None
intraesophageal JJ None
pH NN None
probe NN None
. . None
-DOCSTART- -X- N

abdominal JJ Condition
hysterectomies NNS Condition
. . None
total JJ Condition
abdominal JJ Condition
hysterectomy NN Condition
operations NNS None
. . None
We PRP None
conducted VBD None
this DT None
randomized VBN None
controlled VBD None
clinical JJ None
study NN None
on IN None
61 CD Size
patients NNS None
. . None
The DT None
study NN None
was VBD None
conducted VBN None
in IN None
the DT None
operation NN None
room NN None
, , None
post-anesthesia JJ None
care NN None
unit NN None
, , None
and CC None
inpatient JJ None
clinic NN None
. . None
61 CD None
patients NNS None
into IN None
control NN None
group NN None
( ( None
group NN None
C NNP None
) ) None
, , None
block NN None
group NN None
( ( None
group NN None
B NNP None
) ) None
and CC None
dexketoprofen-block JJ None
group NN None
( ( None
group NN None
DB NNP None
) ) None
-DOCSTART- -X- N

autistic JJ None
children NNS None
-- : None
a DT None
severe JJ None
sleep NN None
problems NNS None
in IN None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
. . None
Participants NNS None
were VBD None
aged VBN None
between IN None
5 CD None
years NNS None
and CC None
16 CD None
years NNS None
10 CD None
months NNS None
, , None
with IN None
a DT None
confirmed JJ None
ASD NNP None
diagnosis NN None
and CC None
severe JJ None
sleep NN None
problems NNS None
, , None
refractory NN None
to TO None
community-based JJ None
interventions NNS None
. . None
Seventy-three JJ None
children NNS None
were VBD None
randomized VBN None
and CC None
analysis NN None
conducted VBN None
on IN None
67 CD None
children NNS None
who WP None
completed VBD None
the DT None
study NN None
. . None
children NNS None
with IN None
ASD NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
sickle JJ Condition
cell NN Condition
disease NN Condition
. . None
patients NNS None
with IN None
SCD NNP Condition
to TO None
quality NN None
of IN None
life NN None
inpatients NNS None
with IN None
SCD NNP Condition
. . None
-DOCSTART- -X- N

type NN Condition
2 CD Condition
diabetes NNS Condition
. . None
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
eight CD Size
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
who WP None
were VBD None
being VBG None
treated VBN None
with IN None
oral JJ None
glucose-lowering JJ None
agents NNS None
. . None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
atherosclerosis NN Condition
in IN None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

cardiac JJ Condition
surgery NN Condition
: : None
a DT None
western JJ None
Canadian JJ None
tertiary NN None
care NN None
hospital NN None
. . None
Consisted NNP None
of IN None
61 CD Size
consecutive JJ None
male NN None
and CC None
female JJ None
patients NNS None
from IN None
ages NNS Age
40 CD Age
to TO Age
80 CD Age
who WP None
were VBD None
scheduled VBN Condition
for IN Condition
cardiac JJ Condition
surgery NN Condition
with IN Condition
cardiopulmonary JJ Condition
bypass NN Condition
. . None
-DOCSTART- -X- N

cardiac JJ Condition
catheterization NN Condition
. . None
118 CD None
left-heart JJ Condition
catheterization NN Condition
patients NNS Condition
who WP None
were VBD None
randomly RB None
assigned VBN None
to TO None
4 CD None
hours NNS None
or CC None
6 CD None
hours NNS None
of IN None
bed NN None
rest NN None
. . None
-DOCSTART- -X- N

distal JJ Condition
femoral JJ Condition
fractures NNS Condition
: : None
distal JJ None
femoral JJ None
fractures NNS None
From IN None
September NNP None
2002 CD None
to TO None
December NNP None
2004 CD None
, , None
68 CD Size
closed VBD None
fractures NNS None
of IN None
the DT None
distal JJ None
femur NN None
were VBD None
treated VBN None
by IN None
bridge NN None
plate NN None
osteosynthesis NN None
using VBG None
DCS NNP None
in IN None
31 CD Size
and CC None
RIMSN NNP None
in IN None
37 CD Size
. . None
distal JJ None
femoral JJ None
fractures NNS None
. . None
-DOCSTART- -X- N

vertebral JJ Condition
basilar JJ Condition
artery NN Condition
ischemic JJ Condition
vertigo NN Condition
] NN None
Ninety NNP Size
patients NNS None
with IN None
VBIV NNP None
were VBD None
randomly RB None
divided VBN None
into IN None
two CD None
groups NNS None
; : None
Another DT None
45 CD None
patients NNS None
( ( None
control VB None
group NN None
) ) None
-DOCSTART- -X- N

left JJ Condition
ventricular JJ Condition
hypertrophy NN Condition
patients NNS None
on IN None
continuous JJ None
ambulatory JJ None
peritoneal JJ None
dialysis NN None
( ( None
CAPD NNP None
) ) None
24 CD Size
CAPD NNP None
patients NNS None
with IN None
LVH NNP None
[ NNP None
left VBD None
ventricular JJ None
mass NN None
index NN None
( ( None
LVMi NNP None
) ) None
> VBD None
110 CD None
g/m2 NN None
for IN None
women NNS Sex
and CC Sex
LVMi NNP Sex
> NNP Sex
137 CD Sex
g/m2 NN Sex
for IN Sex
men NNS Sex
] NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
localized JJ Condition
prostate NN Condition
cancer NN Condition
: : None
From IN None
December NNP None
1997 CD None
through IN None
February NNP None
2003 CD None
, , None
244 CD Size
men NNS Size
with IN None
newly RB None
diagnosed VBN None
localized JJ Condition
prostate NN Condition
cancer NN Condition
-DOCSTART- -X- N

smokers NNS None
with IN None
schizophrenia NN Condition
. . None
Schizophrenia NNP Condition
( ( None
SZ NNP Condition
) ) None
normal JJ Condition
control NN Condition
smokers NNS Condition
( ( None
NC NNP None
) ) None
Twenty-four CD Size
NC NNP Condition
smokers NNS None
and CC None
20 CD Size
smokers NNS None
with IN None
SZ NNP Condition
matched VBD None
on IN None
nicotine JJ None
addiction NN None
severity NN None
smokers NNS None
with IN None
SZ NNP Condition
NC NNP None
smokers NNS None
-DOCSTART- -X- N

autistic JJ None
children NNS None
and CC None
adolescents NNS None
. . None
autistic JJ None
children NNS None
and CC None
adolescents VBZ None
10 CD None
autistic JJ None
subjects NNS None
10 CD None
autistic JJ None
subjects NNS None
20 CD None
subjects NNS None
autistic JJ None
children NNS None
. . None
-DOCSTART- -X- N

components NNS None
in IN None
patients NNS None
aged VBN None
70 CD None
years NNS None
and CC None
younger JJR None
with IN None
osteoarthritis NN None
. . None
22 CD None
patients NNS None
per IN None
group NN None
. . None
All DT None
patients NNS None
-DOCSTART- -X- N

radiation-induced JJ None
skin NN None
disease NN None
Subjects NNPS None
who WP None
were VBD None
undergoing VBG None
a DT None
planned JJ None
course NN None
of IN None
radiation NN None
therapy NN None
after IN None
breast-conserving JJ None
surgery NN None
-DOCSTART- -X- N

Helicobacter NNP Condition
pylori JJ Condition
infection NN Condition
in IN None
India NNP None
. . None
at IN None
Lokmanya NNP None
Tilak NNP None
Municipal NNP None
General NNP None
Hospital NNP None
, , None
Mumbai NNP None
. . None
Two CD None
hundred CD None
and CC None
thirty-one JJ None
patients NNS None
with IN None
dyspepsia NNS None
-DOCSTART- -X- N

cervical JJ None
intraepithelial JJ None
neoplasia NN None
grade VBD None
3 CD None
. . None
cervical JJ None
intraepithelial JJ None
neoplasia NN None
grade VBD None
3 CD None
( ( None
CIN3 NNP None
) ) None
, , None
cervical JJ None
precancer NN None
. . None
women NNS Sex
with IN None
equivocal JJ Condition
( ( Condition
ASCUS NNP Condition
) ) Condition
or CC Condition
mildly RB Condition
abnormal JJ Condition
( ( Condition
LSIL NNP Condition
) ) Condition
Pap NNP Condition
tests NNS Condition
. . None
608 CD Size
women NNS Sex
had VBD None
a DT None
histopathologic JJ None
diagnosis NN None
of IN None
CIN3 NNP None
and CC None
PCR-based JJ None
HPV NNP None
genotyping VBG None
results NNS None
on IN None
cervical JJ None
specimens NNS None
. . None
608 CD Size
women NNS Sex
diagnosed VBN None
with IN None
CIN3 NNP Condition
-DOCSTART- -X- N

rural JJ Condition
family NN Condition
medicine NN None
: : None
December NNP None
2008 CD None
and CC None
April NNP None
2011 CD None
to TO None
improve VB None
CRC NNP None
screening VBG None
in IN None
16 CD None
rural JJ None
family NN None
physician NN None
offices NNS None
. . None
Subjects NNS Condition
due JJ None
for IN None
CRC NNP Condition
screening VBG Condition
This DT None
study NN None
enrolled VBD None
743 CD Size
patients NNS None
. . None
-DOCSTART- -X- N

untreated JJ Condition
irreversible JJ Condition
pulpitis NN Condition
. . Condition
untreated JJ None
teeth NNS None
diagnosed VBN None
with IN None
irreversible JJ None
pulpitis NN None
. . None
Forty NNP Size
emergency NN None
patients NNS None
participated VBD None
, , None
and CC None
each DT None
had VBD None
a DT None
clinical JJ None
diagnosis NN None
of IN None
an DT None
irreversible JJ None
pulpitis NN None
. . None
-DOCSTART- -X- N

Between NNP None
December NNP None
1997 CD None
and CC None
November NNP None
1999 CD None
, , None
57 CD None
consecutive JJ None
eligible JJ None
patients NNS None
with IN None
surgical JJ None
adrenal JJ None
disease NN None
Study NNP None
exclusion NN None
criteria NNS None
were VBD None
patient JJ None
age NN None
greater JJR None
than IN None
80 CD None
years NNS None
, , None
body NN None
mass NN None
index NN None
greater JJR None
than IN None
40 CD None
, , None
bilateral JJ None
adrenalectomy NN None
and CC None
significant JJ None
prior JJ None
abdominal JJ None
surgery NN None
in IN None
the DT None
quadrant NN None
of IN None
interest NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
persistent JJ Condition
atrial JJ Condition
fibrillation NN Condition
: : None
AF NNP Condition
patients NNS None
with IN None
effective JJ None
rhythm NNS None
control NN None
patients NNS None
treated VBN None
with IN None
rate NN None
control NN None
. . None
266 CD Size
AF NNP None
patients NNS None
randomized VBD None
to TO None
rhythm VB None
control NN None
in IN None
the DT None
RACE NNP None
study NN None
, , None
49 CD Size
patients NNS None
turned VBD None
to TO None
long-term JJ None
sinus NN None
rhythm NN None
and CC None
were VBD None
continuously RB None
treated VBN None
with IN None
oral JJ None
anticoagulation NN None
. . None
256 CD Size
rate-control JJ None
patients NNS None
of IN None
RACE NNP None
patients NNS None
who WP None
remained VBD None
on IN None
warfarin NN None
-DOCSTART- -X- N

110 CD None
duodenal JJ None
ulcer NN None
patients NNS None
-DOCSTART- -X- N

healthy JJ None
unvaccinated JJ None
individuals NNS None
. . None
healthy JJ None
unvaccinated JJ None
individuals NNS None
. . None
healthy JJ None
unvaccinated JJ None
individuals NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
. . None
patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
( ( Condition
COPD NNP Condition
) ) Condition
. . None
patients NNS None
with IN None
COPD NNP Condition
. . None
204 CD Size
patients NNS None
patients NNS None
with IN None
COPD NNP Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
limb JJ None
ischaemia NN None
patients NNS None
with IN None
ischaemic JJ None
limbs NNS None
because IN None
of IN None
peripheral JJ None
arterial JJ None
disease NN None
. . None
25 CD None
patients NNS None
( ( None
group NN None
A DT None
) ) None
with IN None
unilateral JJ None
ischaemia NN None
of IN None
the DT None
leg NN None
22 CD None
patients NNS None
( ( None
group NN None
B NNP None
) ) None
with IN None
bilateral JJ None
leg NN None
ischaemia NN None
Two CD None
patients NNS None
were VBD None
excluded VBN None
from IN None
group NN None
B NNP None
after IN None
randomisation NN None
. . None
group NN None
B NNP None
patients NNS None
group NN None
A DT None
patients NNS None
. . None
Two CD None
patients NNS None
-DOCSTART- -X- N

caries NNS Condition
deep JJ Condition
caries NNS Condition
lesions NNS Condition
Inclusion NN None
criteria NNS None
were VBD None
as IN None
follows VBZ None
: : None
patients NNS None
with IN None
permanent JJ None
molars NNS None
presenting VBG None
deep JJ None
caries NNS None
lesions NNS None
( ( None
lesion NN None
affecting VBG None
? . None
1/2 CD None
of IN None
the DT None
dentin NN None
on IN None
radiographic JJ None
examination NN None
) ) None
, , None
positive JJ None
response NN None
to TO None
a DT None
cold JJ None
test NN None
, , None
absence NN None
of IN None
spontaneous JJ None
pain NN None
, , None
negative JJ None
sensitivity NN None
to TO None
percussion NN None
, , None
and CC None
absence NN None
of IN None
periapical JJ None
lesions NNS None
( ( None
radiographic JJ None
examination NN None
) ) None
. . None
baseline NN None
, , None
299 CD None
treatments NNS None
were VBD None
executed VBN None
: : None
PCR NNP None
147 CD None
. . None
period NN None
, , None
213 CD None
teeth NNS None
had VBD None
been VBN None
evaluated VBN None
. . None
-DOCSTART- -X- N

acute NN None
severe JJ None
asthma NN None
not RB None
responding VBG None
to TO None
conventional JJ None
therapy NN None
. . None
children NNS None
with IN None
acute NN None
severe JJ None
asthma NN None
not RB None
responding VBG None
to TO None
conventional JJ None
therapy NN None
. . None
Pediatric NNP None
emergency NN None
service NN None
of IN None
a DT None
large JJ None
teaching NN None
hospital NN None
. . None
47 CD None
children NNS None
aged VBN None
between IN None
1-12 CD None
years NNS None
with IN None
acute NN None
severe JJ None
asthma NN None
showing VBG None
inadequate JJ None
or CC None
poor JJ None
response NN None
to TO None
3 CD None
doses NNS None
of IN None
nebulized JJ None
salbutamol NN None
given VBN None
at IN None
an DT None
interval NN None
of IN None
20 CD None
min NNS None
each DT None
. . None
patients NNS None
not RB None
responding VBG None
to TO None
conventional JJ None
therapy NN None
alone RB None
. . None
-DOCSTART- -X- N

100 CD None
patients NNS None
. . None
patients NNS None
with IN None
a DT None
laryngoscope NN None
. . None
-DOCSTART- -X- N

psychiatric JJ Condition
inpatient JJ None
treatment NN None
: : None
patients NNS None
who WP Condition
receive VBP Condition
psychiatric JJ Condition
treatment NN Condition
. . None
patients NNS None
who WP None
had VBD None
no DT Condition
pre-discharge JJ Condition
contact NN Condition
with IN Condition
outpatient NN Condition
services NNS Condition
discharged VBD None
patients NNS None
who WP None
are VBP None
not RB Condition
well RB Condition
linked VBN Condition
to TO Condition
their PRP$ Condition
outpatient NN Condition
care NN Condition
networks NNS Condition
Approximately RB None
160 CD Size
patients NNS None
are VBP None
recruited VBN None
in IN None
two CD None
care NN None
units NNS None
at IN None
Psychiatrie-Zentrum NNP None
Hard NNP None
Embrach NNP None
and CC None
two CD None
care NN None
units NNS None
at IN None
Klinik NNP None
Schlosstal NNP None
Winterthur NNP None
. . None
-DOCSTART- -X- N

junior JJ Age
high JJ Age
school NN Age
girls NNS Sex
' POS None
volleyball NN None
performance NN None
. . None
72 CD Size
seventh-grade JJ Age
girls NNS Sex
' POS None
-DOCSTART- -X- N

knee NN Condition
arthroplasty NN Condition
: : None
240 CD Size
patients NNS Size
. . None
five CD None
regimens NNS None
( ( None
four CD None
intravenous NN None
, , None
one CD None
local JJ None
; : None
40 CD None
patients NNS None
each DT None
) ) None
with IN None
a DT None
control NN None
group NN None
-DOCSTART- -X- N

ruptured JJ Condition
cerebral JJ Condition
aneurysms NNS Condition
. . None
acute NN Condition
( ( Condition
< JJ Condition
72 CD Condition
hours NNS Condition
) ) Condition
aneurysmal VBP Condition
subarachnoid JJ Condition
hemorrhage NN Condition
( ( Condition
SAH NNP Condition
) ) Condition
. . None
One CD Size
hundred VBD Size
nine CD Size
consecutive JJ Condition
patients NNS Condition
were VBD None
randomly RB Condition
assigned VBN Condition
One CD None
year NN None
postoperatively RB None
, , None
43/41 CD None
( ( None
surgical/endovascular JJ None
) ) None
patients NNS None
-DOCSTART- -X- N

patients NNS None
having VBG None
coronary JJ None
stent JJ None
implantation NN None
treated VBN None
with IN None
prasugrel NN None
. . None
patients NNS None
with IN None
acute JJ None
coronary JJ None
syndromes NNS None
undergoing VBG None
percutaneous JJ None
coronary JJ None
intervention NN None
. . None
total JJ None
298 CD None
consecutive JJ None
patients NNS None
68 CD None
? . None
10 CD None
years NNS None
old JJ None
( ( None
31 CD None
% NN None
> JJ None
75 CD None
years NNS None
old JJ None
) ) None
underwent JJ None
stent JJ None
implantation NN None
and CC None
received VBD None
prasugrel JJ None
therapy NN None
. . None
Patients NNS None
?75 CD None
years NNS None
old JJ None
and CC None
with IN None
body NN None
weight JJ None
?60 NNP None
kg NN None
received VBD None
-DOCSTART- -X- N

after IN Condition
Roux-en-Y NNP Condition
gastric JJ Condition
bypass NN Condition
surgery NN Condition
. . Condition
12 CD Condition
healthy JJ Condition
volunteers NNS Condition
who WP Condition
underwent VBP Condition
gastric JJ Condition
bypass NN Condition
surgery NN Condition
. . Condition
in IN None
healthy JJ None
volunteers NNS None
who WP None
underwent VBP None
gastric JJ None
bypass NN None
surgery NN None
. . None
after IN None
gastric JJ None
bypass NN None
. . None
-DOCSTART- -X- N

humans NNS None
. . None
Sixty-one CD Size
healthy JJ None
adults NNS Age
consumed VBD None
each DT None
of IN None
3 CD None
diets NNS None
for IN None
3 CD None
wk NN None
-DOCSTART- -X- N

central JJ None
precocious JJ None
puberty NN None
. . None
central JJ None
precocious JJ None
puberty NN None
( ( None
CPP NNP None
) ) None
. . None
CPP NNP None
in IN None
children NNS None
. . None
Twenty-two JJ None
U.S. NNP None
medical JJ None
centers NNS None
( ( None
including VBG None
Puerto NNP None
Rico NNP None
) ) None
participated VBD None
. . None
Children NNP None
diagnosed VBD None
with IN None
CPP NNP None
( ( None
n JJ None
= NNP None
84 CD None
) ) None
, , None
who WP None
were VBD None
either CC None
treatment NN None
naive JJ None
or CC None
previously RB None
treated VBN None
with IN None
GnRHa NNP None
, , None
were VBD None
recruited VBN None
. . None
Chronological JJ None
age NN None
at IN None
onset NN None
of IN None
pubertal JJ None
signs NNS None
was VBD None
less JJR None
than IN None
8 CD None
yr NN None
in IN None
girls NNS None
and CC None
less JJR None
than IN None
9 CD None
yr NN None
in IN None
boys NNS None
, , None
and CC None
bone NN None
age NN None
was VBD None
advanced VBN None
over IN None
chronological JJ None
age NN None
at IN None
least JJS None
1 CD None
yr NN None
. . None
-DOCSTART- -X- N

Patients NNS None
with IN None
ASA NNP Condition
I PRP Condition
or CC Condition
II NNP Condition
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
All DT None
patients NNS None
were VBD None
scheduled VBN None
for IN None
varicose JJ None
vein NN None
stripping VBG None
. . None
Male NNP Age
and CC None
female JJ Age
patients NNS None
aged VBN None
18-70 JJ Age
years NNS None
and CC None
weighing VBG None
50-100 JJ None
kg NNS None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
gastric JJ None
ulcer NN None
. . None
Patients NNS None
with IN None
benign JJ None
gastric JJ None
ulcer NN None
Fifty NNP None
two CD None
patients NNS None
entered VBD None
the DT None
trial NN None
, , None
and CC None
12 CD None
were VBD None
withdrawn VBN None
. . None
peptic JJ None
ulcer NN None
. . None
-DOCSTART- -X- N

multiple-dose JJ Condition
bioequivalence NN Condition
studies NNS Condition
-DOCSTART- -X- N

temporomandibular JJ None
joint NN None
pain NN None
Twenty NNP None
subjects NNS None
, , None
who WP None
have VBP None
TMJ NNP None
pain NN None
-DOCSTART- -X- N

1,615 CD None
angiographic JJ None
readings NNS None
in IN None
240 CD Size
patients NNS None
with IN None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
Half NNP None
of IN None
these DT None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
Parkinson NNP Condition
's POS Condition
disease NN Condition
. . None
12 CD Size
patients NNS None
with IN None
Parkinson NNP Condition
's POS Condition
disease NN Condition
and CC None
motor NN Condition
fluctuations NNS Condition
-DOCSTART- -X- N

keratosis NN Condition
pilaris NN Condition
: : None
Keratosis NNP Condition
pilaris NN Condition
METHODS NNP None
Sixteen NNP None
Korean JJ None
patients NNS None
were VBD None
treated VBN None
with IN None
FCR? NNP None
on IN None
both DT None
upper JJ None
arms NNS None
for IN None
five CD None
sessions NNS None
at IN None
2-week JJ None
intervals NNS None
. . None
Clinical JJ None
patients NNS None
with IN None
KP NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
type NN Condition
I PRP Condition
diabetes VBZ Condition
. . None
10 CD Size
adult NN Age
type NN Condition
I PRP Condition
diabetic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

Prophylactic JJ None
amnioinfusion NN None
in IN None
pregnancies NNS None
complicated VBN None
by IN None
oligohydramnios NNS None
: : None
term NN None
and CC None
post-dates NNS None
pregnancies NNS None
with IN None
decreased JJ None
amniotic JJ None
fluid NN None
volume NN None
. . None
Patients NNS None
receiving VBG None
prophylactic JJ None
amnioinfusion NN None
-DOCSTART- -X- N

patients NNS None
with IN None
cancer NN None
of IN None
the DT None
esophagus NN None
. . None
121 CD None
patients NNS None
demonstrated VBD None
a DT None
significant JJ None
advantage NN None
for IN None
survival NN None
in IN None
the DT None
patients NNS None
who WP None
received VBD None
chemotherapy NN None
and CC None
radiation NN None
therapy NN None
. . None
Seven JJ None
patients NNS None
in IN None
the DT None
radiotherapy NN None
group NN None
and CC None
25 CD None
in IN None
the DT None
combined-therapy JJ None
group NN None
-DOCSTART- -X- N

persons NNS None
with IN None
borderline JJ Condition
personality NN Condition
features NNS None
. . None
persons NNS None
with IN None
heightened JJ Condition
borderline NN Condition
personality NN Condition
( ( Condition
BP NNP Condition
) ) Condition
features VBZ None
Individuals NNS None
with IN None
high JJ Condition
levels NNS Condition
of IN None
BP NNP Condition
features NNS None
( ( None
n JJ None
= NNP None
30 CD Size
) ) None
and CC None
controls NNS None
with IN None
low JJ Condition
levels NNS Condition
of IN None
BP NNP Condition
features NNS None
( ( None
n JJ None
= NNP None
44 CD Size
) ) None
high-BP JJ Condition
individuals NNS None
low-BP JJ Condition
controls NNS None
high-BP JJ Condition
individuals NNS None
high-BP JJ Condition
individuals NNS None
-DOCSTART- -X- N

82 CD Size
patients NNS None
having VBG None
postoperative JJ Condition
epidural JJ Condition
analgesia NN Condition
-DOCSTART- -X- N

hereditary JJ Condition
androgenic JJ Condition
alopecia NN Condition
in IN None
young JJ Age
males NNS Age
. . None
young JJ None
males NNS None
with IN None
hereditary JJ None
androgenic JJ Condition
alopecia NN Condition
. . None
alopecia VBN Condition
with IN None
a DT None
mild NN Condition
to TO Condition
moderate VB Condition
perifollicular JJ Condition
inflammation NN Condition
zone NN Condition
. . None
20 CD Size
subjects NNS None
who WP None
received VBD None
two CD None
tablets NNS None
of IN None
ViviScal NNP None
once RB None
daily RB None
and CC None
20 CD Size
who WP None
received VBD None
two CD None
tablets NNS None
of IN None
fish JJ None
extract NN None
once RB None
daily JJ None
for IN None
6 CD None
months NNS None
. . None
The DT None
mean JJ None
patient NN None
age NN None
and CC None
mean JJ None
duration NN None
and CC None
severity NN None
of IN None
baldness NN None
Most JJS None
patients NNS None
had VBD None
been VBN None
treated VBN None
with IN None
long-term JJ None
topical JJ None
2 CD None
% NN None
minoxidil NN None
for IN None
1 CD None
year NN None
or CC None
more JJR None
three CD Size
patients NNS None
withdrew VBD None
from IN None
the DT None
study NN None
before IN None
the DT None
fourth JJ None
month NN None
due JJ None
to TO None
lack VB None
of IN None
therapeutic JJ None
effect NN None
. . None
-DOCSTART- -X- N

primary JJ None
biliary JJ None
cirrhosis NN None
: : None
Twenty-four JJ Size
patients NNS None
with IN None
primary JJ None
biliary JJ None
cirrhosis NN None
and CC None
17 CD None
healthy JJ None
subjects NNS None
were VBD None
studied VBN None
. . None
Primary JJ None
biliary JJ None
cirrhosis NN None
patients NNS None
primary JJ Condition
biliary JJ Condition
cirrhosis NN Condition
patients NNS None
healthy JJ None
subjects NNS None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
and CC None
irritable JJ None
behavior NN None
. . None
children NNS None
with IN None
autism NN None
and CC None
irritable JJ None
behavior NN None
. . None
Thirty-eight JJ None
children NNS None
, , None
ages VBZ None
5-17 CD None
years NNS None
with IN None
autism NN None
and CC None
severe JJ None
behavioral JJ None
disturbance NN None
This DT None
sample NN None
of IN None
38 CD None
was VBD None
a DT None
subset NN None
of IN None
101 CD None
subjects NNS None
who WP None
participated VBD None
in IN None
the DT None
clinical JJ None
trial NN None
; : None
63 CD None
were VBD None
unable JJ None
to TO None
perform VB None
the DT None
cognitive JJ None
tasks NNS None
. . None
Twenty-nine JJ None
boys NNS None
and CC None
9 CD None
girls NNS None
with IN None
autism NN None
and CC None
severe JJ None
behavioral JJ None
disturbance NN None
and CC None
a DT None
mental JJ None
age NN None
> NNP None
or=18 JJ None
months NNS None
completed VBN None
the DT None
cognitive JJ None
part NN None
of IN None
the DT None
study NN None
. . None
children NNS None
with IN None
autism NN None
-DOCSTART- -X- N

stage NN Condition
I PRP Condition
endometrial JJ Condition
cancer NN Condition
. . None
stage NN Condition
I PRP Condition
endometrial JJ Condition
cancer NN Condition
61 CD Size
patients NNS None
with IN None
clinical JJ None
stage NN Condition
I PRP Condition
endometrial JJ Condition
cancer NN Condition
Gynaecology NNP None
Oncology NNP None
Unit NNP None
at IN None
the DT None
Royal NNP None
North NNP None
Shore NNP None
of IN None
Sydney NNP None
, , None
Australia NNP None
. . None
Twenty-nine JJ Size
patients NNS None
were VBD None
treated VBN None
with IN None
laparoscopic NN Condition
assisted VBN Condition
vaginal JJ Condition
hysterectomy NN Condition
( ( None
LAVH NNP Condition
) ) None
and CC None
bilateral JJ Condition
salpingo-oophrectomy NN Condition
( ( None
BSO NNP Condition
) ) None
plus CC None
minus CC None
laparoscopic JJ Condition
pelvic JJ Condition
lymphadenectomy NN Condition
( ( None
LPLA NNP Condition
) ) None
, , None
while IN None
32 CD Size
patients NNS None
were VBD None
treated VBN None
with IN None
the DT None
traditional JJ None
laparotomy NN None
and CC None
underwent JJ None
total JJ None
abdominal JJ None
hysterectomy NN None
( ( None
TAH NNP None
) ) None
and CC None
BSO NNP None
plus CC None
minus CC None
pelvic JJ None
lymphadenectomy NN None
( ( None
PLA NNP None
) ) None
. . None
-DOCSTART- -X- N

autism NN Condition
: : None
children NNS Age
Six NNP Size
children NNS None
enrolled VBD None
children NNS Age
-DOCSTART- -X- N

older JJR None
patients NNS None
with IN None
diabetes NNS Condition
: : None
elderly JJ Age
patients NNS None
patients NNS None
with IN None
diabetes NNS Condition
. . None
elderly JJ None
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
Eleven NNP Size
thousand VBP Size
one CD Size
hundred CD Size
and CC Size
forty JJ Size
patients NNS None
aged VBN None
at IN None
least JJS None
55 CD Age
years NNS None
with IN None
type NN None
2 CD None
diabetes NNS None
( ( None
mean JJ None
66+/-6 CD Age
years NNS None
) ) None
subgroups NNS None
according VBG None
to TO None
age NN None
: : None
below IN Age
65 CD Age
, , None
65-74 JJ Age
and CC None
at IN Age
least JJS Age
75 CD Age
years NNS Age
. . None
patients NNS None
of IN None
at IN None
least JJS None
75 CD None
years NNS None
with IN None
type NN None
2 CD None
diabetes NNS None
. . None
older JJR None
patients NNS None
in IN None
this DT None
age NN None
group NN None
-DOCSTART- -X- N

severe JJ None
irritable JJ None
bowel NN None
syndrome NN None
: : None
Patients NNS None
with IN None
severe JJ None
irritable JJ None
bowel NN None
syndrome NN None
18 CD None
patients NNS None
( ( None
study VB None
I PRP None
) ) None
24 CD None
patients NNS None
( ( None
study VB None
II NNP None
) ) None
. . None
-DOCSTART- -X- N

diabetic JJ Condition
foot NN Condition
ulcers NNS Condition
: : None
diabetic JJ Condition
foot NN Condition
ulcers NNS Condition
. . None
Eighteen NNP Size
diabetic JJ Condition
patients NNS None
with IN None
foot JJ Condition
ulcers NNS Condition
were VBD None
recruited VBN None
through IN None
simple JJ None
nonprobability NN None
sampling VBG None
. . None
-DOCSTART- -X- N

Children NNP None
younger JJR None
than IN None
16 CD None
years NNS None
and CC None
experiencing VBG None
moderate JJ None
to TO None
severe VB None
blunt NN None
head JJ None
injury NN None
group NN None
. . None
One CD None
hundred VBD None
two CD None
patients NNS None
were VBD None
enrolled VBN None
, , None
with IN None
a DT None
median JJ None
age NN None
of IN None
6.1 CD None
years NNS None
. . None
Sixty-eight JJ None
percent NN None
were VBD None
boys NNS None
. . None
2 CD None
treatment NN None
groups NNS None
3 CD None
( ( None
7 CD None
% NN None
) ) None
of IN None
46 CD Size
patients NNS None
3 CD None
( ( None
5 CD None
% NN None
) ) None
of IN None
56 CD Size
patients NNS None
groups NNS None
( ( None
seizure JJ None
rate NN None
increased VBN None
by IN None
1.5 CD None
% NN None
in IN None
the DT None
phenytoin NN None
group NN None
) ) None
children NNS None
may MD None
be VB None
much RB None
-DOCSTART- -X- N

gastrointestinal JJ Condition
cancer NN Condition
: : Condition
Southeastern NNP None
Cancer NNP None
Study NNP None
Group NNP None
experience NN None
, , None
1979 CD None
to TO None
1983 CD None
. . None
gastrointestinal JJ None
cancer NN None
from IN None
1979 CD None
to TO None
1983 CD None
at IN None
30 CD None
member NN None
institutions NNS None
of IN None
the DT None
Southeastern NNP None
Cancer NNP None
Study NNP None
Group NNP None
( ( None
SECSG NNP None
) ) None
. . None
1,087 CD None
patients NNS None
. . None
America NNP None
. . None
-DOCSTART- -X- N

locally RB None
advanced JJ None
or CC None
metastatic JJ None
renal NN Condition
cell NN Condition
carcinoma NN Condition
: : None
treatment-naive JJ None
and CC None
cytokine-pretreated JJ None
patients NNS None
with IN None
advanced JJ None
renal JJ None
cell NN None
carcinoma NN None
( ( None
RCC NNP Condition
) ) None
. . None
Adult NNP None
patients NNS None
with IN None
measurable JJ None
, , None
locally RB None
advanced JJ None
, , None
and/or JJ None
metastatic JJ None
RCC NNP None
Of IN None
435 CD Size
patients NNS None
enrolled VBD None
, , None
233 CD Size
were VBD None
treatment NN None
naive JJ None
( ( None
54 CD None
% NN None
) ) None
and CC None
202 CD Size
were VBD None
cytokine NN None
pretreated VBN None
( ( None
46 CD None
% NN None
) ) None
. . None
treatment-naive JJ None
and CC None
cytokine-pretreated JJ None
patients NNS None
with IN None
advanced JJ None
and/or NNS None
metastatic JJ None
RCC NNP None
. . None
-DOCSTART- -X- N

many JJ None
athletes NNS None
26 CD Size
athletes NNS Size
. . None
stressed JJ Condition
athletes NNS None
-DOCSTART- -X- N

rheumatoid JJ Condition
arthritis NN Condition
. . Condition
patients NNS None
with IN None
rheumatoid JJ Condition
arthritis NN Condition
. . None
Two CD Size
hundred CD Size
and CC Size
one CD Size
functional JJ None
class NN None
I PRP None
and CC None
II NNP None
patients NNS None
with IN None
definite JJ None
or CC None
classic JJ None
rheumatoid NN Condition
arthritis NN Condition
, , None
previously RB None
untreated VBN None
with IN None
disease NN None
modifying VBG None
antirheumatic JJ None
drugs NNS None
. . None
patients NNS None
with IN None
active JJ Condition
rheumatoid NN Condition
arthritis NN Condition
. . None
-DOCSTART- -X- N

antiretroviral-na?ve JJ None
HIV-infected JJ Condition
patients NNS None
treated VBN None
with IN None
first-line JJ None
lopinavir/ritonavir NN None
monotherapy NN None
in IN None
the DT None
MONARK NNP None
trial NN None
. . None
MONotherapy NNP None
AntiRetroviral NNP None
Kaletra NNP None
( ( None
MONARK NNP None
) ) None
is VBZ None
the DT None
first JJ None
randomized JJ None
trial NN None
comparing VBG None
lopinavir/ritonavir JJ None
monotherapy NN None
to TO None
triple VB None
combination NN None
therapy NN None
with IN None
zidovudine/lamivudine NN None
and CC None
lopinavir/ritonavir NN None
in IN None
antiretroviral-na?ve JJ None
patients NNS None
. . None
136 CD None
antiretroviral-na?ve JJ None
patients NNS None
, , None
with IN None
a DT None
CD4 NNP None
cell NN None
count NN None
above IN None
100 CD None
cells/microL NN None
and CC None
a DT None
plasma NN None
HIV NNP None
RNA NNP None
below IN None
100,000 CD None
HIV-1 JJ None
RNA NNP None
copies/mL NN None
, , None
were VBD None
. . None
We PRP None
focus VBP None
here RB None
on IN None
patients NNS None
in IN None
the DT None
lopinavir/ritonavir NN None
monotherapy NN None
arm NN None
followed VBD None
to TO None
week NN None
96 CD None
. . None
The DT None
-DOCSTART- -X- N

adult NN Condition
periodontitis NN Condition
; : Condition
adult NN None
periodontitis NN None
. . None
Eighty NNP None
teeth VBZ None
in IN None
18 CD None
patients NNS None
adult NN None
periodontitis NN None
. . None
-DOCSTART- -X- N

young JJ None
autistic JJ None
children NNS None
: : None
young JJ None
autistic JJ None
children NNS None
Eleven NNP None
children NNS None
with IN None
autistic JJ None
disorder NN None
, , None
aged VBD None
3.0 CD None
to TO None
8.3 CD None
years NNS None
24 CD None
children NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
ages VBZ None
3-8 JJ None
years NNS None
. . None
Phase NNP None
1 CD None
involved VBD None
65 CD Size
children NNS Age
with IN None
ASD NNP Condition
who WP None
received VBD None
one CD None
round NN None
of IN None
DMSA NNP None
( ( None
3 CD None
days NNS None
) ) None
. . None
Participants NNS None
who WP None
had VBD None
high JJ Condition
urinary JJ Condition
excretion NN Condition
of IN Condition
toxic JJ Condition
metals NNS Condition
were VBD None
selected VBN None
to TO None
continue VB None
on IN None
to TO None
phase VB None
2 CD None
. . None
phase NN None
2 CD None
, , None
49 CD Size
participants NNS None
were VBD None
randomly RB None
assigned VBN None
in IN None
a DT None
double-blind JJ None
design NN None
to TO None
receive VB None
an DT None
additional JJ None
6 CD None
rounds NNS None
of IN None
either DT None
DMSA NNP None
or CC None
placebo NN None
. . None
children NNS Age
with IN None
ASD NNP Condition
who WP None
have VBP None
high JJ Condition
urinary JJ Condition
excretion NN Condition
of IN Condition
toxic JJ Condition
metals NNS Condition
-DOCSTART- -X- N

social JJ Condition
phobia NN Condition
: : None
patients NNS None
and CC None
controls NNS None
A DT None
total NN None
of IN None
32 CD Size
social JJ None
phobics NNS None
and CC None
32 CD Size
controls NNS None
Social NNP None
phobics NNS None
social JJ None
phobics NNS None
-DOCSTART- -X- N

humans NNS None
with IN None
experimental JJ None
gingivitis NN None
. . None
159 CD None
periodontally RB None
healthy JJ None
subjects NNS None
abstained VBN None
from IN None
oral JJ None
hygiene NN None
procedures NNS None
plaque NN None
, , None
gingivitis NN None
and CC None
gingival NN None
bleeding NN None
in IN None
the DT None
human JJ None
experimental JJ None
gingivitis NN None
model NN None
. . None
-DOCSTART- -X- N

clomiphene NN None
resistant JJ None
polycystic JJ Condition
ovary JJ Condition
syndrome NN Condition
clomiphene NN Condition
resistant JJ Condition
infertile JJ Condition
women NNS Sex
with IN None
polycystic JJ Condition
ovary JJ Condition
syndrome NN Condition
( ( None
PCOS NNP Condition
) ) None
in IN None
an DT None
infertility NN None
clinic NN None
. . None
clomiphene NN Condition
resistant JJ Condition
women NNS Sex
with IN None
PCOS NNP Condition
. . None
Twelve NNP Size
women NNS Sex
completed VBD None
the DT None
metformin NN None
arm NN None
and CC None
14 CD Size
the DT None
placebo NN None
arm NN None
. . None
clomiphene VB Condition
resistant JJ Condition
infertile JJ Condition
women NNS Sex
with IN None
PCOS NNP Condition
-DOCSTART- -X- N

nephroureterectomy NN None
: : None
nephroureterectomy NN None
for IN None
upper JJ Condition
urinary JJ Condition
tract NN Condition
urothelial JJ Condition
carcinoma NN Condition
. . None
data NN None
from IN None
the DT None
Pirarubicin NNP None
Monotherapy NNP None
Study NNP None
Group NNP None
trial NN None
36 CD Size
patients NNS None
in IN None
the DT None
control NN None
group NN None
, , None
14 CD Size
with IN None
positive JJ None
urine JJ None
cytology NN None
22 CD Size
patients NNS None
with IN None
negative JJ None
cytology NN None
( ( None
P NNP None
= NNP None
0.004 CD None
) ) None
. . None
72 CD Size
patients NNS None
in IN None
the DT None
Pirarubicin NNP None
Monotherapy NNP None
Study NNP None
Group NNP None
trial NN None
Among IN None
the DT None
31 CD None
patients NNS None
, , None
17 CD None
patients NNS None
who WP None
received VBD None
pirarubicin JJ None
instillation NN None
14 CD None
patients NNS None
who WP None
received VBD None
control NN None
treatment NN None
-DOCSTART- -X- N

acute JJ Condition
myocardial JJ Condition
infarction NN Condition
: : None
28 CD None
patients NNS None
presenting VBG None
within IN None
12 CD None
hours NNS None
of IN None
the DT None
onset NN None
of IN None
symptoms NNS None
of IN None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
were VBD None
prospectively RB None
randomized VBN None
. . None
14 CD None
patients NNS None
were VBD None
treated VBN None
with IN None
emergency NN None
angioplasty NN None
and CC None
14 CD None
patients NNS None
patients NNS None
with IN None
acute JJ None
myocardial JJ None
infarction NN None
acute JJ None
myocardial JJ None
infarction NN None
. . None
-DOCSTART- -X- N

A DT None
random JJ None
sample NN None
of IN None
800 CD None
employees NNS None
of IN None
a DT None
steel NN None
manufacturing VBG None
company NN None
All DT None
621 CD None
subjects NNS None
participating VBG None
in IN None
the DT None
research NN None
were VBD None
also RB None
tested VBN None
by IN None
urinalysis NN None
. . None
-DOCSTART- -X- N

youth NN Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
16 CD Size
male NN Sex
youth NN Age
aged VBD Age
12 CD Age
to TO Age
19 CD Age
who WP None
were VBD None
diagnosed VBN None
with IN None
Autistic NNP Condition
or CC Condition
Asperger NNP Condition
's POS Condition
Disorder NNP Condition
. . None
Participants NNS None
younger JJR Age
participants NNS None
aged VBD None
12 CD Age
to TO Age
15 CD Age
young JJ None
people NNS None
diagnosed VBN None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . Condition
young JJ None
people NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
and CC None
without IN None
TIPS NNP None
undergoing VBG None
glutamine JJ None
challenge NN None
: : None
cirrhotic JJ None
patients NNS None
awaiting VBG None
liver JJ None
transplantation NN None
patients NNS Condition
with IN Condition
hepatic JJ Condition
encephalopathy NN Condition
. . Condition
healthy JJ None
patients NNS None
with IN None
cirrhosis NN None
and CC None
no DT None
evidence NN None
of IN None
clinical JJ None
encephalopathy NN None
Eight NNP None
cirrhotics NNS None
( ( None
Child NNP None
's POS None
B NNP None
or CC None
C NNP None
) ) None
without IN None
transjugular JJ None
intrahepatic JJ None
portosystemic JJ None
shunts NNS None
( ( None
TIPS NNP None
) ) None
and CC None
seven CD None
with IN None
TIPS NNP None
patients NNS None
with IN None
cirrhosis NN None
without IN None
TIPS NNP None
-DOCSTART- -X- N

Post-laparoscopic NNP Condition
cholecystectomy NN Condition
pain NN Condition
: : None
Postoperative NNP Condition
pain NN Condition
after IN Condition
laparoscopic NN Condition
cholecystectomy NN Condition
( ( Condition
LC NNP Condition
) ) Condition
Two CD Size
hundred VBD Size
patients NNS None
with IN None
similar JJ None
demographics NNS None
undergoing JJ None
elective JJ None
LC NNP None
four CD None
groups NNS None
of IN None
50 CD Size
patients NNS None
each DT None
patients NNS None
parietal JJ Condition
( ( Condition
somatic JJ Condition
) ) Condition
abdominal JJ Condition
pain NN Condition
. . None
Patients NNS None
in IN None
each DT None
group NN None
all DT None
patients NNS None
-DOCSTART- -X- N

stage NN Condition
II NNP Condition
and CC Condition
stage NN Condition
III NNP Condition
human JJ Condition
colon NN Condition
cancer NN Condition
: : None
254 CD Size
patients NNS None
with IN None
colon NN None
cancer NN None
were VBD None
randomly RB None
assigned VBN None
postoperative JJ None
ASI NNP None
or CC None
no DT None
adjuvant JJ None
treatment NN None
. . None
patients NNS None
with IN None
stage NN None
II NNP None
disease NN None
stage NN None
II NNP None
colon NN None
cancer NN None
. . None
-DOCSTART- -X- N

Finnish JJ None
children NNS None
infants NNS None
at IN None
ages NNS None
2 CD None
, , None
3 CD None
, , None
and CC None
5 CD None
months NNS None
. . None
2398 CD Size
children NNS None
were VBD None
enrolled VBN None
young JJ None
children NNS None
. . None
-DOCSTART- -X- N

multiple JJ None
myeloma NN None
: : None
patients NNS None
entered VBN None
on IN None
the DT None
Eastern NNP Condition
Cooperative NNP Condition
Oncology NNP Condition
Group NNP Condition
phase VBD Condition
III NNP Condition
E9486 NNP Condition
clinical JJ Condition
trial NN Condition
. . None
myeloma NN Condition
patients NNS Condition
CD19+ NNP None
B NNP None
cells NNS None
by IN None
flow JJ None
cytometry NN None
in IN None
previously RB None
untreated JJ None
newly RB None
diagnosed VBN None
myeloma NN None
patients NNS None
in IN None
Eastern NNP None
Cooperative NNP None
Oncology NNP None
Group NNP None
( ( None
ECOG NNP None
) ) None
phase NN None
III NNP None
trial NN None
E9486 NNP None
. . None
There EX None
were VBD None
628 CD Size
patients NNS Size
who WP None
were VBD None
eligible JJ None
for IN None
the DT None
clinical JJ None
protocol NN None
E9486 NNP None
, , None
but CC None
of IN None
these DT None
521 CD Size
were VBD None
also RB None
entered VBN None
on IN None
the DT None
companion NN None
laboratory NN None
study NN None
( ( None
E9487 NNP None
) ) None
and CC None
had VBD None
CD19 NNP None
data NNS None
. . None
patients NNS None
patients NNS None
. . None
-DOCSTART- -X- N

treatment NN None
on IN None
prolactin NN None
levels NNS None
in IN None
children NNS None
with IN None
autism NN None
. . None
children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
. . None
Patients NNPS None
with IN None
autism NN None
( ( None
N NNP None
= NNP None
101 CD None
, , None
5-17 CD None
years NNS None
of IN None
age NN None
) ) None
63 CD None
then RB None
took VBD None
part NN None
in IN None
a DT None
4-month JJ None
open-label JJ None
follow-up JJ None
phase NN None
. . None
children NNS None
with IN None
autism NN None
. . None
children NNS None
and CC None
adolescents NNS None
-DOCSTART- -X- N

a DT None
randomized JJ None
, , None
double-blind JJ None
study NN None
design NN None
, , None
group NN None
1 CD None
( ( None
12 CD Size
patients NNS None
; : None
7 CD Size
males NNS None
, , None
5 CD Size
females NNS None
) ) None
with IN None
serum JJ Condition
LDL-C JJ Condition
levels NNS Condition
higher JJR None
than IN None
170 CD None
mg/dL NN None
and CC None
without IN None
any DT None
other JJ None
risk NN None
factor NN None
for IN None
atherosclerosis NN Condition
received VBD None
three CD None
months NNS None
of IN None
20 CD None
mg/day JJ None
atorvastatin FW None
treatment NN None
while IN None
group NN None
11 CD None
( ( None
8 CD Size
males NNS None
, , None
4 CD Size
females NNS None
) ) None
with IN None
the DT None
same JJ None
characteristics NNS None
received VBD None
80 CD None
mg/day NN None
. . None
-DOCSTART- -X- N

TKA NNP Condition
we PRP None
enrolled VBD None
151 CD Size
patients NNS None
undergoing JJ None
TKA NNP Condition
. . None
Group NNP None
A NNP None
( ( None
n=76 JJ Size
patients NNS None
) ) None
Control NNP None
Group NNP None
B NNP None
( ( None
n=75 JJ Size
patients NNS None
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
patellar JJ Condition
instability NN Condition
. . None
patients NNS None
with IN None
patellofemoral JJ Condition
malalignment NN Condition
and CC Condition
instability NN Condition
. . None
All DT None
patients NNS None
with IN None
patellar JJ Condition
instability NN Condition
who WP None
underwent VBD None
both DT None
CT NNP None
and CC None
MRI NNP None
of IN None
the DT None
knee NN None
from IN None
2003 CD None
to TO None
2011 CD None
were VBD None
included VBN None
( ( None
n JJ None
= $ None
59 CD None
knees NNS None
in IN None
54 CD Size
patients NNS None
) ) None
. . None
-DOCSTART- -X- N

Korean JJ None
patients NNS None
with IN None
mild JJ Condition
to TO Condition
moderate VB Condition
hypertension NN Condition
. . None
Korea NNP None
. . None
Korean JJ None
patients NNS None
with IN None
mild JJ Condition
to TO Condition
moderate VB Condition
hypertension NN Condition
. . None
Eligible JJ None
patients NNS None
were VBD None
Korean NNP None
, , None
aged VBD None
18 CD Age
to TO Age
75 CD Age
years NNS None
, , None
had VBD None
hypertension NN Condition
, , None
and CC None
were VBD None
either RB None
taking VBG None
antihypertensive JJ None
medications NNS None
or CC None
had VBD None
a DT None
documented VBN None
sitting VBG None
diastolic JJ None
blood NN None
pressure NN None
of IN None
90 CD None
to TO None
109 CD None
mm NN None
Hg NNP None
. . None
One CD Size
hundred VBD Size
eighteen JJ Size
patients NNS None
were VBD None
enrolled VBN None
. . None
-DOCSTART- -X- N

This DT None
multicenter NN None
enrolled VBD None
1,214 CD None
healthy JJ None
, , None
nonsmoking JJ None
outpatients NNS None
aged VBD None
15 CD None
to TO None
85 CD None
years NNS None
with IN None
spring NN None
allergic NN None
rhinitis NN None
, , None
positive JJ None
skin NN None
test NN None
to TO None
a DT None
spring NN None
allergen NN None
, , None
and CC None
predefined VBD None
daytime JJ None
nasal NN None
symptoms NNS None
. . None
patients NNS None
with IN None
seasonal JJ None
allergic JJ None
rhinitis NN None
. . None
-DOCSTART- -X- N

primary JJ None
, , None
nonmetastatic JJ None
Ewing NNP None
's POS None
sarcoma NN None
of IN None
bone NN None
: : None
264 CD None
children NNS None
and CC None
adults NNS None
with IN None
previously RB None
untreated VBN None
localized JJ None
Ewing NNP None
's POS None
sarcoma NN None
of IN None
bone NN None
between IN None
1973 CD None
and CC None
1978 CD None
by IN None
83 CD None
institutions NNS None
of IN None
three CD None
national JJ None
study NN None
groups NNS None
: : None
Children NNP None
's POS None
Cancer NNP None
Study NNP None
Group NNP None
, , None
Southwest NNP None
Oncology NNP None
Group NNP None
, , None
and CC None
Cancer NNP None
and CC None
Leukemia NNP None
Group NNP None
B NNP None
. . None
-DOCSTART- -X- N

chronic JJ Condition
idiopathic JJ Condition
urticaria NNS Condition
: : None
patients NNS None
with IN None
chronic JJ Condition
idiopathic JJ Condition
urticaria NN Condition
( ( Condition
CIU NNP Condition
) ) Condition
. . None
247 CD Size
patients NNS None
with IN None
CIU NNP Condition
patients NNS None
who WP None
had VBD None
this DT None
symptom NN None
before IN None
treatment NN None
. . None
-DOCSTART- -X- N

A NNP None
total NN None
of IN None
465 CD Size
patients NNS None
with IN None
primary JJ None
and CC None
multiple JJ None
or CC None
recurrent NN None
, , None
stages VBZ None
Ta NNP None
and CC None
T1 NNP None
superficial JJ Condition
bladder NN Condition
cancer NN Condition
-DOCSTART- -X- N

35 CD Condition
women NNS Condition
with IN Condition
axillary JJ Condition
hair NN Condition
-DOCSTART- -X- N

cesarean JJ None
section NN None
] NNP None
one CD None
hundred CD None
and CC None
eighty VB None
singleton NN None
primiparas IN None
undergoing VBG None
elective JJ None
cesarean JJ None
section NN None
, , None
in IN None
Qingdao NNP None
Municipal NNP None
Hospital NNP None
, , None
and CC None
Qingdao NNP None
Hiser NNP None
Medical NNP None
Center NNP None
, , None
from IN None
November NNP None
2011 CD None
to TO None
March NNP None
2012 CD None
, , None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

primary JJ None
care NN None
patients NNS None
with IN None
untreated JJ Condition
anxiety NN Condition
patients NNS None
with IN None
previously RB None
undetected VBN Condition
anxiety NN Condition
573 CD Size
patients NNS None
who WP None
had VBD None
unrecognized VBN None
and CC None
untreated JJ Condition
anxiety NN Condition
identified VBN None
from IN None
the DT None
approximately RB None
8,000 CD Size
patients NNS None
who WP None
completed VBD None
the DT None
waiting VBG None
room NN None
screening NN None
questionnaire NN None
-DOCSTART- -X- N

[ NNS Condition
Localised VBN Condition
prostate JJ Condition
cancer NN Condition
: : Condition
carcinoma NN Condition
of IN None
the DT None
elderly JJ None
man NN None
-DOCSTART- -X- N

Huntington NNP Condition
's POS Condition
disease NN Condition
: : None
patients NNS None
with IN None
Huntington NNP None
's POS None
disease NN None
. . None
Thirty NNP Size
three CD Size
patients NNS None
with IN None
Huntington NNP None
's POS None
disease NN None
participated VBD None
Patients NNS None
and CC None
their PRP$ None
partners NNS None
patients NNS None
with IN None
Huntington NNP None
's POS None
disease NN None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
early JJ Condition
rheumatoid NN Condition
arthritis NN Condition
: : Condition
rheumatoid NN Condition
arthritis NN Condition
( ( Condition
RA NNP Condition
) ) Condition
patients NNS Condition
with IN Condition
early JJ Condition
RA NNP Condition
initially RB Condition
treated VBD Condition
with IN Condition
a DT Condition
combination NN Condition
of IN Condition
three CD Condition
disease-modifying JJ Condition
antirheumatic JJ Condition
drugs NNS Condition
( ( Condition
DMARDs NNP Condition
) ) Condition
or CC Condition
a DT Condition
single JJ Condition
DMARD NNP Condition
. . Condition
199 CD None
patients NNS None
with IN None
early JJ None
active JJ None
RA NNP None
RA JJ Size
patients NNS Size
. . Size
-DOCSTART- -X- N

management NN None
of IN None
unresectable JJ None
malignant JJ None
mesothelioma NN None
Malignant NNP None
mesothelioma NN None
patients NNS None
with IN None
unresectable JJ None
disease NN None
. . None
mesothelioma NN None
. . None
-DOCSTART- -X- N

HIV-positive JJ Condition
homosexual JJ None
men NNS Sex
: : None
mildly RB None
symptomatic JJ None
HIV-positive JJ Condition
homosexual JJ Condition
and CC None
bisexual JJ Condition
men NNS Sex
. . None
Participants NNS None
were VBD None
recruited VBN None
largely RB None
during IN None
the DT None
era NN None
prior RB None
to TO None
highly RB None
active JJ None
antiretroviral JJ None
therapy NN None
( ( None
HAART NNP None
; : None
1992-1997 JJ None
) ) None
. . None
Men NNPS None
a DT None
psychoeducational JJ None
seminar NN None
group NN None
( ( None
n JJ None
= NNP None
46 CD Size
) ) None
. . None
Men NNP None
in IN None
the DT None
CBSM NNP None
group NN None
HIV-positive JJ None
homosexual JJ None
and CC None
bisexual JJ None
men NNS None
. . None
-DOCSTART- -X- N

clinical JJ None
responses NNS None
in IN None
man NN Sex
. . None
177 CD Size
volunteers NNS None
. . None
-DOCSTART- -X- N

humans NNS Condition
. . None
healthy JJ None
young JJ None
male NN None
volunteers NNS None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
Kawasaki NNP Condition
disease NN None
. . None
acquired VBN None
heart NN Condition
disease NN None
in IN None
America NNP None
's POS None
children NNS None
. . None
infected JJ None
children NNS None
. . None
children NNS None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
. . None
children NNS None
with IN None
autism NN None
, , None
and CC None
2 CD None
) ) None
to TO None
assess VB None
the DT None
feasibility NN None
of IN None
home NN None
recordings NNS None
using VBG None
time-lapse JJ None
videosomnography NN None
in IN None
children NNS None
with IN None
autism NN None
. . None
Participants NNS None
were VBD None
a DT None
subset NN None
of IN None
subjects NNS None
from IN None
two CD None
double JJ None
blind NN None
, , None
placebo-control NN None
, , None
multi-center JJ None
clinical JJ None
trials NNS None
. . None
enrolled VBD None
some DT None
of IN None
the DT None
children NNS None
from IN None
each DT None
of IN None
the DT None
two CD None
trials NNS None
-DOCSTART- -X- N

after IN Condition
nose JJ Condition
surgery NN Condition
61 CD None
inpatients NNS None
with IN None
the DT None
diagnosis NN None
Rhinitis NNP None
following VBG None
nasal JJ None
operation NN None
patients NNS None
following VBG None
nasal JJ None
operations NNS None
rhinitis NN None
following VBG None
nasal JJ None
operation NN None
-DOCSTART- -X- N

adult NN None
normotensive JJ None
or CC None
hypertensive JJ None
hydrocephalus NN None
. . None
new JJ None
hydrostatic JJ None
dual-switch NN None
valve NN None
( ( None
DSV NNP None
) ) None
was VBD None
implanted VBN None
in IN None
35 CD None
adult NN None
patients NNS None
with IN None
hydrocephalus NN None
of IN None
different JJ None
etiology NN None
. . None
26 CD None
patients NNS None
suffered VBD None
from IN None
normotensive JJ None
hydrocephalus NN None
( ( None
10 CD None
idiopathic NN None
and CC None
16 CD None
symptomatic JJ None
) ) None
, , None
and CC None
9 CD None
patients NNS None
from IN None
hypertensive JJ None
hydrocephalus NN None
of IN None
various JJ None
origin NN None
. . None
21 CD None
patients NNS None
35 CD None
patients NNS None
-DOCSTART- -X- N

epileptic JJ None
women NNS None
before IN None
and CC None
during IN None
pregnancy NN None
12225 CD None
females NNS None
. . None
60 CD None
epileptic JJ None
women NNS None
with IN None
periconceptional JJ None
folic JJ None
acid NN None
-DOCSTART- -X- N

outpatient JJ None
oral JJ Condition
surgery NN Condition
. . None
16 CD Size
healthy JJ Condition
patients NNS None
requiring VBG Condition
removal NN Condition
of IN Condition
bilateral JJ Condition
symmetrically-impacted JJ Condition
mandibular JJ Condition
third JJ Condition
molars NNS Condition
-DOCSTART- -X- N

cervical JJ Condition
carcinoma NN Condition
: : None
patients NNS None
affected VBN None
by IN None
cervical JJ None
cancer NN None
undergoing VBG None
radical JJ None
hysterectomy NN None
. . None
Consecutive JJ None
patients NNS None
affected VBN None
by IN None
stage NN None
IB-IIB JJ None
cervical JJ None
carcinoma NN None
scheduled VBN None
for IN None
radical JJ None
surgery NN None
All DT None
patients NNS None
underwent JJ None
classical JJ None
radical JJ None
hysterectomy NN None
. . None
168 CD Size
patients NNS None
entered VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

paclitaxel-induced JJ None
paclitaxel-induced JJ None
Thirty-two JJ Size
patients NNS None
undergoing VBG None
six CD None
courses NNS None
of IN None
paclitaxel-based JJ None
chemotherapy NN Condition
patients NNS None
with IN None
cancer NN Condition
-DOCSTART- -X- N

infectious JJ Condition
and CC Condition
inflammatory JJ Condition
complications NNS Condition
after IN None
oral JJ Condition
surgery NN Condition
procedures NNS None
] VBP None
prevention NN None
and CC None
treatment NN None
of IN None
infectious JJ None
and CC None
inflammatory JJ None
complications NNS None
after IN None
oral JJ None
surgery NN None
procedures NNS None
. . None
outpatient JJ None
-DOCSTART- -X- N

young JJ None
adults NNS None
with IN None
high-functioning JJ None
autism NN None
spectrum NN None
disorders NNS None
: : None
young JJ None
adults NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
high-functioning JJ None
young JJ None
adults NNS None
with IN None
ASD NNP None
( ( None
ages VBZ None
18-23 CD None
) ) None
young JJ None
adults NNS None
young JJ None
adults NNS None
' POS None
young JJ None
adults NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

elderly JJ None
patients NNS None
with IN None
GERD NNP None
] NNP None
patients NNS None
with IN None
GERD NNP None
elderly RB None
. . None
60 CD None
patients NNS None
with IN None
A NNP None
degree NN None
of IN None
ERD NNP None
, , None
consistently RB None
received VBN None
in-patient JJ None
treatment NN None
in IN None
the DT None
Municipal NNP None
KGVV NNP None
, , None
mean JJ None
age NN None
79.0 CD None
+/- JJ None
6.8 CD None
years NNS None
. . None
patients NNS None
with IN None
GERD NNP None
. . None
esophageal NN None
, , None
extraesophageal JJ None
syndrome NN None
, , None
functional JJ None
dyspepsia NN None
with IN None
GERD NNP None
in IN None
the DT None
older JJR None
age NN None
groups NNS None
patients NNS None
with IN None
middle JJ None
and CC None
old JJ None
age NN None
-DOCSTART- -X- N

postmenopausal JJ Condition
bone NN Condition
loss NN Condition
. . None
postmenopausal JJ Condition
osteoporosis NN Condition
. . None
groups NNS None
of IN None
20 CD Size
, , None
60 CD Size
women NNS Sex
Patients NNPS None
who WP None
received VBD Condition
calcium NN Condition
alone RB None
-DOCSTART- -X- N

one CD None
nicotine NN None
transdermal NN None
system NN None
( ( None
Nicoderm NNP None
, , None
Marion NNP None
Merrell NNP None
Dow NNP None
Inc NNP None
, , None
Kansas NNP None
City NNP None
, , None
Mo NNP None
, , None
and CC None
ALZA NNP None
Corporation NNP None
, , None
Palo NNP None
Alto NNP None
, , None
Calif NNP None
) ) None
in IN None
a DT None
population NN None
who WP None
were VBD None
allowed VBN None
to TO None
continue VB None
smoking VBG None
. . None
186 CD None
subjects NNS None
completing VBG None
the DT None
study NN None
-DOCSTART- -X- N

patients NNS None
with IN None
coronary JJ Condition
artery NN Condition
disease NN Condition
( ( Condition
CAD NNP Condition
) ) Condition
. . None
total NN None
of IN None
4,444 CD Size
patients NNS None
with IN None
angina JJ Condition
pectoris NN Condition
or CC None
previous JJ None
myocardial JJ Condition
infarction NN Condition
and CC None
serum VB Condition
cholesterol NN Condition
levels NNS Condition
of IN None
213-310 JJ None
mg/dl NN None
( ( None
5.5-8.0 JJ None
mmol/liter NN None
) ) None
while IN None
treated VBN None
with IN None
a DT None
lipid-lowering JJ None
diet NN None
256 CD Size
patients NNS None
women NNS Sex
and CC None
patients NNS None
of IN None
both DT Sex
sexes NNS Sex
-DOCSTART- -X- N

primary JJ None
care NN None
clinician JJ None
Physician JJ None
groups NNS None
Fourteen NNP Size
physician JJ None
groups NNS None
with IN None
120 CD Size
primary JJ None
care NN None
physician NN None
and CC None
associate JJ None
practitioners NNS None
from IN None
2 CD None
group NN None
model NN None
HMO NNP None
practices NNS None
. . None
clinician JJ None
primary JJ None
care NN None
clinicians NNS None
usual JJ None
care NN None
settings NNS None
. . None
-DOCSTART- -X- N

children NNS Age
being VBG None
treated VBN None
for IN None
acute JJ Condition
lymphoblastic JJ Condition
leukaemia NN Condition
. . None
Children NNP Age
were VBD None
investigated VBN None
who WP None
were VBD None
receiving VBG None
glucocorticoid JJ None
treatment NN None
for IN None
acute JJ Condition
lymphoblastic JJ Condition
leukaemia NN Condition
( ( Condition
ALL DT Condition
) ) Condition
. . None
children NNS Age
Nineteen NNP Size
children NNS Age
( ( None
8 CD Size
male NN Sex
, , None
11 CD Size
female NN Sex
) ) None
with IN None
a DT None
median JJ None
age NN None
5.9 CD Age
years NNS Age
( ( None
range VB None
2.6-13 CD Age
years NNS None
) ) None
were VBD None
recruited VBN None
into IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

Hispanics NNPS Condition
. . None
Hispanics NNPS Condition
Hispanic JJ Condition
patients NNS Condition
Patients NNPS None
were VBD None
recruited VBN None
from IN None
an DT None
urban JJ None
Level NN None
I PRP None
Trauma VBP None
following VBG None
screening NN None
for IN None
an DT None
alcohol-related JJ Condition
injury NN Condition
or CC None
alcohol NN None
problems NNS None
. . None
Five CD Size
hundred VBD Size
thirty-seven JJ Size
Hispanics NNPS None
Hispanics NNPS None
Hispanics NNPS None
. . None
-DOCSTART- -X- N

procedure NN Condition
for IN Condition
prolapse NN Condition
and CC Condition
hemorrhoids NNS Condition
] NNP None
From IN None
November NNP None
2002 CD None
to TO None
July NNP None
2003 CD None
, , None
80 CD Size
patients NNS None
who WP None
received VBD None
PPH NNP None
-DOCSTART- -X- N

obstetric JJ Condition
triage NN Condition
women NNS None
in IN None
labor NN None
rooms NNS None
. . None
women NNS None
who WP None
met VBD None
triage NN None
criteria NNS None
The DT None
total JJ None
sample NN None
size NN None
was VBD None
398 CD None
patients NNS None
. . None
-DOCSTART- -X- N

behaviorally RB Condition
disordered VBN Condition
mentally RB Condition
handicapped JJ Condition
patients NNS None
on IN None
staff NN None
personnel NNS None
in IN None
residential JJ None
care NN None
] NNP None
mentally RB Condition
handicapped JJ Condition
persons NNS None
with IN None
severely RB None
disturbed VBN None
or CC None
autistic JJ Condition
behavior NN Condition
on IN None
their PRP$ None
staff NN None
personal JJ None
which WDT None
had VBD None
an DT None
active JJ None
role NN None
in IN None
the DT None
program NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
rectal JJ Condition
cancer NN Condition
. . None
mid NN None
and CC None
low JJ None
rectal NN None
cancers NNS None
. . None
Some DT None
204 CD Size
patients NNS None
with IN None
mid NNS Condition
and CC Condition
low JJ Condition
rectal NN Condition
adenocarcinomas NN Condition
were VBD None
allocated VBN None
randomly RB None
to TO None
open VB None
( ( None
103 CD None
) ) None
or CC None
laparoscopic NN None
( ( None
101 CD None
) ) None
surgery NN None
. . None
Most JJS None
patients NNS None
had VBD None
stage NN None
II NNP None
or CC None
III NNP None
disease NN None
-DOCSTART- -X- N

posttransplant JJ None
hypertension NN None
in IN None
kidney NN None
allograft NN None
recipients NNS None
. . None
kidney NN None
recipients NNS None
. . None
Thirty-two JJ None
patients NNS None
on IN None
antihypertensive JJ None
treatment NN None
completed VBD None
the DT None
study NN None
. . None
kidney NN None
allograft NN None
recipients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ None
melanoma NN Condition
. . None
Treatment-na?ve CD None
or CC None
previously RB None
treated VBN None
patients NNS None
with IN None
unresectable JJ None
stage NN None
III/IV NNP None
melanoma NN None
( ( None
n JJ None
= NNP None
115 CD None
) ) None
received VBD None
open-label JJ None
ipilimumab NN None
( ( None
10 CD None
mg/kg NN None
every DT None
3 CD None
weeks NNS None
for IN None
four CD None
doses NNS None
) ) None
and CC None
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
. . None
12 CD Size
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

broiler NN None
chicks NNS None
. . None
poultry NN None
broiler NN None
chicks NNS None
infected VBN None
with IN None
Eimeria NNP Condition
maxima NN Condition
. . None
chicks NNS None
from IN None
hatch NN None
to TO None
d VB None
16 CD None
posthatch NN None
. . None
growth NN None
in IN None
young JJ None
broiler NN None
chicks NNS None
infected VBN None
with IN None
E. NNP None
maxima NNS None
. . None
-DOCSTART- -X- N

non-insulin-dependent JJ None
diabetes NNS None
mellitus NN None
. . None
dyslipidemic JJ None
patients NNS None
with IN None
non-insulin-dependent JJ None
diabetes NNS None
mellitus VBP None
, , None
13 CD None
patients NNS None
were VBD None
treated VBN None
in IN None
a DT None
randomized JJ None
crossover NN None
trial NN None
. . None
patients NNS None
patients NNS None
with IN None
non-insulin-dependent JJ None
diabetes NNS None
mellitus NN None
. . None
-DOCSTART- -X- N

locally RB None
advanced JJ Condition
nasopharyngeal JJ Condition
cancer NN Condition
: : None
single JJ None
centre NN None
patients NNS None
with IN None
locoregionally RB Condition
advanced JJ Condition
nasopharyngeal JJ Condition
cancer NN Condition
From NNP None
August NNP None
1999 CD None
to TO None
December NNP None
2004 CD None
, , None
206 CD Size
patients NNS None
with IN None
locally RB None
advanced JJ None
NPC NNP None
were VBD None
randomised VBN None
with IN None
101 CD Size
to TO None
cisplatin VB None
arm NN None
and CC None
105 CD Size
to TO None
carboplatin VB None
arm NN None
. . None
locoregional JJ Condition
advanced JJ Condition
stage NN Condition
NPC NNP Condition
. . None
-DOCSTART- -X- N

age-related JJ None
macular JJ Condition
degeneration NN Condition
; : None
20 CD Size
healthy JJ Condition
volunteers NNS None
-DOCSTART- -X- N

childhood NN None
autism NN None
: : None
children NNS None
with IN None
autism NN None
Sixty NNP None
Thai NNP None
children NNS None
with IN None
autism NN None
, , None
aged VBD None
three CD None
to TO None
nine CD None
years NNS None
Children NNP None
with IN None
autism NN None
-DOCSTART- -X- N

15 CD Condition
and CC Condition
19 CD Condition
healthy JJ Condition
women NNS Condition
, , Condition
respectively RB Condition
. . Condition
-DOCSTART- -X- N

children NNS Age
and CC Age
adolescents NNS Age
with IN None
juvenile JJ Condition
idiopathic JJ Condition
arthritis NN Condition
. . None
children NNS Age
and CC Age
adolescents NNS Age
with IN None
juvenile JJ Condition
idiopathic JJ Condition
arthritis NN Condition
( ( Condition
JIA NNP Condition
) ) Condition
. . None
patients NNS None
with IN None
JIA NNP Condition
aged VBD None
between IN None
8 CD None
and CC None
17 CD None
years NNS None
and CC None
healthy JJ None
controls NNS None
was VBD None
used VBN None
. . None
Fifty-two JJ None
patients NNS None
and CC None
48 CD None
controls NNS None
were VBD None
included VBN None
with IN None
a DT None
mean JJ None
age NN None
of IN None
12.13 CD None
? . None
2.92 CD None
and CC None
11.27 CD None
? . None
1.59 CD None
years NNS None
, , None
respectively RB None
. . None
The DT None
mean JJ None
disease NN None
duration NN None
was VBD None
64 CD None
months NNS None
. . None
in IN None
children NNS None
and CC None
adolescents NNS None
with IN None
JIA NNP None
-DOCSTART- -X- N

children NNS Age
tonsillectomy NN None
with IN None
or CC None
without IN None
adenoidectomy NN None
in IN None
children NNS None
90 CD Size
paediatric JJ None
patients NNS None
, , None
ASA NNP None
I PRP None
, , None
aged VBN None
4-10 CD Age
years NNS Age
children NNS None
undergoing VBG None
general JJ None
anaesthesia NN None
for IN None
tonsillectomy NN Condition
. . None
-DOCSTART- -X- N

hemodialysis NN Condition
arteriovenous JJ Condition
fistula NN Condition
stenoses VBZ Condition
resistant JJ Condition
to TO Condition
conventional JJ Condition
balloon NN Condition
angioplasty NN Condition
. . Condition
hemodialysis NN Condition
autogenous JJ Condition
fistula NN Condition
stenoses VBZ Condition
resistant JJ Condition
to TO Condition
conventional JJ Condition
percutaneous JJ Condition
transluminal JJ Condition
angioplasty NN Condition
( ( Condition
PTA NNP Condition
) ) Condition
. . None
patients NNS None
with IN None
dysfunctional JJ Condition
, , Condition
stenotic JJ Condition
hemodialysis NN Condition
arteriovenous JJ Condition
fistulas NNS Condition
( ( Condition
AVFs NNP Condition
) ) Condition
total NN None
of IN None
516 CD Size
patients NNS None
consented VBN None
to TO None
participate VB None
in IN None
the DT None
study NN None
from IN None
October NNP None
2008 CD None
to TO None
September NNP None
2011 CD None
, , None
85 CD None
% NN None
of IN None
whom WP None
( ( None
n JJ None
= NNP None
439 CD Size
) ) None
had VBD None
technically RB None
successful JJ None
conventional JJ None
PTA NNP None
. . None
71 CD Size
patients NNS None
( ( None
mean JJ None
age NN None
, , None
60 CD Age
y NN None
; : None
49 CD Size
men NNS None
) ) None
with IN None
suboptimal JJ None
PTA NNP None
results NNS None
-DOCSTART- -X- N

cerebral JJ None
metabolic JJ None
ratio NN None
during IN None
maximal JJ None
whole JJ None
body NN None
exercise NN None
. . None
six CD None
male JJ None
oarsmen NNS None
( ( None
23?2 CD None
years NNS None
; : None
mean?S.D. NN None
) ) None
. . None
-DOCSTART- -X- N

young JJ Age
people NNS None
with IN None
familial JJ Condition
adenomatous JJ Condition
polyposis NN Condition
. . None
colorectal JJ Condition
cancer NN Condition
Familial NNP Condition
adenomatous JJ Condition
polyposis NN Condition
( ( None
FAP NNP Condition
) ) None
FAP NNP Condition
patients NNS None
from IN None
10 CD Age
to TO Age
21 CD Age
years NNS Age
of IN None
age NN None
. . None
total NN None
of IN None
206 CD None
randomized JJ None
FAP NNP None
patients NNS None
commenced VBD None
intervention NN None
, , None
of IN None
whom WP None
133 CD None
had VBD None
at IN None
least JJS None
one CD None
follow-up JJ None
endoscopy NN None
and CC None
were VBD None
therefore RB None
included VBN None
in IN None
the DT None
primary JJ None
analysis NN None
. . None
-DOCSTART- -X- N

central JJ Condition
nervous JJ Condition
system NN Condition
relapse NN Condition
in IN None
children NNS Age
with IN None
acute JJ Condition
lymphocytic JJ Condition
leukemia NN Condition
. . None
Eighty-seven JJ Size
children NNS None
with IN None
central JJ Condition
nervous JJ Condition
system NN Condition
( ( Condition
CNS NNP Condition
) ) Condition
leukemia NN Condition
-DOCSTART- -X- N

exercise NN None
therapy NN None
in IN None
patients NNS None
with IN None
acute JJ Condition
low JJ Condition
back RB Condition
pain NN Condition
. . None
patients NNS None
with IN None
acute JJ None
low JJ None
back RB None
pain NN None
. . None
Patients NNS None
with IN None
acute JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
and CC None
a DT None
paid VBN Condition
job NN Condition
were VBD None
included VBN None
for IN None
analysis NN None
. . None
40 CD None
general JJ None
practices NNS None
363 CD Size
patients NNS None
who WP None
were VBD None
gainfully RB None
employed VBN None
were VBD None
included VBN None
. . None
patients NNS None
with IN None
acute JJ None
low JJ None
back RB None
pain NN None
-DOCSTART- -X- N

children NNS Age
undergoing VBG None
automated VBN Condition
peritoneal JJ Condition
dialysis NN Condition
. . None
pediatric JJ Age
patients NNS None
undergoing VBG None
peritoneal JJ Condition
dialysis NN Condition
( ( None
PD NNP Condition
) ) None
. . None
28 CD Size
children NNS Age
( ( None
age NN None
, , None
6 CD Age
mo NN Age
to TO Age
15 CD Age
yr NN Age
) ) None
undergoing NN None
automated VBN Condition
PD NNP Condition
( ( None
APD NNP Condition
) ) None
. . None
children NNS Age
undergoing VBG None
APD NNP Condition
-DOCSTART- -X- N

patients NNS None
with IN None
multivessel JJ None
disease NN None
. . None
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
. . None
patients NNS None
with IN None
multivessel JJ None
disease NN None
suitable JJ None
for IN None
treatment NN None
with IN None
either DT None
procedure NN None
Patients NNPS None
with IN None
multivessel JJ None
disease NN None
were VBD None
randomly RB None
assigned VBN None
to TO None
an DT None
initial JJ None
treatment NN None
strategy NN None
of IN None
CABG NNP None
( ( None
n JJ None
= NNP None
914 CD None
) ) None
or CC None
PTCA NNP None
( ( None
n JJ None
= NNP None
915 CD None
) ) None
Among IN None
diabetic JJ None
patients NNS None
who WP None
were VBD None
being VBG None
treated VBN None
with IN None
insulin NN None
or CC None
oral JJ None
hypoglycemic JJ None
agents NNS None
at IN None
base NN None
line NN None
patients NNS None
with IN None
multivessel JJ None
disease NN None
treated JJ None
diabetics NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
mild JJ Condition
sleep-disordered JJ Condition
breathing NN Condition
( ( Condition
SDB NNP Condition
) ) Condition
. . None
Twenty NNP Size
patients NNS None
with IN None
mild JJ None
SDB NNP None
for IN None
whom WP None
conservative JJ None
treatment NN None
failed VBD None
-DOCSTART- -X- N

anemic JJ None
cancer NN None
surgery NN None
patients NNS None
. . None
cancer NN None
patients NNS None
. . None
Twenty NNP Size
anemic JJ None
sideropenic JJ None
patients NNS None
( ( None
hemoglobin JJ None
< NNP None
/=110 NNP None
g/l NN None
; : None
serum CC None
iron VB None
< JJ None
600 CD None
microg/l NN None
) ) None
with IN None
cancer NN None
of IN None
the DT None
gastrointestinal JJ None
tract NN None
two CD None
groups NNS None
: : None
the DT None
first JJ None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
received VBD None
400 CD None
U/kg NNP None
of IN None
r-Hu JJ None
EPO NNP None
divided VBD None
in IN None
4 CD None
doses NNS None
( ( None
100 CD None
U/kg NNP None
each DT None
, , None
every DT None
4 CD None
days NNS None
) ) None
; : None
the DT None
second JJ None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
received VBD None
200 CD None
U/kg NNP None
of IN None
r-HuEPO NN None
( ( None
50 CD None
U/kg NNP None
each DT None
, , None
every DT None
4 CD None
days NNS None
) ) None
. . None
anemic JJ None
sideropenic JJ None
cancer NN None
patients NNS None
. . None
-DOCSTART- -X- N

prethreshold JJ Condition
retinopathy NN Condition
of IN Condition
prematurity NN Condition
. . None
prethreshold JJ Condition
retinopathy NN Condition
of IN Condition
prematurity NN Condition
( ( Condition
ROP NNP Condition
) ) Condition
Thirty-six JJ None
eyes NNS None
of IN None
18 CD Size
premature NN Size
infants NNS Size
less RBR None
than IN None
34 CD None
weeks NNS None
gestational JJ None
age NN None
and/or NN None
less JJR None
than IN None
1600 CD None
g JJ None
birth NN None
weight NN None
with IN None
prethreshold JJ Condition
ROP NNP Condition
Regression NNP Condition
of IN Condition
ROP NNP Condition
36 CD None
eyes NNS None
-DOCSTART- -X- N

Patients NNPS None
presenting VBG None
for IN None
cataract NN None
surgery NN None
in IN None
one CD None
eye NN None
were VBD None
randomized VBN None
-DOCSTART- -X- N

Japanese JJ None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
. . None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
A DT None
total NN None
of IN None
101 CD None
patients NNS None
were VBD None
stratified VBN None
according VBG None
to TO None
sex NN None
, , None
age NN None
, , None
BMI NNP None
, , None
duration NN None
of IN None
diabetes NNS None
, , None
and CC None
HbA1c NNP None
Japanese JJ None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
-DOCSTART- -X- N

caudal JJ None
route NN None
in IN None
children NNS None
. . None
children NNS None
. . None
Ninety-nine JJ Size
ASA NNP None
I-II NNP None
children NNS None
less JJR None
than IN None
10 CD Age
yr JJ None
old JJ None
scheduled VBN None
for IN None
elective JJ None
sub-umbilical JJ Condition
surgery NN Condition
-DOCSTART- -X- N

locally RB None
advanced JJ None
cervix NN None
carcinoma NN None
: : None
patients NNS None
with IN None
locally RB None
advanced JJ None
cervical JJ None
cancer NN None
( ( None
LACC NNP None
) ) None
Between NNP None
January NNP None
2010 CD None
and CC None
January NNP None
2012 CD None
, , None
44 CD None
patients NNS None
with IN None
International NNP None
Federation NNP None
of IN None
Gynecology NNP None
and CC None
Obstetrics NNP None
( ( None
FIGO NNP None
2009 CD None
) ) None
stage NN None
IIB-IIIB NNP None
squamous JJ None
cell NN None
carcinoma NN None
of IN None
the DT None
cervix NN None
were VBD None
randomized VBN None
-DOCSTART- -X- N

middle-aged JJ None
men NNS Sex
and CC None
women NNS Sex
. . None
middle-aged JJ None
men NNS None
and CC None
women NNS None
. . None
Men NNP None
and CC None
women NNS None
aged VBN None
40-65 JJ Age
y NN Age
( ( None
n JJ None
= NNP None
38 CD Size
) ) None
underwent NN None
a DT None
double-blind NN None
, , None
randomized VBN None
, , None
placebo-controlled JJ None
, , None
crossover JJ None
trial NN None
of IN None
treatment NN None
with IN None
0.7 CD None
g NNS None
DHA/d NNP None
for IN None
3 CD None
mo NNS None
. . None
middle-aged JJ None
men NNS None
and CC None
women NNS None
. . None
-DOCSTART- -X- N

protracted JJ Condition
critical JJ Condition
illness NN Condition
: : Condition
Twenty NNP None
adults NNS None
, , None
critically RB None
ill VB None
for IN None
several JJ None
weeks NNS None
and CC None
supported VBD None
with IN None
normocaloric JJ None
, , None
continuously RB None
administered VBN None
parenteral JJ None
and/or JJ None
enteral JJ None
feeding NN None
-DOCSTART- -X- N

third JJ None
stage NN None
of IN None
labour NN None
. . None
20 CD None
women NNS None
randomly RB None
allocated VBN None
into IN None
two CD None
groups NNS None
of IN None
10 CD None
. . None
third JJ None
stage NN None
of IN None
labour JJ None
-DOCSTART- -X- N

early JJ None
stage NN None
, , None
curable JJ None
prostate NN None
cancer NN None
: : None
In IN None
1,002 CD None
men NNS None
aged VBN None
45-80 JJ None
y NN None
prostate-specific JJ None
antigen NN None
( ( None
PSA NNP None
) ) None
, , None
digital JJ None
rectal JJ None
examination NN None
( ( None
DRE NNP None
) ) None
, , None
and CC None
transrectal JJ None
ultrasonography NN None
7,350 CD None
men NNS None
using VBG None
serum NN None
PSA NNP None
and CC None
DRE NNP None
as IN None
first JJ None
approach NN None
, , None
followed VBN None
by IN None
TRUS NNP None
only RB None
when WRB None
1 CD None
of IN None
these DT None
2 CD None
tests NNS None
was VBD None
abnormal JJ None
. . None
unselected JJ None
, , None
unscreened JJ None
population NN None
-DOCSTART- -X- N

initial JJ None
prodromal JJ Condition
states NNS Condition
of IN Condition
psychosis NN Condition
Germany NNP None
initial JJ None
prodromal JJ Condition
phase NN Condition
of IN Condition
psychosis NN Condition
early JJ None
initial JJ None
prodromal JJ None
state NN None
late JJ None
initial JJ None
prodromal JJ None
state NN None
1212 CD Size
individuals NNS None
seeking VBG None
help NN None
for IN None
mental JJ None
health NN None
problems NNS None
More JJR None
than IN None
388 CD Size
individuals NNS None
fulfilled VBD None
criteria NNS None
for IN None
both DT None
interventions NNS None
and CC None
188 CD Size
( ( None
48.5 CD None
% NN None
) ) None
gave VBD None
informed VBN None
consent NN None
to TO None
participate VB None
in IN None
the DT None
trials NNS None
-DOCSTART- -X- N

inflammatory JJ None
knee NN None
osteoarthritis NN None
. . None
inflammatory JJ None
knee NN None
osteoarthritis NN None
. . None
rheumatology NN None
outpatient NN None
department NN None
. . None
63 CD None
patients NNS None
( ( None
24 CD Sex
male NN Sex
, , None
39 CD Sex
female NN Sex
, , None
mean JJ None
age NN Age
70.5 CD Age
years NNS Age
) ) None
with IN None
bilateral JJ None
symptomatic JJ None
knee NN None
osteoarthritis NN None
with IN None
effusion NN None
. . None
two CD None
groups NNS None
were VBD None
comparable JJ None
at IN None
entry NN None
high JJ None
drop-out NN None
rate NN None
symptomatic JJ None
knee NN None
osteoarthritis NN None
-DOCSTART- -X- N

patients NNS None
with IN None
standard-risk JJ None
acute JJ None
lymphoblastic JJ None
leukemia NN None
: : None
childhood NN None
acute NN None
lymphoblastic JJ None
leukemia NN None
( ( None
ALL DT None
) ) None
more JJR None
than IN None
1000 CD None
subjects NNS None
Children NNP None
with IN None
National NNP None
Cancer NNP None
Institute NNP None
standard-risk NN None
ALL NNP None
-DOCSTART- -X- N

adolescents NNS Age
. . None
Two CD Size
hundred CD Size
and CC Size
thirty-seven JJ Size
students NNS None
, , None
drawn NN None
from IN None
six CD None
homeroom NN None
grade NN None
eight CD None
classes NNS None
-DOCSTART- -X- N

child JJ Age
anxiety NN Condition
for IN None
children NNS Age
from IN None
grades NNS None
4 CD None
to TO None
6 CD None
, , None
using VBG None
random JJ None
assignment NN None
at IN None
the DT None
school-level NN None
children NNS Age
with IN None
anxiety NN Condition
symptoms NNS None
( ( None
N=191 NNP Size
, , None
mean JJ None
age=10.1 NN Age
) ) None
as IN None
screened VBN None
with IN None
self NN None
, , None
parent NN None
, , None
and CC None
teacher-reports NNS None
; : None
the DT None
second JJ None
study NN None
took VBD None
a DT None
universal JJ None
approach NN None
with IN None
full JJ None
classrooms NNS None
of IN None
children NNS None
participating VBG None
( ( None
N=253 NNP Size
, , None
mean JJ None
age=9.8 NN Age
) ) None
. . None
of IN None
children NNS None
with IN None
high-anxiety NN None
symptoms NNS None
-DOCSTART- -X- N

paediatric JJ Condition
tonsillectomy NN Condition
. . Condition
From NNP None
July NNP None
2004 CD None
to TO None
April NNP None
2006 CD None
, , None
80 CD None
patients NNS None
aged VBN None
between IN None
10 CD None
and CC None
15 CD None
years NNS None
, , None
with IN None
tonsillectomy NN None
planned VBN None
for IN None
chronic JJ None
tonsillitis NN None
, , None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

advanced JJ None
gastric JJ None
cancer NN None
patients NNS None
. . None
stage NN None
III NNP None
gastric JJ None
cancer NN None
patients NNS None
. . None
Twenty-one CD None
registered VBD None
patients NNS None
with IN None
stage NN None
III NNP None
gastric JJ None
cancer NN None
stage NN None
III NNP None
gastric JJ None
cancer NN None
patients NNS None
-DOCSTART- -X- N

delusional JJ Condition
patients NNS None
with IN None
schizophrenia NN Condition
. . None
delusional JJ None
schizophrenia NN None
patients NNS None
three CD Size
subject JJ None
groups NNS None
-- : None
patients NNS None
with IN None
schizophrenia NN Condition
with IN Condition
prominent JJ Condition
delusions NNS Condition
, , Condition
patients NNS None
with IN None
schizophrenia NN Condition
without IN Condition
delusions NNS Condition
, , None
and CC None
healthy JJ None
participants NNS None
. . None
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS Condition
ingesting VBG Condition
cephalexin NN Condition
before IN None
and CC None
after IN None
steady-state JJ None
administration NN None
of IN None
ranitidine NN None
or CC None
omeprazole NN None
. . None
-DOCSTART- -X- N

68 CD Condition
women NNS Sex
in IN None
spontaneous JJ Condition
labour JJ Condition
-DOCSTART- -X- N

Fourteen NNP Size
healthy JJ None
, , None
non-smoking JJ None
, , None
Caucasian JJ None
male NN Sex
volunteers NNS None
-DOCSTART- -X- N

children NNS None
and CC None
adolescents NNS None
with IN None
irritability NN Condition
associated VBN None
with IN None
autistic JJ Condition
disorder NN Condition
. . None
children NNS None
and CC None
adolescents NNS None
with IN None
autistic JJ Condition
disorder NN Condition
. . None
Two CD Size
hundred VBD Size
eighteen JJ Size
children NNS None
and CC None
adolescents NNS None
( ( None
aged VBN None
6-17 CD None
years NNS None
) ) None
with IN None
a DT None
diagnosis NN None
of IN None
autistic JJ Condition
disorder NN Condition
, , None
and CC None
with IN None
behaviors NNS None
such JJ None
as IN None
tantrums NNS Condition
, , None
aggression NN Condition
, , Condition
self-injurious JJ Condition
behavior NN Condition
, , Condition
or CC None
a DT None
combination NN None
of IN None
these DT None
symptoms NNS None
children NNS None
and CC None
adolescents NNS None
with IN None
irritability NN Condition
associated VBN None
with IN None
autistic JJ Condition
disorder NN Condition
. . Condition
-DOCSTART- -X- N

autism NN Condition
: : None
Twelve NNP Size
autistic JJ Condition
patients NNS None
ranging VBG None
from IN None
7 CD Age
to TO Age
15 CD Age
years NNS Age
, , None
diagnosed VBD None
according VBG None
to TO None
DSM-III-R NNP None
children NNS Age
. . None
population NN None
of IN None
autistic JJ Condition
children NNS Age
-DOCSTART- -X- N

One CD Age
hundred VBD Age
anaesthetized JJ None
patients NNS None
( ( None
ASA NNP None
1-2 CD None
, , None
aged VBD None
18 CD Age
to TO Age
80 CD Age
years NNS Age
) ) None
-DOCSTART- -X- N

after IN None
rubber NN None
band NN None
ligation NN None
of IN None
hemorrhoids NNS Condition
: : None
After IN None
hemorrhoidal JJ None
banding NN None
, , None
patients NNS None
115 CD Size
patients NNS None
studied VBN None
-DOCSTART- -X- N

periodontal JJ None
healing NN None
. . None
nonsurgical JJ None
therapy NN None
( ( None
scaling VBG None
and CC None
root NN None
planing NN None
, , None
SRP NNP None
) ) None
on IN None
the DT None
subgingival NN None
microbiota NN None
in IN None
chronic NN None
( ( None
CP NNP None
) ) None
and CC None
aggressive JJ None
( ( None
AP NNP None
) ) None
periodontal JJ None
disease NN None
. . None
Ninety-seven NNP None
CP NNP None
and CC None
AP NNP None
subjects NNS None
underwent JJ None
full-mouth JJ None
SRP NNP None
on IN None
2 CD None
consecutive JJ None
days NNS None
. . None
-DOCSTART- -X- N

advanced JJ Condition
gastric JJ Condition
carcinoma NN Condition
. . None
advanced JJ Condition
gastric JJ Condition
carcinoma NN Condition
Two CD Size
hundred VBD Size
patients NNS None
with IN None
untreated JJ Condition
advanced JJ Condition
gastric JJ Condition
carcinoma NN Condition
-DOCSTART- -X- N

adults NNS Age
and CC None
children NNS Age
Participants NNS None
adults NNS None
majority NN None
of IN None
adults NNS None
and CC None
a DT None
sizeable JJ None
proportion NN None
of IN None
4- JJ Age
to TO Age
6-year-olds NNS Age
. . None
both DT None
age NN None
groups NNS None
children NNS None
as RB None
young JJ None
as IN None
4 CD None
children NNS None
-DOCSTART- -X- N

splinting NN None
of IN None
teeth NNS None
in IN None
combination NN None
with IN None
reconstructive JJ Condition
periodontal NN Condition
surgery NN Condition
in IN None
humans NNS Condition
. . None
Forty-five JJ Size
patients NNS None
were VBD None
randomly RB None
treated VBN None
with IN None
a DT None
periodontal JJ Condition
surgery NN Condition
approach NN None
. . None
33 CD Size
patients NNS None
. . None
-DOCSTART- -X- N

Effect NN None
of IN None
resistance NN None
exercise NN None
contraction NN None
mode NN None
and CC None
protein JJ None
supplementation NN None
on IN None
members NNS None
of IN None
the DT None
STARS NNP None
signalling VBG None
pathway RB None
. . None
prolonged JJ None
training NN None
; : None
with IN None
and CC None
without IN None
whey JJ None
protein NN None
supplementation NN None
. . None
-DOCSTART- -X- N

injured JJ Condition
colon NN Condition
: : None
study NN None
was VBD None
carried VBN None
out RP None
at IN None
the DT None
Detroit NNP None
General NNP None
Hospital NNP None
over IN None
a DT None
two CD None
year NN None
period NN None
to TO None
evaluate VB None
methods NNS None
of IN None
management NN None
in IN None
165 CD Size
patients NNS None
with IN None
colonic JJ Condition
injuries NNS Condition
. . None
any DT Condition
patient NN Condition
with IN Condition
a DT Condition
colonic JJ Condition
injury NN Condition
above IN Condition
18 CD Condition
cm NN Condition
patients NNS Condition
with IN Condition
colonic JJ Condition
injury NN Condition
. . None
-DOCSTART- -X- N

retained JJ Condition
placenta NN Condition
. . Condition
women NNS Sex
with IN None
retained JJ None
placenta NN None
. . None
( ( None
10 CD Size
women NNS Size
, , Size
group NN None
1 CD None
) ) None
( ( None
11 CD Size
women NNS Size
, , None
group NN None
2 CD None
) ) None
( ( None
7 CD Size
women NNS Size
, , None
group NN None
3 CD None
) ) None
Nine NNP Size
women NNS Sex
( ( None
group NN None
4 CD None
, , None
controls NNS None
) ) None
underwent VBP None
manual JJ None
removal NN None
of IN None
the DT None
retained JJ None
placenta NN None
. . None
-DOCSTART- -X- N

United NNP None
States NNPS None
General NNP None
surgical JJ None
patients NNS None
including VBG None
those DT None
undergoing JJ None
noncardiac JJ None
thoracic NN None
and CC None
pelvic JJ None
operations NNS None
who WP None
were VBD None
identified VBN None
at IN None
moderate JJ None
to TO None
high JJ None
risk NN None
for IN None
postop JJ None
DVT NNP None
were VBD None
included VBN None
Eight NNP None
hundred VBD None
and CC None
eighty JJ None
eight CD None
patients NNS None
were VBD None
entered VBN None
into IN None
this DT None
trial NN None
and CC None
744 CD None
( ( None
85 CD None
% NN None
) ) None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

PTSD NNP Condition
patients NNS Condition
with IN Condition
Posttraumatic NNP Condition
stress NN Condition
disorder NN Condition
( ( Condition
PTSD NNP Condition
) ) Condition
PTSD JJ None
patients NNS None
were VBD None
recruited VBN None
from IN None
five CD None
primary JJ None
care NN None
clinics NNS None
at IN None
four CD None
Veterans NNS None
Affairs NNP None
healthcare NN None
facilities NNS None
Participants NNS None
were VBD None
195 CD Size
Veterans NNPS None
Their PRP$ None
average JJ None
age NN None
was VBD None
45 CD Age
years NNS Age
, , None
91 CD None
% NN None
were VBD None
male JJ None
, , None
58 CD None
% NN None
were VBD None
white JJ None
, , None
40 CD None
% NN None
served VBN None
in IN None
Iraq NNP None
or CC None
Afghanistan NNP None
, , None
and CC None
42 CD None
% NN None
served VBD None
in IN None
Vietnam NNP None
-DOCSTART- -X- N

young JJ None
children NNS None
with IN None
autism NN None
. . None
young JJ None
children NNS None
with IN None
autism NN None
. . None
Four CD None
young JJ None
boys NNS None
( ( None
ages IN None
4-5 CD None
years NNS None
) ) None
diagnosed VBD None
with IN None
autism NN None
participated VBN None
. . None
The DT None
children NNS None
were VBD None
participants NNS None
in IN None
an DT None
early JJ None
intensive JJ None
behavioural JJ None
intervention NN None
clinic NN None
children NNS None
-DOCSTART- -X- N

dogs NNS None
and CC None
cats NNS None
presented VBD None
as IN None
veterinary JJ None
patients NNS None
in IN None
North NNP None
America NNP None
dogs NNS None
and CC None
cats NNS None
dogs NNS None
dogs NNS Condition
and CC Condition
cats NNS Condition
showing VBG Condition
signs NNS Condition
of IN Condition
flea NN Condition
allergy NN Condition
dermatitis NN Condition
( ( Condition
FAD NNP Condition
) ) Condition
Dogs NNS None
and CC None
cats NNS None
with IN None
naturally RB None
occurring VBG None
flea NN Condition
infestations NNS Condition
, , None
some DT None
of IN None
which WDT None
also RB None
had VBD None
signs NNS None
associated VBN None
with IN None
FAD NNP None
220 CD None
dogs NNS None
, , None
189 CD None
cats NNS None
) ) None
dogs NNS None
and CC None
cats NNS None
diagnosed VBD None
clinically RB None
with IN None
FAD NNP None
397 CD None
dogs NNS None
free JJ None
of IN None
adult NN None
heartworm NN None
infection NN None
from IN None
four CD None
heartworm-endemic JJ None
areas NNS None
of IN None
the DT None
USA NNP None
673 CD None
dogs NNS None
and CC None
347 CD None
cats NNS None
animals NNS None
included VBD None
19 CD None
purebred VBD None
or CC None
crossbred JJ None
Collies NNS None
( ( None
Bearded NNP None
, , None
Border NNP None
, , None
and CC None
unspecified JJ None
) ) None
dogs NNS None
and CC None
cats NNS None
dogs NNS None
and CC None
cats NNS None
-DOCSTART- -X- N

Holstein NNP Condition
steers NNS Sex
Holstein NNP Condition
steers NNS Condition
168 CD Size
Holstein NNP Condition
steers NNS Condition
( ( None
182.7 CD Condition
+/- JJ Condition
27.5 CD Condition
kg NN Condition
) ) None
growing-finishing JJ None
Holstein NNP Condition
steers NNS Condition
with IN None
extended JJ None
feeding NN None
periods NNS None
( ( None
266 CD None
d NN None
) ) None
. . None
-DOCSTART- -X- N

persons NNS None
with IN None
osteoarthritis NN Condition
249 CD Size
adults NNS Age
from IN None
Washington NNP None
State NNP None
aged VBD Age
55 CD Age
to TO Age
75 CD Age
with IN None
a DT None
doctor-confirmed JJ None
diagnosis NN None
of IN None
osteoarthritis NN Condition
-DOCSTART- -X- N

Fifty-nine JJ None
consecutive JJ None
patients NNS None
( ( None
19 CD None
men NNS None
, , None
40 CD None
women NNS None
, , None
mean JJ None
age NN None
60.8 CD None
[ JJ None
27-80 JJ None
] NNP None
years NNS None
) ) None
with IN None
primary JJ None
osteoporosis NN None
-DOCSTART- -X- N

shivering VBG Condition
in IN None
elective JJ Condition
caesarean JJ Condition
section NN Condition
under IN Condition
epidural JJ Condition
analgesia NN Condition
. . None
parturients NNS Condition
who WP None
underwent VBP Condition
elective JJ Condition
Caesarean JJ Condition
section NN Condition
under IN None
epidural JJ Condition
analgesia NN Condition
patients NNS None
-DOCSTART- -X- N

16-community JJ None
trial NN None
to TO None
promote VB None
judicious JJ None
antibiotic JJ None
use NN None
in IN None
Massachusetts NNP None
. . None
young JJ None
children NNS None
commercially RB None
and CC None
Medicaid-insured JJ None
children NNS None
. . None
community-level JJ None
, , None
cluster-randomized JJ None
trial NN None
in IN None
16 CD Size
nonoverlapping VBG None
Massachusetts NNP None
communities NNS None
, , None
studied VBN None
from IN None
1998 CD None
to TO None
2003 CD None
. . None
children NNS Age
who WP None
were VBD None
aged VBN Age
3 CD Age
to TO Age
< VB Age
72 CD Age
months NNS Age
, , None
resided VBN None
in IN None
study NN None
communities NNS None
, , None
and CC None
were VBD None
insured VBN None
by IN None
a DT None
participating VBG None
commercial JJ None
health NN None
plan NN None
or CC None
Medicaid NNP None
. . None
223,135 CD Size
person-years NNS None
of IN None
observation NN None
. . None
Medicaid-insured JJ None
children NNS None
-DOCSTART- -X- N

biliary JJ None
and CC None
gastric JJ None
surgery NN None
. . None
80 CD Size
patients NNS None
undergoing JJ None
biliary JJ None
or CC None
gastric JJ None
surgery NN None
. . None
biliary JJ None
and CC None
gastric JJ None
surgery NN None
. . None
-DOCSTART- -X- N

pneumonia NN Condition
69 CD Size
artificially RB Condition
ventilated JJ Condition
patients NNS None
the DT None
clinical JJ None
, , None
bacteriological JJ None
and CC None
pharmacological JJ None
effects NNS None
of IN None
endotracheally RB None
administered VBN None
tobramycin NN None
-DOCSTART- -X- N

unexpected JJ None
perturbations NNS None
during IN None
human JJ None
walking NN None
. . None
healthy JJ Condition
adults NNS Age
. . None
-DOCSTART- -X- N

laparoscopic NN Condition
tubal JJ Condition
sterilization NN Condition
patients NNS None
undergoing VBG None
laparoscopic JJ Condition
tubal JJ Condition
sterilization NN Condition
with IN None
silastic JJ None
bands NNS None
. . None
One CD Size
hundred VBD Size
five CD Size
women NNS Sex
undergoing VBG None
laparoscopic NN Condition
tubal JJ Condition
sterilization NN Condition
with IN None
silastic JJ None
bands NNS None
-DOCSTART- -X- N

men NNS None
with IN None
localized JJ Condition
prostate NN Condition
cancer NN Condition
. . None
A NNP None
total NN None
of IN None
101 CD None
patients NNS None
radical JJ Condition
external-beam NN Condition
radiation NN Condition
therapy NN Condition
( ( Condition
RT NNP Condition
) ) None
for IN None
localized JJ Condition
cancer NN Condition
of IN Condition
the DT Condition
prostate NN Condition
. . None
-DOCSTART- -X- N

Hawaiian JJ None
youth NN None
and CC None
communities NNS None
. . None
communities NNS None
on IN None
Hawai'i NNP None
Island NNP None
university-based JJ None
research NN None
team NN None
school-based JJ None
substance NN None
use NN None
prevention NN None
curriculum NN None
students NNS None
and CC None
community NN None
-DOCSTART- -X- N

infants NNS Condition
with IN Condition
atopic JJ Condition
dermatitis NN Condition
. . Condition
Atopic NNP None
Child NNP None
. . None
ETAC NNP None
( ( None
Early JJ None
Treatment NN None
of IN None
the DT None
Atopic NNP None
Child NNP None
) ) None
, , None
a DT None
multi-centre JJ None
predominantly RB None
European JJ None
study NN None
to TO None
investigate VB None
the DT None
potential NN None
for IN None
cetirizine NN None
to TO None
prevent VB None
the DT None
development NN None
of IN None
asthma NN None
in IN None
infants NNS None
with IN None
atopic NN None
dermatitis NN None
817 CD None
children NNS None
large JJ None
cohort NN None
of IN None
1-2 JJ None
years NNS None
olds VBZ None
with IN None
already RB None
established VBN None
atopic NN None
dermatitis NN None
, , None
resident NN None
in IN None
different JJ None
countries NNS None
and CC None
in IN None
different JJ None
environments NNS None
. . None
infants NNS None
with IN None
atopic NN None
dermatitis NN None
infants NNS None
-DOCSTART- -X- N

laparoscopic JJ Condition
pelvic JJ Condition
lymphadenectomy NN Condition
for IN Condition
gynecologic JJ Condition
cancer NN Condition
. . Condition
Thirty NNP None
patients NNS None
with IN None
gynecologic JJ None
malignancy NN None
, , None
who WP None
had VBD None
laparoscopic VBN None
pelvic JJ None
lymphadenectomy NN None
lymphocele NNS None
in IN None
10 CD None
patients NNS None
patients NNS None
undergoing VBG None
laparoscopic JJ None
pelvic JJ None
lymphadenectomy NN None
. . None
-DOCSTART- -X- N

20 CD Size
freshly RB None
extracted VBN None
, , None
non-periodontally RB None
involved VBN None
, , None
large JJ None
human JJ None
molars NNS None
. . None
40 CD Size
specimens NNS None
-DOCSTART- -X- N

perineal NN Condition
pain NN Condition
after IN None
perineorrhaphy NN None
: : None
Thailand NNP None
. . None
postpartum NN None
perineal NN None
pain NN None
after IN None
perineorrhaphy NN None
. . None
One NNP None
hundred VBD None
women NNS Age
who WP None
gave VBD None
birth NN None
vaginally RB None
with IN None
episiotomy NN None
and CC None
a DT None
second- JJ Condition
or CC Condition
third-degree JJ Condition
tear NN Condition
-DOCSTART- -X- N

Partial-area JJ None
method NN None
in IN None
bioequivalence NN None
bioequivalence NN None
partial-area JJ None
method NN None
in IN None
establishing VBG None
bioequivalence NN None
. . None
-DOCSTART- -X- N

previously RB None
untreated JJ None
patients NNS None
with IN None
extensive JJ Condition
small JJ Condition
cell NN Condition
lung NN Condition
cancer NN Condition
. . None
One CD Size
hundred CD Size
and CC Size
eleven RB Size
previously RB None
untreated JJ None
patients NNS None
with IN None
extensive JJ Condition
small JJ Condition
cell NN Condition
lung NN Condition
cancer NN Condition
Ninety-six JJ Size
patients NNS Size
were VBD None
evaluable JJ None
for IN None
response NN None
and CC None
toxicity NN None
and CC None
additional JJ None
12 CD Size
patients NNS Size
for IN None
toxicity NN None
only RB None
. . None
-DOCSTART- -X- N

acute NN None
antidepressant JJ None
effects NNS None
of IN None
sleep JJ Condition
deprivation NN Condition
: : None
Early JJ None
morning NN None
sleep JJ Condition
deprivation NN Condition
( ( None
patient JJ None
awake NN None
from IN None
0200 CD None
to TO None
2200 CD None
hours NNS None
) ) None
patients NNS None
with IN None
major JJ Condition
depression NN Condition
. . Condition
16 CD Size
depressed JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

percutaneous JJ None
coronary JJ None
interventions NNS None
( ( None
PCI NNP None
) ) None
. . None
99 CD None
post-percutaneous JJ None
coronary JJ None
interventions NNS None
( ( None
PCI NNP None
) ) None
patients NNS None
patients NNS None
following VBG None
PCI NNP None
. . None
-DOCSTART- -X- N

type NN None
1 CD None
( ( None
insulin-dependent NN None
) ) None
diabetic JJ None
patients NNS None
with IN None
incipient JJ None
nephropathy NN None
. . None
12 CD None
patients NNS None
with IN None
Type NNP None
1 CD None
( ( None
insulin-dependent NN None
) ) None
diabetes VBZ None
and CC None
incipient JJ None
nephropathy NN None
( ( None
persistent JJ None
microalbuminuria NN None
) ) None
. . None
patients NNS None
with IN None
incipient JJ None
diabetic JJ None
nephropathy NN None
. . None
-DOCSTART- -X- N

Ten CD Size
females NNS Sex
ran VBD None
barefoot NN None
over IN None
a DT None
force NN None
plate NN None
in IN None
three CD None
conditions NNS None
: : None
no DT None
heel NN None
lifts NNS None
( ( None
NHL NNP None
) ) None
, , None
with IN None
12 CD None
mm NNS None
heel JJ None
lifts NNS None
( ( None
12HL CD None
) ) None
and CC None
with IN None
18 CD None
mm NNS None
heel JJ None
lifts NNS None
( ( None
18HL CD None
) ) None
. . None
-DOCSTART- -X- N

chronic JJ Condition
heart NN Condition
failure NN Condition
( ( None
CHF NNP Condition
) ) None
patients NNS None
. . None
37 CD None
CHF JJ None
patients NNS None
( ( None
New NNP None
York NNP None
Heart NNP None
Association NNP None
Functional NNP None
Class=2.3?0.5 NNP None
; : None
left VBD None
ventricular JJ None
ejection NN None
fraction NN None
28?7 CD None
% NN None
; : None
age NN None
64?12years CD None
; : None
32:5 CD None
male NN None
: : None
female NN None
) ) None
who WP None
were VBD None
randomised VBN None
to TO None
-DOCSTART- -X- N

mammography NN None
. . None
Participants NNS None
were VBD None
1908 CD None
women NNS None
aged VBD None
50 CD None
to TO None
75 CD None
years NNS None
continuously RB None
enrolled VBD None
in IN None
a DT None
large JJ None
group-model JJ None
HMO NNP None
during IN None
the DT None
study NN None
who WP None
underwent VBD None
a DT None
bilateral JJ None
mammogram NN None
during IN None
the DT None
first JJ None
quarter NN None
of IN None
1994 CD None
and CC None
no DT None
subsequent JJ None
mammogram NN None
during IN None
the DT None
next JJ None
18 CD None
to TO None
21 CD None
months NNS None
. . None
-DOCSTART- -X- N

patients NNS None
after IN None
a DT None
myocardial JJ None
infarction NN None
: : None
post-hospital JJ None
data NNS None
myocardial JJ Condition
infarction NN Condition
( ( Condition
MI NNP Condition
) ) None
patients NNS Condition
admitted VBN Condition
for IN Condition
the DT Condition
first JJ Condition
MI NNP Condition
with IN Condition
recurrent JJ Condition
MI NNP Condition
patients NNS Condition
. . None
An DT None
inception NN None
cohort NN None
of IN None
patients NNS Condition
enrolled VBN Condition
in IN Condition
the DT Condition
Beta-Blocker NNP Condition
in IN Condition
Heart NNP Condition
Attack NNP Condition
Trial NNP Condition
( ( None
n JJ None
= NN None
2830 CD Size
) ) None
was VBD None
included VBN None
. . None
in-hospital JJ None
and CC None
post-hospital JJ None
data NNS None
) ) None
-DOCSTART- -X- N

orthotopic NN None
liver NN None
transplantation NN None
. . None
orthotopic JJ None
liver NN None
transplantation NN None
From IN None
November NNP None
1989 CD None
to TO None
June NNP None
1990 CD None
, , None
13 CD Condition
patients NNS None
23 CD Size
patients NNS None
-DOCSTART- -X- N

Beluga NNP None
, , None
Huso NNP None
huso NN None
( ( None
L. NNP None
) ) None
Beluga NNP None
, , None
Huso NNP None
huso NN None
( ( None
L. NNP None
) ) None
fish NN None
Beluga NNP None
-DOCSTART- -X- N

malaria-suspected JJ None
patients NNS None
sub-Saharan NN None
Africa NNP None
Tanzanian JJ None
trial NN None
. . None
-DOCSTART- -X- N

Graves NNP Condition
' POS Condition
disease NN Condition
] NNP None
Graves NNP Condition
' POS Condition
disease NN Condition
( ( None
GD NNP Condition
) ) None
Sixty NNP Size
cases NNS None
of IN None
GD NNP None
were VBD None
randomly RB None
divided VBN None
Graves NNP None
' POS None
disease NN None
-DOCSTART- -X- N

patients NNS None
with IN None
Stage NNP None
IV NNP None
lung NN None
and CC None
colorectal JJ None
cancer NN None
: : None
patients NNS None
with IN None
cancer NN None
those DT None
with IN None
Stage NNP None
IV NNP None
disease NN None
Sixty-six JJ None
adults NNS None
with IN None
Stage NNP None
IV NNP None
lung NN None
or CC None
colorectal JJ None
cancer NN None
were VBD None
randomized VBN None
RESULTS NNP None
Three CD None
participants NNS None
dropped VBD None
out RP None
and CC None
seven CD None
died VBD None
of IN None
patients NNS None
with IN None
Stage NNP None
IV NNP None
lung NN None
and CC None
colorectal JJ None
cancer NN None
. . None
-DOCSTART- -X- N

coronary JJ None
artery NN None
surgery NN None
. . None
85 CD None
patients NNS None
undergoing JJ None
elective JJ None
coronary JJ None
artery NN None
surgery NN None
. . None
A DT None
total NN None
of IN None
288 CD None
events NNS None
in IN None
which WDT None
the DT None
systolic NN None
blood NN None
pressure NN None
( ( None
SBP NNP None
) ) None
exceeded VBD None
a DT None
predetermined JJ None
trigger NN None
value NN None
were VBD None
observed VBN None
. . None
-DOCSTART- -X- N

women NNS Sex
with IN None
ErbB2 NNP Condition
overexpressing VBG Condition
metastatic JJ Condition
breast NN Condition
cancer NN Condition
. . None
patients NNS None
with IN None
human JJ None
epidermal JJ None
growth NN None
factor NN None
receptor NN None
2 CD None
( ( None
HER2 NNP None
) ) None
-positive VBP None
metastatic JJ None
breast NN None
cancer NN None
( ( None
MBC NNP None
) ) None
women NNS None
with IN None
HER2-positive JJ None
MBC NNP None
. . None
In IN None
this DT None
open-label JJ None
, , None
multicenter NN None
, , None
phase NN None
II NNP None
study NN None
, , None
eligible JJ None
patients NNS None
( ( None
N NNP None
= NNP None
112 CD Size
) ) None
patients NNS None
with IN None
HER2-overexpressing NNP None
MBC NNP None
-DOCSTART- -X- N

exposure NN Condition
to TO Condition
acid VB Condition
fog NN Condition
: : Condition
seven CD None
healthy JJ None
young JJ None
men NNS None
-DOCSTART- -X- N

postoperative JJ Condition
dental NN Condition
pain NN Condition
. . Condition
patients NNS None
experiencing VBG None
acute JJ Condition
pain NN Condition
. . Condition
patients NNS None
with IN None
postoperative JJ Condition
dental NN Condition
pain NN Condition
. . None
A DT None
total NN None
of IN None
498 CD Size
patients NNS None
( ( None
219 CD Size
men NNS Sex
, , None
279 CD Size
women NNS Sex
; : None
mean JJ None
age NN None
, , None
21.5 CD Age
years NNS None
) ) None
participated VBD None
in IN None
this DT None
study NN None
. . None
-DOCSTART- -X- N

71 CD None
normal JJ None
children NNS None
in IN None
three CD None
age NN None
groups NNS None
: : None
36 CD None
to TO None
72 CD None
months NNS None
, , None
15 CD None
to TO None
18 CD None
months NNS None
, , None
and CC None
6 CD None
to TO None
8 CD None
months NNS None
. . None
three CD None
age NN None
groups NNS None
. . None
-DOCSTART- -X- N

humans NNS None
in IN None
vivo NN None
: : None
20 CD Size
healthy JJ None
women NNS Sex
( ( None
median JJ Age
age NN Age
33 CD Age
years NNS Age
, , None
range VBP Age
21-47 JJ Age
; : None
phototype JJ None
I/II NNP None
) ) None
-DOCSTART- -X- N

children NNS Age
with IN None
high-functioning JJ Condition
autism NN Condition
children NNS Age
and CC Age
adolescents NNS Age
with IN None
HFA NNP Condition
-DOCSTART- -X- N

locally RB Condition
advanced JJ Condition
, , Condition
unresectable JJ Condition
, , Condition
nonmetastatic JJ Condition
squamous JJ Condition
cell NN Condition
carcinoma NN Condition
of IN Condition
the DT Condition
head NN Condition
and CC Condition
neck NN Condition
. . Condition
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
. . None
130 CD Size
patients NNS None
with IN None
locally RB None
advanced VBN None
, , None
unresectable JJ None
, , None
nonmetastatic JJ None
squamous JJ None
cell NN None
carcinoma NN None
of IN None
the DT None
head NN None
and CC None
neck NN None
( ( None
SCC NNP None
H NNP None
& CC None
N NNP None
) ) None
-DOCSTART- -X- N

healthy JJ None
subjects NNS None
. . None
Subjects NNS None
normal JJ None
subjects NNS None
-DOCSTART- -X- N

AIDS NNP Condition
: : Condition
10 CD None
patients NNS None
with IN None
AIDS NNP None
and CC None
cryptosporidiosis NN None
-DOCSTART- -X- N

feline NN Condition
osteoarthritis NN Condition
. . None
feline NN None
osteoarthritis NN None
( ( None
OA NNP None
) ) None
Cats NNPS Age
over IN Age
eight CD Age
years NNS Age
of IN Age
age NN Age
with IN None
clinical JJ Condition
signs NNS Condition
of IN Condition
chronic JJ Condition
OA NNP Condition
were VBD None
assigned VBN None
to TO None
one CD None
of IN None
two CD None
groups NNS None
Cats NNPS None
cats NNS None
-DOCSTART- -X- N

Children NNP None
with IN None
autistic JJ None
spectrum NN None
disorders NNS None
. . None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
62 CD None
subjects NNS None
( ( None
3-8 CD None
years NNS None
) ) None
Sixty NNP None
one CD None
children NNS None
completed VBD None
the DT None
study NN None
-DOCSTART- -X- N

chronic JJ None
cigarette NN None
smokers NNS None
. . None
chronic JJ None
cigarette NN None
smokers NNS None
. . None
a DT None
cross-sectional JJ None
comparison NN None
of IN None
smokers NNS None
and CC None
control NN None
subjects NNS None
heavy JJ None
smokers NNS None
moderate JJ Condition
smokers NNS Condition
nonsmokers NNS Condition
. . None
smokers NNS None
-DOCSTART- -X- N

animals NNS None
and CC None
healthy JJ None
humans NNS None
. . None
Twenty-nine JJ Size
patients NNS None
( ( None
6 CD Size
type NN None
1 CD None
and CC None
23 CD Size
type NN None
2 CD None
) ) None
with IN None
gastroparesis NN Condition
at IN None
baseline NN None
and CC None
after IN None
treatment NN None
with IN None
KC NNP None
11458 CD None
in IN None
a DT None
dose NN None
of IN None
8 CD None
mg NNS None
t.d.s. NN None
or CC None
placebo NN None
for IN None
8 CD None
days NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
: : None
100 CD Size
patients NNS None
with IN None
chronic JJ Condition
CAD NNP Condition
, , None
60 CD Size
of IN None
whom WP None
were VBD None
chronic JJ Condition
smokers NNS Condition
. . None
60 CD Size
of IN None
100 CD None
patients NNS None
( ( None
30 CD None
of IN None
whom WP None
were VBD None
smokers NNS Condition
) ) None
and CC None
in IN None
24 CD Size
healthy JJ None
controls NNS None
. . None
Smokers NNS Condition
( ( None
n JJ None
= NNP None
20 CD Size
) ) None
matched VBN None
for IN None
age NN None
, , None
myocardial JJ None
ischemia NN None
, , None
and CC None
other JJ None
risk NN None
factors NNS None
with IN None
20 CD Size
nonsmokers NNS Condition
patients NNS None
with IN None
chronic JJ Condition
CAD NNP Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
locally RB Condition
advanced VBN Condition
resectable JJ Condition
rectal JJ Condition
cancer NN Condition
. . None
Patients NNPS None
with IN None
stage NN Condition
II/III NNP Condition
LARC NNP Condition
Thirty-seven JJ Size
patients NNS None
were VBD None
eligible JJ None
17 CD Size
patients NNS None
13 CD None
patients NNS None
6 CD None
patients NNS None
patients NNS None
with IN None
resectable JJ Condition
LARC NNP Condition
. . None
-DOCSTART- -X- N

parents NNS Condition
of IN Condition
a DT Condition
child NN Condition
diagnosed VBN Condition
with IN Condition
an DT Condition
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . Condition
Fifty-nine JJ None
families NNS None
with IN None
a DT None
child NN None
with IN None
ASD NNP None
aged VBD None
between IN None
2 CD None
and CC None
9 CD None
participated VBN None
parental JJ None
reports NNS None
of IN None
child JJ None
behaviour NN None
and CC None
parenting NN None
styles NNS None
with IN None
the DT None
treatment NN None
effects NNS None
for IN None
child NN None
behaviour NN None
, , None
parental NN None
over IN None
reactivity NN None
and CC None
parental JJ None
verbosity NN None
parents NNS None
of IN None
children NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

severe JJ None
neurological JJ None
manifestations NNS None
in IN None
systemic JJ None
lupus NN None
erythematosus NN None
. . None
Severe NNP None
neurological JJ None
involvement NN None
in IN None
systemic JJ None
lupus NN None
erythematosus NN None
( ( None
NPSLE NNP None
) ) None
two CD None
tertiary JJ None
care NN None
centres NNS None
of IN None
patients NNS None
with IN None
SLE NNP None
according VBG None
to TO None
the DT None
ACR NNP None
criteria NNS None
, , None
with IN None
incident NN None
( ( None
no DT None
more JJR None
than IN None
15 CD None
days NNS None
) ) None
onset NN None
of IN None
severe JJ None
NP NNP None
manifestations NNS None
such JJ None
as IN None
seizures NNS None
, , None
optic JJ None
neuritis NN None
, , None
peripheral JJ None
or CC None
cranial JJ None
neuropathy NN None
, , None
coma NN None
, , None
brainstem NN None
disease NN None
, , None
or CC None
transverse JJ None
myelitis NN None
. . None
32 CD None
patients NNS None
studied VBN None
-DOCSTART- -X- N

3837 CD Size
patients NNS None
with IN None
a DT None
recent JJ None
myocardial JJ None
infarction NN None
. . None
-DOCSTART- -X- N

Bronchial JJ Condition
carcinoma NN Condition
. . None
inoperable JJ None
patients NNS None
with IN None
advanced JJ None
disease NN None
. . None
Forty-eight JJ Size
bronchial JJ Condition
carcinoma NN Condition
patients NNS None
in IN None
clinicoanatomical JJ None
stage NN None
4 CD None
of IN None
the DT None
disease NN None
( ( None
advanced JJ None
disease NN None
) ) None
randomly RB None
assigned VBN None
groups NNS None
-DOCSTART- -X- N

infertile NN Condition
and CC None
pregnant JJ Condition
women NNS Sex
. . None
infertile NN None
and CC None
pregnant JJ None
women NNS None
Three CD None
university NN None
teaching VBG None
hospitals NNS None
in IN None
Hamilton NNP None
, , None
Ontario NNP None
, , None
Canada NNP None
. . None
Infertile NNP None
women NNS None
at IN None
their PRP$ None
first JJ None
visit NN None
to TO None
a DT None
tertiary JJ None
referral JJ None
infertility NN None
clinic NN None
( ( None
n JJ None
= NNP None
94 CD Size
) ) None
and CC None
new JJ None
patients NNS None
seeking VBG None
pre-natal JJ None
care NN None
( ( None
n JJ None
= NNP None
110 CD Size
) ) None
who WP None
had VBD None
smoked VBN None
> NNP None
/= $ None
3 CD None
cigarettes NNS None
in IN None
the DT None
past JJ None
six CD None
months NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
prostatic JJ Condition
adenoma NN Condition
multicenter NN None
patients NNS None
with IN None
prostatic JJ Condition
adenoma NN Condition
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
CFS NNP Condition
patient NN None
with IN None
symptoms NNS None
of IN None
CFS NNP None
. . None
patient NN None
had VBD None
either CC None
chronic JJ None
fatigue NN None
syndrome NN None
, , None
chronic JJ None
neuroendocrineimmune JJ None
dysfunction NN None
syndrome NN None
, , None
or CC None
chronic JJ None
neuroendocrineimmune JJ None
dysfunction NN None
syndrome NN None
-DOCSTART- -X- N

elderly JJ Age
subjects NNS None
. . None
Outpatient JJ None
clinics NNS None
. . None
Two CD Size
hundred CD Size
thirty-eight JJ Size
elderly JJ Age
men NNS Condition
and CC None
women NNS Condition
aged VBD None
60 CD Age
to TO Age
80 CD Age
at IN None
high JJ None
risk NN None
for IN None
cardiovascular JJ Condition
disease NN Condition
three CD None
groups NNS None
. . None
subjects NNS None
group NN None
group NN None
group NN None
. . None
elderly JJ Age
subjects NNS None
. . None
-DOCSTART- -X- N

glaucoma NN None
patients NNS None
. . None
patients NNS None
with IN None
glaucoma NN None
or CC None
ocular JJ None
hypertension NN None
. . None
total NN None
of IN None
89 CD None
patients NNS None
were VBD None
enrolled VBN None
, , None
and CC None
71 CD None
completed VBD None
the DT None
10-week JJ None
treatment NN None
period NN None
. . None
-DOCSTART- -X- N

39 CD None
patients NNS None
being VBG None
treated VBN None
with IN None
high JJ None
flux JJ None
dialysis NN None
. . None
patients NNS None
being VBG None
maintained VBN None
on IN None
high JJ None
flux JJ None
dialysis NN None
. . None
-DOCSTART- -X- N

surgical JJ None
wound NN None
infection NN None
: : None
patients NNS None
following VBG None
colorectal JJ None
surgery NN None
. . None
300 CD None
patients NNS None
aged VBD None
18 CD None
to TO None
80 CD None
years NNS None
who WP None
underwent VBP None
elective JJ None
colorectal NN None
surgery NN None
in IN None
14 CD None
Spanish JJ None
hospitals NNS None
from IN None
March NNP None
1 CD None
, , None
2003 CD None
, , None
to TO None
October NNP None
31 CD None
, , None
2004 CD None
. . None
patients NNS None
undergoing VBG None
colon NN None
or CC None
rectal JJ None
surgery NN None
. . None
-DOCSTART- -X- N

impact NN None
on IN None
nurse JJ None
practices NNS None
. . None
home NN None
health NN None
nurses NNS None
caring VBG None
for IN None
heart NN None
failure NN None
( ( None
HF NNP None
) ) None
patients NNS None
. . None
Information NNP None
on IN None
nurse NN None
practices NNS None
was VBD None
abstracted VBN None
from IN None
the DT None
clinical JJ None
records NNS None
of IN None
patients NNS None
admitted VBN None
between IN None
June NNP None
2000 CD None
and CC None
November NNP None
2001 CD None
to TO None
the DT None
care NN None
of IN None
354 CD None
study NN None
nurses NNS None
at IN None
a DT None
large JJ None
, , None
urban JJ None
, , None
nonprofit JJ None
home NN None
care NN None
agency NN None
. . None
home NN None
health NN None
nurses NNS None
-DOCSTART- -X- N

colorectal JJ Condition
cancer NN Condition
] NNP None
26 CD Size
cases NNS None
composed VBN None
of IN None
11 CD Size
cases NNS None
of IN None
arm NN None
A NNP None
and CC None
15 CD Size
cases NNS None
of IN None
arm NN None
B NNP None
advanced JJ None
colorectal JJ Condition
carcinoma NN Condition
. . None
-DOCSTART- -X- N

outpatient JJ None
colonoscopy NN Condition
100 CD Size
adult NN None
patients NNS None
colonoscopy NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
essential JJ None
hypertension NN None
: : None
46 CD None
patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
essential JJ None
hypertension NN None
. . None
-DOCSTART- -X- N

elderly JJ None
people NNS None
. . None
elderly JJ None
people NNS None
. . None
glaucoma NN None
patients NNS None
, , None
over IN None
60 CD None
years NNS None
of IN None
age NN None
, , None
without IN None
history NN None
of IN None
bronchospasm NN None
and CC None
who WP None
were VBD None
using VBG None
timolol NN None
( ( None
0.5 CD None
% NN None
) ) None
, , None
60 CD None
patients NNS None
elderly JJ None
people NNS None
with IN None
glaucoma NN None
-DOCSTART- -X- N

moderately RB None
hypercholesterolemic JJ Condition
adults NNS Age
: : None
hyperlipidemic JJ Condition
men NNS Sex
and CC None
women NNS Sex
. . Sex
159 CD Size
subjects NNS None
. . None
-DOCSTART- -X- N

term NN None
neonates NNS Age
: : None
81 CD Size
full-term JJ None
neonates NNS None
, , None
up RB None
to TO None
4 CD Age
wk NN Age
of IN None
postnatal JJ None
age NN None
, , None
who WP None
needed VBD None
venepuncture NN None
for IN None
blood NN None
investigations NNS None
. . None
pain VB Condition
in IN None
term NN None
neonates NNS None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
depression NN Condition
and CC Condition
comorbidity NN Condition
of IN Condition
depression NN Condition
and CC Condition
panic NN Condition
. . None
9 CD Size
control NN None
subjects NNS None
, , None
8 CD Size
patients NNS None
suffering VBG None
from IN None
a DT None
major JJ None
depressive JJ None
episode NN None
( ( None
MDE NNP None
) ) None
, , None
and CC None
12 CD Size
patients NNS None
suffering VBG None
from IN None
concurrent JJ None
MDE NNP None
and CC None
panic JJ None
disorder NN None
( ( None
MDE NNP None
+ NNP None
P NNP None
) ) None
. . None
